PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lewis, D				Lewis, Dyani			HOW NERVE STIMULATION IS HELPING PARALYSED PEOPLE WALK AGAIN	NATURE			English	News Item						Neuroscience												Angeli CA, 2018, NEW ENGL J MED, V379, P1244, DOI 10.1056/NEJMoa1803588; Barra B, 2022, NAT NEUROSCI, V25, P924, DOI 10.1038/s41593-022-01106-5; Gill ML, 2018, NAT MED, V24, P1677, DOI 10.1038/s41591-018-0175-7; Inanici F, 2021, IEEE T NEUR SYS REH, V29, P310, DOI 10.1109/TNSRE.2021.3049133; Kathe C., 2022, NATURE; Wagner FB, 2018, NATURE, V563, P65, DOI 10.1038/s41586-018-0649-2	6	0	0	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 17	2022	611	7936					438	438		10.1038/d41586-022-03605-8	http://dx.doi.org/10.1038/d41586-022-03605-8			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6G9SX	36352115	Bronze			2023-01-03	WOS:000885092300013
J	Munshi, L; Mancebo, J; Brochard, LJ				Munshi, Laveena; Mancebo, Jordi; Brochard, Laurent J.			Noninvasive Respiratory Support for Adults with Acute Respiratory Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSITIVE AIRWAY PRESSURE; FLOW NASAL CANNULA; CONVENTIONAL OXYGEN-THERAPY; CARDIOGENIC PULMONARY-EDEMA; MECHANICAL VENTILATION; ACUTE EXACERBATIONS; PLEURAL PRESSURE; HELMET; INTERFACES; COVID-19	Noninvasive Respiratory Support in Acute Respiratory FailureNoninvasive respiratory support can be useful for cardiogenic pulmonary edema and COPD exacerbations. For other conditions, its benefits need to be balanced against the potential harms of delaying intubation.	[Munshi, Laveena; Brochard, Laurent J.] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Munshi, Laveena] Sinai Hlth Syst, Crit Care Dept, Toronto, ON, Canada; [Brochard, Laurent J.] Unity Hlth Toronto, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Mancebo, Jordi] Hosp Univ Santa Creu & St Pau, Dept Intens Care, Barcelona, Spain	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Li Ka Shing Knowledge Institute	Brochard, LJ (corresponding author), Unity Hlth Toronto, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada.; Brochard, LJ (corresponding author), Unity Hlth Toronto, Li Ka Shing Knowledge Inst, Keenan Res Ctr Biomed Sci, 209 Victoria St, Toronto, ON M5B 1T8, Canada.	laurent.brochard@unityhealth.to						Adams CF, 2018, RESP PHYSIOL NEUROBI, V254, P23, DOI 10.1016/j.resp.2018.03.014; Adler D, 2017, AM J RESP CRIT CARE, V196, P200, DOI 10.1164/rccm.201608-1666OC; Althoff MD, 2020, AM J RESP CRIT CARE, V202, P1520, DOI 10.1164/rccm.201910-2021OC; Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; Antonelli M, 2000, JAMA-J AM MED ASSOC, V283, P235, DOI 10.1001/jama.283.2.235; Azoulay E, 2017, INTENS CARE MED, V43, P1808, DOI 10.1007/s00134-017-4947-1; Bellani G, 2017, AM J RESP CRIT CARE, V195, P67, DOI 10.1164/rccm.201606-1306OC; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; Berthelsen PG, 2003, ACTA ANAESTH SCAND, V47, P1190, DOI 10.1046/j.1399-6576.2003.00256.x; Biasucci DG, 2021, MINERVA ANESTESIOL, V87, P1006, DOI 10.23736/S0375-9393.21.15188-0; BROCHARD L, 1989, AM REV RESPIR DIS, V139, P513, DOI 10.1164/ajrccm/139.2.513; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Burns KEA, 2022, THORAX, V77, P752, DOI 10.1136/thoraxjnl-2021-216993; Carteaux G, 2021, ANN INTENSIVE CARE, V11, DOI 10.1186/s13613-021-00828-2; Carteaux G, 2016, CRIT CARE MED, V44, P282, DOI 10.1097/CCM.0000000000001379; Carteaux G, 2012, CHEST, V142, P367, DOI 10.1378/chest.11-2279; Chaudhuri D, 2020, CHEST, V158, P1934, DOI 10.1016/j.chest.2020.06.038; Chiumello D, 2003, INTENS CARE MED, V29, P1671, DOI 10.1007/s00134-003-1825-9; Cordoba-Izquierdo A, 2013, CRIT CARE MED, V41, P60, DOI 10.1097/CCM.0b013e31826764e3; Cortegiani A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54020-5; COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators, 2021, INTENSIVE CARE MED, V47, P60; Cuquemelle E, 2012, RESP CARE, V57, P1571, DOI 10.4187/respcare.01681; Demoule A, 2006, INTENS CARE MED, V32, P1756, DOI 10.1007/s00134-006-0324-1; Drake MG, 2018, ANN AM THORAC SOC, V15, P145, DOI 10.1513/AnnalsATS.201707-548FR; Duan J, 2017, INTENS CARE MED, V43, P192, DOI 10.1007/s00134-016-4601-3; Esteban A, 2004, NEW ENGL J MED, V350, P2452, DOI 10.1056/NEJMoa032736; Fernando SM, 2022, INTENS CARE MED, V48, P137, DOI 10.1007/s00134-021-06581-1; Ferreyro BL, 2020, JAMA-J AM MED ASSOC, V324, P57, DOI 10.1001/jama.2020.9524; Florio G, 2021, CHEST, V159, P2373, DOI 10.1016/j.chest.2021.01.055; Fodil R, 2011, INTENS CARE MED, V37, P257, DOI 10.1007/s00134-010-2066-3; Frat JP, 2018, CRIT CARE MED, V46, P208, DOI 10.1097/CCM.0000000000002818; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Fraticelli AT, 2009, CRIT CARE MED, V37, P939, DOI 10.1097/CCM.0b013e31819b575f; Goligher EC, 2017, AM J RESP CRIT CARE, V195, P1128, DOI 10.1164/rccm.201701-0006ED; Grieco DL, 2022, AM J RESP CRIT CARE, V205, P360, DOI 10.1164/rccm.202105-1212LE; Grieco DL, 2021, JAMA-J AM MED ASSOC, V325, P1731, DOI 10.1001/jama.2021.4682; Grieco DL, 2020, AM J RESP CRIT CARE, V201, P303, DOI 10.1164/rccm.201904-0841OC; Hilbert G, 2001, NEW ENGL J MED, V344, P481, DOI 10.1056/NEJM200102153440703; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Jaber S, 2016, JAMA-J AM MED ASSOC, V315, P1345, DOI 10.1001/jama.2016.2706; Jolliet P, 2017, AM J RESP CRIT CARE, V195, P871, DOI 10.1164/rccm.201601-0083OC; Kelly CR, 2015, NEW ENGL J MED, V372, DOI 10.1056/NEJMvcm1313336; Lenique F, 1997, AM J RESP CRIT CARE, V155, P500, DOI 10.1164/ajrccm.155.2.9032185; Masip J, 2000, LANCET, V356, P2126, DOI 10.1016/S0140-6736(00)03492-9; Mauri T, 2017, AM J RESP CRIT CARE, V195, P1207, DOI 10.1164/rccm.201605-0916OC; Menga LS, 2022, CURR OPIN CRIT CARE, V28, P25, DOI 10.1097/MCC.0000000000000902; Moller W, 2017, J APPL PHYSIOL, V122, P191, DOI 10.1152/japplphysiol.00584.2016; Mokhlesi B, 2019, AM J RESP CRIT CARE, V200, pE6, DOI 10.1164/rccm.201905-1071ST; Morais CCA, 2018, AM J RESP CRIT CARE, V197, P1285, DOI 10.1164/rccm.201706-1244OC; Nava S, 2009, LANCET, V374, P250, DOI 10.1016/S0140-6736(09)60496-7; Only GA, 2021, LANCET RESP MED, V9, P1221, DOI 10.1016/S2213-2600(21)00089-8; Ospina-Tascon GA, 2021, JAMA-J AM MED ASSOC, V326, P2161, DOI 10.1001/jama.2021.20714; Papa GFS, 2012, MINERVA ANESTESIOL, V78, P1146; Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338; Patroniti N, 2003, INTENS CARE MED, V29, P1680, DOI 10.1007/s00134-003-1931-8; Perkins GD, 2022, JAMA-J AM MED ASSOC, V327, P546, DOI 10.1001/jama.2022.0028; Pinkham MI, 2022, J APPL PHYSIOL, V132, P553, DOI 10.1152/japplphysiol.00769.2021; Pinsky MR, 2021, CHEST, V159, P2145, DOI 10.1016/j.chest.2021.02.040; Radermacher P, 2017, AM J RESP CRIT CARE, V196, P964, DOI 10.1164/rccm.201610-2156SO; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Richards GN, 1996, AM J RESP CRIT CARE, V154, P182, DOI 10.1164/ajrccm.154.1.8680678; Roca O, 2019, AM J RESP CRIT CARE, V199, P1368, DOI 10.1164/rccm.201803-0589OC; Rochwerg B, 2020, INTENS CARE MED, V46, P2226, DOI 10.1007/s00134-020-06312-y; Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016; Schmidt M, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03784-2; Squadrone V, 2005, JAMA-J AM MED ASSOC, V293, P589, DOI 10.1001/jama.293.5.589; Thille AW, 2022, AM J RESP CRIT CARE, V205, P440, DOI 10.1164/rccm.202106-1452OC; Thille AW, 2019, JAMA-J AM MED ASSOC, V322, P1465, DOI 10.1001/jama.2019.14901; Thille AW, 2011, RESP CARE, V56, P1526, DOI 10.4187/respcare.00847; Thompson BT, 2017, NEW ENGL J MED, V377, P562, DOI [10.1056/NEJMra1608077, 10.1056/NEJMc1711824]; Tobin MJ, 2020, AM J RESP CRIT CARE, V202, P356, DOI 10.1164/rccm.202006-2157CP; Vieira F, 2022, J APPL PHYSIOL, V132, P1580, DOI 10.1152/japplphysiol.00416.2021; Yoshida T, 2017, AM J RESP CRIT CARE, V195, P985, DOI 10.1164/rccm.201604-0748CP; Yoshida Y, 2008, J ANESTH, V22, P201, DOI 10.1007/s00540-008-0637-z	77	0	0	3	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2022	387	18					1688	1698		10.1056/NEJMra2204556	http://dx.doi.org/10.1056/NEJMra2204556			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6A4CQ	36322846				2023-01-03	WOS:000880604900011
J	Brennan, T				Brennan, Troyen			Pharmaceutical Marketing Revisited - United States v. Biogen Idec	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Brennan, Troyen] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Brennan, T (corresponding author), Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.							AHIP, 2021, NEW STUD MIDST COVID; Raymond N., 2022, REUTERS 0720; Schwartz LM, 2019, JAMA-J AM MED ASSOC, V321, P80, DOI 10.1001/jama.2018.19320; Steinman MA, 2006, ANN INTERN MED, V145, P284, DOI 10.7326/0003-4819-145-4-200608150-00008; United States District Court of Massachusetts, 2022, REL TRIAL BRIEF US V	5	0	0	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2022	387	18					1631	1633		10.1056/NEJMp2210637	http://dx.doi.org/10.1056/NEJMp2210637		OCT 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6A4CQ	36317763				2023-01-03	WOS:000877775900001
J	Daifotis, AG				Daifotis, Anastasia G.			Risks to the 340B Drug Pricing Program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Daifotis, Anastasia G.] Janssen Sci Affairs LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA	Johnson & Johnson; Janssen Pharmaceuticals	Daifotis, AG (corresponding author), Janssen Sci Affairs LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA.	adaifoti@its.jnj.com						[Anonymous], 2021, NOVARTIS PHARM CORPO; [Anonymous], 2022, JOHNSON JOHNSON 0321; Fein AJ., 2021, DRUG CHANNELS 0616; King R., 2021, FIERCE HEALTHCA 1108; Knox RP, 2022, JAMA-J AM MED ASSOC, V327, P1647, DOI 10.1001/jama.2022.5959	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2022	328	11								10.1001/jama.2022.12753	http://dx.doi.org/10.1001/jama.2022.12753			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5A5DY	36125477				2023-01-03	WOS:000862909200028
J	Given, J; Casson, K; Dolk, H; Loane, M				Given, Joanne; Casson, Karen; Dolk, Helen; Loane, Maria			Sociodemographic variation in prescriptions dispensed in early pregnancy in Northern Ireland 2010-2016	PLOS ONE			English	Article							MEDICATION USE; PREVALENCE; HEALTH; WOMEN; CARE; DETERMINANTS; PATTERNS; EPILEPSY; AGE	Aim To establish the prevalence of prescriptions dispensed in early pregnancy by maternal age and area deprivation, for women who gave birth in Northern Ireland (NI) 2011-2016. Study design Population-based linked cohort study. Methods The NI Maternity System (NIMATS) database was used to identify all births to resident mothers in NI between 2011 and 2016. Prescriptions dispensed between the last menstrual period (LMP) and the first antenatal care visit (mean 10.7 weeks) (2010-2016) were extracted from the Enhanced Prescribing Database (EPD) which records all prescriptions dispensed by pharmacists in NI. EPD data were linked to NIMATS using the mother's Health and Care Number. Maternal deprivation based on the NI Multiple Deprivation Measure 2017 was linked using the mother's postcode. Results The cohort included 139,687 pregnancies resulting in live or stillbirths to 106,206 women. A medication was dispensed in 63.5% of pregnancies, and in 48.7% of pregnancies excluding supplements (vitamins, iron, and folic acid). Folic acid was the most commonly dispensed medication (33.1%). Excluding supplements, the mean number of medications was 1.1, with 4.2% having >= 5 medications. The most common non-supplement medications were antibiotics (13.1%), antiemetics (8.7%), analgesics (6.9%), hormonal medications (6.9%) and antidepressants (6.1%). Younger women (<20 years) had more antibiotics while older women (40+ years) had more antidepressants, cardiovascular, antihypertensives, anticoagulant medications and thyroxine. The proportion of women living in the most deprived areas with prescriptions for antidepressants, sedatives, tranquilisers, analgesics, and anti-epileptic medications was double the proportion of women with these medications in the least deprived areas. Conclusion Half of all pregnant women in NI were dispensed a non-supplement medication between LMP and the first antenatal care visit. Younger and older mothers and those living in the most deprived areas were more likely to have medications dispensed. More antidepressants were dispensed in areas of social deprivation.	[Given, Joanne; Casson, Karen; Dolk, Helen; Loane, Maria] Univ Ulster, Fac Life Hlth Sci, Belfast, North Ireland	Ulster University	Loane, M (corresponding author), Univ Ulster, Fac Life Hlth Sci, Belfast, North Ireland.	ma.loane@ulster.ac.uk	Given, Joanne/J-3484-2017	Given, Joanne/0000-0003-4921-1944; Loane, Maria/0000-0002-1206-3637	Economic and Social Research Council [ESL/L007509/1]	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	HD and ML received funding for this study from the Economic and Social Research Council (https://esrc.ukri.org/) grant number ESL/L007509/1 (Administrative Data Research Centre -Northern Ireland). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam MP, 2011, AM J MED GENET C, V157C, P175, DOI 10.1002/ajmg.c.30313; Agresti A., 2019, INTRO CATEGORICAL AN, V3rd; Bakker MK, 2006, BJOG-INT J OBSTET GY, V113, P559, DOI 10.1111/j.1471-0528.2006.00927.x; Berry J, 2005, GUIDE STAT METHODS I; Bjorn Anne-Mette Bay, 2011, Clin Epidemiol, V3, P149, DOI 10.2147/CLEP.S17747; Brough L, 2009, J HUM NUTR DIET, V22, P100, DOI 10.1111/j.1365-277X.2008.00936.x; Bunting BP, 2012, PSYCHOL MED, V42, P1727, DOI 10.1017/S0033291711002510; Campbell E, 2013, EPILEPSY BEHAV, V28, P354, DOI 10.1016/j.yebeh.2013.05.019; Cleary BJ, 2010, PHARMACOEPIDEM DR S, V19, P408, DOI 10.1002/pds.1906; Daw JR, 2011, PHARMACOEPIDEM DR S, V20, P895, DOI 10.1002/pds.2184; de Jonge L, 2015, DRUG SAFETY, V38, P737, DOI 10.1007/s40264-015-0302-z; Demailly R, 2017, PHARMACOEPIDEM DR S, V26, P1126, DOI 10.1002/pds.4265; Dolk H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227908; Joseph KS, 2009, J OBSTET GYNAECOL CA, V31, P422, DOI 10.1016/S1701-2163(16)34173-1; Kendler KS, 2014, PSYCHOL MED, V44, P2537, DOI 10.1017/S0033291713003048; Lupattelli A, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004365; Mazer-Amirshahi M, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.06.013; McDonald H, 2020, J PUBLIC HEALTH-UK, V42, P801, DOI 10.1093/pubmed/fdz184; Mitchell AA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.02.029; Modder J., 2010, MANAGEMENT WOMEN OBE; Mohammed SH, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028238; Molenaar NM, 2020, J AFFECT DISORDERS, V264, P82, DOI 10.1016/j.jad.2019.12.014; National Institute for Health and Care Excellence, 2021, ANTENATAL CARE NG201; National Institute for Health and Care Excellence, 2013, MATERN CHILD NUTR; Neural tube defects (prevention in pregnancy), 2018, BNF BRIT NATL FORMUL; NICE, 2015, DIAB PREGN MAN PREC; Northern Ireland Statistics and Research Agency, 2017, NO IRELAND MULTIPLE; Northern Ireland Statistics and Research Agency, 2017, REGISTRAR GEN NO IRE; Olesen C, 2006, EUR J CLIN PHARMACOL, V62, P547, DOI 10.1007/s00228-006-0119-x; Relton CL, 2005, PUBLIC HEALTH NUTR, V8, P338, DOI 10.1079/PHN2004690; Schneeweiss S, 2005, J CLIN EPIDEMIOL, V58, P323, DOI 10.1016/j.jclinepi.2004.10.012; Sharrar RG, 2013, THER ADV DRUG SAF, V4, P211, DOI 10.1177/2042098613490780; Sillanpaa M, 2004, EPILEPSIA, V45, P971, DOI 10.1111/j.0013-9580.2004.44203.x; Smolina K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128312; Stephansson Olof, 2011, Clin Epidemiol, V3, P43, DOI 10.2147/CLEP.S16305; Tamblyn R, 2014, ANN INTERN MED, V160, P441, DOI 10.7326/M13-1705; Thorpe PG, 2013, PHARMACOEPIDEM DR S, V22, P1013, DOI 10.1002/pds.3495; Tinker SC, 2015, MATERN CHILD HLTH J, V19, P1097, DOI 10.1007/s10995-014-1611-z; Wemakor A, 2014, J AFFECT DISORDERS, V167, P299, DOI 10.1016/j.jad.2014.06.015	39	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2022	17	8							e0267710	10.1371/journal.pone.0267710	http://dx.doi.org/10.1371/journal.pone.0267710			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5V2VT	35994459	Green Published, gold			2023-01-03	WOS:000877093400001
J	Roumeliotis, S; Roumeliotis, A; Georgianos, PI; Thodis, E; Schurgers, LJ; Maresz, K; Eleftheriadis, T; Dounousi, E; Tripepi, G; Mallamaci, F; Liakopoulos, V				Roumeliotis, Stefanos; Roumeliotis, Athanasios; Georgianos, Panagiotis, I; Thodis, Elias; Schurgers, Leon J.; Maresz, Katarzyna; Eleftheriadis, Theodoros; Dounousi, Evangelia; Tripepi, Giovanni; Mallamaci, Francesca; Liakopoulos, Vassilios			Vitamin K In PEritonial DIAlysis (VIKIPEDIA): Rationale and study protocol for a randomized controlled trial	PLOS ONE			English	Article							ARTERIAL STIFFNESS; HEMODIALYSIS-PATIENTS; MATRIX; SUPPLEMENTATION; CALCIFICATION	Vascular calcification (VC) is an active process, resulting from the disturbance of balance between inhibitors and promoters of calcification, in favor of the latter. Matrix Gla Protein, a powerful inhibitor of VC, needs vitamin K to become active. In vitamin K depletion, plasma levels of the inactive form of MGP, dephosphorylated, uncarboxylated MGP (dp-ucMGP) are increased and associated with VC and cardiovascular (CV) outcomes. End Stage Renal Disease (ESRD) patients have increased circulating dp-ucMGP levels and accelerated VC. Vitamin K In PEritoneal DIAlysis (VIKIPEDIA) is a prospective, randomized, open label, placebo-controlled trial, evaluating the effect of vitamin K2 supplementation on arterial stiffness and CV events in ESRD patients undergoing peritoneal dialysis (PD). Forty-four PD patients will be included in the study. At baseline, dp-ucMGP and pulse-wave velocity (PWV) will be assessed and then patients will be randomized (1:1 ratio) to vitamin K (1000 mu g MK-7/day) or placebo for 1.5 years. The primary endpoint of this trial is the change in PWV in the placebo group as compared to the treatment group. Secondary endpoints are the occurrence of CV events, mortality, changes in PD adequacy, change in 24-hour ambulatory blood pressure indexes and aortic systolic blood pressure and changes in calcium/phosphorus/parathormone metabolism. VIKIPEDIA is a new superiority randomized, open label, placebo-controlled trial aiming to determine the effect of vitamin K2 supplementation on VC, CV disease and calcium/phosphorus metabolism, in PD patients.	[Roumeliotis, Stefanos; Roumeliotis, Athanasios; Georgianos, Panagiotis, I; Liakopoulos, Vassilios] Aristotle Univ Thessaloniki, Dept Internal Med 1, Med Sch, AHEPA Hosp, Thessaloniki, Greece; [Thodis, Elias] Democritus Univ Thrace, Sch Med, Dept Nephrol, Alexandroupolis, Greece; [Schurgers, Leon J.] Cardiovasc Res Inst Maastricht, Dept Biochem, Maastricht, Netherlands; [Maresz, Katarzyna] Int Sci & Hlth Fdn, Krakow, Poland; [Eleftheriadis, Theodoros] Univ Thessaly, Fac Med, Dept Nephrol, Larisa, Greece; [Dounousi, Evangelia] Univ Ioannina, Fac Med, Sch Hlth Sci, Dept Nephrol, Ioannina, Greece; [Tripepi, Giovanni; Mallamaci, Francesca] CNR IFC, Clin Epidemiol & Physiopathol Renal Dis & Hyperte, Reggio Di Calabria, Italy	Aristotle University of Thessaloniki; Ahepa University Hospital; Democritus University of Thrace; Maastricht University; University of Thessaly; University of Ioannina; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR)	Roumeliotis, S (corresponding author), Aristotle Univ Thessaloniki, Dept Internal Med 1, Med Sch, AHEPA Hosp, Thessaloniki, Greece.	st_roumeliotis@hotmail.com		Eleftheriadis, Theodoros/0000-0001-9302-1633; Schurgers, Leon/0000-0001-7867-6957; Roumeliotis, Athanasios/0000-0003-0314-9794				Alexandrou ME, 2020, J HYPERTENS, V38, P2393, DOI 10.1097/HJH.0000000000002574; Aoun M, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0609-3; BELLE M, 1995, J IMMUNOASSAY, V16, P213, DOI 10.1080/15321819508013559; Bhaskaran K, 2014, INT J EPIDEMIOL, V43, P1336, DOI 10.1093/ije/dyu080; Blacher J, 2002, CURR OPIN NEPHROL HY, V11, P629, DOI 10.1097/00041552-200211000-00010; Blacher J, 2003, KIDNEY INT, V63, P1852, DOI 10.1046/j.1523-1755.2003.00932.x; Caluwe R, 2014, NEPHROL DIAL TRANSPL, V29, P1385, DOI 10.1093/ndt/gft464; Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586; Cranenburg ECM, 2010, THROMB HAEMOSTASIS, V104, P811, DOI 10.1160/TH09-11-0786; DeLoach SS, 2008, CLIN J AM SOC NEPHRO, V3, P184, DOI 10.2215/CJN.03340807; Eknoyan G., 2003, AM J KIDNEY DIS, V42, P1, DOI [10.1016/S0272-6386(03)00905-3, DOI 10.1016/S0272-6386(03)00905-3]; Fain ME, 2018, AM J HYPERTENS, V31, P735, DOI 10.1093/ajh/hpy049; Frimodt-Moller M, 2008, NEPHROL DIAL TRANSPL, V23, P594, DOI 10.1093/ndt/gfm470; Haroon SWP, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021906; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254; Leenders NHJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28629-x; Levy-Schousboe K, 2021, CLIN KIDNEY J; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; O'Donnell CJ, 2006, ARTERIOSCL THROM VAS, V26, P2769, DOI 10.1161/01.ATV.0000245793.83158.06; Oikonomaki T, 2019, INT UROL NEPHROL, V51, P2037, DOI 10.1007/s11255-019-02275-2; Puzantian H, 2018, AM J HYPERTENS, V31, P988, DOI 10.1093/ajh/hpy079; Rapp N, 2021, NUTRIENTS, V13, DOI 10.3390/nu13103490; Rodriguez RA, 2020, CAN J KIDNEY HEALTH, V7, DOI 10.1177/2054358120906974; Roumeliotis S, 2021, EUR J NUTR, V60, P1701, DOI 10.1007/s00394-020-02469-w; Roumeliotis S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176035; Roumeliotis S, 2020, ADV CLIN CHEM, V98, P91, DOI 10.1016/bs.acc.2020.02.004; Roumeliotis S, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00154; Roumeliotis S, 2021, CURR VASC PHARMACOL, V19, P77, DOI 10.2174/1570161118666200320111745; Roumeliotis S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030628; Schurgers LJ, 2007, BLOOD, V109, P3279, DOI 10.1182/blood-2006-08-040709; Schurgers LJ, 2010, CLIN J AM SOC NEPHRO, V5, P568, DOI 10.2215/CJN.07081009; Schurgers LJ, 2000, HAEMOSTASIS, V30, P298; Townsend RR, 2015, HYPERTENSION, V66, P698, DOI 10.1161/HYP.0000000000000033; Vaios V, 2019, HYPERTENSION, V74, P998, DOI 10.1161/HYPERTENSIONAHA.119.13443; Vaios Vasilios, 2018, Adv Perit Dial, V34, P24; Westenfeld R, 2012, AM J KIDNEY DIS, V59, P186, DOI 10.1053/j.ajkd.2011.10.041; Xu QD, 2019, INT UROL NEPHROL, V51, P527, DOI 10.1007/s11255-019-02080-x	38	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2022	17	8							e0273102	10.1371/journal.pone.0273102	http://dx.doi.org/10.1371/journal.pone.0273102			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4D6CO	35976944	Green Published, gold			2023-01-03	WOS:000847227000077
J	Larkin, HD				Larkin, Howard D.			Finding Ways to Improve Patients' Cancer Immunotherapy Response	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2022	328	6					518	518		10.1001/jama.2022.13253	http://dx.doi.org/10.1001/jama.2022.13253			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4E5FG	35943484				2023-01-03	WOS:000847850400006
J	Liu, DM; Bo, HF; Jin, YC; Li, DY; Zhang, ZX; Gong, K; Lin, Y; Li, SJ				Liu, Dongmei; Bo, Huifeng; Jin, Yongchao; Li, Deyang; Zhang, Zhanxin; Gong, Kai; Lin, Ye; Li, Sijia			Effects of concentration and chain length of the sequence copolymer on interfacial properties of homopolymers/sequence copolymers ternary blends: A DPD simulation study	PLOS ONE			English	Article							DISSIPATIVE PARTICLE DYNAMICS; PHASE-SEPARATION DYNAMICS; MONTE-CARLO-SIMULATION; BLOCK-COPOLYMERS; POLYMER BLEND; MIXTURES; TENSION; ARCHITECTURE; MISCIBILITY; ADSORPTION	The effect of the concentration and chain length of the copolymer AB with sequence length tau = 8 on the interfacial properties of the ternary mixtures A(10)/AB/B-10 are investigated by the dissipative particle dynamics (DPD) simulations. It is found that: i) As the copolymer concentration varies from 0.05 to 0.15, increasing the copolymer enrichment at the center of the interface enlarges the interface width omega and reduces the interfacial tension. However, as the concentration of the sequence copolymers further increases to 0.2, because the interface has formed micelles and the micellization could lower the efficiency of copolymers as a compatibilizer, the interfacial tension exhibits a slightly increase; ii) elevating the copolymer chain length, the copolymer volumes vary from a cylinder shape to a pancake shape. The blends of the copolymer with chain length N-cp = 24 exhibit a wider interfacial width w and a lower interfacial tension gamma, which indicates that the sequenced copolymer N-cp = 24 exhibits a better performance as the compatibilizers. This study illustrates the correlations between the reduction in interfacial tension produced by the sequence copolymers and their molecular parameters, which guide a rational design of an efficient compatibilizer.	[Liu, Dongmei; Bo, Huifeng; Jin, Yongchao; Li, Deyang; Zhang, Zhanxin; Gong, Kai; Lin, Ye] North China Univ Sci & Technol, Sch Sci, Tangshan, Peoples R China; [Li, Sijia] Peoples Police Univ China, Sch Intelligence Policing, Langfang, Peoples R China	North China University of Science & Technology	Gong, K; Lin, Y (corresponding author), North China Univ Sci & Technol, Sch Sci, Tangshan, Peoples R China.	gongkai0524@163.com; linye315317@163.com		Jin, YongChao/0000-0001-9528-5720	Natural Science Foundation of Hebei Province; Science and Technology Project of Hebei Education Department;  [B2020507044];  [QN2022058]	Natural Science Foundation of Hebei Province(Natural Science Foundation of Hebei Province); Science and Technology Project of Hebei Education Department; ; 	We are grateful for the essential supports of Hebei Key Laboratory of Data Science and Application and School of Materials of Sun Yat-sen University.	BALAZS AC, 1989, MACROMOLECULES, V22, P4260, DOI 10.1021/ma00201a021; BROWN HR, 1989, NATURE, V341, P221, DOI 10.1038/341221a0; Chang LW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01249-1; Chen ZY, 2000, J CHEM PHYS, V112, P8665, DOI 10.1063/1.481468; Corsi A, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1854133; Corsi A, 2006, EUROPHYS LETT, V73, P204, DOI 10.1209/epl/i2005-10372-y; Dadmun M, 1996, MACROMOLECULES, V29, P3868, DOI 10.1021/ma951500t; Dadmun MD, 2000, MACROMOLECULES, V33, P9122, DOI 10.1021/ma001228+; Dadmun MD, 2001, MACROMOL THEOR SIMUL, V10, P795, DOI 10.1002/1521-3919(20011101)10:9<795::AID-MATS795>3.0.CO;2-Z; DAI CA, 1994, PHYS REV LETT, V73, P2472, DOI 10.1103/PhysRevLett.73.2472; DAI KH, 1994, MACROMOLECULES, V27, P4544, DOI 10.1021/ma00094a018; Eastwood EA, 2002, MACROMOLECULES, V35, P5069, DOI 10.1021/ma011701z; Gazuz I, 2014, SOFT MATTER, V10, P7247, DOI 10.1039/c4sm01293c; Goodarzi F, 2019, J MOL LIQ, V295, DOI 10.1016/j.molliq.2019.111357; Goodarzi F, 2019, IND ENG CHEM RES, V58, P8817, DOI 10.1021/acs.iecr.9b00504; Goodson AD, 2019, J POLYM SCI POL PHYS, V57, P794, DOI 10.1002/polb.24834; Groot RD, 1998, J CHEM PHYS, V108, P8713, DOI 10.1063/1.476300; Guo HX, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2084947; Hong ZH, 2020, J FOOD ENG, V276, DOI 10.1016/j.jfoodeng.2019.109877; Klos J, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2794330; Klos JS, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2894870; Ko MJ, 2000, POLYMER, V41, P6387, DOI 10.1016/S0032-3861(99)00855-1; Lemos T, 2020, MACROMOL THEOR SIMUL, V29, DOI 10.1002/mats.202000014; Liang XP, 2018, COLLOID SURFACE A, V546, P107, DOI 10.1016/j.colsurfa.2018.02.063; Lin Y, 2005, NATURE, V434, P55, DOI 10.1038/nature03310; Liu DM, 2022, RSC ADV, V12, P3090, DOI 10.1039/d1ra08936f; Liu DM, 2021, RSC ADV, V11, P38316, DOI 10.1039/d1ra07671j; Liu DM, 2021, POLYMERS-BASEL, V13, DOI 10.3390/polym13172866; Liu DM, 2021, POLYMERS-BASEL, V13, DOI 10.3390/polym13142333; Liu DM, 2021, POLYMERS-BASEL, V13, DOI 10.3390/polym13091516; Liu DM, 2015, CHEM J CHINESE U, V36, P2532, DOI 10.7503/cjcu20150297; Liu DM, 2015, CHEM J CHINESE U, V36, P1752, DOI 10.7503/cjcu20150202; Lyatskaya Y, 1996, J PHYS CHEM-US, V100, P1449, DOI 10.1021/jp952422e; Malik R, 2013, MACROMOLECULES, V46, P4207, DOI 10.1021/ma400187u; Malik R, 2010, MACROMOLECULES, V43, P5149, DOI 10.1021/ma100460y; Qian HJ, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1897694; Wang C, 2017, MACROMOL THEOR SIMUL, V26, DOI 10.1002/mats.201700027; Wang SY, 2018, J PETROL SCI ENG, V169, P81, DOI 10.1016/j.petrol.2018.05.036; Zhang YZ, 2018, MOL PHYS, V116, P1851, DOI 10.1080/00268976.2018.1459916; Zhou Y, 2012, J APPL POLYM SCI, V125, P1530, DOI 10.1002/app.36370	41	0	0	8	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2022	17	7								10.1371/journal.pone.0270094	http://dx.doi.org/10.1371/journal.pone.0270094			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4X1CI	35881587	gold, Green Published			2023-01-03	WOS:000860587700017
J	Mangione, CM; Barry, MJ; Nicholson, WK; Cabana, M; Caughey, AB; Chelmow, D; Coker, TR; Davis, EM; Donahue, KE; Jaen, CR; Kubik, M; Li, L; Ogedegbe, G; Pbert, L; Ruiz, JM; Stevermer, J; Wong, JB				Mangione, Carol M.; Barry, Michael J.; Nicholson, Wanda K.; Cabana, Michael; Caughey, Aaron B.; Chelmow, David; Coker, Tumaini Rucker; Davis, Esa M.; Donahue, Katrina E.; Jaen, Carlos Roberto; Kubik, Martha; Li, Li; Ogedegbe, Gbenga; Pbert, Lori; Ruiz, John M.; Stevermer, James; Wong, John B.			Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons US Preventive Services Task Force Recommendation Statement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGENS; MILD COGNITIVE IMPAIRMENT; HEALTH OUTCOMES; RISK-FACTORS; WOMEN; REPLACEMENT; DEMENTIA; HEART	IMPORTANCE Menopause is defined as the cessation of a person's menstrual cycle. It is defined retrospectively, 12 months after the final menstrual period. Perimenopause, or the menopausal transition, is the few-year time period preceding a person's final menstrual period and is characterized by increasing menstrual cycle length variability and periods of amenorrhea, and often symptoms such as vasomotor dysfunction. The prevalence and incidence of most chronic diseases (eg, cardiovascular disease, cancer, osteoporosis, and fracture) increase with age, and US persons who reach menopause are expected on average to live more than another 30 years. OBJECTIVE To update its 2017 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of systemic (ie, oral or transdermal) hormone therapy for the prevention of chronic conditions in postmenopausal persons and whether outcomes vary by age or by timing of intervention after menopause. POPULATION Asymptomatic postmenopausal persons who are considering hormone therapy for the primary prevention of chronic medical conditions. EVIDENCE ASSESSMENT The USPSTF concludes with moderate certainty that the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons with an intact uterus has no net benefit. The USPSTF concludes with moderate certainty that the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal persons who have had a hysterectomy has no net benefit. RECOMMENDATION The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons. (D recommendation) The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal persons who have had a hysterectomy. (D recommendation)	[Mangione, Carol M.] Univ Calif Los Angeles, Los Angeles, CA USA; [Barry, Michael J.] Harvard Med Sch, Boston, MA 02115 USA; [Nicholson, Wanda K.; Donahue, Katrina E.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Cabana, Michael] Albert Einstein Coll Med, New York, NY USA; [Caughey, Aaron B.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Chelmow, David] Virginia Commonwealth Univ, Richmond, VA 23284 USA; [Coker, Tumaini Rucker] Univ Washington, Seattle, WA 98195 USA; [Davis, Esa M.] Univ Pittsburgh, Pittsburgh, PA USA; [Jaen, Carlos Roberto] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Kubik, Martha] George Mason Univ, Fairfax, VA 22030 USA; [Li, Li] Univ Virginia, Charlottesville, VA USA; [Ogedegbe, Gbenga] NYU, New York, NY USA; [Pbert, Lori] Univ Massachusetts, Sch Med, Worcester, MA USA; [Ruiz, John M.] Univ Arizona, Tucson, AZ USA; [Stevermer, James] Univ Missouri, Columbia, MO 65211 USA; [Wong, John B.] Tufts Univ, Sch Med, Boston, MA 02111 USA	University of California System; University of California Los Angeles; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; Yeshiva University; Oregon Health & Science University; Virginia Commonwealth University; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Health San Antonio; George Mason University; University of Virginia; New York University; University of Massachusetts System; University of Massachusetts Worcester; University of Arizona; University of Missouri System; University of Missouri Columbia; Tufts University	Mangione, CM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, 10940 Wilshire Blvd,Ste 700, Los Angeles, CA 90024 USA.	chair@uspstf.net						American Academy of Family Physicians, CLIN PREV SERV REC H; [Anonymous], 2013, Obstet Gynecol, V121, P1407, DOI 10.1097/01.AOG.0000431053.33593.2d; Chlebowski RT, 2020, JAMA-J AM MED ASSOC, V324, P369, DOI 10.1001/jama.2020.9482; Col Nananda F, 2009, Ann Intern Med, V150, pITC4; Curry SJ, 2018, JAMA-J AM MED ASSOC, V319, P2521, DOI 10.1001/jama.2018.7498; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Davidson KW, 2022, JAMA-J AM MED ASSOC, V327, P1577, DOI 10.1001/jama.2022.4983; Davidson KW, 2021, JAMA-J AM MED ASSOC, V326, P736, DOI 10.1001/jama.2021.12531; Gartlehner G., 2022, AHRQ PUBLICATION; Gartlehner G, 2022, JAMA-J AM MED ASSOC, V328, P1747, DOI 10.1001/jama.2022.18324; Grossman DC, 2017, JAMA-J AM MED ASSOC, V318, P2224, DOI 10.1001/jama.2017.18261; Grossman DC, 2017, JAMA-J AM MED ASSOC, V318, P167, DOI 10.1001/jama.2017.7171; Harlow SD, 2012, CLIMACTERIC, V15, P105, DOI [10.3109/13697137.2011.650656, 10.1210/jc.2011-3362, 10.1016/j.fertnstert.2012.01.128, 10.1097/gme.0b013e31824d8f40]; Hauk L, 2013, AM FAM PHYSICIAN, V88, P269; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; Krist AH, 2021, JAMA-J AM MED ASSOC, V325, P1650, DOI 10.1001/jama.2021.4987; Krist AH, 2020, JAMA-J AM MED ASSOC, V324, P2069, DOI 10.1001/jama.2020.21749; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x; McKinlay SM, 1996, MATURITAS, V23, P137, DOI 10.1016/0378-5122(95)00985-X; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Moyer VA, 2014, ANN INTERN MED, V160, P330, DOI 10.7326/M13-2771; Pfizer Inc, PREM PRESCR INF; Prentice RL, 2020, AM J EPIDEMIOL, V189, P972, DOI 10.1093/aje/kwaa033; Prentice RL, 2009, AM J EPIDEMIOL, V170, P12, DOI 10.1093/aje/kwp115; Shifren JL, 2014, MENOPAUSE, V21, P1038, DOI [10.1097/GME.0000000000000319, 10.1097/gme.0000000000000319]; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Siu AL, 2016, ANN INTERN MED, V164, P279, DOI 10.7326/M15-2886; Social Security Administration, 2010, ACT LIF TABL PER LIF; Steinauer JE, 2005, OBSTET GYNECOL, V106, P940, DOI 10.1097/01.AOG.0000180394.08406.15; U.S. Preventative Health Task Force, 2009, ANN INTERN MED; Veerus P, 2006, MATURITAS, V55, P162, DOI 10.1016/j.maturitas.2006.01.012; Watts NB, 2017, J CLIN ENDOCR METAB, V102, P302, DOI 10.1210/jc.2016-3270	36	1	1	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2022	328	17					1740	1746		10.1001/jama.2022.18625	http://dx.doi.org/10.1001/jama.2022.18625			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6C4JN	36318127	Bronze			2023-01-03	WOS:000881982900028
J	Kuehn, BM				Kuehn, Bridget M.			Growing Role of Gabapentin in Opioid-Related Overdoses Highlights Misuse Potential and Off-label Prescribing Practices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material															Denver Health and Hospital Authority; National Institute on Drug Abuse	Denver Health and Hospital Authority; National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	reported receiving research funding from Denver Health and Hospital Authority and the National Institute on Drug Abuse; consulting for the United Way of Broward County Commission on Behavioral Health and Drug Prevention; and receiving an honorarium to speak at the Researched Abuse, Diversion and Addiction-Related Surveillance System annual meeting. Dr Ellis reported that he is a member of the Scientific Advisory Group for the National Drug EarlyWarning System. DrWebster reported receiving payments from pharmaceutical and technology companies BDSI, CognifiSense, Ensysce, Neurana, Pharmacom, Salix, Kempharm, Elysium, and Shinogi for consulting fees, honoraria for CME presentations or other speaking engagements, travel expense reimbursement, expert testimony, and clinical research. DrWebster also reported that he is associate editor of the special populations section of Pain Medicine; chief medical officer of PainScript, a company that makes a digital tool for managing patients with pain and addiction; and author of a book and coproducer of a documentary, both about pain. No other disclosures were reported.		0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	2022	328	13					1283	1285		10.1001/jama.2022.13659	http://dx.doi.org/10.1001/jama.2022.13659			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5F6GU	36069924				2023-01-03	WOS:000866412700001
J	Bowles, S; Hickman, J; Peng, XY; Williamson, WR; Huang, RC; Washington, K; Donegan, D; Welle, CG				Bowles, Spencer; Hickman, Jordan; Peng, Xiaoyu; Williamson, W. Ryan; Huang, Rongchen; Washington, Kayden; Donegan, Dane; Welle, Cristin G.			Vagus nerve stimulation drives selective circuit modulation through cholinergic reinforcement	NEURON			English	Article							CORTICAL MAP PLASTICITY; MOTOR CORTEX; LOCUS-COERULEUS; NEURAL ACTIVITY; NEURONS; VAGAL; MECHANISMS; RECEPTORS; DYNAMICS; SYSTEM	Vagus nerve stimulation (VNS) is a neuromodulation therapy for a broad and expanding set of neurologic con-ditions. However, the mechanism through which VNS influences central nervous system circuitry is not well described, limiting therapeutic optimization. VNS leads to widespread brain activation, but the effects on behavior are remarkably specific, indicating plasticity unique to behaviorally engaged neural circuits. To un-derstand how VNS can lead to specific circuit modulation, we leveraged genetic tools including optogenetics and in vivo calcium imaging in mice learning a skilled reach task. We find that VNS enhances skilled motor learning in healthy animals via a cholinergic reinforcement mechanism, producing a rapid consolidation of an expert reach trajectory. In primary motor cortex (M1), VNS drives precise temporal modulation of neurons that respond to behavioral outcome. This suggests that VNS may accelerate motor refinement in M1 via cholinergic signaling, opening new avenues for optimizing VNS to target specific disease-relevant circuitry.	[Bowles, Spencer; Hickman, Jordan; Peng, Xiaoyu; Huang, Rongchen; Washington, Kayden; Donegan, Dane; Welle, Cristin G.] Univ Colorado, Sch Med, Dept Physiol & Biophys, Aurora, CO 80045 USA; [Bowles, Spencer; Peng, Xiaoyu; Huang, Rongchen; Washington, Kayden; Donegan, Dane; Welle, Cristin G.] Univ Colorado, Sch Med, Dept Neurosurg, Aurora, CO 80045 USA; [Williamson, W. Ryan] Univ Colorado, IDEA Core, Sch Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Welle, CG (corresponding author), Univ Colorado, Sch Med, Dept Physiol & Biophys, Aurora, CO 80045 USA.; Welle, CG (corresponding author), Univ Colorado, Sch Med, Dept Neurosurg, Aurora, CO 80045 USA.	cristin.welle@cuanschutz.edu			DARPA Targeted Neuroplasticity Training (TNT) [HR0011-17-2-0051]; Optogenetics and Neural Engineering (ONE) Core at the University of Colorado School of Medicine; School of Medicine; National Institute of Neurological Disorders and Stroke of the National Institutes of Health [P30NS048154]	DARPA Targeted Neuroplasticity Training (TNT); Optogenetics and Neural Engineering (ONE) Core at the University of Colorado School of Medicine; School of Medicine; National Institute of Neurological Disorders and Stroke of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grant from DARPA Targeted Neuroplasticity Training (TNT) : HR0011-17-2-0051. The Optogenetics and Neural Engineering (ONE) Core at the University of Colorado School of Medicine provided engineering support for this research. The IDEA Core provided data pipeline and software support for this research. The Animal Behavior Core provided support for CPP experiments. These cores are part of the NeuroTechnology Center, funded in part by the School of Medicine and by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number P30NS048154. We thank Sean Hansen for technical assistance in Matlab and manuscript proofreading; Eashan Sahai, Nicole Chen, and Melanie Zhou for technical assistance in mice training and behavior video curation; and Benjamin Temple for early technical assistance with optogenetic procedures.	Adler A, 2019, NEURON, V102, P202, DOI 10.1016/j.neuron.2019.01.036; Aronov D, 2008, SCIENCE, V320, P630, DOI 10.1126/science.1155140; Athalye VR, 2020, CURR OPIN NEUROBIOL, V60, P145, DOI 10.1016/j.conb.2019.11.023; Athalye VR, 2018, SCIENCE, V359, P1024, DOI 10.1126/science.aao6058; Athalye VR, 2017, NEURON, V93, P955, DOI 10.1016/j.neuron.2017.01.016; Beaumont E, 2017, AM J PHYSIOL-HEART C, V313, pH354, DOI 10.1152/ajpheart.00070.2017; BENMENACHEM E, 1994, EPILEPSIA, V35, P616, DOI 10.1111/j.1528-1157.1994.tb02482.x; Biane JS, 2019, J NEUROSCI, V39, P4684, DOI 10.1523/JNEUROSCI.3442-17.2019; Borland MS, 2016, BRAIN STIMUL, V9, P117, DOI 10.1016/j.brs.2015.08.018; Bowles S, 2021, J NEURAL ENG, V18, DOI 10.1088/1741-2552/ac1ed1; Cao VY, 2015, NEURON, V86, P1385, DOI 10.1016/j.neuron.2015.05.022; Censor N, 2012, NAT REV NEUROSCI, V13, P658, DOI 10.1038/nrn3315; Chang YC, 2020, BRAIN STIMUL, V13, P1617, DOI 10.1016/j.brs.2020.09.002; CHASE MH, 1966, EXP NEUROL, V16, P36, DOI 10.1016/0014-4886(66)90084-7; Chen SX, 2015, NAT NEUROSCI, V18, P1109, DOI 10.1038/nn.4049; Chen TW, 2013, NATURE, V499, P295, DOI 10.1038/nature12354; Churchland MM, 2012, NATURE, V487, P51, DOI 10.1038/nature11129; Collins L, 2021, CURR BIOL, V31, P2088, DOI 10.1016/j.cub.2021.02.049; Conner JM, 2010, CEREB CORTEX, V20, P2739, DOI 10.1093/cercor/bhq022; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; Dawson J, 2021, LANCET, V397, P1545, DOI 10.1016/S0140-6736(21)00475-X; Dayan P, 2002, NEURON, V36, P285, DOI 10.1016/S0896-6273(02)00963-7; DETARI L, 1983, ACTA PHYSIOL HUNG, V61, P147; Dhawale AK, 2019, CURR BIOL, V29, P3551, DOI 10.1016/j.cub.2019.08.052; Dhawale AK, 2017, ANNU REV NEUROSCI, V40, P479, DOI 10.1146/annurev-neuro-072116-031548; Do JP, 2016, ELIFE, V5, DOI 10.7554/eLife.13214; DONOGHUE JP, 1994, J CLIN NEUROPHYSIOL, V11, P382; Doya K, 1999, NEURAL NETWORKS, V12, P961, DOI 10.1016/S0893-6080(99)00046-5; Eggermann E, 2014, CELL REP, V9, P1654, DOI 10.1016/j.celrep.2014.11.005; Engineer ND, 2011, NATURE, V470, P101, DOI 10.1038/nature09656; Farrand AQ, 2017, BRAIN STIMUL, V10, P1045, DOI 10.1016/j.brs.2017.08.008; Feldman DE, 2012, NEURON, V75, P556, DOI 10.1016/j.neuron.2012.08.001; Fraschini M, 2013, NEUROSCI LETT, V536, P14, DOI 10.1016/j.neulet.2012.12.044; Ganzer PD, 2018, ELIFE, V7, DOI 10.7554/eLife.32058; Garst-Orozco J, 2014, ELIFE, V3, DOI 10.7554/eLife.03697; GEORGE R, 1995, NEUROLOGY, V45, P224, DOI 10.1212/wnl.45.2.224; Gielow MR, 2017, CELL REP, V18, P1817, DOI 10.1016/j.celrep.2017.01.060; Groves DA, 2005, NEUROSCI BIOBEHAV R, V29, P493, DOI 10.1016/j.neubiorev.2005.01.004; Groves DA, 2005, NEUROSCI LETT, V379, P174, DOI 10.1016/j.neulet.2004.12.055; Guo JZ, 2015, ELIFE, V4, DOI 10.7554/eLife.10774; Guo W, 2019, NEURON, V103, P1164, DOI 10.1016/j.neuron.2019.06.024; Han WF, 2018, CELL, V175, P665, DOI [10.1016/j.cell.2018.10.018, 10.1016/j.cell.2018.08.049]; Hangya B, 2015, CELL, V162, P1155, DOI 10.1016/j.cell.2015.07.057; Heffley W, 2018, NAT NEUROSCI, V21, P1431, DOI 10.1038/s41593-018-0228-8; Hosp JA, 2011, J NEUROSCI, V31, P2481, DOI 10.1523/JNEUROSCI.5411-10.2011; Hulsey DR, 2019, EXP NEUROL, V320, DOI 10.1016/j.expneurol.2019.112975; Hulsey DR, 2017, EXP NEUROL, V289, P21, DOI 10.1016/j.expneurol.2016.12.005; Hulsey DR, 2016, BRAIN STIMUL, V9, P174, DOI 10.1016/j.brs.2015.12.007; Jiang L, 2016, NEURON, V90, P1057, DOI 10.1016/j.neuron.2016.04.028; Jimenez JC, 2018, NEURON, V97, P670, DOI 10.1016/j.neuron.2018.01.016; Kang JI, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00172; Kawai R, 2015, NEURON, V86, P800, DOI 10.1016/j.neuron.2015.03.024; Kimberley TJ, 2018, STROKE, V49, P2789, DOI 10.1161/STROKEAHA.118.022279; Krahl SE, 1998, EPILEPSIA, V39, P709, DOI 10.1111/j.1528-1157.1998.tb01155.x; Kucinski A, 2019, BEHAV NEUROSCI, V133, P121, DOI 10.1037/bne0000290; Lai J, 2021, ENEURO, V8, DOI 10.1523/ENEURO.0522-20.2021; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Leong YC, 2017, NEURON, V93, P451, DOI 10.1016/j.neuron.2016.12.040; Levy S, 2020, NEURON, V107, P954, DOI 10.1016/j.neuron.2020.06.006; Li Q, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15834; Lima SQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006099; Lin SC, 2008, NEURON, V59, P138, DOI 10.1016/j.neuron.2008.04.031; Luft AR, 2009, INT J DEV NEUROSCI, V27, P415, DOI 10.1016/j.ijdevneu.2009.05.004; Makino H, 2016, NEURON, V92, P705, DOI 10.1016/j.neuron.2016.10.029; Mawase F, 2017, J NEUROSCI, V37, P2673, DOI 10.1523/JNEUROSCI.3303-16.2017; Meyers EC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13695-0; Mughrabi IT, 2021, ELIFE, V10, DOI 10.7554/eLife.61270; Musall S, 2019, CURR OPIN NEUROBIOL, V58, P229, DOI 10.1016/j.conb.2019.09.011; Narayanan JT, 2002, EPILEPSIA, V43, P1509, DOI 10.1046/j.1528-1157.2002.16102.x; Neuser MP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17344-9; Oby ER, 2019, P NATL ACAD SCI USA, V116, P15210, DOI 10.1073/pnas.1820296116; Padmashri R, 2019, NEUROSCI LETT, V709, DOI 10.1016/j.neulet.2019.134371; Pekny SE, 2015, J NEUROSCI, V35, P4015, DOI 10.1523/JNEUROSCI.3244-14.2015; Pelot NA, 2017, J NEURAL ENG, V14, DOI 10.1088/1741-2552/aa6a5f; Perez SM, 2014, J NEUROSCI, V34, P9261, DOI 10.1523/JNEUROSCI.0588-14.2014; Peters AJ, 2017, NAT NEUROSCI, V20, P1133, DOI 10.1038/nn.4596; Peters AJ, 2014, NATURE, V510, P263, DOI 10.1038/nature13235; Pnevmatikakis EA, 2017, J NEUROSCI METH, V291, P83, DOI 10.1016/j.jneumeth.2017.07.031; Porter BA, 2012, CEREB CORTEX, V22, P2365, DOI 10.1093/cercor/bhr316; Pruitt DT, 2016, J NEUROTRAUM, V33, P871, DOI 10.1089/neu.2015.3972; Prus AJ, 2009, FRONT NEUROSCI, P59; Puzerey PA, 2018, J NEUROPHYSIOL, V120, P1796, DOI 10.1152/jn.00078.2018; Ramanathan D, 2009, J NEUROSCI, V29, P5992, DOI 10.1523/JNEUROSCI.0230-09.2009; Ramanathan DS, 2015, J NEUROPHYSIOL, V113, P1585, DOI 10.1152/jn.00408.2014; Redgrave JN, 2018, J STROKE CEREBROVASC, V27, P1998, DOI 10.1016/j.jstrokecerebrovasdis.2018.02.056; Reed A, 2011, NEURON, V70, P121, DOI 10.1016/j.neuron.2011.02.038; Reimer J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13289; Ren C, 2022, NEURON, V110, P2334, DOI 10.1016/j.neuron.2022.04.031; RIEKKINEN P, 1990, PHARMACOL BIOCHEM BE, V37, P405, DOI 10.1016/0091-3057(90)90004-2; RIEKKINEN P, 1993, J PHARMACOL EXP THER, V267, P1484; Rossi J, 2011, CELL METAB, V13, P195, DOI 10.1016/j.cmet.2011.01.010; Rush AJ, 2005, BIOL PSYCHIAT, V58, P347, DOI 10.1016/j.biopsych.2005.05.025; Sanes JN, 2000, ANNU REV NEUROSCI, V23, P393, DOI 10.1146/annurev.neuro.23.1.393; Sawaki L, 2002, J NEUROPHYSIOL, V87, P166, DOI 10.1152/jn.00279.2001; Schmitzer-Torbert N, 2005, NEUROSCIENCE, V131, P1, DOI 10.1016/j.neuroscience.2004.09.066; Schwarz LA, 2015, CURR BIOL, V25, pR1051, DOI 10.1016/j.cub.2015.09.039; Scott SH, 2016, TRENDS NEUROSCI, V39, P512, DOI 10.1016/j.tins.2016.06.001; Settell ML, 2020, J NEURAL ENG, V17, DOI 10.1088/1741-2552/ab7ad4; Sheintuch L, 2017, CELL REP, V21, P1102, DOI 10.1016/j.celrep.2017.10.013; Shi C, 2013, NEUROL RES, V35, P263, DOI 10.1179/1743132813Y.0000000167; Shinoe T, 2005, J NEUROSCI, V25, P11194, DOI 10.1523/JNEUROSCI.2338-05.2005; Shmuelof L, 2012, J NEUROPHYSIOL, V108, P578, DOI 10.1152/jn.00856.2011; Smiley JF, 1999, NEUROSCIENCE, V93, P817, DOI 10.1016/S0306-4522(99)00116-5; Tu G, 2022, J NEUROSCI, V42, P4202, DOI 10.1523/JNEUROSCI.1969-21.2022; Tyler R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12178-w; Uehara S, 2019, J NEUROPHYSIOL, V122, P797, DOI 10.1152/jn.00390.2018; Usami K, 2013, IEEE ENG MED BIO, P5348, DOI 10.1109/EMBC.2013.6610757; Weber I, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcab039; Whishaw Ian Q, 2008, J Vis Exp, DOI 10.3791/816; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805; Wickens JR, 2003, CURR OPIN NEUROBIOL, V13, P685, DOI 10.1016/j.conb.2003.10.013; Wolpert DM, 2011, NAT REV NEUROSCI, V12, P739, DOI 10.1038/nrn3112; Wu DD, 2020, NEURAL PLAST, V2020, DOI 10.1155/2020/8841752; Wu HG, 2014, NAT NEUROSCI, V17, P312, DOI 10.1038/nn.3616; Zaborszky L, 2004, J NEUROCYTOL, V33, P265, DOI 10.1023/B:NEUR.0000044188.67442.9d; Zhang KN, 2019, CURR BIOL, V29, P134, DOI 10.1016/j.cub.2018.11.012; Zhao SL, 2011, NAT METHODS, V8, P745, DOI 10.1038/nmeth.1668; Zhou P, 2018, ELIFE, V7, DOI 10.7554/eLife.28728	118	1	1	11	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	SEP 7	2022	110	17					2867	+		10.1016/j.neuron.2022.06.017	http://dx.doi.org/10.1016/j.neuron.2022.06.017			27	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	4X8ZH	35858623				2023-01-03	WOS:000861125500003
J	[Anonymous]				[Anonymous]			Phage therapy suppresses gut inflammation in IBD	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	7	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2022	40	9					1327	1327		10.1038/s41587-022-01477-x	http://dx.doi.org/10.1038/s41587-022-01477-x			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	4L8RE	36085511				2023-01-03	WOS:000852896400014
J	Bryushkova, EA; Skatova, VD; Mutovina, ZY; Zagrebneva, AI; Fomina, DS; Kruglova, TS; Akopyan, AA; Strazhesko, ID; Lukyanov, SA; Tkacheva, ON; Lysenko, MA; Chudakov, DM				Bryushkova, Ekaterina A.; Skatova, Valeria D.; Mutovina, Zinaida Y.; Zagrebneva, Alena, I; Fomina, Daria S.; Kruglova, Tatyana S.; Akopyan, Anna A.; Strazhesko, Irina D.; Lukyanov, Sergey A.; Tkacheva, Olga N.; Lysenko, Maryana A.; Chudakov, Dmitry M.			Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study	PLOS ONE			English	Article							EARLY WARNING SCORE; IL-17A PRODUCTION; SAFETY; INFECTION; EFFICACY; CELLS; INFLAMMATION; METAANALYSIS	Objective The aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive therapy including anti-IL-17A (netakimab), anti-IL-6R (tocilizumab), or JAK1/JAK2 inhibitor (baricitinib) or with a standard-of-care therapy alone. Methods The observational cohort study included 154 adults hospitalized between February and August, 2020 with RT-PCR-confirmed SARS-CoV-2 with National Early Warning Score2 (NEWS2) < 7 and C-reactive protein (CRP) levels <= 140 mg/L on the day of the start of the therapy or observation. Patients were divided into the following groups: I) 4 mg baricitinib, 1 or 2 times a day for an average of 5 days (n = 38); II) 120 mg netakimab, one dose (n = 48); III) 400 mg tocilizumab, one dose (n = 34), IV) SOC only: hydroxychloroquine, antiviral, antibacterial, anticoagulant, and dexamethasone (n = 34). Results CRP levels significantly decreased after 72 h in the tocilizumab (p = 1 x 10(-5)) and netakimab (p = 8 x 10(-4)) groups and remained low after 120 h. The effect was stronger with tocilizumab compared to other groups (p = 0.028). A significant decrease in lactate dehydrogenase (LDH) levels was observed 72 h after netakimab therapy (p = 0.029). NEWS2 scores significantly improved 72 h after tocilizumab (p = 6.8 x 10(-5)) and netakimab (p = 0.01) therapy, and 120 h after the start of tocilizumab (p = 8.6 x 10(-5)), netakimab (p = 0.001), or baricitinib (p = 4.6 x 10(-4)) therapy, but not in the SOC group. Blood neutrophil counts (p = 6.4 x 10(-4)) and neutrophil-to-lymphocyte ratios (p = 0.006) significantly increased 72 h after netakimab therapy and remained high after 120 h. The percentage of patients discharged 5-7 days after the start of therapy was higher in the tocilizumab (44.1%) and netakimab (41.7%) groups than in the baricitinib (31.6%) and SOC (23.5%) groups. Compared to SOC (3 of the 34; 8.8%), mortality was lower in netakimab (0 of the 48; 0%, RR = 0.1 (95% CI: 0.0054 to 1.91)), tocilizumab (0 of the 34; 0%, RR = 0.14 (95% CI: 0.0077 to 2.67)), and baricitinib (1 of the 38; 2.6%, RR = 0.3 (95% CI: 0.033 to 2.73)) groups. Conclusion In hospitalized patients with mild-to-moderate COVID-19, the combination of SOC with anti-IL-17A or anti-IL-6R therapy were superior or comparable to the combination with JAK1/JAK2 inhibitor, and all three were superior to SOC alone. Whereas previous studies did not demonstrate significant benefit of anti-IL-17A therapy for severe COVID-19, our data suggest that such therapy could be a rational choice for mild-to-moderate disease, considering the generally high safety profile of IL-17A blockers. The significant increase in blood neutrophil count in the netakimab group may reflect efflux of neutrophils from inflamed tissues. We therefore hypothesize that neutrophil count and neutrophil-to-lymphocyte ratio could serve as markers of therapeutic efficiency for IL-17A-blocking antibodies in the context of active inflammation.	[Bryushkova, Ekaterina A.; Skatova, Valeria D.; Akopyan, Anna A.; Strazhesko, Irina D.; Lukyanov, Sergey A.; Tkacheva, Olga N.; Lysenko, Maryana A.; Chudakov, Dmitry M.] Pirogov Russian Natl Res Med Univ, Moscow, Russia; [Bryushkova, Ekaterina A.; Skatova, Valeria D.; Chudakov, Dmitry M.] Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow, Russia; [Bryushkova, Ekaterina A.] Lomonosov Moscow State Univ, Moscow, Russia; [Mutovina, Zinaida Y.; Zagrebneva, Alena, I; Fomina, Daria S.; Kruglova, Tatyana S.; Lysenko, Maryana A.] City Clin Hosp 52 Moscow, Healthcare Dept, Moscow, Russia; [Fomina, Daria S.] IM Sechenov First Moscow State Med Univ, Minist Hlth Russian Federat, Moscow, Russia	Pirogov Russian National Research Medical University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Lomonosov Moscow State University; Ministry of Health of the Russian Federation; Sechenov First Moscow State Medical University	Chudakov, DM (corresponding author), Pirogov Russian Natl Res Med Univ, Moscow, Russia.; Chudakov, DM (corresponding author), Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow, Russia.	chudakovdm@gmail.com	Lukyanov, Sergey/HIU-0305-2022; Chudakov, Dmitriy M/G-7741-2014; Bryushkova, Ekaterina/S-4442-2017	Chudakov, Dmitriy M/0000-0003-0430-790X; Bryushkova, Ekaterina/0000-0002-5227-114X	Ministry of Science and Higher Education of the Russian Federation [075-15-2020-807]	Ministry of Science and Higher Education of the Russian Federation	Supported by grant of the Ministry of Science and Higher Education of the Russian Federation. 075-15-2020-807.	Avdeev SN, 2021, CYTOKINE, V146, DOI 10.1016/j.cyto.2021.155627; Bujanda IL, 2021, TRIALS, V22, DOI 10.1186/s13063-020-04999-4; Cantini F, 2020, DRUGS, V80, P1929, DOI 10.1007/s40265-020-01421-w; Charan J, 2021, EXPERT OPIN DRUG SAF, V20, P1125, DOI 10.1080/14740338.2021.1946513; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; De Biasi S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17292-4; Ding Q, 2017, ONCOTARGET, V8, P93704, DOI 10.18632/oncotarget.21474; Gatti M, 2021, BRIT J CLIN PHARMACO, V87, P1533, DOI 10.1111/bcp.14459; Ghazavi A, 2021, CYTOKINE, V137, DOI 10.1016/j.cyto.2020.155323; Guabiraba R, 2013, EUR J IMMUNOL, V43, P1529, DOI 10.1002/eji.201243229; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Gupta S, 2022, J INVEST MED, V70, P55, DOI 10.1136/jim-2021-002001; Hennigan Stephanie, 2008, Ther Clin Risk Manag, V4, P767; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jorgensen SCJ, 2020, PHARMACOTHERAPY, V40, P843, DOI 10.1002/phar.2438; Keystone EC, 2018, J RHEUMATOL, V45, P14, DOI 10.3899/jrheum.161161; [Коротаева Т.В. Korotaeva T.V.], 2020, [Научно-практическая ревматология, Scientific and Practical Rheumatology, Nauchno-prakticheskaya revmatologiya], V58, P480, DOI 10.47360/1995-4484-2020-480-488; Kostakis I, 2021, RESUSCITATION, V159, P150, DOI 10.1016/j.resuscitation.2020.10.039; Kubo S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01510; Lan SH, 2022, EXPERT REV ANTI-INFE, V20, P773, DOI 10.1080/14787210.2022.2004120; Leisman DE, 2020, LANCET RESP MED, V8, P1233, DOI 10.1016/S2213-2600(20)30404-5; Li JT, 2015, J IMMUNOL, V195, P87, DOI 10.4049/jimmunol.1500054; Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025; Marconi VC, 2021, LANCET RESP MED, V9, P1407, DOI 10.1016/S2213-2600(21)00331-3; Martins-Filho PR, 2021, LANCET REG HEALTH-AM, V2, DOI 10.1016/j.lana.2021.100062; Martonik D, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061550; Maslennikov R, 2021, EUR CYTOKINE NETW, V32, P8, DOI 10.1684/ecn.2021.0463; [Мазуров В.И. Mazurov V.I.], 2020, [Современная ревматология, Sovremennaya revmatologiya], V14, P39, DOI 10.14412/1996-7012-2020-4-39-49; McElvaney OJ, 2020, AM J RESP CRIT CARE, V202, P812, DOI 10.1164/rccm.202005-1583OC; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Mikacenic C, 2016, CRIT CARE MED, V44, P496, DOI 10.1097/CCM.0000000000001409; Ministry of Health of Russian Federation, INT GUID PREV DIAGN; Myrstad M, 2020, SCAND J TRAUMA RESUS, V28, DOI 10.1186/s13049-020-00764-3; Neubauer A, 2021, LEUKEMIA, V35, P2917, DOI 10.1038/s41375-021-01374-3; Ogura H, 2008, IMMUNITY, V29, P628, DOI 10.1016/j.immuni.2008.07.018; Pelaia C, 2020, THER ADV RESPIR DIS, V14, DOI 10.1177/1753466620933508; Pettit NN, 2021, J MED VIROL, V93, P1459, DOI 10.1002/jmv.26429; Puig L, 2021, DERMATOLOGY THER, V11, P1319, DOI 10.1007/s13555-021-00554-4; Resende GG, 2022, INFECT DIS-NOR, V54, P591, DOI 10.1080/23744235.2022.2066171; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Rubbert-Roth A, 2018, RHEUMATOL THER, V5, P21, DOI 10.1007/s40744-018-0102-x; Samaee H, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107018; Santa Cruz A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.613422; Schett G, 2020, NAT REV RHEUMATOL, V16, P465, DOI 10.1038/s41584-020-0451-z; Sheppard M, 2017, HUM VACC IMMUNOTHER, V13, P1972, DOI 10.1080/21645515.2017.1316909; Shi JG, 2014, J CLIN PHARMACOL, V54, P1354, DOI 10.1002/jcph.354; Si S, 2020, THER CLIN RISK MANAG, V16, P705, DOI 10.2147/TCRM.S223468; Smith GB, 2019, CLIN MED, V19, P260, DOI 10.7861/clinmedicine.19-3-260; Stebbing J, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe4724; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Szabo PA, 2017, J IMMUNOL, V198, P2805, DOI 10.4049/jimmunol.1601366; Tantibanchachai L., 2021, FDA NEWSROOM PRESS A; WHO Media inquiries News release, 2021, WHO NEWS 0706; Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005; Xie MM, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181987; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yang L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00679-0; Yin YF, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02208-w; Zhang XH, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106749; Zhou X, 2016, MUCOSAL IMMUNOL, V9, P610, DOI 10.1038/mi.2015.85	64	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2022	17	8							e0273340	10.1371/journal.pone.0273340	http://dx.doi.org/10.1371/journal.pone.0273340			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4M1JC	36001576	gold, Green Published			2023-01-03	WOS:000853083500065
J	Yi, Y; Park, YH				Yi, YuMi; Park, Yeon-Hwan			Structural equation model of the relationship between functional ability, mental health, and quality of life in older adults living alone	PLOS ONE			English	Article							BODY-MASS INDEX; COMMUNITY; ARRANGEMENTS; LONELINESS; MOBILITY; PARTICIPATION; DEFINITIONS; PREFERENCES; DISABILITY; PEOPLE	AimsLiving alone, a reality in an increasing number of older adults recently, is a risk factor for low quality of life. This study identified the predictors of quality of life in older adults living alone based on mental health and the International Classification of Functioning, Disability, and Health. MethodsThis secondary data analysis used information from the 2018 Assessing the Requirements of Customized Health Care and Daily Living Support Services survey (N = 1,022), collected from adults aged >= 65 living alone in Siheung City, South Korea, from August to October 2018. The exogenous variables were body functions (hand grip strength, timed "up and go" test score, and body mass index), daily living activities (Korean Instrumental Activities of the Daily Living Scale), social activity participation (social activity engagement, neighbor contacts, and family contacts), and participation in economic activity (frequency). The endogenous variables were mental health (Geriatric Depression Scale Short Form-Korean Version and UCLA Loneliness Scale) and quality of life (EuroQoL-5 Dimension-3 Level and EuroQoL-Visual Analog Scale). ResultsAfter modifying the hypothetical model, which had failed to satisfy the recommended fitness level, the (modified) model had good fitness indices Q (CMIN / df) 2.90, GFI 1, AGFI 1, RMSEA 0.04, CFI 0.90 and PCFI 0.53. Of the nine pathways of the modified model, five were statistically significant. Quality of life was affected by body functions, daily living activities, social activity participation, and mental health. These variables explained 68.2% of the factors affecting quality of life. ConclusionsBy highlighting the role of mental health, this model provides a useful framework for improving the quality of life of older adults who live alone and function at various levels in the community. Focusing on advancing mental health through body functions, daily living activities, and social activity participation can improve quality of life.	[Yi, YuMi] Dong Eui Univ, Coll Nat Sci, Dept Nursing, Busan, South Korea; [Park, Yeon-Hwan] Seoul Natl Univ, Res Inst Nursing Sci, Coll Nursing, Seoul, South Korea; [Park, Yeon-Hwan] Seoul Natl Univ, Coll Nursing, Seoul, South Korea	Dong-Eui University; Seoul National University (SNU); Seoul National University (SNU)	Park, YH (corresponding author), Seoul Natl Univ, Res Inst Nursing Sci, Coll Nursing, Seoul, South Korea.; Park, YH (corresponding author), Seoul Natl Univ, Coll Nursing, Seoul, South Korea.	hanipyh@snu.ac.kr		Park, Yeon-Hwan/0000-0002-5236-6683	Ministry of Health & Welfare, Republic of Korea [HI18C1284]	Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	We would like to thank the older adults who participated in this study. We also gratefully acknowledge the help of the Siheung City Public Health Center, Director Park Munghee, and Mrs. Park Kyungwon for their cooperation with the progress of this study.	Bae BR, 2017, STRUCTURAL EQUATION; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Bilotta C, 2012, HEALTH SOC CARE COMM, V20, P32, DOI 10.1111/j.1365-2524.2011.01011.x; Birman MV, 2016, J HAND SURG-AM, V41, P133, DOI 10.1016/j.jhsa.2015.11.008; Bowling A., 2005, AGEING WELL QUALITY; Bowling Ann, 2009, Curr Gerontol Geriatr Res, V2009, P298950, DOI 10.1155/2009/298950; Bucholz EM, 2012, ARCH INTERN MED, V172, P1084, DOI 10.1001/archinternmed.2012.2649; Chang-Won W., 2002, J KOREAN GERIATRICS, V6, P107; Chen LK, 2014, J AM MED DIR ASSOC, V15, P95, DOI 10.1016/j.jamda.2013.11.025; Cho Sung Hui, 2016, [Korean Journal of Gerontological Social Welfare, 노인복지연구], V71, P35; Covinsky KE, 2013, JAMA INTERN MED, V173, P321, DOI 10.1001/jamainternmed.2013.1617; Dale B, 2012, INT J QUAL STUD HEAL, V7, DOI 10.3402/qhw.v7i0.18456; Davison KK, 2002, J AM GERIATR SOC, V50, P1802, DOI 10.1046/j.1532-5415.2002.50508.x; Depp CA, 2006, AM J GERIAT PSYCHIAT, V14, P6, DOI 10.1097/01.JGP.0000192501.03069.bc; Di Gessa G, 2014, J EPIDEMIOL COMMUN H, V68, P261, DOI 10.1136/jech-2013-202820; Do HK, 2015, ANN GERIATR MED RES, V19, P61, DOI 10.4235/jkgs.2015.19.2.61; Ennis SK, 2014, J GEN INTERN MED, V29, P1451, DOI 10.1007/s11606-014-2904-z; Eun Lee Si, 2016, [Korean Journal of Adult Nursing, 성인간호학회지], V28, P659, DOI 10.7475/kjan.2016.28.6.659; Fujikawa M., 2013, THESIS U WISCONSIN M; Gaymu J, 2008, EUR J AGEING, V5, P5, DOI 10.1007/s10433-008-0072-x; Geirsdottir OG, 2012, J NUTR HEALTH AGING, V16, P62, DOI 10.1007/s12603-011-0076-7; Gorgon E, 2007, PHYSIOTHER RES INT, V12, P72, DOI 10.1002/pri.348; Granic A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149699; Greenfield EA, 2011, J APPL GERONTOL, V30, P524, DOI 10.1177/0733464810364985; Han Sam-Sung, 2012, [The Korean Journal of Health Service Management, 보건의료산업학회지], V6, P29; Henning-Smith C, 2016, J APPL GERONTOL, V35, P39, DOI 10.1177/0733464814530805; HYUN MOON JI, 2018, [The Journal of the Korea Contents Association, 한국콘텐츠학회 논문지], V18, P44, DOI 10.5392/JKCA.2018.18.01.044; Jin-Gu Kim., 2011, [Korean Journal of Gerontological Social Welfare, 노인복지연구], V51, P35; Kang JS, 2010, KOREAN J GERONTOLOGI, V48, P279, DOI [10.21194/kjgsw..48.201006.279, DOI 10.21194/KJGSW..48.201006.279]; Kee B.-S., 1996, J KOREAN NEUROPSYCHI, V35, P298; Kim gs, 2010, AMOS 18 0 ANAL STRUC; Kim Hyunju, 2013, [Korean Journal of Gerontological Social Welfare, 노인복지연구], V60, P97; Kim J-H, 2007, KOREA J POP STUD, V30, P57; Kim Jae Jun, 2017, [Journal of the Korean Society of Biological Therapies in Psychiatry, 생물치료정신의학], V23, P164, DOI 10.22802/jksbtp.2017.23.3.164; Kim MY., 2015, J DIGIT CONVERG, V13, P25, DOI [10.14400/JDC.2015.13.4.25, DOI 10.14400/JDC.2015.13.4.25]; Kim O.S., 1997, J KOREAN ACAD NURS, V27, P871, DOI [DOI 10.4040/JNAS.1997.27.4.871, 10.4040/jnas.1997.27.4.871]; 신성일, 2013, [Korea Journal of Counseling, 상담학연구], V14, P3673; Ko H, 2019, ARCH GERONTOL GERIAT, V83, P239, DOI 10.1016/j.archger.2019.05.009; Kwak Y, 2017, IRAN J PUBLIC HEALTH, V46, P1512; Kwon OK, 2016, P KOREA GERONTOLOGIC, P1; Lau DT, 2009, AM J PUBLIC HEALTH, V99, P1315, DOI 10.2105/AJPH.2008.151142; Lee Hyunji, 2012, [Journal of community welfare, 한국지역사회복지학], V42, P157; Levasseur M, 2010, SOC SCI MED, V71, P2141, DOI 10.1016/j.socscimed.2010.09.041; Liao KH, 2014, INT J OCCUP SAF ERGO, V20, P77, DOI 10.1080/10803548.2014.11077039; Lim Lena L, 2011, Curr Gerontol Geriatr Res, V2011, P673181, DOI 10.1155/2011/673181; Lin PC, 2008, J CLIN NURS, V17, P1610, DOI 10.1111/j.1365-2702.2007.02081.x; Lopes MJ, 2013, REV LAT-AM ENFERM, V21, P52, DOI 10.1590/S0104-11692013000700008; Luna-Heredia E, 2005, CLIN NUTR, V24, P250, DOI 10.1016/j.clnu.2004.10.007; Manacy P., 2008, THESIS FLORIDA STATE; McInnis-Dittrich K., 2014, SOCIAL WORK OLDER AD, V4th ed; McMunn A, 2009, AGEING SOC, V29, P765, DOI 10.1017/S0144686X08008350; Ministry of Health and Welfare Korea Institute for Health and Social Affairs, 2019, 2018 COMPR SURV CHIL; Nakahara J., 2013, INT J PSYCHOL RES, V5, P112, DOI [10.5539/ijps.v5n1p112, DOI 10.5539/IJPS.V5N1P112]; Oh BT., 2017, KOREAN J CLIN GERI, V18, P22, DOI [DOI 10.15656/KJCG.2017.18.1.22, 10.15656/kjcg.2017.18.1.22]; Pain K, 1998, J REHABIL, V64, P5; Park Jeong-Mo, 2016, [Journal of Korean Public Health Nursing, 한국보건간호학회지], V30, P337; Park S-H, 2014, J OCCUP THER AGED DE, V8, P43; Park SY., 2009, J KOREAN PUBLIC HLTH, V23, P78; Passier PECA, 2013, QUAL LIFE RES, V22, P1027, DOI 10.1007/s11136-012-0236-1; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Power JEM, 2019, PSYCHOL AGING, V34, P152, DOI 10.1037/pag0000287; Ran Park Ae, 2017, [The Journal of the Korea Contents Association, 한국콘텐츠학회 논문지], V17, P212, DOI 10.5392/JKCA.2017.17.03.212; Ratcliffe J, 2017, QUAL LIFE RES, V26, P299, DOI 10.1007/s11136-016-1391-6; Rivers CS, 2018, ARCH PHYS MED REHAB, V99, P443, DOI 10.1016/j.apmr.2017.06.012; Rose DJ, 2002, J AGING PHYS ACTIV, V10, P466, DOI 10.1123/japa.10.4.466; RUCHLIN HS, 1991, AM J PUBLIC HEALTH, V81, P498, DOI 10.2105/AJPH.81.4.498; RUSSELL D, 1980, J PERS SOC PSYCHOL, V39, P472, DOI 10.1037/0022-3514.39.3.472; Russell D, 2009, J HEALTH SOC BEHAV, V50, P460, DOI 10.1177/002214650905000406; Russell D, 2009, J GERONTOL B-PSYCHOL, V64, P95, DOI 10.1093/geronb/gbn002; Saito Emiko, 2005, Nurs Health Sci, V7, P29; Scharlach A, 2012, GERONTOLOGIST, V52, P418, DOI 10.1093/geront/gnr083; Sereny M, 2011, RES AGING, V33, P172, DOI 10.1177/0164027510392387; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; So H, 2011, J KOREAN ACAD NURS, V41, P481, DOI 10.4040/jkan.2011.41.4.481; Soo Kim Hyang, 2017, [Journal of the Korea Convergence Society, 한국융합학회논문지], V8, P207, DOI 10.15207/JKCS.2017.8.7.207; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; SUH，Soonrim, 2014, [Journal of the Korea Gerontological Society, 한국노년학], V34, P705; Suk-Jung Han，, 2014, [Journal of Korean Public Health Nursing, 한국보건간호학회지], V28, P333; Sung Soonchang, 2014, [The Korean Society of Living Environmental System, 한국생활환경학회지], V21, P223; Tomioka K, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0491-7; United Nations N. Y., 2017, POPULATION; van Roekel EH, 2014, CANCER EPIDEM BIOMAR, V23, P1394, DOI 10.1158/1055-9965.EPI-13-1144; WHO, 2015, INT CLASS FUNCT DIS; WHOQoL Group, 1994, QUALITY LIFE ASSESSM, P41; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Yoon Soonduck, 2004, [Journal of the Korea Gerontological Society, 한국노년학], V24, P57; Yoshimitsu Koji, 2017, BMC Res Notes, V10, P512, DOI 10.1186/s13104-017-2836-x; Zali M, 2017, EDUC GERONTOL, V43, P582, DOI 10.1080/03601277.2017.1376450; 이소정, 2016, [Social Welfare Policy, 사회복지정책], V43, P165; 주경희, 2011, [Korean Journal of Social Welfare Studies, 사회복지연구], V42, P5; 박경혜, 2006, [Journal of the Korea Gerontological Society, 한국노년학], V26, P275	91	0	0	6	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	8								10.1371/journal.pone.0269003	http://dx.doi.org/10.1371/journal.pone.0269003			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3S0RT	35921330	Green Published, gold			2023-01-03	WOS:000839311900009
J	Gedfie, S; Getawa, S; Kassahun, W; Gashaye, KT; Melku, M				Gedfie, Solomon; Getawa, Solomon; Kassahun, Woldeteklehaymanot; Gashaye, Kiros Terefe; Melku, Mulugeta			Hematological parameters of reproductive-age women using hormonal contraceptives at University of Gondar Comprehensive Specialized Referral Hospital, Northwest Ethiopia: A comparative cross-sectional study	PLOS ONE			English	Article							ORAL-CONTRACEPTIVES; FOLATE STATUS; DESOGESTREL	Background More than one-third of reproductive aged women in Ethiopia use hormonal contraceptives to prevent conception. The present study aimed to compare the hematological parameters of reproductive-age women taking hormonal contraceptives at the University of Gondar Comprehensive Specialized Referral Hospital, Northwest Ethiopia in 2021. Methods A comparative cross-sectional study was conducted from April to June 2021. A total of 240 study participants were recruited by using a consecutive sampling technique. Data on socio-demographic variables and clinical data were collected through face-to-face interviews using a structured questionnaire and medical record reviews, respectively. Three milliliter venous blood was collected for complete blood count analysis using Unicel DxH 800 coulter hematology analyzer. Data was entered into Epi-data 4.4.3.1 version then exported to IBM SPSS v25 for analysis. Kruskal-Wallis H, Dunn-Bonferroni pairwise comparison test, and Spearman's correlation analysis were used for inferential statistics. P<0.05 were considered statistically significant. Result The median and interquartile range of platelet count among combined oral contraceptive users was 285(238-332) which is significantly higher than that of depot medroxyprogesterone acetate users 246(220-226) (p = 0.010), implant user 247(221-297) (p = 0.034), and controls 256(224-278) (p = 0.015). The result also showed long-term use of implant negatively correlated with red blood cell count (p = 0.033). Conclusion This finding concludes that combined oral contraceptive users had a higher platelet counts than controls while long-term use of implants can result in low red blood cells count. Therefore, a baseline evaluation of complete blood count in women desiring contraceptive methods would also be recommended.	[Gedfie, Solomon; Kassahun, Woldeteklehaymanot] Woldia Univ, Dept Med Lab Sci, Coll Med & Hlth Sci, Woldia, Ethiopia; [Getawa, Solomon; Melku, Mulugeta] Univ Gondar, Sch Biomed & Lab Sci, Dept Hematol & Immunohematol, Gondar, Ethiopia; [Gashaye, Kiros Terefe] Univ Gondar, Sch Med, Dept Obstet & Gynecol, Coll Med & Hlth Sci, Gondar, Ethiopia	University of Gondar; University of Gondar	Kassahun, W (corresponding author), Woldia Univ, Dept Med Lab Sci, Coll Med & Hlth Sci, Woldia, Ethiopia.	teklu1142@gmail.com		Getawa, Solomon/0000-0003-2670-9547; Kassahun, Woldeteklehaymanot/0000-0001-5769-0944; Gedfie, Solomon/0000-0001-9964-1964				Abdalla T., 2012, KHARTOUM MED J, V1; Adejumo EN., 2016, J BIOSCIENCES MED, V4, P107; Afsar Nasir Ali, 2005, J Ayub Med Coll Abbottabad, V17, P21; Ahmed YMAA, 2018, EFFECT ORAL CONTRACE; Aitazaz F., 2016, PJP, V12, P10; Akinloye O, 2011, W INDIAN MED J, V60, P308; Al-Chalaby SS., 2006, MEDICAL J TIKRIT U, V1, P56; Al-Zayadi T., 2018, J CHEM BIOPHY SCI SE, P8; Andres E, 2004, EUR J OBSTET GYN R B, V115, P241, DOI 10.1016/S0301-2115(03)00197-0; Balogun OR, 2016, INT J HEALTH SCI-IJH, V10, P499; Bellizzi S, 2018, CONTRACEPTION, V97, P236, DOI 10.1016/j.contraception.2017.11.001; Blumenthal PD, 2008, OBSTET GYNECOL, V112, P670, DOI 10.1097/AOG.0b013e31818425b7; Carr J, 2012, LABMEDICINE, V43, P157, DOI 10.1309/LMEJRJLI8L5ZCDWP; Coffie S., 2020, ASIAN HEMATOLOGY RES, V3, P1; Egbunah M., 2018, JMSCR, V6, P73; Haider S, 2007, CLIN OBSTET GYNECOL, V50, P898, DOI 10.1097/GRF.0b013e318159c20a; Jamil S., 2014, AM J PHYTOMEDICINE C, V2, P580; Klinger G, 2000, GYNECOL ENDOCRINOL, V14, P15, DOI 10.3109/09513590009167655; Klipping C, 2005, CONTRACEPTION, V71, P409, DOI 10.1016/j.contraception.2004.12.005; McArthur JO, 2013, NUTRIENTS, V5, P3634, DOI 10.3390/nu5093634; Merera AM, 2022, J RACIAL ETHN HEALTH, V9, P2340, DOI 10.1007/s40615-021-01171-9; Nakada D, 2014, NATURE, V505, P555, DOI 10.1038/nature12932; Oumer M, 2020, OPEN ACCESS J CONTR, V11, P53, DOI 10.2147/OAJC.S252970; Palmery M, 2013, EUR REV MED PHARMACO, V17, P1804; Rachmilewitz B., 2019, VITAMIN B12, P765; Rakhi J, 2011, J OBSTET GYN INDIA, V61, P626, DOI 10.1007/s13224-011-0107-7; Samsunnahar AkhteQS., 2014, BANGLADESH SOC PHYSL, V9; Schrager S, 2002, AM FAM PHYSICIAN, V65, P2073; Shere M, 2015, J OBSTET GYNAECOL CA, V37, P430, DOI 10.1016/S1701-2163(15)30258-9; Sutterlin MW, 2003, EUR J OBSTET GYN R B, V107, P57, DOI 10.1016/S0301-2115(02)00371-8; Teferra AS., 2015, SCI J PUBLIC HLTH, V3, P143, DOI DOI 10.11648/J.SJPH; VanVoorhis CRW, 2007, TUTOR QUANT METHODS, V3, P43, DOI 10.20982/tqmp.03.2.p043; Wakeman MP., 2019, J ADV MED MED RES, P1	33	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2022	17	11							e0277254	10.1371/journal.pone.0277254	http://dx.doi.org/10.1371/journal.pone.0277254			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6U0HY	36346804	gold, Green Published			2023-01-03	WOS:000894053200018
J	Kim, JT; Kim, K; Ang, L; Lee, HW; Choi, JY; Lee, MS				Kim, Jung Tae; Kim, Kibong; Ang, Lin; Lee, Hye Won; Choi, Jun-Yong; Lee, Myeong Soo			Acupuncture for treating attention deficit hyperactivity disorder in children: A protocol for systematic review and meta-analysis	PLOS ONE			English	Review								Background Attention deficit hyperactivity disorder (ADHD) patients often use complementary and alternative medicine to treat symptoms, and acupuncture is one option. This systematic review aims to assess whether acupuncture is an effective treatment for attention deficit hyperactivity disorder (ADHD). Methods We will search nine databases from their inception: PubMed, AMED, CINAHL, EMBASE, the Cochrane Central Register of Controlled Trials, RISS, KoreaMed, KISS, and the China National Knowledge Infrastructure database. Two investigators will independently review the selected studies, extract the data, and analyze them. The Cochrane Risk of Bias Assessment Tool will be used to assess the risk of bias. Discussion Because this is a systematic review, no ethical approval is needed. The systematic review will be published in a peer-reviewed journal and disseminated both electronically and in print. The review will be updated to support health policy and practice.	[Kim, Jung Tae; Kim, Kibong] Pusan Natl Univ, Sch Korean Med, Dept Korean Pediat, Yangsan, South Korea; [Kim, Jung Tae] IMOM Korean Med Clin, Jeju, South Korea; [Kim, Kibong; Choi, Jun-Yong] Pusan Natl Univ, Korean Med Hosp, Yangsan, South Korea; [Ang, Lin; Lee, Myeong Soo] Korea Inst Oriental Med, KM Sci Res Div, Daejeon, South Korea; [Lee, Hye Won] Korea Inst Oriental Med, KM Convergence Res Div, Daejeon, South Korea; [Choi, Jun-Yong] Pusan Natl Univ, Dept Korean Internal Med, Sch Korean Med, Yangsan, South Korea	Pusan National University; Pusan National University; Korea Institute of Oriental Medicine (KIOM); Korea Institute of Oriental Medicine (KIOM); Pusan National University	Lee, MS (corresponding author), Korea Inst Oriental Med, KM Sci Res Div, Daejeon, South Korea.	drmslee@gmail.com	; Lee, Myeong Soo/C-8147-2013	Kim, Kibong/0000-0001-5724-4653; Lee, Myeong Soo/0000-0001-6651-7641	Korea Institute of Oriental Medicine [KSN2021210]	Korea Institute of Oriental Medicine	No external funding was supported. LA, HWL and MSL were funded internally by the Korea Institute of Oriental Medicine (KSN2021210) (https://www.kiom.re.kr/eng/).The authors alone are responsible for the writing and content of paper. The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, BMJ, V366, DOI [DOI 10.1136/BMJ.L4898, 10.1136/bmj.l4898]; Birch S, 2022, INTEGR MED RES, V11, DOI 10.1016/j.imr.2022.100834; Birch S, 2022, INTEGR MED RES, V11, DOI 10.1016/j.imr.2021.100725; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P842; Chai TQ, 1999, CHIN ACUPUNCT MOX, V19, P5; Chen YC, 2021, COMPLEMENT MED RES, V28, P357, DOI 10.1159/000513655; Dynamed, ATTENTION DEFICIT HY; Feldman HM, 2014, NEW ENGL J MED, V370, P838, DOI 10.1056/NEJMcp1307215; Hu LN, 2018, NEURAL REGEN RES, V13, P477, DOI 10.4103/1673-5374.228731; Kim JT, REVIEWREGISTRY1345 A; Lee IS, 2021, INTEGR MED RES, V10, DOI 10.1016/j.imr.2021.100754; Lee MS, 2011, CHIN J INTEGR MED, V17, P257, DOI 10.1007/s11655-011-0701-7; Li S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007839.pub2; Loo M, 2009, INTEGRATIVE MED CHIL, P178; MacPherson H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000261; National Center for Complementary and Integrative Health, ACUPUNCTURE DEPTH; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Pan W, 2022, INTEGR MED RES, V11, DOI 10.1016/j.imr.2021.100830; Park JY, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84273-y; Qi WC, 2022, INTEGR MED RES, V11, DOI 10.1016/j.imr.2022.100864; Thomas R, 2015, PEDIATRICS, V135, pE994, DOI 10.1542/peds.2014-3482; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Wang TT, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-016-1187-9; Wang XQ, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2624-3; Wolraich M, 2021, ATTENTION DEFICIT HY; Woods D, 2014, ACAD PEDIATR, V14, pS54, DOI 10.1016/j.acap.2014.06.011; World Health Organization, 2002, ACUPUNCTURE REV ANAL; Zhao L, 2020, WORLD J STEM CELLS, V12, P1576, DOI 10.4252/wjsc.v12.i12.1576	28	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2022	17	10							0275504	10.1371/journal.pone.0275504	http://dx.doi.org/10.1371/journal.pone.0275504			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6M7ZK	36215241	gold, Green Published			2023-01-03	WOS:000889081200001
J	Nordling, L; Huang, CC				Nordling, Linda; Huang, Chuchu			'Fungi are amazing': turning mushrooms into vegan leather and meat	NATURE			English	Editorial Material						Careers; Biotechnology; Industry			[Huang, Chuchu] Mycorena, Gothenburg, Sweden		Huang, CC (corresponding author), Mycorena, Gothenburg, Sweden.								0	0	0	19	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 15	2022	609	7927					646	646		10.1038/d41586-022-02922-2	http://dx.doi.org/10.1038/d41586-022-02922-2			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4M1LB	36097059	Bronze			2023-01-03	WOS:000853088800010
J	Pinkham, R; Koon, KK; To, J; Chan, J; Vial, F; Gomm, M; Eckery, DC; Massei, G				Pinkham, Rebecca; Koon, Ka-Kei; To, Jason; Chan, Jason; Vial, Flavie; Gomm, Matt; Eckery, Douglas C.; Massei, Giovanna			Long-term effect of a GnRH-based immunocontraceptive on feral cattle in Hong Kong	PLOS ONE			English	Article							WHITE-TAILED DEER; VACCINE; BEHAVIOR; FERTILITY; CONTRACEPTION; GONACON(TM); PHYSIOLOGY; CONFLICT	Increasing human-wildlife conflicts worldwide are driving the need for multiple solutions to reducing "problem" wildlife and their impacts. Fertility control is advocated as a non-lethal tool to manage free-living wildlife and in particular to control iconic species. Injectable immunocontraceptives, such as GonaCon, stimulate the immune system to produce anti-bodies against the gonadotrophin-releasing hormone (GnRH), which in turn affects the release of reproductive hormones in mammals. Feral cattle (Bos indicus or Bos taurus) in Hong Kong are an iconic species whose numbers and impacts on human activities have increased over the last decade. Previous studies have proven that a primer vaccination and booster dose of GonaCon in female cattle are safe and effective in reducing pregnancy levels one year post-treatment. The aims of this project were 1. to evaluate the longevity of the effect of GonaCon in feral cattle up to four years post-vaccination; and 2. to assess if a second booster dose of GonaCon, administered at either two or four years post-vaccination, extends the contraceptive effect in this species. Vaccination with GonaCon, administered as a primer and booster dose, was effective in causing significant infertility in free-living cattle for at least three years post-vaccination, with the percentage of pregnant animals in the vaccinated group decreasing from 76% at vaccination to 35%, 19% and 7% in years 2, 3 and 4 post-vaccination, compared with 67% at vaccination to 50%, 57% and 14% respectively in the control group. A second booster dose of GonaCon administered either 2 or 4 years after vaccination rendered 100% of the Treated cattle infertile for at least another year. These results suggested that vaccination with GonaCon can reduce feral cattle population growth and that a second booster dose can extend the longevity of the contraceptive effect.	[Pinkham, Rebecca; Vial, Flavie; Gomm, Matt; Massei, Giovanna] Anim & Plant Hlth Agcy, Natl Wildlife Management Ctr, York, N Yorkshire, England; [Koon, Ka-Kei; To, Jason; Chan, Jason] Agr Fisheries & Conservat Dept, Anim Management Operat Div, Hong Kong, Peoples R China; [Eckery, Douglas C.] USDA, APHIS, Natl Wildlife Res Ctr, Ft Collins, CO USA	Animal & Plant Health Agency UK; United States Department of Agriculture (USDA)	Pinkham, R (corresponding author), Anim & Plant Hlth Agcy, Natl Wildlife Management Ctr, York, N Yorkshire, England.	Rebecca.pinkham@apha.gov.uk			Agriculture, Fisheries and Conservation Department in Hong Kong	Agriculture, Fisheries and Conservation Department in Hong Kong	This study was funded by the Agriculture, Fisheries and Conservation Department in Hong Kong. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker DL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201570; Barbato M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231162; BERTEAUX D, 1992, J ZOOL, V228, P265, DOI 10.1111/j.1469-7998.1992.tb04607.x; Commun L, 2016, J VET DIAGN INVEST, V28, P207, DOI 10.1177/1040638716632815; Delsink A, 2012, FREERANGING AFRICAN; Dickman AJ, 2010, ANIM CONSERV, V13, P458, DOI 10.1111/j.1469-1795.2010.00368.x; Druce HC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027952; Duka Toni, 2005, Ecological Management & Restoration, V6, P172, DOI 10.1111/j.1442-8903.2005.00234.x; Fagerstone KA, 2010, INTEGR ZOOL, V5, P15, DOI 10.1111/j.1749-4877.2010.00185.x; Fernando P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050917; Gionfriddo JP, 2011, WILDLIFE SOC B, V35, P142, DOI 10.1002/wsb.32; Gionfriddo JP, 2009, WILDLIFE RES, V36, P177, DOI 10.1071/WR08061; Gray ME, 2010, WILDLIFE RES, V37, P475, DOI 10.1071/WR09175; Habibzadeh F, 2016, BIOCHEM MEDICA, V26, P297, DOI 10.11613/BM.2016.034; HART BL, 1975, HORM BEHAV, V6, P247, DOI 10.1016/0018-506X(75)90012-4; Heydon MJ, 2010, WILDLIFE RES, V37, P731, DOI 10.1071/WR10006; Killian G, 2008, WILDLIFE RES, V35, P531, DOI 10.1071/WR07134; Killian G, 2009, J WILDLIFE DIS, V45, P184, DOI 10.7589/0090-3558-45.1.184; Kirkpatrick JF, 2011, AM J REPROD IMMUNOL, V66, P40, DOI 10.1111/j.1600-0897.2011.01003.x; Lute ML, 2016, CONSERV BIOL, V30, P1200, DOI 10.1111/cobi.12731; Mannen H, 2017, ANIM SCI J, V88, P739, DOI 10.1111/asj.12716; Massei G, 2008, WILDLIFE RES, V35, P540, DOI 10.1071/WR07132; Massei G, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03781; Massei G, 2018, VACCINE, V36, P7393, DOI 10.1016/j.vaccine.2018.09.071; Massei G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121598; Massei G, 2014, WILDLIFE RES, V41, P1, DOI 10.1071/WR13141; Massei G, 2012, WILDLIFE RES, V39, P378, DOI 10.1071/WR11196; Massei G, 2010, WILDLIFE RES, V37, P428, DOI 10.1071/WR08179; Miller LA, 2004, J WILDLIFE DIS, V40, P725, DOI 10.7589/0090-3558-40.4.725; Miller LA, 2000, AM J REPROD IMMUNOL, V44, P266, DOI 10.1111/j.8755-8920.2000.440503.x; Miller LA, 2008, AM J REPROD IMMUNOL, V60, P214, DOI 10.1111/j.1600-0897.2008.00616.x; Powers JG, 2014, WILDLIFE SOC B, V38, P650, DOI 10.1002/wsb.434; Powers JG, 2011, BIOL REPROD, V85, P1152, DOI 10.1095/biolreprod.110.088237; Price EO, 2003, J ANIM SCI, V81, P411; R Core Team, 2020, R LANG ENV STAT COMP; Rutberg AT, 2008, WILDLIFE RES, V35, P494, DOI 10.1071/WR07128; Sharp T., 2011, MODEL ASSESSING RELA, VSecond; Therneau TM, 2020, PACKAGE SURVIVAL ANA; Tizard I., 1982, An introduction to veterinary immunology.	39	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2022	17	8							e0272604	10.1371/journal.pone.0272604	http://dx.doi.org/10.1371/journal.pone.0272604			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4D6CO	35976896	Green Published, gold			2023-01-03	WOS:000847227000050
J	Hill, JD; De Forcrand, C; Cuthel, AM; Adeyemi, OJ; Shallcross, AJ; Grudzen, CR				Hill, Jacob D.; De Forcrand, Claire; Cuthel, Allison M.; Adeyemi, Oluwaseun John; Shallcross, Amanda J.; Grudzen, Corita R.			Emergency provider perspectives on facilitators and barriers to home and community services for older adults with serious life limiting illness: A qualitative study	PLOS ONE			English	Article							PALLIATIVE CARE; INTENSITY; PATIENT	BackgroundOlder adults account for a large proportion of emergency department visits, but those with serious life-limiting illness may benefit most from referral to home and community services instead of hospitalization. We aim to document emergency provider perspectives on facilitators and barriers to accessing home and community services for older adults with serious life-limiting illness. MethodsWe conducted interviewer-administered semi-structured interviews with emergency providers from health systems across the United States to obtain provider perspectives on facilitators and barriers to accessing home and community services. We completed qualitative thematic analysis using an iterative process to develop themes and subthemes to summarize provider responses. ResultsWe interviewed 8 emergency nurses and 10 emergency physicians across 11 health systems. Emergency providers were familiar with local home and community services. Facilitators to accessing these services include care management and social workers. Barriers include services that are not accessible full-time to receive referrals, insurance/payment, and the busy nature of the emergency department. The most helpful reported services were hospice, physical therapy, occupational therapy, and visiting nursing services. Home-based palliative care and full-time emergency department-based care management and social work were the services most desired by providers. Providers expressed support for improving access to home and community services in the hopes of decreasing unnecessary emergency visits and inpatient admissions, and to provide patients with greater options for supportive care. ConclusionObtaining the perspective of emergency providers highlights important considerations to accessing HCS for older-adults with serious life-limiting illness from the emergency department. This study provides foundational information for futures studies and initiatives for improving access to home and community services directly from the emergency department.	[Hill, Jacob D.; Cuthel, Allison M.; Adeyemi, Oluwaseun John; Grudzen, Corita R.] New York Univ, Ronald O Perelman Dept Emergency Med, Grossman Sch Med, New York, NY 10016 USA; [De Forcrand, Claire] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Shallcross, Amanda J.] New York Univ, Dept Populat Hlth, Grossman Sch Med, New York, NY USA	New York University; University of Wisconsin System; University of Wisconsin Madison; New York University	Hill, JD (corresponding author), New York Univ, Ronald O Perelman Dept Emergency Med, Grossman Sch Med, New York, NY 10016 USA.	Jacob.hill@nyulangone.org			National Institutes of Health (NIH) Health Care Systems Research Collaboratory by the NIH Common Fund from the Office of Strategic Coordination within the Office of the NIH Director [U24AT009676]; National Institute on Aging [UG3/UH3 AT009844]; NIH- National Center for Complementary and Integrative Health (NCCIH) [UH3 AT009844]	National Institutes of Health (NIH) Health Care Systems Research Collaboratory by the NIH Common Fund from the Office of Strategic Coordination within the Office of the NIH Director(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH- National Center for Complementary and Integrative Health (NCCIH)	This work is supported within the National Institutes of Health (NIH) Health Care Systems Research Collaboratory by the NIH Common Fund through cooperative agreement [U24AT009676] from the Office of Strategic Coordination within the Office of the NIH Director and cooperative agreement [UG3/UH3 AT009844] from the National Institute on Aging. Support was also provided by the NIH- National Center for Complementary and Integrative Health (NCCIH) through cooperative agreement [UH3 AT009844]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Author CRG has received the UG3/UH3 funding that supports this manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], HOME DEDOOSE; Armstrong MJ, 2020, AM J HOSP PALLIAT ME, V37, P728, DOI 10.1177/1049909119897241; Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Beckstrand RL, 2017, J EMERG NURS, V43, P214, DOI 10.1016/j.jen.2017.03.012; Charmaz K., 2006, CONSTRUCTING GROUNDE; Coyne IT, 1997, J ADV NURS, V26, P623, DOI 10.1046/j.1365-2648.1997.t01-25-00999.x; Flory J, 2004, HEALTH AFFAIR, V23, P194, DOI 10.1377/hlthaff.23.3.194; Frey B. B., 2018, SAGE ENCYCL ED RES M, P1, DOI [10.4135/9781506326139, DOI 10.4135/9781506326139]; Friedman AB, 2022, J AM GERIATR SOC, V70, P501, DOI 10.1111/jgs.17503; Grudzen CR, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030099; Grudzen CR, 2012, J PAIN SYMPTOM MANAG, V43, P1, DOI 10.1016/j.jpainsymman.2011.03.022; Gualano MR, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18158172; Haines KL, 2018, AM J HOSP PALLIAT ME, V35, P1081, DOI 10.1177/1049909117753377; Harasym P, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037466; Hill JD, 2021, AM J HOSP PALLIAT ME, V38, P12, DOI 10.1177/1049909120920230; Kiger ME, 2020, MED TEACH, V42, P846, DOI 10.1080/0142159X.2020.1755030; LoPresti MA, 2016, AM J HOSP PALLIAT ME, V33, P291, DOI 10.1177/1049909114565658; Marsack J, 2018, LGBT HEALTH, V5, P273, DOI 10.1089/lgbt.2016.0182; McKenna P, 2019, CLIN EXP EMERG MED, V6, P189, DOI 10.15441/ceem.18.022; Mullins PM, 2013, ACAD EMERG MED, V20, P479, DOI 10.1111/acem.12134; Niska Richard, 2010, Natl Health Stat Report, P1; Person J, 2013, INT EMERG NURS, V21, P222, DOI 10.1016/j.ienj.2012.10.001; Rainsford S, 2017, PALLIATIVE MED, V31, P895, DOI 10.1177/0269216316685234; Samuels-Kalow ME, 2020, WEST J EMERG MED, V21, P964, DOI 10.5811/westjem.2020.3.45932; Stone SC, 2011, J PALLIAT MED, V14, P1333, DOI 10.1089/jpm.2011.0106; STRUTZEL E, 1968, NURS RES, V17, P364; Teno JM, 2018, JAMA-J AM MED ASSOC, V320, P264, DOI 10.1001/jama.2018.8981; Thomas EV, 2019, BODY IMAGE, V30, P81, DOI 10.1016/j.bodyim.2019.05.007; Vasunilashorn Sarinnapha, 2012, J Aging Res, V2012, P120952, DOI 10.1155/2012/120952; Vincent GK., 2010, NEXT 4 DECADES OLDER; Wennberg JE, 2009, HEALTH AFFAIR, V28, P103, DOI 10.1377/hlthaff.28.1.103; Wilson JG, 2020, J PAIN SYMPTOM MANAG, V59, P372, DOI 10.1016/j.jpainsymman.2019.09.020	32	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2022	17	8							e0270961	10.1371/journal.pone.0270961	http://dx.doi.org/10.1371/journal.pone.0270961			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5A3IT	35930579	gold, Green Published			2023-01-03	WOS:000862784200015
J	Cleary, F; Prieto-Merino, D; Nitsch, D				Cleary, Faye; Prieto-Merino, David; Nitsch, Dorothea			A systematic review of statistical methodology used to evaluate progression of chronic kidney disease using electronic healthcare records	PLOS ONE			English	Review							GLOMERULAR-FILTRATION-RATE; RENAL-FUNCTION DECLINE; RISK PREDICTION; OUTCOMES; IMPACT; COHORT; CKD; POPULATION; FAILURE; EGFR	Background Electronic healthcare records (EHRs) are a useful resource to study chronic kidney disease (CKD) progression prior to starting dialysis, but pose methodological challenges as kidney function tests are not done on everybody, nor are tests evenly spaced. We sought to review previous research of CKD progression using renal function tests in EHRs, investigating methodology used and investigators' recognition of data quality issues. Methods and findings We searched for studies investigating CKD progression using EHRs in 4 databases (Medline, Embase, Global Health and Web of Science) available as of August 2021. Of 80 articles eligible for review, 59 (74%) were published in the last 5.5 years, mostly using EHRs from the UK, USA and East Asian countries. 33 articles (41%) studied rates of change in eGFR, 23 (29%) studied changes in eGFR from baseline and 15 (19%) studied progression to binary eGFR thresholds. Sample completeness data was available in 44 studies (55%) with analysis populations including less than 75% of the target population in 26 studies (33%). Losses to follow-up went unreported in 62 studies (78%) and 11 studies (14%) defined their cohort based on complete data during follow up. Methods capable of handling data quality issues and other methodological challenges were used in a minority of studies. Conclusions Studies based on renal function tests in EHRs may have overstated reliability of findings in the presence of informative missingness. Future renal research requires more explicit statements of data completeness and consideration of i) selection bias and representativeness of sample to the intended target population, ii) ascertainment bias where follow-up depends on risk, and iii) the impact of competing mortality. We recommend that renal progression studies should use statistical methods that take into account variability in renal function, informative censoring and population heterogeneity as appropriate to the study question.	[Cleary, Faye; Prieto-Merino, David; Nitsch, Dorothea] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England	University of London; London School of Hygiene & Tropical Medicine	Cleary, F (corresponding author), London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England.	faye.cleary@lshtm.ac.uk		Nitsch, Dorothea/0000-0001-5767-248X	Medical Research Council [MR/N013638/1]	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council (MR/N013638/1), grant awarded to FC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelhafiz Ahmed H, 2012, Hosp Pract (1995), V40, P49, DOI 10.3810/hp.2012.10.1003; Annor FB, 2015, KIDNEY RES CLIN PRAC, V34, P146, DOI 10.1016/j.krcp.2015.07.002; Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885; Boucquemont J, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-45; Butt AA, 2018, ALIMENT PHARM THER, V48, P35, DOI 10.1111/apt.14799; Cabrera CS, 2020, KIDNEY INT REP, V5, P1651, DOI 10.1016/j.ekir.2020.07.029; Caravaca-Fontan F, 2018, CLIN KIDNEY J, V11, P246, DOI 10.1093/ckj/sfx083; Chakera A, 2016, J NEPHROL, V29, P367, DOI 10.1007/s40620-015-0227-8; Chase HS, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-187; Cummings DM, 2011, J AM BOARD FAM MED, V24, P391, DOI 10.3122/jabfm.2011.04.100186; Diggle PJ, 2015, BIOSTATISTICS, V16, P522, DOI 10.1093/biostatistics/kxu053; Eckardt KU, 2013, LANCET, V382, P158, DOI 10.1016/S0140-6736(13)60439-0; Eriksen BO, 2010, NEPHRON CLIN PRACT, V115, pE41, DOI 10.1159/000286349; Eriksen BO, 2006, KIDNEY INT, V69, P375, DOI 10.1038/sj.ki.5000058; Evans RDR, 2019, KIDNEY INT REP, V4, P48, DOI 10.1016/j.ekir.2018.08.011; Gallant JE, 2005, CLIN INFECT DIS, V40, P1194, DOI 10.1086/428840; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Herget-Rosenthal S, 2013, PREV MED, V57, P357, DOI 10.1016/j.ypmed.2013.06.010; Hill NR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158765; Horne L, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1250-0; Hsu TW, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070932; Inaguma D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239262; Jackevicius CA, 2021, CIRC-CARDIOVASC QUAL, V14, P155, DOI 10.1161/CIRCOUTCOMES.120.007230; Jalal K, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1429-4; Johnson F, 2016, NEPHROLOGY, V21, P506, DOI 10.1111/nep.12649; Koraishy FM, 2017, FAM PRACT, V34, P416, DOI 10.1093/fampra/cmx012; Lamacchia O, 2018, DIABETOL METAB SYNDR, V10, DOI 10.1186/s13098-018-0361-2; Leither MD, 2019, NEPHROL DIAL TRANSPL, V34, P493, DOI 10.1093/ndt/gfy036; Levey AS, 2014, AM J KIDNEY DIS, V64, P821, DOI 10.1053/j.ajkd.2014.07.030; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levin A, 2020, KIDNEY INT, V98, P849, DOI 10.1016/j.kint.2020.07.013; Li L, 2012, AM J KIDNEY DIS, V59, P504, DOI 10.1053/j.ajkd.2011.12.009; Li XM, 2016, ANN HEMATOL, V95, P901, DOI 10.1007/s00277-016-2659-1; Lin YC, 2019, J CACHEXIA SARCOPENI, V10, P756, DOI 10.1002/jcsm.12423; Liu CH, 2014, J NEPHROL, V27, P289, DOI 10.1007/s40620-013-0011-6; Liu D, 2019, INT IMMUNOPHARMACOL, V66, P13, DOI 10.1016/j.intimp.2018.10.044; Lv L, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0763-7; Morales-Alvarez MC, 2019, KIDNEY INT REP, V4, P1230, DOI 10.1016/j.ekir.2019.05.012; Nderitu P, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005581; Neuen BL, 2021, AM J KIDNEY DIS, V78, P350, DOI 10.1053/j.ajkd.2021.02.335; Nichols GA, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-01792-y; Niu SF, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-041210; O'Riordan A, 2009, NEPHROL DIAL TRANSPL, V24, P2276, DOI 10.1093/ndt/gfp112; Oetjens M, 2014, BIOCOMPUT-PAC SYM, P253; Peng YL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67026-1; Perotte A, 2015, J AM MED INFORM ASSN, V22, P872, DOI 10.1093/jamia/ocv024; Posch F, 2019, RES PRACT THROMB HAE, V3, P207, DOI 10.1002/rth2.12189; Rej S, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.19m13045; Rincon-Choles H, 2017, AM J NEPHROL, V46, P315, DOI 10.1159/000481460; Robinson DE, 2021, J BONE MINER RES, V36, P820, DOI 10.1002/jbmr.4235; Shou HC, 2017, CLIN J AM SOC NEPHRO, V12, P1357, DOI 10.2215/CJN.11311116; Singh A, 2015, J BIOMED INFORM, V53, P220, DOI 10.1016/j.jbi.2014.11.005; Tangri N, 2021, BMC NEPHROL, V22, DOI 10.1186/s12882-021-02385-z; The Renal Association, EGFR; Tsai CW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170393; UK Renal Registry, 2018, 20 ANN REP REN AS S1, V139; UK Renal Registry, UK REN REG 22 ANN RE; Vandenbroucke JP, 2007, ANN INTERN MED, V147, pW163, DOI 10.7326/0003-4819-147-8-200710160-00010-w1; VanWagner LB, 2018, TRANSPLANTATION, V102, P1096, DOI 10.1097/TP.0000000000002175; Vejakama P, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000475; Vesga JI, 2021, INT J NEPHROL, V2021, DOI 10.1155/2021/8866446; Viazzi F, 2018, KIDNEY BLOOD PRESS R, V43, P422, DOI 10.1159/000488255; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Wang YT, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00855; Weldegiorgis M, 2020, NEPHROL DIAL TRANSPL, V35, P1562, DOI 10.1093/ndt/gfz059; Yanagawa T, 2021, DIABETOL INT, V12, P268, DOI 10.1007/s13340-020-00483-1; Yao XX, 2017, J AM COLL CARDIOL, V70, P2621, DOI 10.1016/j.jacc.2017.09.1087; Yoo H, 2019, INT J CLIN PHARM-NET, V41, P563, DOI 10.1007/s11096-019-00794-7	68	0	0	7	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2022	17	7							e0264167	10.1371/journal.pone.0264167	http://dx.doi.org/10.1371/journal.pone.0264167			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4Q0KX	35905096	Green Published, gold			2023-01-03	WOS:000855776900003
J	Bellandi, D				Bellandi, Deanna			Global Health Care Facilities Lack Basic Hygiene Services	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	2022	328	15					1490	1491		10.1001/jama.2022.18765	http://dx.doi.org/10.1001/jama.2022.18765			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5M9EQ	36255419				2023-01-03	WOS:000871397000004
J	Kim, Y; Bolton, DAE; Vakula, MN; Bressel, E				Kim, Youngwook; Bolton, David A. E.; Vakula, Michael N.; Bressel, Eadric			Catching and throwing exercises to improve reactive balance: A randomized controlled trial protocol for the comparison of aquatic and dry-land exercise environments	PLOS ONE			English	Article							ANTICIPATORY POSTURAL ADJUSTMENTS; OLDER-ADULTS; SINGLE-SESSION; FALLS; ACTIVATION; RESPONSES; SYSTEMS	Reactive balance, a critical automatic movement pattern in response to a perturbation, is directly linked to fall prevention in older adults. Various exercise interventions have been broadly performed to improve reactive balance and thus prevent falls. Curiously, aquatic exercises have been suggested as an effective balance intervention and a safer alternative to exercises on dry land yet the efficacy of aquatic exercises on reactive balance has not been formally investigated. The present clinical trial aims to identify if skills acquired during aquatic exercise are more effectively transferred to a reactive balance task than land exercise. This study is designed as a double-blinded, randomized controlled clinical trial. Forty-four older adults aged 65 years or above who meet the eligibility criteria will be recruited and randomized into an aquatic exercise group or land exercise group. Each group will participate in the same single bout intervention that includes a ball throwing and catching task. A modified lean-and-release test will be implemented on land immediately before, after, and one week after the single bout intervention. The outcomes will include reaction time, rapid response accuracy, and mini-BESTest scores obtained from stepping and grasping reactions. All statistical analyses will be conducted using an intention-to-treat approach. Our conceptual hypothesis is that participants in the aquatic exercise group will demonstrate more improved outcome scores in the lean-and-release test when compared to those in the land exercise group. The results of the present study are expected to provide evidence to support the benefits of aquatic exercises for improving reactive balance in older adults. Further, participants may find aquatic exercises safer and more motivating, thus encouraging them to participate in further aquatic exercise programs.	[Kim, Youngwook; Bolton, David A. E.; Vakula, Michael N.; Bressel, Eadric] Utah State Univ, Dept Kinesiol & Hlth Sci, Logan, UT USA	Utah System of Higher Education; Utah State University	Kim, Y (corresponding author), Utah State Univ, Dept Kinesiol & Hlth Sci, Logan, UT USA.	youngwook.kim@usu.edu		Kim, Youngwook/0000-0001-8579-6244				Aquatic Exercise Association, 2017, AQ FITN PROF MAN; Aruin AS, 2017, MULT SCLER RELAT DIS, V17, P224, DOI 10.1016/j.msard.2017.08.013; Aruin AS, 2015, EXP BRAIN RES, V233, P649, DOI 10.1007/s00221-014-4144-1; Becker BE, 2008, STRENGTH COND J, V30, P18, DOI 10.1519/SSC.0b013e3181638586; Bergamin M, 2013, CLIN INTERV AGING, V8, P1109, DOI 10.2147/CIA.S44198; Bhatt T, 2009, ARCH PHYS MED REHAB, V90, P34, DOI 10.1016/j.apmr.2008.06.021; Bian ZX, 2011, ANN INTERN MED, V154, P290, DOI 10.7326/0003-4819-154-4-201102150-00016; Blanchette A, 2011, GAIT POSTURE, V34, P358, DOI 10.1016/j.gaitpost.2011.06.001; Bolton DAE, 2020, JOVE-J VIS EXP, DOI 10.3791/60688; Bolton DAE, 2019, CORTEX, V117, P135, DOI 10.1016/j.cortex.2019.03.001; Borrelli JR, 2019, PHYSIOTHER RES INT, V24, DOI 10.1002/pri.1787; Bressel E, 2019, J GERIATR PHYS THER, V42, pE1, DOI 10.1519/JPT.0000000000000192; Bressel E, 2017, J GERIATR PHYS THER, V40, P113, DOI 10.1519/JPT.0000000000000081; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Curuk E, 2020, HUM MOVEMENT SCI, V69, DOI 10.1016/j.humov.2019.102559; Davids K, 2003, SPORTS MED, V33, P245, DOI 10.2165/00007256-200333040-00001; Douris P., 2003, J GERIATR PHYS THER, V26, P3, DOI DOI 10.1519/00139143-200304000-00001; Franchignoni F, 2010, J REHABIL MED, V42, P323, DOI 10.2340/16501977-0537; Geigle PR., 1997, J AQUATIC PHYS, V5, P4; Grissom RJ., 2011, UNIVARIATE MULTIVARI, V2nd, DOI [10.4324/9780203803233, DOI 10.4324/9780203803233]; Harper SA, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11030402; Horak FB, 2009, PHYS THER, V89, P484, DOI 10.2522/ptj.20080071; Inness EL, 2015, GAIT POSTURE, V41, P529, DOI 10.1016/j.gaitpost.2014.12.005; Jagdhane Sailee, 2016, Curr Aging Sci, V9, P295; Kanekar N, 2015, J ELECTROMYOGR KINES, V25, P400, DOI 10.1016/j.jelekin.2014.11.002; Kim Y, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01702-9; Lee Y, 2020, EUR J APPL PHYSIOL, V120, P443, DOI 10.1007/s00421-019-04289-1; Louder T., 2014, INT J AQUATIC RES ED, V8, P53, DOI DOI 10.1123/IJARE.2013-0014; Mansfield A, 2011, PHYS THER, V91, P958, DOI 10.2522/ptj.20100212; Suhaimy MSB, 2020, NEUROREHAB NEURAL RE, V34, P675, DOI 10.1177/1545968320929681; Muir-Hunter SW, 2016, PHYSIOTHERAPY, V102, P29, DOI 10.1016/j.physio.2015.04.011; Ochi A, 2014, AGING CLIN EXP RES, V26, P213, DOI 10.1007/s40520-013-0152-4; Pasanen K, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a295; Saghaei Mahmood, 2004, BMC Med Res Methodol, V4, P26, DOI 10.1186/1471-2288-4-26; Schaefer SY, 2016, PHYSIOTHER RES INT, V21, P147, DOI 10.1002/pri.1628; Shin SS, 2014, J PHYS THER SCI, V26, P359, DOI 10.1589/jpts.26.359; Shumway-Cook A, 2016, MOTOR CONTROL TRANSL; Shumway-Cook A., 2017, POSTURAL CONTROL M 2; Sibley KM, 2021, EXP GERONTOL, V143, DOI 10.1016/j.exger.2020.111151; Simmons V, 1996, J GERONTOL A-BIOL, V51, pM233, DOI 10.1093/gerona/51A.5.M233; Southard V, 2005, GAIT POSTURE, V22, P351, DOI 10.1016/j.gaitpost.2004.11.013; WHO, 2007, WHO GLOB REP FALLP	42	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2022	17	10							e0275733	10.1371/journal.pone.0275733	http://dx.doi.org/10.1371/journal.pone.0275733			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6Q0AL	36223397	gold, Green Published			2023-01-03	WOS:000891284400037
J	Frat, JP; Quenot, JP; Badie, J; Coudroy, R; Guitton, C; Ehrmann, S; Gacouin, A; Merdji, H; Auchabie, J; Daubin, C; Dureau, AF; Thibault, L; Sedillot, N; Rigaud, JP; Demoule, A; Fatah, A; Terzi, N; Simonin, M; Danjou, W; Carteaux, G; Guesdon, C; Pradel, G; Besse, MC; Reignier, J; Beloncle, F; La Combe, B; Prat, G; Nay, MA; de Keizer, J; Ragot, S; Thille, AW				Frat, Jean-Pierre; Quenot, Jean-Pierre; Badie, Julio; Coudroy, Remi; Guitton, Christophe; Ehrmann, Stephan; Gacouin, Arnaud; Merdji, Hamid; Auchabie, Johann; Daubin, Cedric; Dureau, Anne-Florence; Thibault, Laure; Sedillot, Nicholas; Rigaud, Jean-Philippe; Demoule, Alexandre; Fatah, Abdelhamid; Terzi, Nicolas; Simonin, Marine; Danjou, William; Carteaux, Guillaume; Guesdon, Charlotte; Pradel, Gael; Besse, Marie-Catherine; Reignier, Jean; Beloncle, Francois; La Combe, Beatrice; Prat, Gwenael; Nay, Mai-Anh; de Keizer, Joe; Ragot, Stephanie; Thille, Arnaud W.		SOHO-COVID Study Grp; REVA Network	Effect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19 The SOHO-COVID Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									[Frat, Jean-Pierre; Coudroy, Remi; Thille, Arnaud W.] CHU Poitiers, Med Intens Reanimat, 2 Rue Miletrie,CS 90577, F-86021 Poitiers, France; ALIVE, CIC 1402, INSERM, Poitiers, France; [Frat, Jean-Pierre; Coudroy, Remi; de Keizer, Joe; Ragot, Stephanie; Thille, Arnaud W.] Univ Poitiers, Fac Med & Pharm Poitiers, Poitiers, France; [Frat, Jean-Pierre] CRICS TriggerSEP F CRIN Res Network, Dijon, France; [Quenot, Jean-Pierre] CHU Dijon Bourgogne, Med Intens Reanimat, Dijon, France; [Quenot, Jean-Pierre] Univ Bourgogne Franche Comte, Ctr Rech INSERM UMR1231, Equipe Lipness, Dijon, France; [Quenot, Jean-Pierre] Univ Bourgogne Franche Comte, LabEx LipSTIC, Dijon, France; [Quenot, Jean-Pierre] Univ Bourgogne Franche Comte, Module Epidemiol Clin, INSERM, CIC 1432, Dijon, France; [Badie, Julio] Hop Nord Franche Comte, Montbeliard, France; [Guitton, Christophe] CH Mans, Reanimat Med Chirurg, Le Mans, France; [Guitton, Christophe] Univ Angers, Fac Sante, Angers, France; [Ehrmann, Stephan] CHRU Tours, Med Intens Reanimat, Tours, France; [Ehrmann, Stephan] Univ Tours, CIC INSERM 1415, Tours, France; [Ehrmann, Stephan] Univ Tours, Ctr Etud Pathol Resp, INSERM U1100, Tours, France; [Gacouin, Arnaud] CHU Rennes, Hop Pontchaillou, Serv Malad Infect & Reanimat Med, Rennes, France; [Merdji, Hamid] Hop Univ Strasbourg, Med Intens Reanimat, Nouvel Hop Civil, Strasbourg, France; [Merdji, Hamid] Univ Strasbourg UNISTRA, Fac Med, INSERM UMR 1260, Regenerat Nanomed,FMTS, Strasbourg, France; [Auchabie, Johann] CH Cholet, Serv Reanimat Polyvalente, Cholet, France; [Daubin, Cedric] CHU Caen, Med Intens Reanimat, Caen, France; [Dureau, Anne-Florence] GHR Mulhouse Sud Alsace, Med Intens Reanimat, Mulhouse, France; [Thibault, Laure] Grp Hosp Sud La Reunion, Med Intens Reanimat, St Pierre, France; [Sedillot, Nicholas] CH Bourg En Bresse, Serv Reanimat, Bourg En Bresse, France; [Rigaud, Jean-Philippe] CH Dieppe, Med Intens Reanimat, Dieppe, France; [Demoule, Alexandre] Sorbonne Univ, Grp Hosp Univ, AP HP,Dept R3S, Site Pitie Salpetriere,Med Intens & Reanimat, Paris, France; [Demoule, Alexandre] Sorbonne Univ, Paris, France; [Demoule, Alexandre] INSERM, UMRS1158 Neurophysiol Resp Expt & Clin, Paris, France; [Fatah, Abdelhamid] Grp Hosp Nord Dauphine, Serv Reanimat, Bourgoin Jallieu, France; [Terzi, Nicolas] CHU Grenoble Alpes, Med Intens Reanimat, Grenoble, France; [Terzi, Nicolas] Univ Grenoble Alpes, HP2, U1042, INSERM, Grenoble, France; [Simonin, Marine] Hop St Joseph St Luc, Reanimat Polyvalente, Lyon, France; [Danjou, William] CHU La Croix Rousse, Med Intens Reanimat, Hosp Civils Lyon, Lyon, France; [Carteaux, Guillaume] CHU Henri Mondor, AP HP, Med Intens Reanimat, Creteil, France; [Carteaux, Guillaume] Univ Paris Est Creteil, Fac Sante, Grp Rech Clin CARMAS, Creteil, France; [Carteaux, Guillaume] INSERM, IMRB, Unite UMR 955, Creteil, France; [Guesdon, Charlotte] CH Pau, Reanimat Polyvalente, Pau, France; [Pradel, Gael] CH Henri Mondor Aurillac, Serv Reanimat, Aurillac, France; [Besse, Marie-Catherine] CH Bourges, Reanimat Polyvalente, Bourges, France; [Reignier, Jean] CHU Nantes, Med Intens Reanimat, Nantes, France; [Beloncle, Francois] CHU Angers, Dept Med Intens Reanimat & Med Hyperbare, Angers, France; [La Combe, Beatrice] Grp Hosp Bretagne Sud, Serv Reanimat Polyvalente, Lorient, France; [Prat, Gwenael] CHU Brest, Med Intens Reanimat, Brest, France; [Nay, Mai-Anh] CHR Orleans, Med Intens Reanimat, Orleans, France; INSERM, CIC 1402, Poitiers, France	CHU Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; Universite de Poitiers; CHU Dijon Bourgogne; Institut Agro; AgroSup Dijon; Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre Hospitalier Le Mans; Universite d'Angers; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; CHU Rennes; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU Reunion; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Nantes Universite; CHU de Nantes; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Brest; Centre Hospitalier Regional d'Orleans; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers	Frat, JP (corresponding author), CHU Poitiers, Med Intens Reanimat, 2 Rue Miletrie,CS 90577, F-86021 Poitiers, France.	jean-pierre.frat@chu-poitiers.fr	merdji, hamid/GXF-7656-2022	merdji, hamid/0000-0002-4670-1596	"Programme Hospitalier de Recherche Clinique National" 2019 from the French Ministry of Health [PHRC-19-0305]; Fisher & Paykel Healthcare	"Programme Hospitalier de Recherche Clinique National" 2019 from the French Ministry of Health; Fisher & Paykel Healthcare	Financial support was provided by the "Programme Hospitalier de Recherche Clinique National" 2019 from the French Ministry of Health (PHRC-19-0305) and a grant from Fisher & Paykel Healthcare.	Azoulay E, 2018, JAMA-J AM MED ASSOC, V320, P2099, DOI 10.1001/jama.2018.14282; Bonnet N, 2021, ANN INTENSIVE CARE, V11, DOI 10.1186/s13613-021-00825-5; Coudroy R, 2020, THORAX, V75, P805, DOI 10.1136/thoraxjnl-2020-214863; COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators, 2021, INTENSIVE CARE MED, V47, P60, DOI [10.1007/s00134-020-06294-x, DOI 10.1007/S00134-020-06294-X]; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Demoule A, 2020, AM J RESP CRIT CARE, V202, P1039, DOI 10.1164/rccm.202005-2007LE; Franco C, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02130-2020; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Grieco DL, 2021, JAMA-J AM MED ASSOC, V325, P1731, DOI 10.1001/jama.2021.4682; Hernandez-Romieu AC, 2020, CRIT CARE MED, V48, pE1045, DOI 10.1097/CCM.0000000000004600; Islam N, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1137; Maslo C, 2022, JAMA-J AM MED ASSOC, V327, P583, DOI 10.1001/jama.2021.24868; Mauri T, 2017, AM J RESP CRIT CARE, V195, P1207, DOI 10.1164/rccm.201605-0916OC; Moller W, 2017, J APPL PHYSIOL, V122, P191, DOI 10.1152/japplphysiol.00584.2016; Ospina-Tascon GA, 2021, JAMA-J AM MED ASSOC, V326, P2161, DOI 10.1001/jama.2021.20714; Patel M, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000650; Perkins GD, 2022, JAMA-J AM MED ASSOC, V327, P546, DOI 10.1001/jama.2022.0028; Rodriguez M, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0578-8; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Swenson KE, 2021, ANN AM THORAC SOC, V18, P1098, DOI 10.1513/AnnalsATS.202011-1376CME; Tobin MJ, 2020, AM J RESP CRIT CARE, V202, P356, DOI 10.1164/rccm.202006-2157CP; WHO, WHO COR COVID 19 DAS	23	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	2022	328	12					1212	1222		10.1001/jama.2022.15613	http://dx.doi.org/10.1001/jama.2022.15613			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5E8TQ	36166027	Bronze			2023-01-03	WOS:000865895100032
J	De-Madaria, E; Buxbaum, JL; Maisonneuve, P; De Paredes, AGG; Zapater, P; Guilabert, L; Vaillo-Rocamora, A; Rodriguez-Gandia, MA; Donate-Ortega, J; Lozada-Hernandez, EE; Moreno, AJRC; Lira-Aguilar, A; Llovet, LP; Mehta, R; Tandel, R; Navarro, P; Sanchez-Pardo, AM; Sanchez-Marin, C; Cobreros, M; Fernandez-Cabrera, I; Casals-Seoane, F; Deza, DC; Lauret-Brana, E; Marti-Marques, E; Camacho-Montano, LM; Ubieto, V; Ganuza, M; Bolado, F				De-Madaria, E.; Buxbaum, J. L.; Maisonneuve, P.; Garcia de Paredes, A. Garcia; Zapater, P.; Guilabert, L.; Vaillo-Rocamora, A.; Rodriguez-Gandia, M. A.; Donate-Ortega, J.; Lozada-Hernandez, E. E.; Collazo Moreno, A. J. R.; Lira-Aguilar, A.; Llovet, L. P.; Mehta, R.; Tandel, R.; Navarro, P.; Sanchez-Pardo, A. M.; Sanchez-Marin, C.; Cobreros, M.; Fernandez-Cabrera, I; Casals-Seoane, F.; Deza, D. Casas; Lauret-Brana, E.; Marti-Marques, E.; Camacho-Montano, L. M.; Ubieto, V; Ganuza, M.; Bolado, F.		ERICA Consortium	Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE PERFUSION; ORGAN FAILURE; MANAGEMENT; MULTICENTER; MORTALITY; THERAPY; HEMOCONCENTRATION; HYDRATION; OUTCOMES; MARKER	Background Early aggressive hydration is widely recommended for the management of acute pancreatitis, but evidence for this practice is limited. Methods At 18 centers, we randomly assigned patients who presented with acute pancreatitis to receive goal-directed aggressive or moderate resuscitation with lactated Ringer's solution. Aggressive fluid resuscitation consisted of a bolus of 20 ml per kilogram of body weight, followed by 3 ml per kilogram per hour. Moderate fluid resuscitation consisted of a bolus of 10 ml per kilogram in patients with hypovolemia or no bolus in patients with normovolemia, followed by 1.5 ml per kilogram per hour in all patients in this group. Patients were assessed at 12, 24, 48, and 72 hours, and fluid resuscitation was adjusted according to the patient's clinical status. The primary outcome was the development of moderately severe or severe pancreatitis during the hospitalization. The main safety outcome was fluid overload. The planned sample size was 744, with a first planned interim analysis after the enrollment of 248 patients. Results A total of 249 patients were included in the interim analysis. The trial was halted owing to between-group differences in the safety outcomes without a significant difference in the incidence of moderately severe or severe pancreatitis (22.1% in the aggressive-resuscitation group and 17.3% in the moderate-resuscitation group; adjusted relative risk, 1.30; 95% confidence interval [CI], 0.78 to 2.18; P=0.32). Fluid overload developed in 20.5% of the patients who received aggressive resuscitation and in 6.3% of those who received moderate resuscitation (adjusted relative risk, 2.85; 95% CI, 1.36 to 5.94, P=0.004). The median duration of hospitalization was 6 days (interquartile range, 4 to 8) in the aggressive-resuscitation group and 5 days (interquartile range, 3 to 7) in the moderate-resuscitation group. Conclusions In this randomized trial involving patients with acute pancreatitis, early aggressive fluid resuscitation resulted in a higher incidence of fluid overload without improvement in clinical outcomes.	[De-Madaria, E.; Guilabert, L.; Vaillo-Rocamora, A.] Dr Balmis Gen Univ Hosp, Dept Gastroenterol, ISABIAL Inst Invest Sanitaria & Biomed Alicante, Alicante, Spain; [Zapater, P.] Dr Balmis, Dept Clin Pharmacol, ISABIAL Inst Invest Sanitaria & Biomed Alicante, Alicante, Spain; [De-Madaria, E.] Miguel Hernandez Univ, Fac Med, Dept Clin Med, Elche, Spain; [Garcia de Paredes, A. Garcia; Rodriguez-Gandia, M. A.; Donate-Ortega, J.] Univ Alcala, Inst Ramon y Cajal Invest Sanitaria, Hosp Univ Ramon y Cajal, Dept Gastroenterol & Hepatol, Alcala De Henares, Spain; [Zapater, P.; Casals-Seoane, F.] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain; [Casals-Seoane, F.] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa, Gastroenterol Unit, Madrid, Spain; [Lira-Aguilar, A.; Llovet, L. P.; ERICA Consortium] Corp Sanitaria Parc Tauli, Gastroenterol & Digest Endoscopy Unit, Sabadell, Spain; [Navarro, P.; Sanchez-Pardo, A. M.] Hosp Clin Univ Valencia, Dept Gastroenterol, Valencia, Spain; [Sanchez-Marin, C.; Cobreros, M.] Marques de Valdecilla Univ Hosp, Dept Gastroenterol & Hepatol, Santander, Spain; [Fernandez-Cabrera, I] Hosp Dr Negrin, Dept Gastroenterol, Las Palmas Gran Canaria, Spain; [Deza, D. Casas; Camacho-Montano, L. M.] Miguel Servet Univ Hosp, Dept Gastroenterol, Zaragoza, Spain; [Deza, D. Casas; Camacho-Montano, L. M.] Hlth Res Inst Aragon, Zaragoza, Spain; [Lauret-Brana, E.] Cent Asturias Univ Hosp, Inst Invest Sanitaria Principado Asturias, Dept Gastroenterol, Oviedo, Spain; [Marti-Marques, E.] Lucus Augusti Univ Hosp, Dept Gastroenterol, Lugo, Spain; [Ubieto, V; Ganuza, M.; Bolado, F.] Univ Hosp Navarre, Dept Gastroenterol, Pamplona, Spain; [Buxbaum, J. L.] Univ Southern Calif, Div Gastroenterol, Los Angeles, CA 90007 USA; [Maisonneuve, P.] IRCSS European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy; [Lozada-Hernandez, E. E.; Collazo Moreno, A. J. R.] Reg Hosp High Specialty Bajio, Gen Surg Unit, Dept Dis Digest Tract, Leon, Mexico; [Mehta, R.; Tandel, R.] Surat Inst Digest Sci Hosp & Res Ctr, Dept Gastroenterol, Surat, India	General University Hospital of Alicante; Universidad Miguel Hernandez de Elche; Universitat d'Alacant; Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL); General University Hospital of Alicante; Universidad Miguel Hernandez de Elche; Universitat d'Alacant; Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL); Universidad Miguel Hernandez de Elche; Hospital Universitario Ramon y Cajal; Universidad de Alcala; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Hospital Clinic Universitari de Valencia; Hospital Universitario Marques de Valdecilla (HUMV); Miguel Servet University Hospital; Instituto de Investigacion Sanitaria del Principado de Asturias (ISPA); Hospital Universitario Lucus Augusti-Lugo; Servicio Navarro de Salud - Osasunbidea; University of Southern California	De-Madaria, E (corresponding author), Dr Balmis Gen Univ Hosp, Dept Gastroenterol, ISABIAL Inst Invest Sanitaria & Biomed Alicante, Alicante, Spain.; De-Madaria, E (corresponding author), Miguel Hernandez Univ, Fac Med, Dept Clin Med, Elche, Spain.	emadaria@umh.es	Ezquerra, Alberto/HHM-5658-2022; Casas-Deza, Diego/AAB-3462-2020; Campos-Serra, Andrea/AAR-4148-2021; Maisonneuve, Patrick/U-9789-2018; de-Madaria, Enrique/F-5225-2013; Pablo, Navarro/I-4329-2017	Ezquerra, Alberto/0000-0002-1892-6317; Casas-Deza, Diego/0000-0001-6883-8940; Campos-Serra, Andrea/0000-0001-6970-7141; Maisonneuve, Patrick/0000-0002-5309-4704; de-Madaria, Enrique/0000-0002-2412-9541; Pablo, Navarro/0000-0001-6228-3462	Instituto de Salud Carlos III [PI19/01628]; European Commission, European Regional Development Funds; Spanish Association of Gastroenterology; ISABIAL (Instituto de Investigacion Sanitaria y Biomedica de Alicante) [UGP-20-117]; Italian Ministry of Health	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Commission, European Regional Development Funds; Spanish Association of Gastroenterology; ISABIAL (Instituto de Investigacion Sanitaria y Biomedica de Alicante); Italian Ministry of Health(Ministry of Health, Italy)	Supported by grants from Instituto de Salud Carlos III (PI19/01628, co-funded by the European Commission, European Regional Development Funds), the Spanish Association of Gastroenterology (Gonzalo-Mino 2019), and ISABIAL (Instituto de Investigacion Sanitaria y Biomedica de Alicante) (UGP-20-117). Mr. Maisonneuve was supported by the Italian Ministry of Health, Ricerca Corrente, and 5x1000 funds.	Acheampong A, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0970-1; Baillargeon JD, 1998, AM J GASTROENTEROL, V93, P2130; Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Besselink M, 2013, PANCREATOLOGY, V13, pE1, DOI 10.1016/j.pan.2013.07.063; Bolado F, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00440; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Brown A, 2000, PANCREAS, V20, P367, DOI 10.1097/00006676-200005000-00005; Buxbaum JL, 2017, AM J GASTROENTEROL, V112, P797, DOI 10.1038/ajg.2017.40; Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; de-Madaria E, 2021, GUT, V70, P139, DOI 10.1136/gutjnl-2020-320729; de-Madaria E, 2014, CLIN GASTROENTEROL H, V12, P997, DOI 10.1016/j.cgh.2013.10.017; de-Madaria E, 2011, AM J GASTROENTEROL, V106, P1843, DOI 10.1038/ajg.2011.236; Di Martino M, 2021, HPB, V23, P1629, DOI 10.1016/j.hpb.2021.06.426; En-Qiang M, 2009, CHINESE MED J-PEKING, V122, P169, DOI 10.3760/cma.j.issn.0366-6999.2009.02.011; Gardner TB, 2021, ANN INTERN MED, V174, pITC17, DOI 10.7326/AITC202102160; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Hjortrup PB, 2016, INTENS CARE MED, V42, P1695, DOI 10.1007/s00134-016-4500-7; Johnson CD, 2004, GUT, V53, P1340, DOI 10.1136/gut.2004.039883; Juvonen PO, 1999, SCAND J GASTROENTERO, V34, P308; Kahan BC, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-99; Kinnala PJ, 2002, SCAND J GASTROENTERO, V37, P845, DOI 10.1080/713786530; KUSTERER K, 1991, AM J PHYSIOL, V260, pG346, DOI 10.1152/ajpgi.1991.260.2.G346; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; Malbrain MLNG, 2014, ANAESTH INTENSIVE TH, V46, P361, DOI 10.5603/AIT.2014.0060; Mao EQ, 2010, CHINESE MED J-PEKING, V123, P1639, DOI 10.3760/cmaj.issn.0366-6999.2010.13.005; Messmer AS, 2020, CRIT CARE MED, V48, P1862, DOI 10.1097/CCM.0000000000004617; NIEDERAU C, 1988, GASTROENTEROLOGY, V95, P1648, DOI 10.1016/S0016-5085(88)80091-X; Ramirez-Maldonado E, 2021, ANN SURG, V274, P255, DOI 10.1097/SLA.0000000000004596; Singh VK, 2017, UNITED EUR GASTROENT, V5, P491, DOI 10.1177/2050640616671077; Sternby H, 2019, ANN SURG, V270, P348, DOI 10.1097/SLA.0000000000002766; Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218; Todd J, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-85; Vege SS, 2018, GASTROENTEROLOGY, V154, P1103, DOI 10.1053/j.gastro.2018.01.031; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Wu BU, 2008, GUT, V57, P1698, DOI 10.1136/gut.2008.152702; Wu BU, 2011, ARCH INTERN MED, V171, P669, DOI 10.1001/archinternmed.2011.126	38	5	5	24	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 15	2022	387	11					989	1000		10.1056/NEJMoa2202884	http://dx.doi.org/10.1056/NEJMoa2202884			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5E1UZ	36103415				2023-01-03	WOS:000865415300010
J	Fratzl, A; Hofer, SB				Fratzl, Alex; Hofer, Sonja B.			The caudal prethalamus: Inhibitory switchboard for behavioral control?	NEURON			English	Review							VENTRAL LATERAL GENICULATE; ZONA INCERTA LESIONS; RECEPTIVE-FIELD PROPERTIES; SUPERIOR COLLICULUS; VISUAL-CORTEX; INTERGENICULATE LEAFLET; BASAL GANGLIA; DOPAMINERGIC-NEURONS; HYPOTHALAMIC TRACT; BRAIN-STEM	Prethalamic nuclei in the mammalian brain include the zona incerta, the ventral lateral geniculate nucleus, and the intergeniculate leaflet, which provide long-range inhibition to many targets in the midbrain, hindbrain, and thalamus. These nuclei in the caudal prethalamus can integrate sensory and non-sensory information, and together they exert powerful inhibitory control over a wide range of brain functions and behaviors that encompass most aspects of the behavioral repertoire of mammals, including sleep, circadian rhythms, feeding, drinking, predator avoidance, and exploration. In this perspective, we highlight the evidence for this wide-ranging control and lay out the hypothesis that one role of caudal prethalamic nuclei may be that of a behavioral switchboard that-depending on the sensory input, the behavioral context, and the state of the animal-can promote a behavioral strategy and suppress alternative, competing behaviors by modu-lating inhibitory drive onto diverse target areas.	[Fratzl, Alex; Hofer, Sonja B.] UCL, Sainsbury Wellcome Ctr Neural Circuits & Behav, London, England; [Fratzl, Alex] Inst Mol & Clin Ophthalmol Basel, CH-4031 Basel, Switzerland	University of London; University College London	Hofer, SB (corresponding author), UCL, Sainsbury Wellcome Ctr Neural Circuits & Behav, London, England.	s.hofer@ucl.ac.uk			Wellcome [219627/Z/19/Z]; Wellcome Investigator Award [219561/Z/19/Z]; Gatsby Charitable Foundation	Wellcome; Wellcome Investigator Award; Gatsby Charitable Foundation	We thank Tom Mrsic-Flogel, Marcus Stephenson -Jones, Mehran Ahmadlou, and Fred Marbach for comments on the manuscript. This work was supported by the Sainsbury Wellcome Centre Core Grant from the Gatsby Charitable Foundation and Wellcome (219627/Z/19/Z) and a Wellcome Investigator Award (S.B.H., 219561/Z/19/Z) .	Ahmadlou M, 2021, SCIENCE, V372, P704, DOI 10.1126/science.abe9681; Barbier M, 2021, ENEURO, V8, DOI 10.1523/ENEURO.0116-21.2021; Bartho P, 2007, J NEUROSCI, V27, P1670, DOI 10.1523/JNEUROSCI.3768-06.2007; Beltramo R, 2019, SCIENCE, V363, P64, DOI 10.1126/science.aau7052; BIELLO SM, 1991, BRAIN RES, V552, P47, DOI 10.1016/0006-8993(91)90658-I; Blanco-Centurion C, 2021, SLEEP, V44, DOI 10.1093/sleep/zsaa268; Blot A, 2021, NEURON, V109, P1996, DOI 10.1016/j.neuron.2021.04.017; Bolton AD, 2015, CELL REP, V13, P1003, DOI 10.1016/j.celrep.2015.09.046; BOURASSA J, 1995, NEUROSCIENCE, V66, P253, DOI 10.1016/0306-4522(95)00009-8; Branco T, 2020, ANNU REV NEUROSCI, V43, P417, DOI 10.1146/annurev-neuro-100219-122527; BROWN B, 1980, BRAIN RES BULL, V5, P593, DOI 10.1016/0361-9230(80)90266-X; Chen CG, 2018, J NEUROSCI, V38, P3318, DOI 10.1523/JNEUROSCI.2173-17.2018; CHEVALIER G, 1990, TRENDS NEUROSCI, V13, P277, DOI 10.1016/0166-2236(90)90109-N; Chou XL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03581-6; Ciftcioglu UM, 2020, J NEUROSCI, V40, P5019, DOI 10.1523/JNEUROSCI.2602-19.2020; Clark RE, 1997, LEARN MEMORY, V3, P532, DOI 10.1101/lm.3.6.532; Cox J, 2019, NAT REV NEUROSCI, V20, P482, DOI 10.1038/s41583-019-0189-2; Crabtree JW, 2018, FRONT SYST NEUROSCI, V12, DOI 10.3389/fnsys.2018.00041; Crabtree JW, 2002, J NEUROSCI, V22, P8754; De Zeeuw CI, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a021683; Delaunay D, 2009, J COMP NEUROL, V512, P74, DOI 10.1002/cne.21904; Do MTH, 2010, PHYSIOL REV, V90, P1547, DOI 10.1152/physrev.00013.2010; Doykos TK, 2020, J COMP NEUROL, V528, P2254, DOI 10.1002/cne.24888; Edelstein K, 1999, J NEUROSCI, V19, P372, DOI 10.1523/JNEUROSCI.19-01-00372.1999; EDWARDS DA, 1991, BEHAV BRAIN RES, V44, P145, DOI 10.1016/S0166-4328(05)80019-1; Escudero G, 2019, NEUROSCIENCE, V406, P626, DOI 10.1016/j.neuroscience.2019.01.059; Essig J, 2016, TRENDS NEUROSCI, V39, P2, DOI 10.1016/j.tins.2015.12.002; Evans DA, 2018, NATURE, V558, P590, DOI 10.1038/s41586-018-0244-6; EVERED MD, 1976, AM J PHYSIOL, V230, P1049, DOI 10.1152/ajplegacy.1976.230.4.1049; EVERED MD, 1977, AM J PHYSIOL, V233, pR53, DOI 10.1152/ajpregu.1977.233.1.R53; Fernandez DC, 2020, NATURE, V581, P194, DOI 10.1038/s41586-020-2204-1; Fratzl A, 2021, NEURON, V109, P3810, DOI 10.1016/j.neuron.2021.09.003; Gall AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067387; Golden RN, 2005, AM J PSYCHIAT, V162, P656, DOI 10.1176/appi.ajp.162.4.656; Gooley J.J., 2005, PRINCIPLES PRACTICE, P335; GRAYBIEL AM, 1974, EXP BRAIN RES, V20, P303; Groh A, 2014, CEREB CORTEX, V24, P3167, DOI 10.1093/cercor/bht173; Halassa MM, 2016, TRENDS NEUROSCI, V39, P680, DOI 10.1016/j.tins.2016.08.001; Halverson HE, 2010, LEARN MEMORY, V17, P80, DOI 10.1101/lm.1572710; Halverson HE, 2009, LEARN MEMORY, V16, P300, DOI 10.1101/lm.1340909; Hammer S, 2014, NEURAL DEV, V9, DOI 10.1186/1749-8104-9-16; Harrington ME, 1997, NEUROSCI BIOBEHAV R, V21, P705, DOI 10.1016/S0149-7634(96)00019-X; Hattar S, 2006, J COMP NEUROL, V497, P326, DOI 10.1002/cne.20970; Hikosaka O, 2007, PROG BRAIN RES, V160, P209, DOI 10.1016/S0079-6123(06)60012-5; Hikosaka O, 2000, PHYSIOL REV, V80, P953, DOI 10.1152/physrev.2000.80.3.953; HIKOSAKA O, 1983, J NEUROPHYSIOL, V49, P1230; HOFFMANN KP, 1971, EXP BRAIN RES, V12, P120; HOLCOMBE V, 1984, J COMP NEUROL, V225, P469, DOI 10.1002/cne.902250402; Hormigo S, 2020, ENEURO, V7, DOI 10.1523/ENEURO.0390-19.2020; Hu TT, 2019, J NEUROSCI, V39, P9130, DOI 10.1523/JNEUROSCI.1683-19.2019; Hu ZF, 2022, NEURON, V110, P1712, DOI 10.1016/j.neuron.2022.02.009; Huang L, 2019, NEURON, V102, P128, DOI 10.1016/j.neuron.2019.01.037; Huang XD, 2021, NEURON, V109, P347, DOI 10.1016/j.neuron.2020.10.023; HUANG YH, 1972, EXP NEUROL, V37, P269, DOI 10.1016/0014-4886(72)90073-8; Inagaki HK, 2022, CELL, V185, P1065, DOI 10.1016/j.cell.2022.02.006; JAMES MD, 1987, NEUROENDOCRINOLOGY, V45, P348, DOI 10.1159/000124758; JIRIKOWSKI GF, 1991, CELL TISSUE RES, V266, P399, DOI 10.1007/BF00318196; JIRIKOWSKI GF, 1988, NEUROSCIENCE, V25, P237, DOI 10.1016/0306-4522(88)90022-X; JOHNSON RF, 1988, P NATL ACAD SCI USA, V85, P5301, DOI 10.1073/pnas.85.14.5301; Jurkowlaniec E, 1990, Acta Physiol Pol, V41, P85; KAELBER WW, 1979, EXP NEUROL, V63, P177, DOI 10.1016/0014-4886(79)90192-4; Kashef A, 2014, J NEUROPHYSIOL, V112, P2234, DOI 10.1152/jn.00185.2013; Kebschull JM, 2020, SCIENCE, V370, DOI 10.1126/science.abd5059; KIYOHARA T, 1995, BRAIN RES BULL, V38, P193, DOI 10.1016/0361-9230(95)00093-T; Kolmac C, 1999, ANAT EMBRYOL, V199, P265, DOI 10.1007/s004290050227; Kolmac C, 2000, VISUAL NEUROSCI, V17, P313, DOI 10.1017/S0952523800002108; Kolmac CI, 1998, J COMP NEUROL, V396, P544, DOI 10.1002/(SICI)1096-9861(19980713)396:4<544::AID-CNE10>3.0.CO;2-G; KOUTALIDIS O, 1988, J NEUROSCI, V8, P417; Koyama Y, 2003, NEUROSCIENCE, V119, P1209, DOI 10.1016/S0306-4522(03)00173-8; Kratochwil CF, 2017, FRONT NEURAL CIRCUIT, V11, DOI 10.3389/fncir.2017.00033; Lavallee P, 2005, J NEUROSCI, V25, P7489, DOI 10.1523/JNEUROSCI.2301-05.2005; LEGG CR, 1977, PHYSIOL BEHAV, V19, P635, DOI 10.1016/0031-9384(77)90038-5; LEGG CR, 1977, BRAIN RES, V123, P261, DOI 10.1016/0006-8993(77)90478-4; LEGG CR, 1979, BRAIN RES, V177, P461, DOI 10.1016/0006-8993(79)90464-5; Lewandowski MH, 2002, BEHAV BRAIN RES, V128, P13, DOI 10.1016/S0166-4328(01)00264-9; Li ZL, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf6709; LIN CS, 1990, SCIENCE, V248, P1553, DOI 10.1126/science.2360049; Lin RCS, 1997, NEUROSCIENCE, V81, P641, DOI 10.1016/S0306-4522(97)00094-8; Liu J, 2015, ELIFE, V4, DOI 10.7554/eLife.09215; Liu K, 2017, NATURE, V548, P582, DOI 10.1038/nature23663; Livingston CA, 2000, BRAIN RES, V876, P166, DOI 10.1016/S0006-8993(00)02647-0; Livingston CA, 2003, J NEUROPHYSIOL, V90, P226, DOI 10.1152/jn.00033.2003; Lu CW, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87873-w; Ma TP, 1996, NEUROREPORT, V7, P2713, DOI 10.1097/00001756-199611040-00061; MACKENZIE FJ, 1984, NEUROENDOCRINOLOGY, V39, P289, DOI 10.1159/000123995; MAGNIN M, 1974, EXP BRAIN RES, V21, P1; Masri R, 2009, J NEUROPHYSIOL, V102, P181, DOI 10.1152/jn.00152.2009; McElvain LE, 2021, NEURON, V109, P1721, DOI 10.1016/j.neuron.2021.03.017; Meng XW, 1998, NEUROSCI LETT, V256, P89, DOI 10.1016/S0304-3940(98)00771-X; MEYER EL, 1993, PHYSIOL BEHAV, V53, P237, DOI 10.1016/0031-9384(93)90199-P; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; Mitofanis J, 2002, ANAT EMBRYOL, V205, P453, DOI 10.1007/s00429-002-0268-3; Mitrofanis J, 2005, NEUROSCIENCE, V130, P1, DOI 10.1016/j.neuroscience.2004.08.017; Mitrofanis J, 2001, ANAT EMBRYOL, V204, P153, DOI 10.1007/s004290100187; Mitrofanis J, 1999, J COMP NEUROL, V412, P173; MOGENSON GJ, 1985, BRAIN RES, V334, P65, DOI 10.1016/0006-8993(85)90568-2; MOK D, 1986, AM J PHYSIOL, V251, pR823, DOI 10.1152/ajpregu.1986.251.5.R823; MOK D, 1987, BRAIN RES, V407, P332, DOI 10.1016/0006-8993(87)91112-7; Monavarfeshani A, 2017, VISUAL NEUROSCI, V34, DOI 10.1017/S0952523817000098; Moon HC, 2017, J PAIN RES, V10, P1125, DOI 10.2147/JPR.S131104; Moore RY, 2000, J COMP NEUROL, V420, P398, DOI 10.1002/(SICI)1096-9861(20000508)420:3<398::AID-CNE9>3.0.CO;2-9; Morin LP, 2013, EXP NEUROL, V243, P4, DOI 10.1016/j.expneurol.2012.06.026; MUNDINGER F, 1965, CONFIN NEUROL, V26, P222; MURER MG, 1993, NEUROREPORT, V4, P1219, DOI 10.1097/00001756-199309000-00002; NAGATA T, 1984, J COMP NEUROL, V227, P582, DOI 10.1002/cne.902270409; Nakagawa Y, 2019, WIRES DEV BIOL, V8, DOI 10.1002/wdev.345; Nakamura H, 2004, J COMP NEUROL, V473, P439, DOI 10.1002/cne.20074; Nakamura H, 2018, J NEUROSCI RES, V96, P63, DOI 10.1002/jnr.24105; NAQUET R, 1966, ELECTROEN CLIN NEURO, V20, P149, DOI 10.1016/0013-4694(66)90159-3; Nelson AB, 2014, ANNU REV NEUROSCI, V37, P117, DOI 10.1146/annurev-neuro-071013-013916; NICOLELIS MAL, 1995, NEUROSCIENCE, V65, P609, DOI 10.1016/0306-4522(94)00493-O; NICOLELIS MAL, 1992, BRAIN RES, V577, P134, DOI 10.1016/0006-8993(92)90546-L; NIIMI K, 1963, J COMP NEUROL, V121, P313, DOI 10.1002/cne.901210303; OGASAWARA K, 1984, J NEUROPHYSIOL, V52, P1226, DOI 10.1152/jn.1984.52.6.1226; Ogasawara T, 2022, NAT NEUROSCI, V25, P50, DOI 10.1038/s41593-021-00950-1; Ossowska K, 2020, J NEUROL, V267, P591, DOI 10.1007/s00415-019-09486-8; Osterhout JA, 2011, NEURON, V71, P632, DOI 10.1016/j.neuron.2011.07.006; Petersen CCH, 2007, NEURON, V56, P339, DOI 10.1016/j.neuron.2007.09.017; Petronilho A, 2012, PHARMACOL BIOCHEM BE, V101, P360, DOI 10.1016/j.pbb.2012.01.022; Pienaar A, 2018, J PHYSIOL-LONDON, V596, P5461, DOI 10.1113/JP276917; Pinato L, 2009, J CHEM NEUROANAT, V37, P207, DOI 10.1016/j.jchemneu.2009.01.005; Plaha P, 2006, BRAIN, V129, P1732, DOI 10.1093/brain/awl127; Power BD, 1999, J COMP NEUROL, V404, P554; Puelles L, 2013, COMPREHENSIVE DEVELOPMENTAL NEUROSCIENCE: PATTERNING AND CELL TYPE SPECIFICATION IN THE DEVELOPING CNS AND PNS, P151, DOI 10.1016/B978-0-12-397265-1.00048-4; Puelles L, 2021, J COMP NEUROL, V529, P367, DOI 10.1002/cne.24952; Rivlin-Etzion M, 2011, J NEUROSCI, V31, P8760, DOI 10.1523/JNEUROSCI.0564-11.2011; Sabbagh U, 2021, J NEUROCHEM, V159, P479, DOI 10.1111/jnc.15101; Salay LD, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109792; SCHILLER PH, 1974, J NEUROPHYSIOL, V37, P181, DOI 10.1152/jn.1974.37.1.181; SHAMMAHLAGNADO SJ, 1985, NEUROSCIENCE, V15, P109, DOI 10.1016/0306-4522(85)90127-7; Shang CP, 2019, NAT NEUROSCI, V22, P909, DOI 10.1038/s41593-019-0405-4; Shaw V, 2002, ANAT EMBRYOL, V206, P119, DOI 10.1007/s00429-002-0280-7; Sherman SM, 2016, NAT NEUROSCI, V19, P533, DOI 10.1038/nn.4269; Shi HY, 2020, SLEEP, V43, DOI 10.1093/sleep/zsz212; Siddiqui A, 2000, NEUROENDOCRINOLOGY, V72, P272, DOI 10.1159/000054596; Simpson K, 2008, J COMP NEUROL, V507, P1521, DOI 10.1002/cne.21624; Smith VM, 2015, EUR J NEUROSCI, V42, P2805, DOI 10.1111/ejn.13064; SPEAR PD, 1977, J NEUROPHYSIOL, V40, P390, DOI 10.1152/jn.1977.40.2.390; SPENCER SE, 1988, BRAIN RES, V458, P72, DOI 10.1016/0006-8993(88)90497-0; STARZL TE, 1951, J NEUROPHYSIOL, V14, P461, DOI 10.1152/jn.1951.14.6.461; Steinmetz AB, 2013, BEHAV NEUROSCI, V127, P690, DOI 10.1037/a0033729; Steinmetz NA, 2019, NATURE, V576, P266, DOI 10.1038/s41586-019-1787-x; SUMITOMO I, 1979, EXP NEUROL, V66, P721, DOI 10.1016/0014-4886(79)90216-4; TONELLI L, 1995, PHYSIOL BEHAV, V58, P725, DOI 10.1016/0031-9384(95)00128-6; Trageser JC, 2006, J NEUROPHYSIOL, V96, P1456, DOI 10.1152/jn.00423.2006; Trageser JC, 2004, J NEUROSCI, V24, P8911, DOI 10.1523/JNEUROSCI.3218-04.2004; Urbain N, 2007, NEURON, V56, P714, DOI 10.1016/j.neuron.2007.10.023; VAUDANO E, 1992, ANAT EMBRYOL, V186, P583; Venkataraman A, 2021, NEUROPSYCHOPHARMACOL, V46, P1658, DOI 10.1038/s41386-021-01006-5; Venkataraman A, 2019, P NATL ACAD SCI USA, V116, P9072, DOI 10.1073/pnas.1820541116; WAGNER CK, 1995, BRAIN RES, V677, P229, DOI 10.1016/0006-8993(95)00128-D; WALSH LL, 1976, PHYSIOL BEHAV, V16, P211, DOI 10.1016/0031-9384(76)90307-3; WALSH LL, 1973, PHYSIOL BEHAV, V11, P885, DOI 10.1016/0031-9384(73)90285-0; WALSH LL, 1977, PHYSIOL BEHAV, V18, P587, DOI 10.1016/0031-9384(77)90057-9; Wang H, 2020, NEURON, V107, P538, DOI 10.1016/j.neuron.2020.04.027; Wang LP, 2010, J NEUROSCI, V30, P16573, DOI 10.1523/JNEUROSCI.3305-10.2010; Wang XY, 2019, ELIFE, V8, DOI 10.7554/eLife.42728; Watson C, 2014, J ANAT, V224, P95, DOI 10.1111/joa.12132; Weitz AJ, 2019, NEURON, V104, P1153, DOI 10.1016/j.neuron.2019.09.023; WICKELGREN BG, 1969, J NEUROPHYSIOL, V32, P16, DOI 10.1152/jn.1969.32.1.16; Wolff M, 2021, NEUROSCI BIOBEHAV R, V120, P222, DOI 10.1016/j.neubiorev.2020.11.013; Ye QY, 2021, J PHYSIOL-LONDON, V599, P4883, DOI 10.1113/JP282088; Yilmaz M, 2013, CURR BIOL, V23, P2011, DOI 10.1016/j.cub.2013.08.015; Zhang XB, 2017, SCIENCE, V356, P853, DOI 10.1126/science.aam7100; Zhao XY, 2014, NEURON, V84, P202, DOI 10.1016/j.neuron.2014.08.037; Zhao ZD, 2019, NAT NEUROSCI, V22, P921, DOI 10.1038/s41593-019-0404-5; Zhou H, 2021, FRONT BEHAV NEUROSCI, V15, DOI 10.3389/fnbeh.2021.743484; Zhou HH, 2016, NEURON, V89, P209, DOI 10.1016/j.neuron.2015.11.034; Zhou M, 2018, NAT NEUROSCI, V21, P1515, DOI 10.1038/s41593-018-0248-4; ZIMNY R, 1986, J HIRNFORSCH, V27, P159	170	0	0	3	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	SEP 7	2022	110	17					2728	2742		10.1016/j.neuron.2022.07.018	http://dx.doi.org/10.1016/j.neuron.2022.07.018			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	4X7BA	36076337				2023-01-03	WOS:000860992000005
J	Lilje, D; Wiesmann, M; Hasan, D; Ridwan, H; Holzle, F; Nikoubashman, O				Lilje, Daniel; Wiesmann, Martin; Hasan, Dimah; Ridwan, Hani; Hoelzle, Frank; Nikoubashman, Omid			Interventional embolization combined with surgical resection for treatment of extracranial AVM of the head and neck: A monocentric retrospective analysis	PLOS ONE			English	Article							ABSOLUTE ETHANOL EMBOLIZATION; ARTERIOVENOUS-MALFORMATIONS; VASCULAR MALFORMATIONS; ENDOVASCULAR TREATMENT; MANAGEMENT; SCLEROTHERAPY; QUALITY	Objectives The aim of this study was to demonstrate the efficacy and feasibility of treating patients with extracranial arteriovenous malformations (AVM) of the head and neck with interventional embolization followed by surgical resection. Methods We reviewed the charts of all patients between 2012 and 2021 with extracranial AVM of the head and neck scheduled for interdisciplinary treatment according to University Hospital RWTH Aachen's protocol and conducted standardized interviews using a newly developed questionnaire. Interview results, as well as clinical examination and radiographic outcome results were analyzed to help determine the efficacy of our treatment approach. Results We included 10 patients (8 female, 2 male), with a mean age of 33.5 (11-61) years who were scheduled for treatment of the AVM with interventional embolization followed by surgical resection. In 6 of the 10 patients (60%) the lesion was located in extracranial soft tissue only. In one patient (10%), the lesion was located in bone tissue only. A combined intraosseous and oral soft tissue lesion was seen in the remaining 3 patients (30%). Radiographic resolution was achieved in 62.5% of cases and a significant decrease of symptoms was identified (p = 0.002). None of the patients reported dissatisfaction and no major complications occurred. Conclusion An interdisciplinary treatment approach combining neuroradiological interventions with surgical resection appears to be an effective treatment with an acceptable complication rate. Patients treated according to our protocol showed a high satisfaction rate, regardless of the radiographic outcome. Standardized follow-up allows for early detection of recurrences and helps with subjective patient satisfaction.	[Lilje, Daniel; Wiesmann, Martin; Hasan, Dimah; Ridwan, Hani; Nikoubashman, Omid] Univ Hosp RWTH Aachen, Dept Neuroradiol, Aachen, Germany; [Hoelzle, Frank] Univ Hosp RWTH Aachen, Dept Oral & Maxillofacial Surg, Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital	Nikoubashman, O (corresponding author), Univ Hosp RWTH Aachen, Dept Neuroradiol, Aachen, Germany.	onikoubashman@ukaachen.de						Bhandari PS, 2008, INDIAN J PLAST SURG, V41, P183, DOI 10.4103/0970-0358.44943; Murillo-Zumbado Gustavo, 2021, Tecnología en Marcha, V34, P130, DOI [10.18845/tm.v34i4.5274, 10.1103/PhysRevE.106.055304]; Chen WL, 2009, ORAL SURG ORAL MED O, V108, P41, DOI 10.1016/j.tripleo.2009.03.006; Churojana A, 2004, INTERV NEURORADIOL, V10, P37, DOI 10.1177/159101990401000103; Dabus G, 2017, J NEUROINTERV SURG, V9, P92, DOI 10.1136/neurintsurg-2016-012315; Dasgupta R, 2014, SEMIN PEDIATR SURG, V23, P158, DOI 10.1053/j.sempedsurg.2014.06.016; Deng W, 2010, J CRANIOFAC SURG, V21, P916, DOI 10.1097/SCS.0b013e3181d880fd; Fan XD, 2009, AM J NEURORADIOL, V30, P1178, DOI 10.3174/ajnr.A1539; Fernandez-Alvarez V, 2020, AURIS NASUS LARYNX, V47, P181, DOI 10.1016/j.anl.2019.11.008; Gupta AK, 2008, NEUROL INDIA, V56, P167, DOI 10.4103/0028-3886.41995; HAMILTON MG, 1994, NEUROSURGERY, V34, P2; Han YF, 2018, J VASC INTERV RADIOL, V29, P312, DOI 10.1016/j.jvir.2017.10.005; Horbach SER, 2020, QUAL LIFE RES, V29, P1, DOI 10.1007/s11136-019-02301-x; Hsu YC, 2020, ASIAN J SURG, V43, P1016, DOI 10.1016/j.asjsur.2020.05.035; Ishimaru H, 2019, ADV WOUND CARE, V8, P256, DOI 10.1089/wound.2018.0846; Jackson JL, 1997, MIL MED, V162, P273, DOI 10.1093/milmed/162.4.273; Kang GCW, 2008, ANN ACAD MED SINGAP, V37, P165; Kim B, 2015, NEURORADIOLOGY, V57, P377, DOI 10.1007/s00234-014-1483-3; Kitagawa A, 2014, CARDIOVASC INTER RAD, V37, P371, DOI 10.1007/s00270-013-0653-8; Kohout MP, 1998, PLAST RECONSTR SURG, V102, P643, DOI 10.1097/00006534-199809030-00006; Liu AS, 2010, PLAST RECONSTR SURG, V125, P1185, DOI 10.1097/PRS.0b013e3181d18070; Meila D, 2017, J NEUROINTERV SURG, V9, P860, DOI 10.1136/neurintsurg-2016-012570; Nikolsky Eugenia, 2007, J Invasive Cardiol, V19, P208; Pekkola J, 2013, AM J NEURORADIOL, V34, P198, DOI 10.3174/ajnr.A3180; Phillips Jh, 2005, Can J Plast Surg, V13, P23; Pompa V, 2012, EUR REV MED PHARMACO, V16, P407; Pompa V, 2011, ANN ITAL CHIR, V82, P253; Richter GT, 2010, OTOLARYNG HEAD NECK, V142, P184, DOI 10.1016/j.otohns.2009.10.023; Rogers SN, 2009, ARCH OTOLARYNGOL, V135, P369, DOI 10.1001/archoto.2009.7; Rogers SN., 2020, U WASHINGTON QUALITY; Sacks David, 2003, J Vasc Interv Radiol, V14, pS199; Su LX, 2015, J CRANIO MAXILL SURG, V43, P1082, DOI 10.1016/j.jcms.2015.06.007; Thiex R, 2011, AM J NEURORADIOL, V32, P1082, DOI 10.3174/ajnr.A2439; Vuori H, 1991, Qual Assur Health Care, V3, P183; Wang D, 2017, EUR J VASC ENDOVASC, V53, P862, DOI 10.1016/j.ejvs.2017.01.022; YIH WY, 1989, J ORAL MAXIL SURG, V47, P1154; Zhao XP, 2016, BRIT J ORAL MAX SURG, V54, P187, DOI 10.1016/j.bjoms.2015.11.020	37	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2022	17	9							e0273018	10.1371/journal.pone.0273018	http://dx.doi.org/10.1371/journal.pone.0273018			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R4GI	36048777	gold, Green Published			2023-01-03	WOS:000892263300041
J	Hwang, TJ; Kesselheim, AS; Rome, BN				Hwang, Thomas J.; Kesselheim, Aaron S.; Rome, Benjamin N.			New Reforms to Prescription Drug Pricing in the US Opportunities and Challenges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Hwang, Thomas J.; Kesselheim, Aaron S.; Rome, Benjamin N.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 75 Francis St, Boston, MA 02115 USA; [Hwang, Thomas J.; Kesselheim, Aaron S.; Rome, Benjamin N.] Harvard Med Sch, Boston, MA 02115 USA; [Hwang, Thomas J.] Brigham & Womens Hosp, Div Urol Surg, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Kesselheim, AS (corresponding author), 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	akesselheim@bwh.harvard.edu			Arnold Ventures	Arnold Ventures	This work was supported by Arnold Ventures.	[Anonymous], INFLATION REDUCTION; Congressional Budget Office, ESTIMATED BUDGETARY; Hwang TJ, 2019, JAMA-J AM MED ASSOC, V322, P267, DOI 10.1001/jama.2019.7521; Kesselheim AS, 2021, JAMA-J AM MED ASSOC, V325, P819, DOI 10.1001/jama.2021.0009; Rome BN, 2022, JAMA-J AM MED ASSOC, V327, P2145, DOI 10.1001/jama.2022.5542; Rome BN, 2021, CLIN PHARMACOL THER, V109, P367, DOI 10.1002/cpt.1983; Trish EE, 2019, NEW ENGL J MED, V381, P2384, DOI 10.1056/NEJMp1912357	7	3	3	3	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2022	328	11					1041	1042		10.1001/jama.2022.15268	http://dx.doi.org/10.1001/jama.2022.15268		AUG 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5A5DY	35984652				2023-01-03	WOS:000841927800001
J	Kozlov, M				Kozlov, Max			PIG ORGANS PARTIALLY REVIVED IN DEAD ANIMALS - RESEARCHERS ARE STUNNED	NATURE			English	Editorial Material																		Andrijevic D, 2022, NATURE, V608, P405, DOI 10.1038/s41586-022-05016-1; Vrselja Z, 2019, NATURE, V568, P336, DOI 10.1038/s41586-019-1099-1	2	0	0	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 11	2022	608	7922					247	248		10.1038/d41586-022-02112-0	http://dx.doi.org/10.1038/d41586-022-02112-0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3S2QZ	35922494	Bronze			2023-01-03	WOS:000839447400010
J	Bearne, LM; Bieles, J; Peacock, J				Bearne, Lindsay M.; Bieles, Julie; Peacock, Janet			Home-Based, Walking Exercise Behavior Change Intervention vs Usual Care for Adults With Peripheral Artery Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PHYSICAL-ACTIVITY		[Bearne, Lindsay M.] Kingston & St Georges Univ London, Kings Coll London, London, England; [Bieles, Julie] Kings Coll London, London, England; [Peacock, Janet] Dartmouth Coll, Dept Epidemiol, Hanover, NH 03755 USA	St Georges University London; University of London; King's College London; University of London; King's College London; Dartmouth College	Bearne, LM (corresponding author), Kingston Univ, St Georges Campus,Hunter Wing,Sixth Floor, London SW17 0RE, England.; Bearne, LM (corresponding author), St Georges Univ London, Ctr Appl Hlth & Social Care Res, Fac Hlth Social Care & Educ, St Georges Campus,Hunter Wing,Sixth Floor, London SW17 0RE, England.	l.bearne@sgul.kingston.ac.uk						Bearne L, 2022, JAMA-J AM MED ASSOC, V327, P1344, DOI 10.1001/jama.2022.3391; Kaihara T., 2021, EUR J PREV CARDIOL, V29, P1047, DOI [10.1093/eurjpc/zwab146, DOI 10.1093/EURJPC/ZWAB146]; Kambic T, 2021, BIOSENSORS-BASEL, V11, DOI 10.3390/bios11090318; McDermott MM, 2000, ANGIOLOGY, V51, P91, DOI 10.1177/000331970005100201; Yates T, 2017, EUR HEART J, V38, P3232, DOI 10.1093/eurheartj/ehx449	5	0	0	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2022	328	6								10.1001/jama.2022.9750	http://dx.doi.org/10.1001/jama.2022.9750			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4E5FG	35943477				2023-01-03	WOS:000847850400025
J	Balboni, TA; VanderWeele, TJ; Doan-Soares, SD; Long, KNG; Ferrell, BR; Fitchett, G; Koenig, HG; Bain, PA; Puchalski, C; Steinhauser, KE; Sulmasy, DP; Koh, HK				Balboni, Tracy A.; VanderWeele, Tyler J.; Doan-Soares, Stephanie D.; Long, Katelyn N. G.; Ferrell, Betty R.; Fitchett, George; Koenig, Harold G.; Bain, Paul A.; Puchalski, Christina; Steinhauser, Karen E.; Sulmasy, Daniel P.; Koh, Howard K.			Spirituality in Serious Illness and Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ADVANCED CANCER-PATIENTS; MEDICAL-CARE; ASSOCIATIONS; QUALITY; PROVISION; RELIGION; SUPPORT; END	IMPORTANCE Despite growing evidence, the role of spirituality in serious illness and health has not been systematically assessed. OBJECTIVE To review evidence concerning spirituality in serious illness and health and to identify implications for patient care and health outcomes. EVIDENCE REVIEW Searches of PubMed, PsycINFO, and Web of Science identified articles with evidence addressing spirituality in serious illness or health, published January 2000 to April 2022. Independent reviewers screened, summarized, and graded articles that met eligibility criteria. Eligible serious illness studies included 100 or more participants; were prospective cohort studies, cross-sectional descriptive studies, meta-analyses, or randomized clinical trials; and included validated spirituality measures. Eligible health outcome studies prospectively examined associations with spirituality as cohort studies, case-control studies, or meta-analyses with samples of at least 1000 or were randomized trials with samples of at least 100 and used validated spirituality measures. Applying Cochrane criteria, studies were graded as having low, moderate, serious, or critical risk of bias, and studies with serious and critical risk of bias were excluded. Multidisciplinary Delphi panels consisting of clinicians, public health personnel, researchers, health systems leaders, and medical ethicists qualitatively synthesized and assessed the evidence and offered implications for health care. Evidence-synthesis statements and implications were derived from panelists' qualitative input; panelists rated the former on a 9-point scale (from "inconclusive" to "strongest evidence") and ranked the latter by order of priority. FINDINGS Of 8946 articles identified, 371 articles met inclusion criteria for serious illness; of these, 76.9% had low to moderate risk of bias. The Delphi panel review yielded 8 evidence statements supported by evidence categorized as strong and proposed 3 top-ranked implications of this evidence for serious illness: (1) incorporate spiritual care into care for patients with serious illness; (2) incorporate spiritual care education into training of interdisciplinary teams caring for persons with serious illness; and (3) include specialty practitioners of spiritual care in care of patients with serious illness. Of 6485 health outcomes articles, 215 met inclusion criteria; of these, 66.0% had low to moderate risk of bias. The Delphi panel review yielded 8 evidence statements supported by evidence categorized as strong and proposed 3 top-ranked implications of this evidence for health outcomes: (1) incorporate patient-centered and evidence-based approaches regarding associations of spiritual community with improved patient and population health outcomes; (2) increase awareness among health professionals of evidence for protective health associations of spiritual community; and (3) recognize spirituality as a social factor associated with health in research, community assessments, and program implementation. CONCLUSIONS AND RELEVANCE This systematic review, analysis, and process, based on highest-quality evidence available and expert consensus, provided suggested implications for addressing spirituality in serious illness and health outcomes as part of person-centered, value-sensitive care.	[Doan-Soares, Stephanie D.; Koh, Howard K.] Harvard Univ, John F Kennedy Sch Govt, 677 Huntington Ave, Boston, MA 02115 USA; [Balboni, Tracy A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol & Psychosocial Oncol, 75 Francis St, Boston, MA 02115 USA; [Balboni, Tracy A.; Bain, Paul A.] Harvard Med Sch, Boston, MA 02115 USA; [VanderWeele, Tyler J.; Long, Katelyn N. G.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [VanderWeele, Tyler J.; Long, Katelyn N. G.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [VanderWeele, Tyler J.; Long, Katelyn N. G.] Harvard Univ, Inst Quantitat Social Sci, Human Flourishing Program, Cambridge, MA 02138 USA; [Doan-Soares, Stephanie D.; Koh, Howard K.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Ferrell, Betty R.] City Hope Natl Med Ctr, Dept Populat Sci, Div Nursing Res & Educ, Duarte, CA USA; [Fitchett, George] Rush Univ, Med Ctr, Dept Relig Hlth & Human Values, Chicago, IL 60612 USA; [Koenig, Harold G.] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA; [Koenig, Harold G.] Duke Univ, Med Ctr, Dept Behav Sci, Durham, NC USA; [Koenig, Harold G.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Koenig, Harold G.] King Abdulaziz Univ, Dept Med, Jeddah, Saudi Arabia; [Puchalski, Christina] George Washington Univ, George Washington Inst Spiritual & Hlth, Dept Med, Washington, DC USA; [Puchalski, Christina] George Washington Univ, George Washington Inst Spiritual & Hlth, Dept Hlth Care Sci, Washington, DC USA; [Steinhauser, Karen E.] Duke Univ, Med Ctr, Dept Med, Div Palliat Med, Durham, NC 27710 USA; [Steinhauser, Karen E.] Durham VA Hlth Care Syst, Ctr Innovat Accelerate Discovery & Practice Trans, Durham, NC USA; [Sulmasy, Daniel P.] George Washington Univ, Kennedy Inst Eth, Dept Med & Philosophy, Washington, DC USA	Harvard University; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; City of Hope; Rush University; Duke University; Duke University; Duke University; King Abdulaziz University; George Washington University; George Washington University; Duke University; George Washington University	Koh, HK (corresponding author), Harvard Univ, Harvard TH Chan Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA.; Koh, HK (corresponding author), Harvard Univ, John F Kennedy Sch Govt, 677 Huntington Ave, Boston, MA 02115 USA.; Balboni, TA (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	tbalboni@bwh.harvard.edu; hkoh@hsph.harvard.edu			John Templeton Foundation	John Templeton Foundation	This study was supported in part by a grant from the John Templeton Foundation to Drs Balboni, VanderWeele, and Koh.	[Anonymous], REL LANDSC STUD; B?ssing, 2021, SPIRITUAL NEEDS RES, DOI [10.1007/978-3-030-70139-0, DOI 10.1007/978-3-030-70139-0]; Balboni MJ, 2014, J PAIN SYMPTOM MANAG, V48, P400, DOI 10.1016/j.jpainsymman.2013.09.020; Balboni TA, 2007, J CLIN ONCOL, V25, P555, DOI 10.1200/JCO.2006.07.9046; Balboni TA, 2013, JAMA INTERN MED, V173, P1109, DOI 10.1001/jamainternmed.2013.903; Balboni TA, 2010, J CLIN ONCOL, V28, P445, DOI 10.1200/JCO.2009.24.8005; Chida Y, 2009, PSYCHOTHER PSYCHOSOM, V78, P81, DOI 10.1159/000190791; Delgado-Guay MO, 2016, PALLIAT SUPPORT CARE, V14, P341, DOI 10.1017/S147895151500108X; Ferngren G.B., 2014, MED RELIG HIST INTRO; Fitch K., 2001, RAND UCLA APPROPRIAT; Gallup, REL AR AM; Garssen B, 2021, INT J PSYCHOL RELIG, V31, P4, DOI 10.1080/10508619.2020.1729570; Haneuse S, 2019, JAMA-J AM MED ASSOC, V321, P602, DOI 10.1001/jama.2018.21554; Hill PC, 2000, J THEOR SOC BEHAV, V30, P51, DOI 10.1111/1468-5914.00119; Idler EllenL., 2014, RELIG SOCIAL DETERMI, DOI [10.1093/acprof:oso/9780199362202.001.0001, DOI 10.1093/ACPROF:OSO/9780199362202.001.0001]; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Johnson JR, 2014, CRIT CARE MED, V42, P1991, DOI 10.1097/CCM.0000000000000412; Koenig HG, 2017, SOUTH MED J, V110, P412, DOI 10.14423/SMJ.0000000000000657; Koenig Harold G, 2012, ISRN Psychiatry, V2012, P278730, DOI 10.5402/2012/278730; Koenig HG, 2010, INT J PSYCHIAT MED, V40, P391, DOI 10.2190/PM.40.4.c; Koenig HG, 2000, JAMA-J AM MED ASSOC, V284, P1708, DOI 10.1001/jama.284.13.1708; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Mishra S, 2022, SUPPORT CARE CANCER, V30, DOI 10.1007/s00520-021-06564-4; Murphy MK., 1998, HLTH TECHNOLOGY ASSE, V2, pi, DOI [10.3310/hta2030, DOI 10.3310/HTA2030]; National Consensus Project for Quality Palliative Care, 2018, CLIN PRACT GUID QUAL, V4th; Oman D, 2018, WHY RELIG SPIRITUALI, DOI DOI 10.1007/978-3-319-73966-3; Oman D., 2013, HDB PSYCHOL RELIG SP, V2, P23, DOI DOI 10.1558/IMRE.V11I1.96; Puchalski C, 2000, J Palliat Med, V3, P129, DOI 10.1089/jpm.2000.3.129; Puchalski C, 2020, J PALLIAT MED, V23, P777, DOI 10.1089/jpm.2019.0375; Puchalski C, 2009, J PALLIAT MED, V12, P885, DOI 10.1089/jpm.2009.0142; Puchalski CM, 2014, J PALLIAT MED, V17, P105, DOI [10.1089/jpm.2013.9458, 10.1089/jpm.2014.9427]; Sahan S, 2022, J RELIG HEALTH, V61, P786, DOI 10.1007/s10943-021-01454-9; Selman L, 2011, J PAIN SYMPTOM MANAG, V41, P728, DOI 10.1016/j.jpainsymman.2010.06.023; Shiba K, 2022, PSYCHOL MED, DOI 10.1017/S0033291722000551; Sterne JAC, 2021, COCHRANE HDB SYSTEMA; Sulmasy DP, 2006, JAMA-J AM MED ASSOC, V296, P1385, DOI 10.1001/jama.296.11.1385; United Health Foundation, HLTH DISP REP 2021; VanderWeele T.J., 2017, SPIRITUALITY RELIG C, P357; VanderWeele TJ, 2022, AM J EPIDEMIOL, V191, P31, DOI 10.1093/aje/kwab134; VanderWeele TJ, 2021, INT J PSYCHOL RELIG, V31, P21, DOI 10.1080/10508619.2020.1748932	40	5	5	5	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2022	328	2					184	197		10.1001/jama.2022.11086	http://dx.doi.org/10.1001/jama.2022.11086			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3E1GX	35819420				2023-01-03	WOS:000829739800017
J	Pereira, TV; Jueni, P; Saadat, P; Xing, D; Yao, L; Bobos, P; Agarwal, A; Hincapie, CA; da Costa, BR				Pereira, Tiago, V; Jueni, Peter; Saadat, Pakeezah; Xing, Dan; Yao, Liang; Bobos, Pavlos; Agarwal, Arnav; Hincapie, Cesar A.; da Costa, Bruno R.			Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SINGLE INTRAARTICULAR INJECTION; HYALURONIC-ACID; DOUBLE-BLIND; SODIUM HYALURONATE; CONTROLLED-TRIAL; ASSESSING RISK; MULTICENTER; PLACEBO; EFFICACY; SALINE	OBJECTIVE To evaluate the effectiveness and safety of viscosupplementation for pain and function in patients with knee osteoarthritis.DESIGN Systematic review and meta-analysis of randomised trials. DATA SOURCES Searches were conducted of Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases from inception to 11 September 2021. Unpublished trials were identified from the grey literature and trial registries. ELIGIBILITY CRITERIA FOR STUDY SELECTION Randomised trials comparing viscosupplementation with placebo or no intervention for knee osteoarthritis treatment.MAIN OUTCOME MEASURES The prespecified primary outcome was pain intensity. Secondary outcomes were function and serious adverse events. Pain and function were analysed as standardised mean differences (SMDs). The prespecified minimal clinically important between group difference was-0.37 SMD. Serious adverse events were analysed as relative risks.METHODS Two reviewers independently extracted relevant data and assessed the risk of bias of trials using the Cochrane risk of bias tool. The predefined main analysis was based only on large, placebo controlled trials with >= 100 participants per group. Summary results were obtained through a random effects meta -analysis model. Cumulative meta-analysis and trial sequential analysis under a random effects model were also performed.RESULTS 169 trials provided data on 21 163 randomised participants. Evidence of small study effects and publication biases was observed for pain and function (Egger's tests with P<0.001 and asymmetric funnel plots). Twenty four large, placebo controlled trials (8997 randomised participants) included in the main analysis of pain indicated that viscosupplementation was associated with a small reduction in pain intensity compared with placebo (SMD-0.08, 95% confidence interval-0.15 to-0.02), with the lower bound of the 95% confidence interval excluding the minimal clinically important between group difference. This effect corresponds to a difference in pain scores of-2.0 mm (95% confidence interval-3.8 to-0.5 mm) on a 100 mm visual analogue scale. Trial sequential analysis for pain indicated that since 2009 there has been conclusive evidence of clinical equivalence between viscosupplementation and placebo. Similar conclusions were obtained for function. Based on 15 large, placebo controlled trials on 6462 randomised participants, viscosupplementation was associated with a statistically significant higher risk of serious adverse events than placebo (relative risk 1.49, 95% confidence interval 1.12 to 1.98). CONCLUSION Strong conclusive evidence indicates that viscosupplementation leads to a small reduction in knee osteoarthritis pain compared with placebo, but the difference is less than the minimal clinically important between group difference. Strong conclusive evidence indicates that viscosupplementation is also associated with an increased risk of serious adverse events compared with placebo. The findings do not support broad use of viscosupplementation for the treatment of knee osteoarthritis. SYSTEMATIC REVIEW REGISTRATION PROSPERO CRD42021236894.	[Pereira, Tiago, V; Jueni, Peter; Saadat, Pakeezah; Bobos, Pavlos; da Costa, Bruno R.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Appl Hlth Res Ctr, Toronto, ON, Canada; [Pereira, Tiago, V] Univ Leicester, Dept Hlth Sci, Leicester, England; [Jueni, Peter; Saadat, Pakeezah; Agarwal, Arnav; da Costa, Bruno R.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Jueni, Peter] Univ Toronto, Dept Med, Toronto, ON, Canada; [Xing, Dan] Peking Univ, Arthrit Clin & Res Ctr, Peoples Hosp, Beijing, Peoples R China; [Yao, Liang; Agarwal, Arnav] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Bobos, Pavlos] Western Univ, Sch Phys Therapy, Dept Hlth & Rehabil Sci, London, ON, Canada; [Hincapie, Cesar A.] Balgrist Univ Hosp, Fac Med, Dept Chiropract Med, Zurich, Switzerland; [Hincapie, Cesar A.] Univ Zurich, Zurich, Switzerland; [Hincapie, Cesar A.] Univ Zurich, Epidemiol Biostat & Prevent Inst EBPI, Zurich, Switzerland	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Leicester; University of Toronto; University of Toronto; Peking University; McMaster University; Western University (University of Western Ontario); University of Geneva; University of Zurich; University of Zurich; University of Zurich	da Costa, BR (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Appl Hlth Res Ctr, Toronto, ON, Canada.; da Costa, BR (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.	bruno.dacosta@utoronto.ca	Hincapié, Cesar A/AAH-7887-2021; Juni, Peter/Q-8700-2016; Bobos, Pavlos/AAZ-5053-2020	Hincapié, Cesar A/0000-0002-7257-8122; Juni, Peter/0000-0002-5985-0670; Bobos, Pavlos/0000-0002-5098-4840	Arthritis Society [YIO-17-0164]; St Michael's Hospital Foundation; Canada Research Chairs Programme; Arthritis Society Postdoctoral Fellowship Award [20-0000000016]; Chevening Scholarship Programme (Foreign and Commonwealth Office, UK)	Arthritis Society; St Michael's Hospital Foundation; Canada Research Chairs Programme(Canada Research Chairs); Arthritis Society Postdoctoral Fellowship Award; Chevening Scholarship Programme (Foreign and Commonwealth Office, UK)	This work was supported by the Arthritis Society (grant No YIO-17-0164) and by St Michael's Hospital Foundation. PJ is a tier 1 Canada research chair in clinical epidemiology of chronic diseases. This research was completed, in part, with funding from the Canada Research Chairs Programme. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the National Institute for Health Research. PB is supported by the Arthritis Society Postdoctoral Fellowship Award with funding reference No 20-0000000016. TVP was funded by the Chevening Scholarship Programme (Foreign and Commonwealth Office, UK). The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.	Altman RD, 2004, OSTEOARTHR CARTILAGE, V12, P642, DOI 10.1016/j.joca.2004.04.010; Altman RD, 1998, J RHEUMATOL, V25, P2203; Altman RD, 2009, SEMIN ARTHRITIS RHEU, V39, P1, DOI 10.1016/j.semarthrit.2009.04.001; Arden NK, 2014, CURR MED RES OPIN, V30, P279, DOI 10.1185/03007995.2013.855631; Balazs Endre A, 2004, Surg Technol Int, V12, P278; Baltzer AWA, 2009, OSTEOARTHR CARTILAGE, V17, P152, DOI 10.1016/j.joca.2008.06.014; Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011; Bellamy N, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005321.pub2; Brandt KD, 2001, CLIN ORTHOP RELAT R, P130; Chevalier X, 2010, ANN RHEUM DIS, V69, P113, DOI 10.1136/ard.2008.094623; Cui AY, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100587; da Costa BR, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2321; da Costa BR, 2014, EUR HEART J, V35, P3336, DOI 10.1093/eurheartj/ehu424; Day R, 2004, J RHEUMATOL, V31, P775; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Detry MA, 2014, JAMA-J AM MED ASSOC, V312, P85, DOI 10.1001/jama.2014.7523; Dysart S, 2021, AM HEALTH DRUG BENEF, V14, P56; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ehrich EW, 2000, J RHEUMATOL, V27, P2635; European Comission, 2015, CLINC INV SER ADV EV; Ferring Pharmaceuticals, 26 WEEK DOUBL BLIND; Fidia Farmaceutici A, MULT DOUBL BLIND RAN; Hangody L, 2018, CARTILAGE, V9, P276, DOI 10.1177/1947603517703732; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Huang TL, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-221; Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140-6736(19)30417-9; Hunter DJ, 2015, NEW ENGL J MED, V372, P1040, DOI 10.1056/NEJMct1215534; Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V319, P1429, DOI 10.1001/jama.2018.1536; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Jones IA, 2019, NAT REV RHEUMATOL, V15, P77, DOI 10.1038/s41584-018-0123-4; Jorgensen A, 2010, ANN RHEUM DIS, V69, P1097, DOI 10.1136/ard.2009.118042; Jubb RW, 2003, INT J CLIN PRACT, V57, P467; Juni P, 2006, BEST PRACT RES CL RH, V20, P721, DOI 10.1016/j.berh.2006.05.002; Juni P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005328.pub3; Katz JN, 2021, JAMA-J AM MED ASSOC, V325, P568, DOI 10.1001/jama.2020.22171; Ke Y, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891-021-04252-2; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lohmander LS, 1996, ANN RHEUM DIS, V55, P424, DOI 10.1136/ard.55.7.424; McAlindon TE, 2012, NAT REV RHEUMATOL, V8, P635, DOI 10.1038/nrrheum.2012.152; Migliore A, 2021, RHEUMATOL THER, V8, P1617, DOI 10.1007/s40744-021-00363-3; Migliore A, 2019, CLINICOECONOMIC OUTC, V11, P453, DOI 10.2147/CEOR.S194669; Mordin M, 2021, CLIN MED INSIGHTS-AR, V14, DOI 10.1177/11795441211047284; NICE, OST CAR MAN CLINC GU; Nuesch E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3515; Petterson SC, 2019, KNEE SURG SPORT TR A, V27, P1992, DOI 10.1007/s00167-018-5114-0; Pham T, 2004, ANN RHEUM DIS, V63, P1611, DOI 10.1136/ard.2003.019703; Puhl W, 1993, Osteoarthritis Cartilage, V1, P233, DOI 10.1016/S1063-4584(05)80329-2; Quintana JM, 2005, OSTEOARTHR CARTILAGE, V13, P1076, DOI 10.1016/j.joca.2005.06.012; Reichenbach S, 2007, ANN INTERN MED, V146, P580, DOI 10.7326/0003-4819-146-8-200704170-00009; Rogers JR, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.4732; Rutjes AWS, 2012, ANN INTERN MED, V157, P180, DOI 10.7326/0003-4819-157-3-201208070-00473; RYDELL N, 1971, CLIN ORTHOP RELAT R, P25, DOI 10.1097/00003086-197110000-00006; Salaffi F, 2004, EUR J PAIN, V8, P283, DOI 10.1016/j.ejpain.2003.09.004; Schmajuk G, 2014, JAMA INTERN MED, V174, P1702, DOI 10.1001/jamainternmed.2014.3926; Seikagaku Corporation, 2001, SUMM SAF EFF DAT SOD; Seikagaku Corporation, MULT RAND DOUBL BLIN; Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768; Shichikawa K, 1983, Ryumachi, V23, P280; Sterne JAC, 2001, BMJ-BRIT MED J, V322, P226, DOI 10.1136/bmj.322.7280.226; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Strand V, 2012, OSTEOARTHR CARTILAGE, V20, P350, DOI 10.1016/j.joca.2012.01.013; Takamura J, 2019, CARTILAGE, V10, P417, DOI 10.1177/1947603518768015; Teva Pharmaceuticals, DOUBL BLIND RAND STU; Walker E, 2011, J GEN INTERN MED, V26, P192, DOI 10.1007/s11606-010-1513-8; Wandel S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4675; Wetterslev J, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0315-7; Xing D, 2017, INT J RHEUM DIS, V20, P1658, DOI 10.1111/1756-185X.13192; Xing D, 2016, SCI REP-UK, V6, DOI 10.1038/srep32790; Zhu KY, 2022, J BONE JOINT SURG AM, V104, DOI 10.2106/JBJS.21.00832	69	3	3	6	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	2022	378								e069722	10.1136/bmj-2022-069722	http://dx.doi.org/10.1136/bmj-2022-069722			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3E9RH	36333100	Green Published, hybrid			2023-01-03	WOS:000830313300002
J	Lavelle, A; Sokol, H				Lavelle, Aonghus; Sokol, Harry			Understanding and predicting the efficacy of FMT	NATURE MEDICINE			English	Editorial Material							FECAL MICROBIOTA TRANSPLANTATION; RECURRENT; REMISSION; DONOR	Clinical evaluation of FMT is progressing without an adequate understanding of the underlying ecological dynamics; studies are now beginning to fill these gaps, but consensus will be needed on many fronts.	[Lavelle, Aonghus] Univ Coll Cork, APC Microbiome Ireland, Cork, Ireland; [Lavelle, Aonghus] Univ Coll Cork, Dept Anat & Neurosci, Cork, Ireland; [Sokol, Harry] Sorbonne Univ, St Antoine Hosp, AP HP,CRSA, INSERM,Ctr Rech St Antoine,Gastroenterol Dept, Paris, France; [Sokol, Harry] Paris Ctr Microbiome Med FHU, Paris, France; [Sokol, Harry] INRA, UMR1319 Micalis, Jouy En Josas, France; [Sokol, Harry] AgroParisTech, Jouy En Josas, France	University College Cork; University College Cork; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; AgroParisTech; UDICE-French Research Universities; Universite Paris Saclay	Sokol, H (corresponding author), Sorbonne Univ, St Antoine Hosp, AP HP,CRSA, INSERM,Ctr Rech St Antoine,Gastroenterol Dept, Paris, France.; Sokol, H (corresponding author), Paris Ctr Microbiome Med FHU, Paris, France.; Sokol, H (corresponding author), INRA, UMR1319 Micalis, Jouy En Josas, France.; Sokol, H (corresponding author), AgroParisTech, Jouy En Josas, France.	harry.sokol@aphp.fr	sokol, harry/E-2290-2019	sokol, harry/0000-0002-2914-1822				Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Costello SP, 2017, GASTROENTEROLOGY, V152, pS198, DOI 10.1016/S0016-5085(17)30969-1; Danne C, 2021, NAT REV GASTRO HEPAT, V18, P503, DOI 10.1038/s41575-021-00441-5; Goll R, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1794263; Ianiro G, 2022, NAT MED, V28, P1913, DOI 10.1038/s41591-022-01964-3; Kong LJ, 2020, GASTROENTEROLOGY, V159, DOI 10.1053/j.gastro.2020.08.045; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; Mullish BH, 2018, J HOSP INFECT, V100, pS1, DOI 10.1016/j.jhin.2018.07.037; Schmidt TSB, 2022, NAT MED, V28, P1902, DOI 10.1038/s41591-022-01913-0; Sokol H, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-0792-5; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031	12	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1759	1760		10.1038/s41591-022-01991-0	http://dx.doi.org/10.1038/s41591-022-01991-0		SEP 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36109641				2023-01-03	WOS:000854720900009
J	Thomas, ACQ; Brown, A; Hatt, AA; Manta, K; Costa-Parke, A; Kamal, M; Joanisse, S; McGlory, C; Phillips, SM; Kumbhare, D; Parise, G				Thomas, Aaron C. Q.; Brown, Alex; Hatt, Aidan A.; Manta, Katherine; Costa-Parke, Anamaria; Kamal, Michael; Joanisse, Sophie; McGlory, Chris; Phillips, Stuart M.; Kumbhare, Dinesh; Parise, Gianni			Short-term aerobic conditioning prior to resistance training augments muscle hypertrophy and satellite cell content in healthy young men and women	FASEB JOURNAL			English	Article						aerobic conditioning; aerobic training; capillarization; muscle stem cells; resistance training; responder; satellite cells; single-leg cycling	HUMAN SKELETAL-MUSCLE; MYONUCLEAR ADDITION; STEM-CELLS; EXERCISE; CAPILLARIZATION; ACTIVATION; GROWTH; EXPANSION; DYNAMICS; STRENGTH	Factors influencing inter-individual variability of responses to resistance training (RT) remain to be fully elucidated. We have proposed the importance of capillarization in skeletal muscle for the satellite cell (SC) response to RT-induced muscle hypertrophy, and hypothesized that aerobic conditioning (AC) would augment RT-induced adaptations. Fourteen healthy young (22 +/- 2 years) men and women underwent AC via 6 weeks of unilateral cycling followed by 10 weeks of bilateral RT to investigate how AC alters SC content, activity, and muscle hypertrophy following RT. Muscle biopsies were taken at baseline (unilateral), post AC (bilateral), and post RT (bilateral) in the aerobically conditioned (AC + RT) and unconditioned (RT) legs. Immunofluorescence was used to determine muscle capillarization, fiber size, SC content, and activity. Type I and type II fiber cross-sectional area (CSA) increased following RT, and when legs were analyzed independently, AC + RT increased type I, type II, and mixed-fiber CSA, where the RT leg tended to increase type II (p = .05), but not type I or mixed-fiber CSA. SC content, activation, and differentiation increased with RT, where type I total and quiescent SC content was greater in AC + RT compared to the RT leg. Those with the greatest capillary-to-fiber perimeter exchange index before RT had the greatest change in CSA following RT and a significant relationship was observed between type II fiber capillarization and the change in type II-fiber CSA with RT (r = 0.35). This study demonstrates that AC prior to RT can augment RT-induced muscle adaptions and that these differences are associated with increases in capillarization.	[Thomas, Aaron C. Q.; Brown, Alex; Hatt, Aidan A.; Manta, Katherine; Costa-Parke, Anamaria; Kamal, Michael; Joanisse, Sophie; Phillips, Stuart M.; Parise, Gianni] McMaster Univ, Dept Kinesiol, Exercise Metab Res Grp, Hamilton, ON, Canada; [Joanisse, Sophie] Manchester Metropolitan Univ, Dept Sport & Exercise Sci, Musculoskeletal Sci & Sport Med Res Ctr, Fac Sci & Engn, Manchester, Lancs, England; [Joanisse, Sophie] Manchester Metropolitan Univ Inst Sport, Manchester, Lancs, England; [McGlory, Chris] Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON, Canada; [McGlory, Chris] Queens Univ, Dept Med, Kingston, ON, Canada; [Kumbhare, Dinesh] Toronto Rehabil Inst, Toronto, ON, Canada	McMaster University; Manchester Metropolitan University; Queens University - Canada; Queens University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute	Parise, G (corresponding author), McMaster Univ, Dept Kinesiol, Hamilton, ON L8S 4L8, Canada.	pariseg@mcmaster.ca	Phillips, Stuart/B-2343-2009	Phillips, Stuart/0000-0002-1956-4098; Joanisse, Sophie/0000-0001-9983-9401	Natural Sciences and Engineering Research Council of Canada [RGPIN-2016-05633]	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	Natural Sciences and Engineering Research Council of Canada, Grant/ Award Number: RGPIN--2016--05633	Abbiss CR, 2011, J APPL PHYSIOL, V110, P1248, DOI 10.1152/japplphysiol.01247.2010; Allen DL, 1999, MUSCLE NERVE, V22, P1350, DOI 10.1002/(SICI)1097-4598(199910)22:10<1350::AID-MUS3>3.0.CO;2-8; Bellamy LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109739; Bentzinger CF, 2013, EMBO REP, V14, P1062, DOI 10.1038/embor.2013.182; BERGSTROM J, 1975, SCAND J CLIN LAB INV, V35, P606, DOI 10.3109/00365517509095787; Blaauw B, 2014, J MUSCLE RES CELL M, V35, P3, DOI 10.1007/s10974-014-9376-y; Burns KJ, 2014, EUR J APPL PHYSIOL, V114, P961, DOI 10.1007/s00421-014-2830-0; Christov C, 2007, MOL BIOL CELL, V18, P1397, DOI 10.1091/mbc.E06-08-0693; Damas F, 2018, EUR J APPL PHYSIOL, V118, P2607, DOI 10.1007/s00421-018-3984-y; Davidsen PK, 2011, J APPL PHYSIOL, V110, P309, DOI 10.1152/japplphysiol.00901.2010; Dinulovic I, 2017, ADV EXP MED BIOL, V1041, P141, DOI 10.1007/978-3-319-69194-7_8; Dumont NA, 2015, COMPR PHYSIOL, V5, P1027, DOI 10.1002/cphy.c140068; Egginton S, 2009, PFLUG ARCH EUR J PHY, V457, P963, DOI 10.1007/s00424-008-0563-9; Elmer SJ, 2012, MED SCI SPORT EXER, V44, P1504, DOI 10.1249/MSS.0b013e31824fb8bd; Fukada S, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118742; Gliemann L, 2016, EUR J APPL PHYSIOL, V116, P1443, DOI 10.1007/s00421-016-3419-6; Hepple RT, 1997, CAN J APPL PHYSIOL, V22, P11, DOI 10.1139/h97-002; Hiscock N, 2003, AM J PHYSIOL-HEART C, V285, pH1759, DOI 10.1152/ajpheart.00150.2003; Hoier B, 2012, J PHYSIOL-LONDON, V590, P595, DOI 10.1113/jphysiol.2011.216135; Hoier B, 2014, MICROCIRCULATION, V21, P301, DOI 10.1111/micc.12117; Holloway TM, 2018, MED SCI SPORT EXER, V50, P36, DOI 10.1249/MSS.0000000000001409; Joanisse S, 2015, AM J PHYSIOL-REG I, V309, pR1101, DOI 10.1152/ajpregu.00249.2015; Joanisse S, 2013, FASEB J, V27, P4596, DOI 10.1096/fj.13-229799; Kadi F, 2000, HISTOCHEM CELL BIOL, V113, P99, DOI 10.1007/s004180050012; Knuiman P, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0055-9; Kostrominova TY, 2011, MICROSC RES TECHNIQ, V74, P18, DOI 10.1002/jemt.20865; Kraus RM, 2004, J APPL PHYSIOL, V96, P1445, DOI 10.1152/japplphysiol.01031.2003; Kuang S, 2008, CELL STEM CELL, V2, P22, DOI 10.1016/j.stem.2007.12.012; Lundberg TR, 2013, J APPL PHYSIOL, V114, P81, DOI 10.1152/japplphysiol.01013.2012; MacInnis MJ, 2017, APPL PHYSIOL NUTR ME, V42, P563, DOI 10.1139/apnm-2016-0645; Montarras D, 2013, FEBS J, V280, P4036, DOI 10.1111/febs.12372; Morton RW, 2019, J PHYSIOL-LONDON, V597, P4601, DOI 10.1113/JP278056; Murach KA, 2018, PHYSIOLOGY, V33, P26, DOI 10.1152/physiol.00019.2017; Nederveen JP, 2015, ACTA PHYSIOL, V215, P177, DOI 10.1111/apha.12601; Nederveen JP, 2018, J PHYSIOL-LONDON, V596, P1063, DOI 10.1113/JP275155; Nederveen JP, 2017, AM J PHYSIOL-REG I, V312, pR85, DOI 10.1152/ajpregu.00221.2016; Nederveen JP, 2016, J CACHEXIA SARCOPENI, V7, P547, DOI 10.1002/jcsm.12105; Petrella JK, 2008, J APPL PHYSIOL, V104, P1736, DOI 10.1152/japplphysiol.01215.2007; Petrella JK, 2006, AM J PHYSIOL-ENDOC M, V291, pE937, DOI 10.1152/ajpendo.00190.2006; Phillips BE, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003389; Rodgers JT, 2014, NATURE, V510, P393, DOI 10.1038/nature13255; Snijders T, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13278; Snijders T, 2017, J CACHEXIA SARCOPENI, V8, P267, DOI 10.1002/jcsm.12137; Snijders T, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00283; Terzis G, 2008, EUR J APPL PHYSIOL, V102, P145, DOI 10.1007/s00421-007-0564-y; Timmons JA, 2011, J APPL PHYSIOL, V110, P846, DOI 10.1152/japplphysiol.00934.2010; West DWD, 2010, J APPL PHYSIOL, V108, P60, DOI 10.1152/japplphysiol.01147.2009; Whitham M, 2016, NAT REV DRUG DISCOV, V15, P719, DOI 10.1038/nrd.2016.153	48	0	0	5	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2022	36	9							e22500	10.1096/fj.202200398RR	http://dx.doi.org/10.1096/fj.202200398RR			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	3U0JH	35971745				2023-01-03	WOS:000840655900001
J	Todo, T; Ito, H; Ino, Y; Ohtsu, H; Ota, Y; Shibahara, J; Tanaka, M				Todo, Tomoki; Ito, Hirotaka; Ino, Yasushi; Ohtsu, Hiroshi; Ota, Yasunori; Shibahara, Junji; Tanaka, Minoru			Intratumoral oncolytic herpes virus G47 increment for residual or recurrent glioblastoma: a phase 2 trial	NATURE MEDICINE			English	Article; Early Access							IMMUNE CHECKPOINT INHIBITORS; SIMPLEX-VIRUS; MALIGNANT GLIOMA; VECTOR G47-DELTA; BREAST-CANCER; III TRIAL; EFFICACY; THERAPY; COMBINATION; SAFETY	Results from a pivotal single-arm phase 2 trial show that the repeated intratumoral administration of the oncolytic herpes virus G47 increment in residual or recurrent glioblastoma exhibits survival benefit and a safe profile. This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy of G47 increment , a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult patients with residual or recurrent, supratentorial glioblastoma after radiation therapy and temozolomide (UMIN-CTR Clinical Trial Registry UMIN000015995). G47 Delta was administered intratumorally and repeatedly for up to six doses. The primary endpoint of 1-yr survival rate after G47 increment initiation was 84.2% (95% confidence interval, 60.4-96.6; 16 of 19). The prespecified endpoint was met and the trial was terminated early. Regarding secondary endpoints, the median overall survival was 20.2 (16.8-23.6) months after G47 increment initiation and 28.8 (20.1-37.5) months from the initial surgery. The most common G47 increment -related adverse event was fever (17 of 19) followed by vomiting, nausea, lymphocytopenia and leukopenia. On magnetic resonance imaging, enlargement of and contrast-enhancement clearing within the target lesion repeatedly occurred after each G47 increment administration, which was characteristic to this therapy. Thus, the best overall response in 2 yr was partial response in one patient and stable disease in 18 patients. Biopsies revealed increasing numbers of tumor-infiltrating CD4(+)/CD8(+) lymphocytes and persistent low numbers of Foxp3(+) cells. This study showed a survival benefit and good safety profile, which led to the approval of G47 increment as the first oncolytic virus product in Japan.	[Todo, Tomoki; Ito, Hirotaka; Ino, Yasushi] Univ Tokyo, Div Innovat Canc Therapy, Adv Clin Res Ctr, Tokyo, Japan; [Todo, Tomoki; Ito, Hirotaka; Ino, Yasushi; Tanaka, Minoru] Univ Tokyo, Inst Med Sci, Dept Surg Neurooncol, Tokyo, Japan; [Ohtsu, Hiroshi] Natl Ctr Global Hlth & Med Japan, Dept Data Sci, Tokyo, Japan; [Ohtsu, Hiroshi] Juntendo Univ, Leading Ctr Dev & Res Canc Med, Tokyo, Japan; [Ota, Yasunori] Univ Tokyo, Inst Med Sci, Dept Pathol, Tokyo, Japan; [Shibahara, Junji] Kyorin Univ, Sch Med, Dept Pathol, Tokyo, Japan	University of Tokyo; University of Tokyo; Juntendo University; University of Tokyo; Kyorin University	Todo, T (corresponding author), Univ Tokyo, Div Innovat Canc Therapy, Adv Clin Res Ctr, Tokyo, Japan.	toudou-nsu@umin.ac.jp	Ohtsu, Hiroshi/ABF-2536-2021	Ohtsu, Hiroshi/0000-0003-3261-8828; Todo, Tomoki/0000-0003-0523-8010	Japanese Agency for Medical Research and Development (AMED) [JP15ck0106144, JP18ck0106416, JP20lm0203140]; Division of Innovative Cancer Therapy, the Institute of Medical Science, the University of Tokyo	Japanese Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Division of Innovative Cancer Therapy, the Institute of Medical Science, the University of Tokyo	We thank M. Iwai, S. Kanayama, H. Momota, L. Chalise, K. Saiga, E. Ozaki and the members of the Division of Innovative Cancer Therapy, the members of the Therapeutic Vector Development Center and the staff of the Center for Translational Research, the Institute of Medical Science, the University of Tokyo, for their support and assistance in carrying out this clinical study. We also thank R. Nishikawa (Saitama Medical University), S. Aoki (Juntendo University) and K. Yoshimura (Kanazawa University) for serving the Independent Data Monitoring Committee, and Y. Furukawa (the University of Tokyo) for helping us with the genome sequencing of G47.. This research was supported in part by the Japanese Agency for Medical Research and Development (AMED) `Innovative Cancer Medical Practical Research Project' (2015-2020) under grant nos. JP15ck0106144 and JP18ck0106416 and `Translational Research Program' under grant no. JP20lm0203140 to T.T. We thank Y. Okamoto and M. Snape of inScience Communications, Springer Healthcare, for helping us write the first draft of the manuscript. This medical writing assistance was funded by the Division of Innovative Cancer Therapy, the Institute of Medical Science, the University of Tokyo.	Aghi M, 2007, CANCER RES, V67, P440, DOI 10.1158/0008-5472.CAN-06-3145; Andtbacka RHI, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0623-z; Ballman KV, 2007, NEURO-ONCOLOGY, V9, P29, DOI 10.1215/15228517-2006-025; Brahm CG, 2020, CANCERS, V12, DOI 10.3390/cancers12030586; Carpenter AB, 2021, ANN ONCOL, V32, P968, DOI 10.1016/j.annonc.2021.03.197; Carson J, 2010, DRUG FUTURE, V35, P183, DOI 10.1358/dof.2010.035.03.1470166; Chahlavi A, 1999, GENE THER, V6, P1751, DOI 10.1038/sj.gt.3301003; Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005; Dario A, 2006, CURR DRUG SAF, V1, P205, DOI 10.2174/157488606776930535; De Bonis P, 2012, ACTA NEUROCHIR, V154, P1371, DOI 10.1007/s00701-012-1413-2; Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435; Friedman GK, 2021, NEW ENGL J MED, V384, P1613, DOI 10.1056/NEJMoa2024947; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; Fukuhara H, 2005, CLIN CANCER RES, V11, P7886, DOI 10.1158/1078-0432.CCR-05-1090; Fukuhara H, 2016, CANCER SCI, V107, P1373, DOI 10.1111/cas.13027; Ikegami N, 2011, LANCET, V378, P1106, DOI 10.1016/S0140-6736(11)60828-3; Ishino R, 2021, MOL THER, V29, P762, DOI 10.1016/j.ymthe.2020.09.041; Koga T, 2012, CANCER-AM CANCER SOC, V118, P4193, DOI 10.1002/cncr.27372; Lang FF, 2018, J CLIN ONCOL, V36, P1419, DOI 10.1200/JCO.2017.75.8219; Li Yi, 2017, Brain Tumor Res Treat, V5, P1, DOI 10.14791/btrt.2017.5.1.1; Liu R, 2005, GENE THER, V12, P647, DOI 10.1038/sj.gt.3302445; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Ma WQ, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0281-9; Mandel JJ, 2016, J NEURO-ONCOL, V129, P147, DOI 10.1007/s11060-016-2157-2; Markert JM, 2014, MOL THER, V22, P1048, DOI 10.1038/mt.2014.22; Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Oku M, 2021, BRIT J HAEMATOL, V192, P343, DOI 10.1111/bjh.17173; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Roy S, 2015, SOUTH ASIAN J CANCER, V4, P163, DOI 10.4103/2278-330X.175953; Saha D, 2016, CANCER IMMUNOL RES, V4, DOI 10.1158/2326-6066.IMM2016-B116; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Stupp R, 2012, EUR J CANCER, V48, P2192, DOI 10.1016/j.ejca.2012.04.011; Sugawara K, 2021, MOL THER-ONCOLYTICS, V22, P129, DOI 10.1016/j.omto.2021.05.004; Sugawara K, 2020, MOL THER-ONCOLYTICS, V17, P205, DOI 10.1016/j.omto.2020.03.022; Todo T, 1999, HUM GENE THER, V10, P2869, DOI 10.1089/10430349950016591; Todo T, 2001, P NATL ACAD SCI USA, V98, P6396, DOI 10.1073/pnas.101136398; Todo T., NATURE COMMUN; Uchihashi T, 2021, MOL THER-ONCOLYTICS, V22, P388, DOI 10.1016/j.omto.2021.06.008; Van Gool F, 2019, IMMUNITY, V50, P362, DOI 10.1016/j.immuni.2018.12.016; Westphal M, 2006, ACTA NEUROCHIR, V148, P269, DOI 10.1007/s00701-005-0707-z; Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/15228517-5-2-79; Wick A, 2009, J NEUROL, V256, P734, DOI 10.1007/s00415-009-5006-9; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Wu A, 2001, CANCER RES, V61, P3009; Yajima S, 2021, MOL THER-ONCOLYTICS, V23, P402, DOI 10.1016/j.omto.2021.10.012; Yamada T, 2020, MOL THER-ONCOLYTICS, V18, P535, DOI 10.1016/j.omto.2020.08.010	47	13	13	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01897-x	http://dx.doi.org/10.1038/s41591-022-01897-x		JUL 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3C2GI	35864254	Green Published, hybrid			2023-01-03	WOS:000828446700008
J	Raghunathan, K; Raghunathan, A				Raghunathan, Karthik; Raghunathan, Anusha			Effect of Awake Prone Positioning on Patients With COVID-19 and Acute Respiratory Failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Raghunathan, Karthik] Duke Univ, Sch Med, Durham, NC 27710 USA	Duke University	Raghunathan, K (corresponding author), Duke Univ, Med Ctr, 2301 Erwin Rd, Durham, NC 27710 USA.	karthik.raghunathan@duke.edu						Alhazzani W, 2022, JAMA-J AM MED ASSOC, V327, P2104, DOI 10.1001/jama.2022.7993; Fralick M, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-068585; Hofstede G., CLEARLY CULTURAL MAK; Li J, 2022, LANCET RESP MED, V10, P573, DOI 10.1016/S2213-2600(22)00043-1; Raghunathan K, 2012, BMJ QUAL SAF, V21, P617, DOI 10.1136/bmjqs-2011-000608	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	2022	328	13					1354	1354						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5F6GU	36194223				2023-01-03	WOS:000866412700021
J	Lee, HC; Lyell, DJ				Lee, Henry C.; Lyell, Deirdre J.			Active Treatment and Shared Decision-making for Infants Born Extremely Preterm at 22 to 25 Weeks	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ETHNIC-DIFFERENCES; DELIVERY; OUTCOMES		[Lee, Henry C.] Stanford Sch Med, Dept Pediat, Div Neonatol, 453 Quarry Rd, Stanford, CA 94304 USA; [Lyell, Deirdre J.] Stanford Sch Med, Dept Obstet & Gynecol, Div Maternal & Fetal Med, Stanford, CA 94304 USA	Stanford University; Stanford University	Lee, HC (corresponding author), Stanford Sch Med, Dept Pediat, Div Neonatol, 453 Quarry Rd, Stanford, CA 94304 USA.	hclee@stanford.edu	Lee, Henry/GVS-2114-2022		National Institutes of Health (NIH) [R01HD098287]; NIH [R01HD098287]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Dr Lee reported receiving research funding from the National Institutes of Health (NIH) under award R01HD098287 ("Improving outcomes of periviable births via an enhanced prediction tool," the topic of which is related to this Editorial). Dr Lyell reported also receiving research funding from NIH R01HD098287; receiving honoraria from the Society for Maternal-Fetal Medicine and University of California San Francisco; holding stock options in Bloomlife; and being an investor in Zenflow.	Bane S, 2022, J PERINATOL, V42, P1301, DOI 10.1038/s41372-022-01381-x; Boghossian NS, 2020, OBSTET GYNECOL, V135, P885, DOI 10.1097/AOG.0000000000003747; Boland RA, 2021, AUST NZ J OBSTET GYN, V61, P528, DOI 10.1111/ajo.13309; Chen Xuxin, 2022, J Pediatr, V249, P67, DOI 10.1016/j.jpeds.2022.06.013; Dagle JM, 2022, SEMIN PERINATOL, V46, DOI 10.1016/j.semperi.2021.151545; Edmonds BT, 2021, PATIENT EDUC COUNS, V104, P2565, DOI 10.1016/j.pec.2021.03.003; Edmonds BT, 2011, PEDIATRICS, V127, pE1120, DOI 10.1542/peds.2010-2608; Kaemingk BD, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-1865; Kono Y, 2018, BMJ PAEDIATR OPEN, V2, DOI 10.1136/bmjpo-2017-000211; Profit J, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0918; Puia-Dumitrescu M, 2020, J PERINATOL, V40, P781, DOI 10.1038/s41372-020-0614-4; Robles D, 2017, J PERINATOL, V37, P32, DOI 10.1038/jp.2016.174; Rossi RM, 2019, OBSTET GYNECOL, V133, P451, DOI 10.1097/AOG.0000000000003106; Rossi RM, 2018, OBSTET GYNECOL, V132, P107, DOI 10.1097/AOG.0000000000002690; Rysavy M, 2020, JAMA PEDIATR, V174, DOI 10.1001/jamapediatrics.2019.6294; Rysavy MA, 2015, NEW ENGL J MED, V372, P1801, DOI 10.1056/NEJMoa1410689; Venkatesh KK, 2022, JAMA-J AM MED ASSOC, V328, P652, DOI 10.1001/jama.2022.12841; Younge N, 2017, NEW ENGL J MED, V376, P617, DOI 10.1056/NEJMoa1605566	18	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2022	328	7					624	626		10.1001/jama.2022.13364	http://dx.doi.org/10.1001/jama.2022.13364			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D0ZW	35972504				2023-01-03	WOS:000846874500019
J	Schnipper, JL				Schnipper, Jeffrey L.			Annals for Hospitalists Inpatient Notes - Improving Medication Reconciliation in Hospitals	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ERRORS		[Schnipper, Jeffrey L.] Harvard Med Sch, Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Hosp Med Unit, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Schnipper, JL (corresponding author), Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 1620 Tremont St,BC-3, Boston, MA 02120 USA.	jschnipper@bwh.harvard.edu		Schnipper, Jeffrey/0000-0001-7072-0781				Gleason KM, 2010, J GEN INTERN MED, V25, P441, DOI 10.1007/s11606-010-1256-6; Pevnick JM, 2016, BMJ QUAL SAF, V25, P726, DOI 10.1136/bmjqs-2015-004734; Pippins JR, 2008, J GEN INTERN MED, V23, P1414, DOI 10.1007/s11606-008-0687-9; Salanitro Amanda H, 2013, BMC Health Serv Res, V13, P230, DOI 10.1186/1472-6963-13-230; Schnipper JL, 2022, BMJ QUAL SAF, V31, P278, DOI 10.1136/bmjqs-2020-012709	5	0	0	5	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG	2022	175	8					HO2	HO3		10.7326/M22-1954	http://dx.doi.org/10.7326/M22-1954		AUG 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3V2OP	35969870				2023-01-03	WOS:000841501500001
J	Ledford, H				Ledford, Heidi			THE LONG WAIT FOR A LONG-COVID THERAPY	NATURE			English	Editorial Material																		Ayoubkhani D, 2022, BMJ-BRIT MED J, V377, DOI 10.1136/bmj-2021-069676; Davis HE, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101019; Imai K, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14050907; Pretorius E., PREPRINT, DOI [10.21203/rs.3.rs-1205453/v1(2021, DOI 10.21203/RS.3.RS-1205453/V1(2021]; Pretorius E, 2021, CARDIOVASC DIABETOL, V20, DOI 10.1186/s12933-021-01359-7	5	1	1	8	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 11	2022	608	7922					258	260						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3S2QZ	35945375	Bronze			2023-01-03	WOS:000839447400016
J	Zingg, D; Bhin, J; Yemelyanenko, J; Kas, SM; Rolfs, F; Lutz, C; Lee, JK; Klarenbeek, S; Silverman, IM; Annunziato, S; Chan, CS; Piersma, SR; Eijkman, T; Badoux, M; Gogola, E; Siteur, B; Sprengers, J; de Klein, B; de Goeij-de Haas, RR; Riedlinger, GM; Ke, H; Madison, R; Drenth, AP; van der Burg, E; Schut, E; Henneman, L; van Miltenburg, MH; Proost, N; Zhen, HL; Wientjens, E; de Bruijn, R; de Ruiter, JR; Boon, U; de Korte-Grimmerink, R; van Gerwen, B; Feliz, L; Abou-Alfa, GK; Ross, JS; van de Ven, M; Rottenberg, S; Cuppen, E; Chessex, AV; Ali, SM; Burn, TC; Jimenez, CR; Ganesan, S; Wessels, LFA; Jonkers, J				Zingg, Daniel; Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M.; Rolfs, Frank; Lutz, Catrin; Lee, Jessica K.; Klarenbeek, Sjoerd; Silverman, Ian M.; Annunziato, Stefano; Chan, Chang S.; Piersma, Sander R.; Eijkman, Timo; Badoux, Madelon; Gogola, Ewa; Siteur, Bjorn; Sprengers, Justin; de Klein, Bim; de Goeij-de Haas, Richard R.; Riedlinger, Gregory M.; Ke, Hua; Madison, Russell; Drenth, Anne Paulien; van der Burg, Eline; Schut, Eva; Henneman, Linda; van Miltenburg, Martine H.; Proost, Natalie; Zhen, Huiling; Wientjens, Ellen; de Bruijn, Roebi; de Ruiter, Julian R.; Boon, Ute; de Korte-Grimmerink, Renske; van Gerwen, Bastiaan; Feliz, Luis; Abou-Alfa, Ghassan K.; Ross, Jeffrey S.; van de Ven, Marieke; Rottenberg, Sven; Cuppen, Edwin; Chessex, Anne Vaslin; Ali, Siraj M.; Burn, Timothy C.; Jimenez, Connie R.; Ganesan, Shridar; Wessels, Lodewyk F. A.; Jonkers, Jos			Truncated FGFR2 is a clinically actionable oncogene in multiple cancers	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; WHOLE-GENOME; MOUSE MODEL; OPEN-LABEL; E-CADHERIN; PTEN LOSS; GENE; IDENTIFICATION; RNA; SENSITIVITY	Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer(1). However, clinical responses to FGFR inhibitors have remained variable(1-9), emphasizing the need to better understand which FGFR2 alterations are oncogenic and therapeutically targetable. Here we apply transposon-based screening(10,11) and tumour modelling in mice(12,13), and find that the truncation of exon 18 (E18) of Fgfr2 is a potent driver mutation. Human oncogenomic datasets revealed a diverse set of FGFR2 alterations, including rearrangements, E1-E17 partial amplifications, and E18 nonsense and frameshift mutations, each causing the transcription of E18-truncated FGFR2 (FGFR2(Delta E18)). Functional in vitro and in vivo examination of a compendium of FGFR2(Delta E18) and full-length variants pinpointed FGFR2-E18 truncation as single-driver alteration in cancer. By contrast, the oncogenic competence of FGFR2 full-length amplifications depended on a distinct landscape of cooperating driver genes. This suggests that genomic alterations that generate stable FGFR2(Delta E18 )variants are actionable therapeutic targets, which we confirmed in preclinical mouse and human tumour models, and in a clinical trial. We propose that cancers containing any FGFR2 variant with a truncated E18 should be considered for FGFR-targeted therapies.	[Zingg, Daniel; Yemelyanenko, Julia; Kas, Sjors M.; Rolfs, Frank; Lutz, Catrin; Annunziato, Stefano; Eijkman, Timo; Badoux, Madelon; de Klein, Bim; Drenth, Anne Paulien; van der Burg, Eline; Schut, Eva; Henneman, Linda; van Miltenburg, Martine H.; Wientjens, Ellen; de Bruijn, Roebi; de Ruiter, Julian R.; Boon, Ute; Rottenberg, Sven; Jonkers, Jos] Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands; [Bhin, Jinhyuk; Yemelyanenko, Julia; Kas, Sjors M.; Rolfs, Frank; Lutz, Catrin; Annunziato, Stefano; Eijkman, Timo; Badoux, Madelon; de Klein, Bim; Drenth, Anne Paulien; van der Burg, Eline; Schut, Eva; Henneman, Linda; van Miltenburg, Martine H.; Wientjens, Ellen; de Bruijn, Roebi; de Ruiter, Julian R.; Boon, Ute; Cuppen, Edwin; Wessels, Lodewyk F. A.; Jonkers, Jos] Oncode Inst, Utrecht, Netherlands; [Bhin, Jinhyuk; de Bruijn, Roebi; de Ruiter, Julian R.; Wessels, Lodewyk F. A.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands; [Rolfs, Frank; Piersma, Sander R.; de Goeij-de Haas, Richard R.; Jimenez, Connie R.] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, OncoProte Lab,Dept Med Oncol, Amsterdam, Netherlands; [Lee, Jessica K.; Madison, Russell; Ross, Jeffrey S.; Ali, Siraj M.] Fdn Med, Cambridge, MA USA; [Klarenbeek, Sjoerd] Netherlands Canc Inst, Expt Anim Pathol, Amsterdam, Netherlands; [Silverman, Ian M.; Burn, Timothy C.] Incyte Res Inst, Wilmington, DE USA; [Chan, Chang S.; Ke, Hua; Ganesan, Shridar] Rutgers Canc Inst New Jersey, Dept Med, Div Med Oncol, New Brunswick, NJ 08901 USA; [Chan, Chang S.; Riedlinger, Gregory M.; Ke, Hua; Ganesan, Shridar] Rutgers State Univ, Dept Med & Pharmacol, Piscataway, NJ 08901 USA; [Gogola, Ewa; Siteur, Bjorn; Sprengers, Justin; Henneman, Linda; Proost, Natalie; de Korte-Grimmerink, Renske; van Gerwen, Bastiaan; van de Ven, Marieke] Netherlands Canc Inst, Mouse Clin Canc & Aging, Amsterdam, Netherlands; [Riedlinger, Gregory M.] Rutgers Canc Inst New Jersey, Dept Pathol, New Brunswick, NJ USA; [Zhen, Huiling] Incyte, Wilmington, DE USA; [Feliz, Luis] Incyte Biosci Int, Morges, Switzerland; [Abou-Alfa, Ghassan K.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Abou-Alfa, Ghassan K.] Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA; [Ross, Jeffrey S.] Upstate Med Univ, Upstate Univ Hosp, Syracuse, NY USA; [Rottenberg, Sven] Univ Bern, Vetsuisse Fac, Inst Anim Pathol, Bern, Switzerland; [Rottenberg, Sven] Univ Bern, Bern Ctr Precis Med, Bern, Switzerland; [Cuppen, Edwin] Hartwig Med Fdn, Amsterdam, Netherlands; [Cuppen, Edwin] Univ Med Ctr Utrecht, Ctr Mol Med, Utrecht, Netherlands; [Chessex, Anne Vaslin] Debiopharm Int, Lausanne, Switzerland	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Amsterdam; Vrije Universiteit Amsterdam; Foundation Medicine; Netherlands Cancer Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Netherlands Cancer Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Incyte; Memorial Sloan Kettering Cancer Center; Cornell University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Bern; University of Bern; Utrecht University; Utrecht University Medical Center; Debiopharm	Jonkers, J (corresponding author), Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands.; Wessels, LFA; Jonkers, J (corresponding author), Oncode Inst, Utrecht, Netherlands.; Wessels, LFA (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands.; Ganesan, S (corresponding author), Rutgers Canc Inst New Jersey, Dept Med, Div Med Oncol, New Brunswick, NJ 08901 USA.; Ganesan, S (corresponding author), Rutgers State Univ, Dept Med & Pharmacol, Piscataway, NJ 08901 USA.	ganesash@cinj.rutgers.edu; l.wessels@nki.nl; j.jonkers@nki.nl		Zingg, Daniel/0000-0001-6450-2534; Lee, Jessica/0000-0002-4333-5092; Yemelyanenko, Julia/0000-0001-9697-2039; Gogola, Ewa/0000-0002-5733-770X; Silverman, Ian/0000-0003-3819-6726	Dutch Cancer Society [KWF 2017-61169, KWF 2020-12894]; European Research Council (ERC Synergy project Combat-Cancer); ERC [AdG-883877]; Netherlands Organisation for Scientific Research (NWO-Middelgroot project) [91116017]; VUmc-Cancer Center Amsterdam; Swiss National Science Foundation [SNF P2ZHP3_175027, SNF 310030_179360]; German Research Foundation [DFG 319175447]; US National Cancer Institute [NCI P30CA072720]	Dutch Cancer Society(KWF Kankerbestrijding); European Research Council (ERC Synergy project Combat-Cancer)(European Research Council (ERC)); ERC(European Research Council (ERC)European Commission); Netherlands Organisation for Scientific Research (NWO-Middelgroot project); VUmc-Cancer Center Amsterdam; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); German Research Foundation(German Research Foundation (DFG)); US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank D. Zimmerli and I. van der Heijden for experimental support and J. Houthuijzen and A. Moises Da Silva for providing mice; the staff at the NKI animal facility, the animal pathology facility, the flow cytometry facility and the genomics core facility and Rutgers Cancer Institute of New Jersey Biospecimen Repository and Histopathology Service Shared Resource for their technical support; the people from the transgenic and the preclinical intervention units of the Mouse Clinic for Cancer and Ageing (MCCA) at the NKI for their technical support performing the animal experiments; and the staff at Crown Bioscience for their technical support with performing the PDX experiments. This publication and the underlying study have been made possible in part on the basis of the data that the Hartwig Medical Foundation and the Center of Personalised Cancer Treatment (CPCT) have made available to the study as well as the data from the Broad Institute (CCLE and CTRPv2), the Wellcome Sanger Institute (GDSC) and TCGA Research Network. This work was funded by the Dutch Cancer Society (KWF 2017-61169 to J.B., L.F.A.W. and J.J.; KWF 2020-12894 to D.Z., E.C., L.F.A.W. and J.J.), the European Research Council (ERC Synergy project Combat-Cancer to J.J.; ERC AdG-883877 to S.R.), the Netherlands Organisation for Scientific Research (NWO-Middelgroot project 91116017 to C.R.J.), the VUmc-Cancer Center Amsterdam (infrastructure grant to C.R.J.), the Swiss National Science Foundation (SNF P2ZHP3_175027 to D.Z.; SNF 310030_179360 to S.R.), the German Research Foundation (DFG 319175447 to F.R.), and the US National Cancer Institute (NCI P30CA072720 to C.S.C. and S.G.). This work is part of the Oncode Institute, which is partly financed by the Dutch Cancer Society.	Abou-Alfa GK, 2020, LANCET ONCOL, V21, P671, DOI 10.1016/S1470-2045(20)30109-1; Ahdesmaki Miika J, 2016, F1000Res, V5, P2741, DOI 10.12688/f1000research.10082.2; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Alborzi SZ, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008844; Annunziato S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08301-2; Annunziato S, 2016, GENE DEV, V30, P1470, DOI 10.1101/gad.279190.116; [Anonymous], 2019, GRIDSS PURPLE LINX U, DOI [10.1101/781013, DOI 10.1101/781013]; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Beekhof R, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188250; Boelens MC, 2016, CELL REP, V16, P2087, DOI 10.1016/j.celrep.2016.07.059; Bottger F, 2019, CELL REP, V27, P3345, DOI 10.1016/j.celrep.2019.05.057; Cameron DL, 2017, GENOME RES, V27, P2050, DOI 10.1101/gr.222109.117; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cha JYY, 2009, J BIOL CHEM, V284, P6227, DOI 10.1074/jbc.M803998200; Chae YK, 2020, J CLIN ONCOL, V38, P2407, DOI 10.1200/JCO.19.02630; Chen DW, 2019, METHODS MOL BIOL, V1954, P183, DOI 10.1007/978-1-4939-9145-7_12; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Clark TA, 2018, J MOL DIAGN, V20, P686, DOI 10.1016/j.jmoldx.2018.05.004; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; de Ruiter JR, 2017, NUCLEIC ACIDS RES, V45, P7064, DOI 10.1093/nar/gkx461; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Derksen PWB, 2011, DIS MODEL MECH, V4, P347, DOI 10.1242/dmm.006395; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Formisano L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09068-2; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Gao QS, 2018, CELL REP, V23, P227, DOI 10.1016/j.celrep.2018.03.050; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Gogola E, 2018, CANCER CELL, V33, P1078, DOI 10.1016/j.ccell.2018.05.008; Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159-8290.CD-12-0210; Haas BJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1842-9; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; He J, 2016, BLOOD, V127, P3004, DOI 10.1182/blood-2015-08-664649; Henneman L, 2015, P NATL ACAD SCI USA, V112, P8409, DOI 10.1073/pnas.1500223112; Hertzler-Schaefer K, 2014, CELL REP, V6, P818, DOI 10.1016/j.celrep.2014.01.045; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huijbers IJ, 2015, NAT PROTOC, V10, P1755, DOI 10.1038/nprot.2015.114; Hung KL, 2021, NATURE, V600, P731, DOI 10.1038/s41586-021-04116-8; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; ITOH H, 1994, CANCER RES, V54, P3237; Javle M, 2018, J CLIN ONCOL, V36, P276, DOI 10.1200/JCO.2017.75.5009; Jusakul A, 2017, CANCER DISCOV, V7, P1116, DOI 10.1158/2159-8290.CD-17-0368; Kas SM, 2018, CANCER RES, V78, P5668, DOI 10.1158/0008-5472.CAN-18-0757; Kas SM, 2017, NAT GENET, V49, P1219, DOI 10.1038/ng.3905; Katoh M, 2019, NAT REV CLIN ONCOL, V16, P105, DOI 10.1038/s41571-018-0115-y; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; Kim SM, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.48; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Krug K, 2019, MOL CELL PROTEOMICS, V18, P576, DOI 10.1074/mcp.TIR118.000943; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li YI, 2018, NAT GENET, V50, P151, DOI 10.1038/s41588-017-0004-9; Li YL, 2020, NATURE, V578, P112, DOI 10.1038/s41586-019-1913-9; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin C-YG, 2020, BIORXIV, DOI 10.1101/2020.06.14.150524; Lin CC, 2012, CELL, V149, P1514, DOI 10.1016/j.cell.2012.04.033; Liu HY, 2017, CLIN CANCER RES, V23, P974, DOI 10.1158/1078-0432.CCR-15-2448; Liu PCC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231877; Liu ZY, 2013, MOL CELL PROTEOMICS, V12, P1689, DOI 10.1074/mcp.M112.021790; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; Mathur A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098515; Moffa AB, 2004, MOL CANCER RES, V2, P643; Montini E, 2009, J CLIN INVEST, V119, P964, DOI 10.1172/JCI37630; Nadratowska-Wesolowska B, 2014, ONCOGENE, V33, P4823, DOI 10.1038/onc.2013.425; Nakamura IT, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00204-0; Nakanishi Y, 2014, MOL CANCER THER, V13, P2547, DOI 10.1158/1535-7163.MCT-14-0248; Niu XL, 2002, J BIOL CHEM, V277, P31768, DOI 10.1074/jbc.M203995200; Novoradovsky A., 2005, 2005 NSTI Nanotechnology Conference and Trade Show. NSTI Nanotech 2005, P532; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Ota S, 2009, HUM MOL GENET, V18, P2609, DOI 10.1093/hmg/ddp195; Pearson A, 2016, CANCER DISCOV, V6, P838, DOI 10.1158/2159-8290.CD-15-1246; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Qin A, 2019, J THORAC ONCOL, V14, P54, DOI 10.1016/j.jtho.2018.09.014; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rolfs F, 2021, MOL CELL PROTEOMICS, V20, DOI 10.1016/j.mcpro.2021.100078; Rothe B, 2018, STRUCTURE, V26, P209, DOI 10.1016/j.str.2017.12.002; Sakaguchi K, 1999, ONCOGENE, V18, P5497, DOI 10.1038/sj.onc.1202947; Sanchez-Guixe M, 2022, CLIN CANCER RES, V28, P137, DOI 10.1158/1078-0432.CCR-21-1810; Scheinin I, 2014, GENOME RES, V24, P2022, DOI 10.1101/gr.175141.114; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schipper K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11716-6; Seashore-Ludlow B, 2015, CANCER DISCOV, V5, P1210, DOI 10.1158/2159-8290.CD-15-0235; Smirnov P, 2018, NUCLEIC ACIDS RES, V46, pD994, DOI 10.1093/nar/gkx911; Stein A, 2005, NUCLEIC ACIDS RES, V33, pD413, DOI 10.1093/nar/gki037; Subbiah V, 2022, ANN ONCOL, V33, P522, DOI 10.1016/j.annonc.2022.02.001; Szybowska P, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061342; Szybowska P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060518; Tabernero J, 2015, J CLIN ONCOL, V33, P3401, DOI 10.1200/JCO.2014.60.7341; Tannheimer SL, 2000, BREAST CANCER RES, V2, P311, DOI 10.1186/bcr73; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136; Ueda T, 1999, CANCER RES, V59, P6080; Van Cutsem E, 2017, ANN ONCOL, V28, P1316, DOI 10.1093/annonc/mdx107; Voss MH, 2019, CLIN CANCER RES, V25, P2699, DOI 10.1158/1078-0432.CCR-18-1959; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134; Yilmaz S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21211-6; Zhang JC, 2012, CLIN CANCER RES, V18, P6658, DOI 10.1158/1078-0432.CCR-12-2694; Zingg D, 2018, CANCER CELL, V34, P69, DOI 10.1016/j.ccell.2018.06.001	112	4	4	18	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 18	2022	608	7923					609	+		10.1038/s41586-022-05066-5	http://dx.doi.org/10.1038/s41586-022-05066-5		AUG 2022	52	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3W3QS	35948633	Green Published, hybrid			2023-01-03	WOS:000838682300001
J	Hovenkamp, E; Lemus, J; Rai, A; Vishnubhakat, S				Hovenkamp, Erik; Lemus, Jorge; Rai, Arti; Vishnubhakat, Saurabh			Has the PTAB made a difference in drug settlements and generic entry?	NATURE BIOTECHNOLOGY			English	Editorial Material								Legal barriers are preventing generic drug makers from being able to utilize the Patent Trial and Appeal Board for its intended purpose - to serve as a faster and less cumbersome alternative to district court litigation.	[Hovenkamp, Erik] Univ Southern Calif, Gould Sch Law, Los Angeles, CA USA; [Lemus, Jorge] Univ Illinois, Dept Econ, Champaign, IL USA; [Rai, Arti] Duke Univ, Sch Law, Durham, NC 27706 USA; [Vishnubhakat, Saurabh] Benjamin N Cardozo Sch Law, New York, NY USA	University of Southern California; University of Illinois System; University of Illinois Urbana-Champaign; Duke University	Rai, A (corresponding author), Duke Univ, Sch Law, Durham, NC 27706 USA.	rai@law.duke.edu			Arnold Foundation	Arnold Foundation	The authors thank B. Sampat and K. Shadlen for helpful comments and A. Kesselheim for input on data sources. They are also grateful to A. Jakubow for assistance with coding and data gathering, and to A. Stewart for excellent research assistant work. This research was supported by a grant from the Arnold Foundation.	[Anonymous], RXNORM; Dave CV, 2020, HEALTH AFFAIR, V39, P1011, DOI 10.1377/hlthaff.2019.00673; Rai A., BERKELEY TECHNOL LAW; Rome BN, 2021, CLIN PHARMACOL THER, V109, P367, DOI 10.1002/cpt.1983	4	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2022	40	11					1569	1572		10.1038/s41587-022-01526-5	http://dx.doi.org/10.1038/s41587-022-01526-5		NOV 2022	4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	6H0GC	36347984				2023-01-03	WOS:000880281900019
J	Gkekas, A; Varenne, B; Stauf, N; Benzian, H; Listl, S				Gkekas, Athanasios; Varenne, Benoit; Stauf, Nicole; Benzian, Habib; Listl, Stefan			Affordability of essential medicines: The case of fluoride toothpaste in 78 countries	PLOS ONE			English	Article							ORAL-HEALTH; COVERAGE; DISEASES	Background Fluoride toothpaste (FT) has recently been included in the WHO Model List of Essential Medicines. Whereas it is essential for preventing dental caries, its current affordability around the globe remains unclear. This study aimed to analyse the affordability of FT in as many as possible countries worldwide, to capture the extent of variations in FT affordability between high-, middle- and low-income countries. Methods A standardized protocol was developed to collect country-specific information about the characteristics of the cheapest available FT at a regular point of purchase. 82 members of the WHO Global Oral Health Network of Chief Dental Officers (CDOs), directors of WHO Collaborative Centres and other oral health experts collected data using mobile phone technology. In line with established methodologies to assess affordability, the Fluoride Toothpaste Affordability Ratio (FTAR) was calculated as the expenditure associated with the recommended annual consumption of FT relative to the daily wage of the lowest-paid unskilled government worker (FTAR >1 = unaffordable spending on fluoride toothpaste). Results There are significant differences in the affordability of FT across 78 countries. FT was strongly affordable in high-income countries, relatively affordable in upper middle-income countries, and strongly unaffordable in lower middle-income and low-income countries. The affordability of FT across WHO Regions was dependent upon the economic mix of WHO Regions' member states. Conclusion FT is still unaffordable for many people, particularly in low-income settings. Strategies to improve the universal affordability of FT should be part of health policy decisions in order to contribute to reducing dental caries as a global public health problem.	[Gkekas, Athanasios; Listl, Stefan] Univ York, Dept Hlth Sci, York Trials Unit, York, N Yorkshire, England; [Gkekas, Athanasios; Varenne, Benoit] World Hlth Org, Oral Hlth Programme, NCD Dept, Geneva, Switzerland; [Stauf, Nicole] London Sch Hyg & Trop Med, London, England; [Benzian, Habib] New York Univ, Dept Epidemiol & Hlth Promot, WHO Collaborating Ctr Qual Improvement & Evidence, Coll Dent, New York, NY USA; [Listl, Stefan] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Dent Qual & Safety Oral Healthcare, Nijmegen, Netherlands	University of York - UK; World Health Organization; University of London; London School of Hygiene & Tropical Medicine; New York University; Radboud University Nijmegen	Listl, S (corresponding author), Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Dent Qual & Safety Oral Healthcare, Nijmegen, Netherlands.	stefan.listl@radboudumc.nl	Listl, Stefan/S-7600-2017	Listl, Stefan/0000-0002-8176-3397				[Anonymous], 2020, WORLD HLTH ORG; Benzian H., 2015, CHALLENGE ORAL DIS C; Benzian H, 2022, BRIT DENT J, V232, P421, DOI 10.1038/s41415-022-4150-9; Benzian H, 2012, INT DENT J, V62, P213, DOI 10.1111/j.1875-595X.2012.00116.x; Bernabe E, 2020, J DENT RES, V99, P362, DOI 10.1177/0022034520908533; Bernabe E, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4042-0; Coughlan PJ., 2003, LAMOIYAN CORPORATION; Davies G M, 2002, Community Dent Health, V19, P131; Euromonitor International, 2019, BRAND SHAR; GARNAUT R, 1992, ECONOMIC REFORM AND INTERNATIONALISATION: CHINA AND THE PACIFIC REGION, P1; Global Burden of Disease Collaborative Network, 2017, GLOB BURD DIS STUD 2; Goldman AS, 2008, GLOBALIZATION HEALTH, V4, DOI 10.1186/1744-8603-4-7; Hosseinpoor AR, 2012, J DENT RES, V91, P275, DOI 10.1177/0022034511432341; International Monetary Fund, 2019, IMPL PPP CONV RAT IM; Jevdjevic M., 2020, J DENT RES; Macnab A, 2012, HEALTH PROMOT INT, V27, P63, DOI 10.1093/heapro/dar039; O'Donnell O., 2008, Analyzing health equity using household survey data: a guide to techniques and their implementation; Pakhomov GN, 1999, INT DENT J, V49, P27, DOI 10.1111/j.1875-595X.1999.tb00504.x; Peres MA, 2019, LANCET, V394, P249, DOI 10.1016/S0140-6736(19)31146-8; Rasines Graciela, 2010, Evid Based Dent, V11, P6, DOI 10.1038/sj.ebd.6400698; Righolt AJ, 2018, J DENT RES, V97, P501, DOI 10.1177/0022034517750572; 't Hoen Ellen., 2001, WHO WTO WORKSH DIFF; Touger-Decker R, 2003, AM J CLIN NUTR, V78, p881S, DOI 10.1093/ajcn/78.4.881S; van Loveren C, 2005, CARIES RES, V39, P224, DOI 10.1159/000084802; WageIndicator Foundation, 2019, MINIMUM WAGES; Walsh T, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007868.pub3; Wang TT, 2020, B WORLD HEALTH ORGAN, V98, P719, DOI 10.2471/BLT.19.247288; World Bank, 2019, INC SHAR HELD LOW 10; World Bank, 2019, HOUS NPISHS FIN CONS; World Bank, 2019, POP TOT DAT; World Bank, 2019, GNI PPP CONST 2011 I; World Bank, 2019, INFL GDP DEFL ANN DA; World Health Organization, 2021, WHO MOD LIST ESS MED; World Health Organization, 2022, FLUORIDE; World Health Organization, 2008, HLTH ACT INT MEAS ME; World Health Organization, 2019, WORLD REPORT VISION; Wu D, 2020, INT J ACCOUNT INF MA, V28, P184, DOI [10.1016/j.ijid.2020.03.004, 10.1108/IJAIM-12-2018-0148]; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5	38	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2022	17	10							e0275111	10.1371/journal.pone.0275111	http://dx.doi.org/10.1371/journal.pone.0275111			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6J1XA	36260605	Green Submitted, Green Published, gold			2023-01-03	WOS:000886620200023
J	King, A				King, Anthony			A persistent pursuit	NATURE			English	Editorial Material																		Fong L, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju268; Graff JN, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000642; Guan XN, 2022, NATURE, V606, P791, DOI 10.1038/s41586-022-04522-6; Gulley J.L., 2019, J CLIN ONCOL, V37, P1051, DOI [10.1200/JCO.18.02031, DOI 10.1200/JCO.18.02031, DOI 10.1200/JCO.2019.37.15_SUPPL.8001]; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Narayan V, 2022, NAT MED, V28, DOI 10.1038/s41591-022-01726-1; Redman JM, 2020, ANN ONCOL, V31, pS511, DOI 10.1016/j.annonc.2020.08.875; Tran B., 2020, ANN ONCOL, V31, pS507, DOI [10.1016/j.annonc.2021.09.021, DOI 10.1016/J.ANNONC.2020.06.007, 10.1016/j.annonc.2020.08.869, DOI 10.1016/J.ANNONC.2020.08.869]	8	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 15	2022	609	7927					S42	S44		10.1038/d41586-022-02861-y	http://dx.doi.org/10.1038/d41586-022-02861-y			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4P1FN	36104410	Bronze			2023-01-03	WOS:000855141600007
J	Weidenbacher, PAB; Waltari, E; Kobara, ID; Bell, BN; Morris, MK; Cheng, YC; Hanson, C; Pak, JE; Kim, PS				Weidenbacher, Payton A. -B.; Waltari, Eric; de los Rios Kobara, Izumi; Bell, Benjamin N.; Morris, Mary Kate; Cheng, Ya-Chen; Hanson, Carl; Pak, John E.; Kim, Peter S.			Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors	NATURE CHEMICAL BIOLOGY			English	Article							RECEPTOR-BINDING DOMAIN; EVOLUTIONARY CONSERVATION; NEUTRALIZING ANTIBODIES; SEQUENCE; ACE2	Omicron and its subvariants have rendered most authorized monoclonal antibody-based treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ineffective, highlighting the need for biologics capable of overcoming SARS-CoV-2 evolution. These mostly ineffective antibodies target variable epitopes. Here we describe broad-spectrum SARS-CoV-2 inhibitors developed by tethering the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), to known non-neutralizing antibodies that target highly conserved epitopes in the viral spike protein. These inhibitors, called receptor-blocking conserved non-neutralizing antibodies (ReconnAbs), potently neutralize all SARS-CoV-2 variants of concern (VOCs), including Omicron. Neutralization potency is lost when the linker joining the binding and inhibitory ReconnAb components is severed. In addition, a bi-functional ReconnAb, made by linking ACE2 to a bi-specific antibody targeting two non-overlapping conserved epitopes, defined here, shows sub-nanomolar neutralizing activity against all VOCs, including Omicron and BA.2. Given their conserved targets and modular nature, ReconnAbs have the potential to act as broad-spectrum therapeutics against SARS-CoV-2 and other emerging pandemic diseases.	[Weidenbacher, Payton A. -B.; Bell, Benjamin N.; Cheng, Ya-Chen; Kim, Peter S.] Stanford Univ, Sarafan ChEM H, Stanford, CA 94305 USA; [Weidenbacher, Payton A. -B.] Stanford Univ, Dept Chem, Stanford, CA 94305 USA; [Waltari, Eric; Pak, John E.; Kim, Peter S.] Chan Zuckerberg Biohub, San Francisco, CA 94305 USA; [de los Rios Kobara, Izumi] Stanford Univ, Stanford Immunol Program, Sch Med, Stanford, CA 94305 USA; [Bell, Benjamin N.] Stanford Univ, Dept Mol & Cellular Physiol, Sch Med, Stanford, CA 94305 USA; [Morris, Mary Kate; Hanson, Carl] Calif Dept Publ Hlth, Richmond, CA USA; [Kim, Peter S.] Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; California Department of Public Health; Stanford University	Kim, PS (corresponding author), Stanford Univ, Sarafan ChEM H, Stanford, CA 94305 USA.; Kim, PS (corresponding author), Chan Zuckerberg Biohub, San Francisco, CA 94305 USA.; Kim, PS (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	kimpeter@stanford.edu		Kim, Peter/0000-0001-6503-4541; Waltari, Eric/0000-0001-6930-9645; Weidenbacher, Payton/0000-0002-7692-0458; de los Rios Kobara, Izumi/0000-0002-6479-110X; Bell, Ben/0000-0001-5356-0173	National Institutes of Health [DP1AI158125]; Virginia & D. K. Ludwig Fund for Cancer Research; Frank Quattrone and Denise Foderaro Family Research Fund; Chan Zuckerberg Biohub	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Virginia & D. K. Ludwig Fund for Cancer Research; Frank Quattrone and Denise Foderaro Family Research Fund; Chan Zuckerberg Biohub	We thank J. Bloom and A. Greaney for plasmids and cells related to viral neutralization assays; J. DeRisi, K. Zorn, L. Matthew, M. Ott and J. Bloom for Omicron-related plasmids; and I. Anderson at Stanford PAN facilities for rapid production of oligos used throughout this work. We are also grateful to T. Bruun and M. Filsinger Interrante and other members of the Kim laboratory for fruitful discussions and helpful comments on earlier versions of this manuscript. The CMV/R expression vectors for IgG production were received from the National Institutes of Health AIDS Reagent Program. Research reported in this publication was supported by the National Institutes of Health under award number DP1AI158125, the Virginia & D. K. Ludwig Fund for Cancer Research, the Frank Quattrone and Denise Foderaro Family Research Fund and the Chan Zuckerberg Biohub. An earlier version of this manuscript appeared on bioRxiv (https://doi.org/10.1101/2022.01.24.477625).	Amanat F, PLASMABLAST RESPONSE, DOI [10.1101/2021.03.07.21253098v2, DOI 10.1101/2021.03.07.21253098V2, 10.1101/2021.03.07.21253098(2021]; Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408; Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399; Aydillo T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23977-1; Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Bell BN, 2021, PROTEIN SCI, V30, P716, DOI 10.1002/pro.4044; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Burton DR, 2012, SCIENCE, V337, P183, DOI 10.1126/science.1225416; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Celniker G, 2013, ISR J CHEM, V53, P199, DOI 10.1002/ijch.201200096; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Gai SA, 2007, CURR OPIN STRUC BIOL, V17, P467, DOI 10.1016/j.sbi.2007.08.012; Glasgow Anum, 2020, bioRxiv, DOI 10.1101/2020.07.31.231746; Greaney Allison J, 2021, Cell Host Microbe, V29, P463, DOI 10.1016/j.chom.2021.02.003; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; HERZENBERG LA, 1976, SCI AM, V234, P108, DOI 10.1038/scientificamerican0376-108; Higuchi Y., 2020, BIORXIV, DOI [10.1101/2020.09.16.299891v2, DOI 10.1101/2020.09.16.299891V2]; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang KYA, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009352; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; Khoury DS, 2020, NAT REV IMMUNOL, V20, P727, DOI 10.1038/s41577-020-00471-1; Klein C, 2019, METHODS, V154, P21, DOI 10.1016/j.ymeth.2018.11.008; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4; Li WW, 2022, CELL REP, V38, DOI [10.1016/j.celrep.2021.110210, 10.1101/2021.08.02.454546]; Lim SA, 2021, MABS-AUSTIN, V13, DOI 10.1080/19420862.2021.1893426; Liu L, 2022, IEEE T KNOWL DATA EN, V34, P2293, DOI [10.1109/TKDE.2020.3004939, 10.1101/2020.06.17.153486]; Lui, 2020, BIORXIV, DOI [10.1101/2020.05.21.109157v1, DOI 10.1101/2020.05.21.109157V1]; Miao XN, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1804241; OKUNO Y, 1993, J VIROL, V67, P2552, DOI 10.1128/JVI.67.5.2552-2558.1993; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Pronobis MI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160509; Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005; Raybould Matthew I J, 2021, Bioinformatics, V37, P734, DOI 10.1093/bioinformatics/btaa739; Rogers Thomas F, 2020, bioRxiv, DOI 10.1101/2020.05.11.088674; Sauer MM, 2021, NAT STRUCT MOL BIOL, V28, P478, DOI [10.1038/s41594-021-00596-4, 10.1101/2020.12.29.424482]; Schaefer W, 2011, P NATL ACAD SCI USA, V108, P11187, DOI 10.1073/pnas.1019002108; Schmidt F, 2021, NATURE, V600, P512, DOI 10.1038/s41586-021-04005-0; Seydoux E., 2020, BIORXIV, DOI [biorxiv:2020.091298, DOI 10.1101/2020.05.12.091298V1]; Seydoux Emilie, 2020, bioRxiv, DOI 10.1101/2020.05.12.091298; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Song YL, 2020, ANAL CHEM, V92, P9895, DOI 10.1021/acs.analchem.0c01394; Starr TN, 2021, NATURE, V597, P97, DOI 10.1038/s41586-021-03807-6; Starr Tyler N, 2020, bioRxiv, DOI [10.1126/science.abf9302, 10.1101/2020.11.30.405472]; Suurs FV, 2019, PHARMACOL THERAPEUT, V201, P103, DOI 10.1016/j.pharmthera.2019.04.006; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Touret, 2022, BIORXIV, DOI [10.1101/2022.01.01.474639v1, DOI 10.1101/2022.01.01.474639V1]; VanBlargan LA, 2022, NAT MED, V28, P490, DOI 10.1038/s41591-021-01678-y; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424; Weidenbacher PA, 2019, P NATL ACAD SCI USA, V116, P9947, DOI 10.1073/pnas.1822062116; Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759; Westendorf Kathryn, 2022, bioRxiv, DOI 10.1101/2021.04.30.442182; Zalevsky J, 2010, NAT BIOTECHNOL, V28, P157, DOI 10.1038/nbt.1601; Zhou H, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14061334; Zhou PP, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abi9215; Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.22.111005; Zost SJ, 2020, NAT MED, V26, DOI [10.1101/2020.05.12.091462, 10.1038/s41591-020-0998-x]	62	0	0	9	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2022	18	11					1270	+		10.1038/s41589-022-01140-1	http://dx.doi.org/10.1038/s41589-022-01140-1		SEP 2022	21	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	5O8GA	36076082	hybrid, Green Published			2023-01-03	WOS:000852273900001
J	Alshaikh, F; Kurdi, A; Godman, B				Alshaikh, Faisal; Kurdi, Amanj; Godman, Brian			Prevalence of bacterial coinfection and patterns of antibiotics prescribing in patients with COVID-19: A systematic review and meta-analysis	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Meeting Abstract									[Alshaikh, Faisal; Kurdi, Amanj] Univ Strathclyde, Glasgow, Scotland; [Godman, Brian] Sefako Makgatho Hlth Sci Univ, Pretoria, South Africa	University of Strathclyde; Sefako Makgatho Health Sciences University			; Kurdi, Amanj/P-1217-2017	Alshaikh, Faisal/0000-0003-2076-6268; Kurdi, Amanj/0000-0001-5036-1988					0	7	7	3	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	SEP	2022	31			2	SI		656	656						1	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	4U9CX	35913964	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000859084402513
J	Jemal, M; Argaw, A; Taye, A; Sintayehu, T; Kedir, S				Jemal, Musa; Argaw, Alemayehu; Taye, Abonesh; Sintayehu, Tsion; Kedir, Shemsu			Dietary self-care and associated factors among diabetic patients in Jimma University Medical Centre, South West Ethiopia; A path analysis	PLOS ONE			English	Article							ILLNESS PERCEPTIONS; GLYCEMIC CONTROL; TYPE-2; DEPRESSION; ADHERENCE	Background Diabetes Mellitus (DM), a chronic metabolic disorder that caused about 4.2 million deaths and at least 760 billion dollars' expenditure in 2019, has been targeted for action by leaders of WHO member countries. In Ethiopia deaths, due to DM reached 34,262 in 2013. Studies show effective lifestyle interventions; particularly medical nutrition therapy reduces HbA1c by 0.5 to 2%. However, practicing recommended diet is reported to be difficult. Not only Knowledge and practice but also perception studies are therefore necessary to design future health programs. Objective To assess diabetic self-care, dietary practice and associated factors among diabetes patients. Method Institution-basedbased cross-sectional study design was employed from february15-May15, 2020 in Jimma university medical Centre (JUMC). Systematic sampling of every other patient (K = 2.7) was employed to interview 371 participants. A previously validated tool was used to collect data through a face-to-face interview. A path analysis was used to fit the structural model and tests the hypothesized Health Belief Model (HBM) relationships. Result Response rate was 95.4% (354). Around 52% of the participants were male and 76.8% follow diabetic education at least some times. 42.4% and 48% of respondents have good dietary and general self-care practices respectively. With unstandardized coefficient (standard error) self-efficacy0.10 (0.01) being the strongest cues to action0.10 (0.02), perceived threat0.02 (0.01), and perceived barrier-0.08(0.01) constructs of HBM have a significant effect on dietary practice. Knowledge, social support and diabetes distress exert a significant indirect effect on dietary practice through health belief constructs with unstandardized path coefficient (standard error) of 0.22(0.03), 0.02(0.01), and -0.03(0.004) respectively. Conclusion In this study, the proportion of good practice is found to be lower for both dietary as well as general self-care. HBM can best fit to explain variability in dietary self-care practice; therefore, future interventions should be designed to address the vast perception and psychosocial factors influencing dietary self-care practices.	[Jemal, Musa; Kedir, Shemsu] Werabe Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Werabe, Ethiopia; [Argaw, Alemayehu; Taye, Abonesh] Jimma Univ, Coll Hlth Sci, Dept Nutr & Dietet, Jimma, Ethiopia; [Sintayehu, Tsion] Wachemo Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Hosanna, Ethiopia	Jimma University	Jemal, M (corresponding author), Werabe Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Werabe, Ethiopia.	musajemal9@gmail.com		Jemal, Musa/0000-0002-5619-6511; Taye, Abonesh/0000-0003-3588-3387				Abate Teshager Weldegiorgis, 2018, BMC Res Notes, V11, P800, DOI 10.1186/s13104-018-3874-8; Amente Tadele., 2013, SELF CARE PRACTICE I, V2, P1; Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062; American Diabetes Association, 2016, Clin Diabetes, V34, P3, DOI 10.2337/diaclin.34.1.3; [Anonymous], 2011, PREDICTORS ADULT SEL; Ayele AA., 2017, LEVEL ADHERENCE DIET, V7, P1; Ayele K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035515; Bekele H., 2020, SYSTEMATIC REV, V2020; Berhe KK, 2012, INT J PHARM SCI RES, V3, P4219, DOI 10.13040/IJPSR.0975-8232.3(11).4421-24; Chali Segni Wanna, 2018, BMC Res Notes, V11, P833, DOI 10.1186/s13104-018-3939-8; Cho GC, 2020, J MARK ANAL, V8, P189, DOI 10.1057/s41270-020-00089-1; Dehghani-Tafti Abbasali, 2015, Glob J Health Sci, V7, P33, DOI 10.5539/gjhs.v7n5p33; Demilew Yeshalem Mulugeta, 2018, BMC Res Notes, V11, P434, DOI 10.1186/s13104-018-3531-2; Devarajooh C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175096; Ekor R., 2008, MERA DIABETES INT, P475; Emmanuel O., 2015, PATTERNS ADHERENCE M, V3, P115, DOI DOI 10.4103/2321-0656.152808; Federal Democratic Republic of Ethiopia Ministry of health, 2016, NAT STRAT ACT PLAN N; Fitzgerald JT, 1998, DIABETES CARE, V21, P706, DOI 10.2337/diacare.21.5.706; Ganiyu AB., 2008, NONADHERENCE DIET EX, P1, DOI DOI 10.1071/HC13001; Ghimire Saruna, 2017, Int Sch Res Notices, V2017, P1273084, DOI 10.1155/2017/1273084; GIVEN CW, 1983, RES NURS HEALTH, V6, P127, DOI 10.1002/nur.4770060306; Glanz K., 2008, HLTH BEHAV HLTH ED T; Gonzalez JS, 2007, DIABETES CARE, V30, P2222, DOI 10.2337/dc07-0158; Gurmu Y., 2017, FACTORS ASS SELF CAR, P1; International Diabetes Federation, 2019, DIAB AFR; Loganathan A., 2013, J DIABETOL, V3, P4; Mariye Teklewoini, 2018, BMC Res Notes, V11, P380, DOI 10.1186/s13104-018-3489-0; Martinez K, 2018, PSYCHOL HEALTH MED, V23, P171, DOI 10.1080/13548506.2017.1339892; Mc Sharry J, 2011, DIABETIC MED, V28, P1300, DOI 10.1111/j.1464-5491.2011.03298.x; Mende SM., 2016, SO ETHIOPIA, V7; Mohamed AA, 2017, AIP CONF PROC, V1799, DOI 10.1063/1.4972935; Muchiri JW, 2012, HEALTH SA GESONDHEID, V17, DOI 10.4102/hsag.v17i1.614; Nakigudde J, 2009, AFR HEALTH SCI, V9, pS35; Pandey A., 2014, NONADHERENCE LIFESTY, P39; Parajuli Janaki, 2014, BMC Res Notes, V7, P758, DOI 10.1186/1756-0500-7-758; Peyrot M, 2005, DIABETIC MED, V22, P1379, DOI 10.1111/j.1464-5491.2005.01644.x; Saadia Z., 2010, INT J HEAL, DOI DOI 10.5580/1D29; Saleh F, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-431; Schmitt A, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-138; Sumlin LL, 2014, DIABETES EDUCATOR, V40, P731, DOI 10.1177/0145721714538925; Worku A., 2014, DIETARY PRACTICE ASS, P1; World Health Organization, 2016, GLOB REP PSOR	42	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2022	17	8							e0273074	10.1371/journal.pone.0273074	http://dx.doi.org/10.1371/journal.pone.0273074			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4M1JC	36001578	Green Published, gold			2023-01-03	WOS:000853083500056
J	Rubin, R				Rubin, Rita			Pharmacists Allowed to Prescribe COVID-19 Antiviral	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2022	328	7					612	612		10.1001/jama.2022.13680	http://dx.doi.org/10.1001/jama.2022.13680			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D0ZW	35972501				2023-01-03	WOS:000846874500011
J	Assuncao-Costa, L; de Sousa, IC; de Oliveira, MRA; Pinto, CR; Machado, JFF; Valli, CG; de Souza, LEPF				Assuncao-Costa, Lindemberg; de Sousa, Ivellise Costa; Alves de Oliveira, Maria Rafaela; Pinto, Charleston Ribeiro; Fernandes Machado, Juliana Ferreira; Valli, Cleidenete Gomes; Portela Fernandes de Souza, Luis Eugenio			Drug administration errors in Latin America: A systematic review	PLOS ONE			English	Article							MEDICATION ERRORS; INTRAVENOUS MEDICATION	Purpose This study systematically reviewed studies to determine the frequency and nature of medication administration errors in Latin American hospitals. Summary We systematically searched the medical literature of seven electronic databases to identify studies on medication administration errors in Latin American hospitals using the direct observation method. Studies published in English, Spanish, or Portuguese between 1946 and March 2021 were included. A total of 10 studies conducted at 22 hospitals were included in the review. Nursing professionals were the most frequently observed during medication administration and were observers in four of the ten included studies. Total number of error opportunities was used as a parameter to calculate error rates. The administration error rate had a median of 32% (interquartile range 16%-35.8%) with high variability in the described frequencies (9%-64%). Excluding time errors, the median error rate was 9.7% (interquartile range 7.4%-29.5%). Four different definitions of medication errors were used in these studies. The most frequently observed errors were time, dose, and omission. Only four studies described the therapeutic classes or groups involved in the errors, with systemic anti-infectives being the most reported. None of the studies assessed the severity or outcome of the errors. The assessment of the overall risk bias revealed that one study had low risk, three had moderate risk, and three had high risk. In the assessment of the exploratory, observational, and before-after studies, two were classified as having fair quality and one as having poor quality. Conclusion The administration error rate in Latin America was high, even when time errors were excluded. The variation observed in the frequencies can be explained by the different contexts in which the study was conducted. Future research using direct observation techniques is necessary to more accurately estimate the nature and severity of medication administration errors.	[Assuncao-Costa, Lindemberg; Pinto, Charleston Ribeiro] Univ Fed Bahia, Sch Pharm, Dept Med, Salvador, BA, Brazil; [de Sousa, Ivellise Costa; Alves de Oliveira, Maria Rafaela] Univ Hosp Prof Edgard Santos, Dept Pharm, Salvador, BA, Brazil; [Fernandes Machado, Juliana Ferreira] Natl Inst Pharmaceut Assistance & Pharmacoecon, Salvador, BA, Brazil; [Valli, Cleidenete Gomes] Hlth Dept State Bahia, Salvador, BA, Brazil; [Portela Fernandes de Souza, Luis Eugenio] Univ Fed Bahia, Inst Collect Hlth, Salvador, BA, Brazil	Universidade Federal da Bahia; Universidade Federal da Bahia	Assuncao-Costa, L (corresponding author), Univ Fed Bahia, Sch Pharm, Dept Med, Salvador, BA, Brazil.	lindemberg.rn@gmail.com	de Sousa, Ivellise/L-9492-2015	de Sousa, Ivellise/0000-0002-0005-2172; Assuncao-Costa, Lindemberg/0000-0002-8752-7301				Aitken M., 2012, ADV RESPONSIBLE USE, DOI 10.2139/ssrn.2222541; ALLAN EL, 1990, AM J HOSP PHARM, V47, P555, DOI 10.1093/ajhp/47.3.555; Teixeira TCA, 2010, REV ESC ENFERM USP, V44, P139, DOI 10.1590/S0080-62342010000100020; [Anonymous], 2006, SISTEMA MEDICA O AN; [Anonymous], 1998, PREVENTION, P1; [Anonymous], 1993, AM J HOSP PHARM, V50, P305, DOI DOI 10.1093/AJHP/50.2.305; Anselmi ML, 2007, J CLIN NURS, V16, P1839, DOI 10.1111/j.1365-2702.2007.01834.x; Barker KN, 2002, ARCH INTERN MED, V162, P1897, DOI 10.1001/archinte.162.16.1897; Barker KN, 2002, AM J HEALTH-SYST PH, V59, P2314, DOI 10.1093/ajhp/59.23.2314; Berdot S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068856; Bruce J, 2001, DRUG SAFETY, V24, P855, DOI 10.2165/00002018-200124110-00006; Camacho ACLF., 2012, ONLINE BRAZ J NURS, V11; Costa L A, 2006, Farm Hosp, V30, P235; Cousins DH, 2005, QUAL SAF HEALTH CARE, V14, P190, DOI 10.1136/qshc.2003.006676; de Bortoli Cassiani Silvia Helena, 2010, Cienc. enferm., V16, P85, DOI 10.4067/S0717-95532010000100010; De Oliveira MRA, 2018, ERROS ADMINISTRA O M, P54; de Vries EN, 2008, QUAL SAF HEALTH CARE, V17, P216, DOI 10.1136/qshc.2007.023622; Dean B, 2001, AM J HEALTH-SYST PH, V58, P54, DOI 10.1093/ajhp/58.1.54; Donaldson LJ, 2017, LANCET, V389, P1680, DOI 10.1016/S0140-6736(17)31047-4; Ferner RE, 2006, DRUG SAFETY, V29, P1011, DOI 10.2165/00002018-200629110-00001; Franklin BD., 2015, SAFETY MEDICATION US, V1st ed; Gates PJ, 2019, DRUG SAFETY, V42, P1329, DOI 10.1007/s40264-019-00850-1; Gates PJ, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0805; Institute for safe Medication Practice. ISMP, 2017, ISMP MED SAF SELF AS; Jha AK, 2010, QUAL SAF HEALTH CARE, V19, P42, DOI 10.1136/qshc.2008.029165; Joanna Briggs Institute, 2017, CHECK AN CROSS SECT; Keers RN, 2013, ANN PHARMACOTHER, V47, P237, DOI 10.1345/aph.1R147; Kiekkas P, 2011, AM J CRIT CARE, V20, P36, DOI 10.4037/ajcc2011331; Koyama AK, 2020, BMJ QUAL SAF, V29, P595, DOI 10.1136/bmjqs-2019-009552; McLeod MC, 2013, BMJ QUAL SAF, V22, P278, DOI 10.1136/bmjqs-2012-001330; Mekonnen Alemayehu B, 2018, Drugs Real World Outcomes, V5, P1, DOI 10.1007/s40801-017-0125-6; Mendes JR, 2018, EINSTEIN-SAO PAULO, V16, DOI [10.1590/s1679-45082018ao4146, 10.1590/S1679-45082018AO4146]; Reis AMM, 2010, ACTA PAUL ENFERM, V23, P181, DOI 10.1590/S0103-21002010000200005; Nascimento MA., 2016, CAD GRAD BIOL GICAS, V3, P241; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Page MJ., 2021, BMJ, V372, pn160, DOI [10.1136/bmj.n160, DOI 10.1136/BMJ.N160]; Raban MZ, 2014, BMJ QUAL SAF, V23, P414, DOI 10.1136/bmjqs-2013-002118; Renata Grou Volpe Cris, 2014, Br J Nurs, V23, P553; Romero CM, 2013, J CRIT CARE, V28, P451, DOI 10.1016/j.jcrc.2012.11.011; Rostami P, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028170; Smith AL, 2014, REV MED CHILE, V142, P40, DOI 10.4067/S0034-98872014000100007; Sutherland A, 2020, EUR J HOSP PHARM, V27, P3, DOI 10.1136/ejhpharm-2018-001624; Tissot E, 2003, PHARM WORLD SCI, V25, P264, DOI 10.1023/B:PHAR.0000006519.44483.a0; Toffoleto M., 2015, ENFERMER A GLOB, V37, P350; van den Bemt PMLA, 2002, CRIT CARE MED, V30, P846, DOI 10.1097/00003246-200204000-00022; Wells G, NEWCASTLE OTTAWA QUA; Wilson RM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e832; Wirtz V, 2003, PHARM WORLD SCI, V25, P104, DOI 10.1023/A:1024009000113	48	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2022	17	8							e0272123	10.1371/journal.pone.0272123	http://dx.doi.org/10.1371/journal.pone.0272123			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4E8NP	35925985	Green Published, gold			2023-01-03	WOS:000848077100071
J	Wang, Z				Wang, Zhe			Vitamin E boosts immunotherapy	NATURE CELL BIOLOGY			English	Editorial Material												zhe.wang@nature.com							0	0	0	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2022	24	8					1179	1179		10.1038/s41556-022-00979-9	http://dx.doi.org/10.1038/s41556-022-00979-9			1	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	3P7ZR	35941368				2023-01-03	WOS:000837754300001
J	Mullard, A				Mullard, Asher			THE ANTIBODY ENIGMA	NATURE			English	Editorial Material						Drug discovery; SARS-CoV-2; Immunology												Hammitt LL, 2022, NEW ENGL J MED, V386, P837, DOI 10.1056/NEJMoa2110275; Levin MJ, 2022, NEW ENGL J MED, V386, P2188, DOI 10.1056/NEJMoa2116620; Montgomery Hugh, 2022, Lancet Respir Med, V10, P985, DOI 10.1016/S2213-2600(22)00180-1; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Sneller MC, 2022, NATURE, V606, P375, DOI 10.1038/s41586-022-04797-9; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163	6	0	0	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	2022	606	7916					854	856		10.1038/d41586-022-01735-7	http://dx.doi.org/10.1038/d41586-022-01735-7			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2O0RB	35768589	Bronze			2023-01-03	WOS:000818775000003
J	Ye, Y				Ye, Yvaine			TAILORED TREATMENTS	NATURE			English	Editorial Material						Careers; Health care; Personalized medicine; Society												Dai Y, 2021, SCI BULL, V66, P1591, DOI 10.1016/j.scib.2021.01.008; Sun X, 2019, MOL AUTISM, V10, DOI 10.1186/s13229-018-0246-0; Sun Y., 2021, PREPRINT, DOI [10.1101/2020.04.09.20059741, DOI 10.1101/2020.04.09.20059741]; Wang YF, 2018, ACTA OTO-LARYNGOL, V138, P865, DOI 10.1080/00016489.2018.1476777	4	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	2022	606	7916					S49	S51		10.1038/d41586-022-01742-8	http://dx.doi.org/10.1038/d41586-022-01742-8			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2O0RB	35768593	Bronze			2023-01-03	WOS:000818775000001
J	McNamara, M; Lepore, C; Alstott, A				McNamara, Meredithe; Lepore, Christina; Alstott, Anne			Protecting Transgender Health and Challenging Science Denialism in Policy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Transgender Health and Science Denialism Misused clinical research and disinformation have provided legal cover for bans on gender-affirming health care. Collaboration between medical and legal experts could help defeat such bans.	[McNamara, Meredithe; Lepore, Christina] Yale Sch Med, New Haven, CT 06510 USA; [Alstott, Anne] Yale Law Sch, New Haven, CT USA	Yale University; Yale University	McNamara, M (corresponding author), Yale Sch Med, New Haven, CT 06510 USA.							[Anonymous], 2020, BELL TAVISTOCK PORTM; Boulware S., 2022, BIASED SCI TEXAS ALA; Hembree WC, 2017, J CLIN ENDOCR METAB, V102, P3869, DOI [10.1210/jc.2017-01658, 10.1210/jc.2017-02548]; McNamara M., 2022, CRITICAL REV JUNE 20; World Professional Association for Transgender Health, 2022, STANDARDS CARE HLTH	5	0	0	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	2022	387	21					1919	1921		10.1056/NEJMp2213085	http://dx.doi.org/10.1056/NEJMp2213085		NOV 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6M4JU	36409481				2023-01-03	WOS:000886925700001
J	Harlow, AF; Leventhal, AM; Barrington-Trimis, JL				Harlow, Alyssa F.; Leventhal, Adam M.; Barrington-Trimis, Jessica L.			Closing the Loophole on Hemp-Derived Cannabis Products A Public Health Priority	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material; Early Access									[Harlow, Alyssa F.; Leventhal, Adam M.; Barrington-Trimis, Jessica L.] Univ Southern Calif, Keck Sch Med, Dept Populat & Publ Hlth Sci, Los Angeles, CA 90007 USA; [Harlow, Alyssa F.; Leventhal, Adam M.; Barrington-Trimis, Jessica L.] Univ Southern Calif, Keck Sch Med, Inst Addict Sci, Los Angeles, CA 90007 USA	University of Southern California; University of Southern California	Harlow, AF (corresponding author), Univ Southern Calif, Dept Populat & Publ Hlth Sci, 1845 N Soto St, Los Angeles, CA 90032 USA.	afharlow@usc.edu						[Anonymous], 2020, LANCET RESP MED, V8, P831, DOI 10.1016/S2213-2600(20)30360-X; [Anonymous], FEDERAL FOOD DRUG CO; [Anonymous], FARM BILL; Cornwell AM., 2022, IS DELTA 8 THC AVAIL; Leas EC, 2021, AM J PUBLIC HEALTH, V111, P1927, DOI 10.2105/AJPH.2021.306499; Levenson MS, 2021, MEET THC O ACETATE H; US Cannabis Council, UNR DISTR SAL CONS P; US Food and Drug Administration, 5 THINGS KNOW DELT 8	8	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.20620	http://dx.doi.org/10.1001/jama.2022.20620		NOV 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5X6ZL	36331491				2023-01-03	WOS:000878748100001
J	Shashikumar, SA; Gulseren, B; Berlin, NL; Hollingsworth, JM; Maddox, KEJ; Ryan, AM				Shashikumar, Sukruth A.; Gulseren, Baris; Berlin, Nicholas L.; Hollingsworth, John M.; Joynt Maddox, Karen E.; Ryan, Andrew M.			Association of Hospital Participation in Bundled Payments for Care Improvement Advanced With Medicare Spending and Hospital Incentive Payments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY; OUTCOMES; PROGRAM; IMPACT; MODEL	IMPORTANCE Bundled Payments for Care Improvement Advanced (BPCI-A) is a Centers for Medicare & Medicaid Services (CMS) initiative that aims to produce financial savings by incentivizing decreases in clinical spending. Incentives consist of financial bonuses from CMS to hospitals or penalties paid by hospitals to CMS. OBJECTIVE To investigate the association of hospital participation in BPCI-A with spending, and to characterize hospitals receiving financial bonuses vs penalties. DESIGN, SETTING, AND PARTICIPANTS Difference-in-differences and cross-sectional analyses of 4 754 139 patient episodes using 2013-2019 US Medicare claims at 694 participating and 2852 nonparticipating hospitals merged with hospital and market characteristics. EXPOSURES BPCI-A model years 1 and 2 (October 1, 2018, through December 31, 2019). MAIN OUTCOMES AND MEASURES Hospitals' per-episode spending, CMS gross and net spending, and the incentive allocated to each hospital. RESULTS The study identified 694 participating hospitals. The analysis observed a -$175 change in mean per-episode spending (95% CI, -$378 to $28) and an aggregate spending change of -$75.1 million (95% CI, -$162.1 million to $12.0 million) across the 428 670 episodes in BPCI-A model years 1 and 2. However, CMS disbursed $354.3 million (95% CI, $212.0 million to $496.0 million) more in bonuses than it received in penalties. Hospital participation in BPCI-Awas associated with a net loss to CMS of $279.2 million (95% CI, $135.0 million to $423.0 million). Hospitals in the lowest quartile of Medicaid days received a mean penalty of $0.41 million; (95% CI, $0.09 million to $0.72 million), while those in the highest quartile received a mean bonus of $1.57 million; (95% CI, $1.09 million to $2.08 million). Similar patterns were observed for hospitals across increasing quartiles of Disproportionate Share Hospital percentage and of patients from racial and ethnic minority groups. CONCLUSIONS AND RELEVANCE Among US hospitals measured between 2013 and 2019, participation in BPCI-A was significantly associated with an increase in net CMS spending. Bonuses accrued disproportionately to hospitals providing care for marginalized communities.	[Shashikumar, Sukruth A.; Joynt Maddox, Karen E.] Washington Univ, Dept Med, Cardiovasc Div, Sch Med, St Louis, MO USA; [Gulseren, Baris] Univ Michigan, Sch Public Hlth, Ann Arbor, MI USA; [Gulseren, Baris] Univ Michigan, Ctr Evaluating Hlth Reform, Ann Arbor, MI USA; [Berlin, Nicholas L.] Univ Michigan, Dept Surg, Sect Plastic Surg, Ann Arbor, MI USA; [Hollingsworth, John M.] Univ Michigan, Dept Urology, Ann Arbor, MI USA; [Joynt Maddox, Karen E.] Washington Univ St Louis, Inst Publ Hlth, Ctr Hlth Econom & Policy, St Louis, MO USA; [Ryan, Andrew M.] Brown Univ, Sch Publ Hlth, Providence, RI USA	Washington University (WUSTL); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Washington University (WUSTL); Brown University	Ryan, AM (corresponding author), Brown Univ, Sch Publ Hlth, 121 S Main St, Providence, RI 02903 USA.							Agarwal R, 2020, HEALTH AFFAIR, V39, P50, DOI 10.1377/hlthaff.2019.00784; Aggarwal R, 2021, JAMA-J AM MED ASSOC, V325, P1219, DOI 10.1001/jama.2021.0026; Barnett ML, 2020, JAMA-J AM MED ASSOC, V324, P1869, DOI 10.1001/jama.2020.19181; Barnett ML, 2019, NEW ENGL J MED, V380, P252, DOI 10.1056/NEJMsa1809010; Berlin NL, 2021, HEALTH AFFAIR, V40, P1286, DOI 10.1377/hlthaff.2020.01766; Berlin NL, 2020, HEALTH AFFAIR, V39, P1479, DOI 10.1377/hlthaff.2020.00104; Burwell SM, 2015, NEW ENGL J MED, V372, P897, DOI 10.1056/NEJMp1500445; Centers for Medicare and Medicaid Services, BUNDL PAYM CAR IMPR; Centers for Medicare & Medicaid Services, BPCI ADV; Centers for Medicare & Medicaid Services, CMMI MOD CERT; Chen LM, 2018, HEALTH SERV RES, V53, P632, DOI 10.1111/1475-6773.12681; Cher BAY, 2021, HEALTH SERV RES, V56, P635, DOI 10.1111/1475-6773.13675; Chopra Zoey, 2021, Ann Surg, DOI 10.1097/SLA.0000000000004869; Dummit L, CMS BUNDLED PAYMENTS; Dummit LA, 2016, JAMA-J AM MED ASSOC, V316, P1267, DOI 10.1001/jama.2016.12717; Goodman-Bacon A, 2021, J ECONOMETRICS, V225, P254, DOI 10.1016/j.jeconom.2021.03.014; Gu Q, 2014, HEALTH SERV RES, V49, P818, DOI 10.1111/1475-6773.12150; Haas DA, 2019, JAMA INTERN MED, V179, P924, DOI 10.1001/jamainternmed.2019.0480; Joynt KE, 2017, HEALTHCARE-J DEL SCI, V5, P62, DOI 10.1016/j.hjdsi.2016.11.002; Maddox KEJ, 2021, NEW ENGL J MED, V385, P618, DOI 10.1056/NEJMsa2033678; Keating NL, 2021, JAMA-J AM MED ASSOC, V326, P1829, DOI 10.1001/jama.2021.17642; Maddox KEJ, 2021, JAMA-HEALTH FORUM, V2, DOI 10.1001/jamahealthforum.2021.0295; Maddox KEJ, 2022, JAMA-J AM MED ASSOC, V327, P1761, DOI 10.1001/jama.2022.6402; Maddox KEJ, 2019, JAMA-J AM MED ASSOC, V322, P362, DOI 10.1001/jama.2019.7992; Maddox KEJ, 2019, J AM GERIATR SOC, V67, P1027, DOI 10.1111/jgs.15803; Maddox KEJ, 2018, NEW ENGL J MED, V379, P260, DOI [10.1056/NEJMsa1801369, 10.1056/NEJMsa1801569]; Medicare Payment Advisory Commission, 2022, C MED PAYM POL MEDPA; Mulvany C., HEALTHCARE FINANCIAL; Navathe AS, 2020, HEALTH AFFAIR, V39, P58, DOI 10.1377/hlthaff.2019.00466; Newhouse JP, 2013, NEW ENGL J MED, V368, P1465, DOI 10.1056/NEJMp1302981; Office of the Assistant Secretary for Planning and Evaluation, 2016, C SOC RISK FACT PERF; Shashikumar SA, 2022, HEALTH AFFAIR, V41, P375, DOI 10.1377/hlthaff.2021.01448; Shashikumar SA, 2021, JAMA INTERN MED, V181, P330, DOI 10.1001/jamainternmed.2020.7386; Shashikumar SA, 2020, JACC-HEART FAIL, V8, P481, DOI 10.1016/j.jchf.2019.12.012; Smith B, 2021, NEW ENGL J MED, V384, P759, DOI 10.1056/NEJMsb2031138; Sood N, 2011, HEALTH AFFAIR, V30, P1708, DOI 10.1377/hlthaff.2010.0394; Wadhera RK, 2019, NEW ENGL J MED, V380, P2289, DOI 10.1056/NEJMp1901225	37	1	1	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	2022	328	16					1616	1623		10.1001/jama.2022.18529	http://dx.doi.org/10.1001/jama.2022.18529			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6C3UZ	36282256				2023-01-03	WOS:000881945000019
J	Hsu, CK; Lai, CC				Hsu, Chi-Kuei; Lai, Chih-Cheng			Risk of Infection and Hospitalization Among Children and Adolescents in New York After Emergence of the SARS-CoV-2 Omicron Variant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Hsu, Chi-Kuei] E Da Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Lai, Chih-Cheng] Kaohsiung Vet Gen Hosp, Tainan Branch, Dept Internal Med, Tainan, Taiwan	E-Da Hospital; Kaohsiung Veterans General Hospital	Lai, CC (corresponding author), Kaohsiung Vet Gen Hosp, Tainan Branch, Dept Internal Med, 901 Zhonghua Rd, Tainan 71004, Taiwan.	dtmed141@gmail.com						Cohen-Stavi CJ, 2022, NEW ENGL J MED, V387, P227, DOI 10.1056/NEJMoa2205011; Dorabawila V, 2022, JAMA-J AM MED ASSOC, V327, P2242, DOI 10.1001/jama.2022.7319; Fleming-Dutra KE, 2022, JAMA-J AM MED ASSOC, V327, P2210, DOI 10.1001/jama.2022.7493; Sacco C, 2022, LANCET, V400, P97, DOI 10.1016/S0140-6736(22)01185-0; Tan SHX, 2022, NEW ENGL J MED, V387, P525, DOI 10.1056/NEJMoa2203209; US Food and Drug Administration, COR COVID 19 UPD FDA	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	2022	328	14					1460	1460						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5L0OS	36219410				2023-01-03	WOS:000870117100022
J	Kaye, KS; Belley, A; Barth, P; Lahlou, O; Knechtle, P; Motta, P; Velicitat, P				Kaye, Keith S.; Belley, Adam; Barth, Philip; Lahlou, Omar; Knechtle, Philipp; Motta, Paola; Velicitat, Patrick			Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANCE	IMPORTANCE Cefepime/enmetazobactam is a novel beta-lactam/beta-lactamase inhibitor combination and a potential empirical therapy for resistant gram-negative infections. OBJECTIVE To evaluate whether cefepime/enmetazobactam was noninferior to piperacillin/tazobactam for the primary outcome of treatment efficacy in patients with complicated urinary tract infections (UTIs) or acute pyelonephritis. DESIGN, SETTING, AND PARTICIPANTS A phase 3, randomized, double-blind, active-controlled, multicenter, noninferiority clinical trial conducted at 90 sites in Europe, North and Central America, South America, and South Africa. Recruitment occurred between September 24, 2018, and November 2, 2019. Final follow-up occurred November 26, 2019. Participants were adult patients aged 18 years or older with a clinical diagnosis of complicated UTI or acute pyelonephritis caused by gram-negative urinary pathogens. INTERVENTIONS Eligible patients were randomized to receive either cefepime, 2 g/enmetazobactam, 0.5 g (n = 520), or piperacillin, 4 g/tazobactam, 0.5 g (n = 521), by 2-hour infusion every 8 hours for 7 days (up to 14 days in patients with a positive blood culture at baseline). MAIN OUTCOMES AND MEASURES The primary outcome was the proportion of patients in the primary analysis set (patients who received any amount of study drug with a baseline gram-negative pathogen not resistant to either treatment and >= 10(5) colony-forming units [CFU]/mL in urine culture or the same pathogen present in concurrent blood and urine cultures) who achieved overall treatment success (defined as clinical cure combined with microbiological eradication [<10(3) CFU/mL in urine] of infection). Two-sided 95% Cls were computed using the stratified Newcombe method. The prespecified noninferiority margin was -10%. If noninferiority was established, a superiority comparison was also prespecified. RESULTS Among1041patients randomized (mean age, 54.7 years; 573 women [55.0%]),1034 (99.3%) received study drug and 995 (95.6%) completed the trial. Among the primary analysis set, the primary outcome occurred in 79.1% (273/345) of patients receiving cefepime/ enmetazobactam compared with 58.9% (196/333) receiving piperacillin/tazobactam (between-group difference, 21.2% [95% CI, 14.3% to 27.9%]). Treatment-emergent adverse events occurred in 50.0% (258/516) of patients treated with cefepime/enmetazobactam and 44.0% (228/518) with piperacillin/tazobactam; most were mild to moderate in severity (89.9% vs 88.6%, respectively). A total of 1.7% (9/516) of participants who received cefepime/ enmetazobactam and 0.8% (4/518) of those who received piperacillin/tazobactam did not complete the assigned therapy due to adverse events. CONCLUSIONS AND RELEVANCE Among patients with complicated UTI or acute pyelonephritis caused by gram-negative pathogens, cefepime/enmetazobactam, compared with piperacillin/tazobactam, met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiological eradication. Further research is needed to determine the potential role for cefepime/enmetazobactam in the treatment of complicated UTI and pyelonephritis.	[Kaye, Keith S.] Univ Med & Dent New Jersey, New Brunswick, NJ 08901 USA; [Belley, Adam; Barth, Philip; Lahlou, Omar; Velicitat, Patrick] Allecra Therapeut SAS, St Louis, France; [Knechtle, Philipp] Discover Bio Beta Ltd, Pfaffikon SZ, Zurich, Switzerland; [Motta, Paola] Spexis Ltd, CH-4123 Allschwil, Switzerland	Rutgers State University New Brunswick; Rutgers State University Medical Center	Kaye, KS (corresponding author), Univ Med & Dent New Jersey, Div Allergy Immunol & Infect Dis, 125 Paterson St, New Brunswick, NJ 08901 USA.	kk1116@rwjms.rutgers.edu		Knechtle, Philipp/0000-0003-0377-9446	Allecra Therapeutics	Allecra Therapeutics	This study was funded by Allecra Therapeutics.	Belley A, 2021, J GLOB ANTIMICROB RE, V25, P93, DOI 10.1016/j.jgar.2021.02.031; Carmeli Y, 2019, OPEN FORUM INFECT DI, V6, pS539, DOI [10.1093/ofid/ofz360.1341, DOI 10.1093/OFID/OFZ360.1341]; Castanheira M, 2021, JAC-ANTIMICROB RESIS, V3, DOI 10.1093/jacamr/dlab092; Castanheira M, 2019, OPEN FORUM INFECT DI, V6, pS23, DOI 10.1093/ofid/ofy347; Centers for Disease Control and Prevention, 2019, ANTIBIOTIC RESISTANC, DOI [10.15620/cdc:82532, DOI 10.15620/CDC:82532]; Endimiani A, 2008, EXPERT REV ANTI-INFE, V6, P805, DOI 10.1586/14787210.6.6.805; European Medicines Agency, 2022, GUIDELINE EVALUATION; European Medicines Agency, 2018, GUIDELINE EVALUATION; Food and Drug Administration, 2016, COLL RAC ETHN DAT CL; Hayden MK, 2018, JAMA-J AM MED ASSOC, V320, P979, DOI 10.1001/jama.2018.12565; Kaye KS, 2019, CLIN INFECT DIS, V69, P2045, DOI 10.1093/cid/ciz181; Kaye KS, 2018, JAMA-J AM MED ASSOC, V319, P788, DOI 10.1001/jama.2018.0438; Magill SS, 2014, JAMA-J AM MED ASSOC, V312, P1438, DOI 10.1001/jama.2014.12923; McLaughlin M, 2013, ANTIMICROB AGENTS CH, V57, P5131, DOI 10.1128/AAC.00607-13; Morrissey I, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/aac.00514-19, 10.1128/AAC.00514-19]; Motta P, 2020, 30 EUROPEAN C CLIN M; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Papp-Wallace KM, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.00105-19, 10.1128/aac.00105-19]; Pfizer, ZOSYN FULL PRESCR IN; Portsmouth S, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab045; Tamma P., 2022, IDSA GUIDANCE TREATM; U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2018, COMPL UR TRACT INF D; WHO, 2017, GUIDELINES MANAGING	23	0	0	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	2022	328	13					1304	1314		10.1001/jama.2022.17034	http://dx.doi.org/10.1001/jama.2022.17034			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5F6GU	36194218				2023-01-03	WOS:000866412700011
J	Grover, S; Wen, W; Viswanathan, V; Gill, CT; Reinhart, RMG				Grover, Shrey; Wen, Wen; Viswanathan, Vighnesh; Gill, Christopher T.; Reinhart, Robert M. G.			Long-lasting, dissociable improvements in working memory and long-term memory in older adults with repetitive neuromodulation	NATURE NEUROSCIENCE			English	Article							DIRECT-CURRENT STIMULATION; ALTERNATING-CURRENT STIMULATION; THETA OSCILLATIONS; PREFRONTAL CORTEX; DOUBLE-BLIND; GAMMA-TACS; RECALL; PRIMACY; DISEASE; HUMANS	The development of technologies to protect or enhance memory in older people is an enduring goal of translational medicine. Here we describe repetitive (4-day) transcranial alternating current stimulation (tACS) protocols for the selective, sustainable enhancement of auditory-verbal working memory and long-term memory in 65-88-year-old people. Modulation of synchronous low-frequency, but not high-frequency, activity in parietal cortex preferentially improved working memory on day 3 and day 4 and 1 month after intervention, whereas modulation of synchronous high-frequency, but not low-frequency, activity in prefrontal cortex preferentially improved long-term memory on days 2-4 and 1 month after intervention. The rate of memory improvements over 4 days predicted the size of memory benefits 1 month later. Individuals with lower baseline cognitive function experienced larger, more enduring memory improvements. Our findings demonstrate that the plasticity of the aging brain can be selectively and sustainably exploited using repetitive and highly focalized neuromodulation grounded in spatiospectral parameters of memory-specific cortical circuitry. Reinhart et al. show that repetitive transcranial alternating current stimulation (tACS) of unique combinations of rhythmic frequency and stimulation locations produces selective and long-lasting improvements in verbal working memory and long-term memory in older adults.	[Grover, Shrey; Wen, Wen; Viswanathan, Vighnesh; Gill, Christopher T.; Reinhart, Robert M. G.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA; [Reinhart, Robert M. G.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA; [Reinhart, Robert M. G.] Boston Univ, Ctr Syst Neurosci, Boston, MA 02215 USA; [Reinhart, Robert M. G.] Boston Univ, Cognit Neuroimaging Ctr, Boston, MA 02215 USA; [Reinhart, Robert M. G.] Boston Univ, Ctr Res Sensory Commun & Emerging Neural Technol, Boston, MA 02215 USA	Boston University; Boston University; Boston University; Boston University; Boston University	Reinhart, RMG (corresponding author), Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA.; Reinhart, RMG (corresponding author), Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.; Reinhart, RMG (corresponding author), Boston Univ, Ctr Syst Neurosci, Boston, MA 02215 USA.; Reinhart, RMG (corresponding author), Boston Univ, Cognit Neuroimaging Ctr, Boston, MA 02215 USA.; Reinhart, RMG (corresponding author), Boston Univ, Ctr Res Sensory Commun & Emerging Neural Technol, Boston, MA 02215 USA.	rmgr@bu.edu		Grover, Shrey/0000-0003-3168-5543	National Institutes of Health [R01-AG063775, R01-MH114877]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the National Institutes of Health (R01-AG063775 and R01-MH114877) and a generous gift from an individual philanthropist awarded to R.M.G.R. We thank C. Willing and B. Lahner for assistance with data collection and X. (P.) Cheng and the anonymous reviewers for their thoughtful feedback on the manuscript.	Alekseichuk I, 2016, CURR BIOL, V26, P1513, DOI 10.1016/j.cub.2016.04.035; Atkinson R.C., 1968, PSYCHOL LEARNING MOT, DOI [10.1016/S0079-7421(08)60422-3, DOI 10.1016/S0079-7421(08)60422-3]; Axmacher N, 2010, P NATL ACAD SCI USA, V107, P3228, DOI 10.1073/pnas.0911531107; BADDELEY AD, 1973, NEUROPSYCHOLOGIA, V11, P159, DOI 10.1016/0028-3932(73)90003-1; Benchenane K, 2011, CURR OPIN NEUROBIOL, V21, P475, DOI 10.1016/j.conb.2011.01.004; Benussi A, 2021, BRAIN STIMUL, V14, P531, DOI 10.1016/j.brs.2021.03.007; Burke JF, 2014, J NEUROSCI, V34, P11355, DOI 10.1523/JNEUROSCI.2654-13.2014; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P101; Cowan N, 2008, PROG BRAIN RES, V169, P323, DOI 10.1016/S0079-6123(07)00020-9; Deng YQ, 2019, ELIFE, V8, DOI 10.7554/eLife.51184; Edwards D, 2013, NEUROIMAGE, V74, P266, DOI 10.1016/j.neuroimage.2013.01.042; ERICSSON KA, 1995, PSYCHOL REV, V102, P211, DOI 10.1037/0033-295X.102.2.211; Feurra M, 2016, J NEUROPHYSIOL, V116, P153, DOI 10.1152/jn.01080.2015; Fiebelkorn IC, 2019, TRENDS COGN SCI, V23, P87, DOI 10.1016/j.tics.2018.11.009; Field A., 2018, DISCOVERING STAT USI; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5; Grover S, 2021, NAT MED, V27, P232, DOI 10.1038/s41591-020-01173-w; Grover S, 2021, ANNU REV MED, V72, P29, DOI 10.1146/annurev-med-060619-022857; Guida A, 2013, MEM COGNITION, V41, P571, DOI 10.3758/s13421-012-0284-3; Healey MK, 2016, PSYCHOL REV, V123, P23, DOI 10.1037/rev0000015; Herrmann N, 1996, INT J GERIATR PSYCH, V11, P457, DOI 10.1002/(SICI)1099-1166(199605)11:5<457::AID-GPS325>3.0.CO;2-2; Herweg NA, 2020, TRENDS COGN SCI, V24, P208, DOI 10.1016/j.tics.2019.12.006; Heusser AC, 2016, NAT NEUROSCI, V19, P1374, DOI 10.1038/nn.4374; Hoy KE, 2016, J NEURAL TRANSM, V123, P1205, DOI 10.1007/s00702-016-1554-1; Innocenti I, 2013, J COGNITIVE NEUROSCI, V25, P109, DOI 10.1162/jocn_a_00304; Javadi AH, 2017, J NEUROSCI, V37, P9939, DOI 10.1523/JNEUROSCI.0265-17.2017; Karabanov AN, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00213; Kim Hae-Young, 2013, Restor Dent Endod, V38, P52, DOI 10.5395/rde.2013.38.1.52; Klink K, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.00066; Koen JD, 2019, TRENDS COGN SCI, V23, P547, DOI 10.1016/j.tics.2019.04.012; Kohler S, 2004, J COGNITIVE NEUROSCI, V16, P178, DOI 10.1162/089892904322984490; Krause MR, 2019, P NATL ACAD SCI USA, V116, P5747, DOI 10.1073/pnas.1815958116; Lisman JE, 2013, NEURON, V77, P1002, DOI 10.1016/j.neuron.2013.03.007; Long NM, 2015, PSYCHON B REV, V22, P1328, DOI 10.3758/s13423-014-0791-2; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nguyen J, 2018, BRAIN STIMUL, V11, P723, DOI 10.1016/j.brs.2018.02.008; Nomura T, 2019, EXP BRAIN RES, V237, P1709, DOI 10.1007/s00221-019-05543-w; O'Connor AR, 2010, J NEUROSCI, V30, P2924, DOI 10.1523/JNEUROSCI.4225-09.2010; PARKINSON SR, 1982, J GERONTOL, V37, P425, DOI 10.1093/geronj/37.4.425; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Ranganath C, 2005, TRENDS COGN SCI, V9, P374, DOI 10.1016/j.tics.2005.06.009; RAPP PR, 1992, TRENDS NEUROSCI, V15, P340, DOI 10.1016/0166-2236(92)90051-9; Reinhart RMG, 2019, NAT NEUROSCI, V22, P820, DOI 10.1038/s41593-019-0371-x; Reinhart RMG, 2017, P NATL ACAD SCI USA, V114, P11542, DOI 10.1073/pnas.1710257114; Reinhart RMG, 2017, ATTEN PERCEPT PSYCHO, V79, P3, DOI 10.3758/s13414-016-1224-2; Reinhart RMG, 2016, CURR BIOL, V26, P1867, DOI 10.1016/j.cub.2016.05.019; Reinhart RMG, 2015, P NATL ACAD SCI USA, V112, P9448, DOI 10.1073/pnas.1504196112; Reinhart RMG, 2015, P NATL ACAD SCI USA, V112, P625, DOI 10.1073/pnas.1417259112; Samanez-Larkin GR, 2015, NAT REV NEUROSCI, V16, P278, DOI 10.1038/nrn3917; Schutter DJLG, 2016, NEUROPSYCHOLOGIA, V86, P110, DOI 10.1016/j.neuropsychologia.2016.04.011; Schwab BC, 2021, NEUROIMAGE, V237, DOI 10.1016/j.neuroimage.2021.118179; Sederberg PB, 2007, PSYCHOL SCI, V18, P927, DOI 10.1111/j.1467-9280.2007.02003.x; Serruya MD, 2014, CEREB CORTEX, V24, P403, DOI 10.1093/cercor/bhs318; SHALLICE T, 1970, Q J EXP PSYCHOL, V22, P261, DOI 10.1080/00335557043000203; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Soraas A, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.18717; SULLIVAN EV, 1991, BRAIN, V114, P893, DOI 10.1093/brain/114.2.893; Wagner AD, 2001, NEUROIMAGE, V14, P1337, DOI 10.1006/nimg.2001.0936; West S. G., 1995, STRUCTURAL EQUATION, P56; Wynn SC, 2020, NEUROBIOL LEARN MEM, V168, DOI 10.1016/j.nlm.2019.107140	61	3	3	21	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	SEP	2022	25	9					1237	+		10.1038/s41593-022-01132-3	http://dx.doi.org/10.1038/s41593-022-01132-3		AUG 2022	16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	4K0BI	35995877	Bronze			2023-01-03	WOS:000842887700002
J	Park, JW; Yea, JW; Park, J; Oh, SA				Park, Jae Won; Yea, Ji Woon; Park, Jaehyeon; Oh, Se An			Setup uncertainties and appropriate setup margins in the head-tilted supine position of whole-brain radiotherapy (WBRT)	PLOS ONE			English	Article							THERMOPLASTIC MASKS; IMMOBILIZATION	Various applications of head-tilting techniques in whole-brain radiotherapy (WBRT) have been introduced. However, a study on the setup uncertainties and margins in head-tilting techniques has not been reported. This study evaluated the setup uncertainties and determined the appropriate planning target volume (PTV) margins for patients treated in the head-tilted supine (ht-SP) and conventional supine position (c-SP) in WBRT. Thirty patients who received WBRT at our institution between October 2020 and May 2021 in the c-SP and ht-SP were investigated. The DUON head mask (60124, Orfit Industries, Wijnegem, Belgium) was used in the c-SP, and a thermoplastic U-Frame Mask (R420U, Klarity Medical & Equipment Co. Ltd., Lan Yu, China) was used in the ht-SP. Daily setup verification using planning computed tomography (CT) and cone-beam CT was corrected for translational (lateral, longitudinal, and vertical) and rotational (yaw) errors. In the c-SP, the means of systematic errors were -0.80, 0.79, and 0.37 mm and random errors were 0.27, 0.54, and 0.39 mm in the lateral, longitudinal, and vertical translational dimensions, respectively. Whereas, for the ht-SP, the means of systematic errors were -0.07, 0.73, and -0.63 mm, and random errors were 0.75, 1.39, 1.02 mm in the lateral, longitudinal, and vertical translational dimensions, respectively. The PTV margins were calculated using Stroom et al.'s [2 Sigma+0.7 sigma] and van Herk et al.'s recipe [2.5 Sigma+0.7 sigma]. Appropriate PTV margins with van Herk et al.'s recipe in WBRT were <2 mm and 1.5 degrees in the c-SP and <3 mm and 2 degrees in the ht-SP in the translational and rotational directions, respectively. Although the head tilt in the supine position requires more margin, it can be applied as a sufficiently stable and effective position in radiotherapy.	[Park, Jae Won; Yea, Ji Woon; Park, Jaehyeon; Oh, Se An] Yeungnam Univ, Dept Radiat Oncol, Med Ctr, Daegu, South Korea; [Park, Jae Won; Yea, Ji Woon; Park, Jaehyeon; Oh, Se An] Yeungnam Univ, Dept Radiat Oncol, Coll Med, Daegu, South Korea	Yeungnam University; Yeungnam University	Oh, SA (corresponding author), Yeungnam Univ, Dept Radiat Oncol, Med Ctr, Daegu, South Korea.; Oh, SA (corresponding author), Yeungnam Univ, Dept Radiat Oncol, Coll Med, Daegu, South Korea.	sean.oh5235@gmail.com		Oh, SeAn/0000-0002-8835-2814	Yeungnam University	Yeungnam University	This work was supported by the 2021 Yeungnam University Research Grant.	Brown PD, 2018, J CLIN ONCOL, V36, P483, DOI 10.1200/JCO.2017.75.9589; Deng X, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3017-3; Gilbeau L, 2001, RADIOTHER ONCOL, V58, P155, DOI 10.1016/S0167-8140(00)00280-2; He YL, 2021, J APPL CLIN MED PHYS, V22, P156, DOI 10.1002/acm2.13341; Kim SH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216655; Lin YF, 2020, RADIAT PHYS CHEM, V173, DOI 10.1016/j.radphyschem.2020.108884; McTyre Emory, 2013, Surg Neurol Int, V4, pS236, DOI 10.4103/2152-7806.111301; Miao JJ, 2019, J APPL CLIN MED PHYS, V20, P78, DOI 10.1002/acm2.12763; Miura K, 2021, TECHNOL CANCER RES T, V20, DOI 10.1177/1533033820986824; Oh SA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232430; Oh SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156357; Oh SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151709; Oh SJ, 2017, RADIAT ONCOL J, V35, P101, DOI 10.3857/roj.2017.00325; Oh YK, 2014, J APPL CLIN MED PHYS, V15, P85, DOI 10.1120/jacmp.v15i2.4418; Ong CL, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01639-8; Paganelli C, 2018, MED PHYS, V45, pE908, DOI 10.1002/mp.13162; Park J, 2019, RADIAT ONCOL J, V37, P22, DOI 10.3857/roj.2019.00059; Park Jaehyeon, 2019, Yeungnam Univ J Med, V36, P36, DOI 10.12701/yujm.2019.00087; Remeijer P, 2000, INT J RADIAT ONCOL, V46, P1281, DOI 10.1016/S0360-3016(99)00468-X; Rigaud B, 2019, ACTA ONCOL, DOI 10.1080/0284186X.2019.1620331; Sharp L, 2005, INT J RADIAT ONCOL, V61, P250, DOI 10.1016/j.ijrobp.2004.04.047; Shimizu H, 2021, J APPL CLIN MED PHYS, V22, P49, DOI 10.1002/acm2.13151; Stroom JC, 1999, INT J RADIAT ONCOL, V43, P905, DOI 10.1016/S0360-3016(98)00468-4; Suteu Patricia, 2019, Med Pharm Rep, V92, P43, DOI 10.15386/cjmed-1040; Tomihara J, 2021, J APPL CLIN MED PHYS, V22, P360, DOI 10.1002/acm2.13382; Udayashankar AH, 2018, REP PRACT ONCOL RADI, V23, P233, DOI 10.1016/j.rpor.2018.04.007; van Herk M, 2000, INT J RADIAT ONCOL, V47, P1121, DOI 10.1016/S0360-3016(00)00518-6; van Herk M, 2004, SEMIN RADIAT ONCOL, V14, P52, DOI 10.1053/j.semradonc.2003.10.003; Zhang MT, 2016, PHYS MEDICA, V32, P379, DOI 10.1016/j.ejmp.2016.02.002; Zhou JN, 2010, MED DOSIM, V35, P31, DOI 10.1016/j.meddos.2009.01.005	30	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2022	17	8							e0271077	10.1371/journal.pone.0271077	http://dx.doi.org/10.1371/journal.pone.0271077			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4E8NP	35925916	Green Published, gold			2023-01-03	WOS:000848077100031
J	Lindley, KJ; Teal, SB				Lindley, Kathryn J.; Teal, Stephanie B.			Contraception in Women With Cardiovascular Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PRE-CONCEPTION; PREGNANCY	This JAMA Insights in Women's Health series summarizes the prevalence of cardiovascular disease among women of childbearing age, the most effective forms of contraception based on the patient's medical condition and preference, and the risks and adverse effects associated with contraindicated forms of contraception.	[Lindley, Kathryn J.] Washington Univ, Dept Med, Cardiovasc Div, St Louis, MO USA; [Teal, Stephanie B.] Univ Hosp Cleveland, Med Ctr, Dept Obstet & Gynecol & Reprod Biol, 11100 Euclid St,MAC-5034, Cleveland, OH 44106 USA	Washington University (WUSTL); Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	Teal, SB (corresponding author), Univ Hosp Cleveland, Med Ctr, Dept Obstet & Gynecol & Reprod Biol, 11100 Euclid St,MAC-5034, Cleveland, OH 44106 USA.	stephanie.teal@uhhospitals.org						[Anonymous], 2019, Obstet Gynecol, V133, P396, DOI 10.1097/AOG.0000000000003073; Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485; Castillo K, 2022, EUR J OBSTET GYN R B, V270, P231, DOI 10.1016/j.ejogrb.2022.01.020; Davis MB, 2020, J AM COLL CARDIOL, V77, P1763, DOI 10.1016/j.jacc.2021.02.033; Kann L, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6506a1; Kavanaugh Megan L, 2020, F S Rep, V1, P83, DOI 10.1016/j.xfre.2020.06.006; Lindley KJ, 2021, J AM COLL CARDIOL, V77, P1823, DOI 10.1016/j.jacc.2021.02.025; Lindley KJ, 2020, J AM COLL CARDIOL, V77, P1778, DOI 10.1016/j.jacc.2021.02.026; Teal S, 2021, JAMA-J AM MED ASSOC, V326, P2507, DOI 10.1001/jama.2021.21392; Tepper NK, 2016, CONTRACEPTION, V94, P678, DOI 10.1016/j.contraception.2016.04.014	10	0	0	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	2022	328	6					577	578		10.1001/jama.2022.11541	http://dx.doi.org/10.1001/jama.2022.11541		JUL 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4E5FG	35867075				2023-01-03	WOS:000828807400002
J	Pan, PC; Savidge, C; Amsellem, P; Hamilton, S				Pan, Po-ching; Savidge, Christine; Amsellem, Pierre; Hamilton, Stephanie			Comparison between propofol and alfaxalone anesthesia for the evaluation of laryngeal function in healthy dogs utilizing computerized software	PLOS ONE			English	Article							LARYNGOSCOPY; MOTION; PARALYSIS; DIAGNOSIS	Laryngeal paralysis is a well-documented cause of upper respiratory tract obstruction in canines. Diagnosis of laryngeal paralysis is usually made by visual evaluation of laryngeal motion whilst patients are under a light-plane of anesthesia. However, in human studies of laryngeal function evaluation, it has been shown that subjective scoring can lead to significant interobserver variance, which may cause false diagnosis. In this study, we propose to introduce a more objective method of assessing laryngeal function using GlotAnTools and Tracker software to directly measure laryngeal motion in anaesthetized patients. Additionally, two anesthetic agents, alfaxalone and propofol, were compared in this study to assess their relative effect on laryngeal motion and thus their suitability for use in this diagnostic process. This study was a two-stage, cross-over, 1:1 randomization, with two active treatment arms. Ten beagles (10-18 months, five males and five females) were exposed to both anesthetic agents and laryngeal motion was recorded using videoendoscopy. GlotAnTools and Tracker software were applied to the recorded images to measure glottal gap area (A) and length (L). A normalized measure of laryngeal function-computed as A/L-was created, representing the "elongatedness" of the rima glottidis. The glottal gap area was significantly reduced in dogs receiving alfaxalone. This study objectively establishes that alfaxalone impacted laryngeal motion significantly more than propofol and confirms the capability of these computational methods to detect differences in laryngeal motion.	[Pan, Po-ching; Savidge, Christine; Amsellem, Pierre; Hamilton, Stephanie] Univ Prince Edward Isl, Atlantic Vet Coll, Dept Compan Anim, Charlottetown, PE, Canada; [Pan, Po-ching] Cent Toronto Vet Referral Clin, York, ON, Canada; [Savidge, Christine] Tufts Vet Emergency Treatment & Specialties, Walpole, MA USA; [Amsellem, Pierre] Univ Minnesota, Vet Med Ctr, Dept Vet Clin Sci, Minneapolis, MN USA	University of Prince Edward Island; University of Minnesota System; University of Minnesota Twin Cities	Pan, PC (corresponding author), Univ Prince Edward Isl, Atlantic Vet Coll, Dept Compan Anim, Charlottetown, PE, Canada.	ppan@upei.ca		Pan, Po-ching/0000-0003-3382-6039				Ambros B, 2008, AM J VET RES, V69, P1391, DOI 10.2460/ajvr.69.11.1391; Amengual M, 2013, VET ANAESTH ANALG, V40, P115, DOI 10.1111/j.1467-2995.2012.00747.x; Broome C, 2000, AUST VET J, V78, P769, DOI 10.1111/j.1751-0813.2000.tb10449.x; Brown MB, 2019, VET SURG, V48, P70, DOI 10.1111/vsu.13110; BURBIDGE HM, 1995, BRIT VET J, V151, P71, DOI 10.1016/S0007-1935(05)80066-1; Chen G, 2014, COMPUT SPEECH LANG, V28, P1156, DOI 10.1016/j.csl.2013.11.006; Chen G, 2013, J ACOUST SOC AM, V133, P1656, DOI 10.1121/1.4789931; Estes C, 2017, LARYNGOSCOPE, V127, P2100, DOI 10.1002/lary.26570; Ettinger S.J., 2017, TXB VET INTERNAL MED; Gross ME, 2002, J AM ANIM HOSP ASSOC, V38, P503, DOI 10.5326/0380503; Jackson AM, 2004, VET SURG, V33, P102, DOI 10.1111/j.1532-950X.2004.04016.x; Macphail C., 2009, KIRKS CURRENT VET TH, P627; Monnet E, 2016, VET CLIN N AM-SMALL, V46, P709, DOI 10.1016/j.cvsm.2016.02.003; Muir W, 2008, VET ANAESTH ANALG, V35, P451, DOI 10.1111/j.1467-2995.2008.00406.x; Nelissen P, 2012, VET SURG, V41, P876, DOI 10.1111/j.1532-950X.2012.01030.x; Radkey DI, 2018, VET ANAESTH ANALG, V45, P241, DOI 10.1016/j.vaa.2017.08.014; Radlinsky MG, 2009, VET SURG, V38, P434, DOI 10.1111/j.1532-950X.2009.00506.x; Rosow DE, 2010, LARYNGOSCOPE, V120, P1376, DOI 10.1002/lary.20945; Smalle TM, 2017, VET ANAESTH ANALG, V44, P427, DOI 10.1016/j.vaa.2016.05.013; Smith MM, 2000, J AM ANIM HOSP ASSOC, V36, P383, DOI 10.5326/15473317-36-5-383; Tamura J, 2021, J VET MED SCI, V83, P73, DOI 10.1292/jvms.20-0407; Trapani G, 2000, CURR MED CHEM, V7, P249, DOI 10.2174/0929867003375335	22	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	7								10.1371/journal.pone.0270812	http://dx.doi.org/10.1371/journal.pone.0270812			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M5FN	35789223	Green Published, gold			2023-01-03	WOS:000835487000027
J	Gartlehner, G; Patel, SV; Reddy, S; Rains, C; Schwimmer, M; Kahwati, L				Gartlehner, Gerald; Patel, Sheila V.; Reddy, Shivani; Rains, Caroline; Schwimmer, Manny; Kahwati, Leila			Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons Updated Evidence Report and Systematic Review for the US Preventive Services Task Force	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGENS; DOSE TRANSDERMAL ESTRADIOL; BREAST-CANCER INCIDENCE; CORONARY-HEART-DISEASE; PERIPHERAL ARTERIAL-DISEASE; MILD COGNITIVE IMPAIRMENT; HEALTH INITIATIVE MEMORY; BONE-MINERAL DENSITY; REPLACEMENT THERAPY	IMPORTANCE It is uncertain whether hormone therapy should be used for the primary prevention of chronic conditions such as heart disease, osteoporosis, or some types of cancers. OBJECTIVE To update evidence for the US Preventive Services Task Force on the benefits and harms of hormone therapy in reducing risks for chronic conditions. DATA SOURCES PubMed/MEDLINE, Cochrane Library, EMBASE, and trial registries from January 1, 2016, through October 12, 2021; surveillance through July 2022. STUDY SELECTION English-language randomized clinical trials and prospective cohort studies of fair or good quality. DATA EXTRACTION AND SYNTHESIS Dual review of abstracts, full-text articles, and study quality; meta-analyses when at least 3 similar studies were available. MAIN OUTCOMES AND MEASURES Morbidity and mortality related to chronic conditions; health-related quality of life. RESULTS Twenty trials (N = 39145) and 3 cohort studies (N = 1155 410) were included. Participants using estrogen only compared with placebo had significantly lower risks for diabetes over 7.1 years (1050 vs 903 cases; 134 fewer [95% CI, 18-237)) and fractures over 7.2 years (1024 vs 1413 cases; 388 fewer [95% CI, 277-489)) per 10 000 persons. Risks per 10 000 persons were statistically significantly increased for gallbladder disease over 71 years (1113 vs 737 cases; 377 more [95% CI, 234-540)), stroke over 7.2 years (318 vs 239 cases; 79 more [95% CI, 15-159)), venous thromboembolism over 7.2 years (258 vs 181 cases; 77 more [95% CI, 19-153]), and urinary incontinence over 1year (2331 vs 1446 cases; 885 more [95% CI, 659-1135]). Participants using estrogen plus progestin compared with placebo experienced significantly lower risks, per 10 000 persons, for colorectal cancer over 5.6 years (59 vs 93 cases; 34 fewer [95% CI, 9-51]), diabetes over 5.6 years (403 vs 482 cases; 78 fewer [95% CI, 15-133)), and fractures over 5 years (864 vs 1094 cases; 230 fewer [95% CI, 66-372]). Risks, per 10 000 persons, were significantly increased for invasive breast cancer (242 vs 191 cases; 51 more [95% CI, 6-106]), gallbladder disease (723 vs 463 cases; 260 more [95% CI, 169-364)), stroke (187 vs 135 cases; 52 more [95% CI, 12-104)), and venous thromboembolism (246 vs 126 cases; 120 more [95% CI, 68-185]) over 5.6 years; probable dementia (179 vs 91cases; 88 more [95% CI, 15-212]) over 4.0 years; and urinary incontinence (1707 vs 1145 cases; 562 more [95% CI, 412-726]) over 1 year. CONCLUSIONS AND RELEVANCE Use of hormone therapy in postmenopausal persons for the primary prevention of chronic conditions was associated with some benefits but also with an increased risk of harms.	[Gartlehner, Gerald; Patel, Sheila V.; Reddy, Shivani; Rains, Caroline; Kahwati, Leila] Univ North Carolina Chapel Hill, Evidence Based Practice Ctr, RTI Int, Chapel Hill, NC USA; [Gartlehner, Gerald] Danube Univ Krems, Dept Evidence Based Med & Evaluat, Krems An Der Donau, Austria; [Schwimmer, Manny] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA	Research Triangle Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Danube University Krems; University System of Ohio; Ohio State University	Gartlehner, G (corresponding author), RTI Int, 3040 E Cornwallis Rd, Res Triangle Pk, NC 27709 USA.	ggartlehner@rti.org		Reddy, Shivani/0000-0003-2803-6155; Kahwati, Leila/0000-0001-6963-2848; Patel, Sheila/0000-0002-6508-8803; Gartlehner, Gerald/0000-0001-5531-3678				Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; [Anonymous], 2013, Obstet Gynecol, V121, P1407, DOI 10.1097/01.AOG.0000431053.33593.2d; Berkman ND, 2015, J CLIN EPIDEMIOL, V68, P1312, DOI 10.1016/j.jclinepi.2014.11.023; Bethea TN, 2017, CANCER CAUSE CONTROL, V28, P385, DOI 10.1007/s10552-016-0840-4; Bonds DE, 2006, DIABETOLOGIA, V49, P459, DOI 10.1007/s00125-005-0096-0; Brunner RL, 2005, ARCH INTERN MED, V165, P1976, DOI 10.1001/archinte.165.17.1976; Canonico M, 2014, MENOPAUSE, V21, P214, DOI 10.1097/GME.0b013e31829752e0; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Cherry N, 2014, BJOG-INT J OBSTET GY, V121, P700, DOI 10.1111/1471-0528.12598; Cherry N, 2002, LANCET, V360, P2001; Chlebowski RT, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv350; Chlebowski RT, 2020, JAMA-J AM MED ASSOC, V324, P369, DOI 10.1001/jama.2020.9482; Chlebowski RT, 2017, MENOPAUSE, V24, P133, DOI 10.1097/GME.0000000000000733; Chlebowski RT, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv327; Chlebowski RT, 2016, CLIN LUNG CANCER, V17, P10, DOI 10.1016/j.cllc.2015.09.004; Chlebowski RT, 2015, JAMA ONCOL, V1, P296, DOI 10.1001/jamaoncol.2015.0494; Chlebowski RT, 2014, STEROIDS, V90, P53, DOI 10.1016/j.steroids.2014.06.001; Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500; Chlebowski RT, 2010, JNCI-J NATL CANCER I, V102, P1413, DOI 10.1093/jnci/djq285; Chlebowski RT, 2009, LANCET, V374, P1243, DOI 10.1016/S0140-6736(09)61526-9; Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Cirillo DJ, 2005, JAMA-J AM MED ASSOC, V293, P330, DOI 10.1001/jama.293.3.330; Cobin RH, 2017, ENDOCR PRACT, V23, P869, DOI 10.4158/EP171828.PS; Culhane NS, 2003, J FAM PRACTICE, V52, P754; Curb JD, 2006, ARCH INTERN MED, V166, P772, DOI 10.1001/archinte.166.7.772; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Espeland MA, 2017, J GERONTOL A-BIOL, V72, P838, DOI 10.1093/gerona/glw156; Espeland MA, 2013, JAMA INTERN MED, V173, P1429, DOI 10.1001/jamainternmed.2013.7727; Espeland MA, 2010, J AM GERIATR SOC, V58, P1263, DOI 10.1111/j.1532-5415.2010.02953.x; Ettinger B, 2004, OBSTET GYNECOL, V104, P443, DOI 10.1097/01.AOG.0000137833.43248.79; Gallagher JC, 2001, J CLIN ENDOCR METAB, V86, P3618, DOI 10.1210/jc.86.8.3618; Gartlehner G., 2022, AHRQ PUBLICATION; Gartlehner G, 2017, JAMA-J AM MED ASSOC, V318, P2234, DOI 10.1001/jama.2017.16952; Gleason CE, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001833; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grady D, 2002, AM J MED, V113, P543, DOI 10.1016/S0002-9343(02)01270-6; Gramling R, 2009, EPIDEMIOLOGY, V20, P752, DOI 10.1097/EDE.0b013e3181a71279; Greenspan SL, 2005, AM J MED, V118, P1232, DOI 10.1016/j.amjmed.2005.03.004; Grossman DC, 2017, JAMA-J AM MED ASSOC, V318, P2224, DOI 10.1001/jama.2017.18261; Harlow SD, 2012, CLIMACTERIC, V15, P105, DOI [10.3109/13697137.2011.650656, 10.1210/jc.2011-3362, 10.1016/j.fertnstert.2012.01.128, 10.1097/gme.0b013e31824d8f40]; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Heiss G, 2008, JAMA-J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036; Henderson VW, 2016, NEUROLOGY, V87, P699, DOI 10.1212/WNL.0000000000002980; Hendrix SL, 2005, JAMA-J AM MED ASSOC, V293, P935, DOI 10.1001/jama.293.8.935; Hendrix SL, 2006, CIRCULATION, V113, P2425, DOI 10.1161/CIRCULATIONAHA.105.594077; Hendrix Susan L, 2003, J Am Osteopath Assoc, V103, pS3; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; Hodis HN, 2016, NEW ENGL J MED, V374, P1221, DOI 10.1056/NEJMoa1505241; Hsia J, 2004, CIRCULATION, V109, P620, DOI 10.1161/01.CIR.0000115309.63979.92; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Hsia J, 2006, AM HEART J, V152, P170, DOI 10.1016/j.ahj.2005.09.005; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Johnson SR, 2005, OBSTET GYNECOL, V105, P779, DOI 10.1097/01.AOG.0000157116.23249.52; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; Kantarci K, 2016, NEUROLOGY, V87, P887, DOI 10.1212/WNL.0000000000002970; Kato I, 2016, INT J CANCER, V138, P604, DOI 10.1002/ijc.29819; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Liu LJ, 2020, J CARD FAIL, V26, P2, DOI 10.1016/j.cardfail.2019.09.006; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Manson JE, 2019, ANN INTERN MED, V171, P406, DOI 10.7326/M19-0274; Manson JE, 2017, JAMA-J AM MED ASSOC, V318, P927, DOI 10.1001/jama.2017.11217; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Morch LS, 2016, INT J CANCER, V138, P1506, DOI 10.1002/ijc.29878; Park SY, 2016, INT J CANCER, V139, P1241, DOI 10.1002/ijc.30172; Prentice RL, 2021, AM J EPIDEMIOL, V190, P365, DOI 10.1093/aje/kwaa210; Prentice RL, 2020, AM J EPIDEMIOL, V189, P972, DOI 10.1093/aje/kwaa033; Prentice RL, 2009, AM J EPIDEMIOL, V170, P12, DOI 10.1093/aje/kwp115; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Resnick SM, 2006, J CLIN ENDOCR METAB, V91, P1802, DOI 10.1210/jc.2005-2097; Resnick Susan M, 2004, Clin Trials, V1, P440, DOI 10.1191/1740774504cn040oa; Resnick SM, 2009, J CLIN ENDOCR METAB, V94, P4152, DOI 10.1210/jc.2009-1340; Rimoin LP, 2013, DERMATOL THER, V26, P157, DOI 10.1111/dth.12034; Ritenbaugh C, 2008, CANCER EPIDEM BIOMAR, V17, P2609, DOI 10.1158/1055-9965.EPI-08-0385; Rocca WA, 2014, MOL CELL ENDOCRINOL, V389, P7, DOI 10.1016/j.mce.2014.01.020; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Salpeter SR, 2009, AM J MED, V122, P1016, DOI 10.1016/j.amjmed.2009.05.021; Schierbeck LL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6409; Shifren JL, 2014, MENOPAUSE, V21, P1038, DOI [10.1097/GME.0000000000000319, 10.1097/gme.0000000000000319]; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Steinauer JE, 2005, OBSTET GYNECOL, V106, P940, DOI 10.1097/01.AOG.0000180394.08406.15; Tang JY, 2011, J NATL CANCER I, V103, P1469, DOI 10.1093/jnci/djr333; Tierney MC, 2009, PSYCHONEUROENDOCRINO, V34, P1065, DOI 10.1016/j.psyneuen.2009.02.009; Toh S, 2010, ANN INTERN MED, V152, P211, DOI 10.7326/0003-4819-152-4-201002160-00005; United Nations Development Program, 2020, HUMAN DEV REPORT 202; US Food and Drug Administration, 2019, MEN MED HELP YOU; US Preventive Services Task Force, 2021, US PREV SERV TASK FO; Veerus P, 2006, MATURITAS, V55, P162, DOI 10.1016/j.maturitas.2006.01.012; Vickers Madge R, 2007, BMC Womens Health, V7, P2, DOI 10.1186/1472-6874-7-2; Vickers MR, 2007, BMJ-BRIT MED J, V335, P239, DOI 10.1136/bmj.39266.425069.AD; Waetjen LE, 2005, OBSTET GYNECOL, V106, P946, DOI 10.1097/01.AOG.0000182576.48290.6d; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; Watts NB, 2017, J CLIN ENDOCR METAB, V102, P302, DOI 10.1210/jc.2016-3270; West SL., 2010, AHRQ PUBLICATION; Whitmer RA, 2011, ANN NEUROL, V69, P163, DOI 10.1002/ana.22239; Yaffe K, 2006, ARCH NEUROL-CHICAGO, V63, P945, DOI 10.1001/archneur.63.7.945	108	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2022	328	17					1747	1765		10.1001/jama.2022.18324	http://dx.doi.org/10.1001/jama.2022.18324			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6C4JN	36318128	Bronze			2023-01-03	WOS:000881982900029
J	Itagaki, T; Akimoto, Y; Nakano, Y; Ueno, Y; Ishihara, M; Tane, N; Tsunano, Y; Oto, J				Itagaki, Taiga; Akimoto, Yusuke; Nakano, Yuki; Ueno, Yoshitoyo; Ishihara, Manabu; Tane, Natsuki; Tsunano, Yumiko; Oto, Jun			Relationships between double cycling and inspiratory effort with diaphragm thickness during the early phase of mechanical ventilation: A prospective observational study	PLOS ONE			English	Article							PROTECTIVE VENTILATION; LUNG INJURY; CARE; SEDATION; IMPACT; MUSCLE; ASYNCHRONY; PATTERNS; WEAKNESS	Background Increased and decreased diaphragm thickness during mechanical ventilation is associated with poor outcomes. Some types of patient-ventilator asynchrony theoretically cause myotrauma of the diaphragm. However, the effects of double cycling on structural changes in the diaphragm have not been previously evaluated. Hence, this study aimed to investigate the relationship between double cycling during the early phase of mechanical ventilation and changes in diaphragm thickness, and the involvement of inspiratory effort in the occurrence of double cycling. Methods We evaluated adult patients receiving invasive mechanical ventilation for more than 48 h. The end-expiratory diaphragm thickness (Tdi(ee)) was assessed via ultrasonography on days 1, 2, 3, 5 and 7 after the initiation of mechanical ventilation. Then, the maximum rate of change from day 1 (Delta Tdi(ee)%) was evaluated. Concurrently, we recorded esophageal pressure and airway pressure on days 1, 2 and 3 for 1 h during spontaneous breathing. Then, the waveforms were retrospectively analyzed to calculate the incidence of double cycling (double cycling index) and inspiratory esophageal pressure swing (Delta P-es). Finally, the correlation between double cycling index as well as Delta P-es and Delta Tdi(ee)% was investigated using linear regression models. Results In total, 19 patients with a median age of 69 (interquartile range: 65-78) years were enrolled in this study, and all received pressure assist-control ventilation. The Tdi(ee) increased by more than 10% from baseline in nine patients, decreased by more than 10% in nine and remained unchanged in one. The double cycling indexes on days 1, 2 and 3 were 2.2%, 1.3% and 4.5%, respectively. There was a linear correlation between the double cycling index on day 3 and Delta Tdi(ee)% (R-2 = 0.446, p = 0.002). The double cycling index was correlated with the Delta P-es on days 2 (R-2 = 0.319, p = 0.004) and 3 (R-2 = 0.635, p < 0.001). Conclusions Double cycling on the third day of mechanical ventilation was associated with strong inspiratory efforts and, possibly, changes in diaphragm thickness.	[Itagaki, Taiga] Tokushima Univ Hosp, Dept Emergency & Disaster Med, Tokushima, Japan; [Akimoto, Yusuke; Nakano, Yuki; Ueno, Yoshitoyo; Ishihara, Manabu] Tokushima Univ Hosp, Dept Emergency & Crit Care Med, Tokushima, Japan; [Tane, Natsuki; Tsunano, Yumiko; Oto, Jun] Tokushima Univ, Dept Emergency & Crit Care Med, Grad Sch, Tokushima, Japan	Tokushima University; Tokushima University; Tokushima University	Itagaki, T (corresponding author), Tokushima Univ Hosp, Dept Emergency & Disaster Med, Tokushima, Japan.	taiga@tokushima-u.ac.jp		Itagaki, Taiga/0000-0002-8387-834X	JSPS KAKENHI [JP21K16574]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was partly supported by JSPS KAKENHI Grant Number JP21K16574 awarded to Dr. Taiga Itagaki. https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21K16574/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Alhazzani W, 2020, INTENS CARE MED, V46, P1977, DOI 10.1007/s00134-020-06227-8; BAYDUR A, 1982, AM REV RESPIR DIS, V126, P788; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP; Bunnell A, 2015, MUSCLE NERVE, V52, P701, DOI 10.1002/mus.24728; Chanques G, 2013, CRIT CARE MED, V41, P2177, DOI 10.1097/CCM.0b013e31828c2d7a; de Haro C, 2018, CRIT CARE MED, V46, P1385, DOI 10.1097/CCM.0000000000003256; Devabhakthuni S, 2012, ANN PHARMACOTHER, V46, P530, DOI 10.1345/aph.1Q525; Dres M, 2017, INTENS CARE MED, V43, P1441, DOI 10.1007/s00134-017-4928-4; Dres M, 2017, AM J RESP CRIT CARE, V195, P57, DOI 10.1164/rccm.201602-0367OC; Dres M, 2016, CURR OPIN CRIT CARE, V22, P246, DOI 10.1097/MCC.0000000000000307; Ferguson LM, 2006, BRIT J ANAESTH, V96, P384, DOI 10.1093/bja/ael011; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Goligher EC, 2020, AM J RESP CRIT CARE, V202, P950, DOI 10.1164/rccm.202003-0655CP; Goligher EC, 2019, LANCET RESP MED, V7, P90, DOI 10.1016/S2213-2600(18)30366-7; Goligher EC, 2018, AM J RESP CRIT CARE, V197, P204, DOI 10.1164/rccm.201703-0536OC; Goligher EC, 2015, AM J RESP CRIT CARE, V192, P1080, DOI 10.1164/rccm.201503-0620OC; Jiang TX, 1998, AM J RESP CRIT CARE, V157, P230, DOI 10.1164/ajrccm.157.1.9702051; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Mauri T, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.55; Mellado Artigas Ricard, 2021, Anesthesiology, V134, P760, DOI 10.1097/ALN.0000000000003726; Nakanishi N, 2019, J INTENSIVE CARE, V7, DOI 10.1186/s40560-019-0410-4; Orozco-Levi M, 2001, AM J RESP CRIT CARE, V164, P1734, DOI 10.1164/ajrccm.164.9.2011150; Pohlman MC, 2008, CRIT CARE MED, V36, P3019, DOI 10.1097/CCM.0b013e31818b308b; Proske U, 2001, J PHYSIOL-LONDON, V537, P333, DOI 10.1111/j.1469-7793.2001.00333.x; Schepens T, 2019, CURR OPIN CRIT CARE, V25, P77, DOI 10.1097/MCC.0000000000000578; Schreiber A, 2018, CRIT CARE CLIN, V34, P357, DOI 10.1016/j.ccc.2018.03.005; Thille AW, 2006, INTENS CARE MED, V32, P1515, DOI 10.1007/s00134-006-0301-8; Tokioka H, 2001, ANESTH ANALG, V92, P161; Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8; Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP	31	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2022	17	8							e0273173	10.1371/journal.pone.0273173	http://dx.doi.org/10.1371/journal.pone.0273173			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4D6CO	35976965	Green Published, gold			2023-01-03	WOS:000847227000083
J	Dusetzina, SB; Huskamp, HA; Qin, XZ; Keating, NL				Dusetzina, Stacie B.; Huskamp, Haiden A.; Qin, Xuanzi; Keating, Nancy L.			Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PART D; ABANDONMENT; PATIENT	IMPORTANCE Prescription drug spending is a topic of increased interest to the public and policymakers. However, prior assessments have been limited by focusing on retail spending (Part D-covered drugs), omitting clinician-administered (Part B-covered) drug spending, or focusing on all fee-for-service Medicare beneficiaries, regardless of their enrollment into prescription drug coverage. OBJECTIVE To estimate the proportion of health care spending contributed by prescription drugs and to assess spending for retail and clinician-administered prescriptions. DESIGN, SETTING, AND PARTICIPANTS Descriptive, serial, cross-sectional analysis of a 20% random sample of fee-for-service Medicare beneficiaries in the United States from 2008 to 2019 who were continuously enrolled in Parts A (hospital), B (medical), and D (prescription drug) benefits, and not in Medicare Advantage. EXPOSURE Calendar year. MAIN OUTCOMES AND MEASURES Net spending on retail (Part D-covered) and clinician-administered (Part B-covered) prescription drugs; prescription drug spending (spending on Part B-covered and Part D-covered drugs) as a percentage of total per-capita health care spending. Measures were adjusted for inflation and for postsale rebates (for Part D-covered drugs). RESULTS There were 3 201 284 beneficiaries enrolled in Parts A, B, and D in 2008 and 4 502 718 in 2019. In 2019, beneficiaries had a mean (SD) age of 71.7 (12.0) years, documented sex was female for 57.7%, and 69.5% had no low-income subsidies. Total per-capita spending was $16 345 in 2008 and $20 117 in 2019. Comparing 2008 with 2019, per-capita Part A spending was $7106 (95% CI, $7084-$7128) vs $7120 (95% CI, $7098-$7141), Part B drug spending was $720 (95% CI, $713-$728) vs $1641 (95% CI, $1629-$1653), Part B nondrug spending was $5113 (95% CI, $5105-$5122) vs $6702 (95% CI, $6692-$6712), and Part D net spending was $3122 (95% CI, $3117-$3127) vs $3477 (95% CI, $3466-$3489). The proportion of total annual spending attributed to prescription drugs increased from 24.0% in 2008 to 27.2% in 2019, net of estimated rebates and discounts. CONCLUSIONS AND RELEVANCE In 2019, spending on prescription drugs represented approximately 27% of total spending among fee-for-service Medicare beneficiaries enrolled in Part D, even after accounting for postsale rebates.	[Dusetzina, Stacie B.; Qin, Xuanzi] Vanderbilt Univ, Sch Med, Dept Hlth Policy, 2525 West End Ave,Ste 1203, Nashville, TN 37203 USA; [Dusetzina, Stacie B.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Huskamp, Haiden A.; Keating, Nancy L.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA; [Keating, Nancy L.] Brigham & Womens Hosp, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA	Vanderbilt University; Vanderbilt University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Dusetzina, SB (corresponding author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, 2525 West End Ave,Ste 1203, Nashville, TN 37203 USA.	s.dusetzina@vanderbilt.edu			Commonwealth Fund; Arnold Ventures	Commonwealth Fund; Arnold Ventures	This study was supported by the Commonwealth Fund and Arnold Ventures (Dr Dusetzina).	Afendulis CC, 2011, HEALTH SERV RES, V46, P1022, DOI 10.1111/j.1475-6773.2011.01244.x; Anderson KE, 2022, HEALTH SERV RES, V57, P537, DOI 10.1111/1475-6773.13912; [Anonymous], 2022, INFLATION REDUCTION; Ayyagari P, 2017, HEALTH ECON, V26, P536, DOI 10.1002/hec.3326; Board of Trustees Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds, 2021, ANN REP BOARDS TRUST; Centers for Disease Control and Prevention, THER DRUG US; Centers for Medicare and Medicaid Services, 2022, ASP DRUG PRIC FIL; Centers for Medicare & Medicaid Services, ADD A ADD B UPD; Chandra A, 2021, NATL BUREAU EC RES W, DOI [10.3386/w28439, DOI 10.3386/W28439], Patent No. w28439; Congressional Budget Office, PRESCR DRUGS SPEND U; Cubanski J., 2019, KAISER FAMILY FDN; Cubanski J., 2021, KEY FACTS MEDICARE P; Doshi JA, 2018, J CLIN ONCOL, V36, P476, DOI 10.1200/JCO.2017.74.5091; Dunn A, 2018, HEALTH SERV RES, V53, P175, DOI 10.1111/1475-6773.12612; Dusetzina SB, 2022, HEALTH AFFAIR, V41, P487, DOI 10.1377/hlthaff.2021.01742; Fuglesten Biniek J., 2022, TRADITIONAL MED SPEN; Gokhale M, 2020, DIABETES CARE, V43, P2121, DOI 10.2337/dc19-1880; Hartman Micah, 2022, Health Aff (Millwood), V41, P13, DOI 10.1377/hlthaff.2021.01763; Hernandez I, 2020, JAMA-J AM MED ASSOC, V323, P854, DOI 10.1001/jama.2020.1012; Kaplan C, 2014, HEALTH ECON, V23, P1287, DOI 10.1002/hec.2981; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Making Medicines Affordable, 2018, NAT IMP; Martin AB, 2019, HEALTH AFFAIR, V38, P96, DOI 10.1377/hlthaff.2018.05085; Mathews JE., 2019, PAYMENT POLICY PRESC; Medicare Payment Advisory Commission, 2022, C MED HLTH CAR DEL S; Medicare Payment Advisory Commission, 2022, C MED PAYM POL MARCH; Office for the Assistant Secretary for Planning and Evaluation US Department of Health and Human Services, 2020, MED PART B DRUGS TRE; Reed A., 2022, BLOOMBERG LAW 0804; Rome BN, 2022, JAMA-J AM MED ASSOC, V327, P2145, DOI 10.1001/jama.2022.5542; Streeter SB, 2011, J ONCOL PRACT, V7, p46S, DOI 10.1200/JOP.2011.000316	30	1	1	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	2022	328	15					1515	1522		10.1001/jama.2022.17825	http://dx.doi.org/10.1001/jama.2022.17825			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5M9EQ	36255428				2023-01-03	WOS:000871397000017
J	Kebede, AA; Taye, BT; Wondie, KY				Kebede, Azmeraw Ambachew; Taye, Birhan Tsegaw; Wondie, Kindu Yinges			Factors associated with comprehensive knowledge of antenatal care and attitude towards its uptake among women delivered at home in rural Sehala Seyemit district, northern Ethiopia: A community-based cross-sectional study	PLOS ONE			English	Article							SERVICE UTILIZATION; PREGNANT-WOMEN; MOTHERS	Background Despite the current sustainable development goal period (i.e. SDG 3), the prevention of maternal and neonatal mortality is not satisfactory in Ethiopia. Keeping women knowledgeable about antenatal care and maintaining a positive attitude towards its uptake, particularly in the marginalized rural community is crucial. However, evidence regarding the knowledge and attitude of women towards antenatal care uptake is scarce. Therefore, this study aimed to assess factors affecting comprehensive knowledge of antenatal care and attitude towards its uptake among women delivered at home in rural Sehala Seyemit district, northern Ethiopia. Methods A community-based cross-sectional study was conducted from September 1st to October 15th, 2020. A multi-stage sampling technique was used to select 653 women. The data were collected using a semi-structured interview guide. Data were entered into EPI INFO 7.1.2 and analyzed by SPSS version 25. Both bivariable and multivariable logistic regression analyses were undertaken to identify factors associated with women's knowledge of antenatal care and attitude towards its uptake. The level of significant association in the multivariable analysis was determined based on a p-value of < 0.05. Results Women's knowledge of antenatal care and positive attitude towards its uptake was 56.5% and 75.2%, respectively. Older age (AOR = 7.2; 95% CI: 3.43, 15.1), media exposure (AOR = 3.69; 95% CI: 2.41, 5.65), history of abortion (AOR = 11.6; 95% CI: 3.3, 14.6), time to reach health facility (AOR = 4.58; 95% CI: 3.05, 6.88), and history of obstetric danger signs (AOR = 7.3; 95% CI: 3.92, 13.64) were factors significantly associated with knowledge of antenatal care. Furthermore, higher decision-making power (AOR = 8.3; 95% CI: 4.8, 13.83), adequate knowledge of antenatal care (AOR = 2.2; 95% CI: 1.26, 3.71), delivery attended by health extension workers (AOR = 2.3; 95% CI: 1.1, 5.1), and media exposure (AOR = 2.27; 95% CI: 1.30, 3.97) were predictors of a favorable attitude towards antenatal care utilization. Conclusion Although the majority of women in the present study had a favorable attitude towards antenatal care uptake, their knowledge level was inadequate. Strengthening access to transportation, mass media, involvement in household decision-making, and encouraging women to deliver at a health facility by a skilled provider may increase women's knowledge and attitude towards antenatal care uptake, thereby improving maternal healthcare service uptake.	[Kebede, Azmeraw Ambachew; Wondie, Kindu Yinges] Univ Gondar, Sch Midwifery, Dept Clin Midwifery, Coll Med & Hlth Sci, Gondar, Ethiopia; [Taye, Birhan Tsegaw] Sch Nursing & Midwifery, Asrat Woldeyes Hlth Sci Campus, Debre Berhan, Ethiopia	University of Gondar	Kebede, AA (corresponding author), Univ Gondar, Sch Midwifery, Dept Clin Midwifery, Coll Med & Hlth Sci, Gondar, Ethiopia.	azmuzwagholic@gmail.com		Taye, Birhan Tsegaw/0000-0003-2174-3797; Ambachew Kebede, Azmeraw/0000-0003-0831-8470				Ababulgu FA, 2016, ETHIOP J HEALTH SCI, V26, P45, DOI 10.4314/ejhs.v26i1.9; Abdulrida H., 2018, MUSTANSIRIYA MED J, V17; Abera T, 2021, GLOBAL PEDIATR HLTH, V8, DOI 10.1177/2333794X211030157; Adem N., 2017, J CHILD ADOLESC BEHA, V5, DOI DOI 10.4172/2375-4494.1000365; Afaya A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234575; Alshabanah RF., 2018, EGYPT J HOSP MED, V70, P939; Amenu G, 2016, SCIENTIFICA, V2016, DOI 10.1155/2016/3495416; [Anonymous], 2021, NEW GLOB TARG PREV M; Atukunda EC, 2020, INT J WOMENS HEALTH, V12, P423, DOI 10.2147/IJWH.S248240; Ayalew Teshager Workneh, 2018, BMC Res Notes, V11, P819, DOI 10.1186/s13104-018-3928-y; Basha GW, 2019, OBSTET GYNECOL INT, V2019, DOI 10.1155/2019/5036783; Bishanga DR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209672; Bohren MA, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-71; CSA ICF, 2016, ETH DEM HLTH SURV; Dulla D., 2017, NURS HLTH CARE DIVER, V14, P76, DOI DOI 10.21767/2049-5471.10009626; Ethiopian Public Health Institute (EPHI) and ICF [Ethiopia], 2019, ETH MIN HLTH SURV 20; Federal Democratic Republic of Ethiopia Ministry of Health, 2021, REPR HLTH STRAT PLAN; Fekadu GA, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3370-9; Fisseha G, 2017, INT J WOMENS HEALTH, V9, P749, DOI 10.2147/IJWH.S140366; Gebremeskel F, 2015, J ENVIRON PUBLIC HEA, V2015, DOI 10.1155/2015/971506; Ghose B., 2017, BMJ OPEN, P1; Gudayu TW, 2015, AFR J REPROD HEALTH, V19, P94; Health Sector Transformation Plan II 2020/2021-2024/2025, 2021, ETHIOP MINIST HLTH, V25, P1; Henok Andualem., 2015, J MED PHYS BIOPHYS, V16; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Ibrahim HK, 2014, J EGYPT PUBLIC HEAL, V89, P119, DOI 10.1097/01.EPX.0000455673.91730.50; Jackson R, 2016, ETHIOP J HEALTH SCI, V26, P471, DOI 10.4314/ejhs.v26i5.9; Jackson R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150747; Jain Rohit., 2016, INT J REPROD CONTRAC, V9, P354; Jennings L, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-297; Kebede AA, 2020, RES REP NEONATOL, V10, P47, DOI 10.2147/RRN.S257768; Kebede K, 2021, INT J WOMENS HEALTH, V13, P1223, DOI 10.2147/IJWH.S285282; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Kolola T, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-032960; Lindtjorn B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169304; Muyunda B, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00127; Nigatu D, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-79; Ogunba BO, 2020, J NUTR HEAL SCI, V4; Ononokpono Dorothy Ngozi, 2014, Pan Afr Med J, V17 Suppl 1, P2, DOI 10.11694/pamj.supp.2014.17.1.3596; Ousman SK, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00161; Regassa N, 2011, AFR HEALTH SCI, V11, P390; Roro Meselech Assegid, 2014, BMC Res Notes, V7, P556, DOI 10.1186/1756-0500-7-556; Rosliza Muhamad., 2011, MALAYSIAN J PUBLIC H, V11, P13; Shahnaz Akhtar, 2018, INT J SOC SCI MANAG, V5, P155, DOI DOI 10.3126/IJSSM.V5I3.20604; Shukure R., 2018, AM J PEDIATRCIS, V4, P1; Suleman Hassen Sali, 2021, ScientificWorldJournal, V2021, P7146452, DOI 10.1155/2021/7146452; Tanou M, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7150-1; Tegegne TK, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2550-x; Tekelab T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214848; Terefe AN, 2019, HEALTH SERV RES MANA, V6, DOI 10.1177/2333392819866620; Tilahun Tadesse., 2016, INT J NURS MIDWIFERY, V8, P1, DOI DOI 10.5897/IJNM2015.0199; Tuncalp O, 2017, BJOG-INT J OBSTET GY, V124, P860, DOI 10.1111/1471-0528.14599; WHO, 2019, TRENDS MAT MORT 2000; World Health Organization, 2017, WHOMCA1710; Woyessa AH, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4311-3; Yaya S, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1846-6; Zaman SBin., 2018, BMC RES NOTES, P4, DOI DOI 10.1186/S13104-017-3111-X; Zelalem Ayele Desalew, 2014, Int Sch Res Notices, V2014, P917058, DOI 10.1155/2014/917058; Zhao Qi, 2009, BMC Womens Health, V9, P5, DOI 10.1186/1472-6874-9-5; Zile I., 2014, EUR J PUBLIC HEALTH, V24, P1, DOI [10.1051/shsconf/20196802, DOI 10.1051/SHSCONF/20196802]	60	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2022	17	10							e0276125	10.1371/journal.pone.0276125	http://dx.doi.org/10.1371/journal.pone.0276125			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6Q0AL	36223422	gold, Green Published			2023-01-03	WOS:000891284400049
J	Rome, BN; Egilman, AC; Kesselheim, AS				Rome, Benjamin N.; Egilman, Alexander C.; Kesselheim, Aaron S.			Effect of Awake Prone Positioning on Patients With COVID-19 and Acute Respiratory Failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Rome, Benjamin N.; Egilman, Alexander C.; Kesselheim, Aaron S.] Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital	Rome, BN (corresponding author), Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	brome@bwh.harvard.edu						Alhazzani W, 2022, JAMA-J AM MED ASSOC, V327, P2104, DOI 10.1001/jama.2022.7993; Fralick M, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-068585; Hofstede G., CLEARLY CULTURAL MAK; Li J, 2022, LANCET RESP MED, V10, P573, DOI 10.1016/S2213-2600(22)00043-1; Raghunathan K, 2012, BMJ QUAL SAF, V21, P617, DOI 10.1136/bmjqs-2011-000608	5	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	2022	328	13					1353	1354						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5F6GU	36194224				2023-01-03	WOS:000866412700020
J	Wong, CKH; Au, ICH; Lau, KTK; Lau, EHY; Cowling, BJ; Leung, GM				Wong, Carlos K. H.; Au, Ivan C. H.; Lau, Kristy T. K.; Lau, Eric H. Y.; Cowling, Benjamin J.; Leung, Gabriel M.			Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study	LANCET			English	Article								Background Little is known about the real-world effectiveness of oral antivirals against the SARS-CoV-2 omicron (B.1.1.529) variant. We aimed to assess the clinical effectiveness of two oral antiviral drugs among community-dwelling COVID-19 outpatients in Hong Kong. Methods In this observational study, we used data from the Hong Kong Hospital Authority to identify an unselected, territory-wide cohort of non-hospitalised patients with an officially registered diagnosis of SARS-CoV-2 infection between Feb 26 and June 26, 2022, during the period in which the omicron subvariant BA.2.2 was dominant in Hong Kong. We used a retrospective cohort design as primary analysis, and a case-control design as sensitivity analysis. We identified patients with COVID-19 who received either molnupiravir (800 mg twice daily for 5 days) or nirmatrelvir plus ritonavir (nirmatrelvir 300 mg and ritonavir 100 mg twice daily for 5 days, or nirmatrelvir 150 mg and ritonavir 100 mg if estimated glomerular filtration rate was 30-59 mL/min per 1.73 m(2)). Outpatient oral antiviral users were matched with controls using propensity score (1:10) according to age, sex, date of SARS-CoV-2 infection diagnosis, Charlson Comorbidity Index score, and vaccination status. Study outcomes were death, COVID-19-related hospitalisation, and in-hospital disease progression (in-hospital death, invasive mechanical ventilation, or intensive care unit admission). Hazard ratios (HRs) were estimated by Cox regression for the primary analysis, and odds ratios in oral antiviral users compared with non-users by logistic regression for the sensitivity analysis. Findings Among 1 074 856 non-hospitalised patients with COVID-19, 5383 received molnupiravir and 6464 received nirmatrelvir plus ritonavir in the community setting. Patients were followed up for a median of 103 days in the molnupiravir group and 99 days in the nirmatrelvir plus ritonavir group. Compared with nirmatrelvir plus ritonavir users, those on molnupiravir were older (4758 [85.9%] vs 4418 [88.7%] aged >60 years) and less likely to have been fully vaccinated (1850 [33.4%] vs 800 [16.1%]). Molnupiravir use was associated with lower risks of death (HR 0.76 [95% CI 0.61-0.95]) and in-hospital disease progression (0.57 [0.43-0.76]) than non-use was, whereas risk of hospitalisation was similar in both groups (0.98 [0.89-1.06]). Nirmatrelvir plus ritonavir use was associated with lower risks of death (0.34 [0.22-0.52]), hospitalisation (0.76 [0.67-0.86]), and in-hospital disease progression (0.57 [0.38-0.87]) than non-use was. We consistently found reduced risks of mortality and hospitalisation associated with early oral antiviral use among older patients. The findings from the case-control analysis broadly supported those from the primary analysis. Interpretation During Hong Kong's wave of SARS-CoV-2 omicron subvariant BA.2.2, among non-hospitalised patients with COVID-19, early initiation of novel oral antivirals was associated with reduced risks of mortality and in-hospital disease progression. Nirmatrelvir plus ritonavir use was additionally associated with a reduced risk of hospitalisation. Copyright (c) 2022 Elsevier Ltd. All rights reserved.	[Wong, Carlos K. H.; Au, Ivan C. H.; Lau, Kristy T. K.] Univ Hong Kong, Dept Pharmacol & Pharm, Hong Kong, Peoples R China; [Wong, Carlos K. H.] Univ Hong Kong, Dept Family Med & Primary Care, Sch Clin Med, Hong Kong, Peoples R China; [Lau, Eric H. Y.; Cowling, Benjamin J.; Leung, Gabriel M.] Univ Hong Kong, WHO Collaborating Ctr Infect Dis Epidemiol & Cont, Sch Publ Hlth, Hong Kong, Peoples R China; [Wong, Carlos K. H.; Lau, Eric H. Y.; Cowling, Benjamin J.; Leung, Gabriel M.] Univ Hong Kong, LKS Fac Med, Hong Kong, Peoples R China; [Wong, Carlos K. H.; Lau, Eric H. Y.; Cowling, Benjamin J.; Leung, Gabriel M.] Lab Data Discovery Hlth, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; World Health Organization; University of Hong Kong	Wong, CKH (corresponding author), Univ Hong Kong, LKS Fac Med, Dept Pharmacol & Pharm, Hong Kong, Peoples R China.	carlosho@hku.hk			Health and Medical Research Fund, Health Bureau, Government of Hong Kong Special Administrative Region, China	Health and Medical Research Fund, Health Bureau, Government of Hong Kong Special Administrative Region, China	Health and Medical Research Fund, Health Bureau, Government of Hong Kong Special Administrative Region, China.	Arbel R, 2022, NEW ENGL J MED, V387, P790, DOI 10.1056/NEJMoa2204919; Austin PC, 2009, BIOMETRICAL J, V51, P171, DOI 10.1002/bimj.200810488; Bernal AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMoa2116044; Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478; Chen LL, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-31395-0; Dal-Re R., 2022, LANCET INFECT DIS, V22, P231; Dyer O, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2984; Fischer WA, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abl7430; Githaka JM, 2022, BIOINFORM BIOL INSIG, V16, DOI 10.1177/11779322221085077; Hammond J, 2022, NEW ENGL J MED, V386, P1397, DOI 10.1056/NEJMoa2118542; Hospital Authority Task Force on Clinical Management on Infection, 2022, INT REC CLIN MAN AD; Johnson MG, 2022, ANN INTERN MED, V175, P1126, DOI 10.7326/M22-0729; Lee K, 2009, GLOB INST, P1; Lee Todd C, 2022, Open Forum Infect Dis, V9, pofac008, DOI 10.1093/ofid/ofac008; Li PF, 2022, CELL RES, V32, P322, DOI 10.1038/s41422-022-00618-w; McMenamin Martina E, 2022, Lancet Infect Dis, V22, P1435, DOI 10.1016/S1473-3099(22)00345-0; Najjar-Debbiny R, 2022, CLIN INFECT DIS, DOI 10.1093/cid/ciac443; Nyberg T, 2022, LANCET, V399, P1303, DOI 10.1016/S0140-6736(22)00462-7; Pfizer, 2022, PFIZ REP ADD DAT PAX; S. Dryden-Peterson, 2022, medRxiv, DOI 10.1101/2022.06.14.22276393; Sendi P, 2022, CLIN MICROBIOL INFEC, V28, P1230, DOI 10.1016/j.cmi.2022.04.015; Singh AK, 2022, DIABETES METAB SYND, V16, DOI 10.1016/j.dsx.2022.102396; Singh AK, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.102329; Tian LL, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.855496; U.S. Food and Drug Administration, 2021, COR COVID 19 UPD FDA; Ulloa AC, 2022, JAMA-J AM MED ASSOC, V327, P1286, DOI 10.1001/jama.2022.2274; US Food and Drug Administration, 2022, FACT SHEET HEALTHC P; US National Institutes of Health, 2022, THER MAN NONH AD COV; Vena A, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10071141; Waters MD, 2022, ENVIRON MOL MUTAGEN, V63, P37, DOI 10.1002/em.22471; Wen W, 2022, ANN MED, V54, P516, DOI 10.1080/07853890.2022.2034936; Wong CKH, 2021, ECLINICALMEDICINE, V32, DOI 10.1016/j.eclinm.2021.100743; Zhou ST, 2021, J INFECT DIS, V224, P415, DOI 10.1093/infdis/jiab247	33	3	3	13	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 14	2022	400	10359					1213	1222						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5Q7FC	36216007	Green Published, Bronze			2023-01-03	WOS:000873991600022
J	Huang, SL; Lu, WR; Huang, HL; Liu, CL				Huang, Hsiu-Li; Lu, Wei-Ru; Huang, Huei-Ling; Liu, Chien-Liang			The effect of a family-centered advance care planning intervention for persons with cognitive impairment and their family caregivers on end-of-life care discussions and decisions	PLOS ONE			English	Article							EUROPEAN ASSOCIATION; OLDER-ADULTS; DEMENTIA; PEOPLE; PREFERENCES; ENGAGEMENT; HEALTH; RECOMMENDATIONS	Advanced care planning (ACP) includes advance directives (AD), which can specify provisions for palliative care and types of life-sustaining treatments for an individual requiring end-of-life (EoL) care. ACP for persons in the early stages of cognitive decline can decrease anxiety and conflict for family members needing to make decisions about EoL-care, which is especially critical for family caregivers (FCGs) if they play a role as a surrogate regarding healthcare decisions. However, ACP for persons with cognitive impairment (PWCIs) is often overlooked. This study explored the effects of a family-centered ACP intervention on decisions about EoL-care, life-sustaining treatment decisions, and discussions of related topics among PWCIs and FCGs. The study was conducted in outpatient clinics of regional teaching hospitals in northern Taiwan. Participants were dyads consisting of persons diagnosed with mild cognitive impairment or mild dementia and their FCGs. The family-centered ACP intervention was provided by an ACP-trained senior registered nurse. A one-group, pretest-posttest design was used to evaluate the effect of the intervention on 44 dyads. Four structured questionnaires collected data regarding familiarity with ACP, intention to engage in ACP, participation in personal discussions between the dyads about ACP, and consistency between PWCIs and FCGs for decisions about life-sustaining treatments at EoL. Paired t, Kappa, and McNemar tests were used to compare differences between pre-intervention data (pretest) and post-intervention data (posttest). There were significant increases in familiarity with ACP, components of ACP, and the number of topics PWCIs and FCGs personally discussed surrounding EoL-care decisions. There was no change for either group in wanting to have a formal ACP consultation and only modest increases in consistency between PWCIs and FCGs for life-sustaining treatment decisions after completion of the family-centered ACP intervention. Clinicians caring for PWCIs should incorporate family-centered ACP interventions and support ongoing discussions about life-sustaining medical treatments to ensure their preferences regarding EoL-care are respected. The accessibility and availability of consultations about ACP should also be provided.	[Huang, Hsiu-Li] Natl Taipei Univ Nursing & Hlth Sci, Coll Hlth Technol, Dept Long Term Care, Taipei, Taiwan; [Lu, Wei-Ru] Sijhih Cathay Gen Hosp, Dept Nursing, New Taipei, Taiwan; [Huang, Huei-Ling] Chang Gung Univ Sci & Technol, Dept Gerontol & Hlth Care Management, Taoyuan, Taiwan; [Liu, Chien-Liang] Taipei City Hosp, Dementia Ctr, Dept Internal Med, Heping Fuyou Branch, Taipei, Taiwan	National Taipei University of Nursing & Health Science (NTUNHS); Cathay General Hospital; Chang Gung University of Science & Technology; Taipei City Hospital	Huang, SL (corresponding author), Natl Taipei Univ Nursing & Hlth Sci, Coll Hlth Technol, Dept Long Term Care, Taipei, Taiwan.	hsiuli@ntunhs.edu.tw		Huang, Huei-Ling/0000-0003-4186-7586	Ministry of Science and Technology of Taiwan [MOST 106-2314-B-182 -006 -MY3, MOST 109-2314-B-227 -006 -MY3]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan)	This study received a fund from the Ministry of Science and Technology of Taiwan (MOST 106-2314-B-182 -006 -MY3) and (MOST 109-2314-B-227 -006 -MY3). The funder had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; Ayalon L, 2012, INT PSYCHOGERIATR, V24, P1798, DOI 10.1017/S1041610212000877; Boerner K, 2013, J GERONTOL B-PSYCHOL, V68, P246, DOI 10.1093/geronb/gbs161; Bonner GJ, 2014, DEMENTIA-LONDON, V13, P79, DOI 10.1177/1471301212449408; Brazil K, 2018, PALLIATIVE MED, V32, P603, DOI 10.1177/0269216317722413; Bryant J, 2019, PALLIATIVE MED, V33, P262, DOI 10.1177/0269216318801750; Campos B, 2014, CULT DIVERS ETHN MIN, V20, P191, DOI 10.1037/a0034094; Carr D, 2012, J HEALTH SOC BEHAV, V53, P297, DOI [10.1177/0022146512457153, 10.1177/0022146512455427]; Chang WZD, 2020, AM J SPEECH-LANG PAT, V29, P185, DOI 10.1044/2019_AJSLP-19-0028; Cheong K, 2015, BMJ SUPPORT PALLIAT, V5, P63, DOI 10.1136/bmjspcare-2014-000648; Chuang IF, 2020, PATIENT PREFER ADHER, V14, P2377, DOI 10.2147/PPA.S283923; COHEN J, 1988, APPL PSYCH MEAS, V12, P425, DOI 10.1177/014662168801200410; Dening KH, 2013, PALLIATIVE MED, V27, P409, DOI 10.1177/0269216312464094; Dening KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159056; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Dickinson C, 2013, INT PSYCHOGERIATR, V25, P2011, DOI 10.1017/S1041610213001531; Dixon J, 2018, J PAIN SYMPTOM MANAG, V55, P132, DOI 10.1016/j.jpainsymman.2017.04.009; Fazel S, 2000, AM J PSYCHIAT, V157, P1009, DOI 10.1176/appi.ajp.157.6.1009; Fried TR, 2009, J AM GERIATR SOC, V57, P1547, DOI 10.1111/j.1532-5415.2009.02396.x; Geshell L, 2019, J GERIATR PSYCH NEUR, V32, P231, DOI 10.1177/0891988719853040; Hicks MHR, 1999, CULT MED PSYCHIAT, V23, P415, DOI 10.1023/A:1005563918721; Hirschman KB, 2008, ALZ DIS ASSOC DIS, V22, P293, DOI 10.1097/WAD.0b013e318169d669; Hong M, 2019, GERONTOLOGIST, V59, P347, DOI 10.1093/geront/gnx211; Houben CHM, 2014, J AM MED DIR ASSOC, V15, P477, DOI 10.1016/j.jamda.2014.01.008; Huang HL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240684; Huang HL, 2018, INT PSYCHOGERIATR, V30, P341, DOI 10.1017/S1041610217001661; Jo KH, 2012, INT J NURS PRACT, V18, P552, DOI 10.1111/ijn.12009; Kokorelias KM, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4394-5; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lewis M, 2015, AGE AGEING, V44, P1045, DOI 10.1093/ageing/afv138; Lo TJ, 2017, INT PSYCHOGERIATR, V29, P509, DOI 10.1017/S1041610216001903; MAHONEY F I, 1965, Md State Med J, V14, P61; Ministry of Health and Welfare, 2019, PAT RIGHT AUT ACT; Ministry of Health and Welfare, 2013, HOSP PALL CAR ACT; Mitchell SL, 2018, JAMA INTERN MED, V178, P961, DOI 10.1001/jamainternmed.2018.1506; Pettigrew C, 2020, INT PSYCHOGERIATR, V32, P585, DOI 10.1017/S1041610219000784; Rietjens JAC, 2017, LANCET ONCOL, V18, pE543, DOI 10.1016/S1470-2045(17)30582-X; Robinson L, 2012, AGE AGEING, V41, P263, DOI 10.1093/ageing/afr148; Ryan T, 2020, INT PSYCHOGERIATR, V32, P547, DOI 10.1017/S1041610219001820; Sellars M, 2019, PALLIATIVE MED, V33, P274, DOI 10.1177/0269216318809571; Shalowitz DI, 2006, ARCH INTERN MED, V166, P493, DOI 10.1001/archinte.166.5.493; Sudore RL, 2008, J AM GERIATR SOC, V56, P1006, DOI 10.1111/j.1532-5415.2008.01701.x; Tay SY, 2015, J AM MED DIR ASSOC, V16, P957, DOI 10.1016/j.jamda.2015.05.014; van der Steen JT, 2014, PALLIATIVE MED, V28, P197, DOI 10.1177/0269216313493685; Wendrich-van Dael A, 2020, INT J NURS STUD, V107, DOI 10.1016/j.ijnurstu.2020.103576; Yang CL, 2011, CANCER NURS, V34, P98, DOI 10.1097/NCC.0b013e3181f22cac	46	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2022	17	9							e0274096	10.1371/journal.pone.0274096	http://dx.doi.org/10.1371/journal.pone.0274096			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R5TD	36067182	Green Published, gold			2023-01-03	WOS:000892364500044
J	Funston, W; Ruchaud-Sparagano, MH; Scott, J; Powell, J; Cooles, FAH; Shelmerdine, L; McDowell, C; O'Leary, D; Booth, KL; Clark, SC; Ledingham, SJ; Rostron, AJ; Dark, JH; Simpson, AJ				Funston, Wendy; Ruchaud-Sparagano, Marie-Helene; Scott, Jonathan; Powell, Jason; Cooles, Faye A. H.; Shelmerdine, Lauren; McDowell, Cliona; O'Leary, Denis; Booth, Karen L.; Clark, Stephen C.; Ledingham, Simon J.; Rostron, Anthony J.; Dark, John H.; Simpson, A. John			A human model of bilateral pulmonary vein sampling to assess the effects of one-lung ventilation on neutrophil function	PLOS ONE			English	Article							CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; ADHESION MOLECULES; ACTIVATION; DYSFUNCTION; EXPRESSION	BackgroundNeutrophil activation drives lung complications after cardiopulmonary bypass (CPB). Evidence suggests the healthy, ventilated lung may beneficially re-condition pro-inflammatory neutrophils. However, evidence in humans is lacking, due to a paucity of good models. CPB with simultaneous central venous and bilateral pulmonary vein sampling provides an opportunity to model effects of one-lung ventilation. The study's primary objectives were to establish a model of intra-operative, bilateral pulmonary vein sampling and to determine whether neutrophil function differed after passing through inflated or deflated lungs. MethodsSeventeen patients having "on pump" coronary artery bypass grafting (CABG) with one-lung ventilation (in two cohorts with tidal volume 2ml kg(-1) and FiO(2) 0.21, or tidal volume 4 ml kg(-1) and FiO(2) 0.5 respectively) were recruited. Cohort 1 consisted of 9 patients (7 male, median age 62.0 years) and Cohort 2 consisted of 8 male patients (median age 65.5 years). Recruitment was via prospective screening of scheduled elective and non-elective CABG procedures with cardiopulmonary bypass. Each patient had five blood samples taken-central venous blood pre-operatively; central venous blood pre-CPB; central venous blood post-CPB; pulmonary venous blood draining the ventilated lung post-CPB; and pulmonary venous blood draining the deflated lung post-CPB. Neutrophil phagocytosis and priming status were quantified. Plasma cytokines were measured. ResultsPhagocytosis and priming were not significantly different in neutrophils returning from the ventilated lung as compared to the non-ventilated lung. Plasma IL-6, IL-8 and IL-10 were significantly elevated by CPB. ConclusionsThe intra-operative, bilateral pulmonary vein sampling model provides unique opportunities to assess biological effects of interventions to one lung, with the other lung acting as an internal control. Single-lung ventilation during CPB had no significant effects on neutrophil function.	[Funston, Wendy; Ruchaud-Sparagano, Marie-Helene; Scott, Jonathan; Powell, Jason; Cooles, Faye A. H.; Rostron, Anthony J.; Dark, John H.; Simpson, A. John] Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne, England; [Shelmerdine, Lauren] Hlth Educ England North East, Newcastle Upon Tyne, England; [McDowell, Cliona] Royal Hosp, Northern Ireland Clin Trials Unit, Belfast, North Ireland; [O'Leary, Denis] Newcastle Tyne Hosp NHS Fdn Trust, Dept Cardiothorac Anaesthesia, Newcastle Upon Tyne, England; [Booth, Karen L.; Clark, Stephen C.; Ledingham, Simon J.; Dark, John H.] Newcastle Tyne Hosp NHS Fdn Trust, Dept Cardiothorac Surg, Newcastle Upon Tyne, England; [Clark, Stephen C.] Univ Northumbria, Fac Hlth & Life Sci, Newcastle Upon Tyne, England	Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Northumbria University	Funston, W (corresponding author), Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne, England.	wendy.funston@gmail.com		Clark, Stephen/0000-0002-2193-4705; Shelmerdine, Lauren/0000-0001-9944-5437; Simpson, John/0000-0003-4731-7294; Powell, Jason/0000-0002-1199-8406	National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre;  [BH142282 / PD0131]	National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre(National Institute for Health Research (NIHR)); 	The authors would like to thank all the patients for their participation in the study. We would also like to thank Dr Kevin Brennan, Dr Jim Park, Dr Orathi Sanjay, Dr Abraham Samuel, Dr Deirdre Timon, Dr Mahesh Prabu, Dr Mostafa Eladawy, Dr Francesca Caliandro, Dr Henning Pauli, Dr Leena Pardeshi, Dr Elena Assimakopoulou and Dr Vikrant Pathania, all Freeman Hospital, Newcastle upon Tyne, who kindly assisted with inserting the bronchial blocker and undertaking the study ventilation protocols. The assistance from Dr Andrew Filby and his team at the Newcastle University Flow Cytometry Core Facility was also greatly appreciated.	Apostolakis E, 2010, J CARDIAC SURG, V25, P47, DOI 10.1111/j.1540-8191.2009.00823.x; Bignami E, 2016, J CARDIOTHOR VASC AN, V30, P1668, DOI 10.1053/j.jvca.2016.03.015; Chi DM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006454; Chishti AD, 2001, J THORAC CARDIOV SUR, V122, P1162, DOI 10.1067/mtc.2001.116559; Condliffe AM, 1998, CLIN SCI, V94, P461, DOI 10.1042/cs0940461; Faller S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186532; Galinanes M, 1996, CIRCULATION, V94, P364; GILLINOV AM, 1994, ANN THORAC SURG, V57, P126, DOI 10.1016/0003-4975(94)90380-8; Hamano K, 1996, ANN THORAC SURG, V62, P1820, DOI 10.1016/S0003-4975(96)00680-7; Hogevold HE, 1997, PERFUSION-UK, V12, P9, DOI 10.1177/026765919701200103; Ilton MK, 1999, J THORAC CARDIOV SUR, V118, P930, DOI 10.1016/S0022-5223(99)70064-4; Juss JK, 2016, AM J RESP CRIT CARE, V194, P961, DOI 10.1164/rccm.201509-1818OC; KAPLAN EL, 1968, CIRCULATION, V37, pI158; Kuhns Douglas B, 2015, Curr Protoc Immunol, V111, DOI 10.1002/0471142735.im0723s111; Lagier D, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2967-y; Lesouhaitier M, 2022, J LEUKOCYTE BIOL, V111, P867, DOI 10.1002/JLB.5AB1219-737RR; Miralda I, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00217; Morris AC, 2011, BLOOD, V117, P5178, DOI 10.1182/blood-2010-08-304667; Morris AC, 2009, AM J RESP CRIT CARE, V180, P19, DOI 10.1164/rccm.200812-1928OC; Neaga A, 2013, J IMMUNOL METHODS, V390, P9, DOI 10.1016/j.jim.2011.06.027; Ng CSH, 2009, J INVEST SURG, V22, P333, DOI 10.1080/08941930903214776; Pavelkova M, 2006, PHYSIOL RES, V55, P165, DOI 10.33549/physiolres.930662; Pinder EM, 2018, THORAX, V73, P918, DOI 10.1136/thoraxjnl-2017-211323; Roques F, 1999, EUR J CARDIO-THORAC, V15, P816, DOI 10.1016/S1010-7940(99)00106-2; Rothenburger M, 2002, CARDIOVASC SURG, V10, P470, DOI 10.1016/S0967-2109(02)00016-9; Ruchaud-Sparagano MH, 2013, RESPIROLOGY, V18, P1230, DOI 10.1111/resp.12138; SILVA J, 1974, J THORAC CARDIOV SUR, V67, P175; Singh NRP, 2012, EUR J CLIN INVEST, V42, P1342, DOI 10.1111/j.1365-2362.2012.02720.x; Summers C, 2014, THORAX, V69, P623, DOI 10.1136/thoraxjnl-2013-204742; Tarnok A, 2001, CYTOMETRY, V46, P41, DOI 10.1002/1097-0320(20010215)46:1<41::AID-CYTO1036>3.0.CO;2-U; Zheng XM, 2022, WORLD J CLIN CASES, V10, P753, DOI 10.12998/wjcc.v10.i3.753	31	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2022	17	7								10.1371/journal.pone.0271958	http://dx.doi.org/10.1371/journal.pone.0271958			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4X1CI	35881612	Green Accepted, Green Published, gold			2023-01-03	WOS:000860587700011
J	[Anonymous]				[Anonymous]			Update to living systematic review on drug treatments for covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	2022	378								o1717	10.1136/bmj.o1717	http://dx.doi.org/10.1136/bmj.o1717			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5A1OP	35830977	Bronze			2023-01-03	WOS:000862663900019
J	Gaulton, N; Wakelin, G; Young, LV; Wotherspoon, S; Kamal, M; Parise, G; Nederveen, JP; Holwerda, A; Verdijk, LB; van Loon, LJC; Snijders, T; Johnston, AP				Gaulton, Nick; Wakelin, Griffen; Young, Laura V.; Wotherspoon, Scott; Kamal, Michael; Parise, Gianni; Nederveen, Joshua P.; Holwerda, Andy; Verdijk, Lex B.; van Loon, Luc J. C.; Snijders, Tim; Johnston, Adam P.			Twist2-expressing cells reside in human skeletal muscle and are responsive to aging and resistance exercise training	FASEB JOURNAL			English	Article						aging; progenitor cells; sarcopenia; skeletal muscle; Twist2	SATELLITE CELLS; STEM-CELLS	Skeletal muscle is maintained and repaired by sub-laminar, Pax7-expressing satellite cells. However, recent mouse investigations have described a second myogenic progenitor population that resides within the myofiber interstitium and expresses the transcription factor Twist2. Twist2-expressing cells exclusively repair and maintain type IIx/b muscle fibers. Currently, it is unknown if Twist2-expressing cells are present in human skeletal muscle and if they function as myogenic progenitors. Here, we perform a combination of single-cell RNA sequencing analysis and immunofluorescence staining to demonstrate the identity and localization of Twist2-expressing cells in human skeletal muscle. Twist2-expressing cells were identified to be anatomically and transcriptionally comparable to fibro-adipogenic progenitors (FAPs) and lack expression of typical satellite cell markers such as Pax7. Comparative analysis revealed that human and mouse Twist2-expressing cells were highly transcriptionally analogous and resided within the same anatomical structures in vivo. Examination of young and aged skeletal muscle biopsy samples revealed that Twist2-positive cells are more prevalent in aged muscle and increase following 12-weeks of resistance exercise training (RET) in humans. However, the quantity of Twist2-positive cells was not correlated with indices of muscle mass or muscle fiber cross-sectional area (CSA) in young or older muscle, and their abundance was surprisingly, negatively correlated with CSA and myonuclear domain size following RET. Taken together, we have identified cells expressing Twist2 in human skeletal muscle which are responsive to aging and exercise. Further examination of their myogenic potential is warranted.	[Gaulton, Nick; Wakelin, Griffen; Young, Laura V.; Johnston, Adam P.] Univ Prince Edward Isl, Dept Appl Human Sci, Charlottetown, PE, Canada; [Wakelin, Griffen; Johnston, Adam P.] Dalhousie Univ, Dept Med Neurosci, Halifax, NS, Canada; [Wotherspoon, Scott] Queen Elizabeth Hosp, Charlottetown, PE, Canada; [Kamal, Michael; Parise, Gianni] McMaster Univ, Fac Sci, Dept Kinesiol, Hamilton, ON, Canada; [Nederveen, Joshua P.] McMaster Univ, Dept Pediat, Childrens Hosp, Hamilton, ON, Canada; [Holwerda, Andy; Verdijk, Lex B.; van Loon, Luc J. C.; Snijders, Tim] Maastricht Univ, Sch Nutr & Translat Res Metab NUTRIM, Dept Human Biol, Maastricht, Netherlands	University of Prince Edward Island; Dalhousie University; McGill University; McMaster University; McMaster University; Maastricht University	Johnston, AP (corresponding author), Life Sci Res Inst, Brain Repair Ctr, Dept Med Neurosci, 1348 Summer St, Halifax, NS B3H 4R2, Canada.	adamjohnston@dal.ca			Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC) [RGPIN-2016-05747]; USRA; Naomi Cermac Grant	Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC); USRA; Naomi Cermac Grant	Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (NSERC), Grant/Award Number: RGPIN-2016-05747 and USRA; Naomi Cermac Grant	Alasdair C., 2022, AM J PHYSIOL-CELL PH, DOI [10.1152/ajpcell.00364.2022, DOI 10.1152/AJPCELL.00364.2022]; Bellamy LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109739; Bloemberg D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035273; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chen W, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200048; Dalle S, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01045; De Micheli AJ, 2020, SKELET MUSCLE, V10, DOI 10.1186/s13395-020-00236-3; Fragala MS, 2019, J STRENGTH COND RES, V33, P2019, DOI 10.1519/JSC.0000000000003230; Giordani L, 2019, MOL CELL, V74, P609, DOI 10.1016/j.molcel.2019.02.026; Hepple RT, 2016, J PHYSIOL-LONDON, V594, P1965, DOI 10.1113/JP270561; Holwerda AM, 2018, J NUTR, V148, P1723, DOI 10.1093/jn/nxy169; Joanisse S, 2017, GERONTOLOGY, V63, P91, DOI 10.1159/000450922; Johnston APW, 2008, APPL PHYSIOL NUTR ME, V33, P191, DOI 10.1139/H07-141; Kadi F, 2004, J PHYSIOL-LONDON, V558, P1005, DOI 10.1113/jphysiol.2004.065904; Li S, 2019, DEV CELL, V51, P89, DOI 10.1016/j.devcel.2019.08.002; Li S, 2019, GENE DEV, V33, P626, DOI 10.1101/gad.324467.119; Litvinukova M, 2020, NATURE, V588, P466, DOI 10.1038/s41586-020-2797-4; Liu N, 2017, NAT CELL BIOL, V19, P202, DOI 10.1038/ncb3477; Mackey AL, 2007, SCAND J MED SCI SPOR, V17, P34, DOI 10.1111/j.1600-0838.2006.00534.x; McKendry J, 2021, COMPR PHYSIOL, V11, P2249, DOI 10.1002/cphy.c200029; Mcleod JC, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00645; Moore DR, 2018, J CACHEXIA SARCOPENI, V9, P747, DOI 10.1002/jcsm.12306; Morton RW, 2018, CURR OPIN CRIT CARE, V24, P124, DOI 10.1097/MCC.0000000000000488; Murach KA, 2019, J APPL PHYSIOL, V127, P1632, DOI 10.1152/japplphysiol.00624.2019; Ning XX, 2018, J CELL MOL MED, V22, P1383, DOI 10.1111/jcmm.13465; Santilli V, 2014, CLIN CASES MINER BON, V11, P177, DOI 10.11138/ccmbm/2014.11.3.177; Snijders T, 2019, J PHYSIOL-LONDON, V597, P105, DOI 10.1113/JP276260; Snijders T, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00283; Sousa-Victor P, 2014, CELL CYCLE, V13, P3183, DOI 10.4161/15384101.2014.965072; Verdijk LB, 2007, AM J PHYSIOL-ENDOC M, V292, pE151, DOI 10.1152/ajpendo.00278.2006; Verdijk LB, 2014, AGE, V36, P545, DOI 10.1007/s11357-013-9583-2; Verdijk LB, 2009, J GERONTOL A-BIOL, V64, P332, DOI 10.1093/gerona/gln050	32	0	0	5	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2022	36	12							e22642	10.1096/fj.202201349RR	http://dx.doi.org/10.1096/fj.202201349RR			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	6D9SJ	36374263				2023-01-03	WOS:000883024500001
J	Ledford, H				Ledford, Heidi			Cancer drugs are closing in on some of the deadliest mutations	NATURE			English	Editorial Material						Cancer; Biotechnology; Drug discovery	INHIBITOR	The protein KRAS, mutated in many cancers, was deemed 'undruggable'. Now scientists are hoping to save lives with a batch of new compounds that target it. The protein KRAS, mutated in many cancers, was deemed 'undruggable'. Now scientists are hoping to save lives with a batch of new compounds that target it.										Fakih MG, 2022, LANCET ONCOL, V23, P115, DOI 10.1016/S1470-2045(21)00605-7; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Skoulidis F, 2021, NEW ENGL J MED, V384, P2371, DOI 10.1056/NEJMoa2103695; Wang XL, 2021, J MED CHEM, DOI 10.1021/acs.jmedchem.1c01688; Ye JW, 2019, J PHARM ANAL, V9, P217, DOI 10.1016/j.jpha.2019.05.004; Zhang ZY, 2022, CANCER CELL, V40, P1060, DOI 10.1016/j.ccell.2022.07.005	6	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 27	2022	610	7933					620	622		10.1038/d41586-022-03392-2	http://dx.doi.org/10.1038/d41586-022-03392-2			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5N9YQ	36284185	Bronze			2023-01-03	WOS:000872141900015
J	Hara, S; Andresen, H; Solheim, O; Carlsen, SM; Sundstrom, T; Lonne, G; Lonne, VV; Taraldsen, K; Tronvik, EA; Oie, LR; Gulati, AM; Sagberg, LM; Jakola, AS; Solberg, TK; Nygaard, OP; Salvesen, OO; Gulati, S				Hara, Sozaburo; Andresen, Hege; Solheim, Ole; Carlsen, Sven M.; Sundstrom, Terje; Lonne, Greger; Lonne, Vetle V.; Taraldsen, Kristin; Tronvik, Erling A.; Oie, Lise R.; Gulati, Agnete M.; Sagberg, Lisa M.; Jakola, Asgeir S.; Solberg, Tore K.; Nygaard, Oystein P.; Salvesen, Oyvind O.; Gulati, Sasha			Effect of Spinal Cord Burst Stimulation vs Placebo Stimulation on Disability in Patients With Chronic Radicular Pain After Lumbar Spine Surgery A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEUROMODULATION; OUTCOMES; BLIND	IMPORTANCE The use of spinal cord stimulation for chronic pain after lumbar spine surgery is increasing, yet rigorous evidence of its efficacy is lacking. OBJECTIVE To investigate the efficacy of spinal cord burst stimulation, which involves the placement of an implantable pulse generator connected to electrodes with leads that travel into the epidural space posterior to the spinal cord dorsal columns, in patients with chronic radiculopathy after surgery for degenerative lumbar spine disorders. DESIGN, SETTING, AND PARTICIPANTS This placebo-controlled, crossover, randomized clinical trial in 50 patients was conducted at St Olavs University Hospital in Norway, with study enrollment from September 5, 2018, through April 28, 2021. The date of final follow-up was May 20, 2022. INTERVENTIONS Patients underwent two 3-month periods with spinal cord burst stimulation and two 3-month periods with placebo stimulation in a randomized order. Burst stimulation consisted of closely spaced, high-frequency electrical stimuli delivered to the spinal cord. The stimulus consisted of a 40-Hz burst mode of constant-current stimuli with 4 spikes per burst and an amplitude corresponding to 50% to 70% of the paresthesia perception threshold. MAIN OUTCOMES AND MEASURES The primary outcome was difference in change from baseline in the self-reported Oswestry Disability Index (ODI; range, 0 points [no disability] to 100 points [maximum disability]; the minimal clinically important difference was 10 points) score between periods with burst stimulation and placebo stimulation. The secondary outcomes were leg and back pain, quality of life, physical activity levels, and adverse events. RESULTS Among 50 patients who were randomized (mean age, 52.2 [SD, 9.9] years; 27 [54%] were women), 47 (94%) had at least 1 follow-up ODI score and 42 (84%) completed all stimulation randomization periods and ODI measurements. The mean ODI score at baseline was 44.7 points and the mean changes in ODI score were -10.6 points for the burst stimulation periods and -9.3 points for the placebo stimulation periods, resulting in a mean between-group difference of -1.3 points (95% CI, -3.9 to 1.3 points; P=.32). None of the prespecified secondary outcomes showed a significant difference. Nine patients (18%) experienced adverse events, including 4 (8%) who required surgical revision of the implanted system. CONCLUSIONS AND RELEVANCE Among patients with chronic radicular pain after lumbar spine surgery, spinal cord burst stimulation, compared with placebo stimulation, after placement of a spinal cord stimulator resulted in no significant difference in the change from baseline in self-reported back pain-related disability.	[Hara, Sozaburo; Andresen, Hege; Solheim, Ole; Lonne, Vetle V.; Sagberg, Lisa M.; Nygaard, Oystein P.; Gulati, Sasha] St Olavs Univ Hosp, Dept Neurosurg, Trondheim, Norway; [Hara, Sozaburo; Andresen, Hege; Solheim, Ole; Lonne, Vetle V.; Tronvik, Erling A.; Oie, Lise R.; Nygaard, Oystein P.; Gulati, Sasha] Norwegian Univ Sci & Technol, Dept Neuromed & Movement Sci, Trondheim, Norway; [Andresen, Hege; Lonne, Greger; Nygaard, Oystein P.; Gulati, Sasha] St Olavs Univ Hosp, Natl Advisory Unit Spinal Surg, Trondheim, Norway; [Carlsen, Sven M.] St Olavs Univ Hosp, Dept Endocrinol, Trondheim, Norway; [Carlsen, Sven M.] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Trondheim, Norway; [Sundstrom, Terje] Haukeland Hosp, Dept Neurosurg, Bergen, Norway; [Sundstrom, Terje] Univ Bergen, Dept Clin Med, Bergen, Norway; [Lonne, Greger] Innlandet Hosp Trust, Dept Orthoped, Lillehammer, Norway; [Taraldsen, Kristin] Oslo Metropolitan Univ, Oslo, Norway; [Tronvik, Erling A.; Oie, Lise R.] St Olavs Univ Hosp, Dept Neurol, Trondheim, Norway; [Gulati, Agnete M.] St Olavs Univ Hosp, Dept Rheumatol, Trondheim, Norway; [Gulati, Agnete M.] Norwegian Univ Sci & Technol, Off Med Educ, Trondheim, Norway; [Sagberg, Lisa M.; Salvesen, Oyvind O.] Norwegian Univ Sci & Technol, Dept Publ Hlth & Nursing, Trondheim, Norway; [Jakola, Asgeir S.] Sahlgrens Univ Hosp, Dept Neurosurg, Gothenburg, Sweden; [Solberg, Tore K.] Univ Hosp North Norway, Dept Neurosurg, Tromso, Norway; [Solberg, Tore K.] Univ Tromso, Dept Clin Med, Tromso, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); University of Bergen; Haukeland University Hospital; University of Bergen; Innlandet Hospital Trust; Oslo Metropolitan University (OsloMet); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Sahlgrenska University Hospital; UiT The Arctic University of Tromso; University Hospital of North Norway; UiT The Arctic University of Tromso	Gulati, S (corresponding author), St Olavs Univ Hosp, Dept Neurosurg, Trondheim, Norway.	sasha.gulati@ntnu.no		Solheim, Ole/0000-0002-5954-4817	Liaison Committee for Education, Research, and Innovation in Central Norway	Liaison Committee for Education, Research, and Innovation in Central Norway	The trial was funded by the Liaison Committee for Education, Research, and Innovation in Central Norway.	Al-Kaisy A, 2018, NEUROMODULATION, V21, P457, DOI 10.1111/ner.12771; Austevoll IM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.15015; Chakravarthy K, 2019, PAIN MED, V20, pS47, DOI 10.1093/pm/pnz046; De Andres J, 2017, PAIN MED, V18, P2401, DOI 10.1093/pm/pnx241; De Ridder D, 2020, EXPERT REV MED DEVIC, V17, P289, DOI 10.1080/17434440.2020.1736560; De Ridder D, 2013, WORLD NEUROSURG, V80, P642, DOI 10.1016/j.wneu.2013.01.040; Deer T, 2018, NEUROMODULATION, V21, P56, DOI 10.1111/ner.12698; Duarte RV, 2020, PAIN, V161, P24, DOI 10.1097/j.pain.0000000000001689; Duarte RV, 2020, NEUROMODULATION, V23, P10, DOI 10.1111/ner.13018; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Fairbank J C, 1980, Physiotherapy, V66, P271; Ferraro MC, 2022, LANCET NEUROL, V21, P405, DOI 10.1016/S1474-4422(22)00096-5; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Grotle M, 2003, J REHABIL MED, V35, P241, DOI 10.1080/16501970306094; Hayek SM, 2015, NEUROMODULATION, V18, P603, DOI 10.1111/ner.12312; Jensen MP, 2019, EUR J PAIN, V23, P652, DOI 10.1002/ejp.1336; Knotkova H, 2021, LANCET, V397, P2111, DOI 10.1016/S0140-6736(21)00794-7; Lad SP, 2010, NEUROMODULATION, V13, P265, DOI 10.1111/j.1525-1403.2010.00292.x; Lim CY, 2021, KOREAN J ANESTHESIOL, V74, P293, DOI 10.4097/kja.21165; Lundh A, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.MR000033.pub2, 10.1002/14651858.MR000033.pub3]; Madsbu MA, 2017, JAMA SURG, V152, P503, DOI 10.1001/jamasurg.2016.5557; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Nerland US, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1603; O'Brien MW, 2022, GAIT POSTURE, V94, P107, DOI 10.1016/j.gaitpost.2022.03.002; O'Connell NE, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013756.pub2; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Paul AR, 2017, NEUROSURGERY, V81, P1011, DOI 10.1093/neuros/nyx153; Schu S, 2014, NEUROMODULATION, V17, P443, DOI 10.1111/ner.12197; Sdrulla AD, 2018, PAIN PRACT, V18, P1048, DOI 10.1111/papr.12692; Solberg TK, 2005, EUR SPINE J, V14, P1000, DOI 10.1007/s00586-005-0898-2; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; Turner JA, 2010, PAIN, V148, P14, DOI 10.1016/j.pain.2009.08.014; Twisk J, 2013, J CLIN EPIDEMIOL, V66, P1022, DOI 10.1016/j.jclinepi.2013.03.017; Wellek S, 2012, DTSCH ARZTEBL INT, V109, P276, DOI 10.3238/arztebl.2012.0276	34	2	2	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	2022	328	15					1506	1514		10.1001/jama.2022.18231	http://dx.doi.org/10.1001/jama.2022.18231			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5M9EQ	36255427				2023-01-03	WOS:000871397000016
J	Faucon, AL; Messai, N; Pardon, A				Faucon, Anne-Laure; Messai, Nesrine; Pardon, Agathe			A sweet unilateral pleural effusion: pleuro-peritoneal communication in a patient on dialysis	LANCET			English	Editorial Material									[Faucon, Anne-Laure; Pardon, Agathe] Ctr Hosp Sud Francilien, Dept Nephrol, Corbeil Essonnes, France; [Messai, Nesrine] Ctr Hosp Sud Francilien, Dept Nucl Med, Corbeil Essonnes, France; [Faucon, Anne-Laure] Univ Paris Saclay, Ctr Res Epidemiol & Populat Hlth, Clin Epidemiol Unit, INSERM UMRS 1018, Paris, France	Centre Hospitalier Sud Francilien; Centre Hospitalier Sud Francilien; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Faucon, AL (corresponding author), Ctr Hosp Sud Francilien, Dept Nephrol, Corbeil Essonnes, France.; Faucon, AL (corresponding author), Univ Paris Saclay, Ctr Res Epidemiol & Populat Hlth, Clin Epidemiol Unit, INSERM UMRS 1018, Paris, France.	anne-laure.faucon@aphp.fr							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 17	2022	400	10356					920	920						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6O3YZ	36116482				2023-01-03	WOS:000890180700024
J	Christie, B				Christie, Bryan			Assisted dying: Legislation has widespread support in Scotland	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 12	2022	378								o2205	10.1136/bmj.o2205	http://dx.doi.org/10.1136/bmj.o2205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5A9SO	36096516				2023-01-03	WOS:000863219000002
J	Kawai, Y; Okuda, H; Kinoshita, A; Yamamoto, K; Miyazaki, K; Takano, K; Asai, H; Urisono, Y; Fukushima, H				Kawai, Yasuyuki; Okuda, Hirozumi; Kinoshita, Arisa; Yamamoto, Koji; Miyazaki, Keita; Takano, Keisuke; Asai, Hideki; Urisono, Yasuyuki; Fukushima, Hidetada			Visual assessment of interactions among resuscitation activity factors in out-of-hospital cardiopulmonary arrest using a machine learning model	PLOS ONE			English	Article							CARDIAC-ARREST; SURVIVAL; ASSOCIATION	Aim The evaluation of the effects of resuscitation activity factors on the outcome of out-of-hospital cardiopulmonary arrest (OHCA) requires consideration of the interactions among these factors. To improve OHCA success rates, this study assessed the prognostic interactions resulting from simultaneously modifying two prehospital factors using a trained machine learning model. Methods We enrolled 8274 OHCA patients resuscitated by emergency medical services (EMS) in Nara prefecture, Japan, with a unified activity protocol between January 2010 and December 2018; patients younger than 18 and those with noncardiogenic cardiopulmonary arrest were excluded. Next, a three-layer neural network model was constructed to predict the cerebral performance category score of 1 or 2 at one month based on 24 features of prehospital EMS activity. Using this model, we evaluated the prognostic impact of continuously and simultaneously varying the transport time and the defibrillation or drug-administration time in the test data based on heatmaps. Results The average class sensitivity of the prognostic model was more than 0.86, with a full area under the receiver operating characteristics curve of 0.94 (95% confidence interval of 0.92-0.96). By adjusting the two time factors simultaneously, a nonlinear interaction was obtained between the two adjustments, instead of a linear prediction of the outcome. Conclusion Modifications to the parameters using a machine-learning-based prognostic model indicated an interaction among the prognostic factors. These findings could be used to evaluate which factors should be prioritized to reduce time in the trained region of machine learning in order to improve EMS activities.	[Kawai, Yasuyuki; Okuda, Hirozumi; Kinoshita, Arisa; Yamamoto, Koji; Miyazaki, Keita; Takano, Keisuke; Asai, Hideki; Urisono, Yasuyuki; Fukushima, Hidetada] Nara Med Univ, Dept Emergency & Crit Care Med, Kashihara, Nara, Japan	Nara Medical University	Kawai, Y (corresponding author), Nara Med Univ, Dept Emergency & Crit Care Med, Kashihara, Nara, Japan.	k6k6k@naramed-u.ac.jp		Kawai, Yasuyuki/0000-0003-3630-6135				Al-Dury N, 2020, SCAND J TRAUMA RESUS, V28, DOI 10.1186/s13049-020-00742-9; Baekgaard JS, 2017, CIRCULATION, V136, P954, DOI 10.1161/CIRCULATIONAHA.117.029067; Cabinet Office, 2019, WHIT PAP AG SOC WHOL; Char DS, 2018, NEW ENGL J MED, V378, P981, DOI 10.1056/NEJMp1714229; Deans KJ, 2010, ANESTH ANALG, V111, P444, DOI 10.1213/ane.0b013e3181aa8903; Enzan N, 2022, EUR HEART J-ACUTE CA, V11, P389, DOI 10.1093/ehjacc/zuac026; Grossestreuer AV, 2016, RESUSCITATION, V109, P21, DOI 10.1016/j.resuscitation.2016.09.006; Harford S, 2019, RESUSCITATION, V138, P134, DOI 10.1016/j.resuscitation.2019.03.012; Hirano Y, 2021, RESUSCITATION, V158, P49, DOI 10.1016/j.resuscitation.2020.11.020; Jouffroy R, 2019, AM J EMERG MED, V37, P387, DOI 10.1016/j.ajem.2018.05.055; Kiguchi T, 2020, RESUSCITATION, V152, P39, DOI 10.1016/j.resuscitation.2020.02.044; Kwon JM, 2019, RESUSCITATION, V139, P84, DOI 10.1016/j.resuscitation.2019.04.007; Kwon JM, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008678; Martinell L, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1677-2; Maupain C, 2016, EUR HEART J, V37, P3222, DOI 10.1093/eurheartj/ehv556; Nanayakkara S, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002709; Nordberg P, 2019, JAMA-J AM MED ASSOC, V321, P1677, DOI 10.1001/jama.2019.4149; Okubo M, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.20176; Panchal AR, 2020, CIRCULATION, V142, pS366, DOI 10.1161/CIR.0000000000000916; Park SY, 2022, J CLIN MED, V11, DOI 10.3390/jcm11010190; Perkins GD, 2018, NEW ENGL J MED, V379, P711, DOI 10.1056/NEJMoa1806842; Qu WD, 2020, INT J COMPUT ASS RAD, V15, P2041, DOI 10.1007/s11548-020-02260-6; Ran LY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014330; Rea T, 2014, ANN EMERG MED, V64, P1, DOI 10.1016/j.annemergmed.2014.01.014; Schnaubelt S, 2020, RESUSCITATION, V156, P137, DOI 10.1016/j.resuscitation.2020.08.126; Seki T, 2019, RESUSCITATION, V141, P128, DOI 10.1016/j.resuscitation.2019.06.006; SISCOVICK DS, 1993, ANN EMERG MED, V22, P92, DOI 10.1016/S0196-0644(05)80258-6; Skotko BG, 2017, AM J MED GENET A, V173, P889, DOI 10.1002/ajmg.a.38137; Wallace SK, 2013, CIRC-CARDIOVASC QUAL, V6, P148, DOI 10.1161/CIRCOUTCOMES.111.000041; Wang HE, 2018, JAMA-J AM MED ASSOC, V320, P769, DOI 10.1001/jama.2018.7044; Yan SJ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2773-2; Yannopoulos D, 2020, LANCET, V396, P1807, DOI 10.1016/S0140-6736(20)32338-2	32	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2022	17	9							e0273787	10.1371/journal.pone.0273787	http://dx.doi.org/10.1371/journal.pone.0273787			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R5TD	36067174	Green Published, gold			2023-01-03	WOS:000892364500026
J	Schmidt, H; Kjaergaard, J; Hassager, C; Molstrom, S; Grand, J; Borregaard, B; Obling, LR; Veno, S; Sarkisian, L; Mamaev, D; Jensen, LO; Nyholm, B; Hofsten, DE; Josiassen, J; Thomsen, JH; Thune, JJ; Lindholm, MG; Meyer, MAS; Winther-Jensen, M; Sorensen, M; Frydland, M; Beske, RP; Frikke-Schmidt, R; Wiberg, S; Boesgaard, S; Jorgensen, VL; Moller, JE				Schmidt, Henrik; Kjaergaard, Jesper; Hassager, Christian; Molstrom, Simon; Grand, Johannes; Borregaard, Britt; Obling, Laust Roelsgaard E.; Veno, Soren; Sarkisian, Laura; Mamaev, Dmitry; Jensen, Lisette O.; Nyholm, Benjamin; Hofsten, Dan E.; Josiassen, Jakob; Thomsen, Jakob H.; Thune, Jens J.; Lindholm, Matias G.; Meyer, Martin A. Stengaard A.; Winther-Jensen, Matilde; Sorensen, Marc; Frydland, Martin; Beske, Rasmus P.; Frikke-Schmidt, Ruth; Wiberg, Sebastian; Boesgaard, Soren; Jorgensen, Vibeke Lind; Moller, Jacob E.			Oxygen Targets in Comatose Survivors of Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Early Access							EUROPEAN RESUSCITATION COUNCIL; CARE; METAANALYSIS; DYSFUNCTION; THERAPY; SOCIETY; ADULTS; LEVEL	BACKGROUD The appropriate oxygenation target for mechanical ventilation in comatose survivors of out-of-hospital cardiac arrest is unknown. METHODS In this randomized trial with a 2-by-2 factorial design, we randomly assigned comatose adults with out-of-hospital cardiac arrest in a 1:1 ratio to either a restrictive oxygen target of a partial pressure of arterial oxygen (Pao(2)) of 9 to 10 kPa (68 to 75 mm Hg) or a liberal oxygen target of a Pao(2) of 13 to 14 kPa (98 to 105 mm Hg); patients were also assigned to one of two blood-pressure targets (reported separately). The primary outcome was a composite of death from any cause or hospital discharge with severe disability or coma (Cerebral Performance Category [CPC] of 3 or 4; categories range from 1 to 5, with higher values indicating more severe disability), whichever occurred first within 90 days after randomization. Secondary outcomes were neuron-specific enolase levels at 48 hours, death from any cause, the score on the Montreal Cognitive Assessment (ranging from 0 to 30, with higher scores indicating better cognitive ability), the score on the modified Rankin scale (ranging from 0 to 6, with higher scores indicating greater disability), and the CPC at 90 days. RESULTS A total of 789 patients underwent randomization. A primary-outcome event occurred in 126 of 394 patients (32.0%) in the restrictive-target group and in 134 of 395 patients (33.9%) in the liberal-target group (hazard ratio, 0.95; 95% confidence interval, 0.75 to 1.21; P=0.69). At 90 days, death had occurred in 113 patients (28.7%) in the restrictive-target group and in 123 (31.1%) in the liberal-target group. On the CPC, the median category was 1 in the two groups; on the modified Rankin scale, the median score was 2 in the restrictive-target group and 1 in the liberal-target group; and on the Montreal Cognitive Assessment, the median score was 27 in the two groups. At 48 hours, the median neuron-specific enolase level was 17 mu g per liter in the restrictive-target group and 18 mu g per liter in the liberal-target group. The incidence of adverse events was similar in the two groups. CONCLUSIONS Targeting of a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest resulted in a similar incidence of death or severe disability or coma. (Funded by the Novo Nordisk Foundation; BOX ClinicalTrials.gov number, .)	[Schmidt, Henrik; Molstrom, Simon; Veno, Soren; Mamaev, Dmitry] Odense Univ Hosp, Dept Anesthesiol & Intens Care, Odense, Denmark; [Borregaard, Britt; Sarkisian, Laura; Jensen, Lisette O.; Moller, Jacob E.] Odense Univ Hosp, Cardiol, Odense, Denmark; [Schmidt, Henrik; Hassager, Christian; Borregaard, Britt; Jensen, Lisette O.; Moller, Jacob E.] Univ Southern Denmark, Dept Clin Res, Odense, Denmark; [Kjaergaard, Jesper; Hassager, Christian; Grand, Johannes; Obling, Laust Roelsgaard E.; Nyholm, Benjamin; Hofsten, Dan E.; Josiassen, Jakob; Thomsen, Jakob H.; Lindholm, Matias G.; Meyer, Martin A. Stengaard A.; Winther-Jensen, Matilde; Frydland, Martin; Beske, Rasmus P.; Frikke-Schmidt, Ruth; Wiberg, Sebastian; Boesgaard, Soren; Moller, Jacob E.] Copenhagen Univ Hosp, Dept Cardiol, Copenhagen, Denmark; [Sorensen, Marc; Jorgensen, Vibeke Lind] Copenhagen Univ Hosp, Cardiothorac Anesthesiol, Copenhagen, Denmark; [Frikke-Schmidt, Ruth] Copenhagen Univ Hosp, Heart Ctr, Copenhagen, Denmark; [Frikke-Schmidt, Ruth] Copenhagen Univ Hosp, Ctr Diagnost Invest, Dept Clin Biochem, Copenhagen, Denmark; [Kjaergaard, Jesper; Hassager, Christian; Frikke-Schmidt, Ruth] Copenhagen Univ Hosp, Rigshospitalet, Copenhagen, Denmark; [Kjaergaard, Jesper; Hassager, Christian; Frikke-Schmidt, Ruth] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark; [Thune, Jens J.] Copenhagen Univ Hosp Bispebjerg, Dept Cardiol, Copenhagen, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Moller, JE (corresponding author), Odense Univ Hosp, Cardiol, Odense, Denmark.; Moller, JE (corresponding author), Univ Southern Denmark, Dept Clin Res, Odense, Denmark.; Moller, JE (corresponding author), Copenhagen Univ Hosp, Dept Cardiol, Copenhagen, Denmark.	jacob.moeller1@rsyd.dk	Grand, Johannes/I-5627-2015; Meyer, Martin A. S./J-2951-2013; Borregaard, Britt/O-8040-2015	Grand, Johannes/0000-0002-5511-4668; Meyer, Martin A. S./0000-0002-6312-2457; Molstrom, Simon/0000-0002-2778-8075; Beske, Rasmus Paulin/0000-0002-5880-3733; Thomsen, Jakob Hartvig/0000-0002-6782-9599; Sorensen, Marc/0000-0003-4967-3663; Borregaard, Britt/0000-0003-2702-0231; Obling, Laust/0000-0003-2927-3670; Jensen, Lisette Okkels/0000-0002-4838-2429				Bray JE, 2018, RESUSCITATION, V128, P211, DOI 10.1016/j.resuscitation.2018.04.019; Bro-Jeppesen J, 2017, RESUSCITATION, V121, P179, DOI 10.1016/j.resuscitation.2017.09.019; Dankiewicz J, 2021, NEW ENGL J MED, V384, P2283, DOI 10.1056/NEJMoa2100591; Ebmeier SJ, 2018, ANAESTH INTENS CARE, V46, P297, DOI 10.1177/0310057X1804600307; Haywood K, 2018, CIRCULATION, V137, pE783, DOI 10.1161/CIR.0000000000000562; Jakkula P, 2018, INTENS CARE MED, V44, P2112, DOI 10.1007/s00134-018-5453-9; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; Kjaergaard J, 2022, TRIALS, V23, DOI 10.1186/s13063-022-06101-6; Kuisma M, 2006, RESUSCITATION, V69, P199, DOI 10.1016/j.resuscitation.2005.08.010; Mackle D, 2020, NEW ENGL J MED, V382, P989, DOI 10.1056/NEJMoa1903297; Nolan JP, 2015, INTENS CARE MED, V41, P2039, DOI 10.1007/s00134-015-4051-3; Pilcher J, 2012, RESUSCITATION, V83, P417, DOI 10.1016/j.resuscitation.2011.12.021; Roberts BW, 2018, CIRCULATION, V137, P2114, DOI 10.1161/CIRCULATIONAHA.117.032054; Sandroni C, 2021, INTENS CARE MED, V47, P1393, DOI 10.1007/s00134-021-06548-2; Sandroni C, 2014, INTENS CARE MED, V40, P1816, DOI 10.1007/s00134-014-3470-x; Schjorring OL, 2021, NEW ENGL J MED, V384, P1301, DOI 10.1056/NEJMoa2032510; Schneider A, 2009, ANESTH ANALG, V108, P971, DOI 10.1213/ane.0b013e318193ca99; Stammet P, 2015, J AM COLL CARDIOL, V65, P2104, DOI 10.1016/j.jacc.2015.03.538; Thomas M, 2019, BMC EMERG MED, V19, DOI 10.1186/s12873-018-0214-1; van Gils P, 2022, RESUSCITATION, V172, P130, DOI 10.1016/j.resuscitation.2021.12.024; Wiberg S, 2020, EUR HEART J-ACUTE CA, V9, pS138, DOI 10.1177/2048872618814700; Wiberg S, 2016, CIRCULATION, V134, P2115, DOI 10.1161/CIRCULATIONAHA.116.024088; Young P, 2020, INTENS CARE MED, V46, P2411, DOI 10.1007/s00134-020-06196-y; Young P, 2014, RESUSCITATION, V85, P1686, DOI 10.1016/j.resuscitation.2014.09.011; Young PJ, 2020, RESUSCITATION, V157, P15, DOI 10.1016/j.resuscitation.2020.09.036	25	8	8	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.												10.1056/NEJMoa2208686	http://dx.doi.org/10.1056/NEJMoa2208686		AUG 2022	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5Y7FK	36027567				2023-01-03	WOS:000879446400001
J	Birnie, E; Biemond, JJ; Appelman, B; de Bree, GJ; Jonges, M; Welkers, MRA; Wiersinga, WJ				Birnie, Emma; Biemond, Jason J.; Appelman, Brent; de Bree, Godelieve J.; Jonges, Marcel; Welkers, Matthijs R. A.; Wiersinga, W. Joost			Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Birnie, Emma; Biemond, Jason J.; Appelman, Brent; Wiersinga, W. Joost] Amsterdam Univ Med Ctr, Ctr Expt & Mol Med, Amsterdam, Netherlands; [de Bree, Godelieve J.] Amsterdam Univ Med Ctr, Div Infect Dis, Amsterdam, Netherlands; [Jonges, Marcel; Welkers, Matthijs R. A.] Amsterdam Univ Med Ctr, Dept Med Microbiol & Infect Prevent, Amsterdam, Netherlands		Birnie, E (corresponding author), Ctr Expt & Mol Med, Meibergdreef 9, Amsterdam, Netherlands.	e.birnie@amsterdamumc.nl		Appelman, Brent/0000-0002-4560-8410	Netherlands Organization for Health Research and Development [10430142110001]	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development)	This study was funded by grant 10430142110001 from the Netherlands Organization for Health Research and Development.	Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Corey L, 2021, NEW ENGL J MED, V385, P562, DOI 10.1056/NEJMsb2104756; Gupta A, 2022, JAMA-J AM MED ASSOC, V327, P1236, DOI 10.1001/jama.2022.2832; Rockett R, 2022, NEW ENGL J MED, V386, DOI 10.1056/NEJMc2120219; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2022	328	11					1104	1107		10.1001/jama.2022.13854	http://dx.doi.org/10.1001/jama.2022.13854		AUG 2022	4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5A5DY	35913747	Bronze			2023-01-03	WOS:000836398000002
J	Eldridge, N; Wang, Y; Metersky, M; Eckenrode, S; Mathew, J; Sonnenfeld, N; Perdue-Puli, J; Hunt, D; Brady, PJ; McGann, P; Grace, E; Rodrick, D; Drye, E; Krumholz, HM				Eldridge, Noel; Wang, Yun; Metersky, Mark; Eckenrode, Sheila; Mathew, Jasie; Sonnenfeld, Nancy; Perdue-Puli, Jade; Hunt, David; Brady, P. Jeffrey; McGann, Paul; Grace, Erin; Rodrick, David; Drye, Elizabeth; Krumholz, Harlan M.			Trends in Adverse Event Rates in Hospitalized Patients, 2010-2019	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TIME	IMPORTANCE Patient safety is a US national priority, yet lacks a comprehensive assessment of progress over the past decade. OBJECTIVE To determine the change in the rate of adverse events in hospitalized patients. DESIGN, SETTING, AND PARTICIPANTS This serial cross-sectional study used data from the Medicare Patient Safety Monitoring System from 2010 to 2019 to assess in-hospital adverse events in patients. The study included 244 542 adult patients hospitalized in 3156 US acute care hospitals across 4 condition groups from 2010 through 2019: acute myocardial infarction (17%), heart failure (17%), pneumonia (21%), and major surgical procedures (22%); and patients hospitalized from 2012 through 2019 for all other conditions (22%). EXPOSURES Adults aged 18 years or older hospitalized during each included calendar year. MAIN OUTCOMES AND MEASURES Information on adverse events (abstracted from medical records) included 21measures across 4 adverse event domains: adverse drug events, hospital-acquired infections, adverse events after a procedure, and general adverse events (hospital-acquired pressure ulcers and falls). The outcomes were the total change over time for the observed and risk-adjusted adverse event rates in the subpopulations. RESULTS The study sample included 190 286 hospital discharges combined in the 4 condition-based groups of acute myocardial infarction, heart failure, pneumonia, and major surgical procedures (mean age, 68.0 [SD, 15.9] years; 52.6% were female) and 54256 hospital discharges for the group including all other conditions (mean age, 57.7 [SD, 20.7] years; 59.8% were female) from 3156 acute care hospitals across the US. From 2010 to 2019, the total change was from 218 to 139 adverse events per 1000 discharges for acute myocardial infarction, from 168 to 116 adverse events per 1000 discharges for heart failure, from 195 to 119 adverse events per 1000 discharges for pneumonia, and from 204 to 130 adverse events per 1000 discharges for major surgical procedures. From 2012 to 2019, the rate of adverse events for all other conditions remained unchanged at 70 adverse events per 1000 discharges. After adjustment for patient and hospital characteristics, the annual change represented by relative risk in all adverse events per 1000 discharges was 0.94 (95% CI, 0.93-0.94) for acute myocardial infarction, 0.95 (95% CI, 0.94-0.96) for heart failure, 0.94 (95% CI, 0.93-0.95) for pneumonia, 0.93 (95% CI, 0.92-0.94) for major surgical procedures, and 0.97 (95% CI, 0.96-0.99) for all other conditions. The risk-adjusted adverse event rates declined significantly in all patient groups for adverse drug events, hospital-acquired infections, and general adverse events. For patients in the major surgical procedures group, the risk-adjusted rates of events after a procedure declined significantly. CONCLUSIONS AND RELEVANCE In the US between 2010 and 2019, there was a significant decrease in the rates of adverse events abstracted from medical records for patients admitted for acute myocardial infarction, heart failure, pneumonia, and major surgical procedures and there was a significant decrease in the adjusted rates of adverse events between 2012 and 2019 for all other conditions. Further research is needed to understand the extent to which these trends represent a change in patient safety.	[Eldridge, Noel; Perdue-Puli, Jade; Brady, P. Jeffrey; Grace, Erin; Rodrick, David] US Dept Hlth & Human Serv, Agcy Healthcare Res & Qual, Rockville, MD USA; [Eldridge, Noel] Def Hlth Agcy, Falls Church, VA USA; [Wang, Yun] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Richard & Susan Smith Ctr Outcomes Res Cardiol, Div Cardiol, Boston, MA 02115 USA; [Wang, Yun] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Wang, Yun; Eckenrode, Sheila; Mathew, Jasie; Drye, Elizabeth; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Metersky, Mark] Univ Connecticut, Sch Med, Div Pulm & Crit Care Med, Farmington, CT USA; [Sonnenfeld, Nancy; McGann, Paul] US Dept Hlth & Human Serv, Ctr Medicare, Baltimore, MD USA; [Sonnenfeld, Nancy; McGann, Paul] US Dept Hlth & Human Serv, Ctr Medicaid Serv, Baltimore, MD USA; [Hunt, David] US Dept Hlth & Human Serv, Off Natl Coordinator Hlth Informat Technol, Rockville, MD USA; [Brady, P. Jeffrey] Highmark Hlth, Pittsburgh, PA USA; [Drye, Elizabeth] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; [Drye, Elizabeth] Natl Qual Forum, Washington, DC USA; [Krumholz, Harlan M.] Yale Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT USA; [Krumholz, Harlan M.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA	Agency for Healthcare Research & Quality; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Connecticut; Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services; Yale University; Yale University; Yale University	Rodrick, D (corresponding author), Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, 5600 Fishers Ln, Rockville, MD 20857 USA.	david.rodrick@ahrq.hhs.gov			Agency for Healthcare Research and Quality (AHRQ) [HHSA290201800005C]	Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This work was supported by contract HHSA290201800005C from the Agency for Healthcare Research and Quality (AHRQ).	Agency for Healthcare Research and Quality, CLIN CLASSIFICATIONS; Agency for Healthcare Research and Quality, 2020, MAK HEALTHC SAF 3; Agency for Healthcare Research and Quality, HCUPNET HEALTHC COST; Agency for Healthcare Research and Quality U.S. Department of Health and Human Services., 2014, AHRQ NAT SCOR HOSP A; Aggarwal R, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2010.040501; American Hospital Association, AHA DAT INS HOSP QUI; [Anonymous], HOSP INP QUAL REP PR; Baines RJ, 2013, BMJ QUAL SAF, V22, P290, DOI 10.1136/bmjqs-2012-001126; Bates DW, 2018, HEALTH AFFAIR, V37, P1736, DOI 10.1377/hlthaff.2018.0738; Bratzler DW, 2006, CLIN INFECT DIS, V43, P322, DOI 10.1086/505220; Centers for Medicare and Medicaid Services, FIND COMP NURS HOM H; Centers for Medicare and Medicaid Services, HOSP VAL BAS PURCH P; Centers for Medicare & Medicaid Innovation, PROJ EV ACT SUPP PAR; Centers for Medicare & Medicaid Services, PARTN PAT HOSP IMPR; Centers for Medicare & Medicaid Services, HOSP ACQ COND RED PR; Centers for Medicare & Medicaid Services, CMS INN CTR PARTN PA; Centers for Medicare & Medicaid Services; Joint Commission, 2016, SPEC MAN NATL HOSP P; Centers for Medicare & Medicaid Services; Joint Commission, SPEC MAN NAT HOSP IN; Classen DC, 2021, J PATIENT SAF, V17, pE234, DOI 10.1097/PTS.0000000000000322; Furukawa MF, 2020, J PATIENT SAF, V16, P137, DOI 10.1097/PTS.0000000000000257; Hackbarth AD, 2014, J PATIENT SAF, V10, P125, DOI 10.1097/PTS.0000000000000071; Hunt DRVN., 2005, ADV PATIENT SAFETY R; Institute for Healthcare Improvement, SAF IS PERS PARTN PA; Kohn L., 2000, ERR IS HUMAN BUILDIN; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; Shojania KG, 2013, BMJ QUAL SAF, V22, P273, DOI 10.1136/bmjqs-2013-001935; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; US Department of Health and Human Services Office of Inspector General, 2010, ADVERSE EVENTS HOSP; Wang Y, 2014, NEW ENGL J MED, V370, P341, DOI 10.1056/NEJMsa1300991; Zlabek JA, 2011, J AM MED INFORM ASSN, V18, P169, DOI 10.1136/jamia.2010.007229; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	31	3	3	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2022	328	2					173	183		10.1001/jama.2022.9600	http://dx.doi.org/10.1001/jama.2022.9600			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3E1GX	35819424				2023-01-03	WOS:000829739800016
J	Kuner, R; Kuner, T				Kuner, Rohini; Kuner, Thomas			Sounding out pain	SCIENCE			English	Article							MUSIC; THERAPY		[Kuner, Rohini] Heidelberg Univ, Inst Pharmacol, Heidelberg, Germany; [Kuner, Thomas] Heidelberg Univ, Inst Anat & Cell Biol, Dept Funct Neuroanat, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Kuner, R (corresponding author), Heidelberg Univ, Inst Pharmacol, Heidelberg, Germany.	rohini.kuner@pharma.uni-heidelberg.de			Deutsche Forschungsgemeinschaft [SFB1158, B01, B06, B08]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The authors acknowledge funding by Deutsche Forschungsgemeinschaft (SFB1158, project nos.B01,B06, and B08).	Bonetti L, 2021, NEUROIMAGE, V245, DOI 10.1016/j.neuroimage.2021.118735; Cole LC, 2014, PAIN MANAG NURS, V15, P406, DOI 10.1016/j.pmn.2012.08.010; Dobek CE, 2014, J PAIN, V15, P1057, DOI 10.1016/j.jpain.2014.07.006; Hauck M, 2013, PAIN, V154, P539, DOI 10.1016/j.pain.2012.12.016; Kuner R, 2021, PHYSIOL REV, V101, P213, DOI 10.1152/physrev.00040.2019; Millett CR, 2017, J MUSIC THER, V54, P460, DOI 10.1093/jmt/thx014; Sachs ME, 2020, NEUROIMAGE, V218, DOI 10.1016/j.neuroimage.2019.116512; Wang HT, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000417; Zhuo W., 2022, SCIENCE, V377, P198	9	0	0	5	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 8	2022	377	6602					155	156		10.1126/science.add0640	http://dx.doi.org/10.1126/science.add0640			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2T1GK	35857551				2023-01-03	WOS:000822228900023
J	Bernard, SA; Bray, JE; Smith, K; Stephenson, M; Finn, J; Grantham, H; Hein, C; Masters, S; Stub, D; Perkins, GD; Dodge, N; Martin, C; Hopkins, S; Cameron, P				Bernard, Stephen A.; Bray, Janet E.; Smith, Karen; Stephenson, Michael; Finn, Judith; Grantham, Hugh; Hein, Cindy; Masters, Stacey; Stub, Dion; Perkins, Gavin D.; Dodge, Natasha; Martin, Catherine; Hopkins, Sarah; Cameron, Peter		EXACT Investigators	Effect of Lower vs Higher Oxygen Saturation Targets on Survival to Hospital Discharge Among Patients Resuscitated After Out-of-Hospital Cardiac Arrest The EXACT Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Early Access							INTERNATIONAL LIAISON COMMITTEE; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; EUROPEAN RESUSCITATION; STROKE FOUNDATION; OUTCOME REPORTS; TASK-FORCE; HYPEROXIA; METAANALYSIS; COUNCIL	IMPORTANCE The administration of a high fraction of oxygen following return of spontaneous circulation in out-of-hospital cardiac arrest may increase reperfusion brain injury. OBJECTIVE To determine whether targeting a lower oxygen saturation in the early phase of postresuscitation care for out-of-hospital cardiac arrest improves survival at hospital discharge. DESIGN, SETTING, AND PARTICIPANTS This multicenter, parallel-group, randomized clinical trial included unconscious adults with return of spontaneous circulation and a peripheral oxygen saturation (SpO2) of at least 95% while receiving 100% oxygen. The trial was conducted in 2 emergency medical services and 15 hospitals in Victoria and South Australia, Australia, between December 11, 2017, and August 11, 2020, with data collection from ambulance and hospital medical records (final follow-up date, August 25, 2021). The trial enrolled 428 of a planned 1416 patients. INTERVENTIONS Patients were randomized by paramedics to receive oxygen titration to achieve an oxygen saturation of either 90% to 94%(intervention; n = 216) or 98% to 100% (standard care; n = 212) until arrival in the intensive care unit. MAIN OUTCOMES AND MEASURES The primary outcomewas survival to hospital discharge. There were 9 secondary outcomes collected, including hypoxic episodes (SpO(2) <90%) and prespecified serious adverse events, which included hypoxia with rearrest. RESULTS The trial was stopped early due to the COVID-19 pandemic. Of the 428 patients who were randomized, 425 were included in the primary analysis (median age, 65.5 years; 100 [23.5%] women) and all completed the trial. Overall, 82 of 214 patients (38.3%) in the intervention group survived to hospital discharge compared with 101 of 211 (47.9%) in the standard care group (difference, -9.6%[95% CI, -18.9% to -0.2%]; unadjusted odds ratio, 0.68 [95% CI, 0.46-1.00]; P =.05). Of the 9 prespecified secondary outcomes collected during hospital stay, 8 showed no significant difference. A hypoxic episode prior to intensive care was observed in 31.3%(n = 67) of participants in the intervention group and 16.1% (n = 34) in the standard care group (difference, 15.2%[95% CI, 7.2%-23.1%]; OR, 2.37 [95% CI, 1.49-3.79]; P <.001). CONCLUSIONS AND RELEVANCE Among patients achieving return of spontaneous circulation after out-of-hospital cardiac arrest, targeting an oxygen saturation of 90% to 94%, compared with 98% to 100%, until admission to the intensive care unit did not significantly improve survival to hospital discharge. Although the trial is limited by early termination due to the COVID-19 pandemic, the findings do not support use of an oxygen saturation target of 90% to 94% in the out-of-hospital setting after resuscitation from cardiac arrest.	[Bernard, Stephen A.; Bray, Janet E.; Smith, Karen; Stephenson, Michael; Finn, Judith; Stub, Dion; Dodge, Natasha; Cameron, Peter] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Bernard, Stephen A.; Smith, Karen; Stephenson, Michael; Stub, Dion; Hopkins, Sarah] Ambulance Victoria, Melbourne, Vic, Australia; [Bernard, Stephen A.; Bray, Janet E.; Stub, Dion; Cameron, Peter] Alfred Hosp, Melbourne, Vic, Australia; [Bray, Janet E.; Finn, Judith; Grantham, Hugh; Masters, Stacey] Curtin Univ, Prehosp, Resuscitat & Emergency Care Res Unit, Perth, WA, Australia; [Smith, Karen; Stephenson, Michael] Monash Univ, Dept Paramed, Melbourne, Vic, Australia; [Grantham, Hugh] SA Ambulance Serv, Adelaide, SA, Australia; [Grantham, Hugh] Flinders Med Ctr, Adelaide, SA, Australia; [Hein, Cindy] Flinders Univ S Australia, Adelaide, SA, Australia; [Perkins, Gavin D.] Univ Warwick, Warwick, England; [Martin, Catherine] Monash Univ, Data Sci & AI Platform, Melbourne, Vic, Australia	Monash University; Florey Institute of Neuroscience & Mental Health; Curtin University; Monash University; Flinders Medical Centre; Flinders University South Australia; University of Warwick; Monash University	Bernard, SA (corresponding author), Ambulance Victoria, 375 Manningham Rd, Doncaster, Vic 3108, Australia.	stephen.bernard@ambulance.vic.gov.au			National Health and Medical Research Council (NHMRC) [APP1107509]; NHMRC Prehospital Emergency Care Centre of Research Excellence [116453]; NHMRC [1174838]; Medical Research Future Fund fellowship [1139686]; Heart Foundation [104751/105793]; National Institute for Health Research Applied Research Collaboration West Midlands; NHMRC	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Prehospital Emergency Care Centre of Research Excellence(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Future Fund fellowship(Medical Research Future Fund (MRFF)); Heart Foundation; National Institute for Health Research Applied Research Collaboration West Midlands; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The trial was funded by a project grant from the National Health and Medical Research Council (NHMRC; project grant number APP1107509). The Australasian Resuscitation Outcomes Consortium and the NHMRC Prehospital Emergency Care Centre of Research Excellence (number 116453) provided administrative support. Dr Finn receives an NHMRC investigator grant (number 1174838), Dr Cameron receives a Medical Research Future Fund fellowship (number 1139686), and Drs Bray and Stub receive Heart Foundation fellowships (numbers 104751/105793). Dr Perkins is supported by the National Institute for Health Research Applied Research Collaboration West Midlands. Drs Bernard, Bray, Smith, Stephenson, Finn, Grantham, Hein, Stub, Perkins, and Cameron received funding from the NHMRC.	[Anonymous], ARC GUIDELINES; Ball J, 2020, RESUSCITATION, V156, P157, DOI 10.1016/j.resuscitation.2020.09.017; Bernard SA, 2016, CIRCULATION, V134, P797, DOI 10.1161/CIRCULATIONAHA.116.021989; Bray JE, 2019, RESUSCITATION, V139, P208, DOI 10.1016/j.resuscitation.2019.04.023; Bray JE, 2018, RESUSCITATION, V128, P211, DOI 10.1016/j.resuscitation.2018.04.019; Damiani E, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0711-x; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Holmberg MJ, 2020, RESUSCITATION, V152, P107, DOI 10.1016/j.resuscitation.2020.04.031; Ihle JF, 2013, CRIT CARE RESUSC, V15, P186; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Jakkula P, 2018, INTENS CARE MED, V44, P2112, DOI 10.1007/s00134-018-5453-9; JENNETT B, 1975, LANCET, V1, P480; Kempster K, 2021, RESUSCITATION, V166, P21, DOI 10.1016/j.resuscitation.2021.07.003; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Kleinman ME, 2018, CIRCULATION, V137, pE802, DOI 10.1161/CIR.0000000000000561; Kuisma M, 2006, RESUSCITATION, V69, P199, DOI 10.1016/j.resuscitation.2005.08.010; Nolan JP, 2015, INTENS CARE MED, V41, P2039, DOI 10.1007/s00134-015-4051-3; Orkin AM, 2021, JAMA-J AM MED ASSOC, V326, P257, DOI 10.1001/jama.2021.9941; Perkins GD, 2015, CIRCULATION, V132, P1286, DOI 10.1161/CIR.0000000000000144; Pilcher J, 2012, RESUSCITATION, V83, P417, DOI 10.1016/j.resuscitation.2011.12.021; Sandroni C, 2021, INTENS CARE MED, V47, P1393, DOI 10.1007/s00134-021-06548-2; Stub D, 2015, CIRCULATION, V131, P2143, DOI 10.1161/CIRCULATIONAHA.114.014494; Teran F, 2018, RESUSCITATION, V128, pA5, DOI 10.1016/j.resuscitation.2018.05.016; Thomas M, 2019, BMC EMERG MED, V19, DOI 10.1186/s12873-018-0214-1; Vaahersalo J, 2014, CRIT CARE MED, V42, P1463, DOI 10.1097/CCM.0000000000000228; Wang CH, 2014, RESUSCITATION, V85, P1142, DOI 10.1016/j.resuscitation.2014.05.021; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Welsford M, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1825; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, STROKE, V33, P2243, DOI 10.1161/01.STR.0000027437.22450.BD; Young P, 2020, INTENS CARE MED, V46, P2411, DOI 10.1007/s00134-020-06196-y; Young P, 2014, RESUSCITATION, V85, P1686, DOI 10.1016/j.resuscitation.2014.09.011; Young P, 2013, RESUSCITATION, V84, P391, DOI 10.1016/j.resuscitation.2012.08.330; Young PJ, 2020, RESUSCITATION, V157, P15, DOI 10.1016/j.resuscitation.2020.09.036	34	1	1	12	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.17701	http://dx.doi.org/10.1001/jama.2022.17701		OCT 2022	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5U6IM	36286192				2023-01-03	WOS:000876648400005
J	Semler, MW; Casey, JD; Lloyd, BD; Hastings, PG; Hays, MA; Stollings, JL; Buell, KG; Brems, JH; Qian, ET; Seitz, KP; Wang, L; Lindsell, CJ; Freundlich, RE; Wanderer, JP; Han, JH; Bernard, GR; Self, WH; Rice, TW				Semler, Matthew W.; Casey, Jonathan D.; Lloyd, Bradley D.; Hastings, Pamela G.; Hays, Margaret A.; Stollings, Joanna L.; Buell, Kevin G.; Brems, John H.; Qian, Edward T.; Seitz, Kevin P.; Wang, Li; Lindsell, Christopher J.; Freundlich, Robert E.; Wanderer, Jonathan P.; Han, Jin H.; Bernard, Gordon R.; Self, Wesley H.; Rice, Todd W.		PILOT Investigators; Pragmatic Critical Care Res Grp	Oxygen-Saturation Targets for Critically Ill Adults Receiving Mechanical Ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Early Access							RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; CLINICAL-TRIALS; CRITICAL-CARE; HYPEROXIA; REOXYGENATION; STRATEGIES; MANAGEMENT; MORTALITY; TOXICITY	BACKGROUND Invasive mechanical ventilation in critically ill adults involves adjusting the fraction of inspired oxygen to maintain arterial oxygen saturation. The oxygen-saturation target that will optimize clinical outcomes in this patient population remains unknown. METHODS In a pragmatic, cluster-randomized, cluster-crossover trial conducted in the emergency department and medical intensive care unit at an academic center, we assigned adults who were receiving mechanical ventilation to a lower target for oxygen saturation as measured by pulse oximetry (Spo(2)) (90%; goal range, 88 to 92%), an intermediate target (94%; goal range, 92 to 96%), or a higher target (98%; goal range, 96 to 100%). The primary outcome was the number of days alive and free of mechanical ventilation (ventilator-free days) through day 28. The secondary outcome was death by day 28, with data censored at hospital discharge. RESULTS A total of 2541 patients were included in the primary analysis. The median number of ventilator-free days was 20 (interquartile range, 0 to 25) in the lower-target group, 21 (interquartile range, 0 to 25) in the intermediate-target group, and 21 (interquartile range, 0 to 26) in the higher-target group (P=0.81). In-hospital death by day 28 occurred in 281 of the 808 patients (34.8%) in the lower-target group, 292 of the 859 patients (34.0%) in the intermediate-target group, and 290 of the 874 patients (33.2%) in the higher-target group. The incidences of cardiac arrest, arrhythmia, myocardial infarction, stroke, and pneumothorax were similar in the three groups. CONCLUSIONS Among critically ill adults receiving invasive mechanical ventilation, the number of ventilator-free days did not differ among groups in which a lower, intermediate, or higher Spo(2) target was used.	[Semler, Matthew W.; Casey, Jonathan D.; Hays, Margaret A.; Qian, Edward T.; Seitz, Kevin P.; Bernard, Gordon R.; Rice, Todd W.] Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Med Ctr, Nashville, TN 37232 USA; [Lloyd, Bradley D.; Hastings, Pamela G.] Vanderbilt Univ, Div Resp Care, Med Ctr, Nashville, TN 37232 USA; [Stollings, Joanna L.] Vanderbilt Univ, Dept Pharmaceut Serv, Med Ctr, Nashville, TN 37232 USA; [Buell, Kevin G.; Brems, John H.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Wang, Li; Lindsell, Christopher J.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Freundlich, Robert E.; Wanderer, Jonathan P.] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN 37232 USA; [Freundlich, Robert E.; Wanderer, Jonathan P.] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37232 USA; [Han, Jin H.; Self, Wesley H.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN 37232 USA; [Bernard, Gordon R.; Self, Wesley H.; Rice, Todd W.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Clin & Translat Res, Nashville, TN 37232 USA; [Han, Jin H.] Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Semler, MW (corresponding author), Vanderbilt Univ, Med Ctr, C-1216 Med Ctr North,116121st Ave South, Nashville, TN 37232 USA.	matthew.w.semler@vumc.org			National Heart, Lung, and Blood Institute [K23HL143053]; National Center for Advancing Translational Sciences [UL1TR000445]; National Institutes of Health [K23HL153584, T32HL087738, UL1TR002243, 1KL2TR002245, 1K23HL148640, R21AG06312]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by a grant from the National Heart, Lung, and Blood Institute (K23HL143053, to Dr. Semler). The Research Electronic Data Capture (REDCap) tool used for data collection was developed and is maintained with a grant (UL1TR000445, to the Vanderbilt Institute for Clinical and Translational Research) from the National Center for Advancing Translational Sciences. The following authors' work was also supported in part by grants from the National Institutes of Health: Dr. Casey (K23HL153584); Dr. Qian (T32HL087738); Drs. Lindsell, Bernard, and Rice (UL1TR002243, to the Vanderbilt University Medical Center); Dr. Freundlich (1KL2TR002245 and 1K23HL148640); and Dr. Han (R21AG06312).	Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1; Aggarwal Neil R, 2014, Ann Am Thorac Soc, V11, P1449, DOI 10.1513/AnnalsATS.201407-297PS; Allen BS, 2002, J THORAC CARDIOV SUR, V124, P16, DOI 10.1067/mtc.2002.124673; Allen BS, 2001, PERFUSION-UK, V16, P19, DOI 10.1177/026765910101600i104; Asfar P, 2017, LANCET RESP MED, V5, P180, DOI 10.1016/S2213-2600(17)30046-2; Barrot L, 2020, NEW ENGL J MED, V382, P999, DOI 10.1056/NEJMoa1916431; Beasley R, 2015, RESPIROLOGY, V20, P1182, DOI 10.1111/resp.12620; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Buell KG, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01632-4; DAVIS WB, 1983, NEW ENGL J MED, V309, P878, DOI 10.1056/NEJM198310133091502; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Driver BE, 2018, JAMA-J AM MED ASSOC, V319, P2179, DOI 10.1001/jama.2018.6496; Eastwood G, 2012, INTENS CARE MED, V38, P91, DOI 10.1007/s00134-011-2419-6; Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; Fridovich I, 1998, J EXP BIOL, V201, P1203; Gelissen H, 2021, JAMA-J AM MED ASSOC, V326, P940, DOI 10.1001/jama.2021.13011; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; GRIFFITH DE, 1992, CHEST, V101, P392, DOI 10.1378/chest.101.2.392; Harhay MO, 2014, AM J RESP CRIT CARE, V189, P1469, DOI 10.1164/rccm.201401-0056CP; HEFFNER JE, 1989, AM REV RESPIR DIS, V140, P531, DOI 10.1164/ajrccm/140.2.531; Helmerhorst HJF, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1067-6; Helmerhorst HJF, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0023-y; Huerta LE, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1060-0; Kempker Jordan A, 2020, Crit Care Explor, V2, pe0128, DOI 10.1097/CCE.0000000000000128; Mackle D, 2020, NEW ENGL J MED, V382, P989, DOI 10.1056/NEJMoa1903297; McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; O'Driscoll BR, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2016-209729; Panwar R, 2013, ANAESTH INTENS CARE, V41, P505, DOI 10.1177/0310057X1304100412; Parienti JJ, 2007, CONTEMP CLIN TRIALS, V28, P316, DOI 10.1016/j.cct.2006.10.004; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435; Schjorring OL, 2021, NEW ENGL J MED, V384, P1301, DOI 10.1056/NEJMoa2032510; Schmidt H, 2022, NEW ENGL J MED, DOI 10.1056/NEJMoa2208686; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Self WH, 2020, CHEST, V157, P487, DOI 10.1016/j.chest.2019.12.010; Semler MW, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-052013; Semler MW, 2018, NEW ENGL J MED, V378, P829, DOI 10.1056/NEJMoa1711584; Shehabi Y, 2019, NEW ENGL J MED, V380, P2506, DOI 10.1056/NEJMoa1904710; Siemieniuk RAC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4169; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sjoding MW, 2020, NEW ENGL J MED, V383, P2477, DOI 10.1056/NEJMc2029240; Suzuki S, 2013, J CRIT CARE, V28, P647, DOI 10.1016/j.jcrc.2013.03.010; Turner RM, 2007, STAT MED, V26, P274, DOI 10.1002/sim.2537; van den Boom W, 2020, CHEST, V157, P566, DOI 10.1016/j.chest.2019.09.015; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Waxman AB, 1998, J CLIN INVEST, V101, P1970, DOI 10.1172/JCI1337; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Wunsch H, 2011, AM J RESP CRIT CARE, V183, P1666, DOI 10.1164/rccm.201012-1961OC; Wunsch H, 2010, CRIT CARE MED, V38, P1947, DOI 10.1097/CCM.0b013e3181ef4460; Young P, 2020, INTENS CARE MED, V46, P2411, DOI 10.1007/s00134-020-06196-y; Young P, 2020, INTENS CARE MED, V46, P17, DOI 10.1007/s00134-019-05857-x	55	0	0	10	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.												10.1056/NEJMoa2208415	http://dx.doi.org/10.1056/NEJMoa2208415		OCT 2022	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5T7GM	36278971				2023-01-03	WOS:000876030000001
J	Napaporn, J; Buakaew, P; Suksakornthanawat, P; Sripa, S; Jinatongthai, P; Supapaan, T				Napaporn, Jintana; Buakaew, Pitchaporn; Suksakornthanawat, Patarawat; Sripa, Saksit; Jinatongthai, Peerawat; Supapaan, Teeraporn			Analogous comparison of registered brand name drugs of tablets and capsules commercially available in Thailand: A retrospective study	PLOS ONE			English	Article							LOOK-ALIKE	Drug name confusion or similar product packaging and labeling, also known as "look-alike, sound-alike" (LASA) medication error, is one of the most problematic causes of prescribing and dispensing errors. Therefore, this study aimed to compare the similarity of registered brand name drugs of tablets and capsules that are commercially available in Thailand to estimate the magnitude of LASA medication errors. Analogous comparisons of brand names using similarity in orthography (written forms with identical letters) were analyzed retrospectively. Tablets and capsules commercially available in Thailand and registered with the Bureau of Drug Administration, Food and Drug Administration (FDA) in 2012 as "dangerous drugs" and "specially controlled drugs" for humans and animals were included in this study. Descriptive statistics, including frequencies and percentages, were used in this study. The analogous comparison of brand name orthography was scrutinized, and the results revealed 1,668 brand names, which were categorized into three genres as follows: 1) Single brand names from a single manufacturer having the same active pharmaceutical ingredient (API) with numerous registration numbers (1,049 names, 62.89% of the total similarity results) 2) Single brand names from different manufacturers having the same API and possessing several registration numbers (615 names, 36.87% of the total similarity results) 3) Single brand names from different manufacturers with diverse APIs (four brand names, 0.24% of the total similarity results). Analogous results revealed that numerous identical brand names could be derived from the same manufacturers, APIs, dosage strengths, or otherwise. The results of this study recommend improvement on product registration to better ensure patient safety in the future.	[Napaporn, Jintana; Sripa, Saksit; Jinatongthai, Peerawat; Supapaan, Teeraporn] Ubon Ratchathani Univ, Fac Pharmaceut Sci, Ubon Ratchathani, Thailand; [Buakaew, Pitchaporn] Sisaket Hosp, Mueng Dist, Srisaket, Thailand; [Suksakornthanawat, Patarawat] Namphong Hosp, Namphong Dist, Khonkaen, Thailand	Ubon Ratchathani University	Supapaan, T (corresponding author), Ubon Ratchathani Univ, Fac Pharmaceut Sci, Ubon Ratchathani, Thailand.	teeraporn.s@ubu.ac.th		Supapaan, Teeraporn/0000-0002-6887-8181; Jinatongthai, Peerawat/0000-0002-7954-2480	Digital Economy and Society Development Funds; Coordinating Center for Thai Government Science and Technology Scholarship Students (CSTS); National Science and Technology Development Agency (NSTDA); Bureau of Drug Administration, Food and Drug Administration of Thailand	Digital Economy and Society Development Funds; Coordinating Center for Thai Government Science and Technology Scholarship Students (CSTS); National Science and Technology Development Agency (NSTDA); Bureau of Drug Administration, Food and Drug Administration of Thailand	Financial support was provided by the Digital Economy and Society Development Funds awarded to TS. Partial support was provided by the Coordinating Center for Thai Government Science and Technology Scholarship Students (CSTS), National Science and Technology Development Agency (NSTDA) awarded to TS. Material support was provided by the Bureau of Drug Administration, Food and Drug Administration of Thailand awarded to JN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adcock A, DISTRIBUTION MARKETI; Beyea Suzanne C, 2007, AORN J, V86, P861, DOI 10.1016/j.aorn.2007.10.008; Brennan H, 2015, MICH TELECOMM TECH L, V22; Bryan R, 2021, BRIT J CLIN PHARMACO, V87, P336, DOI 10.1111/bcp.14644; Bryan R, 2021, BRIT J CLIN PHARMACO, V87, P386, DOI 10.1111/bcp.14285; Bryan R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145431; Chumchit C, 2013, DISSERTATION; CIOMS Working Group V, 2001, CURRENT CHALLENGES P; Clark KR, 2018, RADIOL TECHNOL, V89, p482CT; Faasse K, 2016, HEALTH PSYCHOL, V35, P187, DOI 10.1037/hea0000282; Gopakumar KM., 2007, INT NONPROPRIETARY N; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Jaam M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253588; Jongprasithporn Manutchanok, 2018, MATEC Web of Conferences, V192, DOI 10.1051/matecconf/201819201051; Kessomboon N., 2018, ISAN J PHARM SCI, V14, P56; Limpanyalert P, 2P SAFETY PATIENT PE; McCoy L, 2005, JT COMM J QUAL PATIE, V31, P47, DOI 10.1016/S1553-7250(05)31007-5; Ministry of Health and Welfare-Laws & Regulations Database of The Republic of China, PHARM AFF ACT 2018; PricewaterhouseCoopers' Health Research Institute, UNL POW PHARM AD APP; Santell JP, 2003, J CLIN PHARMACOL, V43, P760, DOI 10.1177/0091270003254831; Scribner L, PEER MENTORING EFFEC; Sinha A., 2021, STATPEARLS; Social Pharmacy Research Unit (SPR) Faculty of Pharmaceutical Sciences CU, PER REV 2009; The World Health Organization, GUID INN 1997; Tseng HY, 2018, EUR J HOSP PHARM, V25, P96, DOI 10.1136/ejhpharm-2016-001019; Usavakidviree V., 2012, DEV REEVALUATION MOD; WHO Collaborating Centre for Patient Safety Solutions, 2007, PAT SAF SOL, V1, P1; WHO Collaborating Centre for Patient Safety Solutions, PAT SAF SOL PREAMB 2; Wongboonnak P., 2018, HCU J HLTH SCI, V22, P205; Wongboonnak Piyawan, 2017, THAI J PHARM PRACTIC, V9, P251; World Health Organization, 2015, REG STRAT PAT SAF WH	31	0	0	5	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2022	17	10							e0276321	10.1371/journal.pone.0276321	http://dx.doi.org/10.1371/journal.pone.0276321			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6J1XA	36260612	Green Published, gold			2023-01-03	WOS:000886620200054
J	Newson, L; Parody, FH				Newson, Lisa; Parody, Francesca Helen			Investigating the experiences of low-carbohydrate diets for people living with Type 2 Diabetes: A thematic analysis	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; QUALITATIVE RESEARCH; MANAGEMENT; RECOMMENDATIONS; ADULTS; FATS	Low-Carbohydrate Diets (LCDs) are becoming increasingly popular to manage Type 2 diabetes mellitus (T2DM). However, there is a need to identify people with T2DM's understanding of LCDs, their reasons for engaging in such a diet, how they sustain it and any challenges they face. This study aimed to assess the experience of adhering to a LCD within a sample of individuals with T2DM. Ten participants with T2DM were recruited using a self-selecting sampling method from an online diabetes community that promotes LCDs. Participants completed one-to-one digitally recorded semi-structured interviews, which were later transcribed verbatim and data subjected to Thematic Analysis. Five core themes and twelve subthemes were developed during the analysis: (1) Lack of professional guidance; (2) Fear of complications & long-term medication use; (3) Dietary control as motivation; (4) Positive health outcomes; and (5) Social support. The findings are discussed with reference to a psychological model of behaviour, COM-B. Participants reported gaining knowledge and skills to increase their Capability to engage in LCDs, Motivation to manage diabetes outcomes influenced adherence. However, challenges were reported with the Opportunity to engage in behaviour, mainly influenced by social support. Health professionals and significant others may benefit from resources to help build knowledge and understanding and assist with maintaining a LCD long-term.	[Newson, Lisa; Parody, Francesca Helen] Liverpool John Moores Univ, Fac Hlth, Sch Psychol, Liverpool, Merseyside, England; [Parody, Francesca Helen] Wellcome Trust Res Labs, London, England	Liverpool John Moores University; University of Liverpool	Newson, L (corresponding author), Liverpool John Moores Univ, Fac Hlth, Sch Psychol, Liverpool, Merseyside, England.	l.m.newson@ljmu.ac.uk		Newson, Lisa/0000-0002-5874-8762				Ajzen I, 1985, ACTION CONTROL, P11, DOI [10.1007/978-3-642-69746-3_2, DOI 10.1007/978-3-642-69746-3_2]; Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS48, DOI 10.2337/dc20-S005; American Diabetes Association, 2019, Clin Diabetes, V37, P11, DOI 10.2337/cd18-0105; Arnason TG, 2017, WORLD J DIABETES, V8, P154, DOI 10.4239/wjd.v8.i4.154; Australia Diabetes., 2018, DIABETES AUSTR; Booth AO, 2013, PRIM HEALTH CARE RES, V14, P293, DOI 10.1017/S1463423612000412; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Braun V, 2019, QUAL RES SPORT EXERC, V11, P589, DOI 10.1080/2159676X.2019.1628806; Brouns F, 2018, EUR J NUTR, V57, P1301, DOI 10.1007/s00394-018-1636-y; Brown A., 2017, FEELING EUPHORIC LOW; Centers for Disease Control and Prevention, 2011, NAT DIAB FACT SHEET; Choak C., 2012, RES RES METHODS YOUT, P90; Cucuzzella MT., 2017, J INSULIN RESISTANCE, V1, P1, DOI [10.4102/jir.v2i1.30, DOI 10.4102/JIR.V2I1.30]; Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI 10.2337/dci18-0033; Dehghan M, 2017, LANCET, V390, P2050, DOI [10.1016/s0140-6736(17)32252-3, 10.1016/S0140-6736(17)32252-3]; diabetes.co.uk , 2022, EMPOWER YOUR PATIENT; Diabetes UK., 2014, COST DIABETES REPORT; Diabetes UK., 2021, POSITION STATEMENT L; Diabetes UK., 2021, DIABETES UK; Ebbeling CB, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4583; Eenfeldt A., 2020, LOW CARB IS LOW CARB; Evert AB, 2014, DIABETES CARE, V37, pS120, DOI 10.2337/dc14-S120; Fade SA, 2003, J HUM NUTR DIET, V16, P139, DOI 10.1046/j.1365-277X.2003.00433.x; Feinman RD, 2015, NUTRITION, V31, P1, DOI 10.1016/j.nut.2014.06.011; Forouhi NG, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2234; Forouhi NG, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2139; Hallberg SJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040766; Heale Roberta, 2013, Evid Based Nurs, V16, P98, DOI 10.1136/eb-2013-101494; Holman N, 2015, DIABETIC MED, V32, P1119, DOI 10.1111/dme.12791; Huntriss R, 2018, EUR J CLIN NUTR, V72, DOI 10.1038/s41430-017-0019-4; Kelly T, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072557; Kirkpatrick CF, 2019, J CLIN LIPIDOL, V13, P689, DOI 10.1016/j.jacl.2019.08.003; Lean MEJ, 2018, LANCET, V391, P541, DOI 10.1016/S0140-6736(17)33102-1; Masharani U, 2015, EUR J CLIN NUTR, V69, P944, DOI 10.1038/ejcn.2015.39; McArdle PD, 2017, J HUM NUTR DIET, V30, P385, DOI 10.1111/jhn.12436; Michie S., 2014, BEHAVIOUR CHANGE WHE; Morris E, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026460; Murdoch C, 2019, BRIT J GEN PRACT, V69, P360, DOI 10.3399/bjgp19X704525; National Health Service, 2022, EAT WELL NHS; National Institute for Health and Care Execllence (NICE), 2015, TYPE 2 DIAB AD MAN N; Patterson CC, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107842; Sacks FM, 2017, CIRCULATION, V136, pE1, DOI 10.1161/CIR.0000000000000510; Sainsbury E, 2018, DIABETES RES CLIN PR, V139, P239, DOI 10.1016/j.diabres.2018.02.026; Sami W, 2017, INT J HEALTH SCI-IJH, V11, DOI 10.1002/dmrr.2515; Savoca M, 2001, J NUTR EDUC, V33, P224, DOI 10.1016/S1499-4046(06)60035-3; Shao YC, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/2804178; Snorgaard O, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc-2016-000354; Tay J, 2015, AM J CLIN NUTR, V102, P780, DOI 10.3945/ajcn.115.112581; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Vijan S, 2005, DIABETIC MED, V22, P32, DOI 10.1111/j.1464-5491.2004.01342.x; Wang LL, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060661; Webster CC, 2019, DIABETES METAB SYNDR, V12, P2567, DOI 10.2147/DMSO.S227090	52	0	0	9	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2022	17	8							e0273422	10.1371/journal.pone.0273422	http://dx.doi.org/10.1371/journal.pone.0273422			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5V2VT	35994442	gold, Green Published, Green Accepted			2023-01-03	WOS:000877093400052
J	Ebrie, AM; Woldeyohanis, M; Abafita, BJ; Ali, SA; Zemedkun, A; Yimer, Y; Ashebir, Z; Mohammed, S				Ebrie, Ayub Mohammed; Woldeyohanis, Misrak; Abafita, Bedru Jemal; Ali, Siraj Ahmed; Zemedkun, Abebayehu; Yimer, Yusuf; Ashebir, Zewetir; Mohammed, Salih			Hemodynamic and analgesic effect of intrathecal fentanyl with bupivacaine in patients undergoing elective cesarean section; a prospective cohort study	PLOS ONE			English	Article							LOW-DOSE BUPIVACAINE; SPINAL-ANESTHESIA; DELIVERY; EFFICACY; BLOCK	BackgroundSpinal anesthesia with bupivacaine has side effects such as hypotension, respiratory depression, vomiting, and shivering. The side effects are dose-dependent, therefore different approaches have been attempted to avoid spinal-induced complications including lowering the dose of local anesthetic and mixing it with additives like Neuraxial opioids. ObjectiveTo compare the Hemodynamic and analgesic effects of intrathecal fentanyl as an adjuvant with low and conventional doses of bupivacaine in patients undergoing elective cesarean section under spinal anesthesia. MethodologyAn institutional-based prospective cohort study was conducted on 90 patients. Data was collected with chart review, intraoperative observation, and postoperatively patient interview. Data was entered into EPI INFO and transport to SPSS version 23 for analysis of variables using one-way ANOVA, Kruskal Wallis H rank test, and chi-square. ResultHypotension but not bradycardia, was significantly frequent in a conventional dose of bupivacaine alone (CB) group and a conventional dose of bupivacaine with fentanyl (CBF) groups than that of the lower dose of bupivacaine with fentanyl (LBF) groups. Duration of analgesia was significantly longer in LBF (248 +/- 35.6 minutes) and in CBF groups (260.3 +/- 40.3 minutes) than in CB group (167.10 +/- 31.45 minutes). Time for the first analgesic request was significantly later in LBF (304 +/- 47.8 minutes) and CBF (294.6 +/- 99.5 minutes) groups than that in CB group (177 +/- 25.88 minutes). ConclusionThe Lower dose of bupivacaine is associated with less risk of hypotension and faster recovery. Adding fentanyl with the lower dose of bupivacaine in spinal anesthesia for cesarean section could provide comparable anesthesia with the lower risk of hypotension and longer postoperative analgesia.	[Ebrie, Ayub Mohammed; Abafita, Bedru Jemal; Ali, Siraj Ahmed; Zemedkun, Abebayehu] Dilla Univ Coll Med & Hlth Sci, Dept Anesthesiolo, Dilla, Ethiopia; [Woldeyohanis, Misrak; Ashebir, Zewetir] Addis Ababa Univ Coll Hlth Sci, Addis Ababa, Ethiopia; [Yimer, Yusuf; Mohammed, Salih] Wollo Univ, Coll Hlth Sci & Med, Dept Anesthesiol, Dessie, Ethiopia	Dilla University	Ali, SA (corresponding author), Dilla Univ Coll Med & Hlth Sci, Dept Anesthesiolo, Dilla, Ethiopia.	srjmyn@gmail.com	Jemal, Bedru/AAX-4086-2020; ABAFITA, BEDRU JEMAL/GRR-2273-2022	Jemal, Bedru/0000-0002-4194-4724; ABAFITA, BEDRU JEMAL/0000-0002-4194-4724; Ashebir, Zewetir/0000-0001-6615-4078				Abate SM, 2019, SAUDI J ANAESTH, V13, P340, DOI 10.4103/sja.SJA_17_19; Abebe FE, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-015-0114-8; Ali Hassan Mohamed, 2019, Anesth Essays Res, V13, P663, DOI 10.4103/aer.AER_131_19; Arzola C, 2011, BRIT J ANAESTH, V107, P308, DOI 10.1093/bja/aer200; Begum A., 2010, PAK J MED HLTH SCI, V4, P3; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Biswas B, 2002, INDIAN J ANAESTH, V46, P469; Bogra Jaishri, 2005, BMC Anesthesiol, V5, P5; Central Statistical Agency-CSA/Ethiopia ICF, 2017, ETH DEM HLTH SURV 20; Chavan G., 2014, INT J HEALTHCARE BIO, V2, P67; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Cowan CM, 2002, BRIT J ANAESTH, V89, P452; Farzi Farnoush, 2017, Anesth Pain Med, V7, pe12738, DOI 10.5812/aapm.12738; Gauchan S, 2014, Nepal Med Coll J, V16, P5; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; Khezri MB, 2014, PAIN RES TREAT, V2014, DOI 10.1155/2014/513628; Khezri Marzieh-Beigom, 2012, Acta Anaesthesiol Taiwan, V50, P19, DOI 10.1016/j.aat.2012.03.001; Lee YY, 2005, EUR J ANAESTH, V22, P899, DOI 10.1017/S0265021505001523; Mebazaa Mhamed S., 2010, Middle East Journal of Anesthesiology, V20, P673; Mercier FJ, 2012, CURR OPIN ANESTHESIO, V25, P286, DOI 10.1097/ACO.0b013e3283530dab; Ousley R, 2012, ANAESTHESIA, V67, P1356, DOI 10.1111/anae.12034; Palmer SK, 2000, REGIONAL ANALGESIA IN OBSTETRICS, P3; Seyedhejazi M, 2007, PAK J MED SCI, V23, P747; Shashikala TK, 2014, J EVOL MED DENT SCI-, V3, P8980, DOI 10.14260/jemds/2014/3156; Stewart A, 2010, ANESTH ANALG, V111, P1230, DOI 10.1213/ANE.0b013e3181f2eae1; Venkata HG, 2015, SAUDI J ANAESTH, V9, P122, DOI 10.4103/1658-354X.152827; Yesuf KA., 2017, J ANESTH CRIT CARE O, V7, P00278	27	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	7							e0268318	10.1371/journal.pone.0268318	http://dx.doi.org/10.1371/journal.pone.0268318			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M2ZD	35797265	Green Published, gold			2023-01-03	WOS:000835328600015
J	Lane, M; Kirkland, AR; Stroumsa, D				Lane, Megan; Kirkland, Anna R.; Stroumsa, Daphna			Protecting Care for All - Gender-Affirming Care in Section 1557 and Beyond	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Protecting Care for All As states move to target trans people, proposed regulations from the Biden administration would set a national standard for access to care, regardless of gender identity.	[Lane, Megan] Univ Michigan, Dept Plast Surg, Ann Arbor, MI 48109 USA; [Lane, Megan; Kirkland, Anna R.; Stroumsa, Daphna] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA; [Kirkland, Anna R.] Univ Michigan, Dept Womens & Gender Studies, Ann Arbor, MI 48109 USA; [Stroumsa, Daphna] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Lane, M (corresponding author), Univ Michigan, Dept Plast Surg, Ann Arbor, MI 48109 USA.; Lane, M (corresponding author), Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.			Kirkland, Anna/0000-0001-5711-4074; Stroumsa, Daphna/0000-0003-1205-3217				[Anonymous], 2022, PRESS REL AM MED ASS; Guiahi M, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.17008; Keith K., 2020, HLTH AFFAIRS 0818, DOI [10.1377/forefront.20200818.468025/full/, DOI 10.1377/FOREFRONT.20200818.468025/FULL]; Movement Advancement Project, 2022, EQ MAPS HEALTHC LAWS; Sarkissian A., 2022, POLITICO 0817	5	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	2022	387	21					1916	1918		10.1056/NEJMp2212586	http://dx.doi.org/10.1056/NEJMp2212586		NOV 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6M4JU	36409476				2023-01-03	WOS:000886854100001
J	McGinley, MJ; Lee, ST				McGinley, Matthew J.; Lee, Steven T.			Why study mechanisms of brain stimulation therapies? To modulate the right neurons, in the right way, at the right time	NEURON			English	Article							VAGUS NERVE-STIMULATION	Clinical applications of vagus nerve stimulation (VNS) are burgeoning, but mechanistic work lags behind. In this issue of Neuron, Bowles and colleagues show that VNS timed with positive reinforcement improves motor learning and cortical function by a cholinergic mechanism.	[McGinley, Matthew J.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [McGinley, Matthew J.; Lee, Steven T.] Texas Childrens Hosp, Duncan Neurol Res Inst, Houston, TX 77030 USA; [McGinley, Matthew J.] Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA	Baylor College of Medicine; Baylor College of Medicine; Rice University	McGinley, MJ (corresponding author), Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA.; McGinley, MJ (corresponding author), Texas Childrens Hosp, Duncan Neurol Res Inst, Houston, TX 77030 USA.; McGinley, MJ (corresponding author), Rice Univ, Dept Elect & Comp Engn, Houston, TX 77005 USA.	matthew.mcginley@bcm.edu						Bowles S., 2022, NEURON, V110, DOI [10.1016/j.neuron.2022.06.017, DOI 10.1016/J.NEURON.2022.06.017]; Dawson J, 2021, LANCET, V397, P1545, DOI 10.1016/S0140-6736(21)00475-X; George MS, 2010, NEUROPSYCHOPHARMACOL, V35, P301, DOI 10.1038/npp.2009.87; Hulsey DR, 2016, BRAIN STIMUL, V9, P174, DOI 10.1016/j.brs.2015.12.007; Kaniusas E, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00772; McGinley MJ, 2015, NEURON, V87, P179, DOI 10.1016/j.neuron.2015.05.038; Mridha Z, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21730-2; Narayanan JT, 2002, EPILEPSIA, V43, P1509, DOI 10.1046/j.1528-1157.2002.16102.x; Schultz W, 2000, ANNU REV NEUROSCI, V23, P473, DOI 10.1146/annurev.neuro.23.1.473; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Wang Y, 2021, NEUROSCI BIOBEHAV R, V127, P37, DOI 10.1016/j.neubiorev.2021.04.018	11	0	0	4	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	SEP 7	2022	110	17					2709	2712		10.1016/j.neuron.2022.08.004	http://dx.doi.org/10.1016/j.neuron.2022.08.004			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	4X7BA	36076336				2023-01-03	WOS:000860992000003
J	Muttau, N; Mwendafilumba, M; Lewis, B; Kasprzyk, K; Travers, C; Menon, JA; Mutesu-Kapembwa, K; Mangangu, A; Kapesa, H; Manasyan, A				Muttau, Nobutu; Mwendafilumba, Martha; Lewis, Branishka; Kasprzyk, Keilya; Travers, Colm; Menon, J. Anitha; Mutesu-Kapembwa, Kunda; Mangangu, Aaron; Kapesa, Herbert; Manasyan, Albert			Strengthening Kangaroo Mother Care at a tertiary level hospital in Zambia: A prospective descriptive study	PLOS ONE			English	Article							NEONATAL DEATHS; NEWBORN; IMPLEMENTATION; INTERVENTIONS; HEALTH; TRENDS	Background Globally, complications due to preterm birth are the leading contributor to neonatal mortality, resulting in an estimated one million deaths annually. Kangaroo Mother Care (KMC) has been endorsed by the World Health Organisation as a low cost, safe, and effective intervention in reducing morbidity and mortality among preterm infants. The objective of this study was to describe the implementation of a KMC model among preterm infants and its impact on neonatal outcomes at a tertiary level hospital in Lusaka, Zambia. Methods We conducted a prospective descriptive study using data collected from the KMC room at the University Teaching Hospital between January 2016 and September 2017. Mothers and government nurses were trained in KMC. We monitored skin-to-skin and breastfeeding practices, weight at admission, discharge, and length of admission. Results We enrolled 573 neonates into the study. Thirteen extremely low weight infants admitted to the KMC room had graduated to Group A (1,000g-1,499g) at discharge, with a median weight gain of 500g. Of the 419 very low weight neonates at admission, 290 remained in Group A while 129 improved to Group B (1,500g-2,499g), with a median weight gain of 280g. Among the 89 low weight neonates, 1 regressed to Group A, 77 remained in Group B, and 11 improved to Group C (>= 2,500g), individually gaining a median of 100g. Of the seven normal weight neonates, 6 remained in Group C individually gaining a median of 100g, and 1 regressed to Group B. Among all infants enrolled, two (0.35%) died in the KMC room. Conclusions Based on the RE-AIM metrics, our results show that KMC is a feasible intervention that can improve neonatal outcomes among preterm infants in Zambia. The study findings show a promising, practical approach to scaling up KMC in Zambia.	[Muttau, Nobutu; Mwendafilumba, Martha; Lewis, Branishka; Kasprzyk, Keilya; Menon, J. Anitha; Mangangu, Aaron; Kapesa, Herbert; Manasyan, Albert] Ctr Infect Dis Res Zambia, Dept Reprod Maternal Newborn & Child Hlth, Lusaka, Zambia; [Kasprzyk, Keilya] Washington Univ St Louis, Brown Sch, St Louis, MO USA; [Travers, Colm; Manasyan, Albert] Univ Alabama Birmingham, Div Neonatol, Dept Pediat, Birmingham, AL 35294 USA; [Menon, J. Anitha] Univ Zambia, Dept Psychol, Lusaka, Zambia; [Mutesu-Kapembwa, Kunda] Univ Teaching Hosp, Women & Newborn Hosp, Dept Neonatol, Lusaka, Zambia	Washington University (WUSTL); University of Alabama System; University of Alabama Birmingham; University of Zambia; University of Zambia	Manasyan, A (corresponding author), Ctr Infect Dis Res Zambia, Dept Reprod Maternal Newborn & Child Hlth, Lusaka, Zambia.; Manasyan, A (corresponding author), Univ Alabama Birmingham, Div Neonatol, Dept Pediat, Birmingham, AL 35294 USA.	albertmanasyan@uabmc.edu		Muttau, Nobutu/0000-0003-2414-3391	ELMA Foundation [14-F0023]	ELMA Foundation	Research reported in this publication was supported by a grant from The ELMA Foundation (14-F0023).	Amelia Tiara, 2021, Glob Pediatr Health, V8, p2333794X211012390, DOI 10.1177/2333794X211012390; [Anonymous], 2022, IMPACT R AIPHRAPH; Bergh AM, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-293; Bilal SM, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-020-03409-6; Blencowe H, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-S1-S2; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Chan GJ, 2016, J GLOB HEALTH, V6, DOI 10.7189/jogh.06.010701; Conde-Agudelo A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002771.pub3; Cowden C, 2020, BMC PEDIATR, V20, DOI 10.1186/s12887-020-02323-2; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Dawar R, 2019, J TROP PEDIATRICS, V65, P561, DOI 10.1093/tropej/fmz007; Ditekemena J, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-32; Eisman AB, 2020, IMPLEMENT SCI, V15, DOI 10.1186/s13012-020-01069-w; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Health Mo, 2018, KANG MOTH CAR NAT PR; Hospital UT, 2014, ZAMB NAT MAT DEATH S; Hug L, 2019, LANCET GLOB HEALTH, V7, pE710, DOI 10.1016/S2214-109X(19)30163-9; Huye HF, 2014, J NUTR EDUC BEHAV, V46, P34, DOI 10.1016/j.jneb.2013.09.006; Jamali QZ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213225; Jauregui E, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1474-2; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Kinney MV, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-28; Kinshella MLW, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-03646-3; Kourouma KR, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-021-07086-9; Lawn JE, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-S1-S5; Lawn JE, 2010, SEMIN PERINATOL, V34, P371, DOI 10.1053/j.semperi.2010.09.011; Lincetto O, 2000, J TROP PEDIATRICS, V46, P293, DOI 10.1093/tropej/46.5.293; Ludington-Hoe S, 2008, ADV NEONAT CARE, V8; Mathias CT, 2021, AFR J PRIM HEALTH CA, V13, DOI 10.4102/phcfm.v13i1.2856; Media GH, GLOB HLTH MED VID 20; Mikiel-Kostyra K, 2002, ACTA PAEDIATR, V91, P1301, DOI 10.1080/08035250216102; Miyoshi Y, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2231-9; Mony PK, 2021, BMJ GLOB HEALTH, V6, DOI [10.1136/bmjgh-2021-005905, 10.1136/1136/bmjgh-2021-005905]; Moore ER, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub4; Nguah SB, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-99; Nickles D, 2020, J PROF NURS, V36, P70, DOI 10.1016/j.profnurs.2019.08.005; Office CS, 2019, ZAMB DEM HLTH SURV 2; Poggi AD, 2021, EUR REV MED PHARMACO, V25, P2711, DOI 10.26355/eurrev_202103_25434; Sarfo JO, AD CHILD FAM PSYCH I; Silveira RC, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1240-6; Sloan NL, 2011, INT J EPIDEMIOL, V40, P521, DOI 10.1093/ije/dyq174; Smith ER, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-016-0769-5; Suman RPN, 2008, INDIAN PEDIATR, V45, P17; Udani RH, 2013, J NEONATOLOGY, V27, P1; UNICEF WHO UN, UN INT GROUP CHILD M; Vesel L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/1471-2393-15-S2-S5; Vwalika B, 2014, 10 KMC INT C KMC; Vwalika B, 2017, INT J GYNECOL OBSTET, V136, P180, DOI 10.1002/ijgo.12036; World Health Organization, 2015, WHO REC INT IMPR PRE	49	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2022	17	9							e0272444	10.1371/journal.pone.0272444	http://dx.doi.org/10.1371/journal.pone.0272444			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R4GI	36048848	Green Published, gold			2023-01-03	WOS:000892263300025
J	Farrell, B; Galley, E; Jeffs, L; Howell, P; McCarthy, LM				Farrell, Barbara; Galley, Emily; Jeffs, Lianne; Howell, Pam; McCarthy, Lisa M.			"Kind of blurry": Deciphering clues to prevent, investigate and manage prescribing cascades	PLOS ONE			English	Article							SEQUENCE SYMMETRY ANALYSIS; QUALITATIVE RESEARCH	Background Prescribing cascades, where a medication is used to treat the side effect of another medication, contribute to polypharmacy and related morbidity. Little is known about clinicians' and patients' experiences with prescribing cascades. In this study, we explored why and how prescribing cascades occur across a variety of care settings and how they are managed. Methods and findings This descriptive qualitative study employed semi-structured interviews with older adults who may have experienced a prescribing cascade(s), their caregivers, and healthcare providers. Interviewees were recruited through physician referral from a Geriatric Day Hospital, two long-term care homes in Ottawa, Ontario, and through self-referral across Ontario, Canada. An inductive approach was used to code data and determine themes. Thirty-one interviews were conducted for ten unique patient cases. Some interviewees were involved in more than one case, resulting in 22 unique interviewees. Three themes were identified. First, recognition of prescribing cascades is linked to awareness of medication side effects. Second, investigation and management of prescribing cascades is simultaneous and iterative (rather than linear and sequential). Third, prevention of prescribing cascades requires intentional strategies to help people anticipate and recognize medication side effects. Difficulty with recruitment from both long-term care homes and through self-referral was the central limitation. This exemplifies challenges associated with studying a poorly recognized and underexplored phenomenon. Conclusions In order to better recognize, investigate and manage prescribing cascades, clinicians and patients need to know more about medication side effects; they need to ask 'can this be caused by a drug?' when signs and symptoms arise or worsen; and they need access to information about medication experiences to have benefit-risk discussions and make decisions about deprescribing. Approaches for raising public awareness of prescribing cascades should be trialed to raise the profile of this issue and facilitate continued exploration of the phenomenon.	[Farrell, Barbara; Galley, Emily; Howell, Pam] Bruyere Res Inst, Ottawa, ON, Canada; [Farrell, Barbara] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [Farrell, Barbara; McCarthy, Lisa M.] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada; [Jeffs, Lianne] Sinai Hlth, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Jeffs, Lianne] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [McCarthy, Lisa M.] Trillium Hlth Partners, Inst Better Hlth, Mississauga, ON, Canada; [McCarthy, Lisa M.] Univ Toronto, Leslie & Fac Pharm, Toronto, ON, Canada; [McCarthy, Lisa M.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [McCarthy, Lisa M.] Womens Coll Res Inst, Toronto, ON, Canada	University of Ottawa; University of Ottawa; University of Waterloo; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; Trillium Health Partners; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital	McCarthy, LM (corresponding author), Univ Waterloo, Sch Pharm, Waterloo, ON, Canada.; McCarthy, LM (corresponding author), Trillium Hlth Partners, Inst Better Hlth, Mississauga, ON, Canada.; McCarthy, LM (corresponding author), Univ Toronto, Leslie & Fac Pharm, Toronto, ON, Canada.; McCarthy, LM (corresponding author), Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.; McCarthy, LM (corresponding author), Womens Coll Res Inst, Toronto, ON, Canada.	lisa.mccarthy@utoronto.ca	McCarthy, Lisa/O-1857-2016	McCarthy, Lisa/0000-0001-9087-1077	Canadian Institutes of Health Research [376801]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	BF, LMM and LJ received funds from the Canadian Institutes of Health Research https://cihrirsc.gc.ca/e/193.html [grant number 376801, nominated principal applicant: Paula Rochon]. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Bloomstone S, 2020, THER ADV DRUG SAF, V11, DOI 10.1177/2042098620968310; Brath H, 2018, J AM GERIATR SOC, V66, P2079, DOI 10.1111/jgs.15543; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Caelli K., 2003, INT J QUAL METHODS, V2, P1, DOI [10.1177/160940690300200201, DOI 10.1177/160940690300200201]; Caughey GE, 2010, PHARMACOEPIDEM DR S, V19, P977, DOI 10.1002/pds.2009; Chen Y, 2022, J AM MED DIR ASSOC, V23, P468, DOI 10.1016/j.jamda.2021.06.035; Cornish F., 2014, SAGE HDB QUALITATIVE, P79, DOI 10.4135/9781446282243.N6; Doherty Alison Jayne, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101096; Farrell BJ, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01774-7; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Glisczinski D, 2018, J TRANSFORM EDUC, V16, P175, DOI 10.1177/1541344618777367; Linsky A., 2018, PUBLIC POLICY AGING, V28, P129, DOI [10.1093/PPAR/PRY030, DOI 10.1093/PPAR/PRY030]; MacQueen KM, 1998, CAM J, V10, P31, DOI [DOI 10.1177/1525822X980100020301, 10.1177/1525822X980100020301]; McCarthy LM, 2019, J AM GERIATR SOC, V67, P1023, DOI 10.1111/jgs.15800; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Morris EJ, 2022, RES SOC ADMIN PHARM, V18, P3079, DOI 10.1016/j.sapharm.2021.08.003; Morris EJ, 2021, DRUG AGING, V38, P625, DOI 10.1007/s40266-021-00868-0; Nguyen PVQ, 2016, CAN PHARM J, V149, P122, DOI 10.1177/1715163516640811; Nunnari P, 2021, EUR REV MED PHARMACO, V25, P1034, DOI 10.26355/eurrev_202101_24673; Percy WH, 2015, QUAL REP, V20, P76; PharmD CE, 2021, J AM MED DIR ASSOC, V22, P2559, DOI 10.1016/j.jamda.2021.04.021; Piggott KL, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m261; Ponte ML, 2017, MEDICINA-BUENOS AIRE, V77, P13; QSR International Pty Ltd, QUALITATIVE DATA ANA; Read SH, 2021, J AM GERIATR SOC, V69, P2842, DOI 10.1111/jgs.17312; Ribo A., 2014, J PHARMACOVIGIL, V02, P8, DOI [10.4172/2329-6887.1000152, DOI 10.4172/2329-6887.1000152]; Rochon PA, 2017, LANCET, V389, P1778, DOI 10.1016/S0140-6736(17)31188-1; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Savage RD, 2020, JAMA INTERN MED, V180, P643, DOI 10.1001/jamainternmed.2019.7087; Sternberg SA, 2021, EUR GERIATR MED, V12, P475, DOI 10.1007/s41999-021-00480-w; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Trenaman SC, 2021, BMC GERIATR, V21, DOI 10.1186/s12877-021-02246-2; Vouri SM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.18425; Vouri SM, 2018, J AM PHARM ASSOC, V58, P534, DOI 10.1016/j.japh.2018.06.014; World Health Organization, 2017, MED HARM GLOBAL PATI	35	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2022	17	8							e0272418	10.1371/journal.pone.0272418	http://dx.doi.org/10.1371/journal.pone.0272418			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R5UO	36044402	Green Published, gold			2023-01-03	WOS:000892368200019
J	Tu, HA; Liid, N; Liu, W; Fan, ZH; Kong, DZ				Tu, Huan; Liid, Ning; Liu, Wanna; Fan, Zhonghe; Kong, Dezhi			Effects of transcutaneous tibial nerve stimulation on females with overactive bladder syndrome in multiple sclerosis a protocol for a systematic review and meta-analysis	PLOS ONE			English	Review							ELECTRICAL-STIMULATION; CONTINENCE SOCIETY; TERMINOLOGY; WOMEN	Background Overactive bladder (OAB) is a problem that increasingly affects adults and the elderly, especially women. It may affect quality of life, ability to participate and overall wellbeing. Transcutaneous tibial nerve stimulation (TTNS) is a form of neuromodulation involving the use of electrical impulses to address urinary symptoms. There are many randomized controlled trials that have shown that TTNS is effective at treating overactive bladder. In recent years, TTNS has gained increasing attention for this condition. But its effect in females remains controversial and evidence is lacking. Therefore, the main purpose of this study will be to systematically evaluate the effect of TTNS on females with OAB in Multiple sclerosis (MS) by conducting a systematic review and meta-analysis, and also to provide a reference for the application of TTNS in OAB. Methods A systematic review of eligible articles will be conducted using Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. A comprehensive search of the literature will be conducted in PubMed, Web of Science, The Cochrane Library, Chinese National Knowledge Infrastructure Database (CNKI), Wanfang Data, Weipu Electronics, and other databases. We will include randomized controlled trials about TTNS in females with OAB in MS. Two reviewers will screen titles, abstracts, and full texts independently. We will use a hierarchy of recommended assessment, development, and assessment methods to assess the overall certainty of the evidence and report findings accordingly. Endnote X9 will be used to select the studies and Review Manager V.5.4 (Cochrane Collaboration) will be used to conduct the meta-analysis. The mean difference or standard deviation with 95% confidence interval (CI) will be used in the computation of continuous variables to synthesize data. Results The results will provide evidence for judging whether TTNS is effective in females with OAB and MS. Conclusion This study will provide reliable evidence for the effect of TTNS in female patients with OAB and MS.	[Tu, Huan; Liu, Wanna; Fan, Zhonghe; Kong, Dezhi] Chengdu Sport Univ, Sch Sports Med & Hlth, Chengdu, Sichuan, Peoples R China; [Liid, Ning] Chengdu Sport Univ, Inst Sports Med & Hlth, Chengdu, Sichuan, Peoples R China	Chengdu Sport University; Chengdu Sport University	Liid, N (corresponding author), Chengdu Sport Univ, Inst Sports Med & Hlth, Chengdu, Sichuan, Peoples R China.	ilining2020@qq.com		LI, Ning/0000-0002-0394-933X	Key Laboratory of sports medicine in Sichuan Province [2021-A013]	Key Laboratory of sports medicine in Sichuan Province	No. This study was funded by the Key Laboratory of sports medicine in Sichuan Province (Approval No.: 2021-A013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Alve AT, 2020, MATURITAS, V135, P40, DOI 10.1016/j.maturitas.2020.02.008; Casal-Beloy I, 2021, J PEDIATR UROL, V17, DOI 10.1016/j.jpurol.2021.06.011; Chalah MA, 2022, NEUROPHYSIOL CLIN, V52, P28, DOI 10.1016/j.neucli.2021.12.001; Chastan N, 2022, EUR J NEUROL, V29, P1293, DOI 10.1111/ene.15264; Cunniffe N, 2021, J NEUROL, V268, P30, DOI 10.1007/s00415-019-09421-x; Di Rezze S, 2012, CLIN NEUROPHARMACOL, V35, P231, DOI 10.1097/WNF.0b013e3182613dce; Dunya CP, 2021, MULT SCLER J, V27, P621, DOI 10.1177/1352458520926666; Gormley EA, 2015, J UROLOGY, V193, P1572, DOI 10.1016/j.juro.2015.01.087; Halder SK, 2021, BRAIN, V144, P402, DOI 10.1093/brain/awaa427; Haylen BT, 2010, NEUROUROL URODYNAM, V29, P4, DOI 10.1002/nau.20798; Jacomo RH, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1477; Karussis D, 2014, J AUTOIMMUN, V48-49, P134, DOI 10.1016/j.jaut.2014.01.022; Lightner DJ, 2019, J UROLOGY, V202, P558, DOI 10.1097/JU.0000000000000309; Loloi J, 2022, UROL CLIN N AM, V49, P249, DOI 10.1016/j.ucl.2021.12.005; Maddalena S, 2021, J NEUROL, V268, P45, DOI 10.1007/s00415-019-09426-6; Mallmann S, 2020, EUR J OBSTET GYN R B, V250, P203, DOI 10.1016/j.ejogrb.2020.05.005; Martin-Garcia M, 2019, PHYSIOTHERAPY, V105, P469, DOI 10.1016/j.physio.2018.12.002; McGinley MP, 2021, JAMA-J AM MED ASSOC, V325, P765, DOI 10.1001/jama.2020.26858; Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]; Oh J, 2018, CURR OPIN NEUROL, V31, P752, DOI 10.1097/WCO.0000000000000622; Rego RMP, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017755; Scaldazza CV, 2017, INT BRAZ J UROL, V43, P121, DOI [10.1590/S1677-5538.IBJU.2015.0719, 10.1590/s1677-5538.ibju.2015.0719]; Zecca C, 2016, EUR J NEUROL, V23, P1228, DOI 10.1111/ene.13010	24	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2022	17	7							e0269371	10.1371/journal.pone.0269371	http://dx.doi.org/10.1371/journal.pone.0269371			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6B4MU	35901036	Green Published, gold			2023-01-03	WOS:000881309700001
J	Ansell, SM; Radford, J; Connors, JM; Dlugosz-Danecka, M; Kim, WS; Gallamini, A; Ramchandren, R; Friedberg, JW; Advani, R; Hutchings, M; Evens, AM; Smolewski, P; Savage, KJ; Bartlett, NL; Eom, HS; Abramson, JS; Dong, C; Campana, F; Fenton, K; Puhlmann, M; Straus, DJ				Ansell, Stephen M.; Radford, John; Connors, Joseph M.; Dlugosz-Danecka, Monika; Kim, Won-Seog; Gallamini, Andrea; Ramchandren, Radhakrishnan; Friedberg, Jonathan W.; Advani, Ranjana; Hutchings, Martin; Evens, Andrew M.; Smolewski, Piotr; Savage, Kerry J.; Bartlett, Nancy L.; Eom, Hyeon-Seok; Abramson, Jeremy S.; Dong, Cassie; Campana, Frank; Fenton, Keenan; Puhlmann, Markus; Straus, David J.		ECHELON-1 Study Grp	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-LABEL; CHEMOTHERAPY; ABVD; COMBINATION; TOMOGRAPHY; INTERGROUP; THERAPY; BEACOPP; DISEASE; CYCLES	BACKGROUND Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits with first-line therapy with brentuximab vedotin, a CD30-directed antibody-drug conjugate, plus doxorubicin, vinblastine, and dacarbazine (A+AVD), as compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). A planned interim analysis indicated a potential benefit with regard to overall survival; data from a median of 6 years of follow-up are now available. METHODS We randomly assigned patients in a 1:1 ratio to receive up to six cycles of A+AVD or ABVD. The primary end point, modified progression-free survival, has been reported previously. The key secondary end point was overall survival in the intention-to-treat population. Safety was also assessed. RESULTS A total of 664 patients were assigned to receive A+AVD and 670 to receive ABVD. At a median follow-up of 73.0 months, 39 patients in the A+AVD group and 64 in the ABVD group had died (hazard ratio, 0.59; 95% confidence interval [CI], 0.40 to 0.88; P=0.009). The 6-year overall survival estimates were 93.9% (95% CI, 91.6 to 95.5) in the A+AVD group and 89.4% (95% CI, 86.6 to 91.7) in the ABVD group. Progression-free survival was longer with A+AVD than with ABVD (hazard ratio for disease progression or death, 0.68; 95% CI, 0.53 to 0.86). Fewer patients in the A+AVD group than in the ABVD group received subsequent therapy, including transplantation, and fewer second cancers were reported with A+AVD (in 23 vs. 32 patients). Primary prophylaxis with granulocyte colony-stimulating factor was recommended after an increased incidence of febrile neutropenia was observed with A+AVD. More patients had peripheral neuropathy with A+AVD than with ABVD, but most patients in the two groups had resolution or amelioration of the event by the last follow-up. CONCLUSION Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD.	[Ansell, Stephen M.] Mayo Clin, Div Hematol, Rochester, MN 55905 USA; [Radford, John] Univ Manchester, Manchester, Lancs, England; [Radford, John] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Connors, Joseph M.; Savage, Kerry J.] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada; [Dlugosz-Danecka, Monika] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland; [Smolewski, Piotr] Med Univ Lodz, Dept Expt Hematol, Lodz, Poland; [Kim, Won-Seog] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Internal Med, Seoul, South Korea; [Eom, Hyeon-Seok] Natl Canc Ctr, Ctr Hematol Malignancy, Dept Hematol Oncol, Goyang, South Korea; [Gallamini, Andrea] Antoine Lacassagne Canc Ctr, Res & Innovat Dept, Nice, France; [Ramchandren, Radhakrishnan] Univ Tennessee, Grad Sch Med, Knoxville, TN USA; [Friedberg, Jonathan W.] Univ Rochester, Wilmot Canc Inst, Rochester, MN USA; [Straus, David J.] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA; [Advani, Ranjana] Stanford Univ, Div Oncol, Dept Med, Stanford, CA 94305 USA; [Hutchings, Martin] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark; [Evens, Andrew M.] Rutgers Canc Inst New Jersey, Div Blood Disorders, New Brunswick, NJ USA; [Bartlett, Nancy L.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA; [Abramson, Jeremy S.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Dong, Cassie; Campana, Frank] Takeda Dev Ctr Amer, Lexington, KY USA; [Fenton, Keenan; Puhlmann, Markus] Seagen, Bothell, WA USA	Mayo Clinic; University of Manchester; Christie NHS Foundation Trust; University of Manchester; Medical University Lodz; Sungkyunkwan University (SKKU); Samsung Medical Center; National Cancer Center - Korea (NCC); UNICANCER; Centre Antoine Lacassagne; University of Tennessee System; University of Tennessee Health Science Center; University of Rochester; Memorial Sloan Kettering Cancer Center; Stanford University; Rigshospitalet; University of Copenhagen; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Siteman Cancer Center; Washington University (WUSTL); Harvard University; Massachusetts General Hospital	Ansell, SM (corresponding author), Mayo Clin, Div Hematol, Rochester, MN 55905 USA.	ansell.stephen@mayo.edu	Długosz-Danecka, Monika/L-8621-2019; Savage, Kerry/HCH-5539-2022; Radford, John/N-1331-2015	Długosz-Danecka, Monika/0000-0002-8927-4125; Bartlett, Nancy/0000-0001-8470-394X; Advani, Ranjana/0000-0002-3219-2292; Radford, John/0000-0001-7898-2786	Takeda Development Center Americas and Seagen	Takeda Development Center Americas and Seagen	Supported by Takeda Development Center Americas and Seagen	Amin MSA, 2021, CLIN TRANSL ONCOL, V23, P1067, DOI 10.1007/s12094-020-02483-8; Andre MPE, 2020, CANCER MED-US, V9, P6565, DOI 10.1002/cam4.3298; Behringer K, 2005, J CLIN ONCOL, V23, P7555, DOI 10.1200/JCO.2005.08.138; Behringer K, 2013, J CLIN ONCOL, V31, P231, DOI 10.1200/JCO.2012.44.3721; Borchmann P, 2017, LANCET, V390, P2790, DOI 10.1016/S0140-6736(17)32134-7; Bujan L, 2014, FERTIL STERIL, V102, P667, DOI 10.1016/j.fertnstert.2014.06.008; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; Cao A, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-4914; Carde P, 2016, J CLIN ONCOL, V34, P2028, DOI 10.1200/JCO.2015.64.5648; Casasnovas RO, 2019, LANCET ONCOL, V20, P202, DOI 10.1016/S1470-2045(18)30784-8; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Connors JM, 2018, NEW ENGL J MED, V378, P331, DOI 10.1056/NEJMoa1708984; Dalal M, 2020, EXPERT REV HEMATOL, V13, P907, DOI 10.1080/17474086.2020.1793666; Dores GM, 2020, J CLIN ONCOL, V38, P4149, DOI 10.1200/JCO.20.00264; Engert A, 2009, J CLIN ONCOL, V27, P4548, DOI 10.1200/JCO.2008.19.8820; Evens AM, 2022, HAEMATOLOGICA, V107, P1086, DOI 10.3324/haematol.2021.278438; Evens AM, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.02668; Gallamini A, 2018, J CLIN ONCOL, V36, P454, DOI 10.1200/JCO.2017.75.2543; Gardai SJ, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-2469; Gordon LI, 2013, J CLIN ONCOL, V31, P684, DOI 10.1200/JCO.2012.43.4803; Herrera AF, 2018, BLOOD, V131, P1183, DOI 10.1182/blood-2017-10-811224; Johnson P, 2016, NEW ENGL J MED, V374, P2419, DOI 10.1056/NEJMoa1510093; Kreissl S, 2021, LANCET HAEMATOL, V8, pE398, DOI 10.1016/S2352-3026(21)00101-0; Li F, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-3694; Meignan M, 2010, LEUKEMIA LYMPHOMA, V51, P2171, DOI 10.3109/10428194.2010.529208; Oflazoglu E, 2008, BRIT J HAEMATOL, V142, P69, DOI 10.1111/j.1365-2141.2008.07146.x; Skoetz N, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007941.pub3; Stephens DM, 2019, BLOOD, V134, P1238, DOI 10.1182/blood.2019000719; Straus D, 2020, LEUKEMIA LYMPHOMA, V61, P2931, DOI 10.1080/10428194.2020.1791846; Straus DJ, 2021, LANCET HAEMATOL, V8, pE410, DOI 10.1016/S2352-3026(21)00102-2; Straus DJ, 2020, BLOOD, V135, P735, DOI 10.1182/blood.2019003127; Sutherland MSK, 2006, J BIOL CHEM, V281, P10540, DOI 10.1074/jbc.M510026200; Swerdlow AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju207; Viviani S, 2011, NEW ENGL J MED, V365, P203, DOI 10.1056/NEJMoa1100340; Zak DE, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-115481	35	10	10	2	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	2022	387	4					310	320		10.1056/NEJMoa2206125	http://dx.doi.org/10.1056/NEJMoa2206125		JUL 2022	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D8DI	35830649				2023-01-03	WOS:000827507100001
J	Mukushev, M; Ubingazhibov, A; Kydyrbekova, A; Imashev, A; Kimmelman, V; Sandygulova, A				Mukushev, Medet; Ubingazhibov, Aidyn; Kydyrbekova, Aigerim; Imashev, Alfarabi; Kimmelman, Vadim; Sandygulova, Anara			FluentSigners-50: A signer independent benchmark dataset for sign language processing	PLOS ONE			English	Article							RECOGNITION	This paper presents a new large-scale signer independent dataset for Kazakh-Russian Sign Language (KRSL) for the purposes of Sign Language Processing. We envision it to serve as a new benchmark dataset for performance evaluations of Continuous Sign Language Recognition (CSLR) and Translation (CSLT) tasks. The proposed FluentSigners-50 dataset consists of 173 sentences performed by 50 KRSL signers resulting in 43,250 video samples. Dataset contributors recorded videos in real-life settings on a wide variety of backgrounds using various devices such as smartphones and web cameras. Therefore, distance to the camera, camera angles and aspect ratio, video quality, and frame rates varied for each dataset contributor. Additionally, the proposed dataset contains a high degree of linguistic and inter-signer variability and thus is a better training set for recognizing a real-life sign language. FluentSigners-50 baseline is established using two state-of-the-art methods, Stochastic CSLR and TSPNet. To this end, we carefully prepared three benchmark train-test splits for models' evaluations in terms of: signer independence, age independence, and unseen sentences. FluentSigners-50 is publicly available at https://krslproject.github.io/FluentSigners-50/	[Mukushev, Medet; Kydyrbekova, Aigerim; Imashev, Alfarabi; Sandygulova, Anara] Nazarbayev Univ, Sch Engn & Digital Sci, Dept Robot & Mechatron, Nur Sultan, Kazakhstan; [Ubingazhibov, Aidyn] Nazarbayev Univ, Sch Engn & Digital Sci, Dept Comp Sci, Nur Sultan, Kazakhstan; [Kimmelman, Vadim] Univ Bergen, Dept Linguist Literary & Aesthet Studies, Bergen, Norway	Nazarbayev University; Nazarbayev University; University of Bergen	Sandygulova, A (corresponding author), Nazarbayev Univ, Sch Engn & Digital Sci, Dept Robot & Mechatron, Nur Sultan, Kazakhstan.	anara.sandygulova@nu.edu.kz		Kimmelman, Vadim/0000-0002-8748-6845; Mukushev, Medet/0000-0002-3655-9928	Nazarbayev University Faculty Development Competitive Research Grant Program 2019-2021 [110119FD4545]	Nazarbayev University Faculty Development Competitive Research Grant Program 2019-2021	A.S. was awarded the funding by Nazarbayev University Faculty Development Competitive Research Grant Program 2019-2021 for the project "Kazakh Sign Language Automatic Recognition System (K-SLARS)". Award number is 110119FD4545. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albanie S, 2020, EUR C COMP VIS; Alexei Baevski, 2019, Arxiv, DOI arXiv:1904.01038; Allen TE, 2015, RES METHODS SIGN LAN; Alptekin Orbay, 2020, Arxiv, DOI arXiv:2002.00479; Duarte A, 2020, Arxiv, DOI arXiv:2008.08143; Bayley R., 2000, J SOCIOLING, V4, P81, DOI [10.1111/1467-9481.00104, DOI 10.1111/1467-9481.00104]; Ben Swift, 2020, Arxiv, DOI arXiv:2010.05468; Benchiheub M, 2016, 7 INT C LANG RES EV, P7; Bragg D, 2019, ASSETS'19: THE 21ST INTERNATIONAL ACM SIGACCESS CONFERENCE ON COMPUTERS AND ACCESSIBILITY, P16, DOI 10.1145/3308561.3353774; Camgoz Necati Cihan, 2020, 2020 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR). Proceedings, P10020, DOI 10.1109/CVPR42600.2020.01004; Camgoz NC, 2018, PROC CVPR IEEE, P7784, DOI 10.1109/CVPR.2018.00812; Cao Z, 2021, IEEE T PATTERN ANAL, V43, P172, DOI 10.1109/TPAMI.2019.2929257; Carreira J, 2017, PROC CVPR IEEE, P4724, DOI 10.1109/CVPR.2017.502; Cecchetto C., 2012, SIGN LANGUAGE INT HD, P292, DOI DOI 10.1515/9783110261325.292; Chai X., 2014, VIPLTR14SLR001 I COM; Cooper H, 2012, J MACH LEARN RES, V13, P2205; Dreuw P, 2008, SIXTH INTERNATIONAL CONFERENCE ON LANGUAGE RESOURCES AND EVALUATION, LREC 2008, P1115; Graves A., 2006, P 23 INT C MACH LEAR, P369; He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90; Houqiang Li, 2018, Arxiv, DOI arXiv:1801.10111; Huang J., 2018, 32 AAAI C ARTIFICIAL, DOI [10.1609/aaai.v32i1.11903, DOI 10.48550/ARXIV.1801.10111]; Johnston T, 2018, LINGUIST TYPOL, V22, P185, DOI 10.1515/lingty-2018-0008; Kimmelman V, 2022, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.740734; Kimmelman V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233731; Ko SK, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9132683; Koller O, 2020, IEEE T PATTERN ANAL, V42, P2306, DOI 10.1109/TPAMI.2019.2911077; Koller O, 2016, PROC CVPR IEEE, P3793, DOI 10.1109/CVPR.2016.412; Koller O, 2015, COMPUT VIS IMAGE UND, V141, P108, DOI 10.1016/j.cviu.2015.09.013; Lu P., 2010, P NAACL HLT 2010 WOR, P89; Oomen M, 2017, LINGUIST TYPOL, V21, P1, DOI 10.1515/lingty-2017-0001; Oscar Koller, 2020, Arxiv, DOI arXiv:2008.09918; Oszust M, 2013, C HUM SYST INTERACT, P219, DOI 10.1109/HSI.2013.6577826; Papineni K, 2002, 40TH ANNUAL MEETING OF THE ASSOCIATION FOR COMPUTATIONAL LINGUISTICS, PROCEEDINGS OF THE CONFERENCE, P311, DOI 10.3115/1073083.1073135; Paszke A, 2019, ADV NEUR IN, V32; Reza H., 2019, ARXIV; Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y; Schembri A., 2012, SIGN LANGUAGE INT HD, P788, DOI DOI 10.1515/9783110261325.788; Szegedy C., 2016, P IEEE C COMP VIS PA, P2818; Vaswani A., 2017, P NEURIPS, P5998, DOI DOI 10.5555/3295222.3295349; Von Agris U., 2007, HUM COMP INT SIM LIS, V11; Zhang ZH, 2019, IEEE IMAGE PROC, P285, DOI 10.1109/ICIP.2019.8802972; Zhe Niu, 2020, Computer Vision - ECCV 2020 16th European Conference. Proceedings. Lecture Notes in Computer Science (LNCS 12361), P172, DOI 10.1007/978-3-030-58517-4_11; Zhou H, 2019, IEEE INT CON MULTI, P1282, DOI 10.1109/ICME.2019.00223; Zorzi G, 2022, FRONT PSYCHOL, V13, DOI 10.3389/fpsyg.2022.716554	44	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2022	17	9							e0273649	10.1371/journal.pone.0273649	http://dx.doi.org/10.1371/journal.pone.0273649			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R5XR	36094924	gold, Green Published			2023-01-03	WOS:000892376500022
J	Owusuaa, C; van Lent, LGG; Spijker, AV; van der Rijt, CCD; van der Heide, A				Owusuaa, Catherine; van Lent, Liza G. G.; Spijker, Adriaan van 't; van der Rijt, Carin C. D.; van der Heide, Agnes			Discussing prognosis and the end of life with patients with advanced cancer or COPD: A qualitative study	PLOS ONE			English	Article							PALLIATIVE CARE; OF-LIFE; ILLNESS; DISTRESS; OUTCOMES	Objectives To explore patients' experiences and recommendations for discussions about their prognosis and end of life with their physicians. Methods Patients with advanced cancer or advanced chronic obstructive pulmonary disease (COPD) were enrolled in qualitative interviews, which were analyzed with a phenomenological and thematic approach. Results During interviews with fourteen patients (median age 64 years), we identified the following themes for discussion about prognosis and the end of life: topics discussed, the timing, the setting, physician-patient relationship, responsibilities for clinicians, and recommendations. Patients preferred the physician to initiate such discussion, but wanted to decide about its continuation and content. The discussions were facilitated by an established physician-patient relationship or attendance of relatives. Patients with cancer had had discussions about prognosis at rather clear-cut moments of deterioration than patients with COPD. Patients with COPD did not consider end-of-life discussions a responsibility of the pulmonologist. Patients recommended an understandable message, involvement of relatives or other clinicians, sufficient time, and sensitive non-verbal communication. Conclusions Patients appreciated open, sensitive, and negotiable discussions about prognosis and the end of life. Practice implications Patients' recommendations could be used for communication training. Possible differences in the need for such discussions between patients with cancer or COPD warrant further research.	[Owusuaa, Catherine; van Lent, Liza G. G.; van der Rijt, Carin C. D.] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands; [Spijker, Adriaan van 't] Erasmus MC, Dept Med Psychol, Erasmus MC, Rotterdam, Netherlands; [van der Heide, Agnes] Erasmus MC, Dept Publ Hlth, Erasmus Univ Med Ctr, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Owusuaa, C (corresponding author), Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands.	c.owusuaa@erasmusmc.nl		Owusuaa, Catherine/0000-0003-3695-4466; Van der Rijt, Carin C.D./0000-0001-5996-1242	Netherlands Organization for Health Research and Development (ZonMw) [844001209]	Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	C.C.D.vd.R acquired the funding for this study, which was by a grant from the Netherlands Organization for Health Research and Development (ZonMw; https://www.zonmw.nl/en/; grant number 844001209). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Celli B, 2017, INT J CHRONIC OBSTR, V12, P2189, DOI 10.2147/COPD.S136711; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Claessen SJJ, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-42; Curtis JR., 2006, RESP MED, V2, P89; Duenk RG, 2017, INT J CHRONIC OBSTR, V12, P2795, DOI 10.2147/COPD.S141974; Enzinger AC, 2015, J CLIN ONCOL, V33, P3809, DOI 10.1200/JCO.2015.61.9239; Epstein AS, 2016, J CLIN ONCOL, V34, P2398, DOI 10.1200/JCO.2015.63.6696; Fried TR, 2003, J AM GERIATR SOC, V51, P1398, DOI 10.1046/j.1532-5415.2003.51457.x; Giorgi A., 2008, J PHENOMENOL PSYCHOL, V39, P33, DOI DOI 10.1163/156916208X311610; Global Strategy for the Diagnosis MaPoC, 2006, GLOBAL INITIATIVE CH; Goldstein D, 2002, INTERN MED J, V32, P289, DOI 10.1046/j.1445-5994.2002.00230.x; Gott M, 2009, PALLIATIVE MED, V23, P642, DOI 10.1177/0269216309106790; Gough N, 2019, BMJ SUPPORT PALLIAT, V9, P100, DOI 10.1136/bmjspcare-2015-000898; Hagerty RG, 2005, ANN ONCOL, V16, P1005, DOI 10.1093/annonc/mdi211; Houben CHM, 2014, J AM MED DIR ASSOC, V15, P477, DOI 10.1016/j.jamda.2014.01.008; Janssen DJA, 2011, EUR RESPIR J, V38, P268, DOI 10.1183/09031936.00157710; Kirk P, 2004, BMJ-BRIT MED J, V328, P1343, DOI 10.1136/bmj.38103.423576.55; Mack JW, 2010, J CLIN ONCOL, V28, P1203, DOI 10.1200/JCO.2009.25.4672; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; Owusuaa C, 2021, BMJ SUPPORT PALLIAT, DOI 10.1136/bmjspcare-2020-002764; Pooler A, 2014, INT J CHRONIC OBSTR, V9, P315, DOI 10.2147/COPD.S53255; Rietjens JAC, 2017, LANCET ONCOL, V18, pE543, DOI 10.1016/S1470-2045(17)30582-X; STRUTZEL E, 1968, NURS RES, V17, P364; Thoonsen B, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0112-9; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709	26	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2022	17	9							e0274201	10.1371/journal.pone.0274201	http://dx.doi.org/10.1371/journal.pone.0274201			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R1EM	36084060	gold, Green Published			2023-01-03	WOS:000892051000105
J	Martarelli, R; Casanova, G; Lamura, G				Martarelli, Rossella; Casanova, Georgia; Lamura, Giovanni			The impact of long-term care needs on the socio-economic deprivation of older people and their families: A scoping review protocol	PLOS ONE			English	Article							DISABILITY	Major global problems such as population ageing, long-term care and the socio-economic burden of chronically ill older people and their families are urgent issues. Research in this field contributes to the growing international literature on health-related quality-of-life instruments, but little is known about the links between the related variables. Thus, the scoping review this protocol refers to plans to examine the socio-economic consequences of older people's poor health on their economic conditions and their families. In particular, the main aims are: a) to map the main concepts that characterize the body of the reference literature; b) to identify conceptual gaps or unexplored research areas to be addressed; c) to illuminate the difficulties that affect a large number of families with older members to care for, with particular attention to the concept of socio-economic deprivation, which includes material living conditions as well as social aspects (e.g. in the form of loneliness experienced as a consequence of health disorders). This protocol paper fulfils the purpose of clarifying the planned methodological phases, including the sub-phases, and listing the techniques used. A three-step approach is being applied, consisting of: pre-planning phase, protocol phase, and conduction and reporting phase. The preliminary stages of the protocol design are part of a dedicated project within the Open Science Framework platform and included in a Research Square preprint. This proposed project will contribute to multidisciplinary research on the connections between ill health and poverty, and could support critical reflections on the current evidence and guide future policies to alleviate this double burden.	[Martarelli, Rossella; Casanova, Georgia; Lamura, Giovanni] Ctr Socioecon Res Ageing, IRCCS INRCA Natl Inst Hlth & Sci Ageing, Ancona, Italy; [Casanova, Georgia] Univ Valencia, Inst Invest Polit Bienestar Social POLIBIENESTAR, Res Inst Social Welf Policy, Valencia, Spain	University of Valencia	Casanova, G (corresponding author), Ctr Socioecon Res Ageing, IRCCS INRCA Natl Inst Hlth & Sci Ageing, Ancona, Italy.; Casanova, G (corresponding author), Univ Valencia, Inst Invest Polit Bienestar Social POLIBIENESTAR, Res Inst Social Welf Policy, Valencia, Spain.	g.casanova@inrca.it		Casanova, Georgia/0000-0002-3944-873X	Family International Monitor (FIM); International Centre for Family Studies (CISF); Marie Curie European Fellowship Grant [888102]; European Commission [888102]; Marie Curie Individual Fellowship Grant [888102]; Italian Ministry of Health	Family International Monitor (FIM); International Centre for Family Studies (CISF); Marie Curie European Fellowship Grant; European Commission(European CommissionEuropean Commission Joint Research Centre); Marie Curie Individual Fellowship Grant; Italian Ministry of Health(Ministry of Health, Italy)	The study is being supported by the Family International Monitor (FIM) and the International Centre for Family Studies (CISF). Also, GC was supported by the the Marie Curie European Fellowship Grant (Grant Agreement No. 888102). Details: The scoping review this protocol refers to is part of the Horizon 2020-funded SEreDIPE project, i.e. the European Commission is to be considered as a funding body (call for proposal: H2020-MSCA-IF-2019; project code: 888102; project period: 16 March 2021 -15 March 2023). SEreDIPE is an acronym for "Socio-Economic (SE) deprivation related to the effect of the presence of Dependent older people: strategies for Innovative Policies in Europe". Its mission is to investigate social trends and social innovation policies, with particular attention to informal care and the amount that families pay directly for looking after their older members, particularly those afflicted with limitations in activities of daily living (ADLs). POLIBIENESTAR, a research institute of the University of Valencia, is responsible for coordinating this project. The Italian National Institute of Health & Science on Ageing-IRCCS INRCA-is to be referred to as a consortium partner, the others being: Golgi Cenci Foundation (IT), University of Dortmund, Leibniz Institute of Social Sciences (DE), University of Vechta, CoE AgeCare (FI), "National Cancer Institute" Foundation (IT), European Center for Social Welfare Policy and Research, and Eurocarers (Belgium). Grant recipient: Dr. Georgia Casanova (Marie Curie Individual Fellowship Grant; H2020MSCA-IF-2019. Grant Agreement: 888102). The study also partially benefits from funding for current research granted by the Italian Ministry of Health to the National Institute of Health & Science on Ageing (IRCCS. INRCA). https: www.inrca.it/INRCA/MODM2/FIM: https://www.facebook.com/FamilyInternationalMonitor/CISF: https://www.cisf.famigliacristiana.it European Commission: https://cordis.europa.eu/project/id/888102/it The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdi S, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1189-9; Becque YN, 2019, INT J NURS STUD, V97, P28, DOI 10.1016/j.ijnurstu.2019.04.011; Belletti F., 2020, FAMILY INT MONITOR F, V1st; Casanova G, 2020, J AGING SOC POLICY, V32, P55, DOI 10.1080/08959420.2019.1589888; Casanova G, 2017, J AGING SOC POLICY, V29, P201, DOI 10.1080/08959420.2016.1236640; Chen LL, 2020, AGING MENT HEALTH, V24, P1822, DOI 10.1080/13607863.2019.1663491; do Couto AM, 2018, REV BRAS ENFERM, V71, P959, DOI 10.1590/0034-7167-2017-0105; European Commission, INF CAR EUR EXPL FOR; Eurostat, 2021, EUROSTAT STAT EXPLAI; Eurostat, EUROSTAT STAT EXPLAI; familymonitor.net, US; Guimaraes RM, 2020, ARCH GERONTOL GERIAT, V90, DOI 10.1016/j.archger.2020.104157; Hajek A, 2021, AGING MENT HEALTH, V25, P906, DOI 10.1080/13607863.2020.1725740; JBI GLOBAL WIKI, JBI MANUAL EVIDENCE; Lera J, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18010020; Lestari SK, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16081341; Lockwood C, 2019, ASIAN NURS RES, V13, P287, DOI 10.1016/j.anr.2019.11.002; Loibl C., 2018, EC PSYCHOL, P421, DOI [10.1002/9781118926352.ch26, DOI 10.1002/9781118926352.CH26]; Mayston R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182360; Merrilees J., 2014, ENCY NEUROLOGICAL SC, V2nd, P47, DOI [10.1016/B978-0-12-385157-4.00464-4, DOI 10.1016/B978-0-12-385157-4.00464]; Mitra S, 2017, DISABIL HEALTH J, V10, P475, DOI 10.1016/j.dhjo.2017.04.007; Muir T., 2017, OECD HLTH WORKING PA, DOI [10.1787/a411500a-en, DOI 10.1787/A411500A-EN]; Munn Z, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0611-x; Page MJ, 2021, INT J SURG, V88, DOI 10.1016/j.ijsu.2021.105906; Saito M, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16020182; Spasova S., 2018, Eurohealth, V24, P7; United Nations, 2020, UN POPULATION DIVISI; United Nations Department of Economic and Social Affairs Population Division, 2019, WORLD POPULATION PRO; Woo J, 2020, J NUTR HEALTH AGING, V24, P1111, DOI 10.1007/s12603-020-1444-y	29	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2022	17	8							e0273814	10.1371/journal.pone.0273814	http://dx.doi.org/10.1371/journal.pone.0273814			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R5UO	36044478	gold, Green Published, Green Submitted			2023-01-03	WOS:000892368200071
J	Axelrod, ML; Meijers, WC; Screever, EM; Qin, J; Carroll, MG; Sun, XP; Tannous, E; Zhang, YL; Sugiura, A; Taylor, BC; Hanna, A; Zhang, SY; Amancherla, K; Tai, W; Wright, JJ; Wei, SC; Opalenik, SR; Toren, AL; Rathmell, JC; Ferrell, PB; Phillips, EJ; Mallal, S; Johnson, DB; Allison, JP; Moslehi, JJ; Balko, JM				Axelrod, Margaret L.; Meijers, Wouter C.; Screever, Elles M.; Qin, Juan; Carroll, Mary Grace; Sun, Xiaopeng; Tannous, Elie; Zhang, Yueli; Sugiura, Ayaka; Taylor, Brandie C.; Hanna, Ann; Zhang, Shaoyi; Amancherla, Kaushik; Tai, Warren; Wright, Jordan J.; Wei, Spencer C.; Opalenik, Susan R.; Toren, Abigail L.; Rathmell, Jeffrey C.; Ferrell, P. Brent; Phillips, Elizabeth J.; Mallal, Simon; Johnson, Douglas B.; Allison, James P.; Moslehi, Javid J.; Balko, Justin M.			T cells specific for alpha-myosin drive immunotherapy-related myocarditis	NATURE			English	Article							LYMPHOCYTES; EXPRESSION; HEART; MICE	Immune-related adverse events, particularly severe toxicities such as myocarditis, are major challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy(1). The pathogenesis of ICI-associated myocarditis (ICI-MC) is poorly understood. Pdcd1(-/-) Ctla4(-/-) mice recapitulate clinicopathological features of ICI-MC, including myocardial T cell infiltration(2). Here, using single-cell RNA and T cell receptor (TCR) sequencing of cardiac immune infiltrates from Pdcd1(-/-) Ctia4(+/-) mice, we identify clonal effector CD8(+)T cells asthe dominant cell population. Treatment with anti-CD8-depleting, but not anti-CD4-depleting, antibodies improved the survival of Pdcd1(-/-) Ctia4(+/-) mice. Adoptive transfer of immune cells from mice with myocarditis induced fatal myocarditis in recipients, which required CD8(+)T cells. The cardiac-specific protein alpha-myosin, which is absent from the thymus(3,4), was identified asthe cognate antigen source for three major histocompatibility complex class I-restricted TCRs derived from mice with fulminant myocarditis. Peripheral blood T cells from three patients with ICI-MC were expanded by alpha-myosin peptides. Moreover, these a-myosin-expanded T cells shared TCR clonotypes with diseased heart and skeletal muscle, which indicatesthat a-myosin may be a clinically important autoantigen in ICI-MC. These studies underscore the crucial role for cytotoxic CD8(+)T cells, identify a candidate autoantigen in ICI-MC and yield new insights into the pathogenesis of ICI toxicity.	[Axelrod, Margaret L.; Meijers, Wouter C.; Screever, Elles M.; Qin, Juan; Carroll, Mary Grace; Sun, Xiaopeng; Tannous, Elie; Zhang, Yueli; Sugiura, Ayaka; Taylor, Brandie C.; Hanna, Ann; Amancherla, Kaushik; Tai, Warren; Wright, Jordan J.; Opalenik, Susan R.; Toren, Abigail L.; Ferrell, P. Brent; Phillips, Elizabeth J.; Mallal, Simon; Johnson, Douglas B.; Moslehi, Javid J.; Balko, Justin M.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Meijers, Wouter C.; Screever, Elles M.] Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands; [Meijers, Wouter C.; Screever, Elles M.] Erasmus MC, Thorax Ctr, Dept Cardiol, Rotterdam, Netherlands; [Qin, Juan; Zhang, Shaoyi; Moslehi, Javid J.] Univ Calif San Francisco, Div Cardiol, Sect Cardiooncol & Immunol, San Francisco, CA 94159 USA; [Qin, Juan; Zhang, Shaoyi; Moslehi, Javid J.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA; [Tai, Warren] Univ Calif Los Angeles, Sch Med, Div Cardiol, Los Angeles, CA 90024 USA; [Wei, Spencer C.; Allison, James P.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Rathmell, Jeffrey C.; Phillips, Elizabeth J.; Balko, Justin M.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Rathmell, Jeffrey C.; Johnson, Douglas B.; Balko, Justin M.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Rathmell, Jeffrey C.] Vanderbilt Univ, Vanderbilt Ctr Immunobiol, Med Ctr, Nashville, TN USA; [Phillips, Elizabeth J.; Mallal, Simon] Murdoch Univ, Inst Immunol & Infect Dis, Perth, WA, Australia; [Phillips, Elizabeth J.] Vanderbilt Univ, Dept Dermatol, Med Ctr, Nashville, TN USA; [Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; [Mallal, Simon] Vanderbilt Univ, Dept Biomed Informat, Med Ctr, Nashville, TN USA; [Allison, James P.] Univ Texas MD Anderson Canc Ctr, Parker Inst Canc Immunotherapy, Houston, TX 77030 USA	Vanderbilt University; University of Groningen; Erasmus University Rotterdam; Erasmus MC; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University; Vanderbilt University; Vanderbilt University; Murdoch University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; UTMD Anderson Cancer Center	Moslehi, JJ; Balko, JM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.; Moslehi, JJ (corresponding author), Univ Calif San Francisco, Div Cardiol, Sect Cardiooncol & Immunol, San Francisco, CA 94159 USA.; Moslehi, JJ (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.; Balko, JM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Balko, JM (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	Javid.Mostehi@ucst.edu; justin.batko@vumc.org		Tai, Warren/0000-0001-9355-7198; Axelrod, Margaret/0000-0003-4713-8798; /0000-0002-0821-6290	Susan and Luke Simons Directorship in Melanoma; Van Stephenson Melanoma Research Fund; James C. Bradford Melanoma Fund; American Heart Association Career Development Award [929347]; Mandema-Stipendium of the Junior Scientific Masterclass 2020-10 of the University Medical Center Groningen; Dutch Heart Foundation [03-005-2021-T005]; National Natural Science Foundation of China [82100677]; National Institutes of Health [R01HG010863, R01AI152183 U01AI154659]; National Health and Medical Research Council of Australia; NCI/NIH Cancer Center [P30CA068485, S10 OD023475-01A1]; CTSA grant [UL1TR002243]; Vanderbilt Ingram Cancer Center [P30 CA68485]; Vanderbilt Vision Center [P30 EY08126]; NIH/NCRR [G20 RR030956]; NIH High-End Equipment Grant [S10OD025092];  [F30CA236157];  [T32GM007347];  [T32DK007061];  [R01HL141466];  [R01HL155990];  [R01CA227481];  [R01HL156021];  [P30 AI110527]	Susan and Luke Simons Directorship in Melanoma; Van Stephenson Melanoma Research Fund; James C. Bradford Melanoma Fund; American Heart Association Career Development Award(American Heart Association); Mandema-Stipendium of the Junior Scientific Masterclass 2020-10 of the University Medical Center Groningen; Dutch Heart Foundation(Netherlands Heart Foundation); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); NCI/NIH Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CTSA grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Vanderbilt Ingram Cancer Center; Vanderbilt Vision Center; NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH High-End Equipment Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; ; ; ; ; 	We thank the patients and families who donated tissue to this study; M. Madden and M.Korrer for assistance with sample acquisition; members of the J.M.B. laboratory and B. I.Reinfeld for their constructive input; and E. J. Philips, S.Mallal, P.Steinberger and J. Sidney for cell lines and reagents. This work was supported by F30CA236157, T32GM007347 (to M.L.A.), T32DK007061 (to J.J.W.), R01HL141466 (to J.J.M.), R01HL155990 (to J.J.M.), R01CA227481 (to D.B.J. and J.M.B.), R01HL156021 (to J.M.B. and J.J.M.), P30 AI110527 (to S.M.), Susan and Luke Simons Directorship in Melanoma, Van Stephenson Melanoma Research Fund, and James C. Bradford Melanoma Fund (to D.B.J). K.A. is supported by an American Heart Association Career Development Award (929347). W.C.M. is supported by the Mandema-Stipendium of the Junior Scientific Masterclass 2020-10 of the University Medical Center Groningen and by the Dutch Heart Foundation (Dekker grant 03-005-2021-T005). S.Z. is supported by National Natural Science Foundation of China (82100677). E.J.P. receives funding from the National Institutes of Health R01HG010863, R01AI152183 U01AI154659) and from the National Health and Medical Research Council of Australia. J.P.A. is a CPRIT Distinguished Scholar in Cancer Research. We acknowledge the Translational Pathology Shared Resource supported by NCI/NIH Cancer Center Support grant P30CA068485 and the Shared Instrumentation grant S10 OD023475-01A1 for the Leica Bond RX. Staff at The Vanderbilt VANTAGE Core, including A. Jones and L. Raju, provided technical assistance for this work. VANTAGE is supported in part by a CTSA grant (UL1TR002243), the Vanderbilt Ingram Cancer Center (P30 CA68485), the Vanderbilt Vision Center (P30 EY08126), the NIH/NCRR (G20 RR030956), and an NIH High-End Equipment Grant (S10OD025092). Figs. 1a and 4b were created with BioRender.com.	Adamo L, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134700; Ali OH, 2019, EUR J CANCER, V107, P8, DOI 10.1016/j.ejca.2018.11.009; ALTEVOGT P, 1994, EUR J IMMUNOL, V24, P731, DOI 10.1002/eji.1830240336; Andrews MC, 2021, NAT MED, V27, P1432, DOI 10.1038/s41591-021-01406-6; Bonner F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034730; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572; Correale P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9091964; Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005; Eberhardt CS, 2021, NATURE, V597, P279, DOI 10.1038/s41586-021-03862-z; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Fonseca R, 2022, NAT IMMUNOL, V23, P1236, DOI 10.1038/s41590-022-01273-4; Gabrielsen ISM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218858; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gil-Cruz C, 2019, SCIENCE, V366, P881, DOI 10.1126/science.aav3487; Granato M, 2014, J VIROL, V88, P12715, DOI 10.1128/JVI.02199-14; Heather JM, 2022, NUCLEIC ACIDS RES, V50, DOI 10.1093/nar/gkac190; Hu JR, 2019, CARDIOVASC RES, V115, P854, DOI 10.1093/cvr/cvz026; Hua XM, 2020, CIRCULATION, V142, P384, DOI 10.1161/CIRCULATIONAHA.119.043545; Jackson R, 2018, NATURE, V564, P434, DOI 10.1038/s41586-018-0794-7; Ji CH, 2019, CLIN CANCER RES, V25, P4735, DOI 10.1158/1078-0432.CCR-18-4083; Johnson DB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120360; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Jutz S, 2016, J IMMUNOL METHODS, V430, P10, DOI 10.1016/j.jim.2016.01.007; Lee JH, 2014, CARDIOVASC RES, V101, P203, DOI 10.1093/cvr/cvt246; Li O, 2004, J EXP MED, V200, P1083, DOI 10.1084/jem.20040779; Luoma AM, 2020, CELL, V182, P655, DOI 10.1016/j.cell.2020.06.001; Lv HJ, 2011, J CLIN INVEST, V121, P1561, DOI 10.1172/JCI44583; Martini E, 2019, CIRCULATION, V140, P2089, DOI 10.1161/CIRCULATIONAHA.119.041694; Massilamany C, 2011, CELL IMMUNOL, V271, P438, DOI 10.1016/j.cellimm.2011.08.013; Maurice NJ, 2021, J IMMUNOL, V206, P455, DOI 10.4049/jimmunol.2000937; Maurice NJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12980-2; McCulloch JA, 2022, NAT MED, V28, P545, DOI 10.1038/s41591-022-01698-2; Meier SL, 2022, NAT CANCER, V3, P143, DOI 10.1038/s43018-022-00335-8; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moslehi J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145186; Naranbhai V, 2022, LANCET ONCOL, V23, P172, DOI 10.1016/S1470-2045(21)00582-9; Oh HM, 2003, CELL PROLIFERAT, V36, P191, DOI 10.1046/j.1365-2184.2003.00276.x; Okazaki T, 2011, J EXP MED, V208, P395, DOI 10.1084/jem.20100466; Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12; Rieckmann M, 2019, J CLIN INVEST, V129, P4922, DOI 10.1172/JCI123859; Rosskopf Sandra, 2018, Oncotarget, V9, P17608, DOI 10.18632/oncotarget.24807; Salem JE, 2019, NEW ENGL J MED, V380, P2377, DOI 10.1056/NEJMc1901677; Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Scheper W, 2019, NAT MED, V25, P89, DOI 10.1038/s41591-018-0266-5; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Stevens M.H.H., 2016, VEGAN COMMUNITY ECOL; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Szabo PA, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aas9673; Tajiri K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020794; Taylor JA, 2004, J IMMUNOL, V172, P2651, DOI 10.4049/jimmunol.172.4.2651; Van der Borght K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02714; Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923; Wei SC, 2021, CANCER DISCOV, V11, P614, DOI 10.1158/2159-8290.CD-20-0856; Wolfl M, 2014, NAT PROTOC, V9, P950, DOI 10.1038/nprot.2014.064; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Yang XM, 2020, J IMMUNOL, V205, P987, DOI 10.4049/jimmunol.2000330; Zamami Y, 2019, JAMA ONCOL, V5, P1635, DOI 10.1001/jamaoncol.2019.3113; Zhang LL, 2020, CIRCULATION, V141, P2031, DOI 10.1161/CIRCULATIONAHA.119.044703	62	0	0	9	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 24	2022	611	7937					818	+		10.1038/s41586-022-05432-3	http://dx.doi.org/10.1038/s41586-022-05432-3		NOV 2022	30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6L1EM	36385524	Green Submitted			2023-01-03	WOS:000884719900007
J	Haas, MC; Sommer, BB; Karrer, S; Jorger, M; Graf, ES; Huber, M; Baumgartner, D; Bansi, J; Kool, J; Bauer, CM				Haas, Michelle C.; Sommer, Bettina B.; Karrer, Samuel; Joerger, Matthias; Graf, Eveline S.; Huber, Martin; Baumgartner, Daniel; Bansi, Jens; Kool, Jan; Bauer, Christoph M.			Surface electromyographic activity of trunk muscles during trunk control exercises for people after stroke; effect of a mobile and stable seat for rehabilitation	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; SITTING BALANCE; CORE STABILITY; 3-DIMENSIONAL KINEMATICS; MYOELECTRIC ACTIVITY; PERFORMANCE; RECOVERY; SPINE; DISABILITY; PREDICTOR	The aim of this study was to explore differences in trunk muscle activity on a stable and mobile seat for people after stroke and healthy participants. Trunk control exercises are known to have a beneficial effect on trunk control, balance, and mobility after stroke. The effect of such exercises could be enhanced by the use of a mobile seat to provide further training stimuli. However, little research on the musculoskeletal effects of trunk training on mobile seats has been carried out. On a stable and a mobile seat, thirteen people after stroke and fifteen healthy participants performed two selective trunk control exercises, which were lateral flexion initiated by the pelvis and the thorax. The maximal surface electromyography relative to static sitting of the muscles multifidus, erector spinae, and obliquus externus was recorded bilaterally. The effects of group, seat condition, trunk control exercise, and muscle side were investigated employing within-subject linear-mixed-models. Compared to the stable seat, the maximal muscle activity of people after stroke on the mobile seat was higher during the thorax-initiated exercise and lower during the pelvis-initiated exercise. Healthy participants showed opposite results with higher muscle activity on the mobile seat during the pelvis-initiated exercise. For trunk control training on a mobile seat with high muscle activation people after stroke should perform trunk control exercises initiated by the thorax, for training with lower muscle activity people after stroke should initiate selective trunk movements by the pelvis. The results can support the planning of progressive trunk control rehabilitation programs.	[Haas, Michelle C.; Sommer, Bettina B.; Karrer, Samuel; Joerger, Matthias; Graf, Eveline S.; Huber, Martin; Bauer, Christoph M.] Zurich Univ Appl Sci, Sch Hlth Sci, Winterthur, Switzerland; [Baumgartner, Daniel] Zurich Univ Appl Sci, Sch Engn, Winterthur, Switzerland; [Bansi, Jens; Kool, Jan] Valens Rehabil Ctr, Physiotherapy Dept, Valens, Switzerland	Zurich University of Applied Sciences; Zurich University of Applied Sciences	Haas, MC (corresponding author), Zurich Univ Appl Sci, Sch Hlth Sci, Winterthur, Switzerland.	michelle.haas2@zhaw.ch		Graf, Eveline/0000-0003-4740-8145; Kool, Jan/0000-0002-7074-8589	 [43266.1 IP-LS]		This study was funded by Innosuisse (43266.1 IP-LS). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bae SH, 2013, J PHYS THER SCI, V25, P741, DOI 10.1589/jpts.25.741; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bauer CM, 2021, APPL ERGON, V94, DOI 10.1016/j.apergo.2021.103390; Bauer CM, 2018, APPL ERGON, V72, P107, DOI 10.1016/j.apergo.2018.05.008; Ben Kibler W, 2006, SPORTS MED, V36, P189, DOI 10.2165/00007256-200636030-00001; Cabanas-Valdes R, 2017, CLIN REHABIL, V31, P1492, DOI 10.1177/0269215517701804; Cabanas-Valdes R, 2013, NEUROREHABILITATION, V33, P575, DOI 10.3233/NRE-130996; Cai SQ, 2019, J NEUROENG REHABIL, V16, DOI 10.1186/s12984-019-0609-6; Castanharo R, 2014, J ELECTROMYOGR KINES, V24, P114, DOI 10.1016/j.jelekin.2013.11.001; Chuter VH, 2012, GAIT POSTURE, V36, P7, DOI 10.1016/j.gaitpost.2012.02.001; Collins KC, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00472; Davies PM, 1990, RIGHT MIDDLE SELECTI; Duncan M, 2009, J BODYW MOV THER, V13, P364, DOI 10.1016/j.jbmt.2008.11.008; Farahpour N, 2015, CLIN BIOMECH, V30, P411, DOI 10.1016/j.clinbiomech.2015.03.018; Feigin L, 1996, GERONTOLOGY, V42, P348, DOI 10.1159/000213814; Feigin VL, 2021, LANCET NEUROL, V20, P795, DOI 10.1016/S1474-4422(21)00252-0; Feigin VL, 2015, NEUROEPIDEMIOLOGY, V45, P161, DOI 10.1159/000441085; Hart T, 2019, ARCH PHYS MED REHAB, V100, P172, DOI 10.1016/j.apmr.2018.09.109; Haruyama K, 2017, NEUROREHAB NEURAL RE, V31, P240, DOI 10.1177/1545968316675431; Hermens HJ, 1999, SENIAM 8 EUROPEAN RE; Hides J, 2008, MANUAL THER, V13, P43, DOI 10.1016/j.math.2006.07.017; Hsieh CL, 2002, STROKE, V33, P2626, DOI 10.1161/01.STR.0000033930.05931.93; IEC, 2019, 806012782019 IEC; ISO, 244962017 ISO; ISO, 149712007 ISO; Karatas M, 2004, AM J PHYS MED REHAB, V83, P81, DOI 10.1097/01.PHM.0000107486.99756.C7; Karthikbabu S, 2012, NEURAL REGEN RES, V7, P1974, DOI 10.3969/j.issn.1673-5374.2012.25.008; Kim TJ, 2015, ANN REHABIL MED-ARM, V39, P66, DOI 10.5535/arm.2015.39.1.66; Konrad P, 2006, ABC EMG PRACTICAL IN; Kuiken TA, 2003, PROSTHET ORTHOT INT, V27, P48; Kuriyama Naoyuki, 2005, Journal of Nippon Medical School, V72, P165, DOI 10.1272/jnms.72.165; Kuster RP, 2016, HUM FACTORS, V58, P886, DOI 10.1177/0018720816646508; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; Kwakkel G, 2013, INT J STROKE, V8, P25, DOI 10.1111/j.1747-4949.2012.00967.x; Kwakkel G, 1996, AGE AGEING, V25, P479, DOI 10.1093/ageing/25.6.479; Lenth R.V., 2021, EMMEANS ESTIMATED MA; McGill SM, 1999, CLIN BIOMECH, V14, P389, DOI 10.1016/S0268-0033(98)00111-9; Miller EL, 2010, STROKE, V41, P2402, DOI 10.1161/STR.0b013e3181e7512b; Ng J K, 1998, Electromyogr Clin Neurophysiol, V38, P51; O'Sullivan P, 2006, J ORTHOP SPORT PHYS, V36, P19, DOI 10.2519/jospt.2006.36.1.19; Pappalardo A, 2014, NEUROREHABILITATION, V35, P215, DOI 10.3233/NRE-141109; Peach JP, 1998, ARCH PHYS MED REHAB, V79, P663, DOI 10.1016/S0003-9993(98)90041-7; Pereira LM, 2011, J ELECTROMYOGR KINES, V21, P327, DOI 10.1016/j.jelekin.2010.10.003; Perlmutter S, 2010, GAIT POSTURE, V32, P53, DOI 10.1016/j.gaitpost.2010.03.005; R Core Team, 2021, R LANG ENV STAT COMP; Saeys W, 2012, NEUROREHAB NEURAL RE, V26, P231, DOI 10.1177/1545968311416822; Sousa A, 2012, ELECTROMYOGRAPHY NEW, P85; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; Thijs L, 2021, J NEUROENG REHABIL, V18, DOI 10.1186/s12984-021-00910-7; Van Criekinge T, 2019, DISABIL REHABIL, V41, P1751, DOI 10.1080/09638288.2018.1445785; van Nes IJW, 2008, GAIT POSTURE, V28, P507, DOI 10.1016/j.gaitpost.2008.03.004; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Verheyden G, 2006, CLIN REHABIL, V20, P451, DOI 10.1191/0269215505cr955oa; Verheyden G, 2008, NEUROREHAB NEURAL RE, V22, P173, DOI 10.1177/1545968307305456; Verheyden G, 2007, J NEUROL NEUROSUR PS, V78, P694, DOI 10.1136/jnnp.2006.101642; WADE DT, 1983, ARCH PHYS MED REHAB, V64, P24; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; William Revelle, 2021, PROCEDURES PERSONALI; Winter D.A., 2005, BIOMECHANICS MOTOR C, V3rd; Winzeler-Mercay U, 2002, DISABIL REHABIL, V24, P875, DOI 10.1080/09638280210142220	60	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2022	17	7							e0272382	10.1371/journal.pone.0272382	http://dx.doi.org/10.1371/journal.pone.0272382			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4Q0KX	35905083	Green Published, gold			2023-01-03	WOS:000855776900070
J	Padula, WV; Pronovost, PJ				Padula, William, V; Pronovost, Peter J.			Improvements in Hospital Adverse Event Rates Achieving Statistically Significant and Clinically Meaningful Results	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Padula, William, V] Univ Southern Calif, Sch Pharm, Dept Pharmaceut & Hlth Econ, Los Angeles, CA 90007 USA; [Padula, William, V] Univ Southern Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90007 USA; [Pronovost, Peter J.] Univ Hosp Cleveland Med Ctr, Cleveland, OH USA; [Pronovost, Peter J.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA	University of Southern California; University of Southern California; University Hospitals of Cleveland; Case Western Reserve University	Pronovost, PJ (corresponding author), Univ Hosp Cleveland Med Ctr, 3605 Warrensville Ctr Rd, Shaker Hts, OH 44122 USA.	peter.pronovost@uhhospitals.org						Agency for Healthcare Research and Quality, AHRQ NAT SCOR HOSP A; American Hospital Association, FIN EFF COVID 19 HOS; Caron A, 2021, J AM BOARD FAM MED, V34, P1038, DOI 10.3122/jabfm.2021.05.210015; Eldridge N, 2022, JAMA-J AM MED ASSOC, V328, P173, DOI 10.1001/jama.2022.9600; Guidance regarding agency interpretation of, 2019, FED REGISTER, V84, P724, DOI DOI 10.15620/CDC:82532; Herzer KR, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006065; Meddings JA, 2013, ANN INTERN MED, V159, P505, DOI 10.7326/0003-4819-159-8-201310150-00003; Padula WV, 2022, MAYO CLIN PROC, V97, P221, DOI 10.1016/j.mayocp.2021.10.001; Padula WV, 2021, BMJ QUAL SAF, V30, P89, DOI 10.1136/bmjqs-2019-010555; Padula WV, 2019, INT WOUND J, V16, P634, DOI 10.1111/iwj.13071; Padula WV, 2019, BMJ QUAL SAF, V28, P132, DOI 10.1136/bmjqs-2017-007505; Padula WV, 2020, J PATIENT SAF, V16, pE97, DOI 10.1097/PTS.0000000000000517; Pronovost PJ, 2016, BMJ QUAL SAF, V25, P396, DOI 10.1136/bmjqs-2015-004720; Shrank WH, 2019, JAMA-J AM MED ASSOC, V322, P1501, DOI 10.1001/jama.2019.13978; US Department of Health and Human Services, NAT HLTH QUAL ROADM; US Department of Health and Human Services, OFF INSP GEN ADV EV	16	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2022	328	2					148	150						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3E1GX	35819434				2023-01-03	WOS:000829739800013
J	Larkin, HD				Larkin, Howard D.			Expiration Dates Extended on COVID-19 Monoclonal Antibody Therapies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2022	328	1					11	11		10.1001/jama.2022.11033	http://dx.doi.org/10.1001/jama.2022.11033			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	2V1VH	35788810	Bronze			2023-01-03	WOS:000823639100010
J	Hedman, C; Rosso, A; Haggstrom, O; Norden, C; Furst, CJ; Schelin, MEC				Hedman, Christel; Rosso, Aldana; Haggstrom, Ola; Norden, Charlotte; Furst, Carl Johan; Schelin, Maria E. C.			Sedation in specialized palliative care: A cross-sectional study	PLOS ONE			English	Article							ADVANCED CANCER; HOSPICE	Background Palliative sedation is used to relieve refractory symptoms and is part of clinical practice in Sweden. Yet we do not know how frequently this practice occurs, how decision-making takes place, or even which medications are preferentially used. Objectives To understand the current practice of palliative sedation in Sweden. Methods We conducted a retrospective cross-sectional medical record-based study. For 690 consecutive deceased patients from 11 of 12 specialized palliative care units in the southernmost region of Sweden who underwent palliative sedation during 2016, we collected data on whether the patient died during sedation and, for sedated patients, the decision-making process, medication used, and depth of sedation. Results Eight percent of patients were sedated. Almost all (94%) were given midazolam, sometimes in combination with propofol. The proportions of sedation were similar in the patient groups with and without cancer. The largest proportion of the sedated patients died in inpatient care, but 23% died at home, with specialized palliative home care. Among the patients with a decision to sedate, 42% died deeply unconscious, while for those without such a decision the corresponding figure was 16%. In only one case was there more than one physician involved in the decision to use palliative sedation. Conclusion 8% of patients in specialized palliative care received palliative sedation, which is lower than international measures but much increased compared to an earlier Swedish assessment. The level of consciousness achieved often did not correspond to the planned level; this, together with indications of a scattered decision process, shows a need for clear guidelines.	[Hedman, Christel] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Hedman, Christel; Furst, Carl Johan; Schelin, Maria E. C.] Lund Univ, Dept Clin Sci Lund, Div Palliat Care, Lund, Sweden; [Hedman, Christel; Furst, Carl Johan; Schelin, Maria E. C.] Lund Univ, Inst Palliat Care, Lund, Sweden; [Hedman, Christel; Furst, Carl Johan; Schelin, Maria E. C.] Reg Skane, Lund, Sweden; [Hedman, Christel] Stockholms Sjukhem Fdn, R&D Dept, Stockholm, Sweden; [Rosso, Aldana] Lund Univ, Dept Clin Sci Malmo, Div Geriatr Med, Malmo, Sweden; [Haggstrom, Ola] Reg Skane, Unit Palliat Care Kristianstad, Kristianstad, Sweden; [Norden, Charlotte] Reg Skane, Unit Palliat Care Ystad, Ystad, Sweden; [Schelin, Maria E. C.] Skane Univ Hosp, Dept Res & Dev, Lund, Sweden	Karolinska Institutet; Lund University; Lund University; Lund University; Lund University; Skane University Hospital	Hedman, C (corresponding author), Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.; Hedman, C (corresponding author), Lund Univ, Dept Clin Sci Lund, Div Palliat Care, Lund, Sweden.; Hedman, C (corresponding author), Lund Univ, Inst Palliat Care, Lund, Sweden.; Hedman, C (corresponding author), Reg Skane, Lund, Sweden.; Hedman, C (corresponding author), Stockholms Sjukhem Fdn, R&D Dept, Stockholm, Sweden.	Christel.Hedman@ki.se		Rosso, Aldana/0000-0001-6603-2855; Hedman, Christel/0000-0003-4183-7598				Abarshi E, 2017, BMJ SUPPORT PALLIAT, V7, P223, DOI 10.1136/bmjspcare-2016-001159; Arantzamendi M, 2021, J PAIN SYMPTOM MANAG, V61, P831, DOI 10.1016/j.jpainsymman.2020.09.022; Belar A, 2021, PALLIATIVE MED, V35, P295, DOI 10.1177/0269216320974264; Beller EM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010206.pub2; Cherny NI, 2009, PALLIATIVE MED, V23, P581, DOI 10.1177/0269216309107024; Eckerdal Gunnar, 2009, Lakartidningen, V106, P1086; Elsayem A, 2009, SUPPORT CARE CANCER, V17, P53, DOI 10.1007/s00520-008-0459-4; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Hasselaar J., PALLIATIVE SEDATION; Heijltjes MT, 2020, J PAIN SYMPTOM MANAG, V60, P828, DOI 10.1016/j.jpainsymman.2020.06.019; Koike K, 2015, PALLIAT SUPPORT CARE, V13, P157, DOI 10.1017/S1478951513000837; Lux MR, 2017, AM J HOSP PALLIAT ME, V34, P217, DOI 10.1177/1049909115615128; Maltoni M, 2012, SUPPORT CARE CANCER, V20, P2829, DOI 10.1007/s00520-012-1407-x; Martinsson L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186804; Mercadante S, 2014, J PAIN SYMPTOM MANAG, V47, P860, DOI 10.1016/j.jpainsymman.2013.06.019; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V41, P754, DOI 10.1016/j.jpainsymman.2010.07.013; Moens K, 2014, J PAIN SYMPTOM MANAG, V48, P660, DOI 10.1016/j.jpainsymman.2013.11.009; Palacio SP, 2018, SUPPORT CARE CANCER, V26, P3173, DOI 10.1007/s00520-018-4164-7; Prommer Eric, 2020, Palliat Care Soc Pract, V14, p2632352419895527, DOI 10.1177/2632352419895527; Robijn L, 2018, PALLIATIVE MED, V32, P1198, DOI 10.1177/0269216318770342; Robijn L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158188; Schildmann EK, 2015, J PAIN SYMPTOM MANAG, V49, P734, DOI 10.1016/j.jpainsymman.2014.08.013; Schur S, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0121-8; Svenska Lakarsallskapet (Swedish Medical Assosiation, ET RIKTL PALL SED LI	24	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2022	17	7							e0270483	10.1371/journal.pone.0270483	http://dx.doi.org/10.1371/journal.pone.0270483			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4M3RI	35802571	gold, Green Published			2023-01-03	WOS:000853242200077
J	Slomski, A				Slomski, Anita			Almost All "Natural" Skin Care Products Contain Contact Allergens	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2022	328	17					1677	1677						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6C4JN	36318145				2023-01-03	WOS:000881982900043
J	Saccone, MA; Gallivan, RA; Narita, K; Yee, DW; Greer, JR				Saccone, Max A.; Gallivan, Rebecca A.; Narita, Kai; Yee, Daryl W.; Greer, Julia R.			Additive manufacturing of micro-architected metals via hydrogel infusion	NATURE			English	Article; Early Access							3D; COPPER	Metal additive manufacturing (AM) enables the production of high value and high performance components(1) with applications from aerospace(2) to biomedical(3) fields. Layer-by-layer fabrication circumvents the geometric limitations of traditional metalworking techniques, allowing topologically optimized parts to be made rapidly and efficiently(4,5). Existing AM techniques rely on thermally initiated melting or sintering for part shaping, a costly and material-limited process(6-8). We report an AM technique that produces metals and alloys with microscale resolution via vat photopolymerization (VP). Three-dimensional-architected hydrogels are infused with metal precursors, then calcined and reduced to convert the hydrogel scaffolds into miniaturized metal replicas. This approach represents a paradigm shift in VP; the material is selected only after the structure is fabricated. Unlike existing VP strategies, which incorporate target materials or precursors into the photoresin during printing(9-11), our method does not require reoptimization of resins and curing parameters for different materials, enabling quick iteration, compositional tuning and the ability to fabricate multimaterials. We demonstrate AM of metals with critical dimensions of approximately 40 mu m that are challenging to fabricate by using conventional processes. Such hydrogel-derived metals have highly twinned microstructures and unusually high hardness, providing a pathway to create advanced metallic micromaterials.	[Saccone, Max A.] CALTECH, Div Chem & Chem Engn, Pasadena 91125, CA USA; [Gallivan, Rebecca A.; Narita, Kai; Yee, Daryl W.; Greer, Julia R.] CALTECH, Div Engn & Appl Sci, Pasadena 91125, CA USA	California Institute of Technology; California Institute of Technology	Saccone, MA (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena 91125, CA USA.; Yee, DW; Greer, JR (corresponding author), CALTECH, Div Engn & Appl Sci, Pasadena 91125, CA USA.	msaccone@alumni.caltech.edu; daryl.yee@epfl.ch; jrgreer@caltech.edu	Yee, Daryl/ABA-5683-2021	Yee, Daryl/0000-0002-4114-6167; Saccone, Max/0000-0003-3846-2908; Gallivan, Rebecca/0000-0001-6516-2180; Narita, Kai/0000-0002-3867-8234; Greer, Julia/0000-0002-9675-1508	US Department of Energy, Office of Science, Basic Energy Sciences [DE-SC0016945]; Resnick Sustainability Institute at Caltech; Caltech; Masason Foundation	US Department of Energy, Office of Science, Basic Energy Sciences(United States Department of Energy (DOE)); Resnick Sustainability Institute at Caltech; Caltech; Masason Foundation	This work was supported by the US Department of Energy, Office of Science, Basic Energy Sciences under award no. DE-SC0016945. We thank C. Ma for support and assistance with instruments in the Geological and Planetary Sciences Division Analytical Facility at Caltech, as well as M. Xu and X. Pan for assistance with TEM experiments at UC Irvine Materials Research Institute. M.A.S. acknowledges a graduate fellowship from the Resnick Sustainability Institute at Caltech. R.A.G. acknowledges the AI4SCIENCE graduate fellowship at Caltech. K.N. acknowledges a fellowship from the Masason Foundation.	Bahl S, 2019, ADDIT MANUF, V28, P65, DOI 10.1016/j.addma.2019.04.016; Bahr DF, 2005, J MATER RES, V20, P1947, DOI 10.1557/JMR.2005.0244; Bandyopadhyay A, 2018, MAT SCI ENG R, V129, P1, DOI 10.1016/j.mser.2018.04.001; Bansal S, 2005, ELEC COMP C, P71; Bartlett JL, 2019, ADDIT MANUF, V27, P131, DOI 10.1016/j.addma.2019.02.020; Bergerhoff G., 1987, CRYSTALLOGRAPHIC DAT, P77; Chang SY, 2007, J APPL PHYS, V101, DOI 10.1063/1.2432873; Chen ZW, 2019, J EUR CERAM SOC, V39, P661, DOI 10.1016/j.jeurceramsoc.2018.11.013; Danks AE, 2016, MATER HORIZ, V3, P91, DOI 10.1039/c5mh00260e; Dass A, 2019, COATINGS, V9, DOI 10.3390/coatings9070418; DebRoy T, 2018, PROG MATER SCI, V92, P112, DOI 10.1016/j.pmatsci.2017.10.001; Emeis F, 2018, ACTA MATER, V150, P262, DOI 10.1016/j.actamat.2018.02.054; Gun'ko VM, 2017, GELS-BASEL, V3, DOI 10.3390/gels3040037; HALL EO, 1951, P PHYS SOC LOND B, V64, P747, DOI 10.1088/0370-1301/64/9/303; Herzberger J, 2018, ACS MACRO LETT, V7, P493, DOI 10.1021/acsmacrolett.8b00126; Nguyen HX, 2020, CIRP ANN-MANUF TECHN, V69, P177, DOI 10.1016/j.cirp.2020.04.069; Jadhav SD, 2020, ADDIT MANUF, V35, DOI 10.1016/j.addma.2020.101418; Kajtaz M., 2019, MAT SPORTS EQUIPMENT, P161, DOI 10.1016/b978-0-08-102582-6.00005-8; King WE, 2015, APPL PHYS REV, V2, DOI 10.1063/1.4937809; Laureijs RE, 2017, J MANUF SCI E-T ASME, V139, DOI 10.1115/1.4035420; Li Y, 2020, ADV MATER TECHNOL-US, V5, DOI 10.1002/admt.201900981; Ligon SC, 2017, CHEM REV, V117, P10212, DOI 10.1021/acs.chemrev.7b00074; Lisi N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09811-z; Long TE, 2018, SCIENCE, V362, P1244, DOI 10.1126/science.aav5712; Lu L, 2004, SCIENCE, V304, P422, DOI 10.1126/science.1092905; Manoj A, 2021, MATER TODAY-PROC, V44, P1361, DOI 10.1016/j.matpr.2020.11.505; Miyanaji H, 2020, ADDIT MANUF, V32, DOI 10.1016/j.addma.2019.100960; Mooraj S, 2020, SCRIPTA MATER, V177, P146, DOI 10.1016/j.scriptamat.2019.10.013; MOORE JJ, 1995, PROG MATER SCI, V39, P243, DOI 10.1016/0079-6425(94)00011-5; Oran D, 2018, SCIENCE, V362, P1281, DOI 10.1126/science.aau5119; Pande CS, 2004, MAT SCI ENG A-STRUCT, V367, P171, DOI 10.1016/j.msea.2003.09.100; Plocher J, 2019, MATER DESIGN, V183, DOI 10.1016/j.matdes.2019.108164; Roy B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04300-9; Sari N, 2006, J MACROMOL SCI A, V43, P1227, DOI 10.1080/10601320600737484; Senkov ON, 2018, J MATER RES, V33, P3092, DOI 10.1557/jmr.2018.153; Sun C, 2005, SENSOR ACTUAT A-PHYS, V121, P113, DOI 10.1016/j.sna.2004.12.011; Svetlizky D, 2021, MATER TODAY, V49, P271, DOI 10.1016/j.mattod.2021.03.020; Tumbleston JR, 2015, SCIENCE, V347, P1349, DOI 10.1126/science.aaa2397; Vafadar A, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11031213; Velasquez-Garcia LF, 2021, ANNU REV BIOMED ENG, V23, P307, DOI 10.1146/annurev-bioeng-082020-032402; Vyatskikh A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03071-9; Wang C, 2020, ACS APPL MATER INTER, V12, P18683, DOI 10.1021/acsami.0c01100; Yee DW, 2021, POLYM INT, V70, P964, DOI 10.1002/pi.6165; Yee DW, 2021, ADV MATER TECHNOL-US, V6, DOI 10.1002/admt.202000791; Yusuf SM, 2019, METALS-BASEL, V9, DOI 10.3390/met9121286; Zhang B, 2018, J MATER CHEM B, V6, P3246, DOI 10.1039/c8tb00673c; Zhang D, 2021, FRONT OPTOELECTRON, V14, P263, DOI 10.1007/s12200-020-1009-z	47	1	1	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature												10.1038/s41586-022-05433-2	http://dx.doi.org/10.1038/s41586-022-05433-2		OCT 2022	8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6S3YK	36265511	Green Published, Green Submitted			2023-01-03	WOS:000892926400001
J	Akoku, DA; Achombwom Vukugah, T; Abena Tihnje, M; Bigweh Nzubepie, I				Akoku, Derick Akompab; Achombwom Vukugah, Thomas; Abena Tihnje, Mbah; Bigweh Nzubepie, Idris			Childbearing intentions, fertility awareness knowledge and contraceptive use among female university students in Cameroon	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; SEXUAL-BEHAVIOR; SOCIAL MEDIA; DETERMINANTS; ADOLESCENTS; PREGNANCY; ATTITUDES; WOMEN	Objectives The primary objective of this study was to examine the association between fertility awareness knowledge, and contraceptive use among sexually active female university students (FUS) in Cameroon. Methods This study was designed as a secondary data analysis of a cross-sectional survey that was conducted between July and August 2018. We extracted and analyzed relevant data (i.e., socio-demographic characteristics, sexual behavior, fertility-related characteristics, and contraceptive use) using a modified Poisson regression with a robust variance estimator. Prevalence Ratios (PR) and 95% confidence intervals were estimated, and statistical significance was set at P <= 0.05. Results The median age of the sexually active FUS was 23 years (IQR = 21-25) and 99.3% indicated that they wanted to have children. Only 49.3% knew their fertile period and 62.5% of the sexually active FUS were current contraceptive users. We found a statistically significant association between fertility awareness knowledge and period abstinence (PR = 1.57;95%CI: 1.02-2.44, p = 0.049). In multivariate adjusted models, there was a statistically significant association between fertility awareness knowledge and male condom use (APR = 1.29; 95% CI:1.02-1.64, p-value = 0.032) and the withdrawal method (APR = 1.40;95% CI:1.02-1.93, p = 0.038). We found a statistically significant effect modification of "preferred timing to have children" on the association between fertility awareness knowledge and withdrawal method use. There was no association between fertility awareness knowledge and the use of oral contraceptive pills. Conclusion Most of the female students intend to have children in the future, but their fertility awareness knowledge was suboptimal. There was a statistically significant relationship between fertility awareness knowledge, and the use of male condoms and the withdrawal method. The study underscores the need for FUS to be targeted with interventions to help them gain knowledge of their menstrual cycle to better plan or avoid unwanted pregnancy.	[Akoku, Derick Akompab] Hlth Alliance Int, Abidjan, Cote Ivoire; [Achombwom Vukugah, Thomas] Columbia Univ, ICAP, Columbia, Mozambique; [Abena Tihnje, Mbah] Columbia Univ, ICAP, Columbia, Cameroon; [Bigweh Nzubepie, Idris] Georgetown Univ, Ctr Global Hlth Practice & Impact HIV Project, Yaounde, Cameroon		Akoku, DA (corresponding author), Hlth Alliance Int, Abidjan, Cote Ivoire.	aakoku@uw.edu						Adeniji AO Adekanle DA., 2014, GYNECOL OBSTET SUNNY, V4, P196, DOI DOI 10.4172/2161-0932.1000196; Ahmed ZD, 2017, PAN AFR MED J, V26, DOI 10.11604/pamj.2017.26.103.11436; Akinsoji AA, 2015, ETHIOP J HEALTH SCI, V25, P209, DOI 10.4314/ejhs.v25i3.3; Akoku DA, 2020, PAN AFR MED J, V36, DOI 10.11604/pamj.2020.36.333.25078; Alfaraj S, 2019, INT J HEALTH SCI-IJH, V13, P34; Ameyaw EK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220970; Bank World, 2019, MATERNAL MORTALITY R; Bellizzi S, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020429; Berger A., 2012, CHILDS TRENDS RES BR; Byamugisha Josaphat K, 2006, Afr Health Sci, V6, P194; Coetzee Maria H., 2015, Curationis, V38, P1, DOI 10.4102/curationis.v38i2.1535; Darteh EKM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209985; DHS, 2018, CAM DEM HLTH SURV; Dokubo EK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106760; Fekedulegn D, 2010, J CLIN HYPERTENS, V12, P365, DOI 10.1111/j.1751-7176.2010.00264.x; Frank-Herrmann P, 2007, HUM REPROD, V22, P1310, DOI 10.1093/humrep/dem003; GBD 2015 HIV Collaborators, 2016, LANCET HIV, V3, pe361, DOI [10.1016/S2352-3018(16)30087-X, DOI 10.1016/S2352-3018(16)30087-X]; Gelaye AA, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-50; Getahun MB, 2020, INT J WOMENS HEALTH, V12, P701, DOI 10.2147/IJWH.S267675; Hampton K, 2015, AUST FAM PHYSICIAN, V44, P840; Hoque ME., 2011, GEND BEHAV, V9, DOI [10.4314/gab.v9i1.67469, DOI 10.4314/GAB.V9I1.67469]; Hubacher D, 2008, CONTRACEPTION, V78, P73, DOI 10.1016/j.contraception.2008.03.002; Iyanda AE, 2020, INT J PUBLIC HEALTH, V65, P445, DOI 10.1007/s00038-020-01356-9; Jima A., 2016, ETHIOPIA HLTH SC J, V10, DOI [10.21767/1791-809X.1000469, DOI 10.21767/1791-809X.1000469]; Kelleher E, 2020, J PEDIATR ADOL GYNEC, V33, P619, DOI 10.1016/j.jpag.2020.06.016; Kenya National Bureau of Statistics (KNBS) and ICF Micro, 2014, KENYA DEMOGRAPHIC HL; Kwankye SO., 2009, AFRICAN POP STUDIES, V22, P79; Manhart MD., 2013, OSTEOPATHIC FAM PHYS, V5, P2, DOI DOI 10.1016/J.0SFP.2012.09.002; McCurdy RJ, 2015, OBSTET GYNECOL, V125, p85S, DOI 10.1097/01.AOG.0000463240.48074.9f; Mehra D, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.18599; Njotang Philip Nana, 2017, BMC Res Notes, V10, P219, DOI 10.1186/s13104-017-2543-7; Nsubuga H, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0286-6; Ochako R, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1483-1; Ogundipe SO., 2015, INT J SCI RES PUB 20, V5, P1; Ogunjuyigbe Peter O, 2009, Indian J Community Med, V34, P112, DOI 10.4103/0970-0218.51232; Raghupathi V, 2020, ARCH PUBLIC HEALTH, V78, DOI 10.1186/s13690-020-00402-5; Simmons RG, 2020, BEST PRACT RES CL OB, V66, P68, DOI 10.1016/j.bpobgyn.2019.12.003; Snow RC, 2015, GLOB PUBLIC HEALTH, V10, P149, DOI 10.1080/17441692.2014.986178; Somba MJ, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-94; Sweya MN, 2016, ADOLESC HEALTH MED T, V7, P109, DOI 10.2147/AHMT.S108531; Thijssen A, 2014, FACTS VIEWS VIS OBGY, V6, P113; Tilahun T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061335; Uganda Bureau of Statistics (UBOS) and ICF Micro, 2016, UG DEM HLTH SURV KEY; Urrutia RP, 2018, OBSTET GYNECOL, V132, P591, DOI 10.1097/AOG.0000000000002784; Vlassoff Michael, 2014, Issues Brief (Alan Guttmacher Inst), P1; Wong CA, 2014, HEALTHCARE-J DEL SCI, V2, P220, DOI 10.1016/j.hjdsi.2014.10.005	46	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2022	17	10							e0276270	10.1371/journal.pone.0276270	http://dx.doi.org/10.1371/journal.pone.0276270			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6T4DR	36251661	gold, Green Published			2023-01-03	WOS:000893628400048
J	Wang, LF; Sheng, G; Cui, JJ; Yao, YL; Bai, X; Chen, F; Yu, W				Wang, Lifen; Sheng, Gang; Cui, Jinjun; Yao, Yanling; Bai, Xue; Chen, Fan; Yu, Wei			Electroacupuncture attenuates ischemic injury after stroke and promotes angiogenesis via activation of EPO mediated Src and VEGF signaling pathways	PLOS ONE			English	Article							FOCAL CEREBRAL-ISCHEMIA; DOWN-REGULATION; GROWTH-FACTOR; EXPRESSION; KINASE; CELLS; ERYTHROPOIETIN; THROMBECTOMY; INHIBITOR; DISEASE	Although electroacupuncture (EA) has been shown to be effective in the treatment of stroke, its mechanisms of action remain undefined. This study explored the therapeutic effects of EA in rats with cerebral ischemia-reperfusion injury (CIRI) and evaluated its possible mechanisms in promoting angiogenesis. To evaluate the effect of EA, we used 2, 3, 5-Triphenyl-2H-Tetrazolium Chloride (TTC) staining and behavior score to calculate the cerebral infarct volume and neurological deficit score after CIRI. Western blot (WB) analysis was employed to evaluate the expression of cluster of differentiation 34 (CD34), erythropoietin (EPO), vascular endothelial growth factor (VEGF) and phospho-Src (p-Src) in the brain of the rats with CIRI. On the other hand, we established an oxygen-glucose deprivation/reoxygenation (OGD/R) injury model using brain microvascular endothelial cells (BMECs), and analyzed cell viability and expression of VEGF or p-Src using cell counting kit-8 (CCK-8) and WB, respectively. Our data showed that EA at the GV26 acupoint could significantly promote the expression of CD34, EPO, VEGF and p-Src in CIRI rats. Our CCK-8 results demonstrated that intervention with recombinant EPO and VEGF proteins remarkably improved the viability of BMECs after OGD/R, while a Src inhibitor, PP1, reversed this phenotype. The WB results showed that the recombinant EPO protein increased the expression of VEGF and pSrc, which was significantly inhibited by PP1. Taken together, our findings showed that EA at the GV26 acupoint can significantly attenuate ischemic injury after stroke and promote angiogenesis via activation of EPO-mediated Src and VEGF signaling pathways. Besides, the upregulation of VEGF may also be associated with the activation of Src by EPO.	[Wang, Lifen; Sheng, Gang; Yao, Yanling] Shaanxi Prov Hosp Chinese Med, Shaanxi Acad Tradit Chinese Med, Xian, Peoples R China; [Cui, Jinjun] Hebei Cangzhou Hosp Integrated Tradit Chinese Med, Dept Neurol, Cangzhou, Peoples R China; [Bai, Xue; Chen, Fan] Shaanxi Univ Chinese Med, Coll Acupuncture Moxibust & Massage, Xian Yang, Peoples R China; [Yu, Wei] Xian Med Univ, Dept Physiol, Xian, Peoples R China	Shaanxi University of Chinese Medicine; Xi'an Medical University; Shaanxi University of Chinese Medicine; Xi'an Medical University	Yu, W (corresponding author), Xian Med Univ, Dept Physiol, Xian, Peoples R China.	46534699@qq.com			Natural Science Basic Research Program of Shaanxi [2021JM-578]; Xi'an Science and Technology Project [2019115613YX011SF044-10]	Natural Science Basic Research Program of Shaanxi; Xi'an Science and Technology Project	This work was supported by Natural Science Basic Research Program of Shaanxi (Program No. 2021JM-578) and Xi'an Science and Technology Project (Program No. 2019115613YX011SF044-10). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alural B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00475; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Beneduce E, 2019, AM J HEMATOL, V94, P10, DOI 10.1002/ajh.25295; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; Chavez LM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112270; Chen TT, 2020, J CELL MOL MED, V24, P9154, DOI 10.1111/jcmm.15552; Cheranov SY, 2008, BLOOD, V111, P5581, DOI 10.1182/blood-2007-11-126680; Chou HC, 2010, FREE RADICAL BIO MED, V49, P96, DOI 10.1016/j.freeradbiomed.2010.04.001; Geng Y, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/3495836; Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Han XH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/156489; Hankey GJ, 2017, LANCET, V389, P641, DOI 10.1016/S0140-6736(16)30962-X; Huang SE, 2017, EXP THER MED, V14, P905, DOI 10.3892/etm.2017.4621; Ingley E, 2006, J BIOL CHEM, V281, P31920, DOI 10.1074/jbc.M602637200; Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780; Kang KA, 2010, NEUROL RES, V32, pS84, DOI 10.1179/016164109X12537002794246; Kim JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056736; Kimakova P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071519; Li H, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110183; Li J, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-441; Li J, 2021, NEURAL PLAST, V2021, DOI 10.1155/2021/4894881; Man J, 2020, BRAIN RES, V1736, DOI 10.1016/j.brainres.2020.146782; Morihara R, 2016, TRANSL STROKE RES, V7, P111, DOI 10.1007/s12975-016-0448-8; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; O'Donnell MJ, 2016, LANCET, V388, P761, DOI 10.1016/S0140-6736(16)30506-2; Shen MH, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/9438650; Shi L, 2017, NEURAL REGEN RES, V12, P2000, DOI 10.4103/1673-5374.221156; Shu S, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/7297425; Si W, 2019, 3 BIOTECH, V9, DOI 10.1007/s13205-019-1667-y; Sirvent A, 2020, CANCERS, V12, DOI 10.3390/cancers12082014; Summy JM, 2005, MOL CANCER THER, V4, P1900, DOI 10.1158/1535-7163.MCT-05-0171; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Sun P, 2021, J CEREBR BLOOD F MET, V41, P2725, DOI 10.1177/0271678X211010351; Sun W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0490-4; Tanaka F, 2003, LUNG CANCER-J IASLC, V39, P289, DOI 10.1016/S0169-5002(02)00534-2; Vieira SC, 2005, PATHOL RES PRACT, V201, P313, DOI 10.1016/j.prp.2005.01.010; Waltenberger J, 1999, CIRC RES, V85, P12; Wang HJ, 2020, PHYTOMEDICINE, V78, DOI 10.1016/j.phymed.2020.153300; Wang L, 2008, J CEREBR BLOOD F MET, V28, P1361, DOI 10.1038/jcbfm.2008.32; Wang SJ, 2003, NEUROL RES, V25, P516, DOI 10.1179/016164103101201751; Wu YH, 2021, J STROKE CEREBROVASC, V30, DOI 10.1016/j.jstrokecerebrovasdis.2020.105165; Xu H, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/6027421; Yan YL, 2016, KIDNEY INT, V89, P68, DOI 10.1038/ki.2015.293; Yang Y, 2020, CURR NEUROPHARMACOL, V18, P1250, DOI 10.2174/1570159X18666200720173316; Yao SQ, 2020, J MOL NEUROSCI, V70, P1871, DOI 10.1007/s12031-020-01580-1; Yu W, 2014, CURR NEUROVASC RES, V11, P367, DOI 10.2174/1567202611666140908094517; Zheng XW, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00911; Zhou MG, 2016, LANCET, V387, P251, DOI 10.1016/S0140-6736(15)00551-6	49	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2022	17	9							e0274620	10.1371/journal.pone.0274620	http://dx.doi.org/10.1371/journal.pone.0274620			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R1RR	36108080	Green Published, gold			2023-01-03	WOS:000892087100091
J	Bayer-Oglesby, L; Zumbrunn, A; Bachmann, N				Bayer-Oglesby, Lucy; Zumbrunn, Andrea; Bachmann, Nicole		SIHOS Team	Social inequalities, length of hospital stay for chronic conditions and the mediating role of comorbidity and discharge destination: A multilevel analysis of hospital administrative data linked to the population census in Switzerland	PLOS ONE			English	Article							OF-STAY; SOCIOECONOMIC-STATUS; HEALTH LITERACY; LANGUAGE BARRIERS; CARE; CANCER; RISK; MULTIMORBIDITY; EPIDEMIOLOGY; DETERMINANTS	Social factors are recognized determinants of morbidity and mortality and also have an impact on use of medical services. The objective of this study was to assess the associations of educational attainment, social and financial resources, and migration factors with length of hospital stays for chronic conditions. In addition, the study investigated the role of comorbidity and discharge destination in mediating these associations. The study made use of nationwide inpatient data that was linked with Swiss census data. The study sample included n = 141,307 records of n = 92,623 inpatients aged 25 to 84 years, hospitalized between 2010 and 2016 for a chronic condition. Cross-classified multilevel models and mediation analysis were performed. Patients with upper secondary and compulsory education stayed longer in hospital compared to those with tertiary education (beta 0.24 days, 95% CI 0.14-0.33; beta 0.37, 95% CI 0.27-0.47, respectively) when taking into account demographic factors, main diagnosis and clustering on patient and hospital level. However, these effects were almost fully mediated by burden of comorbidity. The effect of living alone on length of stay (beta 0.60 days, 95% CI 0.50-0.70) was partially mediated by both burden of comorbidities (33%) and discharge destination (30.4%). (Semi-) private insurance was associated with prolonged stays, but an inverse effect was observed for colon and breast cancer. Allophone patients had also prolonged hospital stays (beta 0.34, 95% CI 0.13-0.55). Hospital stays could be a window of opportunity to discern patients who need additional time and support to better cope with everyday life after discharge, reducing the risks of future hospital stays. However, inpatient care in Switzerland seems to take into account rather obvious individual needs due to lack of immediate support at home, but not necessarily more hidden needs of patients with low health literacy and less resources to assert their interests within the health system.	[Bayer-Oglesby, Lucy; Zumbrunn, Andrea; Bachmann, Nicole; SIHOS Team] Univ Appl Sci & Arts Northwestern Switzerland, Sch Social Work, Inst Social Work & Hlth, Olten, Switzerland	FHNW University of Applied Sciences & Arts Northwestern Switzerland	Bayer-Oglesby, L (corresponding author), Univ Appl Sci & Arts Northwestern Switzerland, Sch Social Work, Inst Social Work & Hlth, Olten, Switzerland.	lucy.bayer@fhnw.ch		Zumbrunn, Andrea/0000-0002-2823-2589; Bachmann, Nicole/0000-0001-8760-9027; Bayer-Oglesby, Lucy/0000-0001-8750-2158	SNSF National Research Programme "Smarter Health Care" (NRP74) [4, 407440_167506]	SNSF National Research Programme "Smarter Health Care" (NRP74)	This work was supported by the SNSF National Research Programme "Smarter Health Care"(NRP74), project number 4, grant number 407440_167506, applicant LBO. Project and funding description are available at http://www.nfp74.ch/en/projects/in-patient-care/project-bayeroglesby.The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views reported here are the authors' views and do not necessarily reflect the funding organization.	A. Zumbrunn, 2022, medRxiv, DOI 10.1101/2022.01.18.22269480; Abbato S, 2019, J IMMIGR MINOR HEALT, V21, P965, DOI 10.1007/s10903-018-0830-6; Agborsangaya CB, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-201; Agosti P, 2018, EUR J INTERN MED, V57, P25, DOI 10.1016/j.ejim.2018.06.014; Aigner Dennis J., 1973, J ECONOMETRICS, V1, P49, DOI DOI 10.1016/0304-4076(73)90005-5; Aubert Carole E, 2020, Mayo Clin Proc Innov Qual Outcomes, V4, P40, DOI 10.1016/j.mayocpiqo.2019.09.002; Bachmann N., 2014, SOZIALE RESSOURCEN A; Bachmann N, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.871778; Barker KM, 2020, SSM-POPUL HLTH, V12, DOI 10.1016/j.ssmph.2020.100661; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bayer-Oglesby L, 2020, SOCIAL SITUATION HOS; Bayer-Oglesby L, 2021, TECHNICAL REPORT IMP, DOI [10.26041/fhnw-3775, DOI 10.26041/FHNW-3775]; Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885; Bischoff A, 2012, INTERPRETING, V14, P1, DOI 10.1075/intp.14.1.01bis; Brameld KJ, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-61; Braveman P, 2014, PUBLIC HEALTH REP, V129, P19, DOI 10.1177/00333549141291S206; Bundesamt fur Statistik, 2014, BILD; Bundesamt fur Statistik, 1997, DAT MED STAT; Burkert Nathali., 2014, AMBULATORY CARE SENS, P112; Burton-Jeangros C, 2017, EUR J PUBLIC HEALTH, V27, P167, DOI 10.1093/eurpub/ckw113; Busato A, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13152; Cassell A, 2018, BRIT J GEN PRACT, V68, pE245, DOI 10.3399/bjgp18X695465; Chen G, 2014, NEUROIMAGE, V99, P571, DOI 10.1016/j.neuroimage.2014.06.027; Cournane S, 2015, EUR J INTERN MED, V26, P766, DOI 10.1016/j.ejim.2015.09.019; Covinsky KE, 2013, JAMA INTERN MED, V173, P321, DOI 10.1001/jamainternmed.2013.1617; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Filc D, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0115-1; Foraker RE, 2014, J HEALTHC QUAL, V36, P45, DOI 10.1111/j.1945-1474.2012.00211.x; Frolich A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214183; Gehrig M., 2009, BURO BASS, P85; Gehrig M, 2012, EINSATZ WIRKUNG INTE, P48; Ghosh AK, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000025976; Garcia AZG, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/483417; Grose D, 2014, POSTGRAD MED J, V90, P305, DOI 10.1136/postgradmedj-2013-132186; Guggisberg J, 2011, GESUNDHEITSMONITORIN; Guggisberg J., 2020, FORSCHUNGSMANDAT AUF, P59; Hajat Cother, 2018, Prev Med Rep, V12, P284, DOI 10.1016/j.pmedr.2018.10.008; Hayes Andrew F., 2018, LITTLE INTRO MEDIATI, VSecond; Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316; Hopman P, 2016, EUR J INTERN MED, V35, P44, DOI 10.1016/j.ejim.2016.08.025; Hu YY, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7296-x; Iacobucci D, 2012, J CONSUM PSYCHOL, V22, P582, DOI 10.1016/j.jcps.2012.03.006; Jaffee EG, 2017, J HOSP MED, V12, P969, DOI 10.12788/jhm.2848; Jaquet-Chiffelle DO, 2002, PROTECT PATIENTS RIG, P1; Karliner LS, 2012, MED CARE, V50, P283, DOI 10.1097/MLR.0b013e318249c949; Koch D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214194; Kutz A, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4045-x; Kutz A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.8332; Lage DE, 2018, J AM GERIATR SOC, V66, P100, DOI 10.1111/jgs.15150; Lee SW., 2022, LIFE CYCLE, V2, pe3; Lin IP, 2017, HEALTH POLICY, V121, P1001, DOI 10.1016/j.healthpol.2017.06.010; Lindholm M, 2012, J GEN INTERN MED, V27, P1294, DOI 10.1007/s11606-012-2041-5; Lopez L, 2015, J GEN INTERN MED, V30, P783, DOI 10.1007/s11606-015-3213-x; Marmot M, 2012, LANCET, V380, P1011, DOI 10.1016/S0140-6736(12)61228-8; Nimptsch U, 2016, HEALTH SERV RES, V51, P981, DOI 10.1111/1475-6773.12398; Obsan, 2015, NATIONALER GESUNDHEI; Omachi TA, 2013, J GEN INTERN MED, V28, P74, DOI 10.1007/s11606-012-2177-3; Omachi TA, 2010, CHEST, V137, P823, DOI 10.1378/chest.09-0764; Pandolfi P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135116; Pantell Matthew S, 2020, Hosp Pediatr, V10, P12, DOI 10.1542/hpeds.2019-0123; Payne RA, 2013, CAN MED ASSOC J, V185, pE221, DOI 10.1503/cmaj.121349; Perelman J, 2008, SOC SCI MED, V66, P88, DOI 10.1016/j.socscimed.2007.07.013; Pimouguet C, 2017, EUR J PUBLIC HEALTH, V27, P251, DOI 10.1093/eurpub/ckw150; Potterat J, 2019, STRUKTURERHEBUNG EID; Rawal S, 2019, JAMA-J AM MED ASSOC, V322, P1605, DOI 10.1001/jama.2019.13066; Roth S, 2021, OBSAN B; Rozzini R, 2013, JAMA INTERN MED, V173, P323, DOI 10.1001/jamainternmed.2013.1601; Salisbury C, 2012, LANCET, V380, P7, DOI 10.1016/S0140-6736(12)60482-6; Sarfati D, 2011, NEW ZEAL MED J, V124, P76; Simonet ML, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-154; Souza DLB, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-020-10084-x; Stanley J, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021689; Stokes J, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003514; SwissDRG, 2021, REG DEF FALL UNT SWI; Tarr N, 2019, LITERATURREVIEW INTE, P88; Tottenborg SS, 2016, RESP MED, V119, P160, DOI 10.1016/j.rmed.2016.09.007; Trachtenberg AJ, 2014, ANN FAM MED, V12, P402, DOI 10.1370/afm.1683; Tuch A, 2018, OBSAN DOSSIER; Tuch A., 2018, REPORT NO OBSAN B 12; van der Heide I, 2013, J HEALTH COMMUN, V18, P172, DOI 10.1080/10810730.2013.825668; van Rosse F, 2016, INT J NURS STUD, V54, P45, DOI 10.1016/j.ijnurstu.2015.03.012; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Wallar LE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229465; Weaver FM, 2014, HEALTH ECON POLICY L, V9, P71, DOI 10.1017/S1744133113000169; Westney G, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160333; Wheeler AP., 2013, RESTRICTED CUBIC SPL; Wieser S, 2018, EUR J HEALTH ECON, V19, P1149, DOI 10.1007/s10198-018-0963-5; Willems B, 2020, J HEALTH SOC BEHAV, V61, P377, DOI 10.1177/0022146520938708; Witte KK, 2018, HEART, V104, P993, DOI 10.1136/heartjnl-2017-312539; Wurth KM, 2018, J GEN INTERN MED, V33, P1885, DOI 10.1007/s11606-018-4618-0	91	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2022	17	8							e0272265	10.1371/journal.pone.0272265	http://dx.doi.org/10.1371/journal.pone.0272265			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4M1JC	36001555	Green Published, gold, Green Submitted			2023-01-03	WOS:000853083500029
J	Orendacova, M; Kvasnak, E; Vranova, J				Orendacova, Maria; Kvasnak, Eugen; Vranova, Jana			Effect of neurofeedback therapy on neurological post-COVID-19 complications (A pilot study)	PLOS ONE			English	Article							MAJOR DEPRESSIVE DISORDER; ALPHA ASYMMETRY; CHRONIC-FATIGUE; ANXIETY; BIOFEEDBACK; BACK	Objective Anxiety, fatigue and depression are common neurological manifestations after COVID-19. So far, post-COVID complications were treated by rehabilitation, oxygen therapy and immunotherapy. Effects of neurofeedback on post-COVID complications and their potential interrelatedness have not been studied yet. In this pilot study, we investigated the effectiveness of neurofeedback (Othmer method) for treatment of fatigue, anxiety, and depression after COVID-19. Methods 10 participants met inclusion criteria for having positive anamnesis of at least one of the following complications following COVID-19: fatigue, anxiety, and depression which were measured by questionnaires. ANOVA was used for calculating differences in questionnaire score before and after neurofeedback. Pearson's correlation coefficient was used to calculate correlations between anxiety, depression and fatigue. Results After five neurofeedback sessions, there came to significant reduction of severity of post-COVID anxiety and depression persisting for at least one month. Effect of neurofeedback on fatigue was insignificant. Severity of anxiety, fatigue and depression as well as reductions in depression and fatigue were positively correlated with each other. Conclusion These findings showed effectiveness neurofeedback for reducing anxiety and depression after COVID-19 and for studying correlations between neurological complications after COVID-19. However, since our pilot clinical trial was open-label, it is hard to differentiate between neurofeedback-specific and unspecific effects on our participants. Future randomized controlled trials with more robust sample are necessary to investigate feasibility of neurofeedback for post-COVID neurological complications. The study has identification number trial ID ISRCTN49037874 in ISRCTN register of clinical trials (Retrospectively registered).	[Orendacova, Maria; Kvasnak, Eugen; Vranova, Jana] Charles Univ Prague, Fac Med 3, Dept Med Biophys & Med Informat, Prague, Czech Republic	Charles University Prague	Orendacova, M (corresponding author), Charles Univ Prague, Fac Med 3, Dept Med Biophys & Med Informat, Prague, Czech Republic.	maria.orendacova@lf3.cuni.cz			Programme COOPERATIO of Third Faculty of Medicine, Charles University	Programme COOPERATIO of Third Faculty of Medicine, Charles University	This study was supported by Programme COOPERATIO of Third Faculty of Medicine, Charles University. The funders supported decision to publish this manuscript and they had no role in study design, data collection and analysis or preparation of the manuscript.	[Anonymous], 2004, 12 ANN ISNR C 2004, V9, P99; Ayache SS, 2021, J INTEGR NEUROSCI, V20, P745, DOI 10.31083/j.jin2003079; Baptista AF, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.573718; Barizien N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-93546-5; Berger AM, 2018, NEUROSCIENCE, V378, P189, DOI 10.1016/j.neuroscience.2017.06.007; Bilgin A, 2021, J CLIN NURS, DOI 10.1111/jocn.16153; Blazhenets G, 2021, J NUCL MED, V62, P910, DOI 10.2967/jnumed.121.262128; Blitshteyn S, 2021, IMMUNOL RES, V69, P205, DOI 10.1007/s12026-021-09185-5; Caro XJ, 2011, APPL PSYCHOPHYS BIOF, V36, P193, DOI 10.1007/s10484-011-9159-9; Caronna E, 2021, HEADACHE, V61, P1277, DOI 10.1111/head.14197; Carroll E, 2020, EPILEPSIA, V61, pE135, DOI 10.1111/epi.16683; Chen YY, 2020, NEUROPSYCHOPHARMACOL, V45, P1689, DOI 10.1038/s41386-020-0704-1; Cook DB, 2007, NEUROIMAGE, V36, P108, DOI 10.1016/j.neuroimage.2007.02.033; Dono F, 2021, NEUROL SCI, V42, P35, DOI 10.1007/s10072-020-04846-z; Dozois DJA, 1998, PSYCHOL ASSESSMENT, V10, P83, DOI 10.1037/1040-3590.10.2.83; Duffy FH, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-82; Egner T, 2014, NEUROFEEDBACK TREATM; El Sayed S, 2021, NEUROPSYCHOPHARM REP, V41, P50, DOI 10.1002/npr2.12154; Enriquez-Geppert S, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00051; Fernandez-de-las-Pennas C, 2021, J INFECTION, V83, P504, DOI 10.1016/j.jinf.2021.06.022; Fernandez-de-las-Penas C, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052621; Gadea M, 2020, EFFECTS SINGLE SESSI; Gruzelier JH, 2014, NEUROSCI BIOBEHAV R, V44, P159, DOI 10.1016/j.neubiorev.2014.03.015; Guedj E, 2021, EUR J NUCL MED MOL I, V48, P2823, DOI 10.1007/s00259-021-05215-4; Hammer BU, 2011, APPL PSYCHOPHYS BIOF, V36, P251, DOI 10.1007/s10484-011-9165-y; Hammond DC, 2001, NEUROREHABILITATION, V16, P295; Hammond DC, 2008, 1 DO NO HARM ADVERSE; HARDT JV, 1978, SCIENCE, V201, P79, DOI 10.1126/science.663641; Hayden MC, 2021, EFFECTIVENESS 3 WEEK; Diaz MH, 2019, PROCEDIA COMPUT SCI, V162, P974, DOI 10.1016/j.procs.2019.12.075; Jensen MP, 2018, INT J CLIN EXP HYP, V66, P231, DOI 10.1080/00207144.2018.1460546; Kamal M, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13746; Karavidas MK, 2007, APPL PSYCHOPHYS BIOF, V32, P19, DOI 10.1007/s10484-006-9029-z; Kayaaslan B, 2021, J MED VIROL, V93, P6566, DOI 10.1002/jmv.27198; Kincaid Keith J, 2021, eNeurologicalSci, V23, P100340, DOI 10.1016/j.ensci.2021.100340; Komaroff AL, 2021, TRENDS MOL MED, V27, P895, DOI 10.1016/j.molmed.2021.06.002; Kravitz HM, 2006, RANDOMIZED CONTROLLE, V10, P41; Kyzar Evan J, 2021, Brain Behav Immun Health, V16, P100315, DOI 10.1016/j.bbih.2021.100315; Lang XN, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.690121; Larsen S, 2013, PSYCHIAT CLIN N AM, V36, P163, DOI 10.1016/j.psc.2013.01.005; Legarda SB, 2011, J CHILD NEUROL, V26, P1045, DOI 10.1177/0883073811405052; Lehrer P, 2020, APPL PSYCHOPHYS BIOF, V45, P109, DOI 10.1007/s10484-020-09466-z; Lehrer PM, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00756; Lin IM, 2019, CLIN PSYCHOPHARM NEU, V17, P458, DOI 10.9758/cpn.2019.17.3.458; Lu YP, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100484; Luctkar-Flude M, 2017, EUR J INTEGR MED, V12, P172, DOI 10.1016/j.eujim.2017.06.003; Luctkar-Flude M, 2015, INTEGR CANCER THER, V14, P318, DOI 10.1177/1534735415572886; Matalon N., 2021, TRAJECTORIES POSTTRA, V143, P16; Mather M, 2018, CURR OPIN BEHAV SCI, V19, P98, DOI 10.1016/j.cobeha.2017.12.017; MAYBERG HS, 1994, J NEUROPSYCH CLIN N, V6, P428; Mazza MG, 2020, BRAIN BEHAV IMMUN, V89, P594, DOI 10.1016/j.bbi.2020.07.037; Mehler DMA, 2018, NEUROPSYCHOPHARMACOL, V43, P2578, DOI 10.1038/s41386-018-0126-5; Mennella R, 2017, BEHAV RES THER, V92, P32, DOI 10.1016/j.brat.2017.02.002; Michielsen HJ, 2003, J PSYCHOSOM RES, V54, P345, DOI 10.1016/S0022-3999(02)00392-6; Moradi A, 2011, PROCD SOC BEHV, V30, DOI 10.1016/j.sbspro.2011.10.021; Morand A, 2022, EUR J NUCL MED MOL I, V49, P913, DOI 10.1007/s00259-021-05528-4; Mottaz A, 2015, CLIN NEUROPHYSIOL, V126, P1754, DOI 10.1016/j.clinph.2014.11.023; Nan WY, 2012, INT J PSYCHOPHYSIOL, V86, P83, DOI 10.1016/j.ijpsycho.2012.07.182; Othmer SF, 2012, J NEUROTHERAPY INVES, P37; Othmer SF., 2007, HDB NEUROFEEDBACK DY, P109; Othmer SFG., 2019, NEUROFEEDBACK 1 50 Y, P327; Othmer S, 2017, RHYTHMIC STIMULATION PROCEDURES IN NEUROMODULATION, P225, DOI 10.1016/B978-0-12-803726-3.00008-0; Paquette V, 2009, PSYCHIAT RES-NEUROIM, V174, P231, DOI 10.1016/j.pscychresns.2009.06.002; Pilotto A, 2021, NEUROL SCI, V42, P4903, DOI 10.1007/s10072-021-05586-4; Prim JH, 2019, J PAIN RES, V12, P3265, DOI 10.2147/JPR.S208030; Reisert M, 2021, NEUROIMAGE, V231, DOI 10.1016/j.neuroimage.2021.117852; Riddle J, 2020, BRAIN STIMUL, V13, P576, DOI 10.1016/j.brs.2019.12.016; Rudroff T, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10121012; Sangare A, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10110845; Scheinost D, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.24; Sime A., 2004, J NEUROTHER, V8, P59, DOI [10.1300/J184v08n01_05, 10.1300/j184v08n01_05]; Staab JP, 2007, OTOL NEUROTOL, V28, P854, DOI 10.1097/MAO.0b013e31805c74a7; Steer R.A., 1997, EVALUATING STRESS BO, P23; Studies C., 2018, NEUROREGULATION, V5, P30; Sung CW, 2016, PSYCHOPHYSIOLOGY, V53, P455, DOI 10.1111/psyp.12575; Takamura M, 2020, J AFFECT DISORDERS, V271, P224, DOI 10.1016/j.jad.2020.03.080; Taquet M, 2021, LANCET PSYCHIAT, V8, P416, DOI 10.1016/S2215-0366(21)00084-5; Townsend L, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247280; Vezzani A, 2014, EPILEPSY CURR, V14, P3, DOI 10.5698/1535-7511-14.s2.3; Walker JE, 2011, CLIN EEG NEUROSCI, V42, P59, DOI 10.1177/155005941104200112; Walker JE, 2010, APPL PSYCHOPHYS BIOF, V35, P25, DOI 10.1007/s10484-009-9107-0; Wang SY, 2019, J AFFECT DISORDERS, V257, P287, DOI 10.1016/j.jad.2019.07.026; Workman C., 2021, BRAIN STIMUL, V14, P1672, DOI [10.1016/j.brs.2021.10.268, DOI 10.1016/J.BRS.2021.10.268]; Workman CD, 2020, BRAIN STIMUL, V13, P263, DOI 10.1016/j.brs.2019.09.012; Yang CL, 2020, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01421; Younger D.S., 2021, WORLD J NEUROSCI, V11, P17, DOI 10.4236/wjns.2021.111003; Yu SH, 2020, CLIN PSYCHOPHARM NEU, V18, P375, DOI 10.9758/cpn.2020.18.3.375; Zhou YY, 2021, J MICROBIOL, V59, P941, DOI 10.1007/s12275-021-1206-5	88	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2022	17	7							e0271350	10.1371/journal.pone.0271350	http://dx.doi.org/10.1371/journal.pone.0271350			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5Z7YE	35895740	gold, Green Published			2023-01-03	WOS:000880183400054
J	Myburgh, JA; Seppelt, IM; Goodman, F; Billot, L; Correa, M; Davis, JS; Gordon, AC; Hammond, NE; Iredell, J; Li, Q; Micallef, S; Miller, J; Mysore, J; Taylor, C; Young, PJ; Cuthbertson, BH; Finfer, SR				Myburgh, John A.; Seppelt, Ian M.; Goodman, Fiona; Billot, Laurent; Correa, Maryam; Davis, Joshua S.; Gordon, Anthony C.; Hammond, Naomi E.; Iredell, Jon; Li, Qiang; Micallef, Sharon; Miller, Jennene; Mysore, Jayanthi; Taylor, Colman; Young, Paul J.; Cuthbertson, Brian H.; Finfer, Simon R.		SuDDICU Investigators Australian	Effect of Selective Decontamination of the Digestive Tract on Hospital Mortality in Critically Ill Patients Receiving Mechanical Ventilation A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Early Access							INTENSIVE-CARE; ANTIBIOTIC-RESISTANCE; PREVENTION; OROPHARYNX; SDD	IMPORTANCE Whether selective decontamination of the digestive tract (SDD) reduces mortality in critically ill patients remains uncertain. OBJECTIVE To determine whether SDD reduces in-hospital mortality in critically ill adults. DESIGN, SETTING, AND PARTICIPANTS A cluster, crossover, randomized clinical trial that recruited 5982 mechanically ventilated adults from 19 intensive care units (ICUs) in Australia between April 2018 and May 2021 (final follow-up, August 2021). A contemporaneous ecological assessment recruited 8599 patients from participating ICUs between May 2017 and August 2021. INTERVENTIONS ICUs were randomly assigned to adopt or not adopt a SDD strategy for 2 alternating 12-month periods, separated by a 3-month interperiod gap. Patients in the SDD group (n = 2791) received a 6-hourly application of an oral paste and administration of a gastric suspension containing colistin, tobramycin, and nystatin for the duration of mechanical ventilation, plus a 4-day course of an intravenous antibiotic with a suitable antimicrobial spectrum. Patients in the control group (n = 3191) received standard care. MAIN OUTCOMES AND MEASURES The primary outcomewas in-hospital mortality within 90 days. There were 8 secondary outcomes, including the proportion of patients with new positive blood cultures, antibiotic-resistant organisms (AROs), and Clostridioides difficile infections. For the ecological assessment, a noninferiority margin of 2% was prespecified for 3 outcomes including new cultures of AROs. RESULTS Of 5982 patients (mean age, 58.3 years; 36.8% women) enrolled from 19 ICUs, all patients completed the trial. There were 753/2791 (27.0%) and 928/3191 (29.1%) in-hospital deaths in the SDD and standard care groups, respectively (mean difference, -1.7%[95% CI, -4.8% to 1.3%]; odds ratio, 0.91 [95% CI, 0.82-1.02]; P =.12). Of 8 prespecified secondary outcomes, 6 showed no significant differences. In the SDD vs standard care groups, 23.1% vs 34.6% had new ARO cultures (absolute difference, -11.0%; 95% CI, -14.7% to -7.3%), 5.6% vs 8.1% had new positive blood cultures (absolute difference, -1.95%; 95% CI, -3.5% to -0.4%), and 0.5% vs 0.9% had new C difficile infections (absolute difference, -0.24%; 95% CI, -0.6% to 0.1%). In 8599 patients enrolled in the ecological assessment, use of SDD was not shown to be noninferior with regard to the change in the proportion of patients who developed new AROs (-3.3% vs -1.59%; mean difference, -1.71%[1-sided 97.5% CI, - infinity to 4.31%] and 0.88% vs 0.55%; mean difference, -0.32%[1-sided 97.5% CI, - infinity to 5.47%]) in the first and second periods, respectively. CONCLUSIONS AND RELEVANCE Among critically ill patients receiving mechanical ventilation, SDD, compared with standard care without SDD, did not significantly reduce in-hospital mortality. However, the confidence interval around the effect estimate includes a clinically important benefit.	[Myburgh, John A.; Seppelt, Ian M.; Goodman, Fiona; Billot, Laurent; Correa, Maryam; Davis, Joshua S.; Hammond, Naomi E.; Iredell, Jon; Micallef, Sharon; Miller, Jennene; Mysore, Jayanthi; Taylor, Colman; Young, Paul J.; Finfer, Simon R.] George Inst Global Hlth, Crit Care Div, Sydney, NSW, Australia; [Myburgh, John A.; Billot, Laurent; Hammond, Naomi E.; Finfer, Simon R.] Univ New South Wales, Fac Med, Sydney, NSW, Australia; [Myburgh, John A.; Miller, Jennene] St George Hosp, Sydney, NSW, Australia; [Seppelt, Ian M.; Iredell, Jon] Univ Sydney, Fac Med, Sydney, NSW, Australia; [Seppelt, Ian M.] Nepean Hosp, Sydney, NSW, Australia; [Seppelt, Ian M.] Macquarie Univ, Fac Med & Hlth Sci, Sydney, NSW, Australia; [Davis, Joshua S.] John Hunter Hosp, Newcastle, NSW, Australia; [Davis, Joshua S.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia; [Davis, Joshua S.] Menzies Sch Heath Res, Newcastle, NSW, Australia; [Gordon, Anthony C.; Finfer, Simon R.] Imperial Coll London, Fac Med, London, England; [Hammond, Naomi E.] Royal North Shore Hosp, Sydney, NSW, Australia; [Iredell, Jon] Westmeath Inst Med Res, Ctr Infect Dis & Microbiol, Sydney, Australia; [Miller, Jennene] Liverpool Hosp, Sydney, NSW, Australia; [Young, Paul J.] Wellington Hosp, Wellington, New Zealand; [Young, Paul J.] Med Res Inst New Zealand, Wellington, New Zealand; [Cuthbertson, Brian H.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Cuthbertson, Brian H.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada	George Institute for Global Health; University of Sydney; University of New South Wales Sydney; St George Hospital; University of Sydney; Nepean Hospital; Macquarie University; John Hunter Hospital; University of Newcastle; Imperial College London; Royal North Shore Hospital; Liverpool Hospital; Medical Research Institute Of New Zealand; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Myburgh, JA (corresponding author), George Inst Global Hlth, 1 King St, Newtown, NSW 2042, Australia.	jmyburgh@georgeinstitute.org.au		Finfer, Simon/0000-0002-2785-5864; Billot, Laurent/0000-0002-4975-9793	National Health and Medical Research Council of Australia [1084244]; National Health and Medical Research Council of Australia; Department of Anesthesiology and Pain Medicine, University of Toronto; NIHR; Health Research Council of New Zealand	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Department of Anesthesiology and Pain Medicine, University of Toronto; NIHR(National Institute for Health Research (NIHR)); Health Research Council of New Zealand(Health Research Council of New Zealand)	This trial was supported by project grant 1084244 from the National Health and Medical Research Council of Australia as well as a leadership fellowship to Dr Myburgh, practitioner fellowships to Drs Finfer and Iredell, a career development fellowship to Dr Davis, and an Emerging Leader Investigator grant to Dr Hammond from the National Health and Medical Research Council of Australia. This trial was also supported by a merit award from the Department of Anesthesiology and Pain Medicine, University of Toronto, to Dr Cuthbertson; by a research professorship from the NIHR and infrastructure support from the NIHR Imperial Biomedical Research Centre to Dr Gordon; and by a clinical practitioner research fellowship from the Health Research Council of New Zealand to Dr Young. The George Institute for Global Health was the principal sponsor for this trial. Drug preparations were purchased and manufactured under contract with the George Institute for Global Health by Verita Pharma.	Canter RR, 2014, BRIT J ANAESTH, V113, P610, DOI 10.1093/bja/aeu108; Cuthbertson BH, 2013, CRIT CARE, V17, DOI 10.1186/cc13096; Daneman N, 2013, LANCET INFECT DIS, V13, P328, DOI 10.1016/S1473-3099(12)70322-5; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Duncan EM, 2014, J CRIT CARE, V29, P634, DOI 10.1016/j.jcrc.2014.03.013; Evans L, 2021, INTENS CARE MED, V47, P1181, DOI 10.1007/s00134-021-06506-y; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; HOLM S, 1979, SCAND J STAT, V6, P65; Kenward MG, 2009, COMPUT STAT DATA AN, V53, P2583, DOI 10.1016/j.csda.2008.12.013; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Minozzi S, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000022.pub4; Morgan KE, 2017, STAT MED, V36, P318, DOI 10.1002/sim.7137; Oostdijk EAN, 2014, JAMA-J AM MED ASSOC, V312, P1429, DOI 10.1001/jama.2014.7247; Oostdijk EAN, 2010, AM J RESP CRIT CARE, V181, P452, DOI 10.1164/rccm.200908-1210OC; Plantinga NL, 2018, CLIN MICROBIOL INFEC, V24, P505, DOI 10.1016/j.cmi.2017.08.019; Roquilly A, 2015, CLIN INFECT DIS, V60, P64, DOI 10.1093/cid/ciu740; SCHIMPFF SC, 1980, ANN INTERN MED, V93, P358, DOI 10.7326/0003-4819-93-2-358; Silvestri L, 2010, CRIT CARE MED, V38, P1370, DOI 10.1097/CCM.0b013e3181d9db8c; Stoutenbeek CP, 2007, INTENS CARE MED, V33, P261, DOI 10.1007/s00134-006-0455-4; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; SuDDICU Investigators, 2021, CRIT CARE RESUSC, V23, P183, DOI [10.51893/2021.2.oa5, DOI 10.51893/2021.2.OA5]; VANSAENE HKF, 1991, J HOSP INFECT, V18, P261, DOI 10.1016/0195-6701(91)90184-A; Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835; Wittekamp BH, 2018, JAMA-J AM MED ASSOC, V320, P2087, DOI 10.1001/jama.2018.13765; Wittekamp BHJ, 2020, INTENS CARE MED, V46, P343, DOI 10.1007/s00134-019-05883-9; World Health Organization, DDD; Wunderink RG, 2010, AM J RESP CRIT CARE, V181, P426, DOI 10.1164/rccm.200912-1821ED	29	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.17927	http://dx.doi.org/10.1001/jama.2022.17927		OCT 2022	11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5U6IM	36286097				2023-01-03	WOS:000876648400001
J	[Anonymous]				[Anonymous]			Update to living WHO guideline on drugs for covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	3	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 15	2022	378								o2224	10.1136/bmj.o2224	http://dx.doi.org/10.1136/bmj.o2224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6M3LX	36109041				2023-01-03	WOS:000888774200006
J	Zhao, Y; Zhou, B; Zhang, GY; Xu, SX; Yang, JP; Deng, SZ; Yao, ZM; Geng, Q; Ouyang, B; Xia, T				Zhao, Yu; Zhou, Bo; Zhang, Guangyin; Xu, Shixin; Yang, Jipeng; Deng, Shizhe; Yao, Zengmin; Geng, Qiang; Ouyang, Bin; Xia, Tian			The effect of acupuncture on oxidative stress: A systematic review and meta-analysis of animal models	PLOS ONE			English	Review							ELECTROACUPUNCTURE PRETREATMENT; ALZHEIMERS-DISEASE; INJURY; RATS; ANTIOXIDANTS; PATHOGENESIS; INFLAMMATION; MECHANISMS; EXPRESSION; PARAMETERS	Introduction Oxidative stress is involved in the occurrence and development of multiple diseases. Acupuncture shows an excellent clinical efficacy in practical application but its mechanism remains unclear. This systematic review and meta-analysis was aimed at assessing the effect of acupuncture on oxidative stress in animal models. Methods PubMed, Embase, and Web of Science database were retrieved for randomized controlled trials about acupuncture on oxidative stress in animal models from inception to August 2021. Two reviewers independently screened and extracted articles according to inclusion and exclusion criteria. We used the mean difference (MD)/standardized mean difference (SMD) to perform an effect size analysis and selected fixed-effect or random-effect models to pool the data, depending on a 95% confidence interval (CI). Results A total of 12 studies comprising 125 samples were included in the quantitative meta-analysis. Compared with sham acupuncture, acupuncture (manual acupuncture, electropuncture, and laser acupuncture) reduced the level of malondialdehyde (SMD, -3.03; CI, -4.40, -1.65; p < 0.00001) and increased the levels of superoxide dismutase (SMD, 3.39; CI, 1.99, 4.79; p <0.00001), glutathione peroxidase (SMD, 2.21; CI, 1.10, 3.32; p <0.00001), and catalase (SMD, 2.80; CI, 0.57, 5.03; p = 0.01). Conclusion This meta-analysis indicated that acupuncture can regulate oxidative stress by lowering the lipid peroxidation and activating the antioxidant enzyme system. In consideration of heterogeneity between studies, future studies should be performed by complying with strict standards and increasing sample size in animal experiments to reduce bias.	[Zhao, Yu; Yao, Zengmin; Geng, Qiang; Ouyang, Bin] Tianjin Univ Tradit Chinese Med, Androl Dept, Teaching Hosp 1, Tianjin, Peoples R China; [Zhao, Yu; Zhou, Bo; Zhang, Guangyin; Xu, Shixin; Yang, Jipeng; Deng, Shizhe; Yao, Zengmin; Geng, Qiang; Ouyang, Bin; Xia, Tian] Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin, Peoples R China; [Zhou, Bo; Zhang, Guangyin] Tianjin Univ Tradit Chinese Med, Psychosomat Med Dept, Teaching Hosp 1, Tianjin, Peoples R China; [Xu, Shixin] Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Tradit Res Tradit Chinese Med Pre, Teaching Hosp 1, Tianjin, Peoples R China; [Yang, Jipeng; Deng, Shizhe] Tianjin Univ Tradit Chinese Med, Acupuncture & Moxibust Dept, Teaching Hosp 1, Tianjin, Peoples R China; [Xia, Tian] Tianjin Univ Tradit Chinese Med, Reprod Ctr Dept, Teaching Hosp 1, Tianjin, Peoples R China	Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Xia, T (corresponding author), Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin, Peoples R China.; Xia, T (corresponding author), Tianjin Univ Tradit Chinese Med, Reprod Ctr Dept, Teaching Hosp 1, Tianjin, Peoples R China.	xiatian76@163.com		Zhao, Yu/0000-0003-3975-155X	Ministry of Science and Technology of the People's Republic of China [2018YFC1706001]	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China)	This research was funded by the Ministry of Science and Technology of the People's Republic of China (Project Grant no. 2018YFC1706001). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal A, 2019, WORLD J MENS HEALTH, V37, P296, DOI 10.5534/wjmh.190055; Agarwal A, 2017, TRANSL ANDROL UROL, V6, pS695, DOI 10.21037/tau.2017.05.40; Ahmad W, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0379-z; Aitken RJ, 2017, MOL REPROD DEV, V84, P1039, DOI 10.1002/mrd.22871; Allen CL, 2009, INT J STROKE, V4, P461, DOI 10.1111/j.1747-4949.2009.00387.x; Alvarado-Sanchez BG, 2019, NEUROCHEM RES, V44, P498, DOI 10.1007/s11064-018-02704-1; Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438; Bektas H, 2010, STROKE, V41, P2539, DOI 10.1161/STROKEAHA.110.591362; Brandes RP, 2010, FREE RADICAL BIO MED, V49, P687, DOI 10.1016/j.freeradbiomed.2010.04.030; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Butterfield DA, 2007, FREE RADICAL BIO MED, V43, P658, DOI 10.1016/j.freeradbiomed.2007.05.037; Butterfield DA, 2002, NEUROBIOL AGING, V23, P655; Chang SC, 2019, ACUPUNCT MED, V37, P340, DOI 10.1136/acupmed-2017-011577; Chavez LM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112270; Chen CH, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9030248; Chen Y, 2016, BRAIN RES BULL, V127, P248, DOI 10.1016/j.brainresbull.2016.10.009; Chen ZC, 2014, NEUROSCI BULL, V30, P271, DOI 10.1007/s12264-013-1423-y; Cheng M, 2020, J MOL NEUROSCI, V70, P2031, DOI 10.1007/s12031-020-01609-5; Cherian DA, 2019, J PHARM BIOALLIED SC, V11, pS297, DOI [10.4103/jpbs.JPBS_17_19, 10.4103/JPBS.JPBS_17_19]; Chon TY, 2013, MAYO CLIN PROC, V88, P1141, DOI 10.1016/j.mayocp.2013.06.009; Crack PJ, 2005, FREE RADICAL BIO MED, V38, P1433, DOI 10.1016/j.freeradbiomed.2005.01.019; Digitizer G.G., 2020, GETDATA GRAPH DIGITI; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Forstermann U, 2010, PFLUG ARCH EUR J PHY, V459, P923, DOI 10.1007/s00424-010-0808-2; Forman HJ, 2021, NAT REV DRUG DISCOV, V20, P689, DOI 10.1038/s41573-021-00233-1; Frantz AL, 2017, NEUROSCI LETT, V661, P33, DOI 10.1016/j.neulet.2017.09.044; Garrido-Maraver J, 2014, FRONT BIOSCI-LANDMRK, V19, P619, DOI 10.2741/4231; Gerrits EG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089719; Guo F, 2014, BRAIN RES, V1573, P84, DOI 10.1016/j.brainres.2014.05.020; Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Jia YJ, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2064-x; Jiang KP, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.875103; Jittiwat J, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/1204709; Jittiwat J, 2017, J ACUPUNCT MERIDIAN, V10, P324, DOI 10.1016/j.jams.2017.08.003; Juul F, 2021, ADV NUTR, V12, P1673, DOI 10.1093/advances/nmab049; Kahles T, 2010, NEUROBIOL DIS, V40, P185, DOI 10.1016/j.nbd.2010.05.023; Khongrum J, 2015, J ACUPUNCT MERIDIAN, V8, P183, DOI 10.1016/j.jams.2015.06.008; Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010; Koekkoek WAC, 2016, NUTR CLIN PRACT, V31, P457, DOI 10.1177/0884533616653832; Kreuz S, 2016, EPIGENOMICS-UK, V8, P843, DOI 10.2217/epi-2016-0002; Kucuk EV, 2016, ANDROLOGIA, V48, P1080, DOI 10.1111/and.12541; Leung SB, 2016, CHIN MED-UK, V11, DOI 10.1186/s13020-016-0110-0; Li C, 2020, J SURG RES, V256, P258, DOI 10.1016/j.jss.2020.06.056; Li MH, 2017, J TRADIT CHIN MED, V37, P171; Lima LP, 2012, AESTHET PLAST SURG, V36, P1230, DOI 10.1007/s00266-012-9926-x; Liu CZ, 2006, NEUROSCI LETT, V393, P45, DOI 10.1016/j.neulet.2005.09.049; Liu JS, 2012, AM J PHYSIOL-REG I, V303, pR209, DOI 10.1152/ajpregu.00301.2010; Liu ZB, 2013, J TRADIT CHIN MED, V33, P399, DOI 10.1016/S0254-6272(13)60186-7; Matsuzawa-Nagata N, 2008, METABOLISM, V57, P1071, DOI 10.1016/j.metabol.2008.03.010; Mooventhan A, 2020, J Complement Integr Med, V17, DOI 10.1515/jcim-2019-0100; Muratori M, 2015, MOL MED, V21, DOI 10.2119/molmed.2014.00158; Orellana-Urzua S, 2020, CURR PHARM DESIGN, V26, P4246, DOI 10.2174/1381612826666200708133912; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Palma F, 2020, MENOPAUSE, V27, P1060, DOI 10.1097/GME.0000000000001626; Phillips M, 2004, CLIN CHIM ACTA, V344, P189, DOI 10.1016/j.cccn.2004.02.025; Phunchago N, 2015, J ACUPUNCT MERIDIAN, V8, P23, DOI 10.1016/j.jams.2014.11.008; Qu F, 2020, J CELL PHYSIOL, V235, P2441, DOI 10.1002/jcp.29148; Senoner T, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092090; Shi GX, 2015, SCI REP-UK, V5, DOI 10.1038/srep17981; Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037; Sies H, 2015, REDOX BIOL, V4, P180, DOI 10.1016/j.redox.2015.01.002; Siu FKW, 2005, LIFE SCI, V77, P386, DOI 10.1016/j.lfs.2004.10.069; Sutalangka C, 2013, J ACUPUNCT MERIDIAN, V6, P247, DOI 10.1016/j.jams.2013.07.001; Takahashi T, 2013, INT REV NEUROBIOL, V111, P273, DOI 10.1016/B978-0-12-411545-3.00014-6; Tamagno E, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10091479; Tian LG, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3987134; Truong T, 2017, HUM REPROD, V32, P2404, DOI 10.1093/humrep/dex330; Wang HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019790; Wang XL, 2014, BBA-MOL BASIS DIS, V1842, P1240, DOI 10.1016/j.bbadis.2013.10.015; Willcox JK, 2004, CRIT REV FOOD SCI, V44, P275, DOI 10.1080/10408690490468489; Yang B, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/1905995; Yu JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104924; Yu YP, 2010, BRAIN RES, V1336, P58, DOI 10.1016/j.brainres.2010.04.020; Zhang PJ, 2020, FRONT MED-PRC, V14, P583, DOI 10.1007/s11684-019-0729-1; Zhang XZ, 2014, NEUROCHEM INT, V65, P23, DOI 10.1016/j.neuint.2013.12.004; Zhao FY, 2021, J ACUPUNCT TUINA SCI, V19, P157, DOI 10.1007/s11726-021-1240-1; Zhuang Y, 2013, INT REV NEUROBIOL, V111, P1, DOI 10.1016/B978-0-12-411545-3.00001-8	81	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2022	17	9							e0271098	10.1371/journal.pone.0271098	http://dx.doi.org/10.1371/journal.pone.0271098			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R1EM	36084019	gold, Green Published			2023-01-03	WOS:000892051000016
J	Nguyen, MLT; Schotland, SV; Howell, JD				Nguyen, Michelle-Linh T.; Schotland, Samuel, V; Howell, Joel D.			From Individualized Interactions to Standardized Schedules: A History of Time Organization in US Outpatient Medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CONSULTATION LENGTH; VISIT DURATION; OFFICE VISITS; MOTORS PART	Many outpatient physicians and patients feel that current scheduling systems do not afford enough time for direct patient-physician interaction, leaving patients feeling unheard and physicians feeling demoralized. This dissatisfaction degrades patients' trust in the health care system and contributes to workforce moral injury and burnout. In the hopes of understanding the roots of this time stress and helping to guide future decisions about how to organize physicians' time, this article describes changes in the organization of U.S. outpatient physicians' time, starting from care at home in the late 19th century. It discusses the origins of the appointment system, which was invented to be highly personalized, with assistants adjusting appointment durations to accommodate clinical activities, specific patient needs, and individual physician proclivities. The article then describes how centralization of appointment scheduling became more common as U.S. medicine became increasingly consolidated into larger and larger groups and health systems. This distanced schedulers from the people and care they were organizing and necessitated standardized appointment durations, which did not accommodate individual patient and physician needs. With the rise of managerialism, schedulers became increasingly accountable to administrators rather than patients and physicians. Whereas early appointment systems depended on personal connection between schedulers and the physicians and patients they supported, today's schedulers have few such interactions. The widespread shift to centralized scheduling and standardized time slots has contributed to misalignment among time allocation, patient care, and health care workforce well-being and is likely exacerbating ongoing tensions among patients, physicians, and administrators.	[Nguyen, Michelle-Linh T.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, Natl Clinician Scholars Program, San Francisco, CA USA; [Nguyen, Michelle-Linh T.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA; [Schotland, Samuel, V] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Schotland, Samuel, V] Yale Univ, Program Hist Sci & Med, New Haven, CT USA; [Howell, Joel D.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Howell, Joel D.] Univ Michigan, Dept Hist, Ann Arbor, MI 48109 USA; [Howell, Joel D.] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; Yale University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nguyen, MLT (corresponding author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco Mission Bay Campus Valley Tower, San Francisco, CA 94158 USA.	Michelle-Linh.Nguyen@ucsf.edu		Howell, Joel/0000-0002-0527-4700	Health Resources and Services Administration of the U.S. Department of Health and Human Services [T32HP19025]	Health Resources and Services Administration of the U.S. Department of Health and Human Services	This project was supported by salary support (Dr. Nguyen) from the Health Resources and Services Administration of the U.S. Department of Health and Human Services under grant number T32HP19025 for Research in Primary Care. This funding agency was not involved in the design, implementation, or analysis of this study.	Abbasi J, 2022, JAMA-J AM MED ASSOC, V327, P1435, DOI 10.1001/jama.2022.5074; Adler-Milstein J, 2020, J AM MED INFORM ASSN, V27, P531, DOI 10.1093/jamia/ocz220; [Anonymous], 1919, W V MED J, P1; [Anonymous], 1894, JAMA-J AM MED ASSOC, V23, P556, DOI [10.1001/jama.1894.02421190034006, DOI 10.1001/JAMA.1894.02421190034006]; [Anonymous], 1952, MED ECON, V29, P243; [Anonymous], 1952, MED ECON, V29, P223; [Anonymous], 1883, CINCINNATI ENQUIRER, P5; [Anonymous], 1894, MED SENTINEL, P238; [Anonymous], 1961, TIME; Arnold-Forster A, 2021, WASH POST; Arnold-Forster A, 2022, NEW ENGL J MED, V386, P4, DOI 10.1056/NEJMp2112095; Berger M L, 1973, J Hist Med Allied Sci, V28, P319; Bliss MC, 1899, JOY ILLUSTRATIONS LI; Boustan LP, 2013, 19041 NBER, DOI [10.3386/w19041, DOI 10.3386/W19041]; Brandt AM, 2000, MED 20 CENTURY; Bredow M, 1964, MED ASSISTANT; Bredow M, 1958, MED ASSISTANT GUIDEB; Bredow M, 1966, MED SECRETARIAL PROC; Bredow M., 1943, HDB MED SECRETARY; BURNHAM JC, 1982, SCIENCE, V215, P1474, DOI 10.1126/science.7038876; Cathell DW, 1889, BOOK PHYS HIMSELF TH; Chandler AlfredD, 1977, VISIBLE HAND MANAGER; Chapin CF, 2015, ENSURING AMERICA'S HEALTH: THE PUBLIC CREATION OF THE CORPORATE HEALTH CARE SYSTEM, P1, DOI 10.1017/CBO9781107045347; Chapin RD, 1924, ANN AM ACAD POLIT SS, V116, P1, DOI 10.1177/000271622411600101; Chen LM, 2009, ARCH INTERN MED, V169, P1866, DOI 10.1001/archinternmed.2009.341; Collins SD, 1940, PUBLIC HEALTH REP, V55, P1977, DOI 10.2307/4583495; DeCamp M, 2021, ANN INTERN MED, V174, P844, DOI 10.7326/M20-7093; Detmold M, 1944, AM J NURS, V44, P196, DOI 10.2307/3456592; Durbin RL, 1963, HOSP MANAGE, V95, P63; Enteman WF, 1993, MANAGERIALISM EMERGE; Gainty C., 2019, Mod Am Hist, V2, P249, DOI [10.1017/mah.2019.10, DOI 10.1017/MAH.2019.10]; Gainty C, 2012, DISSERTATION; Garland J, 1954, PHYS HIS PRACTICE; Guy GP, 2012, J ONCOL PRACT, V8, p2S, DOI 10.1200/JOP.2011.000493; Han PKJ, 1997, ANN INTERN MED, V127, P910, DOI 10.7326/0003-4819-127-10-199711150-00010; Howell JD, 1995, TECHNOLOGY HOSP TRAN; Howell JD, 2010, HEALTH AFFAIR, V29, P760, DOI 10.1377/hlthaff.2010.0014; Hsiang EY, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3403; Ingelfinger F J, 1973, N Engl J Med, V289, P480, DOI 10.1056/NEJM197308302890911; Kash B, 2016, J HOSP MED MANAGE, V1, P8, DOI DOI 10.4172/2471-9781.100008; Linzer M, 2016, J GEN INTERN MED, V31, P1004, DOI 10.1007/s11606-016-3720-4; Linzer M, 2015, J GEN INTERN MED, V30, P1584, DOI 10.1007/s11606-015-3341-3; Linzer M, 2009, ANN INTERN MED, V151, P28, DOI 10.7326/0003-4819-151-1-200907070-00006; Long JC, 1924, ANN AM ACAD POLIT SS, V116, P18, DOI 10.1177/000271622411600104; Matulis JC, 2021, J GEN INTERN MED, V36, P511, DOI 10.1007/s11606-020-06058-9; Metzner C A, 1972, Med Care, V10, P279, DOI 10.1097/00005650-197207000-00001; Miller BM, 1960, MED SECRETARYS ASSIS; Montori V., 2019, NEJM, DOI [10.1056/CAT.19.0696, DOI 10.1056/CAT.19.0696]; Moore MD, 2022, TWENT CENTURY BR HIS, V33, P203, DOI 10.1093/tcbh/hwab040; Nolen W, 1972, SURGEONS WORLD, P345; Ofri D, 2019, NEW ENGL J MED, V380, P1197, DOI 10.1056/NEJMp1814019; Orton PK, 2016, FAM PRACT, V33, P529, DOI 10.1093/fampra/cmw056; Ostbye T, 2005, ANN FAM MED, V3, P209, DOI 10.1370/afm.310; Prasad K, 2020, J GEN INTERN MED, V35, P465, DOI 10.1007/s11606-019-05343-6; Reid CC, 1922, OSTEOPATHIC PHYS, P25; Risse GB, 1981, WISCONSIN MED HIST P; Sheridan Bakktel H, 1949, MED ECON, V26, P41; Sinsky C, 2016, ANN INTERN MED, V165, P753, DOI 10.7326/M16-0961; Smith C, 1962, MED ECON, V39, P61; Smith E, 2016, VICE; Smith EO, 1909, JAMA-J AM MED ASSOC, V52, P809, DOI [10.1001/jama.1909.02540360065027, DOI 10.1001/JAMA.1909.02540360065027]; Soukhanov AH, 1979, WEBSTERS MED OFFICE; Starr P., 1982, SOCIAL TRANSFORMATIO; Stowe SM, 2011, DOCTORING S SO PHYS; Surbakti EF, 2018, KNE LIFE SCI, P41, DOI 10.18502/kls.v4i9.3556; Sweet V., 2017, SLOW MED WAY HEALING; Thomas VC, 1923, SUCCESSFUL PHYS; Tomes Nancy, 2016, REMAKING AM PATIENT; Twiddy D, 2017, GETTING PAID BLOG FP; U.S. Department of Health Education and Welfare, 1959, PUBLIC HLTH SERVICE, V709, P11; United States Census Bureau, 1975, BICENTENNIAL EDITION; Verghese A, 2018, NEW YORK TIMES MAGAZ; Wyeth Incorporated, 1944, LIFE 0221, P26	73	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT	2022	175	10					1468	+		10.7326/M22-1575	http://dx.doi.org/10.7326/M22-1575		AUG 2022	8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5M3CC	36037467				2023-01-03	WOS:000868413200002
J	Hess, DC; Blauenfeldt, RA; Andersen, G				Hess, David C.; Blauenfeldt, Rolf A.; Andersen, Grethe			Remote Ischemic Conditioning Feasible and Potentially Beneficial for Ischemic Stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Hess, David C.] Augusta Univ, Med Coll Georgia, Dept Neurol, 1120 15th St, Augusta, GA 30912 USA; [Blauenfeldt, Rolf A.; Andersen, Grethe] Aarhus Univ, Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark; [Blauenfeldt, Rolf A.; Andersen, Grethe] Aarhus Univ, Aarhus Univ Hosp, Dept Clin Med, Aarhus, Denmark	University System of Georgia; Augusta University; Aarhus University; Aarhus University	Hess, DC (corresponding author), Augusta Univ, Med Coll Georgia, Dept Neurol, 1120 15th St, Augusta, GA 30912 USA.	dhess@augusta.edu		Blauenfeldt, Rolf/0000-0002-4846-9516	National Institutes of Health [R01 NS099455, 1UO1NS113356, R01NS112511]; TrygFonden; Novo Nordisk Foundation; Vilhelm Petersens Mindelegat	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); TrygFonden; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Vilhelm Petersens Mindelegat	Dr Hess reported having a patent with Augusta University and Athersys Inc for stem cells in neurologic diseases and being on the scientific advisory board for Athersys, Inc. Dr Blauenfeldt reported receiving personal fees from Bayer and Novo Nordisk. The authors reported receiving support from the National Institutes of Health (R01 NS099455, Dr Hess; 1UO1NS113356, Dr Hess; R01NS112511, Drs Hess, Blauenfeldt, and Andersen), Vilhelm Petersens Mindelegat, TrygFonden, and the Novo Nordisk Foundation (Dr Andersen).	Blauenfeldt RA, 2020, EUR STROKE J, V5, P94, DOI 10.1177/2396987319884408; Chen HS, 2022, JAMA-J AM MED ASSOC, V328, P627, DOI 10.1001/jama.2022.13123; Cranston JS, 2017, STROKE, V48, P2946, DOI 10.1161/STROKEAHA.117.017496; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Hausenloy DJ, 2019, LANCET, V394, P1415, DOI 10.1016/S0140-6736(19)32039-2; Hess DC, 2013, STROKE, V44, P1191, DOI 10.1161/STROKEAHA.112.678482; Hess DC, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2015.223; Hougaard KD, 2014, STROKE, V45, P159, DOI 10.1161/STROKEAHA.113.001346; Lyden P, 2021, STROKE, V52, P3063, DOI 10.1161/STROKEAHA.121.034947; Lyden PD, 2022, STROKE, V53, P1802, DOI 10.1161/STROKEAHA.121.038047; Ma JQ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69122-8; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Pico F, 2020, JAMA NEUROL, V77, P725, DOI 10.1001/jamaneurol.2020.0326; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Saini V, 2021, NEUROLOGY, V97, pS6, DOI 10.1212/WNL.0000000000012781; Vaibhav K, 2018, J EXP MED, V215, P2636, DOI 10.1084/jem.20171905; Wallin MT, 2019, LANCET NEUROL, V18, P269, DOI 10.1016/S1474-4422(18)30443-5	18	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2022	328	7					622	624		10.1001/jama.2022.13365	http://dx.doi.org/10.1001/jama.2022.13365			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D0ZW	35972503				2023-01-03	WOS:000846874500018
J	Christie, JD; Chiocca, EA				Christie, John D.; Chiocca, E. Antonio			Treat and repeat: oncolytic virus therapy for brain cancer	NATURE MEDICINE			English	Editorial Material; Early Access							GLIOBLASTOMA		[Christie, John D.; Chiocca, E. Antonio] Harvard Med Sch, Brigham & Womens Hosp, Harvey Cushing Neurooncol Labs, Dept Neurosurg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Chiocca, EA (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Harvey Cushing Neurooncol Labs, Dept Neurosurg, Boston, MA 02115 USA.	eachiocca@bwh.harvard.edu						Alayo QA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61736-2; Alvarez-Breckenridge CA, 2012, NAT MED, V18, P1827, DOI 10.1038/nm.3013; Bagley SJ, 2022, CLIN CANCER RES, V28, P594, DOI 10.1158/1078-0432.CCR-21-2750; Chiocca EA, 2019, NEURO-ONCOLOGY, V21, P14, DOI 10.1093/neuonc/noy170; Chiocca EA, 2014, CANCER IMMUNOL RES, V2, P295, DOI 10.1158/2326-6066.CIR-14-0015; Goonan J., PRNEWSWIRE; Johnson DR, 2022, J NEURO-ONCOL, V158, P139, DOI 10.1007/s11060-021-03853-0; Milano MT, 2010, INT J RADIAT ONCOL, V78, P1147, DOI 10.1016/j.ijrobp.2009.09.018; Otani Y, 2022, CLIN CANCER RES, V28, P1460, DOI 10.1158/1078-0432.CCR-21-2347; Todo T, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-31262-y; Todo T, 2022, NAT MED, DOI 10.1038/s41591-022-01897-x; Wheeler LA, 2016, NEURO-ONCOLOGY, V18, P1137, DOI 10.1093/neuonc/now002	12	0	0	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01901-4	http://dx.doi.org/10.1038/s41591-022-01901-4		JUL 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3C2GI	35864255				2023-01-03	WOS:000828446700005
J	Orive, G; Lertxundi, U; Brodin, T; Manning, P				Orive, Gorka; Lertxundi, Unax; Brodin, Tomas; Manning, Peter			Greening the pharmacy	SCIENCE			English	Editorial Material									[Orive, Gorka] Univ Basque Country, Sch Pharm, Lab Pharmaceut, UPV EHU, Vitoria, Spain; [Orive, Gorka] Biomed Res Networking Ctr Bioengn Biomat & Nanome, Vitoria, Spain; [Orive, Gorka] NanoBioCel Res Grp, Bioaraba, Vitoria, Spain; [Orive, Gorka] Singapore Eye Res Inst, Singapore, Singapore; [Lertxundi, Unax] Araba Psychiat Hosp, Bioaraba Hlth Res Inst, Osakidetza Basque Hlth Serv, Pharm Serv,Araba Mental Hlth Network, Vitoria, Spain; [Brodin, Tomas] Swedish Univ Agr Sci, Dept Wildlife Fish & Environm Studies, Umea, Sweden; [Manning, Peter] Senckenberg Biodivers & Climate Res Ctr, Frankfurt, Germany; [Manning, Peter] Univ Bergen, Dept Biol Sci, Bergen, Norway	University of Basque Country; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Bioaraba Health Research Institute; National University of Singapore; Singapore National Eye Center; Bioaraba Health Research Institute; Swedish University of Agricultural Sciences; Senckenberg Biodiversitat & Klima- Forschungszentrum (BiK-F); Senckenberg Gesellschaft fur Naturforschung (SGN); University of Bergen	Orive, G (corresponding author), Univ Basque Country, Sch Pharm, Lab Pharmaceut, UPV EHU, Vitoria, Spain.; Orive, G (corresponding author), Biomed Res Networking Ctr Bioengn Biomat & Nanome, Vitoria, Spain.; Orive, G (corresponding author), NanoBioCel Res Grp, Bioaraba, Vitoria, Spain.; Orive, G (corresponding author), Singapore Eye Res Inst, Singapore, Singapore.	gorka.orive@ehu.eus; peter.manning@uib.no	Manning, Peter/I-6523-2012	Manning, Peter/0000-0002-7940-2023; Brodin, Tomas/0000-0003-1086-7567				Bernhardt E.S., 2017, FRONT ECOL ENVIRON, V15, P84, DOI [10.1002/fee.1450, DOI 10.1002/FEE.1450]; Centering Healthcare Institute, 2020, CENT HEALTHC I AW 24; Cerveny D, 2021, ENVIRON INT, V146, DOI 10.1016/j.envint.2020.106188; Domingo-Echaburu S, 2021, SCI TOTAL ENVIRON, V800, DOI 10.1016/j.scitotenv.2021.149412; European Commission, 2019, COMM EUR GREEN DEAL; Gunnarsson L, 2019, ENVIRON INT, V129, P320, DOI 10.1016/j.envint.2019.04.075; Kidd KA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0578; Oaks JL, 2004, NATURE, V427, P630, DOI 10.1038/nature02317; Orive G, 2020, LANCET, V395, P1112, DOI 10.1016/S0140-6736(20)30053-2; Poiverino G, 2021, P ROY SOC B-BIOL SCI, V288, DOI 10.1098/rspb.2020.2294; Richmond EK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06822-w; Santos MM, 2016, AQUAT TOXICOL, V174, P1, DOI 10.1016/j.aquatox.2016.02.001; UN WWDR, 2017, ANN REP 2017 UNREDD, DOI DOI 10.1017/CBO9781107415324.004; Wang H, 2018, INT J HYG ENVIR HEAL, V221, P479, DOI 10.1016/j.ijheh.2018.01.012; Wilkinson JL, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2113947119	15	1	1	13	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 15	2022	377	6603					259	260		10.1126/science.abp9554	http://dx.doi.org/10.1126/science.abp9554			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3F7GX	35857602				2023-01-03	WOS:000830834200017
J	Cheskes, S; Verbeek, PR; Drennan, IR; McLeod, SL; Turner, L; Pinto, R; Feldman, M; Davis, M; Vaillancourt, C; Morrison, LJ; Dorian, P; Scales, DC				Cheskes, Sheldon; Verbeek, P. Richard; Drennan, Ian R. R.; McLeod, Shelley L. L.; Turner, Linda; Pinto, Ruxandra; Feldman, Michael; Davis, Matthew; Vaillancourt, Christian; Morrison, Laurie J. J.; Dorian, Paul; Scales, Damon C. C.			Defibrillation Strategies for Refractory Ventricular Fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEQUENTIAL EXTERNAL DEFIBRILLATION; AMERICAN-HEART-ASSOCIATION; HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; RANDOMIZED-TRIALS; GUIDELINES UPDATE; DESIGN; CARDIOVERSION; SURVIVAL; CANADA	BackgroundDespite advances in defibrillation technology, shock-refractory ventricular fibrillation remains common during out-of-hospital cardiac arrest. Double sequential external defibrillation (DSED; rapid sequential shocks from two defibrillators) and vector-change (VC) defibrillation (switching defibrillation pads to an anterior-posterior position) have been proposed as defibrillation strategies to improve outcomes in patients with refractory ventricular fibrillation.MethodsWe conducted a cluster-randomized trial with crossover among six Canadian paramedic services to evaluate DSED and VC defibrillation as compared with standard defibrillation in adult patients with refractory ventricular fibrillation during out-of-hospital cardiac arrest. Patients were treated with one of these three techniques according to the strategy that was randomly assigned to the paramedic service. The primary outcome was survival to hospital discharge. Secondary outcomes included termination of ventricular fibrillation, return of spontaneous circulation, and a good neurologic outcome, defined as a modified Rankin scale score of 2 or lower (indicating no symptoms to slight disability) at hospital discharge.ResultsA total of 405 patients were enrolled before the data and safety monitoring board stopped the trial because of the coronavirus disease 2019 pandemic. A total of 136 patients (33.6%) were assigned to receive standard defibrillation, 144 (35.6%) to receive VC defibrillation, and 125 (30.9%) to receive DSED. Survival to hospital discharge was more common in the DSED group than in the standard group (30.4% vs. 13.3%; relative risk, 2.21; 95% confidence interval [CI], 1.33 to 3.67) and more common in the VC group than in the standard group (21.7% vs. 13.3%; relative risk, 1.71; 95% CI, 1.01 to 2.88). DSED but not VC defibrillation was associated with a higher percentage of patients having a good neurologic outcome than standard defibrillation (relative risk, 2.21 [95% CI, 1.26 to 3.88] and 1.48 [95% CI, 0.81 to 2.71], respectively).ConclusionsAmong patients with refractory ventricular fibrillation, survival to hospital discharge occurred more frequently among those who received DSED or VC defibrillation than among those who received standard defibrillation. (Funded by the Heart and Stroke Foundation of Canada; DOSE VF ClinicalTrials.gov number, .)	[Cheskes, Sheldon; Drennan, Ian R. R.; McLeod, Shelley L. L.] Univ Toronto, Dept Family & Commu n Med, Div Emergency Med, Toronto, ON, Canada; [Verbeek, P. Richard; Morrison, Laurie J. J.] Univ Toronto, Div Emergency Med, Dept Med, Toronto, ON, Canada; [Pinto, Ruxandra; Scales, Damon C. C.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Pinto, Ruxandra; Dorian, Paul; Scales, Damon C. C.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Cheskes, Sheldon; Verbeek, P. Richard; Turner, Linda; Feldman, Michael] Sunnybrook Ctr Pre Hosp Med, Dept Emergency Serv, Toronto, ON, Canada; [Drennan, Ian R. R.; Morrison, Laurie J. J.] Sunnybrook Ctr Pre Hosp Med, Dept Crit Care Med, Toronto, ON, Canada; [McLeod, Shelley L. L.] Sunnybrook Hlth Sci Ctr, Sinai Hlth, Schwartz Reisman Emergency Med Inst, Toronto, ON, Canada; [Dorian, Paul] Unity Hlth Toronto, Div Cardiol, Toronto, ON, Canada; [Davis, Matthew] Univ Western Ontario, London Hlth Sci Ctr, Dept Med, Div Emergency Med, London, England; [Vaillancourt, Christian] Ottawa Hosp Res Inst, Dept Emergency Med, Ottawa, ON, Canada; [Cheskes, Sheldon] Univ Toronto, Temerty Fac Med, Dept Family & Community Med, Div Emergency Med, 77 Browns Line, Ste 100, Toronto, ON M8W 3S2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sinai Health System Toronto; Sunnybrook Health Science Center; Western University (University of Western Ontario); University of Ottawa; Ottawa Hospital Research Institute; University of Toronto	Cheskes, S (corresponding author), Univ Toronto, Temerty Fac Med, Dept Family & Community Med, Div Emergency Med, 77 Browns Line, Ste 100, Toronto, ON M8W 3S2, Canada.	sheldon.cheskes@sunnybrook.ca	Cheskes, Sheldon/I-4456-2015; Morrison, Laurie Jean/A-6325-2012	Cheskes, Sheldon/0000-0001-7835-3074; Morrison, Laurie Jean/0000-0001-8369-9774	Heart and Stroke Foundation of Canada	Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada)	Supported by the Heart and Stroke Foundation of Canada Grant-in-Aid program.	Alaeddini J, 2005, PACE, V28, P3, DOI 10.1111/j.1540-8159.2005.09155.x; Andersen LW, 2018, RESUSCITATION, V125, P79, DOI 10.1016/j.resuscitation.2018.02.006; Cabanas JG, 2015, PREHOSP EMERG CARE, V19, P126, DOI 10.3109/10903127.2014.942476; Cheskes S, 2020, RESUSCITATION, V150, P178, DOI 10.1016/j.resuscitation.2020.02.010; Cheskes S, 2019, RESUSCITATION, V139, P275, DOI 10.1016/j.resuscitation.2019.04.038; Cortez E, 2016, RESUSCITATION, V108, P82, DOI 10.1016/j.resuscitation.2016.08.002; Davis M., 2018, CJEM, V20, pS67; Deakin CD, 2020, RESUSCITATION, V155, P24, DOI 10.1016/j.resuscitation.2020.06.008; Delorenzo A, 2019, RESUSCITATION, V135, P124, DOI 10.1016/j.resuscitation.2018.10.025; Drennan IR, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04904-z; Emmerson AC, 2017, RESUSCITATION, V117, P97, DOI 10.1016/j.resuscitation.2017.06.011; Freidlin B, 2008, CLIN CANCER RES, V14, P4368, DOI 10.1158/1078-0432.CCR-08-0325; Gerstein NS, 2018, ANN EMERG MED, V71, P109, DOI 10.1016/j.annemergmed.2017.04.005; Gerstein NS, 2015, J CARDIOTHOR VASC AN, V29, P421, DOI 10.1053/j.jvca.2013.10.016; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Hazinski MF, 2010, CIRCULATION, V122, P8250, DOI 10.1161/CIRCULATIONAHA.110.970897; Heidet M, 2020, RESUSCITATION, V152, P133, DOI 10.1016/j.resuscitation.2020.05.008; HOCH DH, 1994, J AM COLL CARDIOL, V23, P1141, DOI 10.1016/0735-1097(94)90602-5; Holmen J, 2017, RESUSCITATION, V113, P33, DOI 10.1016/j.resuscitation.2017.01.006; Hussey MA, 2007, CONTEMP CLIN TRIALS, V28, P182, DOI 10.1016/j.cct.2006.05.007; IDEKER RE, 1991, PACE, V14, P227, DOI 10.1111/j.1540-8159.1991.tb05093.x; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; Johnston M, 2016, PREHOSP EMERG CARE, V20, P662, DOI 10.3109/10903127.2016.1168891; JONES DL, 1988, J AM COLL CARDIOL, V11, P590, DOI 10.1016/0735-1097(88)91536-7; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Link MS, 2010, CIRCULATION, V122, pS706, DOI 10.1161/CIRCULATIONAHA.110.970954; Marrouche NF, 2001, PACE, V24, P1321, DOI 10.1046/j.1460-9592.2001.01321.x; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; Morgan KE, 2017, STAT MED, V36, P318, DOI 10.1002/sim.7137; Morrison LJ, 2005, RESUSCITATION, V66, P149, DOI 10.1016/j.resuscitation.2004.11.031; Murray DM, 2004, AM J PUBLIC HEALTH, V94, P423, DOI 10.2105/AJPH.94.3.423; Nadkarni VM, 2010, CIRCULATION, V122, P8276, DOI 10.1161/CIRCULATIONAHA.110.970921; Neumar RW, 2015, CIRCULATION, V132, pS315, DOI 10.1161/CIR.0000000000000252; Parmar MKB, 2014, LANCET, V384, P283, DOI 10.1016/S0140-6736(14)61122-3; Spies DM, 2020, RESUSCITATION, V157, P219, DOI 10.1016/j.resuscitation.2020.09.029; Turner RM, 2007, STAT MED, V26, P274, DOI 10.1002/sim.2537; Walsh M, 2014, J CLIN EPIDEMIOL, V67, P622, DOI 10.1016/j.jclinepi.2013.10.019; Wason JMS, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-364	39	4	4	3	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	2022	387	21					1947	1956		10.1056/NEJMoa2207304	http://dx.doi.org/10.1056/NEJMoa2207304		NOV 2022	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6M4JU	36342151				2023-01-03	WOS:000880368000001
J	Chaft, JE; Oezkan, F; Kris, MG; Bunn, PA; Wistuba, II; Kwiatkowski, DJ; Owen, DH; Tang, Y; Johnson, BE; Lee, JM; Lozanski, G; Pietrzak, M; Seweryn, M; Byun, WY; Schulze, K; Nicholas, A; Johnson, A; Grindheim, J; Hilz, S; Shames, DS; Rivard, C; Toloza, E; Haura, EB; McNamee, CJ; Patterson, GA; Waqar, SN; Rusch, VW; Carbone, DP				Chaft, Jamie E.; Oezkan, Filiz; Kris, Mark G.; Bunn, Paul A.; Wistuba, Ignacio I.; Kwiatkowski, David J.; Owen, Dwight H.; Tang, Yan; Johnson, Bruce E.; Lee, Jay M.; Lozanski, Gerard; Pietrzak, Maciej; Seweryn, Michal; Byun, Woo Yul; Schulze, Katja; Nicholas, Alan; Johnson, Ann; Grindheim, Jessica; Hilz, Stephanie; Shames, David S.; Rivard, Chris; Toloza, Eric; Haura, Eric B.; McNamee, Ciaran J.; Patterson, G. Alexander; Waqar, Saiama N.; Rusch, Valerie W.; Carbone, David P.		LCMC Study Investigators	Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial	NATURE MEDICINE			English	Article; Early Access							PATHOLOGICAL RESPONSE; HLA-E; CHEMOTHERAPY; MULTICENTER; BLOCKADE; CRITERIA; COMPLEX	In an ongoing, open-label, single-arm phase II study (NCT02927301), 181 patients with untreated, resectable, stage IB-IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathological response (MPR; <= 10% viable malignant cells) in resected tumors without EGFR or ALK alterations. Of the 143 patients in the primary end point analysis, the MPR was 20% (95% confidence interval, 14-28%). With a minimum duration of follow-up of 3 years, the 3-year survival rate of 80% was encouraging. The most common adverse events during the neoadjuvant phase were fatigue (39%, 71 of 181) and procedural pain (29%, 53 of 181), along with expected immune-related toxicities; there were no unexpected safety signals. In exploratory analyses, MPR was predicted using the pre-treatment peripheral blood immunophenotype based on 14 immune cell subsets. Immune cell subsets predictive of MPR in the peripheral blood were also identified in the tumor microenvironment and were associated with MPR. This study of neoadjuvant atezolizumab in a large cohort of patients with resectable non-small cell lung cancer was safe and met its primary end point of MPR >= 15%. Data from this single-arm, non-randomized trial suggest that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab, but additional studies are needed to determine whether these profiles can inform patient selection and new therapeutic approaches.	[Chaft, Jamie E.; Kris, Mark G.; Rusch, Valerie W.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Chaft, Jamie E.; Kris, Mark G.] Weill Cornell Med Coll, New York, NY USA; [Oezkan, Filiz; Owen, Dwight H.; Carbone, David P.] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Oezkan, Filiz] Univ Med Essen, Univ Duisburg Essen, Dept Intervent Pulmonol, Ruhrlandklin, Essen, Germany; [Oezkan, Filiz] German Canc Res Ctr, A420, Heidelberg, Germany; [Oezkan, Filiz] Univ Med Mannheim, Fac Univ Heidelberg, Sect Pulmonol, Med Dept 5, Mannheim, Germany; [Bunn, Paul A.; Rivard, Chris] Univ Colorado, Sch Med, Aurora, CO USA; [Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Kwiatkowski, David J.; Johnson, Bruce E.; McNamee, Ciaran J.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Kwiatkowski, David J.; Tang, Yan; Johnson, Bruce E.; McNamee, Ciaran J.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Owen, Dwight H.; Lozanski, Gerard; Pietrzak, Maciej; Seweryn, Michal; Byun, Woo Yul] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA; [Lee, Jay M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Seweryn, Michal] Univ Lodz, Dept Mol Biophys, Biobank Lab, Lodz, Poland; [Seweryn, Michal] Univ Lodz, Ctr Data Anal Modeling & Computat Sci, Lodz, Poland; [Schulze, Katja; Nicholas, Alan; Johnson, Ann; Grindheim, Jessica; Hilz, Stephanie; Shames, David S.] Genentech Inc, San Francisco, CA 94080 USA; [Toloza, Eric; Haura, Eric B.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Patterson, G. Alexander; Waqar, Saiama N.] Washington Univ, Sch Med, St Louis, MO USA; [Carbone, David P.] Pelotonia Inst Immunooncol, Columbus, OH 43210 USA	Memorial Sloan Kettering Cancer Center; Cornell University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Lodz; University of Lodz; Roche Holding; Genentech; H Lee Moffitt Cancer Center & Research Institute; Washington University (WUSTL)	Carbone, DP (corresponding author), Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA.; Carbone, DP (corresponding author), Pelotonia Inst Immunooncol, Columbus, OH 43210 USA.	david.carbone@osumc.edu		Byun, Woo Yul/0000-0001-8686-638X; Kwiatkowski, David/0000-0002-5668-5219	Deutsche Forschungsgemeinschaft [OE698/1-1]; Genentech	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Genentech(Roche HoldingGenentech)	The authors thank the patients and their families, the study investigators and clinical site staff and the collaborating laboratories for biomarker testing. The authors thank J. Minna, LCMC3 Steering Committee member and consultant. The authors thank R.L. Kitzler and R. Pearson for their contributions to the IMMUNOME analysis. Clinical trial and operations support was provided by E. Brandao, Senior Clinical Trial Leader, M. Rocha, Clinical Program Leader, A. Gopalakrishnan, Senior Biosample Operations Manager and A. Stone, Principal Biosample Operations Manager. The LCMC3 study was funded by Genentech. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Ashfield MedComms, an Ashfield Health company and was funded by Genentech. F.O. was supported by the Deutsche Forschungsgemeinschaft (OE698/1-1).	Anagnostou V, 2019, CANCER RES, V79, P1214, DOI 10.1158/0008-5472.CAN-18-1127; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Borst L, 2020, CLIN CANCER RES, V26, P5549, DOI 10.1158/1078-0432.CCR-19-2095; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brierley J, 2017, TNM CLASSIFICATION M, VEighth, DOI DOI 10.1002/9780471420194.TNMC26.PUB3; Carenza C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01325; Cascone T, 2021, NAT MED, V27, P504, DOI 10.1038/s41591-020-01224-2; Caushi JX, 2021, NATURE, V596, P126, DOI 10.1038/s41586-021-03752-4; Chaft JE, 2016, J THORAC ONCOL, V11, P537, DOI 10.1016/j.jtho.2015.12.104; Dacic S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.106; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fehlings M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0695-9; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Forde PM, 2022, NEW ENGL J MED, V386, P1973, DOI 10.1056/NEJMoa2202170; Hellmann MD, 2014, LANCET ONCOL, V15, pE42, DOI 10.1016/S1470-2045(13)70334-6; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Kamiya T, 2019, J CLIN INVEST, V129, P2094, DOI 10.1172/JCI123955; Khan M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00167; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Liu L, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.597468; Nielsen N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031959; Pataer A, 2021, J THORAC ONCOL, V16, P1289, DOI 10.1016/j.jtho.2021.03.029; Pataer A, 2012, J THORAC ONCOL, V7, P825, DOI 10.1097/JTO.0b013e318247504a; Peng Q, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18570-x; Provencio M, 2020, LANCET ONCOL, V21, P1413, DOI 10.1016/S1470-2045(20)30453-8; Rempala GA, 2013, J MATH BIOL, V67, P1339, DOI 10.1007/s00285-012-0589-7; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Scagliotti GV, 2012, J CLIN ONCOL, V30, P172, DOI 10.1200/JCO.2010.33.7089; Shu CA, 2020, LANCET ONCOL, V21, P786, DOI 10.1016/S1470-2045(20)30140-6; Socinski MA., 2018, NEW ENGL J MED, V378, P2288, DOI [DOI 10.1056/NEJMOA1716948, 10.1056/NEJMoa1716948]; The Comprehensive R Archive Network, 2021, PLSMS LIN SMOOTH PRE; Travis WD, 2020, J THORAC ONCOL, V15, P709, DOI 10.1016/j.jtho.2020.01.005; van Hall T, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0761-3; Villa-Alvarez M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02917; Voss SD, 1998, J IMMUNOL, V160, P1618; Wakelee HA, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.8500; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Wu CL, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608614; Wu TD, 2016, METHODS MOL BIOL, V1418, P283, DOI 10.1007/978-1-4939-3578-9_15; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057	43	2	2	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01962-5	http://dx.doi.org/10.1038/s41591-022-01962-5		SEP 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4L9HT	36097216	Green Published, hybrid			2023-01-03	WOS:000852940800010
J	Lin, X; Li, XQ; Bai, YQ; Liu, Q; Xiang, WL				Lin, Xi; Li, Xiaoqin; Bai, Yongqi; Liu, Qin; Xiang, Weilan			Death-coping self-efficacy and its influencing factors among Chinese nurses: A cross-sectional study	PLOS ONE			English	Article							PALLIATIVE CARE; HOSPICE; PERSPECTIVES	Background Nurses are the main caregivers of dying patients. Facing or dealing with death-related events is inevitable. Death-coping self-efficacy (DCS) is very important, as it can reduce the risk of nursing staff to adverse emotional distress, help them participate in end-of-life care and improve the quality of care of patients. Methods Using the convenient sampling method, this study included a total of 572 nurses from a tertiary hospital in Hangzhou, China. The status and influencing factors of the DCS of nurses were explored using a general information questionnaire and DCS scale. Results The scores of each parameter, ranging from low to high, were in the order of coping with grief, preparation for death and hospice care. Factors influencing nurses' DCS included attendance in hospice care education courses within the previous year, experience of accompanying the family members of the deceased and attitude towards death. Conclusions The overall self-efficacy of nurses in palliative care was at a medium level. Moreover, their self-efficacy in coping with grief and preparation for death should be strengthened. Managers of medical institutions can assess the death-coping ability of nurses, which helps provide corresponding support and training for nurses at an early stage. Nurses should receive guidance in grief adjustment and emotion regulation. Medical units should provide nurses with a platform for continuous training and education, use of death-related theoretical models and frameworks to guide nurses in dealing with death-related events, reduce nurses' negative mood and jointly promote their mental health.	[Lin, Xi; Li, Xiaoqin; Bai, Yongqi; Liu, Qin] Southwest Med Univ, Affiliated Hosp, Dept Pediat, Luzhou, Sichuan, Peoples R China; [Lin, Xi; Li, Xiaoqin; Bai, Yongqi; Liu, Qin] Sichuan Clin Res Ctr Birth Defects, Luzhou, Sichuan, Peoples R China; [Lin, Xi; Liu, Qin] Southwest Med Univ, Affiliated Hosp, Dept Nursing, Luzhou, Sichuan, Peoples R China; [Xiang, Weilan] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Nursing, Hangzhou, Zhejiang, Peoples R China	Southwest Medical University; Southwest Medical University; Zhejiang University	Bai, YQ; Liu, Q (corresponding author), Southwest Med Univ, Affiliated Hosp, Dept Pediat, Luzhou, Sichuan, Peoples R China.; Bai, YQ; Liu, Q (corresponding author), Sichuan Clin Res Ctr Birth Defects, Luzhou, Sichuan, Peoples R China.; Liu, Q (corresponding author), Southwest Med Univ, Affiliated Hosp, Dept Nursing, Luzhou, Sichuan, Peoples R China.	luzhou1991@yeah.net; liuqin18@126.com						Ay MA, 2019, NURS ETHICS, V26, P1442, DOI 10.1177/0969733017748481; Barnett MD, 2021, J CLIN PSYCHOL MED S, V28, P295, DOI 10.1007/s10880-020-09714-8; Barnett MD, 2019, J NURS MANAGE, V27, P775, DOI 10.1111/jonm.12737; Bernales-Turpo D, 2022, J PRIM CARE COMMUNIT, V13, DOI 10.1177/21501319221101845; Blazeviciene A, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00637-7; Buss MK, 2017, MAYO CLIN PROC, V92, P280, DOI 10.1016/j.mayocp.2016.11.007; Candela ML, 2020, SUPPORT CARE CANCER, V28, P4493, DOI 10.1007/s00520-020-05300-8; Chang LJ., 2006, TAIWAN J HOSPICE PAL, V11, P1; Chang WP, 2018, APPL NURS RES, V44, P25, DOI 10.1016/j.apnr.2018.09.005; Chen HY., 2017, TAIWAN J HLTH SCI, V4, P21; Cheung JTK, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0317-1; Dahlin C, 2015, SEMIN ONCOL NURS, V31, P327, DOI 10.1016/j.soncn.2015.08.008; Dehghani F, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00567-4; Dong FQ, 2016, EUR J ONCOL NURS, V21, P189, DOI 10.1016/j.ejon.2015.10.003; Evenblij K, 2019, BMC PALLIAT CARE, V18, DOI 10.1186/s12904-018-0388-z; Ganz FD, 2019, NURS CRIT CARE, V24, P141, DOI 10.1111/nicc.12395; Henderson A, 2016, NURS EDUC TODAY, V39, P141, DOI 10.1016/j.nedt.2016.01.005; Holland DE, 2021, PROF CASE MANAG, V26, P53, DOI 10.1097/NCM.0000000000000485; Holopainen G, 2019, NURS ETHICS, V26, P7, DOI 10.1177/0969733016687161; Huang QS, 2015, CHINESE MED J-PEKING, V128, P279, DOI 10.4103/0366-6999.149241; Ibanez-Masero O, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16142469; Kaasalainen S, 2013, INT J PALLIAT NURS, V19, P477, DOI 10.12968/ijpn.2013.19.10.477; Kapoor S, 2018, AM J HOSP PALLIAT ME, V35, P1337, DOI 10.1177/1049909118768247; Kim JS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236390; Kim S, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00581-6; Lee TW, 2010, J ADV NURS, V66, P839, DOI 10.1111/j.1365-2648.2009.05244.x; Lien Ru-Yu, 2020, Hu Li Za Zhi, V67, P33, DOI 10.6224/JN.202010_67(5).06; Lin X, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252430; Ling M, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00959-y; LOCKE EA, 1987, ACAD MANAGE REV, V12, P169, DOI 10.2307/258004; McNeil MJ, 2022, JAMA NETW OPEN, V5, DOI [10.1001/jamanetworkopen.20223245, 10.1001/jamanetworkopen.2022.1245]; Miller-Lewis L, 2019, PALLIAT SUPPORT CARE, V17, P550, DOI 10.1017/S1478951518000937; Mo YY, 2020, J NURS MANAGE, V28, P1002, DOI 10.1111/jonm.13014; [彭晶 Peng Jing], 2019, [中国护理管理, Chinese Nursing Management], V19, P1306; Pesut B, 2020, BMC NURS, V19, DOI 10.1186/s12912-020-0404-5; Pfister D, 2013, J PALLIAT MED, V16, P794, DOI 10.1089/jpm.2012.0586; ROBBINS RA, 1992, DEATH STUD, V16, P557, DOI 10.1080/07481189208252598; Malak-Kolaei FS, 2020, OMEGA-J DEATH DYING, DOI 10.1177/0030222820959235; Tjernberg J, 2020, BMC NURS, V19, DOI 10.1186/s12912-020-00514-x; Wallace CL, 2020, J PAIN SYMPTOM MANAG, V60, pE70, DOI 10.1016/j.jpainsymman.2020.04.012; White C, 2019, BMJ SUPPORT PALLIAT, V9, P202, DOI 10.1136/bmjspcare-2015-000935; Yang HL., 2016, TAIWAN J HOSPICE PAL, V21, P16; Zhang YT, 2018, INT EMERG NURS, V37, P13, DOI 10.1016/j.ienj.2017.07.001; Zheng RS, 2021, J ADV NURS, V77, P795, DOI 10.1111/jan.14621; Zheng RS, 2022, CANCER NURS, V45, pE388, DOI 10.1097/NCC.0000000000000839; Zheng ZH, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00692-0	46	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2022	17	9							e0274540	10.1371/journal.pone.0274540	http://dx.doi.org/10.1371/journal.pone.0274540			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R5XR	36094947	Green Published, gold			2023-01-03	WOS:000892376500054
J	Chatila, WK; Kim, JK; Walch, H; Marco, MR; Chen, CT; Wu, F; Omer, DM; Khalil, DN; Ganesh, K; Qu, X; Luthra, A; Choi, SH; Ho, YJ; Kundra, R; Groves, KI; Chow, OS; Cercek, A; Weiser, MR; Widmar, M; Wei, IH; Pappou, EP; Nash, GM; Paty, PB; Shi, Q; Vakiani, E; Selcuklu, SD; Donoghue, MTA; Solit, DB; Berger, MF; Shia, JR; Pelossof, R; Romesser, PB; Yaeger, R; Smith, JJ; Schultz, N; Sanchez-Vega, F; Garcia-Aguilar, J				Chatila, Walid K.; Kim, Jin K.; Walch, Henry; Marco, Michael R.; Chen, Chin-Tung; Wu, Fan; Omer, Dana M.; Khalil, Danny N.; Ganesh, Karuna; Qu, Xuan; Luthra, Anisha; Choi, Seo-Hyun; Ho, Yu-Jui; Kundra, Ritika; Groves, Katharine I.; Chow, Oliver S.; Cercek, Andrea; Weiser, Martin R.; Widmar, Maria; Wei, Iris H.; Pappou, Emmanouil P.; Nash, Garrett M.; Paty, Philip B.; Shi, Qian; Vakiani, Efsevia; Duygu Selcuklu, S.; Donoghue, Mark T. A.; Solit, David B.; Berger, Michael F.; Shia, Jinru; Pelossof, Raphael; Romesser, Paul B.; Yaeger, Rona; Smith, J. Joshua; Schultz, Nikolaus; Sanchez-Vega, Francisco; Garcia-Aguilar, Julio			Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer	NATURE MEDICINE			English	Article; Early Access							PATHOLOGICAL COMPLETE RESPONSE; DOSE-ESCALATION; LANDSCAPE; SIGNATURES; HETEROGENEITY; EXPRESSION; INHIBITOR; MUTATIONS; EXCISION; INTERVAL	The incidence of rectal cancer is increasing in patients younger than 50 years. Locally advanced rectal cancer is still treated with neoadjuvant radiation, chemotherapy and surgery, but recent evidence suggests that patients with a complete response can avoid surgery permanently. To define correlates of response to neoadjuvant therapy, we analyzed genomic and transcriptomic profiles of 738 untreated rectal cancers. APC mutations were less frequent in the lower than in the middle and upper rectum, which could explain the more aggressive behavior of distal tumors. No somatic alterations had significant associations with response to neoadjuvant therapy in a treatment-agnostic manner, but KRAS mutations were associated with faster relapse in patients treated with neoadjuvant chemoradiation followed by consolidative chemotherapy. Overexpression of IGF2 and L1CAM was associated with decreased response to neoadjuvant therapy. RNA-sequencing estimates of immune infiltration identified a subset of microsatellite-stable immune hot tumors with increased response and prolonged disease-free survival. DNA and RNA sequencing in large cohorts of patients with rectal cancer treated with neoadjuvant therapies identifies biomarkers of response that could inform patient selection for non-operative treatment strategies.	[Chatila, Walid K.; Walch, Henry; Luthra, Anisha; Kundra, Ritika; Duygu Selcuklu, S.; Donoghue, Mark T. A.; Solit, David B.; Berger, Michael F.; Schultz, Nikolaus] Mem Sloan Kettering Canc Ctr, Marie Josee & Henry R Kravis Ctr Mol Oncol, 1275 York Ave, New York, NY 10021 USA; [Chatila, Walid K.; Walch, Henry; Luthra, Anisha; Kundra, Ritika; Schultz, Nikolaus; Sanchez-Vega, Francisco] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA; [Chatila, Walid K.] Weill Cornell Med Coll, Tri Inst Program Computat Biol & Med, New York, NY USA; [Kim, Jin K.; Marco, Michael R.; Chen, Chin-Tung; Wu, Fan; Omer, Dana M.; Qu, Xuan; Luthra, Anisha; Choi, Seo-Hyun; Groves, Katharine I.; Weiser, Martin R.; Widmar, Maria; Wei, Iris H.; Pappou, Emmanouil P.; Nash, Garrett M.; Paty, Philip B.; Pelossof, Raphael; Smith, J. Joshua; Sanchez-Vega, Francisco; Garcia-Aguilar, Julio] Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, 1275 York Ave, New York, NY 10021 USA; [Chen, Chin-Tung; Wu, Fan; Ganesh, Karuna; Cercek, Andrea; Weiser, Martin R.; Pappou, Emmanouil P.; Paty, Philip B.; Vakiani, Efsevia; Shia, Jinru; Pelossof, Raphael; Romesser, Paul B.; Yaeger, Rona; Smith, J. Joshua; Sanchez-Vega, Francisco; Garcia-Aguilar, Julio] Mem Sloan Kettering Canc Ctr, Colorectal Canc Res Ctr, 1275 York Ave, New York, NY 10021 USA; [Khalil, Danny N.; Ganesh, Karuna; Solit, David B.; Romesser, Paul B.; Yaeger, Rona] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Khalil, Danny N.] Parker Inst Canc Immunotherapy, New York, NY USA; [Khalil, Danny N.] Weill Cornell Med, New York, NY USA; [Ho, Yu-Jui] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY USA; [Groves, Katharine I.; Berger, Michael F.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY USA; [Chow, Oliver S.] New York Presbyterian, Dept Cardiothorac Surg, Weill Cornell Med, New York, NY USA; [Shi, Qian] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA; [Vakiani, Efsevia; Berger, Michael F.; Shia, Jinru] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA; [Romesser, Paul B.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; NewYork-Presbyterian Hospital; Mayo Clinic; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Sanchez-Vega, F (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA.; Sanchez-Vega, F; Garcia-Aguilar, J (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, 1275 York Ave, New York, NY 10021 USA.; Sanchez-Vega, F; Garcia-Aguilar, J (corresponding author), Mem Sloan Kettering Canc Ctr, Colorectal Canc Res Ctr, 1275 York Ave, New York, NY 10021 USA.	sanchezf@mskcc.org; garciaaj@mskcc.org		Wu, Fan/0000-0002-3960-320X; Ganesh, Karuna/0000-0002-4948-1082; Kim, Jin/0000-0002-4373-1431	National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) [P30 CA008748-53]; NCI Cancer Center Support Grant (CCSG) [P30 CA08748]; National Institutes of Health (NIH) [T32 GM132083]; NIH/NCI early career development award [K08 CA255574]; NIH/NCI [R37 248289]	National Cancer Institute (NCI) Cancer Center Support Grant (CCSG); NCI Cancer Center Support Grant (CCSG)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI early career development award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors acknowledge the use of services provided by the Molecular Cytology Core Facility, funded by the National Cancer Institute (NCI) Cancer Center Support Grant (CCSG, P30 CA008748-53). The authors also acknowledge the use of the Integrated Genomics Operation Core, funded by the NCI Cancer Center Support Grant (CCSG, P30 CA08748), Cycle for Survival, and the Marie-Josee and Henry R. Kravis Center for Molecular Oncology. W.K.C. is supported by a National Institutes of Health (NIH) research training grant (T32 GM132083). P.B.R. is supported by an NIH/NCI early career development award (K08 CA255574). J.J.S. is supported by an NIH/NCI R37 248289 award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; [Anonymous], 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360; Bielski CM, 2018, CANCER CELL, V34, P852, DOI 10.1016/j.ccell.2018.10.003; Bielski CM, 2018, NAT GENET, V50, P1189, DOI 10.1038/s41588-018-0165-1; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cercek A, 2020, CLIN CANCER RES, V26, P3271, DOI 10.1158/1078-0432.CCR-19-3728; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Cheng LJ, 2019, J GASTROINTEST SURG, V23, P1474, DOI 10.1007/s11605-018-04072-1; Chow OS, 2016, ANN SURG ONCOL, V23, P2548, DOI 10.1245/s10434-016-5205-4; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Cleary JM, 2021, CLIN CANCER RES, V27, P2996, DOI 10.1158/1078-0432.CCR-21-0066; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Eide PW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16747-x; El Din KS, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06766-9; El Sissy C, 2020, CLIN CANCER RES, V26, P5198, DOI 10.1158/1078-0432.CCR-20-0337; Francois Y, 1999, J CLIN ONCOL, V17, P2396, DOI 10.1200/JCO.1999.17.8.2396; Ganesh K, 2020, NAT CANCER, V1, P28, DOI 10.1038/s43018-019-0006-x; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia-Aguilar J, 2022, J CLIN ONCOL, V40, P2546, DOI 10.1200/JCO.22.00032; Garcia-Aguilar J, 2015, LANCET ONCOL, V16, P1537, DOI 10.1016/S1470-2045(15)00215-6; Garcia-Aguilar J, 2015, LANCET ONCOL, V16, P957, DOI 10.1016/S1470-2045(15)00004-2; Garcia-Aguilar J, 2011, ANN SURG, V254, P486, DOI 10.1097/SLA.0b013e31822b8cfa; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Kamran SC, 2019, CLIN CANCER RES, V25, P5561, DOI 10.1158/1078-0432.CCR-19-0908; Kim JK, 2021, MOL ONCOL, V15, P2766, DOI 10.1002/1878-0261.12960; Kirilovsky Amos, 2022, Oncotarget, V13, P18, DOI 10.18632/oncotarget.28100; Korkeila E, 2009, BRIT J CANCER, V100, P874, DOI 10.1038/sj.bjc.6604949; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee MS, 2017, J NATL COMPR CANC NE, V15, P411, DOI 10.6004/jnccn.2017.0038; Lee-Kong SA, 2012, DIS COLON RECTUM, V55, P990, DOI 10.1097/DCR.0b013e31825bd80c; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu Y, 2018, CANCER CELL, V33, P721, DOI 10.1016/j.ccell.2018.03.010; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marr R, 2005, ANN SURG, V242, P74, DOI 10.1097/01.sla.0000167926.60908.15; Mondaca S, 2020, GASTROENTEROLOGY, V159, P1975, DOI 10.1053/j.gastro.2020.07.041; Moore HG, 2004, DIS COLON RECTUM, V47, P279, DOI 10.1007/s10350-003-0062-1; Nagtegaal ID, 2005, J CLIN ONCOL, V23, P9257, DOI 10.1200/JCO.2005.02.9231; Nikolouzakis TK, 2019, ANN GASTROENTEROL, V32, P431, DOI 10.20524/aog.2019.0407; Nishimura T, 2000, CANCER CHEMOTH PHARM, V46, pS52, DOI 10.1007/PL00014051; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Patel SV, 2016, J SURG ONCOL, V114, P637, DOI 10.1002/jso.24358; Probst CP, 2015, J AM COLL SURGEONS, V221, P430, DOI 10.1016/j.jamcollsurg.2015.04.010; Rahma OE, 2021, JAMA ONCOL, V7, P1225, DOI 10.1001/jamaoncol.2021.1683; Roxburgh CSD, 2019, COLORECTAL DIS, V21, P1140, DOI 10.1111/codi.14713; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Schrag D, 2019, CLIN TRIALS, V16, P165, DOI 10.1177/1740774518824539; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Smith JJ, 2019, JAMA ONCOL, V5, DOI 10.1001/jamaoncol.2018.5896; Smith JJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1632-z; Taylor AM, 2018, CANCER CELL, V33, P676, DOI 10.1016/j.ccell.2018.03.007; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Yang H, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07255-9; Zanella ER, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010445; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	69	5	5	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01930-z	http://dx.doi.org/10.1038/s41591-022-01930-z		AUG 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3T9PT	35970919				2023-01-03	WOS:000840603000002
J	Cohen, SH; Louie, TJ; Sims, M; Wang, EEL; Memisoglu, A; McGovern, BH; von Moltke, L				Cohen, Stuart H.; Louie, Thomas J.; Sims, Matthew; Wang, Elaine E. L.; Memisoglu, Asli; McGovern, Barbara H.; von Moltke, Lisa			Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter; Early Access									[Cohen, Stuart H.] Univ Calif Davis Hlth, Sacramento, CA USA; [Louie, Thomas J.] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada; [Sims, Matthew] Beaumont Hlth, Royal Oak, MI USA; [Sims, Matthew] Oakland Univ, William Beaumont Sch Med, Royal Oak, MI USA; [Wang, Elaine E. L.; Memisoglu, Asli; McGovern, Barbara H.; von Moltke, Lisa] Seres Therapeut, 200 Sidney St, Cambridge, MA 02139 USA	University of Calgary; Beaumont Health; Oakland University	McGovern, BH (corresponding author), Seres Therapeut, 200 Sidney St, Cambridge, MA 02139 USA.	bmcgovern@serestherapeutics.com			Seres Therapeutics	Seres Therapeutics	This study was sponsored by Seres Therapeutics.	Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047; Feuerstadt P, 2022, NEW ENGL J MED, V386, P220, DOI 10.1056/NEJMoa2106516; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Seekatz AM, 2014, J CLIN INVEST, V124, P4182, DOI 10.1172/JCI72336; Theriot CM, 2015, ANNU REV MICROBIOL, V69, P445, DOI 10.1146/annurev-micro-091014-104115	5	1	1	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.16476	http://dx.doi.org/10.1001/jama.2022.16476		OCT 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5M0NV	36260754				2023-01-03	WOS:000870804400001
J	Koo, H; Morrow, CD				Koo, Hyunmin; Morrow, Casey D.			Time series strain tracking analysis post fecal transplantation identifies individual specific patterns of fecal dominant donor, recipient, and unrelated microbial strains	PLOS ONE			English	Article							READ ALIGNMENT; RESISTANCE	Background Fecal microbial transplantation (FMT) has been used with the therapeutic intent to change the functions of the gut microbial community in metabolism and host immunity. For most of these therapies, the recipients are not given antibiotics to eliminate the microbial community prior to transplant with donor fecal microbes resulting in the initial gut microbial community following FMT consisting of a consortium of donor and recipient microbes. The detailed analysis of the fecal samples from these FMT over time provides a unique opportunity to study the changes in the gut microbial strain community that occurs following the introduction of new microbial strains (donor) into an established community (recipient). Methods In this study, we have metagenomic data set consisting of 5 FMT that contained donor, recipient and recipient post FMT taken multiple times for periods up to 535 days after the FMT. We used two established strain tracking methods, Window-based Single Nucleotide Variant (SNV) Similarity (WSS) and StrainPhlAn, to determine the presence of donor and recipient microbial strains following FMT. To assess recombination between donor and recipient strains of Bacteroides vulgatus post FMT, we used BLAST+ to analyze the data sets for Bacteroidales-specific antimicrobial proteins (BSAP-3) that have known functions to restrict species specific replication. Results We found that Alistipes onderdonkii, Alistipes shahii, Alistipes putredinis, and Parabacteroides merdae, all had patterns post FMT consisting of either dominant donor or recipient microbial strains in the feces. In contrast, the analysis of Bacteroides spp. in five FMT pairs revealed inter-individual oscillation over time with the appearance of either donor or recipient fecal strain dominance. In some instances, B. vulgatus and B. uniformis were also identified after FMT that were not related to either the donor or recipient. Finally, in one of the FMT, we identified a distinct B. vulgatus strain post-FMT that matched the pre-FMT strain but was BSAP-3 positive, suggesting a possible recombination event between the donor and recipient strains. Conclusion The complex oscillating patterns of the appearance of fecal dominant donor, recipient or unrelated strains following extended times post FMT provide new insights into the dynamics of the microbial community interactions with the recipients following FMT. The result from our analysis has implications for the use of FMT to predictably change the biological functions of the gut community in metabolism and host immunity.	[Koo, Hyunmin] Univ Alabama Birmingham, Hugh Kaul Precis Med Inst, Dept Genet, Birmingham, AL 35294 USA; [Morrow, Casey D.] Univ Alabama Birmingham, Hugh Kaul Precis Med Inst, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Koo, H (corresponding author), Univ Alabama Birmingham, Hugh Kaul Precis Med Inst, Dept Genet, Birmingham, AL 35294 USA.; Morrow, CD (corresponding author), Univ Alabama Birmingham, Hugh Kaul Precis Med Inst, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA.	khmkhm87@uab.edu; caseym@uab.edu			UAB School of Medicine	UAB School of Medicine	We thank the UAB Information Technology Research Computing group for providing the high-performance computing support necessary for bioinformatics analyses. We thank Davar et al. for depositing their extensive metagenomic DNA sequencing analysis used in our study. We also thank UAB School of Medicine for supporting this study.	Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Buffie CG, 2013, NAT REV IMMUNOL, V13, P790, DOI 10.1038/nri3535; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Coyne MJ, 2014, MBIO, V5, DOI 10.1128/mBio.01305-14; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; Donaldson GP, 2016, NAT REV MICROBIOL, V14, P20, DOI 10.1038/nrmicro3552; Truong DT, 2017, GENOME RES, V27, P626, DOI 10.1101/gr.216242.116; Fischer M, 2017, GUT MICROBES, V8, P289, DOI 10.1080/19490976.2016.1273998; Franzosa EA, 2015, P NATL ACAD SCI USA, V112, pE2930, DOI 10.1073/pnas.1423854112; Koo H., 2022, PREPRINTS, DOI [10.21203/rs.3.rs-1689105/v1, DOI 10.21203/RS.3.RS-1689105/V1]; Koo H, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-021-02312-0; Koo H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242021; Koo H, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.549844; Koo H, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.192200; Koo H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226111; Koo H, 2019, NPJ BIOFILMS MICROBI, V5, DOI 10.1038/s41522-019-0103-8; Kumar R, 2017, NPJ BIOFILMS MICROBI, V3, DOI 10.1038/s41522-017-0020-7; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Lakhani SV, 2008, NUTR RES, V28, P293, DOI 10.1016/j.nutres.2008.03.002; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Li DH, 2015, BIOINFORMATICS, V31, P1674, DOI 10.1093/bioinformatics/btv033; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Roshan N, 2020, INFECT DIS THER, V9, P935, DOI 10.1007/s40121-020-00339-w; Russell AB, 2014, CELL HOST MICROBE, V16, P227, DOI 10.1016/j.chom.2014.07.007; Seekatz AM, 2014, MBIO, V5, DOI 10.1128/mBio.00893-14; Segata N, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00190-17; Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/NMETH.2066, 10.1038/nmeth.2066]; Smillie CS, 2018, CELL HOST MICROBE, V23, P229, DOI 10.1016/j.chom.2018.01.003; Staley C, 2016, MBIO, V7, DOI 10.1128/mBio.01965-16; Stecher G, 2020, MOL BIOL EVOL, V37, P1237, DOI 10.1093/molbev/msz312; Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101; Truong DT, 2015, NAT METHODS, V12, P902, DOI 10.1038/nmeth.3589; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Wexler AG, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.26; Wilson BC, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00002; Zaneveld JR, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.121; Zhao Q, 2018, IMMUNOLOGY, V154, P28, DOI 10.1111/imm.12896	40	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2022	17	9							e0274633	10.1371/journal.pone.0274633	http://dx.doi.org/10.1371/journal.pone.0274633			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R1RR	36107983	Green Published, gold			2023-01-03	WOS:000892087100093
J	Webster, P				Webster, Paul			Worries grow about medically assisted dying in Canada	LANCET			English	Editorial Material																			0	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 10	2022	400	10355					801	802						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5V9YX	36088940				2023-01-03	WOS:000877580600010
J	Heyland, DK; Wibbenmeyer, L; Pollack, JA; Friedman, B; Turgeon, AF; Eshraghi, N; Jeschke, MG; Belisle, S; Grau, D; Mandell, S; Velamuri, SR; Hundeshagen, G; Moiemen, N; Shokrollahi, K; Foster, K; Huss, F; Collins, D; Savetamal, A; Gurney, JM; Depetris, N; Stoppe, C; Ortiz-Reyes, L; Garrel, D; Day, AG				Heyland, Daren K.; Wibbenmeyer, Lucy; Pollack, Jonathan A.; Friedman, Bruce; Turgeon, Alexis F.; Eshraghi, Niknam; Jeschke, Marc G.; Belisle, Sylvain; Grau, Daisy; Mandell, Samuel; Velamuri, Sai R.; Hundeshagen, Gabriel; Moiemen, Naiem; Shokrollahi, Kayvan; Foster, Kevin; Huss, Fredrik; Collins, Declan; Savetamal, Alisa; Gurney, Jennifer M.; Depetris, Nadia; Stoppe, Christian; Ortiz-Reyes, Luis; Garrel, Dominique; Day, Andrew G.			A Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUTRITION; DEPLETION; TESTS; MODEL; ICU	BACKGROUNDGlutamine is thought to have beneficial effects on the metabolic and stress response to severe injury. Clinical trials involving patients with burns and other critically ill patients have shown conflicting results regarding the benefits and risks of glutamine supplementation. METHODS In a double-blind, randomized, placebo-controlled trial, we assigned patients with deep second-or third-degree burns (affecting >= 10% to >= 20% of total body-surface area, depending on age) within 72 hours after hospital admission to receive 0.5 g per kilogram of body weight per day of enterally delivered glutamine or placebo. Trial agents were given every 4 hours through a feeding tube or three or four times a day by mouth until 7 days after the last skin grafting procedure, discharge from the acute care unit, or 3 months after admission, whichever came first. The primary outcome was the time to discharge alive from the hospital, with data censored at 90 days. We calculated subdistribution hazard ratios for discharge alive, which took into account death as a competing risk. RESULTS A total of 1209 patients with severe burns (mean burn size, 33% of total body-surface area) underwent randomization, and 1200 were included in the analysis (596 patients in the glutamine group and 604 in the placebo group). The median time to discharge alive from the hospital was 40 days (interquartile range, 24 to 87) in the glutamine group and 38 days (interquartile range, 22 to 75) in the placebo group (subdistribution hazard ratio for discharge alive, 0.91; 95% confidence interval [CI], 0.80 to 1.04; P = 0.17). Mortality at 6 months was 17.2% in the glutamine group and 16.2% in the placebo group (hazard ratio for death, 1.06; 95% CI, 0.80 to 1.41). No substantial between-group differences in serious adverse events were observed. CONCLUSIONS In patients with severe burns, supplemental glutamine did not reduce the time to discharge alive from the hospital.	[Heyland, Daren K.; Ortiz-Reyes, Luis] Queens Univ, Clin Evaluat Res Unit, Kingston, ON, Canada; [Heyland, Daren K.; Ortiz-Reyes, Luis] Queens Univ, Res Inst, Kingston Hlth Sci Ctr, Kingston, ON, Canada; [Heyland, Daren K.; Ortiz-Reyes, Luis] Queens Univ, Dept Crit Care Med, Kingston, ON, Canada; [Heyland, Daren K.] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada; [Turgeon, Alexis F.] Univ Laval, Fac Med, Dept Anesthesiol & Crit Care Med, Div Crit Care Med, Quebec City, PQ, Canada; [Turgeon, Alexis F.] Univ Laval Res Ctr, Populat Hlth & Optimal Hlth Pract Unit Trauma Emer, Quebec City, PQ, Canada; [Turgeon, Alexis F.] Univ Laval Res Ctr, Canada Res Chair Crit Care Neurol & Trauma, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada; [Jeschke, Marc G.] Univ Toronto, Ross Tilley Burn Ctr, Sunnybrook Hlth Sci Ctr, Dept Surg,Dept Immunol,Div Plast Surg, Toronto, ON, Canada; [Jeschke, Marc G.] Univ Toronto, Inst Med Sci, Ross Tilley Burn Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Jeschke, Marc G.] Sunnybrook Res Inst, Toronto, ON, Canada; [Belisle, Sylvain] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Belisle, Sylvain] Univ Montreal, Dept Anesthesiol, Montreal, PQ, Canada; [Garrel, Dominique] Univ Montreal, Fac Med, Dept Nutr, Montreal, PQ, Canada; [Wibbenmeyer, Lucy] Univ Iowa, Iowa City, IA USA; [Pollack, Jonathan A.] Mercy Hosp, Burn Ctr, St. Louis, MO USA; [Friedman, Bruce] Joseph M Still Res Fdn, Augusta, GA USA; [Eshraghi, Niknam] Legacy Oregon Burn Ctr, Portland, OR USA; [Eshraghi, Niknam] Oregon Hlth & Sci Univ, Portland, OR USA; [Grau, Daisy] Ctr Nacl Quemaduras & Cirugia Reconstruct, Internal Med, Asuncion, Paraguay; [Mandell, Samuel] UT Southwestern Med Ctr, Dallas, TX USA; [Gurney, Jennifer M.] Joint Base San Antonio Ft Sam Houston, San Antonio, TX USA; [Velamuri, Sai R.] Univ Tennessee Hlth Sci Ctr, Knoxville, TN USA; [Velamuri, Sai R.] Firefighters Burn Ctr, Memphis, TN USA; [Hundeshagen, Gabriel] Heidelberg Univ, Burn Trauma Ctr, BG Trauma Ctr Ludwigshafen, Dept Hand Plast & Reconstruct Surg, Heidelberg, Germany; [Stoppe, Christian] Univ Hosp Wurzburg, Dept Anesthesiol Intens Care Med & Pain Therapy, Wurzburg, Germany; [Moiemen, Naiem] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp Birmingham, Birmingham, England; [Shokrollahi, Kayvan] Whiston Hosp, Mersey Reg Burn Ctr, St Helens & Knowesley NHS Trust, Prescot, England; [Shokrollahi, Kayvan] Manchester Metropolitan Univ, Manchester, England; [Collins, Declan] Chelsea & Westminster Hosp London, Plast Surg & Burns, London, England; [Foster, Kevin] Arizona Burn Ctr Valleywise Hlth, Maricopa Med Ctr, Phoenix, AZ USA; [Huss, Fredrik] Uppsala Univ, Dept Surg Sci, Plast Surg, Uppsala, Sweden; [Huss, Fredrik] Uppsala Univ Hosp, Burn Ctr, Dept Plast & Maxillofacial Surg, Uppsala, Sweden; [Savetamal, Alisa] Yale New Haven Hlth Bridgeport Hosp, Connecticut Burn Ctr, Bridgeport, CT USA; [Depetris, Nadia] Azienda Osped Univ, Ctr Traumatol Ortoped, Citta Salute & Sci Torino, Turin, Italy	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; Laval University; Laval University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Universite de Montreal; Universite de Montreal; Universite de Montreal; University of Iowa; Saint Johns Mercy Medical Center; Oregon Health & Science University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Tennessee Medical Center; University of Tennessee System; University of Tennessee Health Science Center; Ruprecht Karls University Heidelberg; University of Wurzburg; University of Birmingham; Whiston Hospital; Manchester Metropolitan University; Uppsala University; Uppsala University; Uppsala University Hospital; A.O.U. Citta della Salute e della Scienza di Torino; University of Turin	Heyland, DK (corresponding author), Queens Univ, Clin Evaluat Res Unit, Kingston, ON, Canada.; Heyland, DK (corresponding author), Queens Univ, Res Inst, Kingston Hlth Sci Ctr, Kingston, ON, Canada.; Heyland, DK (corresponding author), Queens Univ, Dept Crit Care Med, Kingston, ON, Canada.; Heyland, DK (corresponding author), Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada.		Jeschke, Marc/D-3501-2019; galet, colette/C-4620-2011	Jeschke, Marc/0000-0003-0870-1664; Collins, Declan/0000-0003-3191-3606; galet, colette/0000-0002-5931-2143				Sanchez JLA, 2007, ARCH SURG-CHICAGO, V142, P50, DOI 10.1001/archsurg.142.1.50; [Anonymous], 2021, COMP PAR NUTR GLUT S; Bessey PQ, 2014, J BURN CARE RES, V35, pS218, DOI 10.1097/BCR.0000000000000080; Czapran A, 2015, BURNS, V41, P510, DOI 10.1016/j.burns.2014.09.013; Dechartres A, 2011, ANN INTERN MED, V155, P39, DOI 10.7326/0003-4819-155-1-201107050-00006; Duchateau L, 2002, COMPUT STAT DATA AN, V40, P603, DOI 10.1016/S0167-9473(02)00057-9; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Greenhalgh DG, 2019, NEW ENGL J MED, V380, P2349, DOI 10.1056/NEJMra1807442; Heyland D, 2013, NEW ENGL J MED, V368, P1489, DOI 10.1056/NEJMoa1212722; Heyland Daren K, 2017, Scars Burn Heal, V3, p2059513117745241, DOI 10.1177/2059513117745241; Heyland DK, 2010, JPEN-PARENTER ENTER, V34, P697, DOI 10.1177/0148607110362993; James SL, 2020, INJURY PREV, V26, P36, DOI 10.1136/injuryprev-2019-043299; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kieser M, 2003, STAT MED, V22, P3571, DOI 10.1002/sim.1585; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Matsuyama T, 2021, CELL DEATH DIFFER, V28, P3199, DOI 10.1038/s41418-021-00892-y; Oehler R, 2002, BRIT J NUTR, V87, pS17, DOI 10.1079/BJN2001453; Oudemans-van Straaten HM, 2001, INTENS CARE MED, V27, P84, DOI 10.1007/s001340000703; PARRYBILLINGS M, 1990, LANCET, V336, P523, DOI 10.1016/0140-6736(90)92083-T; Peck MD, 2012, BURNS, V38, P630, DOI 10.1016/j.burns.2011.12.028; PLANAS M, 1993, JPEN-PARENTER ENTER, V17, P299, DOI 10.1177/0148607193017003299; Pritchett YL, 2015, STAT BIOPHARM RES, V7, P309, DOI 10.1080/19466315.2015.1098564; Roth E, 1982, Clin Nutr, V1, P25, DOI 10.1016/0261-5614(82)90004-8; Rousseau AF, 2013, CLIN NUTR, V32, P497, DOI 10.1016/j.clnu.2013.02.012; van Zanten ARH, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1002-x; van Zanten ARH, 2014, JAMA-J AM MED ASSOC, V312, P514, DOI 10.1001/jama.2014.7698; Ware DL, 1996, QUALITY LIFE PHARMAC, P337; Wischmeyer PE, 2007, CRIT CARE MED, V35, pS541, DOI 10.1097/01.CCM.0000278064.32780.D3; Zhou YP, 2003, JPEN-PARENTER ENTER, V27, P241, DOI 10.1177/0148607103027004241	30	0	0	9	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 15	2022	387	11					1001	1010		10.1056/NEJMoa2203364	http://dx.doi.org/10.1056/NEJMoa2203364		SEP 2022	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5E1UZ	36082909				2023-01-03	WOS:000852749800001
J	Huschtscha, Z; Young, P; Parr, A; Porter, J; Costa, R				Huschtscha, Zoya; Young, Pascale; Parr, Alexandra; Porter, Judi; Costa, Ricardo			Does intestinal epithelial integrity status in response to high-protein dairy milk beverage with or without progressive resistance training impact systemic inflammatory responses in an active aging population?	PLOS ONE			English	Article							EXERTIONAL-HEAT-STRESS; INDUCED GASTROINTESTINAL SYNDROME; SKELETAL-MUSCLE; CIRCULATORY ENDOTOXIN; ULTRA-MARATHON; EXERCISE; HEALTH; SYMPTOMS; STRENGTH; MASS	Increased resting systemic anti-inflammatory responses have previously been reported after a period of progressive resistance training (PRT) with daily consumption of a high-protein dairy beverage. The study aimed to investigate the independent and combined effects of consuming a high protein dairy milk beverage with or without a PRT on markers of intestinal epithelial integrity and selected systemic inflammatory responses in active older (>= 50 yrs) adults. Thirty two (males n = 24, females n = 8) active older adults [mean (SD): Age 62 (7) years, weight 74.2 (14.0) kg, height 1.73 (10.0) cm, BMI 24.9 (4.0) kg/m(2), and body fat mass: 25.8 (9.1)%)], that reported exercising >= 3/week (211 (91) min/week) were randomly allocated into one of four groups: dairy milk (DM), exercise and dairy milk (EX+DM), exercise alone (EX), and control (CON). Groups with EX underwent 12-weeks whole-body PRT program (x3 sessions/week), groups with DM consumed the beverage twice daily (30g protein/day), and CON was required to carry out their ad libitum dietary and exercise habits. Plasma concentrations of CRP, IL-1 beta, IL-1ra, LBP, and sCD14 were determined by ELISA from samples collected at weeks 0, 6, and 12. Data were analyzed (SPSS v25.0) for group and time differences using a two-way repeated-measures ANOVA with post hoc analysis. No significant differences were observed for any of the measured plasma biomarkers. The previously observed increase in anti-inflammatory cytokine response is likely due to a muscular cellular response and not an indication of intestinal epithelial integrity disturbance and/ or subsequent translocation of luminal originated pathogenic bacterial compounds.	[Huschtscha, Zoya; Young, Pascale; Parr, Alexandra; Porter, Judi; Costa, Ricardo] Monash Univ, Dept Nutr Dietet Food, Notting Hill, Vic, Australia; [Porter, Judi] Deakin Univ, Sch Exercise & Nutr Sci, Burwood Campus, Melbourne, Vic, Australia	Monash University; Deakin University	Costa, R (corresponding author), Monash Univ, Dept Nutr Dietet Food, Notting Hill, Vic, Australia.	ricardo.costa@monash.edu	da Costa, Ricardo/I-1572-2014	da Costa, Ricardo/0000-0003-3069-486X	Lion Dairy and Drinks, Australia, as part of Monash University Graduate Research Industry Partnership-Food and Dairy program	Lion Dairy and Drinks, Australia, as part of Monash University Graduate Research Industry Partnership-Food and Dairy program	Research funding (ZH and RC) was provided by Lion Dairy and Drinks, Australia, as part of Monash University Graduate Research Industry Partnership-Food and Dairy program.	Alvarez-Rodriguez L, 2012, CELL IMMUNOL, V273, P124, DOI 10.1016/j.cellimm.2012.01.001; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Beaudart C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169548; Boutagy NE, 2016, BIOCHIMIE, V124, P11, DOI 10.1016/j.biochi.2015.06.020; Costa RJS, 2017, ALIMENT PHARM THER, V46, P246, DOI 10.1111/apt.14157; Costa Ricardo J S, 2020, Temperature (Austin), V7, P58, DOI 10.1080/23328940.2019.1597676; Deng B, 2012, J IMMUNOL, V189, P3669, DOI 10.4049/jimmunol.1103180; Department of Health and Aged Care, 2021, COMM AUSTR AUSTR PHY; Draganidis D, 2016, J NUTR, V146, P1940, DOI 10.3945/jn.116.230912; Frontera WR, 2000, J APPL PHYSIOL, V88, P1321; Gaskell SK, 2021, MED SCI SPORT EXER, V53, P1056, DOI 10.1249/MSS.0000000000002546; Gaskell SK, 2020, APPL PHYSIOL NUTR ME, V45, P569, DOI 10.1139/apnm-2019-0187; Gill SK, 2015, INT J SPORTS MED, V36, P688, DOI 10.1055/s-0034-1398535; Gill SK, 2015, EXERC IMMUNOL REV, V21, P114; Goodpaster BH, 2006, J GERONTOL A-BIOL, V61, P1059, DOI 10.1093/gerona/61.10.1059; Guerville M, 2016, AM J PHYSIOL-GASTR L, V311, pG1, DOI 10.1152/ajpgi.00098.2016; Hirose L, 2004, EXERC IMMUNOL REV, V10, P75; Huschtscha Z, 2021, SPORTS MED-OPEN, V7, DOI 10.1186/s40798-021-00323-9; Huschtscha Z, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.644865; Mohammad S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.594150; Peake J, 2010, AM J PHYSIOL-REG I, V298, pR1485, DOI 10.1152/ajpregu.00467.2009; Phillips MD, 2010, MED SCI SPORT EXER, V42, P314, DOI 10.1249/MSS.0b013e3181b11ab7; Russo I, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.628863; Sardeli AV, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040423; Schaap LA, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.10.049; Selkirk GA, 2008, AM J PHYSIOL-REG I, V295, pR611, DOI 10.1152/ajpregu.00917.2007; Snipe RMJ, 2018, INT J SPORTS MED, V39, P255, DOI 10.1055/s-0043-122742; Snipe RMJ, 2018, EUR J APPL PHYSIOL, V118, P389, DOI 10.1007/s00421-017-3781-z; Snipe RMJ, 2017, APPL PHYSIOL NUTR ME, V42, P1283, DOI 10.1139/apnm-2017-0361; van Wijck K, 2013, AM J PHYSIOL-REG I, V304, pR356, DOI 10.1152/ajpregu.00294.2012; Visser M, 2002, J GERONTOL A-BIOL, V57, pM326, DOI 10.1093/gerona/57.5.M326; World Health Organization, GLOBAL RECOMMENDATIO	32	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2022	17	9							e0274210	10.1371/journal.pone.0274210	http://dx.doi.org/10.1371/journal.pone.0274210			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R9TT	36054131	Green Published, gold			2023-01-03	WOS:000892641400067
J	Neto, EC; Perumal, TM; Pratap, A; Tediarjo, A; Bot, BM; Mangravite, L; Omberg, L				Neto, Elias Chaibub; Perumal, Thanneer M.; Pratap, Abhishek; Tediarjo, Aryton; Bot, Brian M.; Mangravite, Lara; Omberg, Larsson			Disentangling personalized treatment effects from "time-of-the-day" confounding in mobile health studies	PLOS ONE			English	Article							PARTIAL GRANGER CAUSALITY; EXOGENOUS INPUTS; HETEROSKEDASTICITY; INFERENCE; MODEL	Ideally, a patient's response to medication can be monitored by measuring changes in performance of some activity. In observational studies, however, any detected association between treatment ("on-medication" vs "off-medication") and the outcome (performance in the activity) might be due to confounders. In particular, causal inferences at the personalized level are especially vulnerable to confounding effects that arise in a cyclic fashion. For quick acting medications, effects can be confounded by circadian rhythms and daily routines. Using the time-of-the-day as a surrogate for these confounders and the performance measurements as captured on a smartphone, we propose a personalized statistical approach to disentangle putative treatment and "time-of-the-day" effects, that leverages conditional independence relations spanned by causal graphical models involving the treatment, time-of-the-day, and outcome variables. Our approach is based on conditional independence tests implemented via standard and temporal linear regression models. Using synthetic data, we investigate when and how residual autocorrelation can affect the standard tests, and how time series modeling (namely, ARIMA and robust regression via HAC covariance matrix estimators) can remedy these issues. In particular, our simulations illustrate that when patients perform their activities in a paired fashion, positive autocorrelation can lead to conservative results for the standard regression approach (i.e., lead to deflated true positive detection), whereas negative autocorrelation can lead to anticonservative behavior (i.e., lead to inflated false positive detection). The adoption of time series methods, on the other hand, leads to well controlled type I error rates. We illustrate the application of our methodology with data from a Parkinson's disease mobile health study.	[Neto, Elias Chaibub; Perumal, Thanneer M.; Pratap, Abhishek; Tediarjo, Aryton; Bot, Brian M.; Mangravite, Lara; Omberg, Larsson] Sage Bionetworks, Seattle, WA 98121 USA; [Perumal, Thanneer M.] Roche Innovat Ctr Basel, Pharmaceut Res & Early Dev, Basel, Basel Stadt, Switzerland; [Pratap, Abhishek] Univ Toronto, Ctr Addict & Mental Hlth, Dept Psychiat, Toronto, ON, Canada	Roche Holding; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Neto, EC (corresponding author), Sage Bionetworks, Seattle, WA 98121 USA.	elias.chaibub.neto@sagebionetworks.org		Pratap, Abhishek/0000-0002-5289-6932; Chaibub Neto, Elias/0000-0002-9575-861X; Omberg, Larsson/0000-0002-4719-9120	Robert Wood Johnson Foundation; NINDS [5U01NS107009-04, 5P50NS108676-04]	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded through a grant from the Robert Wood Johnson Foundation, and by NINDS grants 5U01NS107009-04 and 5P50NS108676-04. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abhishek Pratap, 2017, Arxiv, DOI arXiv:1706.09574; Ahlskog JE., 2015, NEW PARKINSONS DIS T, V2nd ed; Tank A, 2018, Arxiv, DOI arXiv:1802.05842; Andrew D Trister, 2017, Arxiv, DOI arXiv:1604.01055; Arora S, 2015, PARKINSONISM RELAT D, V21, P650, DOI 10.1016/j.parkreldis.2015.02.026; Arora S, 2014, INT CONF ACOUST SPEE, DOI 10.1109/ICASSP.2014.6854280; Bell D, 1996, ECON LETT, V51, P7, DOI 10.1016/0165-1765(95)00791-1; Bot BM, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.11; Chan YFY, 2017, NAT BIOTECHNOL, V35, P354, DOI 10.1038/nbt.3826; Chickering D. M., 2003, Journal of Machine Learning Research, V3, P507, DOI 10.1162/153244303321897717; Chu TJ, 2008, J MACH LEARN RES, V9, P967; Dang XH, 2018, ARXIV; Datta DD, 2012, INT FINANCE DISCUSSI; Demiralp S, 2003, OXFORD B ECON STAT, V65, P745, DOI 10.1046/j.0305-9049.2003.00087.x; Doerr M, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.6521; Entner D., 2010, PROBABILISTIC GRAPHI, P121; Friend SH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1206; Gerhardus A., 2020, ADV NEURAL INFORM PR, P12615; GEURTS M, 1977, J MARKETING RES, V14, P269, DOI 10.2307/3150485; Glymour C, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00524; GRANGER CWJ, 1969, ECONOMETRICA, V37, P424, DOI 10.2307/1912791; GRANGER CWJ, 1980, J ECON DYN CONTROL, V2, P329, DOI 10.1016/0165-1889(80)90069-X; Gregorova M, 2015, ARXIV; Guo SX, 2008, J NEUROSCI METH, V172, P79, DOI 10.1016/j.jneumeth.2008.04.011; HECKERMAN D, 1995, MACH LEARN, V20, P197, DOI 10.1023/A:1022623210503; Hoover KD, 2005, ECONOMET THEOR, V21, P69, DOI 10.1017/S026646660505005X; Hoyer P.O., 2009, ADV NEURAL INFORM PR; Huang BW, 2019, PR MACH LEARN RES, V97; Huang BW, 2018, KDD'18: PROCEEDINGS OF THE 24TH ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY & DATA MINING, P1551, DOI 10.1145/3219819.3220104; Huber R, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102159; Hung YC, 2014, ELECTRON J STAT, V8, P1940, DOI 10.1214/14-EJS940; Hyndman RJ, 2008, J STAT SOFTW, V27, P1, DOI 10.18637/jss.v027.i03; Hyvarinen A., 2008, PROC INT C MACH LEAR, P424; Hyvarinen A, 2010, J MACH LEARN RES, V11, P1709; Jan Kautz, 2020, Arxiv, DOI arXiv:2001.01885; Lauritzen S.L., 1996, GRAPHICAL MODELS; Madras D., 2020, ARXIV; Malinsky D., 2018, P 2018 ACM SIGKDD WO, V92, P23; Mastakouri A. A., 2021, PROC INT C MACH LEAR, V139, P7502; McConnell MV, 2017, JAMA CARDIOL, V2, P67, DOI 10.1001/jamacardio.2016.4395; MCGREGOR JR, 1989, BIOMETRIKA, V76, P735; Meng Y., 2019, ARXIV; Moneta A, 2006, P JOINT C INF SCI KA; Moraffah R, 2021, KNOWL INF SYST, V63, P3041, DOI 10.1007/s10115-021-01621-0; Nauta M, 2019, MACH LEARN KNOW EXTR, V1, DOI 10.3390/make1010019; Neto EC, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0178-x; Neto EC, 2016, BIOCOMPUT-PAC SYM, P273; NEWEY WK, 1987, ECONOMETRICA, V55, P703, DOI 10.2307/1913610; NEWEY WK, 1994, REV ECON STUD, V61, P631, DOI 10.2307/2297912; Omberg L, 2022, NAT BIOTECHNOL, V40, P480, DOI 10.1038/s41587-021-00974-9; Peters J., 2013, ADV NEURAL INFORM PR, P154; R Core Team, 2020, R LANG ENV STAT COMP; Rho SH, 2019, ECONOMET THEOR, V35, P601, DOI 10.1017/S0266466618000117; Rodas CB, 2021, ARXIV; Roelstraete B, 2012, J NEUROSCI METH, V206, P73, DOI 10.1016/j.jneumeth.2012.01.010; Rothenhausler D, 2015, ADV NEUR IN, V28; Runge J, 2018, CHAOS, V28, DOI 10.1063/1.5025050; Runge J., 2020, ARXIV; Runge J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau4996; Runge J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10105-3; Schaechtle U., 2013, 23 INT JOINT C ARTIF; Schork NJ, 2015, NATURE, V520, P609, DOI 10.1038/520609a; Shimizu S, 2006, J MACH LEARN RES, V7, P2003; Shumway RH, 2011, SPRINGER TEXTS STAT, P1, DOI 10.1007/978-1-4419-7865-3; Snyder PT., 2020, J OPEN SOURCE SOFTW, V5, P2106, DOI [10.21105/joss.02106, DOI 10.21105/JOSS.02106]; Spirtes P., 2000, CAUSATION PREDICTION; Topol EJ, 2012, CREATIVE DESTRUCTION; Verma T., 1990, READINGS UNCERTAIN R; Vesel C, 2020, J AM MED INFORM ASSN, V27, P1007, DOI 10.1093/jamia/ocaa057; Xu CX, 2019, PROCEEDINGS OF THE 28TH ACM INTERNATIONAL CONFERENCE ON INFORMATION & KNOWLEDGE MANAGEMENT (CIKM '19), P1853, DOI 10.1145/3357384.3357864; Zeileis A, 2004, J STAT SOFTWARE, V10, P1; Zhang K., 2009, P 25 C UNC ART INT	72	0	0	4	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2022	17	8							e0271766	10.1371/journal.pone.0271766	http://dx.doi.org/10.1371/journal.pone.0271766			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4E8NP	35925980	Green Published, gold			2023-01-03	WOS:000848077100049
J	Vierboom, YC				Vierboom, Yana C.			How does it all end? Trends and disparities in health at the end of life	PLOS ONE			English	Article							LAST YEARS; UNITED-STATES; DISABILITY; TRAJECTORIES; AGE; DEATH; EXPECTANCY; MORBIDITY; AMERICANS; GENDER	Objectives To consider trends and disparities in end-of-life health in the US. Methods I use data from the National Health Interview Survey, linked to death records through 2015, for respondents who died at ages 65+ to compare the prevalence of three health outcomes in the last six years of life across time, sex, age, race, and educational attainment. Self-rated health (SRH) is available for respondents interviewed in years 1987-2014, while information on activities of daily living (ADL) and instrumental activities of daily living (IADL) is available for the period 1997-2014. Results By the end of the study period, individuals reported two fewer months of fair/poor health at the end of life than those dying in earlier years. In contrast, time lived with at least one activity limitation at the end of life generally remained comparable. Compared to men, women on average reported an additional year of living with an IADL limitation before death, and an additional eight months with an ADL limitation. Despite sex differences in disability, both sexes reported similar periods of fair/poor SRH before death. Similarly, while individuals who lived to older ages experienced a longer disabled period before death than individuals who died at younger ages, all age groups were equally likely to report fair/poor SRH. Black adults and adults with less formal schooling also spent more time with an end-of-life disability. For men, these racial and socioeconomic disparities lessened as death approached. For women, inequalities persisted until death. Discussion These findings suggest that despite increasing life expectancy, the period of poor health and disability prior to death has not recently been extended. Black women and women with less than a high school degree, require extended support at the end of life.	[Vierboom, Yana C.] Max Planck Inst Demog Res, Rostock, Germany	Max Planck Society	Vierboom, YC (corresponding author), Max Planck Inst Demog Res, Rostock, Germany.	vierboom@demogr.mpg.de						Alley DE, 2010, AM J EPIDEMIOL, V172, P558, DOI 10.1093/aje/kwq168; Beltran-Sanchez H, 2016, J EPIDEMIOL COMMUN H, V70, P1011, DOI 10.1136/jech-2015-206722; Blewett L., 2016, IPUMS HLTH SURVEYS N, DOI DOI 10.18128/D070.V6.2; Boen C, 2020, J GERONTOL B-PSYCHOL, V75, P1937, DOI 10.1093/geronb/gbz068; Cai LM, 2007, DEMOGRAPHY, V44, P479, DOI 10.1353/dem.2007.0022; Carr D, 2019, ANNU REV SOCIOL, V45, P515, DOI 10.1146/annurev-soc-073018-022524; Case A, 2005, DEMOGRAPHY, V42, P189, DOI 10.1353/dem.2005.0011; Chae DH, 2020, HEALTH PSYCHOL, V39, P209, DOI 10.1037/hea0000832; Chiu CT, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2018.100347; Cohen-Mansfield J, 2018, J GERONTOL B-PSYCHOL, V73, P564, DOI 10.1093/geronb/gbx093; Crimmins EM, 2016, AM J PUBLIC HEALTH, V106, P1287, DOI 10.2105/AJPH.2016.303120; Crimmins EM, 2009, DEMOGRAPHY, V46, P627, DOI 10.1353/dem.0.0070; Crimmins EM, 2001, SOC SCI MED, V52, P1629, DOI 10.1016/S0277-9536(00)00273-2; Cutler D.M., 2013, NBER WORKING PAPER S; Diegelmann M, 2016, PSYCHOL AGING, V31, P672, DOI 10.1037/pag0000114; Family Caregiver Alliance, 2019, CAR STAT DEM; Freedman VA, 2008, SOC SCI MED, V66, P1588, DOI 10.1016/j.socscimed.2007.11.037; Gerstorf D, 2013, DEV PSYCHOL, V49, P1805, DOI 10.1037/a0031340; Gill TM, 2010, NEW ENGL J MED, V362, P1173, DOI 10.1056/NEJMoa0909087; Jacob ME, 2018, J GERONTOL A-BIOL, V73, P194, DOI 10.1093/gerona/glx194; Johnson R.W., 2006, PROFILE FRAIL OLDER; Jylha M, 2009, SOC SCI MED, V69, P307, DOI 10.1016/j.socscimed.2009.05.013; Kelly A, 2010, J AM GERIATR SOC, V58, P1701, DOI 10.1111/j.1532-5415.2010.03005.x; Liao YL, 1999, AM J EPIDEMIOL, V149, P1097; Lunney JR, 2018, J GEN INTERN MED, V33, P177, DOI 10.1007/s11606-017-4232-6; Mehta NK, 2019, SSM-POPUL HLTH, V8, DOI 10.1016/j.ssmph.2019.100438; ORand A.M., 2018, FUTURE DIRECTIONS DE; Preston SH, 2006, DEMOGRAPHY, V43, P631, DOI 10.1353/dem.2006.0037; Prus SG, 2007, SOCIOL HEALTH ILL, V29, P275, DOI 10.1111/j.1467-9566.2007.00547.x; Raab M, 2018, DEMOGR RES, V38, P1619, DOI 10.4054/DemRes.2018.38.53; Riffe T., 2016, VIENNA YB POPULATION, V14, P229, DOI DOI 10.1553/POPULATIONYEARBOOK2016S229; Sanderson WC, 2013, POPUL DEV REV, V39, P673, DOI 10.1111/j.1728-4457.2013.00633.x; Smith AK, 2013, JAMA INTERN MED, V173, P1506, DOI 10.1001/jamainternmed.2013.8738; Stenholm S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107879; Taylor MG, 2011, J GERONTOL B-PSYCHOL, V66, P729, DOI 10.1093/geronb/gbr104; Tingey JL, 2020, REHABIL PSYCHOL, V65, P63, DOI 10.1037/rep0000307; Wang YC, 2011, LANCET, V378, P815, DOI 10.1016/S0140-6736(11)60814-3; Warner DF, 2011, SOC SCI MED, V72, P1236, DOI 10.1016/j.socscimed.2011.02.034; Wilson RS, 2007, PSYCHOSOM MED, V69, P131, DOI 10.1097/PSY.0b013e31803130ae	39	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2022	17	7							e0267551	10.1371/journal.pone.0267551	http://dx.doi.org/10.1371/journal.pone.0267551			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5Z7YE	35895597	gold, Green Published			2023-01-03	WOS:000880183400009
J	Godolphin, PJ; Fisher, DJ; Berry, LR; Derde, LPG; Diaz, JV; Gordon, AC; Lorenzi, E; Marshall, JC; Murthy, S; Shankar-Hari, M; Sterne, JAC; Tierney, JF; Vale, CL				Godolphin, Peter J.; Fisher, David J.; Berry, Lindsay R.; Derde, Lennie P. G.; Diaz, Janet, V; Gordon, Anthony C.; Lorenzi, Elizabeth; Marshall, John C.; Murthy, Srinivas; Shankar-Hari, Manu; Sterne, Jonathan A. C.; Tierney, Jayne F.; Vale, Claire L.			Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis	PLOS ONE			English	Article							CONSISTENCY; INCONSISTENCY	Background A recent prospective meta-analysis demonstrated that interleukin-6 antagonists are associated with lower all-cause mortality in hospitalised patients with COVID-19, compared with usual care or placebo. However, emerging evidence suggests that clinicians are favouring the use of tocilizumab over sarilumab. A new randomised comparison of these agents from the REMAP-CAP trial shows similar effects on in-hospital mortality. Therefore, we initiated a network meta-analysis, to estimate pairwise associations between tocilizumab, sarilumab and usual care or placebo with 28-day mortality, in COVID-19 patients receiving concomitant corticosteroids and ventilation, based on all available direct and indirect evidence. Methods Eligible trials randomised hospitalised patients with COVID-19 that compared tocilizumab or sarilumab with usual care or placebo in the prospective meta-analysis or that directly compared tocilizumab with sarilumab. Data were restricted to patients receiving corticosteroids and either non-invasive or invasive ventilation at randomisation. Pairwise associations between tocilizumab, sarilumab and usual care or placebo for all-cause mortality 28 days after randomisation were estimated using a frequentist contrastbased network meta-analysis of odds ratios (ORs), implementing multivariate fixed-effects models that assume consistency between the direct and indirect evidence. Findings One trial (REMAP-CAP) was identified that directly compared tocilizumab with sarilumab and supplied results on all-cause mortality at 28-days. This network meta-analysis was based on 898 eligible patients (278 deaths) from REMAP-CAP and 3710 eligible patients from 18 trials (1278 deaths) from the prospective meta-analysis. Summary ORs were similar for tocilizumab [0.82 [0.71-0.95, p = 0.008]] and sarilumab [0.80 [0.61-1.04, p = 0.09]] compared with usual care or placebo. The summary OR for 28-day mortality comparing tocilizumab with sarilumab was 1.03 [95%CI 0.81-1.32, p = 0.80]. The p-value for the global test of inconsistency was 0.28. Conclusions Administration of either tocilizumab or sarilumab was associated with lower 28-day all-cause mortality compared with usual care or placebo. The association is not dependent on the choice of interleukin-6 receptor antagonist.	[Godolphin, Peter J.; Fisher, David J.; Tierney, Jayne F.; Vale, Claire L.] UCL, Inst Clin Trials & Methodol, MRC Clin Trials Unit, London, England; [Berry, Lindsay R.; Lorenzi, Elizabeth] Berry Consultants, Austin, TX USA; [Derde, Lennie P. G.] Univ Med Ctr Utrecht, Dept Intens Care Med, Utrecht, Netherlands; [Derde, Lennie P. G.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Diaz, Janet, V] WHO, Clin Unit, Hlth Emergencies Programme, Geneva, Switzerland; [Gordon, Anthony C.] Imperial Coll London, Div Anaesthet Pain Med & Intens Care, London, England; [Marshall, John C.] Univ Toronto, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada; [Murthy, Srinivas] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada; [Shankar-Hari, Manu] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [Shankar-Hari, Manu] NHS Lothian, Dept Crit Care Med, Royal Infirm Edinburgh, Edinburgh, Midlothian, Scotland; [Sterne, Jonathan A. C.] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England; [Sterne, Jonathan A. C.] NIHR Bristol Biomed Res Ctr, Bristol, Avon, England; [Sterne, Jonathan A. C.] Hlth Data Res UK South West, Bristol, Avon, England	Medical Research Council Clinical Trials Unit; University of London; University College London; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; World Health Organization; Imperial College London; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of British Columbia; University of Edinburgh; Royal Infirmary of Edinburgh; University of Bristol	Godolphin, PJ (corresponding author), UCL, Inst Clin Trials & Methodol, MRC Clin Trials Unit, London, England.	p.godolphin@ucl.ac.uk	Godolphin, Peter/AAO-5845-2020; Derde, Lennie/AAF-2725-2021	Godolphin, Peter/0000-0003-0648-0992; Derde, Lennie/0000-0002-3577-5629; Fisher, David/0000-0002-2512-2296; Sterne, Jonathan/0000-0001-8496-6053	Prostate Cancer UK [RIA 16-ST2-020]; National Institute for Health Research [NIHR301653, NIHR-CS-2016-16-011, RP-2015-06-018]; Medical Research Council [MC_UU_00004/06]	Prostate Cancer UK; National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by Prostate Cancer UK in the form of funds to PJG and DJF [RIA 16-ST2-020], by the National Institute for Health Research in the form of funds to PJG [NIHR301653], by the Medical Research Council in the form of funds to DJF, JFT, and CLV [MC_UU_00004/06], by the National Institute for Health Research in the form of funds to MS-H [NIHR-CS-2016-16-011], and by the National Institute for Health Research in the form of funds to ACG [RP-2015-06-018].	Broman N, 2022, CLIN MICROBIOL INFEC, V28, P844, DOI 10.1016/j.cmi.2022.02.027; Declercq J, 2021, LANCET RESP MED, V9, P1427, DOI 10.1016/S2213-2600(21)00377-5; Derde L.P.G., 2021, PREPRINT, DOI [10.1101/2021.06.18.21259133, DOI 10.1101/2021.06.18.21259133]; Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767; Garcia-Vicuna R, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.819621; Godolphin PJ, 2022, NAT MED, V28, P429, DOI 10.1038/s41591-021-01675-1; Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMc2108482]; Hermine O, 2022, EUR RESPIR J, V60, DOI 10.1183/13993003.02523-2021; Higgins JPT, 2012, RES SYNTH METHODS, V3, P98, DOI 10.1002/jrsm.1044; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Jackson D, 2017, STAT METHODS MED RES, V26, P2853, DOI 10.1177/0962280215611702; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630; Rosas IO, 2021, NEW ENGL J MED, V384, P1503, DOI 10.1056/NEJMoa2028700; Rosas IO, 2022, ECLINICALMEDICINE, V47, DOI 10.1016/j.eclinm.2022.101409; Rosas IO, 2021, INTENS CARE MED, V47, P1258, DOI 10.1007/s00134-021-06507-x; Rutgers A, 2021, SSRN; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI [10.1056/NEJMoa2030340, 10.1056/NEJMc2100217]; Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016; Shankar-Hari M, 2021, JAMA-J AM MED ASSOC, V326, P499, DOI 10.1001/jama.2021.11330; Sivapalasingam S, 2022, CLIN INFECT DIS, V75, pE380, DOI 10.1093/cid/ciac153; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Tierney JF, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003629; Vale C, 2021, ANTIINTERLEUKIN 6 TH; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; White IR, 2015, STATA J, V15, P951, DOI 10.1177/1536867X1501500403; White IR, 2012, RES SYNTH METHODS, V3, P111, DOI 10.1002/jrsm.1045; White IR, 2011, STATA J, V11, P255, DOI 10.1177/1536867X1101100206; Zeng LN, 2021, J CLIN EPIDEMIOL, V137, P163, DOI 10.1016/j.jclinepi.2021.03.026; Zeraatkar D, 2022, BMJ MED, V1, DOI [10.1136/bmjmed-2021-000036, DOI 10.1136/BMJMED-2021-000036]	31	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2022	17	7							e0270668	10.1371/journal.pone.0270668	http://dx.doi.org/10.1371/journal.pone.0270668			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Z6OJ	35802687	Green Published, gold			2023-01-03	WOS:000844536800068
J	Auger, S; Davis, A; Rosenberg, AJ				Auger, Samuel; Davis, Andrew; Rosenberg, Ari J.			Recommendations for Care of Survivors of Head and Neck Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Auger, Samuel] Univ Chicago, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA; [Davis, Andrew] Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA; [Rosenberg, Ari J.] Univ Chicago, Sect Hematol & Oncol, Dept Med, Chicago, IL 60637 USA; [Rosenberg, Ari J.] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; Robert H. Lurie Comprehensive Cancer Center; University of Chicago	Rosenberg, AJ (corresponding author), Univ Chicago, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	arirosenberg@medicine.bsd.uchicago.edu						Cadoni G, 2017, ACTA OTORHINOLARYNGO, V37, P458, DOI 10.14639/0392-100X-1246; Cramer JD, 2021, JAMA OTOLARYNGOL, V147, P1071, DOI 10.1001/jamaoto.2021.2776; Ellington TD, 2020, MMWR-MORBID MORTAL W, V69, P433, DOI 10.15585/mmwr.mm6915a1; Goyal N, 2022, LARYNGOSCOPE INVEST, V7, P70, DOI 10.1002/lio2.702; McDowell L, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.834068; Mody MD, 2021, LANCET, V398, P2289, DOI 10.1016/S0140-6736(21)01550-6; Nekhlyudov L, 2017, J CLIN ONCOL, V35, P1606, DOI 10.1200/JCO.2016.71.8478; Osazuwa-Peters N, 2018, CANCER-AM CANCER SOC, V124, P4072, DOI 10.1002/cncr.31675; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Vawda N, 2019, INT J RADIAT ONCOL, V103, P1125, DOI 10.1016/j.ijrobp.2018.11.046	10	0	0	2	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	2022	328	16					1637	1638		10.1001/jama.2022.17064	http://dx.doi.org/10.1001/jama.2022.17064		OCT 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6C3UZ	36201185	Bronze			2023-01-03	WOS:000864837800001
J	Tran, A; Rochwerg, B				Tran, Alexandre; Rochwerg, Bram			In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Tran, Alexandre] Univ Ottawa, Ottawa, ON, Canada; [Rochwerg, Bram] McMaster Univ, Hamilton, ON, Canada	University of Ottawa; McMaster University	Tran, A (corresponding author), Univ Ottawa, Ottawa, ON, Canada.				National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	National Institute of Allergy and Infectious Diseases. Eli Lilly provided baricitinib, and Gilead Sciences provided remdesivir.	[Anonymous], 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj.o80; COVID-19 Treatment Guidelines Panel, 2022, NIH COVID 19 TREATM	2	0	0	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT	2022	175	10					JC115	JC115		10.7326/J22-0074	http://dx.doi.org/10.7326/J22-0074		OCT 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5M3CC	36191322				2023-01-03	WOS:000868414400005
J	Choudhury, NJ; Riely, GJ				Choudhury, Noura J.; Riely, Georgory J.			Serplulimab With Chemotherapy in Extensive-Stage SCLC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CELL LUNG-CANCER		[Choudhury, Noura J.; Riely, Georgory J.] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, Div Solid Tumor, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Choudhury, Noura J.; Riely, Georgory J.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Riely, GJ (corresponding author), Weill Cornell Med Coll, 1275 York Ave, New York, NY 10065 USA.	riely@mskcc.org						Cheng Y, 2022, JAMA-J AM MED ASSOC, V328, P1223, DOI 10.1001/jama.2022.16464; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Huang RY, 2015, EBIOMEDICINE, V2, P1677, DOI 10.1016/j.ebiom.2015.09.031; Paz-Ares L, 2019, LANCET, V394, P1929, DOI 10.1016/S0140-6736(19)32222-6; Rudin CM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00235-0; Rudin CM, 2020, J CLIN ONCOL, V38, P2369, DOI 10.1200/JCO.20.00793; Singh H, SINT LOC ADV MET NON; Sun JM, 2015, ANN ONCOL, V26, P161, DOI 10.1093/annonc/mdu504; US Food and Drug Administration, DIV PLANS IMPR ENR P; Wang SC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01571-0; Yang YP, 2020, J THORAC ONCOL, V15, P1636, DOI 10.1016/j.jtho.2020.07.014	12	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	2022	328	12					1205	1207		10.1001/jama.2022.16442	http://dx.doi.org/10.1001/jama.2022.16442			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5E8TQ	36166047				2023-01-03	WOS:000865895100029
J	Bennell, KL; Schwartz, S; Teo, PL; Hawkins, S; Mackenzie, D; McManus, F; Lamb, KE; Kimp, AJ; Metcalf, B; Hunter, DJ; Hinman, RS				Bennell, Kim L.; Schwartz, Sarah; Teo, Pek Ling; Hawkins, Stephanie; Mackenzie, Dave; McManus, Fiona; Lamb, Karen E.; Kimp, Alexander J.; Metcalf, Ben; Hunter, David J.; Hinman, Rana S.			Effectiveness of an Unsupervised Online Yoga Program on Pain and Function in People With Knee Osteoarthritis A Randomized Clinical Trial	ANNALS OF INTERNAL MEDICINE			English	Article							LOWER-EXTREMITY OSTEOARTHRITIS; CONSENSUS DEVELOPMENT; PHYSICAL-ACTIVITY; OUTCOME MEASURES; HIP; EXERCISE; SCALE; RECOMMENDATIONS; ADHERENCE; FEASIBILITY	Background: Yoga is a mind-body exercise typically done in groups in person, but this delivery method can be inconvenient, inaccessible, and costly. Effective online programs may increase access to exercise for knee osteoarthritis. Objective: To evaluate the effectiveness of an unsupervised 12-week online yoga program. Design: Two-group superiority randomized trial. (Australian New Zealand Clinical Trials Registry: ACTRN12620000012976) Setting: Community. Participants: 212 adults with symptomatic knee osteoarthritis. Intervention: Both groups received online osteoarthritis information (control). The yoga group also received access to an unsupervised online yoga program delivered via prerecorded videos over 12 weeks (1 video per week, with each session to be performed 3 times per week), with optional continuation thereafter. Measurements: Primary outcomes were changes in knee pain during walking (0 to 10 on a numerical rating scale) and physical function (0 to 68 on the Western Ontario and McMaster Universities Osteoarthritis Index) at 12 weeks (primary time point) and 24 weeks, analyzed using mixed-effects linear regression models. Secondary outcomes were self-reported overall knee pain, stiffness, depression, anxiety, stress, global change, quality of life, self-efficacy, fear of movement, and balance confidence. Adverse events were also collected. Results: A total of 195 (92%) and 189 (89%) participants provided 12- and 24-week primary outcomes, respectively. Compared with control at 12 weeks, yoga improved function (between-group mean difference in change, -4.0 [95% CI, -6.8 to -1.3]) but not knee pain during walking (between-group mean difference in change, -0.6 [CI, -1.2 to 0.1]), with more yoga participants than control participants achieving the minimal clinically important difference (MCID) for both outcomes. At 12 weeks, knee stiffness, quality of life, and arthritis self-efficacy improved more with yoga than the control intervention. Benefits were not maintained at 24 weeks. Adverse events were minor. Limitation: Participants were unblinded. Conclusion: Compared with online education, an unsupervised online yoga program improved physical function but not knee pain at 12 weeks in people with knee osteoarthritis, although the improvement did not reach the MCID and was not sustained at 24 weeks.	[Bennell, Kim L.; Schwartz, Sarah; Teo, Pek Ling; Hawkins, Stephanie; Mackenzie, Dave; Kimp, Alexander J.; Metcalf, Ben; Hinman, Rana S.] Univ Melbourne, Ctr Hlth, Dept Physiotherapy, Melbourne, Vic, Australia; [McManus, Fiona] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Lamb, Karen E.] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia; [Lamb, Karen E.] Univ Melbourne, Methods & Implementat Support Clin Hlth Res Hub, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia; [Hunter, David J.] Univ Sydney, Sydney Musculoskeletal Hlth, Sydney, NSW, Australia	University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; University of Sydney	Bennell, KL (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Dept Physiotherapy, Sch Hlth Sci,Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia.	k.bennell@unimelb.edu.au	; Lamb, Karen/P-4988-2016	Mackenzie, David/0000-0003-3604-9378; Kimp, Alexander/0000-0003-2757-2239; McManus, Fiona/0000-0002-1001-8146; Teo, Pek Ling/0000-0003-1657-1820; Lamb, Karen/0000-0001-9782-8450; Metcalf, Ben/0000-0002-4945-3217	National Health and Medical Research Council [1091302]; National Health and Medical Research Council Centres of Research Excellence [1079078]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council Centres of Research Excellence	By a National Health and Medical Research Council Program Grant (#1091302) and the Centres of Research Excellence (#1079078).	Alaiti RK, 2022, CLIN J PAIN, V38, P502, DOI 10.1097/AJP.0000000000001047; Allen KD, 2018, OSTEOARTHR CARTILAGE, V26, P383, DOI 10.1016/j.joca.2017.12.008; [Anonymous], AD PREEX SCREEN SYST; Australian Bureau of Statistics, 2018, HOUS US INF TECHN; Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011; Bellamy N, 1997, J RHEUMATOL, V24, P768; Bellamy N, 1997, J RHEUMATOL, V24, P799; BELLAMY N, 1992, J RHEUMATOL, V19, P451; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bennell KL, 2017, ARTHRIT CARE RES, V69, P84, DOI 10.1002/acr.22915; Bossen D, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2662; Brinsley J, 2021, J ALTERN COMPLEM MED, V27, P893, DOI 10.1089/acm.2021.0062; Brosnan P, 2021, COMPLEMENT THER MED, V60, DOI 10.1016/j.ctim.2021.102742; Carpenter JR, 2013, J WILEY, DOI [10.1002/9781119942283, DOI 10.1002/9781119942283]; Cheung C, 2016, J AGING PHYS ACTIV, V24, P181, DOI 10.1123/japa.2015-0048; Delbaere K, 2010, BRIT J SPORT MED, V44, P1029, DOI 10.1136/bjsm.2009.060350; Dobson F, 2016, AM J PHYS MED REHAB, V95, P372, DOI 10.1097/PHM.0000000000000448; Dore AL, 2015, ARTHRIT CARE RES, V67, P633, DOI 10.1002/acr.22499; Elwy AR, 2014, AM J PREV MED, V47, P220, DOI 10.1016/j.amepre.2014.03.012; Eyles JP, 2020, AUST J GEN PRACT, V49, P438, DOI 10.31128/AJGP-08-19-5051-02; Fitzmaurice GM., 2011, APPL LONGITUDINAL AN; Fransen M, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2015-095424; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Hay SI, 2017, LANCET, V389, pE1; Huberty J, 2018, INTEGR CANCER THER, V17, P1150, DOI 10.1177/1534735418808595; Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI [10.1002/art.41142, 10.1002/acr.24131]; Lauche R, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926-019-0846-5; Liao CD, 2020, ARTHRIT CARE RES, V72, P1703, DOI 10.1002/acr.24097; Lima YL, 2022, ARTHRIT CARE RES, DOI 10.1002/acr.24983; Lin CWC, 2010, PHYS THER, V90, P839, DOI 10.2522/ptj.20100084; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; Manlapaz DG, 2019, PM&R, V11, P745, DOI 10.1002/pmrj.12066; Martin AC, 2019, INT J YOGA, V12, P37, DOI 10.4103/ijoy.IJOY_5_18; McAlindon TE, 2015, OSTEOARTHR CARTILAGE, V23, P747, DOI 10.1016/j.joca.2015.03.005; McHugh M, 2020, ARTHRIT CARE RES, V72, P219, DOI 10.1002/acr.24235; Meade LB, 2018, MUSCULOSKELET CARE, V16, P409, DOI 10.1002/msc.1240; Meade LB, 2019, BRIT J HEALTH PSYCH, V24, P10, DOI 10.1111/bjhp.12324; Michie S, 2011, PSYCHOL HEALTH, V26, P1479, DOI 10.1080/08870446.2010.540664; Moonaz S, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-045812; Moustgaard H, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6802; National Institute of Health and Care Excellence (NICE), 2014, OST CAR MAN CLIN GUI; Nicolson PJA, 2018, ARTHRIT CARE RES, V70, P388, DOI 10.1002/acr.23297; Osborne RH, 2003, J CLIN EPIDEMIOL, V56, P138, DOI 10.1016/S0895-4356(02)00601-7; Osteoarthritis Action Alliance; CDC; Arthritis Foundation, 2020, NAT PUBL HLTH AG OST; Park J, 2020, EXP GERONTOL, V134, DOI 10.1016/j.exger.2020.110886; Pisters MF, 2010, ARTHRIT CARE RES, V62, P1087, DOI 10.1002/acr.20182; Quicke J G, 2020, Osteoarthr Cartil Open, V2, P100113, DOI 10.1016/j.ocarto.2020.100113; Sakellariou G, 2017, ANN RHEUM DIS, V76, P1484, DOI 10.1136/annrheumdis-2016-210815; Shelby RA, 2012, ARTHRIT CARE RES, V64, P862, DOI 10.1002/acr.21626; Stubbs B, 2016, AGE AGEING, V45, P228, DOI 10.1093/ageing/afw001; Talley KMC, 2008, J AM GERIATR SOC, V56, P328, DOI 10.1111/j.1532-5415.2007.01550.x; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; Uebelacker L, 2018, J PSYCHIATR PRACT, V24, P60, DOI 10.1097/PRA.0000000000000286; van Schoor NM, 2020, SEMIN ARTHRITIS RHEU, V50, P380, DOI 10.1016/j.semarthrit.2020.02.006; Wasserstein RL, 2019, AM STAT, V73, P1, DOI 10.1080/00031305.2019.1583913; Zernicke KA, 2014, PSYCHOSOM MED, V76, P257, DOI 10.1097/PSY.0000000000000053; Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015; Zhang Y, 2021, J ALTERN COMPLEM MED, V27, P778, DOI 10.1089/acm.2020.0506	58	0	0	7	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT	2022	175	10					1345	+		10.7326/M22-1761	http://dx.doi.org/10.7326/M22-1761		SEP 2022	15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5M3CC	36122378				2023-01-03	WOS:000860851400004
J	Burdet, C; Ader, F				Burdet, Charles; Ader, Florence			Real-world effectiveness of oral antivirals for COVID-19	LANCET			English	Editorial Material									[Burdet, Charles] Univ Paris, IAME, INSERM, F-75018 Paris, France; [Burdet, Charles] Ctr Integre Univ Sante & Serv Sociaux Mauricie et, Direct Sante Publ & Responsabilite Populat, Trois Rivieres, PQ, Canada; [Ader, Florence] Hop Croix Rousse, Hosp Civils Lyon, Dept Malad Infect & Trop, F-69004 Lyon, France; [Ader, Florence] Univ Claude Bernard Lyon 1, CIRI, INSERM, CNRS,UMR5308,ENS Lyon,U1111, F-69372 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ader, F (corresponding author), Hop Croix Rousse, Hosp Civils Lyon, Dept Malad Infect & Trop, F-69004 Lyon, France.; Ader, F (corresponding author), Univ Claude Bernard Lyon 1, CIRI, INSERM, CNRS,UMR5308,ENS Lyon,U1111, F-69372 Lyon, France.	florence.ader@chu-lyon.fr						Bernal AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMoa2116044; Coulson JM, 2022, J INFECTION, V85, P476, DOI 10.1016/j.jinf.2022.06.011; Hammond J, 2022, NEW ENGL J MED, V386, P1397, DOI 10.1056/NEJMoa2118542; Najjar-Debbiny R, 2022, CLIN INFECT DIS, DOI 10.1093/cid/ciac443; Rubin R, 2022, JAMA-J AM MED ASSOC, DOI 10.1001/jama.2022.9925; Takashita E, 2022, NEW ENGL J MED, V387, P468, DOI 10.1056/NEJMc2207519; Vangeel L, 2022, ANTIVIR RES, V198, DOI 10.1016/j.antiviral.2022.105252; Wong CKH, 2022, LANCET, V400, P1213, DOI 10.1016/S0140-6736(22)01586-0	8	0	0	2	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 14	2022	400	10359					1175	1176						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5Q7FC	36215994	Bronze, Green Published			2023-01-03	WOS:000873991600004
J	Bramante, CT; Huling, JD; Tignanelli, CJ; Buse, JB; Liebovitz, DM; Nicklas, JM; Cohen, K; Puskarich, MA; Belani, HK; Proper, JL; Siegel, LK; Klatt, NR; Odde, DJ; Luke, DG; Anderson, B; Karger, AB; Ingraham, NE; Hartman, KM; Rao, V; Hagen, AA; Patel, B; Fenno, SL; Avula, N; Reddy, NV; Erickson, SM; Lindberg, S; Fricton, R; Lee, S; Zaman, A; Saveraid, HG; Tordsen, WJ; Pullen, MF; Biros, M; Sherwood, NE; Thompson, JL; Boulware, DR; Murray, TA				Bramante, C. T.; Huling, J. D.; Tignanelli, C. J.; Buse, J. B.; Liebovitz, D. M.; Nicklas, J. M.; Cohen, K.; Puskarich, M. A.; Belani, H. K.; Proper, J. L.; Siegel, L. K.; Klatt, N. R.; Odde, D. J.; Luke, D. G.; Anderson, B.; Karger, A. B.; Ingraham, N. E.; Hartman, K. M.; Rao, V; Hagen, A. A.; Patel, B.; Fenno, S. L.; Avula, N.; Reddy, N., V; Erickson, S. M.; Lindberg, S.; Fricton, R.; Lee, S.; Zaman, A.; Saveraid, H. G.; Tordsen, W. J.; Pullen, M. F.; Biros, M.; Sherwood, N. E.; Thompson, J. L.; Boulware, D. R.; Murray, T. A.		COVID-OUT Trial Team	Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-C; PHARMACOKINETICS; REPLICATION; INHIBITION; MORTALITY	Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Methods In this phase 3, double-blind, randomized, placebo-controlled trial, we used a 2-by-3 factorial design to test the effectiveness of three repurposed drugs - metformin, ivermectin, and fluvoxamine - in preventing serious SARS-CoV-2 infection in nonhospitalized adults who had been enrolled within 3 days after a confirmed diagnosis of infection and less than 7 days after the onset of symptoms. The patients were between the ages of 30 and 85 years, and all had either overweight or obesity. The primary composite end point was hypoxemia (<= 93% oxygen saturation on home oximetry), emergency department visit, hospitalization, or death. All analyses used controls who had undergone concurrent randomization and were adjusted for SARS-CoV-2 vaccination and receipt of other trial medications. Results A total of 1431 patients underwent randomization; of these patients, 1323 were included in the primary analysis. The median age of the patients was 46 years; 56% were female (6% of whom were pregnant), and 52% had been vaccinated. The adjusted odds ratio for a primary event was 0.84 (95% confidence interval [CI], 0.66 to 1.09; P=0.19) with metformin, 1.05 (95% CI, 0.76 to 1.45; P=0.78) with ivermectin, and 0.94 (95% CI, 0.66 to 1.36; P=0.75) with fluvoxamine. In prespecified secondary analyses, the adjusted odds ratio for emergency department visit, hospitalization, or death was 0.58 (95% CI, 0.35 to 0.94) with metformin, 1.39 (95% CI, 0.72 to 2.69) with ivermectin, and 1.17 (95% CI, 0.57 to 2.40) with fluvoxamine. The adjusted odds ratio for hospitalization or death was 0.47 (95% CI, 0.20 to 1.11) with metformin, 0.73 (95% CI, 0.19 to 2.77) with ivermectin, and 1.11 (95% CI, 0.33 to 3.76) with fluvoxamine. Conclusions None of the three medications that were evaluated prevented the occurrence of hypoxemia, an emergency department visit, hospitalization, or death associated with Covid-19. (Funded by the Parsemus Foundation and others; COVID-OUT ClinicalTrials.gov number, NCT04510194.)	[Bramante, C. T.; Ingraham, N. E.; Hartman, K. M.; Hagen, A. A.; Patel, B.; Fenno, S. L.; Avula, N.; Reddy, N., V; Erickson, S. M.; Saveraid, H. G.; Pullen, M. F.; Boulware, D. R.] Univ Minnesota, Dept Med, Fairview, MN USA; [Tignanelli, C. J.; Klatt, N. R.] Univ Minnesota, Dept Surg, Fairview, MN USA; [Puskarich, M. A.; Biros, M.] Univ Minnesota, Dept Emergency Med, Fairview, MN USA; [Karger, A. B.] Univ Minnesota, Lab Med & Pathol, Fairview, MN USA; [Huling, J. D.; Proper, J. L.; Siegel, L. K.; Rao, V; Lindberg, S.; Murray, T. A.] Univ Minnesota, Med Sch, Div Biostat, Fairview, MN USA; [Sherwood, N. E.] Univ Minnesota, Div Epidemiol & Community Hlth, Fairview, MN USA; [Odde, D. J.] Univ Minnesota, Sch Publ Hlth, Fairview, MN USA; [Odde, D. J.] Univ Minnesota, Dept Biomed Engn, Fairview, MN USA; [Puskarich, M. A.; Tordsen, W. J.; Biros, M.] Univ Minnesota, Dept Emergency Med, Hennepin Cty Med Ctr, Fairview, MN USA; [Luke, D. G.] Univ Minnesota, Invest Drug Serv Pharm, Fairview, MN USA; [Cohen, K.] Optum Labs, United Hlth Grp, Minnetonka, MN USA; [Buse, J. B.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA; [Liebovitz, D. M.; Fricton, R.; Lee, S.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL USA; [Nicklas, J. M.; Zaman, A.] Univ Colorado, Dept Med, Sch Med, Anschutz Med Campus, Aurora, CO USA; [Belani, H. K.] Olive View Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA; [Anderson, B.] Emory Univ, Sch Med, Atlanta Vet Affairs Med Ctr, Atlanta, GA USA; [Anderson, B.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA; [Thompson, J. L.] Vanderbilt Univ, Med Ctr, Dept Obstet & Gynecol, Nashville, TN 37232 USA	University of Minnesota System; University of Minnesota System; University of Minnesota System; University of Minnesota System; University of Minnesota System; University of Minnesota System; University of Minnesota System; University of Minnesota System; Hennepin County Medical Center; University of Minnesota System; University of Minnesota System; UnitedHealth Group Incorporated; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Northwestern University; Feinberg School of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University; Vanderbilt University	Bramante, CT (corresponding author), Univ Minnesota, Div Gen Internal Med & Pediat, MMC 1932, Minneapolis, MN 55414 USA.	bramante@umn.edu	; Puskarich, Michael/N-7849-2014; Liebovitz, David/AAI-9398-2020	Sherwood, Nancy/0000-0002-3365-9018; Tignanelli, Christopher/0000-0002-8079-5565; Avula, Nandini/0000-0001-5323-2639; Ingraham, Nicholas/0000-0002-0292-0594; Pullen, Matthew/0000-0002-4644-7487; Erickson, Spencer/0000-0003-0220-4712; Bramante, Carolyn T./0000-0001-5858-2080; Karger, Amy/0000-0002-2781-3824; Boulware, David/0000-0002-4715-0060; Buse, John/0000-0002-9723-3876; Puskarich, Michael/0000-0001-6358-4670; Liebovitz, David/0000-0002-2518-5940	Parsemus Foundation; Rainwater Charitable Foundation; UnitedHealth Group Foundation; National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) [KL2TR002492, UL1TR002494]; National Institute of Diabetes and Digestive and Kidney Diseases of the NIH [K23 DK124654-01-A1]; NCATS [UL1TR002489]; National Heart, Lung, and Blood Institute of the NIH [K23HL133604]; Institute for Engineering in Medicine; Medtronic Professorship for Engineering in Medicine; National Cancer Institute of the NIH [U54 CA210190, P01 CA254849]; Medtronic Faculty Fellowship; Fast Grants	Parsemus Foundation; Rainwater Charitable Foundation; UnitedHealth Group Foundation; National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institute of Diabetes and Digestive and Kidney Diseases of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Heart, Lung, and Blood Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Institute for Engineering in Medicine; Medtronic Professorship for Engineering in Medicine; National Cancer Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medtronic Faculty Fellowship; Fast Grants	Supported by the Parsemus Foundation, Rainwater Charitable Foundation, Fast Grants, and UnitedHealth Group Foundation. The fluvoxamine placebo tablets were donated by Apotex Pharmaceuticals. The ivermectin placebo and active tablets were donated by Edenbridge Pharmaceuticals. Dr. Bramante was supported by grants (KL2TR002492 and UL1TR002494) from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and by a grant (K23 DK124654-01-A1) from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. Dr. Buse was supported by a grant (UL1TR002489) from NCATS. Dr. Nicklas was supported by a grant (K23HL133604) from the National Heart, Lung, and Blood Institute of the NIH. Dr. Odde was supported by the Institute for Engineering in Medicine, the Medtronic Professorship for Engineering in Medicine, and by grants (U54 CA210190 and P01 CA254849) from the National Cancer Institute of the NIH. Dr. Murray was supported in part by the Medtronic Faculty Fellowship.	A.Haase, 2020, bioRxiv, DOI 10.1101/2020.05.22.111237; Bernal AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMoa2116044; Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331; Bolo NR, 2000, NEUROPSYCHOPHARMACOL, V23, P428, DOI 10.1016/S0893-133X(00)00116-0; Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638; Bramante CT, 2022, OPEN FORUM INFECT DI, V9, DOI 10.1093/ofid/ofac066; Bramante CT, 2021, J MED VIROL, V93, P4273, DOI 10.1002/jmv.26873; Bramante CT, 2021, LANCET HEALTH LONGEV, V2, pE34, DOI 10.1016/S2666-7568(20)30033-7; Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x; Cheng F, 2016, J VIROL, V90, P6515, DOI 10.1128/JVI.00624-16; Connors JM, 2021, JAMA-J AM MED ASSOC, V326, P1703, DOI 10.1001/jama.2021.17272; Crouse AB, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.600439; del Campo JA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191805; Division of Industry and Consumer Education (DICE) US Food and Drug Administration, 2021, PULS OX ACC LIM FDA; Dodds MG, 2022, LANCET GLOB HEALTH, V10, pE332, DOI 10.1016/S2214-109X(22)00006-7; Facente SN, 2021, DRUGS, V81, P2081, DOI 10.1007/s40265-021-01636-5; Farfan-Morales CN, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.749770; FDA, 2020, J CLIN MED, DOI DOI 10.3390/JCM11206138; FDA, 2022, FDA NEWS RELEAS 0211; Ferdinands JM, 2022, MMWR-MORBID MORTAL W, V71, P255, DOI 10.15585/mmwr.mm7107e2; Food and Drug Administration, 2017, MULT ENDP CLIN TRIAL; Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9; Hales Craig M, 2017, NCHS Data Brief, P1; Hammond J, 2022, NEW ENGL J MED, V386, P1397, DOI 10.1056/NEJMoa2118542; Karam BS, 2021, J MED VIROL, V93, P1843, DOI 10.1002/jmv.26728; Keehner J, 2021, NEW ENGL J MED, V385, P1330, DOI 10.1056/NEJMc2112981; Lee TC, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.6269; Lenze EJ, 2020, JAMA-J AM MED ASSOC, V324, P2292, DOI 10.1001/jama.2020.22760; Li Y, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.704666; Lopez-Medina E, 2021, JAMA-J AM MED ASSOC, V325, P1426, DOI 10.1001/jama.2021.3071; Luo P, 2020, AM J TROP MED HYG, V103, P69, DOI 10.4269/ajtmh.20-0375; Marzolini C, 2022, ANN INTERN MED, V175, P744, DOI 10.7326/M22-0281; MENG XL, 1992, BIOMETRIKA, V79, P103, DOI 10.1093/biomet/79.1.103; Nakashima K, 2011, MICROBIOL IMMUNOL, V55, P774, DOI 10.1111/j.1348-0421.2011.00382.x; Newberry AM, 2005, CHEST, V128, P3681, DOI 10.1378/chest.128.5.3681; O'Brien MP, 2021, NEW ENGL J MED, V385, P1184, DOI 10.1056/NEJMoa2109682; Oldenburg CE, 2021, JAMA-J AM MED ASSOC, V326, P490, DOI 10.1001/jama.2021.11517; Popp M, 2021, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD015017.pub2, 10.1002/14651858.CD015017]; Portmann-Baracco A, 2020, ARCH BRONCONEUMOL, V56, P831, DOI 10.1016/j.arbres.2020.06.011; Postler TS, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97441-x; Reis Gilmar, 2022, Lancet Reg Health Am, V6, P100142, DOI 10.1016/j.lana.2021.100142; Reis G, 2022, LANCET GLOB HEALTH, V10, pE36, DOI 10.1016/S2214-109X(21)00448-4; Schaller MA, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.148003; Seftel D, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab050; Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207; Stauffer WM, 2020, JAMA-J AM MED ASSOC, V324, P623, DOI 10.1001/jama.2020.13170; Thompson Mark G, 2022, MMWR Morb Mortal Wkly Rep, V71, P139, DOI 10.15585/mmwr.mm7104e3; Timmins P, 2005, CLIN PHARMACOKINET, V44, P721, DOI 10.2165/00003088-200544070-00004; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Xian HX, 2021, IMMUNITY, V54, P1463, DOI 10.1016/j.immuni.2021.05.004; Xin G, 2016, SCI REP-UK, V6, DOI 10.1038/srep36222; Yu JW, 2012, INT J INFECT DIS, V16, pE436, DOI 10.1016/j.ijid.2012.02.004	52	11	11	7	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	2022	387	7					599	610		10.1056/NEJMoa2201662	http://dx.doi.org/10.1056/NEJMoa2201662		AUG 2022	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D8EB	36070710	Bronze			2023-01-03	WOS:000883681200008
J	Venkatesh, KK; Lynch, CD; Costantine, MM; Backes, CH; Slaughter, JL; Frey, HA; Huang, XN; Landon, MB; Klebanoff, MA; Khan, SS; Grobman, WA				Venkatesh, Kartik K.; Lynch, Courtney D.; Costantine, Maged M.; Backes, Carl H.; Slaughter, Jonathan L.; Frey, Heather A.; Huang, Xiaoning; Landon, Mark B.; Klebanoff, Mark A.; Khan, Sadiya S.; Grobman, William A.			Trends in Active Treatment of Live-born Neonates Between 22 Weeks 0 Days and 25 Weeks 6 Days by Gestational Age and Maternal Race and Ethnicity in the US, 2014 to 2020	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRETERM INFANTS; CARE PRACTICES; OUTCOMES; RESUSCITATION; MORBIDITY; MORTALITY; VIABILITY; BIRTH	IMPORTANCE Birth in the periviable period between 22 weeks 0 days and 25 weeks 6 days' gestation is a major source of neonatal morbidity and mortality, and the decision to initiate active life-saving treatment is challenging. OBJECTIVE To assess whether the frequency of active treatment among live-born neonates in the periviable period has changed over time and whether active treatment differed by gestational age at birth and race and ethnicity. DESIGN, SETTING, AND PARTICIPANTS Serial cross-sectional descriptive study using National Center for Health Statistics natality data from 2014 to 2020 for 61908 singleton live births without clinical anomalies between 22 weeks 0 days and 25 weeks 6 days in the US. EXPOSURES Year of delivery, gestational age at birth, and race and ethnicity of the pregnant individual, stratified as non-Hispanic Asian/Pacific Islander. non-Hispanic Black. Hispanic/Latina, and non-Hispanic White. MAIN OUTCOMES AND MEASURES Active treatment, determined by whether there was an attempt to treat the neonate and defined as a composite of surfactant therapy, immediate assisted ventilation at birth, assisted ventilation more than 6 hours in duration, and/or antibiotic therapy. Frequencies, mean annual percent change (APC), and adjusted risk ratios (aRRs) were estimated. RESULTS Of 26 986 716 live births, 61 908 (0.2%) were periviable live births included in this study: 5% were Asian/Pacific Islander, 37% Black, 24% Hispanic, and 34% White; and 14% were born at 22 weeks, 21% at 23 weeks, 30% at 24 weeks, and 34% at 25 weeks. Fifty-two percent of neonates received active treatment. From 2014 to 2020, the overall frequency (mean APC per year) of active treatment increased significantly (3.9% [95% CI, 3.0% to 4.9%]), as well as among all racial and ethnic subgroups (Asian/Pacific Islander: 3.4% [95% CI, 0.8% to 6.0%]); Black: 47% [95% CI, 3.4% to 5.9%]; Hispanic: 4.7% [95% CI, 3.4% to 5.9%]; and White: 3.1% [95% Cl, 11% to 4.4%]) and among each gestational age range (22 weeks: 14.4% [95% CI, 11.1% to 17.7%] and 25 weeks: 2.9% [95% CI, 1.5% to 4.2%]). Compared with neonates born to White individuals (57.0%), neonates born to Asian/Pacific Islander (46.2%; risk difference [RD], -10.81 [95% CI, -12.75 to -8.88]; aRR, 0.82 [95% CI, [0.79-0.86]), Black (51.6%; RD, -5.42 [95% CI, -6.36 to -4.50]; aRR, 0.90 [95% CI, 0.89 to 0.92]), and Hispanic (48.0%; RD, -9.03 [95% CI, -10.07 to -7.99]; aRR, 0.83 [95% CI, 0.81 to 0.85]) individuals were significantly less likely to receive active treatment. CONCLUSIONS AND RELEVANCE From 2014 to 2020 in the US, the frequency of active treatment among neonates born alive between 22 weeks 0 days and 25 weeks 6 days significantly increased, and there were differences in rates of active treatment by race and ethnicity.	[Venkatesh, Kartik K.; Lynch, Courtney D.; Costantine, Maged M.; Frey, Heather A.; Landon, Mark B.; Klebanoff, Mark A.; Grobman, William A.] Ohio State Univ, Dept Obstet & Gynecol, Div Maternal Fetal Med, Coll Med, 395 W 12th Ave,Floor 5, Columbus, OH 43210 USA; [Lynch, Courtney D.; Backes, Carl H.; Slaughter, Jonathan L.; Klebanoff, Mark A.] Nationwide Childrens Hosp, Ctr Perinatal Res, Abigail Wexner Res Inst, Columbus, OH USA; [Backes, Carl H.; Slaughter, Jonathan L.] Ohio State Univ, Dept Pediat, Div Neonatol, Coll Med, Columbus, OH 43210 USA; [Huang, Xiaoning; Khan, Sadiya S.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Khan, Sadiya S.] Northwestern Univ, Dept Med, Div Cardiol, Feinberg Sch Med, Chicago, IL 60611 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Venkatesh, KK (corresponding author), Ohio State Univ, Dept Obstet & Gynecol, Div Maternal Fetal Med, Coll Med, 395 W 12th Ave,Floor 5, Columbus, OH 43210 USA.	Kartik.venkatesh@osumc.edu	Slaughter, Jonathan L/E-4102-2011; Huang, Xiaoning/HHN-7229-2022	Slaughter, Jonathan L/0000-0001-6831-7520; Huang, Xiaoning/0000-0001-5813-5993	Care Innovation and Community Improvement Program at The Ohio State University; National Heart, Lung, and Blood Institute [HL161514]	Care Innovation and Community Improvement Program at The Ohio State University; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by the Care Innovation and Community Improvement Program at The Ohio State University (Dr Venkatesh) and by National Heart, Lung, and Blood Institute grant HL161514 (Dr Khan).	Ananth CV, 2017, CLIN PERINATOL, V44, P333, DOI 10.1016/j.clp.2017.01.002; [Anonymous], 2016, Obstet Gynecol, V127, pe157, DOI 10.1097/AOG.0000000000001483; Backes CH, 2021, AM J OBSTET GYNECOL, V224, P158, DOI 10.1016/j.ajog.2020.07.051; Batton DG, 2009, PEDIATRICS, V124, P422, DOI 10.1542/peds.2009-1060; Bell EF, 2022, JAMA-J AM MED ASSOC, V327, P248, DOI 10.1001/jama.2021.23580; Boghossian NS, 2020, OBSTET GYNECOL, V135, P885, DOI 10.1097/AOG.0000000000003747; Brunkhorst J, 2014, SEMIN FETAL NEONAT M, V19, P290, DOI 10.1016/j.siny.2014.08.001; Burris HH, 2021, J PERINATOL, V41, P365, DOI 10.1038/s41372-021-00917-x; Cummings J, 2015, PEDIATRICS, V136, P588, DOI 10.1542/peds.2015-2336; Dupont-Thibodeau A, 2014, SEMIN PERINATOL, V38, P31, DOI 10.1053/j.semperi.2013.07.006; Edmonds BT, 2015, J PERINATOL, V35, P161, DOI 10.1038/jp.2014.175; Edmonds BT, 2019, J MATERN-FETAL NEO M, V32, P820, DOI 10.1080/14767058.2017.1393066; Edmonds BT, 2015, PATIENT EDUC COUNS, V98, P49, DOI 10.1016/j.pec.2014.09.014; Edmonds BT, 2011, PEDIATRICS, V127, pE1120, DOI 10.1542/peds.2010-2608; Ehret DEY, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3235; Guarneri C., 2012, METHODS ASSIGNING RA; Horbar JD, 2019, JAMA PEDIATR, V173, P455, DOI 10.1001/jamapediatrics.2019.0241; Howell EA, 2018, JAMA PEDIATR, V172, P269, DOI 10.1001/jamapediatrics.2017.4402; Institute of Medicine, 2003, UNEQUAL TREATMENT CO; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Litmanovitz I, 2015, J PERINATOL, V35, P705, DOI 10.1038/jp.2015.48; Lorch SA, 2016, PEDIATR RES, V79, P141, DOI 10.1038/pr.2015.199; Martin Joyce A, 2015, Natl Vital Stat Rep, V64, P1; Matthews T J, 2015, Natl Vital Stat Rep, V64, P1; McKenzie F, 2016, J PERINATOL, V36, P522, DOI 10.1038/jp.2016.15; Mehra R, 2017, SOC SCI MED, V191, P237, DOI 10.1016/j.socscimed.2017.09.018; National Center for Vital Statistics, GUID COMPL FACC WORK; Ondusko DS, 2022, AM J PERINAT, V39, P1204, DOI 10.1055/s-0040-1721717; Parker JD, 2004, PUBLIC HEALTH REP, V119, P192, DOI 10.1177/003335490411900213; Profit J, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0918; Rysavy MA, 2015, NEW ENGL J MED, V372, P1801, DOI 10.1056/NEJMoa1410689; Salihu HM, 2013, SEMIN PERINATOL, V37, P389, DOI 10.1053/j.semperi.2013.06.021; Shah NS, 2021, JAMA-J AM MED ASSOC, V326, P660, DOI 10.1001/jama.2021.7217; Stoll BJ, 2015, JAMA-J AM MED ASSOC, V314, P1039, DOI 10.1001/jama.2015.10244; Travers CP, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.6757; Edmonds BT, 2021, J PERINATOL, V41, P396, DOI 10.1038/s41372-020-0739-5; Wallace ME, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.11.1026	37	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2022	328	7					652	662		10.1001/jama.2022.12841	http://dx.doi.org/10.1001/jama.2022.12841			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D0ZW	35972487				2023-01-03	WOS:000846874500022
J	Audemard-Verger, A; Le Gouge, A; Pestre, V; Courjon, J; Langlois, V; Vareil, MO; Devaux, M; Bienvenu, B; Leroy, V; Goulabchand, R; Colombain, L; Bigot, A; Guimard, T; Douadi, Y; Urbanski, G; Faucher, JF; Maulin, L; Lioger, B; Talarmin, JP; Groh, M; Emmerich, J; Deriaz, S; Ferreira-Maldent, N; Cook, AR; Lengelle, C; Bourgoin, H; Mekinian, A; Aouba, A; Maillot, F; Caille, A				Audemard-Verger, Alexandra; Le Gouge, Amelie; Pestre, Vincent; Courjon, Johan; Langlois, Vincent; Vareil, Marc-Olivier; Devaux, Mathilde; Bienvenu, Boris; Leroy, Vincent; Goulabchand, Radjiv; Colombain, Lea; Bigot, Adrien; Guimard, Thomas; Douadi, Youcef; Urbanski, Geoffrey; Faucher, Jean Francois; Maulin, Laurence; Lioger, Bertrand; Talarmin, Jean-Philippe; Groh, Matthieu; Emmerich, Joseph; Deriaz, Sophie; Ferreira-Maldent, Nicole; Cook, Ann-Rose; Lengelle, Celine; Bourgoin, Helene; Mekinian, Arsene; Aouba, Achille; Maillot, Francois; Caille, Agnes			Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial	PLOS ONE			English	Article							RECEPTOR BLOCKADE; INTERLEUKIN-1	Objective We aimed to investigate whether anakinra, an interleukin-1 receptor inhibitor, could improve outcome in moderate COVID-19 patients. Methods In this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen. We randomly assigned patients to receive intravenous anakinra plus optimized standard of care (oSOC) vs. oSOC alone. The primary outcome was treatment success at day 14 defined as patient alive and not requiring mechanical ventilation or extracorporeal membrane oxygenation. Results Between 27th April and 6th October 2020, we enrolled 71 patients (240 patients planned to been enrolled): 37 were assigned to the anakinra group and 34 to oSOC group. The study ended prematurely by recommendation of the data and safety monitoring board due to safety concerns. On day 14, the proportion of treatment success was significantly lower in the anakinra group 70% (n = 26) vs. 91% (n = 31) in the oSOC group: risk difference-21 percentage points (95% CI, -39 to -2), odds ratio 0.23 (95% CI, 0.06 to 0.91), p = 0.027. After a 28-day follow-up, 9 patients in the anakinra group and 3 in the oSOC group had died. Overall survival at day 28 was 75% (95% CI, 62% to 91%) in the anakinra group versus 91% (95% CI, 82% to 100%) (p = 0.06) in the oSOC group. Serious adverse events occurred in 19 (51%) patients in the anakinra group and 18 (53%) in the oSOC group (p = 0.89). Conclusion This trial did not show efficacy of anakinra in patients with COVID-19. Furthermore, contrary to our hypothesis, we found that anakinra was inferior to oSOC in patients with moderate COVID-19 pneumonia.	[Audemard-Verger, Alexandra; Bigot, Adrien; Deriaz, Sophie; Ferreira-Maldent, Nicole; Cook, Ann-Rose; Maillot, Francois] CHRU Tours, Dept Internal Med & Clin Immunol, Tours, France; [Audemard-Verger, Alexandra; Maillot, Francois; Caille, Agnes] Univ Tours, Tours, France; [Le Gouge, Amelie; Caille, Agnes] CHRU Tours, INSERM CIC1415, Tours, France; [Pestre, Vincent] CH Avignon, Dept Internal Med & Infect Dis, Avignon, France; [Courjon, Johan] Univ Cote dAzur, Dept Infect Dis, CHU Nice, Nice, France; [Langlois, Vincent] CH Havre, Dept Internal Med, Le Havre, France; [Vareil, Marc-Olivier] CH Bayonne, Dept Infect Dis, Bayonne, France; [Devaux, Mathilde] CH Poissy, Dept Internal Med, Poissy, France; [Bienvenu, Boris] Hop St Joseph, Dept Internal Med, Marseille, France; [Leroy, Vincent] Clin Tessier, Dept Infect Dis, Valenciennes, France; [Goulabchand, Radjiv] Univ Montpellier, Nimes Univ Hosp, Internal Med Dept, Nimes, France; [Goulabchand, Radjiv] Univ Montpellier, Nimes Univ Hosp, Dept Infect & Trop Dis, Nimes, France; [Colombain, Lea] CH Perpignan, Dept Infect Dis, Perpignan, France; [Guimard, Thomas] CH la Roche sur Yon, Dept Infect Dis, La Roche Sur Yon, France; [Douadi, Youcef] CH St Quentin, Dept Infect Dis, St Quentin en Yvelines, France; [Urbanski, Geoffrey] CHU Angers, Dept Internal Med & Clin Immunol, Angers, France; [Faucher, Jean Francois] CHU Limoges, Dept Infect Dis, Limoges, France; [Maulin, Laurence] CH Aix Provence, Dept Infect Dis, Aix En Provence, France; [Lioger, Bertrand] CH Blois, Dept Internal Med, Blois, Loir & Cher, France; [Talarmin, Jean-Philippe] CH Quimper, Dept Internal Med & Infect Dis, Quimper, France; [Groh, Matthieu] Hop Foch, Dept Internal Med, Suresnes, France; [Emmerich, Joseph] GH St Joseph, Dept Vasc Med, Paris, France; [Emmerich, Joseph] Univ Paris, INSERM CRESS 1153, Paris, France; [Lengelle, Celine] CHRU Tours, Clin Res Vigilance Unit, Tours, France; [Bourgoin, Helene] CHRU Tours, Dept Pharmacol, Tours, France; [Mekinian, Arsene] Sorbonne Univ, Dept Internal Med, Hop St Antoine, Paris, France; [Aouba, Achille] CHU Caen, Dept Internal Med, Caen, France	CHU Tours; Universite de Tours; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Nimes; CHD Vendee; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Limoges; Hospital Foch; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU Tours; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Caen NORMANDIE; Universite de Caen Normandie	Audemard-Verger, A (corresponding author), CHRU Tours, Dept Internal Med & Clin Immunol, Tours, France.; Audemard-Verger, A (corresponding author), Univ Tours, Tours, France.	a.audemard-verger@chu-tours.fr			foundation of the Tours university hospital through the endowment fund of the university hospital of Tours	foundation of the Tours university hospital through the endowment fund of the university hospital of Tours	ANACONDA was supported by the foundation of the Tours university hospital through the endowment fund of the university hospital of Tours. Sobi supplied anakinra free of charge. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706; Cauchois R, 2020, P NATL ACAD SCI USA, V117, P18951, DOI 10.1073/pnas.2009017117; Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007; Dinarello CA, 2013, SEMIN IMMUNOL, V25, P469, DOI 10.1016/j.smim.2013.10.008; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8; Jouan Y, 2020, J EXP MED, V217, DOI 10.1084/jem.20200872; Kyriazopoulou E, 2021, NAT MED, V27, P1752, DOI 10.1038/s41591-021-01499-z; Mariette X, 2021, LANCET RESP MED, V9, P295, DOI 10.1016/S2213-2600(20)30556-7; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Mehta P, 2020, LANCET RHEUMATOL, V2, pE358, DOI 10.1016/S2665-9913(20)30096-5; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402; Spangfors M, 2016, INTENS CRIT CARE NUR, V37, P62, DOI 10.1016/j.iccn.2016.05.007; Vastert SJ, 2019, RHEUMATOLOGY, V58, P9, DOI 10.1093/rheumatology/kez350; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	18	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2022	17	8							e0269065	10.1371/journal.pone.0269065	http://dx.doi.org/10.1371/journal.pone.0269065			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4E8NP	35925914	Green Published, gold			2023-01-03	WOS:000848077100010
J	Jensen, CL; Rodriguez, KE; MacLean, EL; Abdul Wahab, AH; Sabbaghi, A; O'Haire, ME				Jensen, Clare L.; Rodriguez, Kerri E.; MacLean, Evan L.; Abdul Wahab, Ahmad Hakeem; Sabbaghi, Arman; O'Haire, Marguerite E.			Characterizing veteran and PTSD service dog teams: Exploring potential mechanisms of symptom change and canine predictors of efficacy	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; COMPLEMENTARY TREATMENT; MILITARY MEMBERS; TRAINING METHODS; SCALE; PET; REGULARIZATION; ATTACHMENT; MEDICINE; CORTISOL	Psychiatric service dogs are an emerging complementary intervention for posttraumatic stress disorder (PTSD). Initial evidence suggests that partnership with a service dog may be related to less PTSD symptom severity. However, it remains unclear how or why this might occur. To address this gap, we conducted a longitudinal investigation of 82 post-9/11 military members or veterans and their PTSD service dogs to (1) evaluate service dog characteristics as potential predictors of efficacy, (2) assess dog and human characteristics as potential predictors of veteran-dog bond, and (3) explore potential mechanisms for mental health outcomes. Aim 1 results demonstrated that most service dog characteristics did not predict veterans' mental health outcomes, but lower service dog excitability was associated with less PTSD symptom severity at follow-up. Aim 2 results showed that closer dog-veteran relationships were associated with less excitable dog temperament. Aim 3 results indicated that worse mental health at follow-up was associated with greater use of the specifically trained PTSD service dog task to initiate a social greeting ("make a friend"), whereas better mental health was related to less use of dominance-based training methods, lower perceived emotional/logistical costs of service dog partnership, and closer veteran-dog relationships. More frequent use of the trained service dog task to signal when someone approaches from behind (cover/watch back) was associated with greater anxiety, but less PTSD symptom severity. Overall, veterans spent an average of 82% of their time with service dogs (assessed via Bluetooth proximity between dog collar and veteran smartphone), and most frequently asked their service dogs to perform the trained task for calming their anxiety (calm/comfort anxiety). The present study provides subjective and objective metrics of the heterogeneity among veteran-service dog dyads while also suggesting which of the assessed metrics might be potential mechanisms involved in the intervention.	[Jensen, Clare L.; Rodriguez, Kerri E.; O'Haire, Marguerite E.] Purdue Univ, Ctr Human Anim Bond, Coll Vet Med, W Lafayette, IN USA; [Rodriguez, Kerri E.] Colorado State Univ, Sch Social Work, Human Anim Bond Colorado, Ft Collins, CO USA; [MacLean, Evan L.] Univ Arizona, Sch Anthropol, Arizona Canine Cognit Ctr, Tucson, AZ USA; [Abdul Wahab, Ahmad Hakeem] Janssen Pharmaceut, Titusville, NJ USA; [Abdul Wahab, Ahmad Hakeem; Sabbaghi, Arman] Purdue Univ, Dept Stat, West Lafayette, PA USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Colorado State University; University of Arizona; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson USA	O'Haire, ME (corresponding author), Purdue Univ, Ctr Human Anim Bond, Coll Vet Med, W Lafayette, IN USA.	mohaire@purdue.edu		Jensen, Clare/0000-0002-4664-5774	National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [R21HD091896]; National Institutes of Health National Center for Complementary and Integrative Health (NCCIH) [R21HD091896]; Merrick Pet Care; Dogtopia Foundation; Petco Love	National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institutes of Health National Center for Complementary and Integrative Health (NCCIH); Merrick Pet Care; Dogtopia Foundation; Petco Love	This project was supported by grants awarded to Dr. O'Haire from the National Institutes of Health (#R21HD091896) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD; https://www.nichd.nih.gov/) and National Center for Complementary and Integrative Health (NCCIH; https://www.nccih.nih.gov/), Merrick Pet Care (https://www.merrickpetcare.com/), Petco Love (https://petcolove.org/), and Dogtopia Foundation (https://www.dogtopiafoundation.org/).Funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADA, 2010, REV REQ SERV AN; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5th; Arata S, 2010, J VET MED SCI, V72, P539, DOI 10.1292/jvms.09-0512; ARON A, 1992, J PERS SOC PSYCHOL, V63, P596, DOI 10.1037/0022-3514.63.4.596; Barcelos AM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68446-9; Batt LS, 2008, J VET BEHAV, V3, P143, DOI 10.1016/j.jveb.2008.04.003; Beck A. M., 2014, Animal Frontiers, V4, P32, DOI 10.2527/af.2014-0019; Beetz AM, 2017, APPL DEV SCI, V21, P139, DOI 10.1080/10888691.2016.1262263; Bergen-Cico D, 2018, J ALTERN COMPLEM MED, V24, P1166, DOI 10.1089/acm.2018.0179; Blackwell EJ, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-93; Blevins CA, 2015, J TRAUMA STRESS, V28, P489, DOI 10.1002/jts.22059; Bovin MJ, 2016, PSYCHOL ASSESSMENT, V28, P1379, DOI 10.1037/pas0000254; Bray EE, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00049; Calafiore G, 2001, AUTOMATICA, V37, P573, DOI 10.1016/S0005-1098(00)00189-8; Carr DC, 2019, AGING MENT HEALTH, V23, P1452, DOI 10.1080/13607863.2018.1503999; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Cobb ML, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.666898; CRAN Team, 2020, CRAN; Crowe TK, 2018, DISABIL REHABIL, V40, P2953, DOI 10.1080/09638288.2017.1363301; Dwyer F, 2006, ANTHROZOOS, V19, P243, DOI 10.2752/089279306785415592; Ehrhart MG, 2009, PERS INDIV DIFFER, V47, P900, DOI 10.1016/j.paid.2009.07.012; Friard O, 2016, METHODS ECOL EVOL, V7, P1325, DOI 10.1111/2041-210X.12584; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Fulton JJ, 2015, J ANXIETY DISORD, V31, P98, DOI 10.1016/j.janxdis.2015.02.003; Galovski T, 2004, AGGRESS VIOLENT BEH, V9, P477, DOI 10.1016/S1359-1789(03)00045-4; Gray PB, 2011, ANTHROZOOS, V24, P17, DOI 10.2752/175303711X12923300467285; Handlin L, 2012, ANTHROZOOS, V25, P215, DOI 10.2752/175303712X13316289505468; Hiby EF, 2004, ANIM WELFARE, V13, P63; Hoge CW, 2014, PSYCHIAT SERV, V65, P997, DOI 10.1176/appi.ps.201300307; Hoglin A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88201-y; Hsu YY, 2003, J AM VET MED ASSOC, V223, P1293, DOI 10.2460/javma.2003.223.1293; Imai K, 2013, J R STAT SOC A STAT, V176, P5, DOI 10.1111/j.1467-985X.2012.01032.x; JOHNSON TP, 1992, ANTHROZOOS, V5, P160, DOI 10.2752/089279392787011395; Kangaslampi S, 2022, CURR PSYCHOL, V41, P258, DOI 10.1007/s12144-019-00478-5; Kloep ML, 2017, AM J ORTHOPSYCHIAT, V87, P425, DOI 10.1037/ort0000254; Kuhn Max, 2020, CRAN; LaFollette MR, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00023; Libby DJ, 2012, PSYCHIAT SERV, V63, P1134, DOI 10.1176/appi.ps.201100456; Long JS, 2000, AM STAT, V54, P217, DOI 10.2307/2685594; Lopez-Zeron G, 2017, J FAM THER, V39, P580, DOI 10.1111/1467-6427.12089; Lue TW, 2008, JAVMA-J AM VET MED A, V232, P531, DOI 10.2460/javma.232.4.531; MacLean EL, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.675782; MacLean EL, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01606; McClendon J., 2020, CURR TREAT OPT PSYCH, V7, P275, DOI DOI 10.1007/S40501-020-00212-0; Moshier SJ, 2018, J ABNORM PSYCHOL, V127, P541, DOI 10.1037/abn0000368; O'Haire ME, 2018, J CONSULT CLIN PSYCH, V86, P179, DOI 10.1037/ccp0000267; Pacella ML, 2013, J ANXIETY DISORD, V27, P33, DOI 10.1016/j.janxdis.2012.08.004; Payne E, 2015, PSYCHOL RES BEHAV MA, V8, P71, DOI 10.2147/PRBM.S74972; Polheber JP, 2014, J BEHAV MED, V37, P860, DOI 10.1007/s10865-013-9546-1; Robbins ML, 2014, WILEY-BL HB BEHAV SC, P429; Rodriguez KE, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01638; Rodriguez KE, 2018, PSYCHONEUROENDOCRINO, V98, P202, DOI 10.1016/j.psyneuen.2018.04.026; Ross PT, 2020, PERSPECT MED EDUC, V9, P318, DOI 10.1007/s40037-020-00602-3; Schalet BD, 2016, J CLIN EPIDEMIOL, V73, P119, DOI 10.1016/j.jclinepi.2015.08.036; Scotland-Coogan D., 2022, Society & Animals, V30, P547, DOI 10.1163/15685306-00001682; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Smith Y., 2019, CLINICIANS GUIDE TRE, P477; Spoont MR, 2017, PSYCHIAT SERV, V68, P231, DOI 10.1176/appi.ps.201600086; Stumbo SP, 2019, J CONSULT CLIN PSYCH, V87, P118, DOI 10.1037/ccp0000352; Tanielian T., 2008, INVISIBLE WOUNDS WAR, V1; US Department of Veterans Affairs & US Department of Defense, 2017, VA DOD CLIN PRACTICE; Vespa JE., THOSE WHO SERVED AME, P18; Walther S, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00001; Weathers F. W., 2013, THEPTSDCHECKLISTFORD, V10; Weathers FW, 2018, PSYCHOL ASSESSMENT, V30, P383, DOI 10.1037/pas0000486; White N, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14060658; Williamson L., 2021, J VETERANS STUD, V7, P1, DOI DOI 10.21061/JVS.V7I1.194; Wilson EO., 1984, BIOPHILIA INTERNET; Wood LJ, 2007, SOC ANIM, V15, P43, DOI 10.1163/156853007X169333; Wynn GH, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0600-2; Yarborough BJH, 2018, PSYCHIATR REHABIL J, V41, P118, DOI 10.1037/prj0000294; Yarborough BJH, 2017, PSYCHIAT SERV, V68, P730, DOI 10.1176/appi.ps.201500383; Ziv G, 2017, J VET BEHAV, V19, P50, DOI 10.1016/j.jveb.2017.02.004; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	74	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2022	17	7							e0269186	10.1371/journal.pone.0269186	http://dx.doi.org/10.1371/journal.pone.0269186			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5Z7YE	35895599	gold, Green Published			2023-01-03	WOS:000880183400021
J	Larkin, HD				Larkin, Howard D.			Code Blue-What to Do When the Shooting Starts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	2022	328	4					315	317		10.1001/jama.2022.11253	http://dx.doi.org/10.1001/jama.2022.11253			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3R7ST	35793120				2023-01-03	WOS:000839108600001
J	Ying, C; Jin, CM; Zeng, SY; Chao, M; Hu, X				Ying, Chang; Jin, Chengmeng; Zeng, Siying; Chao, Ming; Hu, Xun			Alkalization of cellular pH leads to cancer cell death by disrupting autophagy and mitochondrial function	ONCOGENE			English	Article							PERMEABILITY TRANSITION PORE; ACTIVATED PROTEIN-KINASE; HEPATOCELLULAR-CARCINOMA; TRANSARTERIAL CHEMOEMBOLIZATION; INHIBITION; AMPK; MODULATION; MACHINERY; APOPTOSIS; EFFICACY	We previously found that lactic acidosis in the tumor environment was permissive to cancer cell surviving under glucose deprivation and demonstrated that neutralizing lactic acidosis restored cancer cell susceptibility to glucose deprivation. We then reported that alternate infusion of bicarbonate and anticancer agent into tumors via tumor feeding artery markedly enhanced the efficacy of transarterial chemoembolization (TACE) in the local control of hepatocellular carcinoma (HCC). Here we sought to further investigate the mechanism by which bicarbonate enhances the anticancer activity of TACE. We propose that interfering cellular pH by bicarbonate could induce a cascade of molecular events leading to cancer cell death. Alkalizing cellular pH by bicarbonate decreased pH gradient (Delta pH), membrane potential (Delta psi(m)), and proton motive force (Delta p) across the inner membrane of mitochondria; disruption of oxidative phosphorylation (OXPHOS) due to collapsed Delta p led to a significant increase in adenosine monophosphate (AMP), which activated the classical AMPK-mediated autophagy. Meanwhile, the autophagic flux was ultimately blocked by increased cellular pH, reduced OXPHOS, and inhibition of lysosomal proton pump in alkalized lysosome. Bicarbonate also induced persistent mitochondrial permeability (MPT) and damaged mitochondria. Collectively, this study reveals that interfering cellular pH may provide a valuable approach to treat cancer.	[Ying, Chang; Jin, Chengmeng; Zeng, Siying; Hu, Xun] Zhejiang Univ, Affiliated Hosp 2, Canc Inst,Key Lab Canc Intervent & Prevent, Sch Med,China Natl Minist Educ,Zhejiang Prov Key, Hangzhou, Peoples R China; [Chao, Ming] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Intervent Radiol,Dept Radiol, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Hu, X (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Canc Inst,Key Lab Canc Intervent & Prevent, Sch Med,China Natl Minist Educ,Zhejiang Prov Key, Hangzhou, Peoples R China.; Chao, M (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Intervent Radiol,Dept Radiol, Hangzhou, Peoples R China.	chaoming@zju.edu.cn; huxun@zju.edu.cn	Zeng, Siying/HDO-3064-2022		China Natural Sciences Foundation [82073038, 81772947]; Zhejiang Provincial Department of Sciences and Technologies [2018C03009]; Fundamental Research Funds for the Central Universities [2017XZZX001-01, 2019FZJD009]; National Ministry of Education, China	China Natural Sciences Foundation(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Department of Sciences and Technologies; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Ministry of Education, China(Ministry of Education, China)	This work has been supported in part by China Natural Sciences Foundation projects (82073038, 81772947 to XH), a key project (2018C03009) funded by Zhejiang Provincial Department of Sciences and Technologies (to XH & MC), and the Fundamental Research Funds for the Central Universities (2017XZZX001-01, 2019FZJD009, to XH), National Ministry of Education, China. We thank Dr. Guo-Hua Fong (University of Connecticut School of Medicine, USA) for critical readings of our manuscript and constructive comments, Dr. Wei Liu (Zhejiang University) for the kind gift of plasmids GFP-LC3, Cherry-GFP-LC3, and Dr. Shanrong Cai for the statistical assistance (Zhejiang University).	Ahmad F, 2019, J LIPID RES, V60, P98, DOI 10.1194/jlr.M088245; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bartel K, 2019, J BIOL CHEM, V294, P17239, DOI 10.1074/jbc.RA119.010243; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Caricato R, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00319; Chao M, 2016, ELIFE, V5, DOI [10.7554/eLife.15691, 10.7754/eLife.15691]; Chen JC, 2019, J BIOL CHEM, V294, P11994, DOI 10.1074/jbc.RA118.007161; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; de Vasconcelos NM, 2019, CELL DEATH DIFFER, V26, P146, DOI 10.1038/s41418-018-0106-7; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, 2019, J Hepatol, V70, P817, DOI 10.1016/j.jhep.2019.01.020; Gong YN, 2017, CELL, V169, P286, DOI 10.1016/j.cell.2017.03.020; Goodall ML, 2016, DEV CELL, V37, P337, DOI 10.1016/j.devcel.2016.04.018; Gowans GJ, 2013, CELL METAB, V18, P556, DOI 10.1016/j.cmet.2013.08.019; Hawley SA, 2016, DIABETES, V65, P2784, DOI 10.2337/db16-0058; Hu X, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.47; Ibrahim-Hashim A, 2012, J UROLOGY, V188, P624, DOI 10.1016/j.juro.2012.03.113; Jansen MC, 2005, EJSO-EUR J SURG ONC, V31, P331, DOI 10.1016/j.ejso.2004.10.011; Jin CM, 2020, J BIOL CHEM, V295, P6425, DOI 10.1074/jbc.RA119.012312; Ju JS, 2010, AUTOPHAGY, V6, P929, DOI 10.4161/auto.6.7.12785; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kloditz K, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0146-x; Lencioni R, 2016, HEPATOLOGY, V64, P106, DOI 10.1002/hep.28453; Liu B, 2014, AUTOPHAGY, V10, P416, DOI 10.4161/auto.27286; Liu J, 2020, CELL CHEM BIOL, V27, P420, DOI 10.1016/j.chembiol.2020.02.005; Liu YE, 2020, MEDCOMM, V1, P129, DOI 10.1002/mco2.16; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Malhi H, 2006, HEPATOLOGY, V43, pS31, DOI 10.1002/hep.21062; Martin NK, 2012, BRIT J CANCER, V106, P1280, DOI 10.1038/bjc.2012.58; Martin NK, 2011, MATH BIOSCI, V230, P1, DOI 10.1016/j.mbs.2010.12.002; Mauvezin C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8007; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Pasquier A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11170-4; Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587; Perry SW, 2011, BIOTECHNIQUES, V50, P98, DOI 10.2144/000113610; Piscaglia F, 2018, LIVER CANCER, V7, P104, DOI 10.1159/000485471; Piscaglia F, 2010, DIGEST LIVER DIS, V42, pS258, DOI 10.1016/S1590-8658(10)60514-2; Poburko D, 2011, J BIOL CHEM, V286, P11672, DOI 10.1074/jbc.M110.159962; Raoul JL, 2011, CANCER TREAT REV, V37, P212, DOI 10.1016/j.ctrv.2010.07.006; Rasola A, 2010, P NATL ACAD SCI USA, V107, P726, DOI 10.1073/pnas.0912742107; Russo M, 2018, BIOCHEM PHARMACOL, V153, P51, DOI 10.1016/j.bcp.2018.02.007; Shlomovitz I, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0437-0; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Wu H, 2012, J PATHOL, V227, P189, DOI 10.1002/path.3978; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Xie JS, 2014, SCI REP-UK, V4, DOI 10.1038/srep04927; Yang KX, 2016, NANOMEDICINE-UK, V11, DOI 10.2217/nnm-2016-0289; Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865; Yue W, 2013, AUTOPHAGY, V9, P714, DOI 10.4161/auto.23997; Zargarian S, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2002711; Zois CE, 2009, AUTOPHAGY, V5, P442, DOI 10.4161/auto.5.4.7667	58	0	0	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3886	3897		10.1038/s41388-022-02396-6	http://dx.doi.org/10.1038/s41388-022-02396-6		JUL 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35780182				2023-01-03	WOS:000819907600001
J	Stark, EL; Gariepy, AM; Son, M				Stark, Elisabeth L.; Gariepy, Aileen M.; Son, Moeun			What Is Long-Acting Reversible Contraception? Long-acting reversible contraception (LARC) is long-lasting and easily reversible birth control	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Stark, Elisabeth L.; Son, Moeun] Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06510 USA; [Gariepy, Aileen M.] Weill Cornell Med, Dept Obstet & Gynecol, New York, NY USA	Yale University; Cornell University	Stark, EL (corresponding author), Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06510 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	2022	328	13					1362	1362		10.1001/jama.2022.14239	http://dx.doi.org/10.1001/jama.2022.14239			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5F6GU	35960529	Bronze			2023-01-03	WOS:000866412700025
J	Liu, J; Peng, R; Tan, Q; Li, BC; Chen, JY; Liu, GY; Wang, YW; Li, C; Li, J; Wang, H				Liu, Jing; Peng, Rui; Tan, Qian; Li, Bocun; Chen, Jianyi; Liu, Guangya; Wang, Yawen; Li, Chao; Li, Jia; Wang, Hua			Proteomic analysis of rat colonic mucosa following acupuncture treatment for irritable bowel syndrome with diarrhea	PLOS ONE			English	Article							SMALL-INTESTINE; STRESS; ELECTROACUPUNCTURE; DIAGNOSIS; IDENTIFICATION; STIMULATION; PREDOMINANT; MECHANISMS; GENE; IBS	To investigate the molecular pathological mechanisms of irritable bowel syndrome with diarrhea (IBS-D) and elucidate the effects of acupuncture on IBS-D colonic mucosa protein abundance in rats, a label-free high-throughput liquid chromatography-tandem mass spectrometry (LC-MS)-based proteomics analysis was used to survey the global changes of colonic mucosa proteins between different groups. Sixteen Sprague-Dawley (SD) male rats were randomly divided into four groups: the control group (C); the IBS-D model group (M); the syndrome differentiation acupuncture group (SD) and the traditional acupuncture group (T). IBS-D model rats were obtained using the CAS (chronic acute combining stress model) method. Comparative bioinformatics analysis of the proteomic data was analyzed using MaxQuant software, Perseus software, online tools DAVID, VENNY and STRING. Functional enrichment and network analyses revealed a close relationship between IBS-D and several biological processes including energy metabolism, muscular excitation/contraction, and both traditional acupuncture and syndrome differentiation acupuncture can reverse the impairments of normal energy metabolism. Moreover, the syndrome differentiation acupuncture can regulate the protein cluster relating inflammation, wound repair and cell protection against oxidative stress which is associated with acupuncture analgesic effect. Differentially expressed proteins Atp5a1 and Bpnt1 were selected as representative proteins and subjected to western blotting. In conclusion, our study provides further insight into the pathological and molecular mechanisms of IBS-D and acupuncture treatments, and serves as an experimental basis for clinical applications.	[Liu, Jing; Peng, Rui; Tan, Qian; Li, Bocun; Chen, Jianyi; Liu, Guangya; Wang, Yawen; Li, Chao; Li, Jia; Wang, Hua] Hubei Univ Chinese Med, Acupuncture Moxibust & Orthoped Coll, Wuhan, Hubei, Peoples R China	Hubei University of Chinese Medicine	Li, J; Wang, H (corresponding author), Hubei Univ Chinese Med, Acupuncture Moxibust & Orthoped Coll, Wuhan, Hubei, Peoples R China.	ljlijia@163.com; hwang.tcm@china.com		Li, Jia/0000-0003-0444-2263	Scientific Research Plan Program of Department of Education of Hubei Province [Q20202005]	Scientific Research Plan Program of Department of Education of Hubei Province	This research was funded by the Scientific Research Plan Program of Department of Education of Hubei Province, grant number: Q20202005. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bai MR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03355-0; Bai T, 2017, J GASTROEN HEPATOL, V32, P1018, DOI 10.1111/jgh.13642; Boltin D, 2014, BEST PRACT RES CL GA, V28, P981, DOI 10.1016/j.bpg.2014.09.001; Bonaz B, 2009, GASTROEN CLIN BIOL, V33, pS48, DOI 10.1016/S0399-8320(09)71525-8; Brzozowski B, 2016, CURR NEUROPHARMACOL, V14, P892, DOI 10.2174/1570159X14666160404124127; Chao GQ, 2014, WORLD J GASTROENTERO, V20, P1871, DOI 10.3748/wjg.v20.i7.1871; Chen JDDZ, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/138645; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Deng WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111988; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; El-Salhy M, 2012, WORLD J GASTROENTERO, V18, P5151, DOI 10.3748/wjg.v18.i37.5151; Fischer SGL, 2013, INT J MOL SCI, V14, P7784, DOI 10.3390/ijms14047784; Fond G, 2014, EUR ARCH PSY CLIN N, V264, P651, DOI 10.1007/s00406-014-0502-z; Glembotski CC, 2012, J BIOL CHEM, V287, P25893, DOI 10.1074/jbc.M112.356345; Goo YA, 2012, J PROTEOME RES, V11, P5650, DOI 10.1021/pr3004437; Ho RST, 2015, ADV INTEGR MED, V2, P143, DOI 10.1016/j.aimed.2016.02.004; Holtmann GJ, 2016, LANCET GASTROENTEROL, V1, P133, DOI 10.1016/S2468-1253(16)30023-1; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; Iwa M, 2006, DIGEST DIS SCI, V51, P1493, DOI 10.1007/s10620-006-9083-7; Li H, 2015, WORLD J GASTROENTERO, V21, P8304, DOI 10.3748/wjg.v21.i27.8304; Li J, 2020, NEUROSCI LETT, V723, DOI 10.1016/j.neulet.2020.134865; Li S, 2016, J NEUROGASTROENTEROL, V22, P310, DOI 10.5056/jnm15082; [李晓洁 Li Xiaojie], 2020, [中国实验动物学报, Acta Laboratorium Animalis Scientia Sinica], V28, P593; Li YJ., 2017, J TRADITIONAL CHINES, V4, P39, DOI [10.1016/j.jtcms.2017.05.006, DOI 10.1016/J.JTCMS.2017.05.006]; MacPherson H, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-150; Manabe N, 2010, NEUROGASTROENT MOTIL, V22, DOI 10.1111/j.1365-2982.2009.01442.x; Manheimer E, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005111.pub3; Minowa T, 2000, ELECTROPHORESIS, V21, P1782; Pei LX, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010877; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Qin HY, 2014, WORLD J GASTROENTERO, V20, P14126, DOI 10.3748/wjg.v20.i39.14126; Ren Bin-Bin, 2012, Zhongguo Zhen Jiu, V32, P765; Shi Jun-Jie, 2013, Zhen Ci Yan Jiu, V38, P181; Spiller R, 2007, GUT, V56, P1770, DOI 10.1136/gut.2007.119446; Sun J LR., 2020, SHANGHAI J ACUP MOXI, V39, P456; Tai ZX FX, 2020, ACTA LAB ANIM SCI SI, V28; Thakur ER, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.13143; Tian FJ HX., 2013, CHINA J CHINESE MED, V01, P125; Tsigaridas A, 2018, J PROTEOMICS, V188, P167, DOI 10.1016/j.jprot.2017.07.019; WHITEHEAD WE, 1980, DIGEST DIS SCI, V25, P404, DOI 10.1007/BF01395503; Wu IXY, 2019, THER ADV GASTROENTER, V12, DOI 10.1177/1756284818820438; Xing JH, 2004, ALTERN THER HEALTH M, V10, P38; Yang ZB, 2006, WORLD J GASTROENTERO, V12, P5557, DOI 10.3748/wjg.v12.i34.5557; Yin CS, 2008, RES VET SCI, V84, P159, DOI 10.1016/j.rvsc.2007.04.004; Zhao JM, 2018, CHIN J INTEGR MED, V24, P328, DOI 10.1007/s11655-018-2838-0; Zheng S XJ, 2018, J CLIN ACUPUNCTURE M, V34, P66; Zivaljevic A, 2019, WORLD J TRAD CHINESE, V5, P181, DOI 10.4103/wjtcm.wjtcm_24_19; 张艳佶, 2020, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V31, P990	48	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2022	17	9							e0273853	10.1371/journal.pone.0273853	http://dx.doi.org/10.1371/journal.pone.0273853			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R5XR	36094925	Green Published, gold			2023-01-03	WOS:000892376500024
J	Coskun, A; Yegen, C; Arbak, S; Attaallah, W; Gunal, O; Elmas, MA; Ucal, Y; Can, O; Bas, B; Yildirim, Z; Seckin, I; Demirci, S; Serteser, M; Ozpinar, A; Belce, A; Basdemir, G; Moldur, DE; Derelioglu, EI; Yozgatli, TK; Erdemgil, Y; Unsal, I				Coskun, Abdurrahman; Yegen, Cumhur; Arbak, Serap; Attaallah, Wafi; Gunal, Omer; Elmas, Merve Acikel; Ucal, Yasemin; Can, Ozge; Bas, Banu; Yildirim, Zeynep; Seckin, Ismail; Demirci, Sibel; Serteser, Mustafa; Ozpinar, Aysel; Belce, Ahmet; Basdemir, Gulcin; Moldur, Derya Emel; Derelioglu, Ecenur Izzete; Yozgatli, Tahir Koray; Erdemgil, Yigit; Unsal, Ibrahim			Melatonin in preservation solutions prevents ischemic injury in rat kidneys	PLOS ONE			English	Article							INITIAL PERFUSION; ORGAN; PROTEINURIA; TRANSPLANTATION; PERSPECTIVES; MIDKINE; GRAFT	Transplantation is lifesaving and the most effective treatment for end-stage organ failure. The transplantation success depends on the functional preservation of organs prior to transplantation. Currently, the University of Wisconsin (UW) and histidine-tryptophan-ketoglutarate (HTK) are the most commonly used preservation solutions. Despite intensive efforts, the functional preservation of solid organs prior to transplantation is limited to hours. In this study, we modified the UW solution containing components from both the UW and HTK solutions and analyzed their tissue-protective effect against ischemic injury. The composition of the UW solution was changed by reducing hydroxyethyl starch concentration and adding Histidine/Histidine-HCI which is the main component of HTK solution. Additionally, the preservation solutions were supplemented with melatonin and glucosamine. The protective effects of the preservation solutions were assessed by biochemical and microscopical analysis at 2, 10, 24, and 72 h after preserving the rat kidneys with static cold storage. Lactate dehydrogenase (LDH) activity in preservation solutions was measured at 2, 10, 24, and 72. It was not detectable at 2 h of preservation in all groups and 10 h of preservation in modified UW+melatonin (mUW-m) and modified UW+glucosamine (mUW-g) groups. At the 72nd hour, the lowest LDH activity (0.91 IU/g (0.63-1.17)) was measured in the mUW-m group. In comparison to the UW group, histopathological damage score was low in modified UW (mUW), mUW-m, and mUW-g groups at 10, 24, and 72 hours. The mUW-m solution at low temperature was an effective and suitable solution to protect renal tissue for up to 72 h.	[Coskun, Abdurrahman; Ucal, Yasemin; Bas, Banu; Yildirim, Zeynep; Serteser, Mustafa; Ozpinar, Aysel; Erdemgil, Yigit] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Med Biochem, Istanbul, Turkey; [Coskun, Abdurrahman; Serteser, Mustafa; Unsal, Ibrahim] Acibadem Labmed Clin Labs, Istanbul, Turkey; [Yegen, Cumhur; Attaallah, Wafi; Gunal, Omer] Marmara Univ, Sch Med, Dept Gen Surg, Istanbul, Turkey; [Arbak, Serap; Elmas, Merve Acikel] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Histol & Embryol, Istanbul, Turkey; [Can, Ozge] Acibadem Mehmet Ali Aydinlar Univ, Fac Engn, Dept Med Engn, Istanbul, Turkey; [Seckin, Ismail] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Dept Histol & Embryol, Istanbul, Turkey; [Demirci, Sibel] Biruni Univ, Sch Med, Dept Histol & Embryol, Istanbul, Turkey; [Belce, Ahmet] Biruni Univ, Sch Med, Dept Med Biochem, Istanbul, Turkey; [Basdemir, Gulcin] Mem Hosp, Dept Pathol, Istanbul, Turkey; [Moldur, Derya Emel; Derelioglu, Ecenur Izzete; Yozgatli, Tahir Koray] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Istanbul, Turkey	Acibadem University; Acibadem Hastaneleri; Acibadem Hospitals Group; Marmara University; Acibadem University; Acibadem University; Istanbul University - Cerrahpasa; Biruni University; Biruni University; Acibadem University	Coskun, A (corresponding author), Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Med Biochem, Istanbul, Turkey.; Coskun, A (corresponding author), Acibadem Labmed Clin Labs, Istanbul, Turkey.	coskun2002@gmail.com	Coskun, Abdurrahman/C-3906-2015	Coskun, Abdurrahman/0000-0002-1273-0604	Scientific and Technological Research Council of Turkey (TUBITAK) [113S847]	Scientific and Technological Research Council of Turkey (TUBITAK)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK))	This research was funded by The Scientific and Technological Research Council of Turkey (TUBITAK), grant number 113S847. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams LD., 2004, CURR PROTOC MOL BIOL, DOI [10.1002/0471142727.mb1004s67, DOI 10.1002/0471142727.MB1004S67]; Amer H, 2007, AM J TRANSPLANT, V7, P2748, DOI 10.1111/j.1600-6143.2007.02006.x; Arifin WN, 2017, MALAYS J MED SCI, V24, P101, DOI 10.21315/mjms2017.24.5.11; Bobulescu IA, 2005, CURR OPIN NEPHROL HY, V14, P485, DOI 10.1097/01.mnh.0000174146.52915.5d; BRETSCHNEIDER HJ, 1980, THORAC CARDIOV SURG, V28, P295, DOI 10.1055/s-2007-1022099; Chen W, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abj4906; COLLINS GM, 1969, LANCET, V2, P1219, DOI 10.1016/S0140-6736(69)90753-3; Coskun A, 2019, CURR PROTEOMICS, V16, P119, DOI 10.2174/1570164615666180905104543; Coskun A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168755; Deng SL, 2017, FREE RADICAL BIO MED, V113, P347, DOI 10.1016/j.freeradbiomed.2017.10.342; DREIKORN K, 1980, EUR UROL, V6, P221; Feng L, 2007, LIVER TRANSPLANT, V13, P1125, DOI 10.1002/lt.21208; Galano A, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12514; Galano A, 2018, MOLECULES, V23, DOI 10.3390/molecules23030530; Giwa S, 2017, NAT BIOTECHNOL, V35, P530, DOI 10.1038/nbt.3889; Guibert EE, 2011, TRANSFUS MED HEMOTH, V38, P125, DOI 10.1159/000327033; Gunal O, 2010, TURK J MED SCI, V40, P465, DOI 10.3906/sag-0811-26; Haberal M, 2019, EXP CLIN TRANSPLANT, V17, P287, DOI 10.6002/ect.bups2019; Hardeland R, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12525; Henrotin Yves, 2013, BMC Res Notes, V6, P115, DOI 10.1186/1756-0500-6-115; Ito Etsuro, 2015, Biophysics (Nagoya-shi), V11, P33, DOI 10.2142/biophysics.11.33; Jones B, 2012, B WORLD HEALTH ORGAN, V90, P718, DOI 10.2471/BLT.12.021012; Kang NR, 2009, J KOREAN MED SCI, V24, pS129, DOI 10.3346/jkms.2009.24.S1.S129; Karakoyun R, 2019, J TRANSPLANT, V2019, DOI 10.1155/2019/8150736; King TC., 2007, ELSEVIERS INTEGR PAT, P1; Kosugi T, 2012, NEPHROL DIAL TRANSPL, V27, P16, DOI 10.1093/ndt/gfr652; Lee CY, 2009, ORGANOGENESIS, V5, P105, DOI 10.4161/org.5.3.9582; Lee DH, 2017, ONCOTARGET, V8, P51096, DOI 10.18632/oncotarget.17002; Lepoittevin M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23094989; Maathuis MHJ, 2007, TRANSPLANTATION, V83, P1289, DOI 10.1097/01.tp.0000265586.66475.cc; Malek M, 2015, J RENAL INJ PREV, V4, P20, DOI 10.12861/jrip.2015.06; Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267; Muhlbacher F, 1999, TRANSPLANT P, V31, P2069, DOI 10.1016/S0041-1345(99)00265-1; Naik AS, 2019, NEPHROL DIAL TRANSPL, V34, P1232, DOI 10.1093/ndt/gfy350; Omurtag GZ, 2005, J PHARM PHARMACOL, V57, P623, DOI 10.1211/0022357055939; Patrakka J, 2009, NAT REV NEPHROL, V5, P463, DOI 10.1038/nrneph.2009.108; Rastogi S, 2021, J THERM BIOL, V98, DOI 10.1016/j.jtherbio.2021.102941; Salvadori Maurizio, 2015, World J Transplant, V5, P52, DOI 10.5500/wjt.v5.i2.52; Sato W, 2001, J IMMUNOL, V167, P3463, DOI 10.4049/jimmunol.167.6.3463; Serdar CC, 2021, BIOCHEM MEDICA, V31, DOI 10.11613/BM.2021.010502; Simon RR, 2011, DIABETES-METAB RES, V27, P14, DOI 10.1002/dmrr.1150; Spiegel HU, 2001, SPR SP SURG SER, P265; Stiegler P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113509; Tsampalieros A, 2015, TRANSPLANTATION, V99, P2049, DOI 10.1097/TP.0000000000000894; van der Hoeven J A, 1996, Transpl Int, V9 Suppl 1, pS452; van der Plaats A, 2004, TRANSPL INT, V17, P227, DOI 10.1007/s00147-004-0705-8; Voigt MR, 2013, PROG TRANSPLANT, V23, P383, DOI 10.7182/pit2013100; Webster J, 2012, METHODS MOL BIOL, V800, P227, DOI 10.1007/978-1-61779-349-3_15; Wu MY, 2018, CELL PHYSIOL BIOCHEM, V46, P1650, DOI 10.1159/000489241; Zahedipour F, 2017, BIOMED PHARMACOTHER, V95, P1051, DOI 10.1016/j.biopha.2017.08.122	50	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2022	17	8							e0273921	10.1371/journal.pone.0273921	http://dx.doi.org/10.1371/journal.pone.0273921			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R5UO	36044512	Green Published, gold			2023-01-03	WOS:000892368200080
J	Larkin, HD				Larkin, Howard D.			RNA Interference Therapy Approved for Hereditary Type of Amyloidosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2022	328	5					416	416						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3U1CS	35916861				2023-01-03	WOS:000840708300026
J	McGaghie, WC; Barsuk, JH; Wayne, DB				McGaghie, William C.; Barsuk, Jeffrey H.; Wayne, Diane B.			Point-of-Care Cardiopulmonary Resuscitation Training and Survival With Favorable Neurologic Outcome in Cardiac Arrest in Pediatric ICUs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[McGaghie, William C.; Wayne, Diane B.] Northwestern Univ, Feinberg Sch Med, Dept Med Educ, 1-200 McGaw Pavil,240 E Huron St, Chicago, IL 60611 USA; [Barsuk, Jeffrey H.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	McGaghie, WC (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med Educ, 1-200 McGaw Pavil,240 E Huron St, Chicago, IL 60611 USA.	wcmc@northwestern.edu						Cheng A, 2018, CIRCULATION, V138, pE82, DOI 10.1161/CIR.0000000000000583; Didwania Aashish, 2011, J Grad Med Educ, V3, P211, DOI 10.4300/JGME-D-10-00144.1; Ericsson KA, 2006, CAMBRIDGE HANDBOOK OF EXPERTISE AND EXPERT PERFORMANCE, P1, DOI 10.2277/ 0521600812; Sutton RM, 2022, JAMA-J AM MED ASSOC, V327, P934, DOI 10.1001/jama.2022.1738; Wayne DB, 2008, CHEST, V133, P56, DOI 10.1378/chest.07-0131	5	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2022	328	5					479	479						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3U1CS	35916851				2023-01-03	WOS:000840708300017
J	Cui, ZF; Zeng, C; Huang, FR; Yuan, FW; Yan, JY; Zhao, Y; Zhou, YF; Hankey, W; Jin, VX; Huang, JT; Staats, HF; Everitt, JI; Sempowski, GD; Wang, HY; Dong, YZ; Liu, SL; Wang, QB				Cui, Zhifen; Zeng, Cong; Huang, Furong; Yuan, Fuwen; Yan, Jingyue; Zhao, Yue; Zhou, Yufan; Hankey, William; Jin, Victor X.; Huang, Jiaoti; Staats, Herman F.; Everitt, Jeffrey, I; Sempowski, Gregory D.; Wang, Hongyan; Dong, Yizhou; Liu, Shan-Lu; Wang, Qianben			Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection	NATURE CHEMICAL BIOLOGY			English	Article							T-CELL SELECTION; CATHEPSIN-L; RNA; CORONAVIRUS; INHIBITORS; DELIVERY; CRISPR	SARS-CoV-2 entry into cells requires specific host proteases; however, no successful in vivo applications of host protease inhibitors have yet been reported for treatment of SARS-CoV-2 pathogenesis. Here we describe a chemically engineered nanosystem encapsulating CRISPR-Cas13d, developed to specifically target lung protease cathepsin L (Ctsl) messenger RNA to block SARS-CoV-2 infection in mice. We show that this nanosystem decreases lung Ctsl expression in normal mice efficiently, specifically and safely. We further show that this approach extends survival of mice lethally infected with SARS-CoV-2, correlating with decreased lung virus burden, reduced expression of proinflammatory cytokines/chemokines and diminished severity of pulmonary interstitial inflammation. Postinfection treatment by this nanosystem dramatically lowers the lung virus burden and alleviates virus-induced pathological changes. Our results indicate that targeting lung protease mRNA by Cas13d nanosystem represents a unique strategy for controlling SARS-CoV-2 infection and demonstrate that CRISPR can be used as a potential treatment for SARS-CoV-2 infection.	[Cui, Zhifen; Huang, Furong; Yuan, Fuwen; Zhao, Yue; Hankey, William; Huang, Jiaoti; Staats, Herman F.; Everitt, Jeffrey, I; Sempowski, Gregory D.; Wang, Hongyan; Wang, Qianben] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA; [Zeng, Cong; Liu, Shan-Lu] Ohio State Univ, Viruses & Emerging Pathogens Program, Infect Dis Inst, Ctr Retrovirus Res, Columbus, OH 43210 USA; [Yan, Jingyue; Dong, Yizhou] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Yan, Jingyue; Dong, Yizhou] Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmacol, 500 W 12Th Ave, Columbus, OH 43210 USA; [Yan, Jingyue; Dong, Yizhou] Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA; [Zhao, Yue] China Med Univ, Dept Pathol, Coll Basic Med Sci, Shenyang, Peoples R China; [Zhao, Yue] China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China; [Zhou, Yufan; Jin, Victor X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA; [Staats, Herman F.; Sempowski, Gregory D.] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC USA; [Staats, Herman F.; Sempowski, Gregory D.] Duke Univ, Sch Med, Reg Biocontainment Lab, Durham, NC USA	Duke University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; China Medical University; China Medical University; University of Texas System; University of Texas Health San Antonio; Duke University; Duke University	Wang, QB (corresponding author), Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.; Liu, SL (corresponding author), Ohio State Univ, Viruses & Emerging Pathogens Program, Infect Dis Inst, Ctr Retrovirus Res, Columbus, OH 43210 USA.; Dong, YZ (corresponding author), Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA.; Dong, YZ (corresponding author), Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmacol, 500 W 12Th Ave, Columbus, OH 43210 USA.; Dong, YZ (corresponding author), Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA.	dong.525@osu.edu; liu.6244@osu.edu; qianben.wang@duke.edu	Zhao, Yue/AGZ-4412-2022	Zhao, Yue/0000-0002-0110-0359; Everitt, Jeffrey/0000-0003-0273-6284; Cui, Zhifen/0000-0002-5223-930X; Sempowski, Gregory/0000-0003-0391-6594; Zeng, Cong/0000-0003-4423-3634	NIH/NIAID [UC6-AI058607, R01 AI150473]; NIH/NCI [U54 CA260582]; Department of Pathology, Duke University School of Medicine; NIH/NIGMS [R35 GM144117]	NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Pathology, Duke University School of Medicine; NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Karlsson, K. Riebe, R. Asrican and T. Oguin III from the Duke RBL for performing authentic SARS-CoV-2 infection experiments in vitro and in vivo. We thank Z. Su from the Duke BioRepository and Precision Pathology Center for performing the IHC assays. We also thank L. Wang from the Animal Histopathology and Laboratory Medicine Core at UNC-Chapel Hill for performing animal hematological and clinical chemistry tests. We thank M. Sokolsky and A. Shankar Kumbhar from Nanomedicines Characterization Core Facility and Nanopformulation Core Facility at UNC-Chapel Hill for TEM and limulus test (to determine endotoxin level in LNPs). We thank M. Wiesner (Duke) for allowing us to use his Zetasizer. The following reagents were deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281; SARS-Related Coronavirus 2, Isolate hCoV-19/USA/PHC658/2021 (Lineage B.1.617.2; Delta Variant), NR-55611, contributed by R. Webby and A. Patel. This work was supported by the Department of Pathology, Duke University School of Medicine (to Q.W.); NIH/NIAID (grant no. UC6-AI058607) (to Duke RBL); NIH/NIAID (grant no. R01 AI150473), NIH/NCI (grant no. U54 CA260582) and an anonymous private donor to The Ohio State University (to S.-L.L.) and NIH/NIGMS (grant no. R35 GM144117) (to Y.D.).	Abbott TR, 2020, CELL, V181, P865, DOI 10.1016/j.cell.2020.04.020; Arce VM, 2021, CELL MOL IMMUNOL, V18, P513, DOI 10.1038/s41423-020-00616-1; Baddeley Helen J E, 2021, Front Genome Ed, V3, P745559, DOI 10.3389/fgeed.2021.745559; Beers C, 2005, J IMMUNOL, V174, P1205, DOI 10.4049/jimmunol.174.3.1205; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bernal AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMoa2116044; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Blanchard EL, 2021, NAT BIOTECHNOL, V39, P717, DOI 10.1038/s41587-021-00822-w; Chen Z, 2018, P NATL ACAD SCI USA, V115, P6810, DOI 10.1073/pnas.1718811115; Cheng Q, 2020, NAT NANOTECHNOL, V15, P313, DOI 10.1038/s41565-020-0669-6; Chou SHY, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.12131; Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003; Cox DBT, 2017, SCIENCE, V358, P1019, DOI 10.1126/science.aaq0180; Daniloski Z, 2021, CELL, V184, P92, DOI 10.1016/j.cell.2020.10.030; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1101/2020.05.28.20115758, 10.1038/s41591-020-1051-9]; Eoh J, 2019, BIOMATER SCI-UK, V7, P1240, DOI 10.1039/c8bm01310a; Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386; Hammond J, 2022, NEW ENGL J MED, V386, P1397, DOI 10.1056/NEJMoa2118542; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Honey K, 2002, J EXP MED, V195, P1349, DOI 10.1084/jem.20011904; Konermann S, 2018, CELL, V173, P665, DOI 10.1016/j.cell.2018.02.033; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Lamb YN, 2022, DRUGS, V82, P585, DOI 10.1007/s40265-022-01692-5; Ledford H, 2021, NATURE, V599, P358, DOI 10.1038/d41586-021-03074-5; Li B, 2018, NAT PROTOC, V13, P899, DOI 10.1038/nprot.2018.004; Li B, 2016, BIOCONJUGATE CHEM, V27, P849, DOI 10.1021/acs.bioconjchem.6b00090; Liu TX, 2020, PHARMACOL THERAPEUT, V213, DOI 10.1016/j.pharmthera.2020.107587; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Meganck RM, 2021, NAT MED, V27, P401, DOI 10.1038/s41591-021-01282-0; Meng B, 2022, NATURE, V603, P706, DOI 10.1038/s41586-022-04474-x; Mlcochova P, 2021, NATURE, V599, P114, DOI 10.1038/s41586-021-03944-y; Mullard A, 2018, NAT REV DRUG DISCOV, V17, P613, DOI 10.1038/nrd.2018.152; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Oladunni FS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19891-7; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Planas D, 2022, NATURE, V602, P671, DOI 10.1038/s41586-021-04389-z; Saunders KO, 2021, NATURE, V594, P553, DOI 10.1038/s41586-021-03594-0; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; Sigoillot FD, 2012, NAT METHODS, V9, P363, DOI [10.1038/nmeth.1898, 10.1038/NMETH.1898]; Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102; Smieszek SP, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.106004; Steuten K, 2021, ACS INFECT DIS, V7, P1457, DOI 10.1021/acsinfecdis.0c00815; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; Tong S, 2019, NAT REV MATER, V4, P726, DOI 10.1038/s41578-019-0145-9; Wei J, 2021, CELL, V184, P76, DOI 10.1016/j.cell.2020.10.028; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; Yadati T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071679; Yang AC, 2021, NATURE, V595, P565, DOI 10.1038/s41586-021-03710-0; Yin H, 2016, NAT BIOTECHNOL, V34, P328, DOI 10.1038/nbt.3471; Yinda CK, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009195; Zeng C, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.143213; Zhao MM, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00558-8; Zheng J, 2021, NATURE, V589, P603, DOI 10.1038/s41586-020-2943-z; Zhou ST, 2021, J INFECT DIS, V224, P415, DOI 10.1093/infdis/jiab247; Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011	55	1	1	21	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2022	18	10					1056	+		10.1038/s41589-022-01094-4	http://dx.doi.org/10.1038/s41589-022-01094-4		JUL 2022	30	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	4W2VO	35879545	Bronze			2023-01-03	WOS:000829719000003
J	Whittall, J; Orkin, A; Handford, C; Klaiman, M; Leece, P; Charles, MJ; Wright, A; Turner, SM; Morrison, L; Strike, C; Campbell, D				Whittall, Jonathan; Orkin, Aaron; Handford, Curtis; Klaiman, Michelle; Leece, Pamela; Charles, Mercy J.; Wright, Amy; Turner, Suzanne M.; Morrison, Laurie; Strike, Carol; Campbell, Douglas			Resuscitation simulation among people who are likely to witness opioid overdose: Experiences from the SOONER Trial	PLOS ONE			English	Article							NALOXONE; CARE	The opioid crisis is a growing public health emergency and increasing resources are being directed towards overdose education. Simulation has emerged as a novel strategy for training overdose response, yet little is known about training non-clinicians in bystander resuscitation. Understanding the perspectives of individuals who are likely to experience or witness opioid overdose is critical to ensure that emergency response is effective. The Surviving Opioid Overdose with Naloxone Education and Resuscitation (SOONER) study evaluates the effectiveness of a novel naloxone education and distribution tool among people who are non-clinicians and likely to witness opioid overdose. Participants' resuscitation skills are evaluated using a realistic overdose simulation as the primary outcome of the trial. The purpose of our study is to describe the experience of participants with the simulation process in the SOONER study. We employed a semi-structured debriefing interview and a follow up qualitative interview to understand the experience of participants with simulation. A qualitative content analysis was performed using data from 21 participants who participated in the SOONER study. Our qualitative analysis identified 5 themes and 17 subthemes which described the experience of participants within the simulation process. These themes included realism, valuing practical experience, improving self-efficacy, gaining new perspective and bidirectional learning. Our analysis found that simulation was a positive and empowering experience for participants in the SOONER trial, most of whom are marginalized in society. Our study supports the notion that expanding simulation-based education to non-clinicians may offer an acceptable and effective way of supplementing current opioid overdose education strategies. Increasing the accessibility of simulation-based education may represent a paradigm shift whereby simulation is transformed from a primarily academic practice into a patient-based community resource.	[Whittall, Jonathan; Orkin, Aaron; Handford, Curtis] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Orkin, Aaron] Inner City Hlth Associates, Toronto, ON, Canada; [Orkin, Aaron] St Josephs Hlth Ctr, Dept Emergency Med, Unity Hlth Toronto, Toronto, ON, Canada; [Klaiman, Michelle] St Michaels Hosp, Dept Emergency Med, Unity Hlth, Toronto, ON, Canada; [Leece, Pamela; Wright, Amy] Publ Hlth Ontario, Toronto, ON, Canada; [Charles, Mercy J.; Campbell, Douglas] St Michaels Hosp, Li Ka Shing Knowledge Inst, Appl Hlth Res Ctr AHRC, Unity Hlth, Toronto, ON, Canada; [Wright, Amy] St Michaels Hosp, Canada SOONER Project Community Advisory Comm, Unity Hlth, Toronto, ON, Canada; [Turner, Suzanne M.] McMaster Univ, Dept Family Med, Hamilton, ON, Canada; [Morrison, Laurie] St Michaels Hosp, Li Ka Shing Knowledge Inst, Rescu, Toronto, ON, Canada; [Strike, Carol] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Campbell, Douglas] Univ Toronto, Dept Paediat, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Joseph's Health Centre, Toronto; Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster University; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto	Campbell, D (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Appl Hlth Res Ctr AHRC, Unity Hlth, Toronto, ON, Canada.; Campbell, D (corresponding author), Univ Toronto, Dept Paediat, Toronto, ON, Canada.	Douglas.Campbell@unityhealth.to	Orkin, Aaron/K-2500-2014	Orkin, Aaron/0000-0002-1111-8720				Abelsson A, 2018, AUSTRALAS J PARAMEDI, V15, P594; Adamson K, 2015, NURS EDUC PERSPECT, V36, P281, DOI 10.5480/15-1655; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Canadian Institute for Health Information (CA), 2018, OP REL HARMS CAN; Edwards F., PREVENTATIVE MED REP, V20; Eppich W, 2015, SIMUL HEALTHC, V10, P106, DOI 10.1097/SIH.0000000000000072; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Fernandez-Mendez F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9837508; Franko TS, 2019, J AM PHARM ASSOC, V59, P375, DOI 10.1016/j.japh.2018.12.022; Friedrich MJ, 2002, JAMA-J AM MED ASSOC, V288, P2808, DOI 10.1001/jama.288.22.2808; Gaba D. M., 2001, Simulation & Gaming, V32, P175, DOI 10.1177/104687810103200206; Goldberg SA, 2018, PREHOSP EMERG CARE, V22, P788, DOI 10.1080/10903127.2018.1461284; Goldshtein D, 2020, BMJ SIMUL TECHNOL EN, V6, P3, DOI 10.1136/bmjstel-2018-000387; Kneebone Roger L, 2016, Adv Simul (Lond), V1, P27, DOI 10.1186/s41077-016-0028-8; Kobayashi L, 2017, SIMUL HEALTHC, V12, P22, DOI 10.1097/SIH.0000000000000182; Kreek MJ, 2011, ANN NY ACAD SCI, V1231, P65, DOI 10.1111/j.1749-6632.2011.06152.x; Massoth C, 2019, BMC MED EDUC, V19, DOI 10.1186/s12909-019-1464-7; Nimbalkar Archana, 2015, BMC Res Notes, V8, P636, DOI 10.1186/s13104-015-1623-9; Orkin A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029436; Orkin AM, 2021, RESUSC PLUS, V6, DOI 10.1016/j.resplu.2021.100131; Ornato JP, 2020, AM J EMERG MED, V38, P1787, DOI 10.1016/j.ajem.2020.05.103; Petrosoniak Andrew, 2018, Adv Simul (Lond), V3, P8, DOI 10.1186/s41077-018-0067-4; Petrosoniak A, 2017, EMERG MED AUSTRALAS, V29, P83, DOI 10.1111/1742-6723.12705; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Sahu Sandeep, 2010, J Emerg Trauma Shock, V3, P378, DOI 10.4103/0974-2700.70758; Schneider KE, 2021, INT J DRUG POLICY, V92, DOI 10.1016/j.drugpo.2020.102859; Smink DS, 2017, JAMA SURG, V152, P825, DOI 10.1001/jamasurg.2017.1086; Wakeman SE, 2017, J GEN INTERN MED, V32, P17, DOI 10.1007/s11606-016-3799-7; Wen LS, 2020, LANCET, V396, P1316, DOI 10.1016/S0140-6736(20)32113-9; Wenger E., 1998, SYSTEMS THINKER, V9, P2	30	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	7								10.1371/journal.pone.0270829	http://dx.doi.org/10.1371/journal.pone.0270829			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M5FN	35789220	gold, Green Published			2023-01-03	WOS:000835487000013
J	Huang, YT; Jiang, MY; Hwang, JC				Huang, Yun-Ting; Jiang, Ming-Yan; Hwang, Jyh-Chang			Albumin to prealbumin ratio in peritoneal dialysis patients: Clinical implication and outcome prediction	PLOS ONE			English	Article							NUTRITIONAL-STATUS; SERUM PREALBUMIN; HEMODIALYSIS; MORTALITY; PROTEIN; INFLAMMATION; HYPOKALEMIA; SURVIVAL; MASS	Background Serum prealbumin level is slightly higher, whereas albumin is lower in peritoneal dialysis (PD) than hemodialysis (HD) patients. It is unknown whether albumin to prealbumin ratio (APR) is associated with mortality risk among PD patients. This study aimed to evaluate the clinical implications of APR and its prediction value on long-term outcomes of PD patients. Methods The study population were prevalent PD patients at a tertiary hospital. Based on APR, a total of 220 PD patients were divided into 3 groups: group 1: top tertile, median APR: 121.1; IQR:109.5-131.9 (n = 73, male: 37%; age: 5913); group 2: middle tertile, median APR: 97.1; IQR 93.5-100.0 (n = 73, male:37%; age: 5414), and group3: bottom tertile, median APR: 81.3; IQR:76.8-85.0 (n = 74, male:38%; 54 +/- 11). Patients were followed up for a maximum of 5 years. Outcome of interest was all-cause mortality. Results Group 1 was characterized by older age, higher prevalence of diabetes, lower nPCR, higher Davies score and hs-CRP level. APR positively correlated to hs-CRP (beta = 0.149, p = 0.045), but negatively correlated to nPCR (beta = -0.161, p = 0.034). Hyperprealbuminemia, accounting for 0%, 23.3%, and 82.4% in groups 1,2, and 3, was associated with a lower risk for mortality (HR:0.41, 95%CI = 0.23-0.73). The cumulative survival is significantly lower in group 1 than the other two groups. By multivariable Cox regression, APR (HR:1.02; 95%CI:1.01-1.03) was found to be an independent predictor of long-term mortality. Conclusion PD patients with high APR are characterized by having more comorbidities and marked malnutrition-inflammation status, and are associated with long-term mortality, whereas hyperprealbuminemia and lower APR are favorable prognostic factors.	[Huang, Yun-Ting; Jiang, Ming-Yan; Hwang, Jyh-Chang] Chi Mei Med Ctr, Div Nephrol, Tainan, Taiwan; [Jiang, Ming-Yan] Chia Nan Univ Pharm & Sci, Dept Pharm, Tainan, Taiwan	Chi Mei Hospital; Chia Nan University of Pharmacy & Science	Hwang, JC (corresponding author), Chi Mei Med Ctr, Div Nephrol, Tainan, Taiwan.	alfonjch@gmail.com		Jiang, Ming-Yan/0000-0002-9817-3131				Baxmann AC, 2008, CLIN J AM SOC NEPHRO, V3, P348, DOI 10.2215/CJN.02870707; Beck FK, 2002, AM FAM PHYSICIAN, V65, P1575; Cano NJM, 2002, CLIN CHEM LAB MED, V40, P1313, DOI 10.1515/CCLM.2002.226; Chertow GM, 2005, KIDNEY INT, V68, P2794, DOI 10.1111/j.1523-1755.2005.00751.x; Cueto-Manzano AM, 2000, KIDNEY INT, V57, P314, DOI 10.1046/j.1523-1755.2000.00817.x; Davies SJ, 2002, NEPHROL DIAL TRANSPL, V17, P1085, DOI 10.1093/ndt/17.6.1085; Davis CJ, 2012, JPEN-PARENTER ENTER, V36, P197, DOI 10.1177/0148607111413896; Don BR, 2004, SEMIN DIALYSIS, V17, P432, DOI 10.1111/j.0894-0959.2004.17603.x; Fein PA, 2003, KIDNEY INT, V64, pS87, DOI 10.1046/j.1523-1755.64.s87.13.x; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Goldwasser P, 2002, KIDNEY INT, V62, P276, DOI 10.1046/j.1523-1755.2002.00415.x; Hao N, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1433-8; Heimburger O, 2000, AM J KIDNEY DIS, V36, P1213, DOI 10.1053/ajkd.2000.19837; Hwang JC, 2011, BLOOD PURIFICAT, V32, P254, DOI 10.1159/000325226; Ikizler TA, 2013, KIDNEY INT, V84, P1096, DOI 10.1038/ki.2013.147; Keshaviah P R, 1991, ASAIO Trans, V37, pM400; Kopple JD, 2000, KIDNEY INT, V57, P1688, DOI 10.1046/j.1523-1755.2000.00014.x; Lee KH, 2016, KIDNEY RES CLIN PRAC, V35, P169, DOI 10.1016/j.krcp.2016.06.002; Maraj M, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010069; Mehrotra R, 2011, AM J KIDNEY DIS, V58, P418, DOI 10.1053/j.ajkd.2011.03.018; Rambod M, 2008, AM J CLIN NUTR, V88, P1485, DOI 10.3945/ajcn.2008.25906; Shinaberger CS, 2006, AM J KIDNEY DIS, V48, P37, DOI 10.1053/j.ajkd.2006.03.049; Steiber A, 2007, J RENAL NUTR, V17, P336, DOI 10.1053/j.jrn.2007.05.004; Szeto CC, 2005, AM J KIDNEY DIS, V46, P128, DOI 10.1053/j.ajkd.2005.03.015	24	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2022	17	11							e0276159	10.1371/journal.pone.0276159	http://dx.doi.org/10.1371/journal.pone.0276159			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6U0HY	36346823	Green Published, gold			2023-01-03	WOS:000894053200007
J	Kong, FT; Lu, MT; Dong, J; Wang, DH; Shi, JY; Li, ZH				Kong, Fantu; Lu, Meiting; Dong, Jie; Wang, Donghui; Shi, Junyue; Li, Zhenghuan			Effect of linear accelerator carbon fiber couch on radiotherapy dose	PLOS ONE			English	Article							REGION; TOP	This study aimed to explore the effect of carbon fiber couch on radiotherapy dose attenuation and gamma pass rate in intensity-modulated radiotherapy (IMRT) plans. A phantom inserted with an ionization chamber was placed at different positions of the couch, and the dose was measured by the chamber. Under the same positioning, the phantom dose was calculated using the real and virtual couch images, and the difference in the planned dose of radiotherapy was compared. Ten clinical IMRT plans were selected as dose verification data, and the gamma pass rates were compared between couch addition and non-addition conditions. When the radiation field was near 110 degrees and 250 degrees, the measured value attenuation coefficient of the ionization chamber at the joint of the couch was up to 34%; the attenuation coefficient of the treatment couch from the actual couch image calculated using the treatment planning system (TPS) was up to 33%; the attenuation coefficient of the virtual couch calculated using the TPS was up to 4.0%. The gamma pass rate of the dose verification near gantry angles 110 degrees and 250 degrees was low, and that of the joint could be lower than 85% under the condition of 3%/3 mm. The gamma pass rates of the radiation field passing through the couch were all affected. The dose was affected by the radiation field passing through the couch, with the largest effect when passing through the joint part of the treatment couch, followed by that of the main couch plate and extension plate. When the irradiation field passed through the joint and near 110 degrees and 250 degrees of the main couch, the dose difference was large, making it unsuitable for treatment.	[Kong, Fantu; Lu, Meiting; Dong, Jie; Wang, Donghui; Li, Zhenghuan] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China; [Shi, Junyue] Foresea Life Insurance Guangzhou Gen Hosp, Guangzhou, Peoples R China; [Shi, Junyue] China Inst Atom Energy, Beijing, Peoples R China	Sun Yat Sen University; China Institute of Atomic Energy	Li, ZH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China.; Shi, JY (corresponding author), Foresea Life Insurance Guangzhou Gen Hosp, Guangzhou, Peoples R China.; Shi, JY (corresponding author), China Inst Atom Energy, Beijing, Peoples R China.	shijunyue@aliyun.com; huanliz2819@163.com		Kong, Fantu/0000-0003-3649-6194	Postdoctoral research foundation of china [2019M6632]	Postdoctoral research foundation of china(China Postdoctoral Science Foundation)	Postdoctoral research foundation of china, Award Number: No.2019M6632, Recipient: Donghui Wang.	[Anonymous], 2013, RAD ONCOLOGY ACCESSO, P27; [曹婷婷 Cao Tingting], 2018, [中国医学物理学杂志, Chinese Journal of Medical Physics], V35, P14; Dingyu L., 2016, RADIOL PRACT, V31, P662; Feiyue S., 2016, CHINA MED DEVICES, V31, P108, DOI [10.3760/cma.j.issn.1004-4221.2016.06.016, DOI 10.3760/CMA.J.ISSN.1004-4221.2016.06.016]; Fraass B, 1998, MED PHYS, V25, P1773, DOI 10.1118/1.598373; Hongbo G., 2018, CHIN J CANC PREV TRE, V25, P1376, DOI [10.16073/j.cnki.cjcpt, DOI 10.16073/J.CNKI.CJCPT]; International commission on radiation units and measurements, 1976, 24 ICRU; Liangying W., 2017, CHIN J MED DEV, V23, P1; Njeh CF, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-190; Olch AJ, 2014, MED PHYS, V41, DOI 10.1118/1.4876299; Pulliam KB, 2011, PHYS MED BIOL, V56, P7435, DOI 10.1088/0031-9155/56/23/007; Sheykhoo A, 2017, REP PRACT ONCOL RADI, V22, P19, DOI 10.1016/j.rpor.2016.09.001; [时颖华 Shi Yinghua], 2019, [中国医学物理学杂志, Chinese Journal of Medical Physics], V36, P867; Shuting C., 2018, CHIN J MED DEV, V31, P41; Smith DW, 2010, MED PHYS, V37, P3595, DOI 10.1118/1.3451114; [宋洪兵 Song Hongbing], 2021, [中国医学物理学杂志, Chinese Journal of Medical Physics], V38, P157; Tugrul T, 2018, REP PRACT ONCOL RADI, V23, P1, DOI 10.1016/j.rpor.2017.10.004; [尹朝晟 Yin Zhaosheng], 2016, [中国医学物理学杂志, Chinese Journal of Medical Physics], V33, P770; [张若辉 Zhang Ruohui], 2016, [中华放射肿瘤学杂志, Chinese Journal of Radiation Oncology], V25, P618	19	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2022	17	11							e0277332	10.1371/journal.pone.0277332	http://dx.doi.org/10.1371/journal.pone.0277332			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6U0HY	36346802	Green Published, gold			2023-01-03	WOS:000894053200021
J	Lamkin, M				Lamkin, Matt			The Supreme Court Decision on Federal Prescribing Rules for Controlled Substances	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint explains how a recent Supreme Court decision clarifies rules for prescribing controlled substances so that patients are not denied appropriate care and physicians are not unjustly prosecuted.	[Lamkin, Matt] Univ Tulsa, Coll Law, Tulsa, OK 74104 USA	University of Tulsa	Lamkin, M (corresponding author), Univ Tulsa, Coll Law, Tulsa, OK 74104 USA.	matt-lamkin@utulsa.edu						[Anonymous], 2022, RUAN US 597US; [Anonymous], 2006, GONZALES OREGON 546U; DeMio T., 2019, CINCINNATI ENQUIRER; Drug Enforcement Administration, 21 CFR 130604 A; Sedney CL, 2022, SUBST ABUSE TREAT PR, V17, DOI 10.1186/s13011-022-00447-5; United States Department of Justice, ATT GEN SESS ANN NEW; US Food and Drug Administration, FDA ID HARM REP SUDD; Yenerall J, 2020, DRUG ALCOHOL DEPEN, V206, DOI 10.1016/j.drugalcdep.2019.107591	8	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	2022	328	15					1499	1500		10.1001/jama.2022.18308	http://dx.doi.org/10.1001/jama.2022.18308		OCT 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5M9EQ	36190715				2023-01-03	WOS:000864837100001
J	Arabi, YM; Aldekhyl, S; Al Qahtani, S; Al-Dorzi, HM; Abdukahil, SA; Al Harbi, MK; Al Qasim, E; Kharaba, A; Albrahim, T; Alshahrani, MS; Al-Fares, AA; Al Bshabshe, A; Mady, A; Al Duhailib, Z; Algethamy, H; Jose, J; Al Mutairi, M; Al Zumai, O; Al Haji, H; Alaqeily, A; Al Aseri, Z; Al-Omari, A; Al-Dawood, A; Tlayjeh, H				Arabi, Yaseen M.; Aldekhyl, Sara; Al Qahtani, Saad; Al-Dorzi, Hasan M.; Abdukahil, Sheryl Ann; Al Harbi, Mohammed Khulaif; Al Qasim, Eman; Kharaba, Ayman; Albrahim, Talal; Alshahrani, Mohammed S.; Al-Fares, Abdulrahman A.; Al Bshabshe, Ali; Mady, Ahmed; Al Duhailib, Zainab; Algethamy, Haifa; Jose, Jesna; Al Mutairi, Mohammed; Al Zumai, Omar; Al Haji, Hussain; Alaqeily, Ahmed; Al Aseri, Zohair; Al-Omari, Awad; Al-Dawood, Abdulaziz; Tlayjeh, Haytham		Saudi Critical Care Trials Grp	Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19 The HELMET-COVID Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTCOMES	IMPORTANCE Helmet noninvasive ventilation has been used in patients with COVID-19 with the premise that helmet interface is more effective than mask interface in delivering prolonged treatments with high positive airway pressure, but data about its effectiveness are limited. OBJECTIVE To evaluate whether helmet noninvasive ventilation compared with usual respiratory support reduces mortality in patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia. DESIGN, SETTING, AND PARTICIPANTS Thiswas a multicenter, pragmatic, randomized clinical trial that was conducted in 8 sites in Saudi Arabia and Kuwait between February 8, 2021, and November 16, 2021. Adult patients with acute hypoxemic respiratory failure (n = 320) due to suspected or confirmed COVID-19 were included. The final follow-up date for the primary outcome was December 14, 2021. INTERVENTIONS Patients were randomized to receive helmet noninvasive ventilation (n = 159) or usual respiratory support (n = 161), which included mask noninvasive ventilation, high-flow nasal oxygen, and standard oxygen. MAIN OUTCOMES AND MEASURES The primary outcomewas 28-day all-cause mortality. There were 12 prespecified secondary outcomes, including endotracheal intubation, barotrauma, skin pressure injury, and serious adverse events. RESULTS Among 322 patients who were randomized, 320 were included in the primary analysis, all of whom completed the trial. Median age was 58 years, and 187 were men (58.4%). Within 28 days, 43 of 159 patients (27.0%) died in the helmet noninvasive ventilation group compared with 42 of 161 (26.1%) in the usual respiratory support group (risk difference, 1.0%[95% CI, -8.7% to 10.6%]; relative risk, 1.04 [95% CI, 0.72-1.49]; P =.85). Within 28 days, 75 of 159 patients (47.2%) required endotracheal intubation in the helmet noninvasive ventilation group compared with 81 of 161 (50.3%) in the usual respiratory support group (risk difference, -3.1% [95% CI, -14.1% to 7.8%]; relative risk, 0.94 [95% CI, 0.75-1.17]). There were no significant differences between the 2 groups in any of the prespecified secondary end points. Barotrauma occurred in 30 of 159 patients (18.9%) in the helmet noninvasive ventilation group and 25 of 161 (15.5%) in the usual respiratory support group. Skin pressure injury occurred in 5 of 159 patients (3.1%) in the helmet noninvasive ventilation group and 10 of 161 (6.2%) in the usual respiratory support group. There were 2 serious adverse events in the helmet noninvasive ventilation group and 1 in the usual respiratory support group. CONCLUSIONS AND RELEVANCE Results of this study suggest that helmet noninvasive ventilation did not significantly reduce 28-day mortality compared with usual respiratory support among patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia. However, interpretation of the findings is limited by imprecision in the effect estimate, which does not exclude potentially clinically important benefit or harm.	[Arabi, Yaseen M.; Aldekhyl, Sara; Al Qahtani, Saad; Al-Dorzi, Hasan M.; Abdukahil, Sheryl Ann; Al Qasim, Eman; Jose, Jesna; Al-Dawood, Abdulaziz; Tlayjeh, Haytham] Minist Natl Guard Hlth Affairs, Dept Intens Care, Riyadh, Saudi Arabia; [Arabi, Yaseen M.; Aldekhyl, Sara; Al Qahtani, Saad; Al-Dorzi, Hasan M.; Abdukahil, Sheryl Ann; Al Harbi, Mohammed Khulaif; Al Qasim, Eman; Al Mutairi, Mohammed; Al Zumai, Omar; Al Haji, Hussain; Alaqeily, Ahmed; Al-Dawood, Abdulaziz; Tlayjeh, Haytham] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia; [Arabi, Yaseen M.; Aldekhyl, Sara; Al Qahtani, Saad; Al-Dorzi, Hasan M.; Abdukahil, Sheryl Ann; Al Harbi, Mohammed Khulaif; Al Qasim, Eman; Jose, Jesna; Al Mutairi, Mohammed; Al Zumai, Omar; Al Haji, Hussain; Alaqeily, Ahmed; Al-Dawood, Abdulaziz; Tlayjeh, Haytham] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia; [Al Harbi, Mohammed Khulaif] Minist Natl Guard Hlth Affairs, Dept Anesthesia, Riyadh, Saudi Arabia; [Kharaba, Ayman] King Fahad Hosp, Dept Pulm, Madinah, Saudi Arabia; [Kharaba, Ayman] King Fahad Hosp, Crit Care Dept, Madinah, Saudi Arabia; [Albrahim, Talal] Imam Abdulrahman Bin Faisal Univ, King Fahad Hosp Univ, Dept Crit Care, Al Khobar, Saudi Arabia; [Alshahrani, Mohammed S.] Imam Abdulrahman Bin Faisal Univ, King Fahad Hosp Univ, Dept Emergency & Crit Care, Al Khobar, Saudi Arabia; [Al-Fares, Abdulrahman A.] Al Amiri Hosp, Minist Hlth, Dept Anesthesia Crit Care Med & Pain Med, Kuwait, Kuwait; [Al Bshabshe, Ali] King Khalid Univ, Aseer Cent Hosp, Dept Crit Care Med, Abha, Saudi Arabia; [Mady, Ahmed] King Saud Med City, Dept Intens Care, Riyadh, Saudi Arabia; [Mady, Ahmed] Tanta Univ, Coll Med, Tanta, Egypt; [Al Duhailib, Zainab] King Faisal Specialist Hosp & Res Ctr, Adult Crit Care Med Dept, Riyadh, Saudi Arabia; [Algethamy, Haifa] King Abdulaziz Univ, King Abdulaziz Univ Hosp, Dept Anesthesia & Crit Care, Jeddah, Saudi Arabia; [Jose, Jesna] King Abdullah Int Med Res Ctr, Dept Bioinformat & Biostat, Riyadh, Saudi Arabia; [Al Mutairi, Mohammed; Al Zumai, Omar; Al Haji, Hussain; Alaqeily, Ahmed] Minist Natl Guard Hlth Affairs, Resp Serv Dept, Riyadh, Saudi Arabia; [Al Aseri, Zohair] King Saud Univ, Coll Med, Emergency Dept, Riyadh, Saudi Arabia; [Al Aseri, Zohair] King Saud Univ, Coll Med, Dept Intens Care, Riyadh, Saudi Arabia; [Al-Omari, Awad] Alfaisal Univ, Crit Care & Infect Dis Dept, Dr Sulaiman Al Habib Med Grp, Riyadh, Saudi Arabia; [Al-Omari, Awad] Alfaisal Univ, Infect Control Dept, Dr Sulaiman Al Habib Med Grp, Riyadh, Saudi Arabia	King Saud Bin Abdulaziz University for Health Sciences; Ministry of National Guard - Health Affairs; King Saud Bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center (KAIMRC); King Saud Bin Abdulaziz University for Health Sciences; King Saud Bin Abdulaziz University for Health Sciences; Ministry of National Guard - Health Affairs; Imam Abdulrahman Bin Faisal University; Imam Abdulrahman Bin Faisal University; Amiri Hospital; Assir Central Hospital; King Khalid University; King Saud Medical City; Egyptian Knowledge Bank (EKB); Tanta University; King Faisal Specialist Hospital & Research Center; King Abdulaziz University; King Abdulaziz University Hospital - Jeddah; King Saud University; King Abdulaziz University Hospital - Riyadh; King Saud Bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center (KAIMRC); King Saud Bin Abdulaziz University for Health Sciences; Ministry of National Guard - Health Affairs; King Saud University; King Saud University; Alfaisal University; Alfaisal University	Arabi, YM (corresponding author), King Saud Bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, Dept Intens Care, Coll Med,Minist Natl Guard Hlth Affairs, ICU 1425,POB 22490, Riyadh 11426, Saudi Arabia.	yaseenarabi@yahoo.com	al bshabshe, ali/CAI-2698-2022; Al Aseri, Zohair/A-6098-2018	al bshabshe, ali/0000-0003-0974-7226; Al Aseri, Zohair/0000-0001-9869-7544; Al-Dorzi, Hasan M/0000-0002-3772-8949	King Abdullah International Medical Research Center, Riyadh, Saudi Arabia [RC20/306R]	King Abdullah International Medical Research Center, Riyadh, Saudi Arabia	The trial was funded by King Abdullah International Medical Research Center (grant RC20/306R), Riyadh, Saudi Arabia.	Arabi Y, 2022, TRIALS, V23, DOI 10.1186/s13063-021-05988-x; Arabi YM, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-052169; Avari H, 2021, AM J RESP CRIT CARE, V203, P1112, DOI 10.1164/rccm.202008-3070OC; Bellani G, 2021, ANN AM THORAC SOC, V18, P1020, DOI 10.1513/AnnalsATS.202008-1080OC; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Benjamini Y., 1995, J R STAT SOC, V57, P289; Chaudhuri D, 2022, EUR RESPIR J, V59, DOI 10.1183/13993003.01269-2021; Reyes LF, 2022, ERJ OPEN RES, V8, DOI 10.1183/23120541.00552-2021; Ferreyro BL, 2020, JAMA-J AM MED ASSOC, V324, P57, DOI 10.1001/jama.2020.9524; Grieco DL, 2021, INTENS CARE MED, V47, P851, DOI 10.1007/s00134-021-06459-2; Grieco DL, 2021, JAMA-J AM MED ASSOC, V325, P1731, DOI 10.1001/jama.2021.4682; Grieco DL, 2020, AM J RESP CRIT CARE, V201, P303, DOI 10.1164/rccm.201904-0841OC; Hasan SS, 2020, EXPERT REV RESP MED, V14, P1149, DOI 10.1080/17476348.2020.1804365; Nava S, 2009, CRIT CARE MED, V37, P2111, DOI 10.1097/CCM.0b013e3181a5e6b5; Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338; Perkins GD, 2022, JAMA-J AM MED ASSOC, V327, P546, DOI 10.1001/jama.2022.0028; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Schmidt M, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03784-2; Serafim RB, 2021, CLIN MICROBIOL INFEC, V27, P47, DOI 10.1016/j.cmi.2020.10.017; U.S. Food & Drug Administration, 2020, COR COVID 19 UPD DAI; UteMuti-Schuenemann GE, 2022, ANN INTERN MED, V175, pW6, DOI 10.7326/L21-0424; Vargas F, 2009, CRIT CARE MED, V37, P1921, DOI 10.1097/CCM.0b013e31819fff93; Winck JC, 2021, PULMONOLOGY, V27, P305, DOI 10.1016/j.pulmoe.2020.12.005	23	2	2	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2022	328	11					1063	1072		10.1001/jama.2022.15599	http://dx.doi.org/10.1001/jama.2022.15599			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5A5DY	36125473				2023-01-03	WOS:000862909200020
J	Castellino, SM; Pei, QL; Parsons, SK; Hodgson, D; McCarten, K; Horton, T; Cho, SV; Wu, Y; Punnett, A; Dave, H; Henderson, TO; Hoppe, BS; Charpentier, AM; Keller, FG; Kelly, KM				Castellino, Sharon M. M.; Pei, Qinglin; Parsons, Susan K. K.; Hodgson, David; McCarten, Kathleen; Horton, Terzah; Cho, Steve; Wu, Yue; Punnett, Angela; Dave, Hema; Henderson, Tara O. O.; Hoppe, Bradford S. S.; Charpentier, Anne-Marie; Keller, Frank G. G.; Kelly, Kara M. M.			Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-LABEL; STAGE-III; CHILDREN; ADOLESCENTS; SCAN	Background In adults with advanced-stage Hodgkin's lymphoma, the CD30-directed antibody-drug conjugate brentuximab vedotin combined with multiagent chemotherapy has been shown to have greater efficacy, but also more toxic effects, than chemotherapy alone. The efficacy of this targeted therapy approach in children and adolescents with Hodgkin's lymphoma is unclear. Methods We conducted an open-label, multicenter, randomized, phase 3 trial involving patients 2 to 21 years of age with previously untreated Hodgkin's lymphoma of stage IIB with bulk tumor or stage IIIB, IVA, or IVB. Patients were assigned to receive five 21-day cycles of brentuximab vedotin with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (brentuximab vedotin group) or the standard pediatric regimen of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (standard-care group). Slow-responding lesions, defined by a score of 4 or 5 (on a 5-point scale, with scores of 1 to 3 indicating rapid-responding lesions), were identified on centrally reviewed positron-emission tomography-computed tomography after two cycles. Involved-site radiation therapy was administered after the fifth cycle of therapy to slow-responding lesions and to large mediastinal adenopathy that was present at diagnosis. The primary end point was event-free survival, defined as the time until disease progression occurred, relapse occurred, a second malignant neoplasm developed, or the patient died. Safety and overall survival were assessed. Results Of 600 patients who were enrolled across 153 institutions, 587 were eligible. At a median follow-up of 42.1 months (range, 0.1 to 80.9), the 3-year event-free survival was 92.1% (95% confidence interval [CI], 88.4 to 94.7) in the brentuximab vedotin group, as compared with 82.5% (95% CI, 77.4 to 86.5) in the standard-care group (hazard ratio for event or death, 0.41; 95% CI, 0.25 to 0.67; P < 0.001). The percentage of patients who received involved-site radiation therapy did not differ substantially between the brentuximab vedotin group and the standard-care group (53.4% and 56.8%, respectively). Toxic effects were similar in the two groups. Overall survival at 3 years was 99.3% (95% CI, 97.3 to 99.8) in the brentuximab vedotin group and 98.5% (95% CI, 96.0 to 99.4) in the standard-care group. Conclusions The addition of brentuximab vedotin to standard chemotherapy resulted in superior efficacy, with a 59% lower risk of an event or death, and no increase in the incidence of toxic effects at 3 years.	[Castellino, Sharon M. M.] Emory Univ, Sch Med, Dept Pediat, 2015 Uppergate Dr,ECC436, Atlanta, GA 30322 USA; [Castellino, Sharon M. M.; Keller, Frank G. G.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Castellino, Sharon M. M.; Keller, Frank G. G.] Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA; [Pei, Qinglin; Wu, Yue] Univ Florida, Stat & Data Ctr, Dept Biostat, Childrens Oncol Grp, Gainesville, FL USA; [Hoppe, Bradford S. S.] Mayo Clin Florida, Dept Radiat Oncol, Jacksonville, FL USA; [Parsons, Susan K. K.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA; [Parsons, Susan K. K.] Tufts Med Ctr, Tufts Canc Ctr, Boston, MA USA; [Hodgson, David] Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada; [Hodgson, David; Punnett, Angela] Univ Toronto, Toronto, ON, Canada; [Punnett, Angela] Hosp Sick Children, Div Hematol Oncol, Toronto, ON, Canada; [Charpentier, Anne-Marie] CHU Montreal, Dept Radiat Oncol, Montreal, PQ, Canada; [McCarten, Kathleen] Imaging & Radiat Oncol Core Rhode Isl, Imaging & Radiat Oncol Core Rhode Isl, Lincoln, RI USA; [Horton, Terzah] Baylor Coll Med, Texas Childrens Hosp, Dept Pediat, Houston, TX USA; [Cho, Steve] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI USA; [Dave, Hema] Childrens Natl Hosp, Dept Pediat, Washington, DC USA; [Dave, Hema] George Washington Sch Med & Hlth Sci, Washington, DC USA; [Henderson, Tara O. O.] Univ Chicago, Comer Childrens Hosp, Pritzker Sch Med, Dept Pediat, Chicago, IL USA; [Kelly, Kara M. M.] SUNY Buffalo, Roswell Park Comprehens Canc Ctr, Jacobs Sch Med & Biomed Sci, Dept Pediat, Buffalo, NY USA	Emory University; Emory University; Children's Healthcare of Atlanta (CHOA); Children's Oncology Group (COG); State University System of Florida; University of Florida; Mayo Clinic; Tufts Medical Center; Tufts Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Universite de Montreal; Baylor College of Medicine; University of Wisconsin System; University of Wisconsin Madison; Children's National Health System; George Washington University; University of Chicago; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Castellino, SM (corresponding author), Emory Univ, Sch Med, Dept Pediat, 2015 Uppergate Dr,ECC436, Atlanta, GA 30322 USA.	sharon.castellino@choa.org		Castellino, Sharon/0000-0001-8367-2002	National Institutes of Health [U10CA098543, U10CA180899, U10CA180886]; Quality Assurance Review Center [U10CA29511]; Imaging and Radiology Oncology Core Rhode Island [U24CA180803]; Leukemia and Lymphoma Society; St. Baldrick's Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Quality Assurance Review Center; Imaging and Radiology Oncology Core Rhode Island; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); St. Baldrick's Foundation	Supported in part by grants from the National Institutes of Health (U10CA098543, U10CA180899, and U10CA180886; all to the Children's Oncology Group), the Quality Assurance Review Center (U10CA29511), Imaging and Radiology Oncology Core Rhode Island (U24CA180803), the Leukemia and Lymphoma Society (to Drs. Parsons and Henderson), and St. Baldrick's Foundation (to the Children's Oncology Group). Support for editing of an earlier version of the manuscript was provided by the Children's Healthcare of Atlanta and Emory University Pediatric Grant Editing and Manuscript Support Core	Castellino SM, 2019, BRIT J HAEMATOL, V187, P573, DOI 10.1111/bjh.16197; Castellino SM, 2011, BLOOD, V117, P1806, DOI 10.1182/blood-2010-04-278796; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Cole PD, 2018, LANCET ONCOL, V19, P1229, DOI 10.1016/S1470-2045(18)30426-1; Connors JM, 2018, NEW ENGL J MED, V378, P331, DOI 10.1056/NEJMoa1708984; Flerlage JE, 2021, J NATL COMPR CANC NE, V19, P733, DOI 10.6004/jnccn.2021.0027; Flerlage JE, 2016, CANCER CHEMOTH PHARM, V78, P1217, DOI 10.1007/s00280-016-3180-x; Friedman DL, 2014, J CLIN ONCOL, V32, P3651, DOI 10.1200/JCO.2013.52.5410; Johnson P, 2016, NEW ENGL J MED, V374, P2419, DOI 10.1056/NEJMoa1510093; Kahn JM, 2022, LANCET HAEMATOL, V9, pE49, DOI 10.1016/S2352-3026(21)00349-5; Kelly KM, 2019, BRIT J HAEMATOL, V187, P39, DOI 10.1111/bjh.16014; Kelly KM, 2013, PEDIATR BLOOD CANCER, V60, P972, DOI 10.1002/pbc.24423; Mauz-Korholz C, 2022, LANCET ONCOL, V23, P125, DOI 10.1016/S1470-2045(21)00470-8; Meignan M, 2009, LEUKEMIA LYMPHOMA, V50, P1257, DOI 10.1080/10428190903040048; Metzger ML, 2021, J CLIN ONCOL, V39, P2276, DOI 10.1200/JCO.20.03286; National Cancer Institute, 2019, CANC STAT FACTS HODG; Oeffinger KC, 2021, J CLIN ONCOL, V39, P2266, DOI 10.1200/JCO.20.01186; Renfro Lindsay A, 2019, JCO Precis Oncol, V3, DOI 10.1200/PO.19.00060; Smith EML, 2013, CANCER NURS, V36, pE49, DOI 10.1097/NCC.0b013e318299ad23; Straus DJ, 2021, LANCET HAEMATOL, V8, pE410, DOI 10.1016/S2352-3026(21)00102-2	20	2	2	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2022	387	18					1649	1660		10.1056/NEJMoa2206660	http://dx.doi.org/10.1056/NEJMoa2206660			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6A4CQ	36322844				2023-01-03	WOS:000880604900008
J	Naggie, S; Boulware, DR; Lindsell, CJ; Stewart, TG; Gentile, N; Collins, S; McCarthy, MW; Jayaweera, D; Castro, M; Sulkowski, M; McTigue, K; Thicklin, F; Felker, GM; Ginde, AA; Bramante, CT; Slandzicki, AJ; Gabriel, A; Shah, NS; Lenert, LA; Dunsmore, SE; Adam, SJ; DeLong, A; Hanna, G; Remaly, A; Wilder, R; Wilson, S; Shenkman, E; Hernandez, AF				Naggie, Susanna; Boulware, David R.; Lindsell, Christopher J.; Stewart, Thomas G.; Gentile, Nina; Collins, Sean; McCarthy, Matthew William; Jayaweera, Dushyantha; Castro, Mario; Sulkowski, Mark; McTigue, Kathleen; Thicklin, Florence; Felker, G. Michael; Ginde, Adit A.; Bramante, Carolyn T.; Slandzicki, Alex J.; Gabriel, Ahab; Shah, Nirav S.; Lenert, Leslie A.; Dunsmore, Sarah E.; Adam, Stacey J.; DeLong, Allison; Hanna, George; Remaly, April; Wilder, Rhonda; Wilson, Sybil; Shenkman, Elizabeth; Hernandez, Adrian F.		Accelerating COVID-19 Therapeutic	Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19 A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								IMPORTANCE The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is unknown. OBJECTIVE To evaluate the efficacy of ivermectin, 400 pg/kg, daily for 3 days compared with placebo for the treatment of early mild to moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS ACTIV-6, an ongoing, decentralized, double-blind, randomized, placebo-controlled platform trial, was designed to evaluate repurposed therapies in outpatients with mild to moderate COVID-19. A total of 1591 participants aged 30 years and older with confirmed COVID-19, experiencing 2 or more symptoms of acute infection for 7 days or less, were enrolled from June 23, 2021, through February 4, 2022, with follow-up data through May 31, 2022, at 93 sites in the US. INTERVENTIONS Participants were randomized to receive ivermectin, 400 mu g/kg (n = 817), daily for 3 days or placebo (n = 774). MAIN OUTCOMES AND MEASURES Time to sustained recovery, defined as at least 3 consecutive days without symptoms. There were 7 secondary outcomes, including a composite of hospitalization or death by day 28. RESULTS Among 1800 participants who were randomized (mean [SD] age, 48 [12] years; 932 women [58,6%); 753 [47.3%) reported receiving at least 2 doses of a SARS-CoV-2 vaccine), 1591 completed the trial. The hazard ratio (HR) for improvement in time to recovery was 1.07 (95% credible interval [Crl], 0.96-1.17; posterior P value [HR >1] = .91). The median time to recovery was 12 days (IQR, 11-13) in the ivermectin group and 13 days (IQR, 12-14) in the placebo group. There were 10 hospitalizations or deaths in the ivermectin group and 9 in the placebo group (1.2% vs 1.2%; HR, 1.1 [95% Crl, 0.4-2.6]). The most common serious adverse events were COVID-19 pneumonia (ivermectin [n = 5]; placebo [n = 7]) and venous thromboembolism (ivermectin [n =1]; placebo [n = 5]). CONCLUSIONS AND RELEVANCE Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19.	[Naggie, Susanna; Felker, G. Michael; DeLong, Allison; Remaly, April; Wilder, Rhonda; Wilson, Sybil; Hernandez, Adrian F.] Duke Univ, Duke Clin Res Inst, Sch Med, 300 W Morgan St Ste 800, Durham, NC 27701 USA; [Naggie, Susanna; Felker, G. Michael; Hernandez, Adrian F.] Duke Univ, Dept Med, Sch Med, Durham, NC 27701 USA; [Boulware, David R.; Bramante, Carolyn T.] Univ Minnesota, Div Infect Dis & Int Med, Minneapolis, MN USA; [Lindsell, Christopher J.; Stewart, Thomas G.; Collins, Sean] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Gentile, Nina] Temple Univ, Dept Emergency Med, Lewis Katz Sch Med, Philadelphia, PA 19122 USA; [McCarthy, Matthew William] Weill Cornell Med, Dept Med, New York, NY USA; [Jayaweera, Dushyantha] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Castro, Mario] Univ Missouri, Div Pulm Crit Care & Sleep Med, Sch Med, Kansas City, KS USA; [Sulkowski, Mark] Johns Hopkins Univ, Div Infect Dis, Baltimore, MD USA; [McTigue, Kathleen] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA; [Thicklin, Florence] Stakeholder Advisory Comm, Pittsburgh, PA USA; [Ginde, Adit A.] Univ Colorado Denver Anschutz, Dept Emergency Med, Denver, CO USA; [Slandzicki, Alex J.] Clin Trials Ctr Middle Tennessee, Franklin, TN USA; [Gabriel, Ahab] Focus Clin Res Solut, Charlotte, NC USA; [Shah, Nirav S.] NorthShore Univ HealthSyst, Evanston, IL USA; [Lenert, Leslie A.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA; [Dunsmore, Sarah E.] Natl Ctr Adv Translat Sci, Bethesda, MD USA; [Adam, Stacey J.] Fdn Natl Inst Hlth, Bethesda, MD USA; [Hanna, George] Biomed Adv Res & Dev Author, Washington, DC USA; [Shenkman, Elizabeth] Univ Florida, Coll Med, Dept Hlth Outcomes & Biomed Informat, Gainesville, FL USA	Duke University; Duke University; University of Minnesota System; University of Minnesota Twin Cities; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Cornell University; University of Miami; University of Missouri System; University of Missouri Kansas City; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; NorthShore University Health System; Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS); National Institutes of Health (NIH) - USA; State University System of Florida; University of Florida	Naggie, S (corresponding author), Duke Univ, Duke Clin Res Inst, Sch Med, 300 W Morgan St Ste 800, Durham, NC 27701 USA.	susanna.naggie@duke.edu		Williamson, John/0000-0002-3840-7143	NCATS [3U24TR001608-05W1]; Vanderbilt University Medical Center Recruitment Innovation Core [U24TR001579]; Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority [75A50122C00037]; Vanderbilt University Medical Center Clinical and Translational Science Award from NCATS [UL1TR002243]	NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Vanderbilt University Medical Center Recruitment Innovation Core; Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority; Vanderbilt University Medical Center Clinical and Translational Science Award from NCATS	ACTIV-6 is funded by NCATS (3U24TR001608-05W1) and the Vanderbilt University Medical Center Recruitment Innovation Core (U24TR001579). Additional support for this study was provided by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (contract No.75A50122C00037). The Vanderbilt University Medical Center Clinical and Translational Science Award from NCATS (UL1TR002243) supported the REDCap infrastructure.	Bernal AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMoa2116044; Caly Leon, 2020, Antiviral Res, V178, P104787, DOI 10.1016/j.antiviral.2020.104787; Elgazzar A, PREPRINT; Hill A, 2022, OPEN FORUM INFECT DI, V9, DOI 10.1093/ofid/ofab645; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Kory P, 2021, J INTENSIVE CARE MED, V36, P135, DOI 10.1177/0885066620973585; Lenze EJ, 2020, JAMA-J AM MED ASSOC, V324, P2292, DOI 10.1001/jama.2020.22760; Lim SCL, 2022, JAMA INTERN MED, V182, P426, DOI 10.1001/jamainternmed.2022.0189; Lopez-Medina E, 2021, JAMA-J AM MED ASSOC, V325, P1426, DOI 10.1001/jama.2021.3071; R Core Team, R LANG ENV STAT COMP; Reis G, 2022, NEW ENGL J MED, DOI 10.1056/NEJMoa2115869; Reis G, 2022, LANCET GLOB HEALTH, V10, pE36, DOI 10.1016/S2214-109X(21)00448-4; Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8; Yu Ly-Mee, 2021, Lancet, V398, P843, DOI 10.1016/S0140-6736(21)01744-X	15	0	0	3	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	2022	328	16					1595	1603		10.1001/jama.2022.18590	http://dx.doi.org/10.1001/jama.2022.18590		OCT 2022	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6C3UZ	36269852	Bronze			2023-01-03	WOS:000870804800001
J	Bellandi, D				Bellandi, Deanna			Rotavirus Leads Global Diarrhea Hospitalizations Among Young Children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	2022	328	15								10.1001/jama.2022.15474	http://dx.doi.org/10.1001/jama.2022.15474			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5M9EQ	36255422				2023-01-03	WOS:000871397000006
J	Davis, CS; Carr, DH				Davis, Corey S.; Carr, Derek H.			Repealing State Drug-Paraphernalia Laws - The Need for Federal Leadership	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Repealing State Drug-Paraphernalia Laws Amid the drug-overdose crisis, the federal government's efforts to support evidence-based harm-reduction measures could be expanded to include encouraging states to repeal drug-paraphernalia laws.	[Davis, Corey S.] Network Publ Hlth Law, Los Angeles, CA 90060 USA; [Davis, Corey S.] NYU, Grossman Sch Med, Dept Populat Hlth, New York, NY USA; [Carr, Derek H.] Vital Strategies, New York, NY USA	New York University	Davis, CS (corresponding author), Network Publ Hlth Law, Los Angeles, CA 90060 USA.							Broz D, 2021, AM J PREV MED, V61, pS118, DOI 10.1016/j.amepre.2021.05.044; Davis CS, 2019, AM J PUBLIC HEALTH, V109, P1564, DOI 10.2105/AJPH.2019.305268; GUINAN MD, 1983, NOTRE DAME LAW REV, V58, P833; Legislative Analysis and Public Policy Association, 2021, MOD SYR SERV PROGR A; The White House, 2022, FACT SHEET ADDR ADD	5	0	0	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2022	387	15					1344	1346		10.1056/NEJMp2207866	http://dx.doi.org/10.1056/NEJMp2207866			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6B8KB	36214589				2023-01-03	WOS:000881574600006
J	Liu, WW; Zhang, HM; Zhang, HC; Lyu, TZ; Yuan, SW				Liu, Wenwei; Zhang, Huimin; Zhang, Haichen; Lyu, Tongzhou; Yuan, Suwei			Prevalence and associated factors of inappropriate hospital admissions and days of children in a secondary hospital in Shanghai, China	PLOS ONE			English	Article							APPROPRIATENESS EVALUATION PROTOCOL; STAY; UNIT	Background Although the appropriateness of hospital utilization of adults and the elderly in China was audited by several studies, the appropriateness of hospital use by children in Shanghai remains to be determined. This study aims to assess the level of inappropriate hospital admissions and hospital days, to detect factors associated with inappropriateness, and to elucidate reasons for inappropriateness. Methods A retrospective review of the records of 291 admissions and 1449 hospital days of children inpatients from a secondary hospital in Shanghai was performed by two reviewers using the Chinese version Pediatric Appropriateness Evaluation Protocol (C-PAEP). Demographics, socio-economic characteristics, and other admission- or hospital stay-related information were collected and analyzed to determine factors associated with inappropriateness utilizing multivariate regression models. Results 38.5% (n = 112) of admissions and 9.5% (n = 137) of hospital days were categorized as inappropriate, according to the C-PAEP. Children who were non-Shanghai residents (p < 0.001), admitted through the emergency sector (p = 0.030), and/or received services in a surgical ward (p < 0.001) had a higher risk of being admitted inappropriately. Payment method (p = 0.006), service type (p < 0.001), comorbidity (p = 0.016), length of stay (p = 0.007), and appropriateness of admission (p < 0.001) were found to be associated with prevalence of inappropriate hospital days. Approximately three-fourths of the inappropriate admissions were premature admissions (75.9%, n = 85). The most frequent reasons for inappropriate hospital days were awaiting test results (34.3%, n = 47), awaiting surgery (19.7%, n = 27), awaiting test execution (10.9%, n = 15), and family unprepared for home care (10.9%, n = 15). Conclusions Although the extent of inappropriate hospital days was moderate compared with that found by previous investigations, the prevalence of inappropriateness of admission was considerable. To enhance the appropriateness of hospital care for children, interventions could be implemented according to the associated factors and identified causes.	[Liu, Wenwei] Shanghai Normal Univ, Coll Philosophy Law & Polit Sci, Shanghai, Peoples R China; [Zhang, Huimin] Shanghai Jiao Tong Univ, Sch Int & Publ Affairs, Shanghai, Peoples R China; [Zhang, Haichen] Shanghai Xuhui Mental Hlth Ctr, Shanghai, Peoples R China; [Lyu, Tongzhou] East China Normal Univ, Sch Polit & Int Relat, Shanghai, Peoples R China; [Yuan, Suwei] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Shanghai, Peoples R China; [Yuan, Suwei] Shanghai Jiao Tong Univ, China Hosp Dev Inst, Shanghai, Peoples R China	Shanghai Normal University; Shanghai Jiao Tong University; East China Normal University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yuan, SW (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Shanghai, Peoples R China.; Yuan, SW (corresponding author), Shanghai Jiao Tong Univ, China Hosp Dev Inst, Shanghai, Peoples R China.	yuansuwei@sjtu.edu.cn			National Natural Science Foundation [72004136]; Shanghai Public Health Excellent Talent Project [GWV-10.2-YQ51]; Postdoctoral Research Foundation of China [2019M661537]; Philosophy and Social Science Foundation of Hunan Province [2019EZZ003]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Shanghai Public Health Excellent Talent Project; Postdoctoral Research Foundation of China(China Postdoctoral Science Foundation); Philosophy and Social Science Foundation of Hunan Province	The study was funded by the National Natural Science Foundation (number: 72004136), the Shanghai Public Health Excellent Talent Project (number: GWV-10.2-YQ51), the Postdoctoral Research Foundation of China (number: 2019M661537), and the Philosophy and Social Science Foundation of Hunan Province (number: 2019EZZ003).	Al-Tehewy M., 2009, Eastern Mediterranean Health Journal, V15, P1126; Angelillo IF, 2000, PUBLIC HEALTH, V114, P9, DOI 10.1038/sj.ph.1900609; Arab-Zozani M, 2020, VALUE HEALTH REG ISS, V21, P105, DOI 10.1016/j.vhri.2019.07.011; Bianco A, 2003, PEDIATRICS, V112, P124, DOI 10.1542/peds.112.1.124; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Brabrand M, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-152; Rodriguez FC, 2006, ARCH BRONCONEUMOL, V42, P440, DOI 10.1016/S1579-2129(06)60566-1; Esmail A, 2000, J PUBLIC HEALTH MED, V22, P231, DOI 10.1093/pubmed/22.2.231; Esmaili A, 2014, IRAN RED CRESCENT ME, V16, DOI 10.5812/ircmj.16602; GERTMAN PM, 1981, MED CARE, V19, P855, DOI 10.1097/00005650-198108000-00005; Ghods Ali Asghar, 2014, Glob J Health Sci, V7, P82, DOI 10.5539/gjhs.v7n3p82; GLOOR JE, 1993, PEDIATRICS, V91, P70; Hu XM, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026443; Huang G, 2016, CHINESE HLTH EC, P64; Katz M, 2001, ISRAEL MED ASSOC J, V3, P501; KEMPER KJ, 1988, NEW ENGL J MED, V318, P1033, DOI 10.1056/NEJM198804213181605; KREGER BE, 1989, PEDIATRICS, V84, P242; Li F, 2012, CHINESE HLTH EC, V31, P42; Liu WW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208146; Liu WW, 2017, INT J QUAL HEALTH C, V29, P699, DOI 10.1093/intqhc/mzx091; Liu WW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136498; Morrison AK, 2013, ACAD PEDIATR, V13, P421, DOI 10.1016/j.acap.2013.03.001; National Health and Family Planning Commission of the People's Republic of China, 2017, CHIN HLTH STAT YB 20; National Health and Family Planning Commission of the People's Republic of China, 2019, CHIN HLTH STAT YB 20; OhAiseadha C, 2016, INT J HEALTH POLICY, V5, P643, DOI 10.15171/ijhpm.2016.53; Pileggi C, 2004, PUBLIC HEALTH, V118, P284, DOI 10.1016/j.puhe.2003.06.002; Restuccia J D, 1987, Health Care Manage Rev, V12, P17; RESTUCCIA JD, 1995, INT J QUAL HEALTH C, V7, P253, DOI 10.1093/intqhc/7.3.253; Shafik MH, 2012, MED PRIN PRACT, V21, P516, DOI 10.1159/000339084; Soria-Aledo V, 2009, AM J MED QUAL, V24, P321, DOI 10.1177/1062860609337252; Vincitorio D, 2010, J PUBLIC HEALTH-HEID, V18, P497, DOI 10.1007/s10389-010-0325-y; Werneke U, 1997, ARCH DIS CHILD, V77, P294, DOI 10.1136/adc.77.4.294; Zhang Y, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0649-3	33	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2022	17	10							e0275645	10.1371/journal.pone.0275645	http://dx.doi.org/10.1371/journal.pone.0275645			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6P6RS	36201444	gold, Green Published			2023-01-03	WOS:000891056500001
J	Ma, ZW; Bourquard, C; Gao, QM; Jiang, SB; De Iure-Grimmel, T; Huo, R; Li, X; He, ZX; Yang, Z; Yang, G; Wang, YX; Lam, E; Gao, ZH; Supponen, O; Li, JY				Ma, Zhenwei; Bourquard, Claire; Gao, Qiman; Jiang, Shuaibing; De Iure-Grimmel, Tristan; Huo, Ran; Li, Xuan; He, Zixin; Yang, Zhen; Yang, Galen; Wang, Yixiang; Lam, Edmond; Gao, Zu-Hua; Supponen, Outi; Li, Jianyu			Controlled tough bioadhesion mediated by ultrasound	SCIENCE			English	Article								Tough bioadhesion has important implications in engineering and medicine but remains challenging to form and control. We report an ultrasound (US)-mediated strategy to achieve tough bioadhesion with controllability and fatigue resistance. Without chemical reaction, the US can amplify the adhesion energy and interfacial fatigue threshold between hydrogels and porcine skin by up to 100 and 10 times. Combined experiments and theoretical modeling suggest that the key mechanism is US-induced cavitation, which propels and immobilizes anchoring primers into tissues with mitigated barrier effects. Our strategy achieves spatial patterning of tough bioadhesion, on-demand detachment, and transdermal drug delivery. This work expands the material repertoire for tough bioadhesion and enables bioadhesive technologies with high-level controllability.	[Ma, Zhenwei; Jiang, Shuaibing; Huo, Ran; Li, Xuan; He, Zixin; Yang, Zhen; Li, Jianyu] McGill Univ, Dept Mech Engn, Montreal, PQ H3A 0C3, Canada; [Bourquard, Claire; Supponen, Outi] Swiss Fed Inst Technol, Dept Mech & Proc Engn, Inst Fluid Dynam, CH-8092 Zurich, Switzerland; [Gao, Qiman] McGill Univ, Fac Dent Med & Oral Hlth Sci, Montreal, PQ H3A 1G1, Canada; [De Iure-Grimmel, Tristan] McGill Univ, Dept Bioengn, Montreal, PQ H3A 0E9, Canada; [Yang, Galen; Lam, Edmond] McGill Univ, Dept Chem, Montreal, PQ H3A 0B8, Canada; [Wang, Yixiang] McGill Univ, Dept Food Sci & Agr Chem, Ste Anne De Bellevue, PQ H9X 3V9, Canada; [Lam, Edmond] Natl Res Council Canada, Aquat & Crop Resource Dev Res Ctr, Montreal, PQ H4P 2R2, Canada; [Gao, Zu-Hua] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z7, Canada; [Li, Jianyu] McGill Univ, Dept Biomed Engn, Montreal, PQ H3A 2B4, Canada	McGill University; Swiss Federal Institutes of Technology Domain; ETH Zurich; McGill University; McGill University; McGill University; McGill University; National Research Council Canada; University of British Columbia; McGill University	Li, JY (corresponding author), McGill Univ, Dept Mech Engn, Montreal, PQ H3A 0C3, Canada.; Supponen, O (corresponding author), Swiss Fed Inst Technol, Dept Mech & Proc Engn, Inst Fluid Dynam, CH-8092 Zurich, Switzerland.; Li, JY (corresponding author), McGill Univ, Dept Biomed Engn, Montreal, PQ H3A 2B4, Canada.	outis@ethz.ch; jianyu.li@mcgill.ca	Li, Jianyu/ABF-1357-2020	Li, Jianyu/0000-0002-1128-6804; He, Zixin/0000-0003-3417-2188; Li, Xuan/0000-0002-6088-6451; Wang, Yixiang/0000-0001-8386-7491; Ma, Zhenwei/0000-0002-7209-9842; Jiang, Shuaibing/0000-0002-7402-0587; Yang, Zhen/0000-0003-4345-2130; Bourquard, Claire/0000-0003-0669-3648	Natural Sciences and Engineering Research Council of Canada [RGPIN-2018-04146, RGPIN-201904498]; Canada Foundation for Innovation [37719]; Fonds de Recherche du Quebec -Nature et Technologies [FRQ-NT NC-270740]; Canada Research Chair Program; ETH Zurich; National Research Council Canada Industrial Biotechnology program; Fonds de Recherche du Quebec -Nature et Technologies (B2X doctoral research scholarship) [268520]	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Fonds de Recherche du Quebec -Nature et Technologies; Canada Research Chair Program(Canada Research Chairs); ETH Zurich(ETH Zurich); National Research Council Canada Industrial Biotechnology program; Fonds de Recherche du Quebec -Nature et Technologies (B2X doctoral research scholarship)	This work was supported by the Natural Sciences and Engineering Research Council of Canada (grant RGPIN-2018-04146 to J.L. and grant RGPIN-201904498 to Y.W.); the Canada Foundation for Innovation (grant 37719 to JL); Fonds de Recherche du Quebec -Nature et Technologies (grant FRQ-NT NC-270740 to J.L. and B2X doctoral research scholarship 268520 to Z.M.); the Canada Research Chair Program (J.L.); ETH Zurich (O.S. and C.B.); and the National Research Council Canada Industrial Biotechnology program (E.L.).	Artzi N, 2009, ADV MATER, V21, P3399, DOI 10.1002/adma.200900340; Brown HR, 1996, MACROMOLECULES, V29, P798, DOI 10.1021/ma951123k; Chen XY, 2020, P NATL ACAD SCI USA, V117, P15497, DOI 10.1073/pnas.2006389117; Demene C, 2021, NAT BIOMED ENG, V5, P219, DOI 10.1038/s41551-021-00697-x; Ding SY, 2016, NAT REV MATER, V1, DOI [10.1038/natrevmats.2016.21, 10.1038/natrevmats.2016.71]; Duck F, 2018, J ACOUST SOC AM, V144, P2490, DOI 10.1121/1.5063578; Kim G, 2019, P NATL ACAD SCI USA, V116, P10214, DOI 10.1073/pnas.1901047116; Li J, 2017, SCIENCE, V357, P378, DOI 10.1126/science.aah6362; Liu K, 2022, BIOACT MATER, V13, P260, DOI 10.1016/j.bioactmat.2021.11.003; Lovegrove C., 2006, NAT CLIN PRACT ONCOL, V3, P8; Ma ZW, 2022, SCIENCE, V377, P751, DOI 10.1126/science.abn8699; Ma ZW, 2021, ADV MATER, V33, DOI 10.1002/adma.202007663; Mahdavi A, 2008, P NATL ACAD SCI USA, V105, P2307, DOI 10.1073/pnas.0712117105; Nam S, 2021, CHEM REV, V121, P11336, DOI 10.1021/acs.chemrev.0c00798; Ni X, 2020, EXTREME MECH LETT, V34, DOI 10.1016/j.eml.2019.100601; Rezai AR, 2020, P NATL ACAD SCI USA, V117, P9180, DOI 10.1073/pnas.2002571117; Rose S, 2014, NATURE, V505, P382, DOI 10.1038/nature12806; Schoellhammer CM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa5937; Wang CH, 2018, NAT BIOMED ENG, V2, P687, DOI 10.1038/s41551-018-0287-x; Yang JW, 2018, ADV MATER, V30, DOI 10.1002/adma.201800671; Yang SY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2715; Yang Z, 2021, MECH MATER, V157, DOI 10.1016/j.mechmat.2021.103800; Yuk H, 2019, NATURE, V575, P169, DOI 10.1038/s41586-019-1710-5	23	7	7	221	221	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	2022	377	6607					751	755		10.1126/science.abn8699	http://dx.doi.org/10.1126/science.abn8699			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3V2NW	35951702				2023-01-03	WOS:000841499400035
J	Ganguly, K; Khanna, P; Morecraft, RJ; Lin, DJ				Ganguly, Karunesh; Khanna, Preeya; Morecraft, Robert J.; Lin, David J.			Modulation of neural co-firing to enhance network transmission and improve motor function after stroke	NEURON			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; INDUCED MOVEMENT THERAPY; CORTICAL-LESIONS; CORTICOSPINAL PROJECTION; ELECTRICAL-STIMULATION; SENSORIMOTOR CORTEX; NEURONAL-ACTIVITY; ISCHEMIC-STROKE; PREMOTOR CORTEX; DOUBLE-BLIND	Stroke is a leading cause of disability. While neurotechnology has shown promise for improving upper limb recovery after stroke, efficacy in clinical trials has been variable. Our central thesis is that to improve clinical translation, we need to develop a common neurophysiological framework for understanding how neurotechnology alters network activity. Our perspective discusses principles for how motor networks, both healthy and those recovering from stroke, subserve reach-to-grasp movements. We focus on neural processing at the resolution of single movements, the timescale at which neurotechnologies are applied, and discuss how this activity might drive long-term plasticity. We propose that future studies should focus on cross-area communication and bridging our understanding of timescales ranging from single trials within a session to across multiple sessions. We hope that this perspective establishes a combined path forward for preclinical and clinical research with the goal of more robust clinical translation of neurotechnology.	[Ganguly, Karunesh; Khanna, Preeya] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Ganguly, Karunesh; Khanna, Preeya] SFVAHCS, Neurol Serv, San Francisco, CA 94107 USA; [Morecraft, Robert J.] Univ South Dakota, Sanford Sch Med, Div Basic Biomed Sci, Lab Neurol Sci, Vermillion, SD 57069 USA; [Lin, David J.] Massachusetts Gen Hosp, Ctr Neurotechnol & Neurorecovery, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Boston, MA USA; [Lin, David J.] Providence VA Med Ctr, Ctr Neurorestorat & Neurotechnol, Rehabil R&D Serv, Providence, RI USA	University of California System; University of California San Francisco; University of South Dakota; Harvard University; Massachusetts General Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Ganguly, K (corresponding author), Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA 94143 USA.; Ganguly, K (corresponding author), SFVAHCS, Neurol Serv, San Francisco, CA 94107 USA.	karunesh.ganguly@ucsf.edu		Ganguly, Karunesh/0000-0002-2570-9943				Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Allman C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5651; Athalye VR, 2017, NEURON, V93, P955, DOI 10.1016/j.neuron.2017.01.016; Baker SN, 2007, CURR OPIN NEUROBIOL, V17, P649, DOI 10.1016/j.conb.2008.01.007; Balbinot G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27101-0; Balzer J., 2022, PREPRINT; Bhagat NA, 2020, NEUROIMAGE-CLIN, V28, DOI 10.1016/j.nicl.2020.102502; Bonstrup M, 2019, ANN NEUROL, V86, P853, DOI 10.1002/ana.25615; Bolognini N, 2011, NEUROREHAB NEURAL RE, V25, P819, DOI 10.1177/1545968311411056; Boyne P., 2021, MAPPING HUMAN CORTIC; Boyne P, 2021, J NEUROSCI RES, V99, P3392, DOI 10.1002/jnr.24975; Buch E, 2008, STROKE, V39, P910, DOI 10.1161/STROKEAHA.107.505313; Buch ER, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109193; Buford JA, 2004, EXP BRAIN RES, V159, P284, DOI 10.1007/s00221-004-1956-4; Buzsaki G, 2012, NAT REV NEUROSCI, V13, P407, DOI 10.1038/nrn3241; Byblow WD, 2015, ANN NEUROL, V78, P848, DOI 10.1002/ana.24472; Cagnan H, 2019, P NATL ACAD SCI USA, V116, P16095, DOI 10.1073/pnas.1819975116; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Carrico C, 2016, STROKE, V47, P1879, DOI 10.1161/STROKEAHA.116.012671; Cassidy JM, 2020, STROKE, V51, P1442, DOI 10.1161/STROKEAHA.120.028932; Cassidy JM, 2018, STROKE, V49, P433, DOI 10.1161/STROKEAHA.117.018844; Catani M, 2005, BRAIN, V128, P2224, DOI 10.1093/brain/awh622; Churchland MM, 2012, NATURE, V487, P51, DOI 10.1038/nature11129; Cisek P, 2003, J NEUROPHYSIOL, V89, P922, DOI 10.1152/jn.00607.2002; Clarkson AN, 2009, BIOCHEM SOC T, V37, P1412, DOI 10.1042/BST0371412; Conforto AB, 2018, NEUROREHAB NEURAL RE, V32, P863, DOI 10.1177/1545968318798943; Conforto AB, 2010, NEUROREHAB NEURAL RE, V24, P263, DOI 10.1177/1545968309349946; Cooperrider J, 2020, CURR PHYS MED REHAB, V8, P57, DOI 10.1007/s40141-019-00253-4; Coscia M, 2019, BRAIN, V142, P2182, DOI 10.1093/brain/awz181; Cramer SC, 2008, ANN NEUROL, V63, P549, DOI 10.1002/ana.21412; Crammond DJ, 2000, J NEUROPHYSIOL, V84, P986, DOI 10.1152/jn.2000.84.2.986; Dann B, 2016, ELIFE, V5, DOI 10.7554/eLife.15719; DARIANSMITH C, 1993, J COMP NEUROL, V335, P200, DOI 10.1002/cne.903350205; Darling WG, 2018, J NEUROSCI, V38, P6323, DOI 10.1523/JNEUROSCI.0403-18.2018; Darling WG, 2016, EXP NEUROL, V281, P37, DOI 10.1016/j.expneurol.2016.04.004; Darling WG, 2011, J INTEGR NEUROSCI, V10, P353, DOI 10.1142/S0219635211002737; Davare M, 2011, CURR OPIN NEUROBIOL, V21, P565, DOI 10.1016/j.conb.2011.05.021; Dawson J, 2021, LANCET, V397, P1545, DOI 10.1016/S0140-6736(21)00475-X; Desmurget M, 2010, J NEUROSCI, V30, P7685, DOI 10.1523/JNEUROSCI.0163-10.2010; Dromerick Alexander W, 2021, Proc Natl Acad Sci U S A, V118, DOI 10.1073/pnas.2026676118; Dronkers NF, 2007, BRAIN, V130, P1432, DOI 10.1093/brain/awm042; DUM RP, 1991, J NEUROSCI, V11, P667; Duss Simone B., 2017, Neurobiology of Sleep and Circadian Rhythms, V2, P94, DOI 10.1016/j.nbscr.2016.11.003; Elsner B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009645.pub2; Engineer ND, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00280; Esposito MS, 2014, NATURE, V508, P351, DOI 10.1038/nature13023; Facchin L, 2020, J NEUROSCI, V40, P8637, DOI 10.1523/JNEUROSCI.0373-20.2020; FETZ EE, 1992, BEHAV BRAIN SCI, V15, P679; Ford GA, 2019, LANCET NEUROL, V18, P530, DOI 10.1016/S1474-4422(19)30147-4; Fox MD, 2018, NEW ENGL J MED, V379, P2237, DOI 10.1056/NEJMra1706158; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Gaidica M, 2020, FRONT NEURAL CIRCUIT, V14, DOI 10.3389/fncir.2020.00052; Gallego JA, 2017, NEURON, V94, P978, DOI 10.1016/j.neuron.2017.05.025; Ganguly K, 2013, NEURON, V80, P729, DOI 10.1016/j.neuron.2013.10.028; Ganguly K, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000153; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; Godlove J, 2016, ANN CLIN TRANSL NEUR, V3, P956, DOI 10.1002/acn3.368; Gordon J., 1987, MOVEMENT SCI FDN PHY; Grefkes C, 2014, LANCET NEUROL, V13, P206, DOI 10.1016/S1474-4422(13)70264-3; Grefkes C, 2011, BRAIN, V134, P1264, DOI 10.1093/brain/awr033; Guggisberg AG, 2019, CLIN NEUROPHYSIOL, V130, P1098, DOI 10.1016/j.clinph.2019.04.004; Gulati T, 2017, NAT NEUROSCI, V20, P1277, DOI 10.1038/nn.4601; Guo L, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109370; Hahn G, 2019, NAT REV NEUROSCI, V20, P117, DOI 10.1038/s41583-018-0094-0; Hall TM, 2014, NEURON, V83, P1185, DOI 10.1016/j.neuron.2014.07.022; Harvey RL, 2018, STROKE, V49, P2138, DOI 10.1161/STROKEAHA.117.020607; Hikosaka O, 2018, J NEURAL TRANSM, V125, P515, DOI 10.1007/s00702-017-1691-1; Hsu WY, 2012, STROKE, V43, P1849, DOI 10.1161/STROKEAHA.111.649756; Hummel FC, 2006, LANCET NEUROL, V5, P708, DOI 10.1016/S1474-4422(06)70525-7; Ishida A, 2019, J NEUROSCI, V39, P7306, DOI 10.1523/JNEUROSCI.0649-19.2019; Ito KL, 2022, NEUROREHAB NEURAL RE, V36, P179, DOI 10.1177/15459683211068441; Jin X, 2015, CURR OPIN NEUROBIOL, V33, P188, DOI 10.1016/j.conb.2015.06.011; Johansson RS, 2009, NAT REV NEUROSCI, V10, P345, DOI 10.1038/nrn2621; Joy MT, 2021, NAT REV NEUROSCI, V22, P38, DOI 10.1038/s41583-020-00396-7; Kaufman MT, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0085-16.2016; KENNEDY PR, 1986, BRAIN RES, V364, P124, DOI 10.1016/0006-8993(86)90993-5; Khanna P, 2021, CELL, V184, P912, DOI 10.1016/j.cell.2021.01.023; Khanna P, 2017, ELIFE, V6, DOI 10.7554/eLife.24573; Kim J, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110426; Kim J, 2019, CELL, V179, P514, DOI 10.1016/j.cell.2019.08.040; Kondapavulur S, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-30069-1; Kwakkel G, 2021, STROKE, V52, P3407, DOI 10.1161/STROKEAHA.121.035648; LAWRENCE DG, 1968, BRAIN, V91, P1, DOI 10.1093/brain/91.1.1; Lebedev MA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54760-4; Lemke SM, 2019, NAT NEUROSCI, V22, P1122, DOI 10.1038/s41593-019-0407-2; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Levin MF, 2019, NEUROREHAB NEURAL RE, V33, P432, DOI 10.1177/1545968319847969; Levy RM, 2016, NEUROREHAB NEURAL RE, V30, P107, DOI 10.1177/1545968315575613; Li BS, 2017, ELIFE, V6, DOI 10.7554/eLife.30552; Liew SL, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcab254; Lin D.J., 2019, CORTICOSPINAL TRACT, DOI [10.1161/ STROKEAHA.119.025898, DOI 10.1161/STROKEAHA.119.025898]; Lin DJ, 2021, NEUROLOGY, V96, pE2576, DOI 10.1212/WNL.0000000000011992; Lin DJ, 2018, STROKE, V49, P3107, DOI 10.1161/STROKEAHA.118.021359; Liu AL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07233-7; Logiaco L, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109090; M. Kaneshige, 2022, bioRxiv, DOI 10.1101/2022.03.16.484577; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Maraka S, 2014, ANN CLIN TRANSL NEUR, V1, P891, DOI 10.1002/acn3.132; Marshall RS, 2000, STROKE, V31, P656, DOI 10.1161/01.STR.31.3.656; McNeal DW, 2010, J COMP NEUROL, V518, P586, DOI 10.1002/cne.22218; McPherson JG, 2018, J PHYSIOL-LONDON, V596, P1211, DOI 10.1113/JP274968; Meyer S, 2016, NEUROREHAB NEURAL RE, V30, P731, DOI 10.1177/1545968315624779; Michaels JA, 2020, P NATL ACAD SCI USA, V117, P32124, DOI 10.1073/pnas.2005087117; Morecraft RJ, 2019, J COMP NEUROL, V527, P2761, DOI 10.1002/cne.24706; Morecraft RJ, 2013, J COMP NEUROL, V521, P4205, DOI 10.1002/cne.23410; MUSHIAKE H, 1991, J NEUROPHYSIOL, V66, P705, DOI 10.1152/jn.1991.66.3.705; MUSTARD BE, 1987, EXP BRAIN RES, V66, P247; Nashef A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2012658118; Natraj N, 2022, NEURON, V110, P154, DOI 10.1016/j.neuron.2021.10.002; Nishibe M, 2015, NEUROREHAB NEURAL RE, V29, P472, DOI 10.1177/1545968314543499; Nita DA, 2007, CEREB CORTEX, V17, P272, DOI 10.1093/cercor/bhj145; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Olivares-Moreno R, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.686481; Ostergard TA, 2019, EPILEPSY BEHAV, V91, P13, DOI 10.1016/j.yebeh.2018.06.036; Otchy TM, 2015, NATURE, V528, P358, DOI 10.1038/nature16442; Parikh V, 2007, NEURON, V56, P141, DOI 10.1016/j.neuron.2007.08.025; Park HJ, 2015, BRAIN STIMUL, V8, P1043, DOI 10.1016/j.brs.2015.06.020; Park J, 2020, ANNU REV NEUROSCI, V43, P485, DOI 10.1146/annurev-neuro-070918-050452; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037, DOI 10.1152/jn.1995.74.3.1037; Peters AJ, 2014, NATURE, V510, P263, DOI 10.1038/nature13235; Plautz EJ, 2003, NEUROL RES, V25, P801, DOI 10.1179/016164103771953880; Plautz EJ, 2000, NEUROBIOL LEARN MEM, V74, P27, DOI 10.1006/nlme.1999.3934; Porter R, 1993, CORTICOSPINAL FUNCTI; Prut Y, 1999, NATURE, V401, P590, DOI 10.1038/44145; Ramanathan DS, 2018, NAT MED, V24, P1257, DOI 10.1038/s41591-018-0058-y; Ramos-Murguialday A, 2013, ANN NEUROL, V74, P100, DOI 10.1002/ana.23879; Riehle A., 2005, MOTOR CORTEX VOLUNTA; Rimmele DL, 2018, STROKE, V49, P2928, DOI 10.1161/STROKEAHA.118.022706; Rizzolatti G, 2001, NEURON, V31, P889, DOI 10.1016/S0896-6273(01)00423-8; Rondina JM, 2016, NEUROIMAGE-CLIN, V12, P372, DOI 10.1016/j.nicl.2016.07.014; Rossiter HE, 2014, J NEUROPHYSIOL, V112, P2053, DOI 10.1152/jn.00345.2014; Rouse AG, 2018, CELL REP, V25, P3158, DOI 10.1016/j.celrep.2018.11.057; SATO H, 1987, J NEUROPHYSIOL, V58, P765, DOI 10.1152/jn.1987.58.4.765; Sauerbrei BA, 2020, NATURE, V577, P386, DOI 10.1038/s41586-019-1869-9; Schaffelhofer S, 2016, ELIFE, V5, DOI 10.7554/eLife.15278; Schalk G, 2007, J NEURAL ENG, V4, P264, DOI 10.1088/1741-2560/4/3/012; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; Schwarz A, 2019, STROKE, V50, P718, DOI 10.1161/STROKEAHA.118.023531; Semedo JD, 2019, NEURON, V102, P249, DOI 10.1016/j.neuron.2019.01.026; Shalit U, 2012, CEREB CORTEX, V22, P1904, DOI 10.1093/cercor/bhr267; Shenoy KV, 2013, ANNU REV NEUROSCI, V36, P337, DOI 10.1146/annurev-neuro-062111-150509; Sobinov AR, 2021, NAT REV NEUROSCI, V22, P741, DOI 10.1038/s41583-021-00528-7; Stinear CM, 2012, BRAIN, V135, P2527, DOI 10.1093/brain/aws146; STRICK PL, 1974, J COMP NEUROL, V153, P77, DOI 10.1002/cne.901530107; Suresh AK, 2020, ELIFE, V9, DOI 10.7554/eLife.58848; Tang CW, 2020, NEUROREHAB NEURAL RE, V34, P450, DOI 10.1177/1545968320913502; Tohyama T, 2017, P NATL ACAD SCI USA, V114, P604, DOI 10.1073/pnas.1610787114; Tu-Chan AP, 2017, J NEUROENG REHABIL, V14, DOI 10.1186/s12984-017-0323-1; Tumer EC, 2007, NATURE, V450, P1240, DOI 10.1038/nature06390; Tzagarakis C, 2010, J NEUROSCI, V30, P11270, DOI 10.1523/JNEUROSCI.6026-09.2010; van Dellen E, 2013, NEUROIMAGE, V83, P524, DOI 10.1016/j.neuroimage.2013.06.009; Veuthey TL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17902-1; Voroslakos M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02928-3; Wagner FB, 2018, NATURE, V563, P65, DOI 10.1038/s41586-018-0649-2; WHISHAW IQ, 1992, BEHAV BRAIN RES, V47, P59, DOI 10.1016/S0166-4328(05)80252-9; Wittenberg GF, 2003, NEUROREHAB NEURAL RE, V17, P48, DOI 10.1177/0888439002250456; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Yang G, 2014, SCIENCE, V344, P1173, DOI 10.1126/science.1249098; Yin HH, 2009, NAT NEUROSCI, V12, P333, DOI 10.1038/nn.2261; Zaaimi B, 2012, BRAIN, V135, P2277, DOI 10.1093/brain/aws115; Zackowski KM, 2004, BRAIN, V127, P1035, DOI 10.1093/brain/awh116; Ziemann U, 2008, BRAIN STIMUL, V1, P164, DOI 10.1016/j.brs.2008.06.006; Zimmermann JB, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00087	170	1	1	10	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	AUG 3	2022	110	15					2363	2385		10.1016/j.neuron.2022.06.024	http://dx.doi.org/10.1016/j.neuron.2022.06.024			23	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3Y7IQ	35926452				2023-01-03	WOS:000843895500005
J	Bagg, MK; Wand, BM; Cashin, AG; Lee, H; Hubscher, M; Stanton, TR; O'Connell, NE; O'Hagan, ET; Rizzo, RRN; Wewege, MA; Rabey, M; Goodall, S; Saing, S; Lo, SN; Luomajoki, H; Herbert, RD; Maher, CG; Moseley, GL; McAuley, JH				Bagg, Matthew K.; Wand, Benedict M.; Cashin, Aidan G.; Lee, Hopin; Hubscher, Markus; Stanton, Tasha R.; O'Connell, Neil E.; O'Hagan, Edel T.; Rizzo, Rodrigo R. N.; Wewege, Michael A.; Rabey, Martin; Goodall, Stephen; Saing, Sopany; Lo, Serigne N.; Luomajoki, Hannu; Herbert, Robert D.; Maher, Chris G.; Moseley, G. Lorimer; McAuley, James H.			Effect of Graded Sensorimotor Retraining on Pain Intensity in Patients With Chronic Low Back Pain A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								IMPORTANCE The effects of altered neural processing, defined as altering neural networks responsible for perceptions of pain and function, on chronic pain remains unclear. OBJECTIVE To estimate the effect of a graded sensorimotor retraining intervention (RESOLVE) on pain intensity in people with chronic low back pain. DESIGN, SETTING, AND PARTICIPANTS This parallel, 2-group, randomized clinical trial recruited participants with chronic (>3 months) nonspecific low back pain from primary care and community settings. A total of 276 adults were randomized (in a 1:1 ratio) to the intervention or sham procedure and attention control groups delivered by clinicians at a medical research institute in Sydney, Australia. The first participant was randomized on December 10, 2015, and the last was randomized on July 25, 2019. Follow-up was completed on February 3, 2020. INTERVENTIONS Participants randomized to the intervention group (n = 138) were asked to participate in 12 weekly clinical sessions and home training designed to educate them about and assist them with movement and physical activity while experiencing lower back pain. Participants randomized to the control group (n = 138) were asked to participate in 12 weekly clinical sessions and home training that required similar time as the intervention but did not focus on education, movement, and physical activity. The control group included sham laser and shortwave diathermy applied to the back and sham noninvasive brain stimulation. MAIN OUTCOMES AND MEASURES The primary outcomewas pain intensity at 18weeks, measured on an 11-point numerical rating scale (range, 0 [no pain] to 10 [worst pain imaginable]) for which the between-group minimum clinically important difference is 1.0 point. RESULTS Among 276 randomized patients (mean [SD] age, 46 [14.3] years; 138 [50%] women), 261 (95%) completed follow-up at 18 weeks. The mean pain intensity was 5.6 at baseline and 3.1 at 18 weeks in the intervention group and 5.8 at baseline and 4.0 at 18 weeks in the control group, with an estimated between-group mean difference at 18 weeks of -1.0 point ([95% CI, -1.5 to -0.4]; P =.001), favoring the intervention group. CONCLUSIONS AND RELEVANCE In this randomized clinical trial conducted at a single center among patients with chronic low back pain, graded sensorimotor retraining, compared with a sham procedure and attention control, significantly improved pain intensity at 18 weeks. The improvements in pain intensity were small, and further research is needed to understand the generalizability of the findings.	[Bagg, Matthew K.; Cashin, Aidan G.; Herbert, Robert D.] Neurosci Res Australia, Margarete Ainsworth Bldg,Barker St, Sydney, NSW 2031, Australia; [Bagg, Matthew K.; Cashin, Aidan G.; Hubscher, Markus; O'Hagan, Edel T.; Rizzo, Rodrigo R. N.; Wewege, Michael A.; Rabey, Martin; McAuley, James H.] Neurosci Res Australia, Ctr Pain IMPACT Investigating Mech Pain Adv Clin, Sydney, NSW, Australia; [Bagg, Matthew K.] Curtin Univ, Fac Hlth Sci, Curtin Hlth Innovat Res Inst, Perth, WA, Australia; [Bagg, Matthew K.] Perron Inst Neurol & Translat Sci, Perth, WA, Australia; [Wand, Benedict M.] Univ Notre Dame Australia, Fac Med Nursing & Midwifery & Hlth Sci, Fremantle, WA, Australia; [Cashin, Aidan G.; Rizzo, Rodrigo R. N.; Wewege, Michael A.; McAuley, James H.] Univ New South Wales, Sch Hlth Sci, Sydney, NSW, Australia; [Lee, Hopin] Univ Oxford, Ctr Stat Med, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [Lee, Hopin] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia; [Stanton, Tasha R.; Moseley, G. Lorimer] Univ South Australia, IIMPACT Innovat IMPlementat & Clin Translat Hlth, Adelaide, SA, Australia; [O'Connell, Neil E.] Brunel Univ London, Ctr Hlth & Wellbeing Lifecourse, Dept Hlth Sci, Uxbridge, Middx, England; [O'Hagan, Edel T.] Univ New South Wales, Prince Wales Clin Sch, Sydney, NSW, Australia; [Goodall, Stephen; Saing, Sopany] Univ Technol Sydney, Fac Hlth, Ctr Hlth Econ Res & Evaluat, Sydney, NSW, Australia; [Lo, Serigne N.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Lo, Serigne N.] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat, Dammam, Saudi Arabia; [Luomajoki, Hannu] Zurich Univ Appl Sci, Sch Hlth Profess, Inst Physiotherapy, Winterthur, Switzerland; [Maher, Chris G.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia; [Maher, Chris G.] Univ Sydney, Inst Musculoskeletal Hlth, Sydney, NSW, Australia; [Maher, Chris G.] Sydney Local Hlth Dist, Sydney, NSW, Australia	Neuroscience Research Australia; Neuroscience Research Australia; Curtin University; University of Notre Dame Australia; University of New South Wales Sydney; University of Oxford; University of Newcastle; University of South Australia; Brunel University; University of New South Wales Sydney; University of Technology Sydney; Melanoma Institute Australia; University of Sydney; Imam Abdulrahman Bin Faisal University; Zurich University of Applied Sciences; University of Sydney; University of Sydney	McAuley, JH (corresponding author), Neurosci Res Australia, Margarete Ainsworth Bldg,Barker St, Sydney, NSW 2031, Australia.	j.mcauley@neura.edu.au	McAuley, James Henry/HHC-3949-2022; Bagg, Matthew/GSN-4849-2022; Maher, Christopher/AAC-6267-2019; Moseley, Lorimer/A-7095-2009; Stanton, Tasha/F-4038-2013	McAuley, James Henry/0000-0002-0550-828X; Maher, Christopher/0000-0002-1628-7857; Wand, Benedict/0000-0002-0297-0292; O'Hagan, Edel T/0000-0002-1914-5918; Saing, Sopany/0000-0001-5913-9654; Moseley, Lorimer/0000-0002-3750-4945; Stanton, Tasha/0000-0001-7106-4456	National Health and Medical Research Council of Australia [ID1087045]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was funded by the National Health and Medical Research Council of Australia (ID1087045).	Bagg MK, 2021, BRAZ J PHYS THER, V25, P103, DOI 10.1016/j.bjpt.2020.06.002; Bagg Matthew K, 2017, J Physiother, V63, P47, DOI 10.1016/j.jphys.2016.11.001; Buchbinder R, 2018, LANCET, V391, P2384, DOI 10.1016/S0140-6736(18)30488-4; Busse JW, 2015, J RHEUMATOL, V42, P1962, DOI 10.3899/jrheum.141440; Cashin AG, 2020, J CLIN EPIDEMIOL, V126, P106, DOI 10.1016/j.jclinepi.2020.06.025; Chou R, 2017, ANN INTERN MED, V166, P480, DOI 10.7326/M16-2458; Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4; Dunn G, 2005, STAT METHODS MED RES, V14, P369, DOI 10.1191/0962280205sm403oa; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Foster NE, 2018, LANCET, V391, P2368, DOI 10.1016/S0140-6736(18)30489-6; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; GBD results, GLOBAL DATA HLTH EXC; Hartvigsen J, 2018, LANCET, V391, P2356, DOI 10.1016/S0140-6736(18)30480-X; Hayden JA, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009790.pub2; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Knezevic NN, 2021, LANCET, V398, P78, DOI 10.1016/S0140-6736(21)00733-9; Kreidler SM, 2013, J STAT SOFTW, V54, P1, DOI 10.18637/jss.v054.i10; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Costa LDM, 2012, CAN MED ASSOC J, V184, pE613, DOI 10.1503/cmaj.111271; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Rubinstein SM, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l689; Shaheed CA, 2016, JAMA INTERN MED, V176, P958, DOI 10.1001/jamainternmed.2016.1251; Soer R, 2012, SPINE J, V12, P1035, DOI 10.1016/j.spinee.2012.10.030	24	2	2	4	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2022	328	5					430	439		10.1001/jama.2022.9930	http://dx.doi.org/10.1001/jama.2022.9930			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3U1CS	35916848				2023-01-03	WOS:000840708300008
J	Larkin, HD				Larkin, Howard D.			New Guidance Aims to Improve Community Access to Naloxone	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	2022	328	17					1679	1679						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6C4JN	36318149				2023-01-03	WOS:000881982900047
J	Amaria, RN; Postow, M; Burton, EM; Tezlaff, MT; Ross, MI; Torres-Cabala, C; Glitza, IC; Duan, F; Milton, DR; Busam, K; Simpson, L; McQuade, JL; Wong, MK; Gershenwald, JE; Lee, JE; Goepfert, RP; Keung, EZ; Fisher, SB; Betof-Warner, A; Shoushtari, AN; Callahan, M; Coit, D; Bartlett, EK; Bello, D; Momtaz, P; Nicholas, C; Gu, AD; Zhang, XJ; Korivi, BR; Patnana, M; Patel, SP; Diab, A; Lucci, A; Prieto, VG; Davies, MA; Allison, JP; Sharma, P; Wargo, JA; Ariyan, C; Tawbi, HA				Amaria, Rodabe N.; Postow, Michael; Burton, Elizabeth M.; Tezlaff, Michael T.; Ross, Merrick, I; Torres-Cabala, Carlos; Glitza, Isabella C.; Duan, Fei; Milton, Denai R.; Busam, Klaus; Simpson, Lauren; McQuade, Jennifer L.; Wong, Michael K.; Gershenwald, Jeffrey E.; Lee, Jeffrey E.; Goepfert, Ryan P.; Keung, Emily Z.; Fisher, Sarah B.; Betof-Warner, Allison; Shoushtari, Alexander N.; Callahan, Margaret; Coit, Daniel; Bartlett, Edmund K.; Bello, Danielle; Momtaz, Parisa; Nicholas, Courtney; Gu, Aidi; Zhang, Xuejun; Korivi, Brinda Rao; Patnana, Madhavi; Patel, Sapna P.; Diab, Adi; Lucci, Anthony; Prieto, Victor G.; Davies, Michael A.; Allison, James P.; Sharma, Padmanee; Wargo, Jennifer A.; Ariyan, Charlotte; Tawbi, Hussein A.			Neoadjuvant relatlimab and nivolumab in resectable melanoma	NATURE			English	Article							ADJUVANT DABRAFENIB; SURVIVAL; IMMUNOTHERAPY; TRAMETINIB; THERAPY; CELLS; LAG-3	Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma(1). We investigated this regimen in patients with resectable clinical stage III or oligometastatic stage IV melanoma (NCT02519322). Patients received two neoadjuvant doses (nivolumab 480 mg and relatlimab 160 mg intravenously every 4 weeks) followed by surgery, and then ten doses of adjuvant combination therapy. The primary end point was pathologic complete response (pCR) rate(2). The combination resulted in 57% pCR rate and 70% overall pathologic response rate among 30 patients treated. The radiographic response rate using Response Evaluation Criteria in Solid Tumors 1.1 was 57%. No grade 3-4 immune-related adverse events were observed in the neoadjuvant setting. The 1- and 2-year recurrence-free survival rate was 100% and 92% for patients with any pathologic response, compared to 88% and 55% for patients who did not have a pathologic response (P = 0.005). Increased immune cell infiltration at baseline, and decrease in M2 macrophages during treatment, were associated with pathologic response. Our results indicate that neoadjuvant relatlimab and nivolumab induces a high pCR rate. Safety during neoadjuvant therapy is favourable compared to other combination immunotherapy regimens. These data, in combination with the results of the RELATIVITY-047 trial(1), provide further confirmation of the efficacy and safety of this new immunotherapy regimen.	[Amaria, Rodabe N.; Burton, Elizabeth M.; Glitza, Isabella C.; Simpson, Lauren; McQuade, Jennifer L.; Wong, Michael K.; Patel, Sapna P.; Diab, Adi; Davies, Michael A.; Tawbi, Hussein A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Postow, Michael; Betof-Warner, Allison; Shoushtari, Alexander N.; Callahan, Margaret; Momtaz, Parisa] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Postow, Michael; Betof-Warner, Allison; Shoushtari, Alexander N.; Callahan, Margaret; Momtaz, Parisa] Weill Cornea Med Coll, New York, NY USA; [Tezlaff, Michael T.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Ross, Merrick, I; Gershenwald, Jeffrey E.; Lee, Jeffrey E.; Keung, Emily Z.; Fisher, Sarah B.; Lucci, Anthony; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Torres-Cabala, Carlos; Prieto, Victor G.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Duan, Fei; Nicholas, Courtney; Gu, Aidi; Zhang, Xuejun; Allison, James P.; Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Milton, Denai R.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Busam, Klaus] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Goepfert, Ryan P.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Coit, Daniel; Bartlett, Edmund K.; Bello, Danielle; Ariyan, Charlotte] Mem Sloan Kettering Canc Ctr, Dept Surg Oncol, 1275 York Ave, New York, NY 10021 USA; [Korivi, Brinda Rao; Patnana, Madhavi] Univ Texas MD Anderson Canc Ctr, Dept Radiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Amaria, RN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA.	rnamaria@mdanderson.org			National Institutes of Health/National Cancer Institute [P30 CA08748]; Parker Institute for Cancer Immunotherapy at MSKCC	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Parker Institute for Cancer Immunotherapy at MSKCC	We would like to acknowledge the Melanoma Informatics, Tissue Resource and Translational Pathology Core at The University of Texas MD Anderson Cancer Center. This project was supported by the generous philanthropic contributions to The University of Texas MD Anderson Cancer Moon Shots Program. M. Postow is supported by Cancer Center Support Grant P30 CA08748 from the National Institutes of Health/National Cancer Institute. C.A. is supported by a pilot grant from the Parker Institute for Cancer Immunotherapy at MSKCC.	Amaria RN, 2019, LANCET ONCOL, V20, pE378, DOI 10.1016/S1470-2045(19)30332-8; Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Amaria RN, 2018, LANCET ONCOL, V19, P181, DOI 10.1016/S1470-2045(18)30015-9; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Ascierto PA, 2017, ANN ONCOL, V28; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Cortazar P, 2019, LANCET, V393, P986; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Gershenwald JE, 2017, CA-CANCER J CLIN, V67, P472, DOI 10.3322/caac.21409; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Jordan KR, 2013, CANCER IMMUNOL IMMUN, V62, P1711, DOI 10.1007/s00262-013-1475-x; Kasi A, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.30097; Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577; Llao-Cid L, 2021, LEUKEMIA, V35, P3152, DOI 10.1038/s41375-021-01198-1; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Long GV, 2021, CANCER RES, V81; Long GV, 2019, LANCET ONCOL, V20, P961, DOI 10.1016/S1470-2045(19)30331-6; Menzies AM, 2021, NAT MED, V27, P301, DOI 10.1038/s41591-020-01188-3; Nowicka Malgorzata, 2017, F1000Res, V6, P748, DOI 10.12688/f1000research.11622.3; Petrelli F, 2014, EUR UROL, V65, P350, DOI 10.1016/j.eururo.2013.06.049; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rozeman EA, 2021, NAT MED, V27, P256, DOI 10.1038/s41591-020-01211-7; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Tawbi HA, 2022, NEW ENGL J MED, V386, P24, DOI 10.1056/NEJMoa2109970; Tetzlaff MT, 2018, ANN ONCOL, V29, P1861, DOI 10.1093/annonc/mdy226; Topalian SL, 2020, J CLIN ONCOL, V38, P2476, DOI 10.1200/JCO.20.00201; US Department of Health and Human Services N., 2010, COMMON TERMINOLOGY C; van Akkooi ACJ, 2022, ANN SURG ONCOL, V29, P3694, DOI 10.1245/s10434-021-11236-y; Vos JL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26472-9; Weber, 2022, PIG CELL MEL RES, V35, P97; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620	34	1	1	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 3	2022	611	7934					155	+		10.1038/s41586-022-05368-8	http://dx.doi.org/10.1038/s41586-022-05368-8		OCT 2022	20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5X0BB	36289334	Green Published, hybrid			2023-01-03	WOS:000875061600014
J	Hammond, NE; Myburgh, J; Seppelt, I; Garside, T; Vlok, R; Mahendran, S; Adigbli, D; Finfer, S; Gao, Y; Goodman, F; Guyatt, G; Santos, JA; Venkatesh, B; Yao, L; Di Tanna, GL; Delaney, A				Hammond, Naomi E.; Myburgh, John; Seppelt, Ian; Garside, Tessa; Vlok, Ruan; Mahendran, Sajeev; Adigbli, Derick; Finfer, Simon; Gao, Ya; Goodman, Fiona; Guyatt, Gordon; Santos, Joseph Alvin; Venkatesh, Balasubramanian; Yao, Liam; Di Tanna, Gian Luca; Delaney, Anthony			Association Between Selective Decontamination of the Digestive Tract and In-Hospital Mortality in Intensive Care Unit Patients Receiving Mechanical Ventilation A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review; Early Access							CRITICALLY-ILL PATIENTS; CAMPAIGN INTERNATIONAL GUIDELINES; MULTIPLE TRAUMA PATIENTS; DOUBLE-BLIND; CONTROLLED-TRIAL; ANTIBIOTIC-PROPHYLAXIS; ORAL DECONTAMINATION; ACQUIRED INFECTIONS; INTUBATED PATIENTS; PREVENTION	IMPORTANCE The effectiveness of selective decontamination of the digestive tract (SDD) in critically ill adults receiving mechanical ventilation is uncertain. OBJECTIVE To determine whether SDD is associated with reduced risk of death in adults receiving mechanical ventilation in intensive care units (ICUs) compared with standard care. DATA SOURCES The primary search was conducted using MEDLINE, EMBASE, and CENTRAL databases until September 2022. STUDY SELECTION Randomized clinical trials including adults receiving mechanical ventilation in the ICU comparing SDD vs standard care or placebo. DATA EXTRACTION AND SYNTHESIS Data extraction and risk of bias assessmentswere performed in duplicate. The primary analysis was conducted using a bayesian framework. MAIN OUTCOMES AND MEASURES The primary outcomewas hospital mortality. Subgroups included SDD with an intravenous agent compared with SDD without an intravenous agent. There were 8 secondary outcomes including the incidence of ventilator-associated pneumonia, ICU-acquired bacteremia, and the incidence of positive cultures of antimicrobial-resistant organisms. RESULTS There were 32 randomized clinical trials including 24 389 participants in the analysis. The median age of participants in the included studies was 54 years (IQR, 44-60), and the median proportion of female trial participants was 33%(IQR, 25%-38%). Data from 30 trials including 24 034 participants contributed to the primary outcome. The pooled estimated risk ratio (RR) for mortality for SDD compared with standard care was 0.91 (95% credible interval [CrI], 0.82-0.99; I2 = 33.9%; moderate certainty) with a 99.3% posterior probability that SDD reduced hospital mortality. The beneficial association of SDD was evident in trials with an intravenous agent (RR, 0.84 [95% CrI, 0.74-0.94]), but not in trials without an intravenous agent (RR, 1.01 [95% CrI, 0.91-1.11]) (P value for the interaction between subgroups =.02). SDD was associated with reduced risk of ventilator-associated pneumonia (RR, 0.44 [95% CrI, 0.36-0.54]) and ICU-acquired bacteremia (RR, 0.68 [95% CrI, 0.57-0.81]). Available data regarding the incidence of positive cultures of antimicrobial-resistant organisms were not amenable to pooling and were of very low certainty. CONCLUSIONS AND RELEVANCE Among adults in the ICU treated with mechanical ventilation, the use of SDD compared with standard care or placebo was associated with lower hospital mortality. Evidence regarding the effect of SDD on antimicrobial resistance was of very low certainty.	[Hammond, Naomi E.; Myburgh, John; Seppelt, Ian; Garside, Tessa; Adigbli, Derick; Finfer, Simon; Goodman, Fiona; Venkatesh, Balasubramanian; Delaney, Anthony] George Inst Global Hlth, Crit Care Program, Sydney, NSW, Australia; [Hammond, Naomi E.; Myburgh, John; Seppelt, Ian; Garside, Tessa; Adigbli, Derick; Finfer, Simon; Goodman, Fiona; Venkatesh, Balasubramanian; Delaney, Anthony] Univ New South Wales, Sydney, NSW, Australia; [Hammond, Naomi E.; Garside, Tessa; Vlok, Ruan; Mahendran, Sajeev; Adigbli, Derick; Delaney, Anthony] Royal North Shore Hosp, Malcolm Fisher Dept Intens Care, Sydney, NSW, Australia; [Myburgh, John] St George Hosp, Dept Intens Care, Kogarah, NSW, Australia; [Seppelt, Ian] Nepean Hosp, Dept Intens Care Med, Penrith, NSW, Australia; [Finfer, Simon] Imperial Coll, Sch Publ Hlth, George Inst Global Hlth, London, England; [Gao, Ya] Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China; [Gao, Ya; Yao, Liam] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Guyatt, Gordon] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Santos, Joseph Alvin; Di Tanna, Gian Luca] Univ New South Wales, George Inst Global Hlth, Biostat & Data Sci Div, Meta Res & Evidence Synth, Sydney, NSW, Australia; [Venkatesh, Balasubramanian] Wesley & Princess Alexandra Hosp, Intens Care Unit, Woolloongabba, Qld, Australia; [Di Tanna, Gian Luca] Univ Appl Sci & Arts Southern Switzerland, Dept Innovat Technol, Viganello Lugano, Switzerland	George Institute for Global Health; University of Sydney; University of New South Wales Sydney; Royal North Shore Hospital; St George Hospital; Nepean Hospital; University of Sydney; Imperial College London; Lanzhou University; McMaster University; McMaster University; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; Wesley Hospital	Delaney, A (corresponding author), George Inst Global Hlth, 1 King St,Level 5, Newtown, NSW 2042, Australia.	adelaney@georgeinstitute.org.au		Finfer, Simon/0000-0002-2785-5864; Hammond, Naomi/0000-0002-6559-7747; Delaney, Anthony/0000-0002-1015-7146; Myburgh, John/0000-0003-4088-7016; Santos, Joseph Alvin/0000-0002-8195-3887	George Institute for Global Health; National Health and Medical Research Council of Australia Emerging Leader Investigator Grant; National Health and Medical Research Council of Australia Leadership Investigator Grant; National Health and Medical Research Council	George Institute for Global Health; National Health and Medical Research Council of Australia Emerging Leader Investigator Grant(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council of Australia Leadership Investigator Grant(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Funding for administrative and communications support was provided by The George Institute for Global Health. Funding support from National Health and Medical Research Council of Australia Emerging Leader Investigator Grant was provided to Dr Hammond. National Health and Medical Research Council of Australia Leadership Investigator Grant was provided to Drs Myburgh and Venkatesh. Dr Finfer is supported by a Practitioner Fellowship from the National Health and Medical Research Council.	AbeleHorn M, 1997, INTENS CARE MED, V23, P187, DOI 10.1007/s001340050314; AERDTS SJA, 1991, CHEST, V100, P783, DOI 10.1378/chest.100.3.783; Bergmans DCJJ, 2001, AM J RESP CRIT CARE, V164, P382, DOI 10.1164/ajrccm.164.3.2005003; BLAIR P, 1991, SURGERY, V110, P303; Camus C, 2005, CRIT CARE MED, V33, P307, DOI 10.1097/01.CCM.0000152224.01949.01; COCKERILL FR, 1992, ANN INTERN MED, V117, P545, DOI 10.7326/0003-4819-117-7-545; Covidence, BETTER SYSTEMATIC RE; Daneman N, 2013, LANCET INFECT DIS, V13, P328, DOI 10.1016/S1473-3099(12)70322-5; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; de La Cal MA, 2005, ANN SURG, V241, P424, DOI 10.1097/01.sla.0000154148.58154.d5; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Dellinger RP, 2013, INTENS CARE MED, V39, P165, DOI [10.1097/CCM.0b013e31827e83af, 10.1007/s00134-012-2769-8]; DistillerSR, TOOL ASSESS RISK BIA; Evans L, 2021, CRIT CARE MED, V49, pE1063, DOI 10.1097/CCM.0000000000005337; Garcia MS, 1998, AM J RESP CRIT CARE, V158, P908, DOI 10.1164/ajrccm.158.3.9712079; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; Gaussorgues P., 1991, REANIMATION SOINS IN, V7, P169; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; IntHout J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010247; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Jacobs S., 1992, CLIN INTENSIVE CARE, V3, P52; Julian Higgins JT, 2022, COCHRANE HDB SYSTEMA; KERVER AJH, 1988, CRIT CARE MED, V16, P1087, DOI 10.1097/00003246-198811000-00001; Koeman M, 2006, AM J RESP CRIT CARE, V173, P1348, DOI 10.1164/rccm.200505-820OC; KORINEK AM, 1993, CRIT CARE MED, V21, P1466, DOI 10.1097/00003246-199310000-00013; Krueger WA, 2002, AM J RESP CRIT CARE, V166, P1029, DOI 10.1164/rccm.2105141; LANGLOISKARAGA A, 1995, PHARM WORLD SCI, V17, P12, DOI 10.1007/BF01875552; Lewis RJ, 2018, JAMA-J AM MED ASSOC, V320, P2208, DOI 10.1001/jama.2018.16916; Liberati A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000022.pub3; McKenzie J., 2016, CLUSTER RANDOMISED C; Minozzi S, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000022.pub4; Myburgh JA, 2022, JAMA-J AM MED ASSOC, DOI 10.1001/jama.2022.17927; N. E. Hammond, 2022, medRxiv, DOI 10.1101/2022.03.18.22272586; Ochodo EA, 2022, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013208.pub2; Oostdijk EAN, 2010, AM J RESP CRIT CARE, V181, P452, DOI 10.1164/rccm.200908-1210OC; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Palomar M., 1997, CLIN INTENSIVE CARE, V8, P228, DOI [10.3109/tcic.8.5.228.235, DOI 10.3109/TCIC.8.5.228.235]; Papoti S., 2019, INTENSIVE CARE MED E, V7; Pneumatikos I, 2002, INTENS CARE MED, V28, P432, DOI 10.1007/s00134-002-1238-1; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; Quinio B, 1996, CHEST, V109, P765, DOI 10.1378/chest.109.3.765; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; ROCHA LA, 1992, INTENS CARE MED, V18, P398, DOI 10.1007/BF01694341; RODRIGUEZROLDAN JM, 1990, CRIT CARE MED, V18, P1239, DOI 10.1097/00003246-199011000-00011; Rover C, 2020, J STAT SOFTW, V93, P1, DOI 10.18637/jss.v093.i06; Schandelmaier S, 2020, CAN MED ASSOC J, V192, pE901, DOI 10.1503/cmaj.200077; Stoutenbeek CP, 2007, INTENS CARE MED, V33, P261, DOI 10.1007/s00134-006-0455-4; STOUTENBEEK CP, 1984, INTENS CARE MED, V10, P185, DOI 10.1007/BF00259435; Turner RM, 2015, STAT MED, V34, P984, DOI 10.1002/sim.6381; ULRICH C, 1989, INTENS CARE MED, V15, P424, DOI 10.1007/BF00255597; UNERTL K, 1987, INTENS CARE MED, V13, P106; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135; WIENER J, 1995, CLIN INFECT DIS, V20, P861, DOI 10.1093/clinids/20.4.861; Wittekamp BH, 2018, JAMA-J AM MED ASSOC, V320, P2087, DOI 10.1001/jama.2018.13765	55	3	3	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.19709	http://dx.doi.org/10.1001/jama.2022.19709		OCT 2022	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5U6IM	36286098				2023-01-03	WOS:000876648400006
J	Hwang, TJ; Kesselheim, AS; Vokinger, KN				Hwang, Thomas J.; Kesselheim, Aaron S.; Vokinger, Kerstin N.			Reforming the World Health Organization's Essential Medicines List Essential but Unaffordable	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material; Early Access									[Hwang, Thomas J.; Kesselheim, Aaron S.; Vokinger, Kerstin N.] Harvard Med Sch, Boston, MA USA; [Hwang, Thomas J.; Kesselheim, Aaron S.; Vokinger, Kerstin N.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Program Regulat Therapeut & Law PORTAL, Boston, MA USA; [Hwang, Thomas J.] Brigham & Womens Hosp, Div Urol Surg, Boston, MA USA; [Hwang, Thomas J.] Dana Farber Canc Inst, Boston, MA USA; [Vokinger, Kerstin N.] Univ Zurich, Lab Technol Markets & Regulat, Zurich, Switzerland; Univ Zurich, Inst Law, Zurich, Switzerland	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; University of Zurich; University of Zurich	Kesselheim, AS (corresponding author), 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.				Arnold Ventures; Swiss National Science Foundation; Swiss Cancer Research Foundation	Arnold Ventures; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer Research Foundation	Dr Kesselheim reports support from Arnold Ventures. Dr Vokinger reports support from the Swiss National Science Foundation and the Swiss Cancer Research Foundation.	Cherny NI, 2017, ANN ONCOL, V28, P2340, DOI 10.1093/annonc/mdx310; Farmer P, 2003, B WORLD HEALTH ORGAN, V81, P699; World Health Organization, WHO MED STRAT REP SE; World Health Organization, 2021, SEL US ESS MED 2021	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.												10.1001/jama.2022.19459	http://dx.doi.org/10.1001/jama.2022.19459		OCT 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5S0HX	36279114	Green Accepted			2023-01-03	WOS:000874883400002
J	Liang, HY; Lee, MD; Lin, KC; Lin, LH; Yu, S				Liang, Hui-Yu; Lee, Ming-Der; Lin, Kuan-Chia; Lin, Lieh-Hann; Yu, Shu			Determinants of the health care service choices of long-term mechanical ventilation patients: Applying andersen's behavioral model	PLOS ONE			English	Article							FAMILY CAREGIVERS; MEDICAL-CARE; EXPENDITURES; OUTCOMES; ACCESS; NEEDS	Aims The number of ventilator-dependent patients is rapidly increasing globally. As a result, long-term mechanical ventilation (LTMV) patients face the choice of receiving health care in respiratory care wards (RCWs) rather than at home. In this study, we applied Andersen's behavioral theoretical model (ABM) to investigate the determinants of the health care service decisions of patients receiving LTMV. Methods A cross-sectional research design and cluster random sampling were used to select 365 participants from nine RCWs and eight home care facilities in northern Taiwan. Data were collected in face-to-face interviews using a structured questionnaire. Results Of the predisposing factors, advanced age and an education level of at least junior high school influenced the choice to use RCW services. Being married, living with extended family, and medium or higher socioeconomic status were associated with the decision to use home care services. Of the enabling factors, patients with more caregivers, those whose family caregivers held strong beliefs about providing care, and those who perceived greater social support from health care providers were more likely to choose home care services. Of the need factors examined, poor cognitive function and higher dependence on assistance for activities of daily living (ADL) increased the probability of patients choosing RCW services. Hierarchical logistic regression analysis indicated that our final model accounted for 44.8% of the observed variance in health care service choice. Conclusions ABM enables an improved understanding of the health care service choices of LTMV patients. Our findings also highlight the importance of rigorously assessing patient needs and helping patients choose the most appropriate health care service.	[Liang, Hui-Yu] Natl Taipei Univ Nursing & Hlth Sci, Sch Nursing, Taipei, Taiwan; [Lee, Ming-Der] Natl Taipei Univ Nursing & Hlth Sci, Dept Long Term Care, Taipei, Taiwan; [Lin, Kuan-Chia] Natl Yang Ming Chiao Tung Univ, Inst Hosp & Hlth Care Adm, Community Res Ctr, Taipei, Taiwan; [Lin, Lieh-Hann] Hsu Med Fdn, Dept Emergency Med, Lotung Poh Ai Hosp, Yilan, Taiwan; [Yu, Shu] Natl Yang Ming Chiao Tung Univ, Sch Nursing, Taipei, Taiwan	National Taipei University of Nursing & Health Science (NTUNHS); National Taipei University of Nursing & Health Science (NTUNHS); National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Yu, S (corresponding author), Natl Yang Ming Chiao Tung Univ, Sch Nursing, Taipei, Taiwan.	yushu@nycu.edu.tw			National Yang-Ming University Hospital [RD2017-009]	National Yang-Ming University Hospital	This study was funded by the National Yang-Ming University Hospital (project No: RD2017-009). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALBERT SM, 1992, SOC SCI MED, V35, P699, DOI 10.1016/0277-9536(92)90008-E; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ANDERSEN RM, 1983, HEALTH SERV RES, V18, P49; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Andersen RM., 2013, IMPROVING ACCESS CAR, V4th ed; Babitsch Birgit, 2012, Psychosoc Med, V9, pDoc11, DOI 10.3205/psm000089; Carson SS, 2012, RESP CARE, V57, P848, DOI 10.4187/respcare.01736; Chang SL., 2006, STUDY SOCIOECONOMIC; Choi S, 2015, J GERONTOL SOC WORK, V58, P149, DOI 10.1080/01634372.2014.943447; Divo MJ, 2010, RESP CARE, V55, P1693; Dorin L, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-233; Evans R, 2012, CAN RESPIR J, V19, P373, DOI 10.1155/2012/452898; Fahle S, 2016, FISC STUD, V37, P785, DOI 10.1111/j.1475-5890.2016.12126; Filc D, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0115-1; Fu YY, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0436-1; Gehlbach BK, 2011, AM J CRIT CARE, V20, P378, DOI 10.4037/ajcc2011827; Greenberger H, 2003, J ADV NURS, V41, P332, DOI 10.1046/j.1365-2648.2003.02531.x; Hill AD, 2017, ANN AM THORAC SOC, V14, P355, DOI 10.1513/AnnalsATS.201610-792OC; Hollingshead A.B., 1957, 2 FACTOR INDEX SOCIA; Hsu HC., 2002, THESIS NATL TAIWAN U; Huang TT, 2010, J CLIN NURS, V19, P1686, DOI 10.1111/j.1365-2702.2009.03007.x; Hung MC, 2011, CRIT CARE, V15, DOI 10.1186/cc10128; Kahn JM, 2010, JAMA-J AM MED ASSOC, V303, P2253, DOI 10.1001/jama.2010.761; Katz MH., 2011, MULTIVARIABLE ANAL P, V3 ed, DOI [DOI 10.1017/CBO9780511974175, 10.1017/CBO9780511974175]; Kim EY, 2013, INT NURS REV, V60, P520, DOI 10.1111/inr.12057; Kim EY, 2006, J ADV NURS, V54, P511, DOI 10.1111/j.1365-2648.2006.03839.x; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Ku SC YC., 2010, CRIT CARE MED, V11, P25, DOI [10.30035/TCCM.201003.0004, DOI 10.30035/TCCM.201003.0004]; Lee YC., 2000, DIRECT INDIRECT DETE; Lin SC., 2005, SOCIOL EDUC; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; Liu CJ, 2013, RESP CARE, V58, P676, DOI 10.4187/respcare.01242; Liu JF, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007396; Lone NI, 2011, CRIT CARE, V15, DOI 10.1186/cc10117; Luppa M, 2010, AGE AGEING, V39, P31, DOI 10.1093/ageing/afp202; MAHONEY F I, 1965, Md State Med J, V14, P61; McKim DA, 2011, CAN RESPIR J, V18, P197, DOI 10.1155/2011/139769; National Health Insurance Administration Ministry of Health and Welfare, 2022, INTEGRATED DELIVERY; Nelson JE, 2005, J CRIT CARE, V20, P79, DOI 10.1016/j.jcrc.2004.11.003; Ni TF., 2001, STUDY LIFE QUALITY V; Pai SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179274; Peng TR, 2003, GERONTOLOGIST, V43, P503, DOI 10.1093/geront/43.4.503; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Ren LB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21983-w; Rose L, 2015, J CRIT CARE, V30, P25, DOI 10.1016/j.jcrc.2014.07.023; Saeed BII, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1603-y; Solli H, 2018, INFORM HEALTH SOC CA, V43, P207, DOI 10.1080/17538157.2017.1364245; Su HM., 2009, STUDY CAREGIVERS CAR; Tsao YS., 2002, STUDY RELATIONSHIP E; Tzeng SF., 2005, UTILIZATION FACTORS; Wu CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089213; Yamamoto N, 1997, J HEALTH SOC BEHAV, V38, P164, DOI 10.2307/2955423; Zhang LW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182219; Zilberberg MD, 2008, CRIT CARE MED, V36, P724, DOI 10.1097/CCM.0B013E31816536F7; Zilberberg MD, 2012, CRIT CARE MED, V40, P18, DOI 10.1097/CCM.0b013e31822e9ffd	55	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2022	17	9							e0274303	10.1371/journal.pone.0274303	http://dx.doi.org/10.1371/journal.pone.0274303			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R1EM	36084012	Green Published, gold			2023-01-03	WOS:000892051000125
J	Thomas, HJ; Marsh, CE; Maslen, BA; Lester, L; Naylor, LH; Green, DJ				Thomas, Hannah J.; Marsh, Channa E.; Maslen, Barbara A.; Lester, Leanne; Naylor, Louise H.; Green, Daniel J.			Endurance versus resistance training in treatment of cardiovascular risk factors: A randomized cross-over trial	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; REDUCTION INTERVENTION; DEFINED EXERCISE; WEIGHT-LOSS; FITNESS; EVENTS; ADULTS; NONRESPONDERS; ADAPTATION; RATIONALE	Background Individual variability in traditional cardiovascular risk factor responses to different exercise modalities has not been directly addressed in humans using a randomized cross-over design. Methods Body weight and body mass index, resting blood pressure, blood glucose, insulin and lipids were assessed in 68 healthy untrained adults (26 +/- 6 years) who underwent three-months of exercise training targeted at improving cardiopulmonary fitness (endurance) and skeletal muscle function (resistance), separated by three-months washout. Results There were significant increases in weight and body mass index following resistance (+0.8 kg, P<0.01; and +0.26 kg/m(2), P<0.01, respectively), but not endurance (+0.1 kg, P = 0.75; and +0.03 kg/m(2), P = 0.70, respectively). Although no significant group changes resulted from training in other cardiovascular risk factors, the positive response rate for all variables ranged from 27-49% for resistance and 42-58% for endurance. Between 39-59% of individuals who did not respond to resistance nonetheless responded to endurance, and 28-54% who did not respond to endurance responded to resistance. Conclusion Whilst, on average, 12 weeks of resistance or endurance did not change most cardiovascular risk factors, many subjects showed robust positive responses. Exercise modality had an impact on the proportion of subjects who responded to training, and non-response to one mode of training did not imply non-response to the alternate mode. Although the effect of exercise on a single risk factor may be modest, the effect on overall cardiovascular risk profile can be dramatic.	[Thomas, Hannah J.; Marsh, Channa E.; Maslen, Barbara A.; Lester, Leanne; Naylor, Louise H.; Green, Daniel J.] Univ Western Australia, Sch Human Sci Exercise & Sport Sci, Perth, WA, Australia	University of Western Australia	Green, DJ (corresponding author), Univ Western Australia, Sch Human Sci Exercise & Sport Sci, Perth, WA, Australia.	danny.green@uwa.edu.au	Green, Daniel John/B-7379-2013	Green, Daniel John/0000-0003-3226-2921; Naylor, Louise/0000-0002-6210-912X	NHMRC Principal Research Fellowship [APP1080914]	NHMRC Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	DG was supported by a NHMRC Principal Research Fellowship (APP1080914). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen LB, 2016, LANCET, V388, P1255, DOI 10.1016/S0140-6736(16)30960-6; Astorino TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097638; Bateman LA, 2011, AM J CARDIOL, V108, P838, DOI 10.1016/j.amjcard.2011.04.037; Blair SN, 2009, ANN EPIDEMIOL, V19, P253, DOI 10.1016/j.annepidem.2009.01.019; Bonafiglia JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167790; Bouchard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037887; Chudyk A, 2011, DIABETES CARE, V34, P1228, DOI 10.2337/dc10-1881; Churchward-Venne TA, 2015, J AM MED DIR ASSOC, V16, P400, DOI 10.1016/j.jamda.2015.01.071; Daniels J, 2013, DANIELS RUNNING FORM, V3rd; Das P, 2016, LANCET, V388, P1254, DOI 10.1016/S0140-6736(16)31070-4; de Koning L, 2007, EUR HEART J, V28, P850, DOI 10.1093/eurheartj/ehm026; Douketis JD, 2005, INT J OBESITY, V29, P1153, DOI 10.1038/sj.ijo.0802982; Gast KB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052036; Gould AL, 1998, CIRCULATION, V97, P946; Green DJ, 2008, J APPL PHYSIOL, V105, P766, DOI 10.1152/japplphysiol.01028.2007; Green DJ, 2017, PHYSIOL REV, V97, P495, DOI 10.1152/physrev.00014.2016; Hambrecht R, 2000, NEW ENGL J MED, V342, P454, DOI 10.1056/NEJM200002173420702; Hamer M, 2009, MED SCI SPORT EXER, V41, P1206, DOI 10.1249/MSS.0b013e3181971247; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Hautala AJ, 2006, EUR J APPL PHYSIOL, V96, P535, DOI 10.1007/s00421-005-0116-2; Ho SS, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-704; Jacobson TA, 2007, CLIN THER, V29, P763, DOI 10.1016/j.clinthera.2007.05.002; Joyner MJ, 2009, J PHYSIOL-LONDON, V587, P5551, DOI 10.1113/jphysiol.2009.179432; Karavirta L, 2011, MED SCI SPORT EXER, V43, P484, DOI 10.1249/MSS.0b013e3181f1bf0d; Kraus WE, 2001, MED SCI SPORT EXER, V33, P1774, DOI 10.1097/00005768-200110000-00025; Lavie CJ, 2009, J AM COLL CARDIOL, V53, P1925, DOI 10.1016/j.jacc.2008.12.068; Leon AS, 2001, MED SCI SPORT EXER, V33, pS502, DOI 10.1097/00005768-200106001-00021; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Maiorana A, 2000, AM J PHYSIOL-HEART C, V279, pH1999, DOI 10.1152/ajpheart.2000.279.4.H1999; Maiorana A, 2003, SPORTS MED, V33, P1013, DOI 10.2165/00007256-200333140-00001; Maiorana A, 2000, J APPL PHYSIOL, V88, P1565, DOI 10.1152/jappl.2000.88.5.1565; Mann TN, 2014, SPORTS MED, V44, P1113, DOI 10.1007/s40279-014-0197-3; Marsh CE, 2020, CONT CLIN TRIAL COMM, V19, DOI 10.1016/j.conctc.2020.100584; Marsh CE, 2020, J PHYSIOL-LONDON, V598, P3845, DOI 10.1113/JP280048; Montero D, 2017, J PHYSIOL-LONDON, V595, P3377, DOI 10.1113/JP273480; Mora S, 2007, CIRCULATION, V116, P2110, DOI 10.1161/CIRCULATIONAHA.107.729939; Morss GM, 2004, MED SCI SPORT EXER, V36, P336, DOI 10.1249/01.MSS.0000113738.06267.E5; Myers J, 2003, CIRCULATION, V107, pE2, DOI 10.1161/01.CIR.0000048890.59383.8D; Nystoriak Matthew A, 2018, Front Cardiovasc Med, V5, P135, DOI 10.3389/fcvm.2018.00135; Ross R, 2019, BRIT J SPORT MED, V53, P1141, DOI 10.1136/bjsports-2018-100328; Ross R, 2015, MAYO CLIN PROC, V90, P1506, DOI 10.1016/j.mayocp.2015.07.024; Schroeder EC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210292; Sisson SB, 2009, MED SCI SPORT EXER, V41, P539, DOI 10.1249/MSS.0b013e3181896c4e; Skinner JS, 2001, J APPL PHYSIOL, V90, P1770, DOI 10.1152/jappl.2001.90.5.1770; Spence AL, 2011, J PHYSIOL-LONDON, V589, P5443, DOI 10.1113/jphysiol.2011.217125; Thomas HJ, 2021, MED SCI SPORT EXER, V53, P58, DOI 10.1249/MSS.0000000000002461; Thompson AM, 2008, CONTEMP CLIN TRIALS, V29, P418, DOI 10.1016/j.cct.2007.09.009; Tremblay MS, 2011, APPL PHYSIOL NUTR ME, V36, P36, DOI [10.1139/H11-009, 10.1139/H11-010]; Williamson DA, 2015, OBESITY, V23, P2319, DOI 10.1002/oby.21358; Wilund KR, 2002, METABOLISM, V51, P1053, DOI 10.1053/meta.2002.33356	50	0	0	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2022	17	9							e0274082	10.1371/journal.pone.0274082	http://dx.doi.org/10.1371/journal.pone.0274082			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R5TD	36067151	Green Published, gold			2023-01-03	WOS:000892364500043
J	Huyid, LD; Tungid, PT; Nhu, LNQ; Linh, NT; Tra, DT; Thao, NVP; Tien, TX; Hai, HH; Van Khoa, V; Phuong, NTA; Longid, HB; Linhid, BP				Huyid, Le Duc; Tungid, Pham Thanh; Nhu, Le Nguyen Quynh; Linh, Nguyen Tuan; Tra, Dinh Thanh; Thao, Nguyen Vu Phuong; Tien, Tran Xuan; Hai, Hoang Huu; Van Khoa, Vo; Phuong, Nguyen Thi Anh; Longid, Hoang Bao; Linhid, Bui Phuong			The willingness to perform first aid among high school students and associated factors in Hue, Vietnam	PLOS ONE			English	Article							BYSTANDER CARDIOPULMONARY-RESUSCITATION; KNOWLEDGE; ATTITUDES; CPR; SCHOOLCHILDREN; CHILDREN; NUMBER	Background Adolescents who are willing to perform first aid can help prevent injuries and ultimately death among themselves and others involved in accidents or injuries. This study aims to estimate the prevalence of students' willingness to perform first aid procedures and additionally examine associated factors among high school students in Hue, Vietnam. Methods A cross-sectional study utilizing multi-stage stratified random sampling was conducted between April to July 2020 by investigating 798 high school students in Hue, Vietnam. Participants were invited to complete a self-reported questionnaire pertaining to individual demographic characteristics, personal perception of self-efficacy, and willingness to perform first aid. To better interpret these findings, both multivariable linear and Poisson regression models were fitted to evaluate the association between individual student characteristics and the willingness to perform first aid. Results The prevalence of having willingness to perform first aid (defined as.4 points out of 5 to all three questions) was 49.9% (95%CI:28.6-71.2%). The major reported barriers in performing first aid were fear of making mistakes and hurting victims (34.4%, 95%CI:31.9-37.0%), no prior first aid training (29.8%, 95%CI:25.9-33.9%), and forgetting first aid steps (23.0%, 95%CI:15.8-32.2%). By employing the multivariable linear regression model, it was identified that students with high (beta = 0.614, 95%CI:0.009-1.219) or very high (beta = 1.64, 95%CI:0.857-2.422) levels of self-efficacy appeared to be more willing to perform first aid. Similarly, in the Poisson regression models, compared to neutral students, students who reported high (PR = 1.214, 95%CI:1.048-1.407) or very high (PR = 1.871, 95%CI:1.049-3.337) levels of self-efficacy were more willing to perform first aid. Conclusions The level of willingness to perform first aid among high school students in this study population was found to be moderate. Therefore, integrating activities to promote self-efficacy in first aid training could be considered a progressive step towards improving a student's willingness to provide such life-saving procedures.	[Huyid, Le Duc] Hue Univ, Univ Med & Pharm, Hlth Personnel Training Inst, Hue, Vietnam; [Huyid, Le Duc] Taipei Med Univ, Sch Hlth Care Adm, Coll Management, Taipei, Taiwan; [Tungid, Pham Thanh] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Tungid, Pham Thanh] Hanoi Med Univ, Dept Physiol, Hanoi, Vietnam; [Tungid, Pham Thanh; Linhid, Bui Phuong] Res Adv Consortium Hlth, Hanoi, Vietnam; [Nhu, Le Nguyen Quynh] Daklak Ctr Dis Control & Prevent, Daklak, Vietnam; [Linh, Nguyen Tuan; Tra, Dinh Thanh; Thao, Nguyen Vu Phuong; Tien, Tran Xuan] Hue Univ, Univ Med & Pharm, Hue, Vietnam; [Hai, Hoang Huu] Danang Univ Med Technol & Pharm, Fac Publ Hlth, Dept Epidemiol & Stat, Da Nang, Vietnam; [Van Khoa, Vo] Hue Univ, Univ Med & Pharm, Dept Obstet & Gynecol, Hue, Vietnam; [Phuong, Nguyen Thi Anh] Hue Univ, Univ Med & Pharm, Fac Nursing, Hue, Vietnam; [Phuong, Nguyen Thi Anh] Hue Univ, Univ Med & Pharm, Fac Int Educ, Hue, Vietnam; [Phuong, Nguyen Thi Anh] Hue Univ, Univ Med & Pharm, Off Sci Technol & Int Relat, Hue, Vietnam; [Longid, Hoang Bao] Inst Gastroenterol & Hepatol, Hanoi, Vietnam; [Linhid, Bui Phuong] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA	Hue University; Taipei Medical University; Harvard University; Harvard T.H. Chan School of Public Health; Hanoi Medical University; Hue University; Danang University of Medical Technology & Pharmacy; Hue University; Hue University; Hue University; Hue University; Harvard University; Harvard T.H. Chan School of Public Health	Huyid, LD (corresponding author), Hue Univ, Univ Med & Pharm, Hlth Personnel Training Inst, Hue, Vietnam.; Huyid, LD (corresponding author), Taipei Med Univ, Sch Hlth Care Adm, Coll Management, Taipei, Taiwan.	leduchuy@hueuni.edu.vn		Hoang, Bao Long/0000-0002-2829-3875; Pham, Tung/0000-0002-7242-8976; Le Duc, Huy/0000-0002-3129-027X	Research Advancement Consortium in Health (REACH)	Research Advancement Consortium in Health (REACH)	The study received funding (for study design and data acquisition) from the Research Advancement Consortium in Health (REACH) -a non-profit entity in Vietnam, of which Linh Bui and Tung Pham are co-managers. Linh Bui and Tung Pham did not receive any payment or compensation from this position at REACH. On behalf of REACH, they provided consultancy on study design, data collection and analysis, and preparation of the manuscript. However, Linh Bui and Tung Pham had no role in the decision to publish this study, and this final decision belongs to the funded research team.	Al-Hajj S, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08523-w; Asian Development Bank, 2020, VIET NAM SECONDARY E, V0, DOI [10.22617/TCS200036-2, DOI 10.22617/TCS200036-2]; Bakke HK, 2017, BMC EMERG MED, V17, DOI 10.1186/s12873-017-0116-7; Bandura A., 2006, GUIDE CONSTRUCTING S, P32; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; Bartlett MS, 1950, B J PSYCHOL-STAT SEC, V3, P77, DOI 10.1111/j.2044-8317.1950.tb00285.x; BARTLETT MS, 1954, J ROY STAT SOC B, V16, P296; Birkun A, 2018, WORLD J EMERG MED, V9, P237, DOI 10.5847/wjem.j.1920-8642.2018.04.001; Bottiger BW, 2015, LANCET, V385, P2353, DOI 10.1016/S0140-6736(15)61099-6; Bohn A, 2015, CURR OPIN CRIT CARE, V21, P220, DOI 10.1097/MCC.0000000000000204; BRISLIN RW, 1970, J CROSS CULT PSYCHOL, V1, P185, DOI 10.1177/135910457000100301; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10; Chair SY, 2014, HONG KONG MED J, V20, P126, DOI 10.12809/hkmj134076; Chen M, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3250485; Chen WS, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0519-5; Chen ZQ, 2010, EMERG MED J, V27, P907, DOI 10.1136/emj.2009.079558; Chew KS, 2008, INT J EMERG MED, V1, P301, DOI 10.1007/s12245-008-0070-y; De Smedt L, 2019, ACTA CLIN BELG, V74, P297, DOI 10.1080/17843286.2018.1482087; Engeland Anders, 2002, Inj Control Saf Promot, V9, P99, DOI 10.1076/icsp.9.2.99.8702; European Resuscitation Council, 2015, KIDS SAV LIV; Health Environment Management Agency Vietnamese Ministry of Health, 2017, REP INJ SIT; Hernan MA, 2002, AM J EPIDEMIOL, V155, P176, DOI 10.1093/aje/155.2.176; Hoque DME, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070762; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; International Federation of Red Cross and Red Crescent Societies, 2020, US, DOI [10.1163/2210-7975_HRD-9813-2015012, DOI 10.1163/2210-7975_HRD-9813-2015012]; KAISER HF, 1970, PSYCHOMETRIKA, V35, P401, DOI 10.1007/BF02291817; KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575; Kassambara Alboukadel, 2020, CRAN; Kuramoto N, 2008, RESUSCITATION, V79, P475, DOI 10.1016/j.resuscitation.2008.07.005; Lwanga S.K., 1991, SAMPLE SIZE DETERMIN; Ma AWW, 2015, HONG KONG J EMERG ME, V22, P3, DOI 10.1177/102490791502200101; Ministry of Education and Training, 2020, PROM REG JUN HIGH SC; Parnell MM, 2006, EMERG MED J, V23, P899, DOI 10.1136/emj.2006.041160; Pei L, 2019, Int J Nurs Sci, V6, P65, DOI 10.1016/j.ijnss.2018.11.003; Peltzer K, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14030280; Rahman NHNA, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-37; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; Sharif NAM, 2018, ENFERM CLIN, V28, P13, DOI 10.1016/S1130-8621(18)30028-7; Sleet DA, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15091921; StataCorp, 2017, STATA STAT SOFTWARE; Taniguchi T, 2007, RESUSCITATION, V75, P82, DOI 10.1016/j.resuscitation.2007.02.019; Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd; The Thua Thien Hue Provincial Department of Education and Training, 2021, US; Thua Thien Hue Portals, 2021, HUE CIT GEN INF; Tran Minh Nhat Ha Van Anh Bao, 2017, VIETNAM J PREVENTIVE, V27; UNICEF, 2020, CHILDR VIET NAM; VanderWeele TJ, 2019, EUR J EPIDEMIOL, V34, pCP3, DOI 10.1007/s10654-019-00494-6; VanderWeele TJ, 2011, BIOMETRICS, V67, P1406, DOI 10.1111/j.1541-0420.2011.01619.x; VANKERSCHAVER E, 1989, RESUSCITATION, V17, P211, DOI 10.1016/0300-9572(89)90037-3; Vietnamese Ministry of Education and Training, 2007, DEC NO 4458 BGDDT RE; Wei YL, 2013, ACCIDENT ANAL PREV, V52, P182, DOI 10.1016/j.aap.2012.12.002; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Williamson T, 2013, EMERG THEMES EPIDEMI, V10, DOI 10.1186/1742-7622-10-14; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483; World Health Organization Centers for Disease Control and Prevention (CDC), 2013, GLOB SCH BAS STUD HL; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	56	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2022	17	7							e0271567	10.1371/journal.pone.0271567	http://dx.doi.org/10.1371/journal.pone.0271567			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5Z7YL	35895665	Green Published, gold			2023-01-03	WOS:000880184100001
J	Wu, YW; Comstock, BA; Gonzalez, FF; Mayock, DE; Goodman, AM; Maitre, NL; Chang, T; Van Meurs, KP; Lampland, AL; Bendel-Stenzel, E; Mathur, AM; Wu, TW; Riley, D; Mietzsch, U; Chalak, L; Flibotte, J; Weitkamp, JH; Ahmad, KA; Yanowitz, TD; Baserga, M; Poindexter, BB; Rogers, EE; Lowe, JR; Kuban, KCK; O'Shea, TM; Wisnowski, JL; McKinstry, RC; Bluml, S; Bonifacio, S; Benninger, KL; Rao, R; Smyser, CD; Sokol, GM; Merhar, S; Schreiber, MD; Glass, HC; Heagerty, PJ; Juul, SE				Wu, Y. W.; Comstock, B. A.; Gonzalez, F. F.; Mayock, D. E.; Goodman, A. M.; Maitre, N. L.; Chang, T.; Van Meurs, K. P.; Lampland, A. L.; Bendel-Stenzel, E.; Mathur, A. M.; Wu, T-W; Riley, D.; Mietzsch, U.; Chalak, L.; Flibotte, J.; Weitkamp, J-H; Ahmad, K. A.; Yanowitz, T. D.; Baserga, M.; Poindexter, B. B.; Rogers, E. E.; Lowe, J. R.; Kuban, K. C. K.; O'Shea, T. M.; Wisnowski, J. L.; McKinstry, R. C.; Bluml, S.; Bonifacio, S.; Benninger, K. L.; Rao, R.; Smyser, C. D.; Sokol, G. M.; Merhar, S.; Schreiber, M. D.; Glass, H. C.; Heagerty, P. J.; Juul, S. E.		HEAL Consortium	Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IN-VITRO; RECOMBINANT ERYTHROPOIETIN; PERINATAL ASPHYXIA; NEUROPROTECTION; HYPOTHERMIA; NEUROGENESIS; MODERATE; INJURY; SAFETY; MODELS	BACKGROUND Neonatal hypoxic-ischemic encephalopathy is an important cause of death as well as long-term disability in survivors. Erythropoietin has been hypothesized to have neuroprotective effects in infants with hypoxic-ischemic encephalopathy, but its effects on neurodevelopmental outcomes when given in conjunction with therapeutic hypothermia are unknown. METHODS In a multicenter, double-blind, randomized, placebo-controlled trial, we assigned 501 infants born at 36 weeks or more of gestation with moderate or severe hypoxic-ischemic encephalopathy to receive erythropoietin or placebo, in conjunction with standard therapeutic hypothermia. Erythropoietin (1000 U per kilogram of body weight) or saline placebo was administered intravenously within 26 hours after birth, as well as at 2, 3, 4, and 7 days of age. The primary outcome was death or neurodevelopmental impairment at 22 to 36 months of age. Neurodevelopmental impairment was defined as cerebral palsy, a Gross Motor Function Classification System level of at least 1 (on a scale of 0 [normal] to 5 [most impaired]), or a cognitive score of less than 90 (which corresponds to 0.67 SD below the mean, with higher scores indicating better performance) on the Bayley Scales of Infant and Toddler Development, third edition. RESULTS Of 500 infants in the modified intention-to-treat analysis, 257 received erythropoietin and 243 received placebo. The incidence of death or neurodevelopmental impairment was 52.5% in the erythropoietin group and 49.5% in the placebo group (relative risk, 1.03; 95% confidence interval [CI], 0.86 to 1.24; P=0.74). The mean number of serious adverse events per child was higher in the erythropoietin group than in the placebo group (0.86 vs. 0.67; relative risk, 1.26; 95% CI, 1.01 to 1.57). CONCLUSIONS The administration of erythropoietin to newborns undergoing therapeutic hypothermia for hypoxic-ischemic encephalopathy did not result in a lower risk of death or neurodevelopmental impairment than placebo and was associated with a higher rate of serious adverse events. number, .)	[Wu, Y. W.; Goodman, A. M.; Glass, H. C.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; [Wu, Y. W.; Gonzalez, F. F.; Rogers, E. E.; Glass, H. C.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA; [Glass, H. C.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94158 USA; [Van Meurs, K. P.; Bonifacio, S.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Wu, T-W; Wisnowski, J. L.] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90007 USA; [Wisnowski, J. L.; Bluml, S.] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Radiol, Los Angeles, CA 90007 USA; [Wu, T-W; Wisnowski, J. L.] Univ Southern Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90007 USA; [Wisnowski, J. L.; Bluml, S.] Univ Southern Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90007 USA; [Comstock, B. A.; Heagerty, P. J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Mayock, D. E.; Mietzsch, U.; Juul, S. E.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Maitre, N. L.] Emory Univ, Dept Pediat, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA; [Maitre, N. L.; Poindexter, B. B.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Chang, T.] George Washington Sch Med & Hlth Sci, Childrens Natl Hosp, Div Neurol, Washington, DC USA; [Chang, T.] George Washington Sch Med & Hlth Sci, Dept Neurol, Washington, DC USA; [Lampland, A. L.] Childrens Minnesota, Dept Neonatol, St Paul, MN USA; [Bendel-Stenzel, E.] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN USA; [Mathur, A. M.] St Louis Univ, Sch Med, Dept Pediat, St Louis, MO 63104 USA; [McKinstry, R. C.; Smyser, C. D.] Washington Univ, St Louis Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Rao, R.; Smyser, C. D.] Washington Univ, St Louis Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Smyser, C. D.] Washington Univ, St Louis Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Riley, D.] Texas Christian Univ, Dept Pediat, Cook Childrens Med Ctr, Ft Worth, TX 76129 USA; [Riley, D.] Univ North Texas, Hlth Sci Ctr, Dept Pediat, Ft Worth, TX USA; [Chalak, L.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA; [Ahmad, K. A.] Childrens Hosp San Antonio, Pediat Med Grp San Antonio, San Antonio, TX USA; [Ahmad, K. A.] Methodist Childrens Hosp, San Antonio, TX USA; [Mietzsch, U.; Sokol, G. M.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Flibotte, J.] Univ Penn, Perelman Sch Med, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 02115 USA; [Flibotte, J.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 02115 USA; [Yanowitz, T. D.] Univ Pittsburgh, Sch Med, Dept Pediat, UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA 15261 USA; [Yanowitz, T. D.] UPMC Magee Womens Hosp, Dept Pediat, Pittsburgh, PA USA; [Weitkamp, J-H] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Baserga, M.] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Lowe, J. R.] Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA; [Kuban, K. C. K.] Boston Univ, Med Ctr, Dept Pediat, Boston, MA USA; [O'Shea, T. M.] Univ N Carolina, Chapel Hill Sch Med, Dept Pediat, Chapel Hill, NC 27515 USA; [Benninger, K. L.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA; [Merhar, S.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Merhar, S.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Schreiber, M. D.] Univ Chicago, Dept Pediat, Chicago, IL USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Children's Healthcare of Atlanta (CHOA); Emory University; Emory University; Children's National Health System; George Washington University; George Washington University; Children's Hospitals & Clinics of Minnesota; Mayo Clinic; Saint Louis University; Saint Louis University; Washington University (WUSTL); Saint Louis University; Washington University (WUSTL); Saint Louis University; Washington University (WUSTL); Cook Children's Medical Center; Texas Christian University; University of North Texas System; University of North Texas Denton; University of Texas System; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University Bloomington; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Vanderbilt University; Utah System of Higher Education; University of Utah; University of New Mexico; Boston University; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Chicago	Wu, YW (corresponding author), Univ Calif San Francisco, Div Child Neurol, 675 Nelson Rising Lane,Suite 411,Box 0663, San Francisco, CA 94158 USA.	wuy@ucsf.edu		Weitkamp, Joern-Hendrik/0000-0002-6654-4823	National Institute of Neurological Disorders and Stroke of the National Institutes of Health [U01NS092764, U01NS092553]	National Institute of Neurological Disorders and Stroke of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award numbers U01NS092764 and U01NS092553.	Achenbach T.M., 2001, MULTICULTURAL SUPPLE; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Benders MJ, 2014, J PEDIATR-US, V164, P481, DOI 10.1016/j.jpeds.2013.10.084; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Bolte K, 2020, J PERINAT MED, V48, P744, DOI 10.1515/jpm-2020-0070; Dhillon SK, 2021, J PHYSIOL-LONDON, V599, P3593, DOI 10.1113/JP281269; DuPont TL, 2021, J PERINATOL, V41, P1339, DOI 10.1038/s41372-021-01081-y; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Fan XY, 2013, PEDIATR RES, V73, P18, DOI 10.1038/pr.2012.139; Fang AY, 2013, PEDIATR RES, V73, P12, DOI 10.1038/pr.2012.138; Garg B, 2018, J MATERN-FETAL NEO M, V31, P3214, DOI 10.1080/14767058.2017.1366982; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Gonzalez FF, 2013, STROKE, V44, P753, DOI 10.1161/STROKEAHA.111.000104; Gonzalez FF, 2009, DEV NEUROSCI-BASEL, V31, P403, DOI 10.1159/000232558; Juul S, 2004, CLIN PERINATOL, V31, P129, DOI 10.1016/j.clp.2004.03.004; Juul SE, 2008, DEV NEUROSCI-BASEL, V30, P231, DOI 10.1159/000110348; Juul SE, 2020, NEW ENGL J MED, V382, P233, DOI 10.1056/NEJMoa1907423; Juul SE, 2018, NEONATOLOGY, V113, P331, DOI 10.1159/000486820; Kuban KCK, 2008, J PEDIATR-US, V153, P466, DOI 10.1016/j.jpeds.2008.04.013; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Larpthaveesarp A, 2016, NEUROBIOL DIS, V93, P57, DOI 10.1016/j.nbd.2016.04.006; Malla RR, 2017, J PERINATOL, V37, P596, DOI 10.1038/jp.2017.17; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Osredkar D, 2010, NEUROBIOL DIS, V38, P259, DOI 10.1016/j.nbd.2010.01.015; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Pang R, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcaa211; Reitmeir R, 2011, BRAIN, V134, P84, DOI 10.1093/brain/awq344; Rogers EE, 2014, PEDIATR NEUROL, V51, P657, DOI 10.1016/j.pediatrneurol.2014.08.010; Ruegger CM, 2015, NEONATOLOGY, V108, P198, DOI 10.1159/000437248; Spasojevic SD, 2013, J MATERN-FETAL NEO M, V26, P1506, DOI 10.3109/14767058.2013.789846; Traudt Christopher M, 2013, Methods Mol Biol, V982, P113, DOI 10.1007/978-1-62703-308-4_7; Trivedi SB, 2017, PEDIATR RADIOL, V47, P1491, DOI 10.1007/s00247-017-3893-y; van Buuren S, 2011, J STAT SOFTW, V45, P1; van der Kooij MA, 2008, BRAIN RES REV, V59, P22, DOI 10.1016/j.brainresrev.2008.04.007; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang Z, 2021, BMC PEDIATR, V21, DOI 10.1186/s12887-021-02737-6; Wassink G, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcab172; Wisnowski JL, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-043852; Wu YW, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2016-0191; Wu YW, 2012, PEDIATRICS, V130, P683, DOI 10.1542/peds.2012-0498	40	3	3	6	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 14	2022	387	2					148	159		10.1056/NEJMoa2119660	http://dx.doi.org/10.1056/NEJMoa2119660			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3M7RJ	35830641				2023-01-03	WOS:000835654500010
J	Buder, F; Selejan, SR; Hohl, M; Kindermann, M; Herr, C; Lepper, PM; Bals, R; Salzberger, B; Mahfoud, F; Bohm, M				Buder, Felix; Selejan, Simina-Ramona; Hohl, Mathias; Kindermann, Michael; Herr, Christian; Lepper, Philipp M.; Bals, Robert; Salzberger, Bernd; Mahfoud, Felix; Boehm, Michael			Glycyrrhizin through liquorice intake modulates ACE2 and HMGB1 levels-A pilot study in healthy individuals with implications for COVID-19 and ARDS	PLOS ONE			English	Article							THERAPEUTIC TARGET; PROTEIN; HIGH-MOBILITY-GROUP-BOX-1; REPLICATION; BINDS; HMG-1; SARS	Background Glycyrrhizin, an active component of liquorice root extract, exhibits antiviral and immunomodulatory properties by direct inhibition of the pro-inflammatory alarmin HMGB1 (High-mobility group box 1). Objective The aim of this study was to explore the role of liquorice intake on the viral entry receptor ACE2 (angiotensin-converting enzyme 2) and the immunoregulatory HMGB1 in healthy individuals and to explore HMGB1 expression in coronavirus disease 2019 (COVID-19) or non-COVID-19 in ARDS (acute respiratory distress syndrome patients). Material and methods This study enrolled 43 individuals, including hospitalised patients with i) acute respiratory distress syndrome (ARDS) due to COVID-19 (n = 7) or other underlying causes (n = 12), ii) mild COVID-19 (n = 4) and iii) healthy volunteers (n = 20). Healthy individuals took 50 g of liquorice (containing 3% liquorice root extract) daily for 7 days, while blood samples were collected at baseline and on day 3 and 7. Changes in ACE2 and HMGB1 levels were determined by Western blot analysis and enzyme-linked immunosorbent assay, respectively. Additionally, HMGB1 levels were measured in hospitalised COVID-19 patients with mild disease or COVID-19 associated acute respiratory distress syndrome (ARDS) and compared with a non-COVID-19-ARDS group. Results Liquorice intake significantly reduced after 7 days both cellular membranous ACE2 expression (-51% compared to baseline levels, p = 0.008) and plasma HMGB1 levels (-17% compared to baseline levels, p<0.001) in healthy individuals. Half of the individuals had a reduction in ACE2 levels of at least 30%. HMGB1 levels in patients with mild COVID-19 and ARDS patients with and without COVID-19 were significantly higher compared with those of healthy individuals (+317%, p = 0.002), but they were not different between COVID-19 and non-COVID-19 ARDS. Conclusions Liquorice intake modulates ACE2 and HMGB1 levels in healthy individuals. HMGB1 is enhanced in mild COVID-19 and in ARDS with and without COVID-19, warranting evaluation of HMGB1 as a potential treatment target and glycyrrhizin, which is an active component of liquorice root extract, as a potential treatment in COVID-19 and non-COVID-19 respiratory disease.	[Buder, Felix; Selejan, Simina-Ramona; Hohl, Mathias; Mahfoud, Felix; Boehm, Michael] Univ Saarland, Univ Hosp, Dept Internal Med Cardiol Angiol & Intens Care Me, Homburg, Saar, Germany; [Kindermann, Michael] Caritas Hosp St Theresia Saarbrucken, Dept Internal Med Cardiol & Intens Care Med, Saarbrucken, Germany; [Herr, Christian; Lepper, Philipp M.; Bals, Robert] Univ Saarland, Univ Hosp, Dept Internal Med Pulmonol Allergol & Crit Care, Homburg, Saar, Germany; [Bals, Robert] Helmholtz Ctr Infect Res HZI, Helmholtz Inst Pharmaceut Res Saarland HIPS, Saarland Univ Campus, Saarbrucken, Germany; Univ Hosp Regensburg, Dept Infect Control & Infect Dis, Regensburg, Germany; [Boehm, Michael] Univ Cape Town, Fac Hlth Sci, Cape Heart Inst, Cape Town, South Africa	Saarland University; Universitatsklinikum des Saarlandes; Saarland University; Universitatsklinikum des Saarlandes; Helmholtz Association; Helmholtz-Center for Infection Research; Saarland University; University of Regensburg; University of Cape Town	Buder, F (corresponding author), Univ Saarland, Univ Hosp, Dept Internal Med Cardiol Angiol & Intens Care Me, Homburg, Saar, Germany.	felix.buder@uks.eu		Lepper, Philipp/0000-0003-3620-0912	Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) [322900939 (SFB TRR219)]; Rolf M. Schwiete Stiftung [2020-013]; Saarland University; state of Saarland; Chinesisch-Deutsche Zentrum fur Wissenschaftsfrderung [C-0025]	Deutsche Forschungsgemeinschaft (DFG; German Research Foundation)(German Research Foundation (DFG)); Rolf M. Schwiete Stiftung; Saarland University; state of Saarland; Chinesisch-Deutsche Zentrum fur Wissenschaftsfrderung	FB, SRS, MH, FM, MB were funded by the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) project ID 322900939 (SFB TRR219). This study was supported by grants from the Rolf M. Schwiete Stiftung (2020-013), the Chinesisch-Deutsche Zentrum fur Wissenschaftsfrderung (C-0025), the Saarland University, and the state of Saarland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKAMATSU H, 1991, PLANTA MED, V57, P119, DOI 10.1055/s-2006-960045; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Andersson U, 2018, EXPERT OPIN THER TAR, V22, P263, DOI 10.1080/14728222.2018.1439924; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bundesinstitut fur gesundheitlichen Verbraucherschutz und Veterinarmedizin, 1999, BGVV RAT VORS BEIM V; Chen H., 2020, PREPRINT; Chen L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041193; Chen RC, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05672; Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X; CONN JW, 1968, J AMER MED ASSOC, V205, P492, DOI 10.1001/jama.205.7.492; Crance JM, 2003, ANTIVIR RES, V58, P73, DOI 10.1016/S0166-3542(02)00185-7; Faramarzi H, 2021, medRxiv, DOI 10.1101/2021.11.20.21266229; FENWICK GR, 1990, FOOD CHEM, V38, P119, DOI 10.1016/0308-8146(90)90159-2; Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1; Gong G, 2012, ACTA PHARMACOL SIN, V33, P11, DOI 10.1038/aps.2011.151; Gu JR, 2022, INT IMMUNOPHARMACOL, V108, DOI 10.1016/j.intimp.2022.108730; Hoever G, 2005, J MED CHEM, V48, P1256, DOI 10.1021/jm0493008; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Jezova D, 2021, NUTRIENTS, V13, DOI 10.3390/nu13072321; Jia Weina, 2015, ScientificWorldJournal, V2015, P731765, DOI 10.1155/2015/731765; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Moisy D, 2012, J VIROL, V86, P9122, DOI 10.1128/JVI.00789-12; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Richardson T., 2004, SWEETS HIST TEMPTATI; Sakai-Sugino K, 2017, DRUG DISCOV THER, V11, P246, DOI 10.5582/ddt.2017.01048; Sakamoto R, 2001, BIOL PHARM BULL, V24, P906, DOI 10.1248/bpb.24.906; Scientific Committee on Food, 2003, EUROPEAN COMMISSION; Tseng CC, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/804654; van de Sand L, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040609; van Zoelen MAD, 2008, SHOCK, V29, P441, DOI 10.1097/SHK.0b013e318157eddd; Wang H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136564; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yamaguchi H, 2012, BIOINFORMATION, V8, P1147, DOI 10.6026/97320630081147; Yanagawa Y, 2004, CURR THER RES CLIN E, V65, P26, DOI 10.1016/S0011-393X(04)90002-1; Yao ZR, 2019, MOLECULES, V24, DOI 10.3390/molecules24193545; Zhao F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9719647	38	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2022	17	10							e0275181	10.1371/journal.pone.0275181	http://dx.doi.org/10.1371/journal.pone.0275181			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6T4DR	36251689	gold, Green Published			2023-01-03	WOS:000893628400012
J	Ybarra, M; Weissman, R				Ybarra, Michael; Weissman, Rachel			Recent Trends in Prescription Drug Launch Prices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Ybarra, Michael; Weissman, Rachel] Pharmaceut Res & Manufacturers Amer PhRMA, 950 F St NW,Ste 300, Washington, DC 20004 USA		Ybarra, M (corresponding author), Pharmaceut Res & Manufacturers Amer PhRMA, 950 F St NW,Ste 300, Washington, DC 20004 USA.	mybarra@phrma.org						IQVIA, US MED US SPEND US T; Roehrig C, PROJECTIONS NONRETAI; Rome BN, 2022, JAMA-J AM MED ASSOC, V327, P2145, DOI 10.1001/jama.2022.5542; Silseth S, ANAL PRESCRIPTION DR	4	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	2022	328	13					1352	1352						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5F6GU	36194225				2023-01-03	WOS:000866412700018
J	Iacobucci, G				Iacobucci, Gareth			Patients cut back on drugs to save on prescription fees as cost of living crisis bites	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		British Heart Foundation, POL STAT PRESCR CHAR; NHS, SAV MON PRESCR PREP; NHS, WHO CAN GET FREE PRE	3	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 30	2022	378								o2363	10.1136/bmj.o2363	http://dx.doi.org/10.1136/bmj.o2363			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6D6DZ	36180079				2023-01-03	WOS:000882780000017
J	Knox, RP; Sarpatwari, A				Knox, Ryan P.; Sarpatwari, Ameet			Risks to the 340B Drug Pricing Program Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Knox, Ryan P.] Harvard Med Sch, Harvard MIT Ctr Regulatory Sci, Boston, MA 02115 USA; [Sarpatwari, Ameet] Harvard Med Sch, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon, Brigham & Womens Hosp, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sarpatwari, A (corresponding author), Harvard Med Sch, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon, Brigham & Womens Hosp, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	asarpatwari@bwh.harvard.edu			Arnold Ventures	Arnold Ventures	Dr Sarpatwari's work is supported by Arnold Ventures.	[Anonymous], 2022, 340B CRIT PROGR HLTH; [Anonymous], 2021, SANOFI AVENTIS US LL; [Anonymous], 2022, CONTR PHARM RESTR RE; [Anonymous], 2021, NOVARTIS PHARM CORP; Knox RP, 2022, JAMA-J AM MED ASSOC, V327, P1647, DOI 10.1001/jama.2022.5959; Nikpay S, 2022, AM J MANAG CARE, V28, P133, DOI 10.37765/ajmc.2022.88840	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	2022	328	11					1109	1110		10.1001/jama.2022.12756	http://dx.doi.org/10.1001/jama.2022.12756			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5A5DY	36125474				2023-01-03	WOS:000862909200029
J	Lamper, C; Huijnen, IPJ; Kroese, MEAL; Koke, AJ; Brouwer, G; Ruwaard, D; Verbunt, JAMCF				Lamper, Cynthia; Huijnen, Ivan P. J.; Kroese, Marielle E. A. L.; Koke, Albere J.; Brouwer, Gijs; Ruwaard, Dirk; Verbunt, Jeanine A. M. C. F.			Exploring the feasibility of a network of organizations for pain rehabilitation: What are the lessons learned?	PLOS ONE			English	Article							LOW-BACK-PAIN; HEALTH-CARE PROVIDERS; QUALITATIVE RESEARCH; PROFESSIONAL AUTONOMY; PATIENT-CARE; ATTITUDES; BELIEFS; RECOMMENDATIONS; PREVALENCE; MANAGEMENT	Background and aims Integration of care is lacking for chronic musculoskeletal pain patients. Network Pain Rehabilitation Limburg, a transmural health care network, has been designed to provide integrated rehabilitation care from a biopsychosocial perspective to improve patients' levels of functioning. This feasibility study aims to provide insight into barriers and facilitators for the development, implementation, and transferability. Methods This study was conducted with a three-phase iterative and incremental design from October 2017 to October 2018. The network comprises two rehabilitation practices, and three local primary care networks, with a general practitioner together with, a mental health practice nurse, and a physiotherapist or exercise therapist. These stakeholders with a random sample of participating patients took part in evaluations, consisting of interviews, focus groups, and observations. Field notes and observations were recorded during meetings. The Consolidated Framework for Implementation Research guided data collection and analysis. Results were used to refine the next phase. Results According to health care professionals, guidelines and treatment protocols facilitate consistency and transparency in collaboration, biopsychosocial language, and treatment. One mentioned barrier is the stigmatization of chronic pain by the general population. In regular care, approaches are often more biomedical than biopsychosocial, causing patients to resist participating. The current organization of health care acts as a barrier, complicating implementation between and within practices. Health care professionals were enthusiastic about the iterative, bottom-up development. A critical mass of participating organizations is needed for proper implementation. Conclusion Network Pain Rehabilitation Limburg is feasible in daily practice if barriers are overcome and facilitators of development, implementation, and transferability are promoted. These findings will be used to refine Network Pain Rehabilitation Limburg. A large-scale process and effect evaluation will be performed. Our implementation strategies and results may assist other health care organizations aspiring to implement a transmural network using a similar model.	[Lamper, Cynthia; Huijnen, Ivan P. J.; Koke, Albere J.; Verbunt, Jeanine A. M. C. F.] Maastricht Univ, Fac Hlth Med & Life Sci, Sch Publ Hlth & Primary Care CAPHRI, Dept Rehabil Med Functioning Participat & Rehabil, Maastricht, Netherlands; [Huijnen, Ivan P. J.; Koke, Albere J.; Verbunt, Jeanine A. M. C. F.] Ctr Expertise Rehabil & Audiol, Adelante, Hoensbroek, Netherlands; [Kroese, Marielle E. A. L.; Brouwer, Gijs; Ruwaard, Dirk] Maastricht Univ, Fac Hlth Med & Life Sci, Sch Publ Hlth & Primary Care CAPHRI, Dept Hlth Serv Res, Maastricht, Netherlands	Maastricht University; Maastricht University	Lamper, C; Huijnen, IPJ (corresponding author), Maastricht Univ, Fac Hlth Med & Life Sci, Sch Publ Hlth & Primary Care CAPHRI, Dept Rehabil Med Functioning Participat & Rehabil, Maastricht, Netherlands.; Huijnen, IPJ (corresponding author), Ctr Expertise Rehabil & Audiol, Adelante, Hoensbroek, Netherlands.	cynthia.lamper@maastrichtuniversity.nl; ivan.huijnen@maastrichtuniversity.nl	; Lamper, Cynthia/P-2570-2018	Huijnen, Ivan/0000-0002-5134-4087; Ruwaard, Dirk/0000-0003-4887-8413; Lamper, Cynthia/0000-0001-7577-827X	Dutch: Centraal Ziekenfonds; Dutch: Stichting Volksgezondheidszorg Zuid Nederland	Dutch: Centraal Ziekenfonds; Dutch: Stichting Volksgezondheidszorg Zuid Nederland	Funding was received from the non-profit private health insurers: CZ (in Dutch: Centraal Ziekenfonds; https://www.cz.nl), VGZ (in Dutch: Stichting Volksgezondheidszorg Zuid Nederland; https://www.vgz.nl/), Zilveren Kruis (https://www.zilverenkruis.nl).This applies for: Ivan P.J. Huijnen Albere J. Koke, Jeanine A.M.C.F. Verbunt.	Altman M, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.180128; Alwashmi MF, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/11656; [Anonymous], 2011, REGIERAAD KWALITEIT; [Anonymous], 2018, ZORGSTANDAARD CHRONI; Bekkering GE, 2011, NETH J MED, V69, P141; Boonstra A.M., 2019, NEDERLANDS TIJDSCHRI, V41, P22; Boonstra AM., 2011, NEDERLANDSTALIG TIJD, V30; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Breivik H, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1229; Bushnell MC, 2013, NAT REV NEUROSCI, V14, P502, DOI 10.1038/nrn3516; Cottrell E, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-4; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Darlow B, 2012, EUR J PAIN, V16, P3, DOI 10.1016/j.ejpain.2011.06.006; De Ruddere L, 2016, PAIN, V157, P1607, DOI 10.1097/j.pain.0000000000000512; Domenech J, 2011, PAIN, V152, P2557, DOI 10.1016/j.pain.2011.07.023; Federatie Medisch Specialisten, 2019, HANDR IMPL JUIST ZOR; Forman J., 2008, EMPIRICAL RES BIOETH; Foster NE, 2010, PAIN, V148, P398, DOI 10.1016/j.pain.2009.11.002; Gatchel RJ, 2007, PSYCHOL BULL, V133, P581, DOI 10.1037/0033-2909.133.4.581; Grol RPTM, 2007, MILBANK Q, V85, P93, DOI 10.1111/j.1468-0009.2007.00478.x; Gulliksen J, 2005, HUM COM INT, V8, P17, DOI 10.1007/1-4020-4113-6_2; Guzman J, 2001, BMJ-BRIT MED J, V322, P1511, DOI 10.1136/bmj.322.7301.1511; Hanna J, 2020, J SUBST ABUSE TREAT, V108, P104, DOI 10.1016/j.jsat.2019.06.012; Heale Roberta, 2013, Evid Based Nurs, V16, P98, DOI 10.1136/eb-2013-101494; Hill CE, 2005, J COUNS PSYCHOL, V52, P196, DOI 10.1037/0022-0167.52.2.196; Holden MA, 2009, ARTHRIT RHEUM-ARTHR, V61, P1511, DOI 10.1002/art.24829; Holopainen R, 2020, PAIN, V161, P1150, DOI 10.1097/j.pain.0000000000001809; Hoogland J, 2000, THEOR MED BIOETH, V21, P457, DOI 10.1023/A:1009925423036; Houben RMA, 2005, EUR J PAIN, V9, P173, DOI 10.1016/j.ejpain.2004.05.002; Huisstede BMA, 2008, CLIN J PAIN, V24, P253, DOI 10.1097/AJP.0b013e318160a8b4; Jackson T, 2014, J PAIN, V15, P800, DOI 10.1016/j.jpain.2014.05.002; Jellema P, 2005, PAIN, V118, P350, DOI 10.1016/j.pain.2005.09.002; Jung H.P., 2018, HUIS WETEN, V61, P39, DOI [10.1007/s12445-018-0062-y, DOI 10.1007/S12445-018-0062-Y]; Keith RE, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0550-7; Koke AJA, 2017, EUR J PAIN, V21, P434, DOI 10.1002/ejp.937; Krol M, 2013, CQ INDEX MODULE PIJN; Lamper C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025962; Lerman SF, 2015, PSYCHOSOM MED, V77, P333, DOI 10.1097/PSY.0000000000000158; Linton SJ, 2018, PAIN, V159, P2437, DOI 10.1097/j.pain.0000000000001308; Mooren vd F., 2019, WERKG ZORG WELZ UITK; Murray E, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-6; Nijs J, 2021, LANCET RHEUMATOL, V3, pE383, DOI 10.1016/S2665-9913(21)00032-1; Niv D, 2007, EUR J PAIN, V11, P487, DOI 10.1016/j.ejpain.2007.03.005; Paganoni S, 2018, AM J PHYS MED REHAB, V97, P679, DOI 10.1097/PHM.0000000000000980; Pagliari C, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.2.e15; Peerenboom PBG, 2013, MEDISCH SPECIALISTIS; Polder JJ, 2000, THEOR MED BIOETH, V21, P477, DOI 10.1023/A:1009977407106; Pool JJM, 2010, SPINE, V35, P1017, DOI 10.1097/BRS.0b013e3181c212ee; Ross J, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0510-7; Sandelowski M, 2003, QUAL HEALTH RES, V13, P781, DOI 10.1177/1049732303013006003; Singer SJ, 2011, MED CARE RES REV, V68, P112, DOI 10.1177/1077558710371485; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; van der Horst H., 2018, HUIS WETEN, P30, DOI [10.1007/s12445-018-0056-9, DOI 10.1007/S12445-018-0056-9]; van Tulder M, 2006, EUR SPINE J, V15, pS169, DOI 10.1007/s00586-006-1071-2; Waterschoot FPC, 2016, INT J REHABIL RES, V39, P48, DOI 10.1097/MRR.0000000000000144; Waugh Olivia C, 2014, J Pain, V15, DOI 10.1016/j.jpain.2014.02.001; Werkgroep Pijnrevalidatie Nederland, 2017, MED SPEC REV BIJ CHR; World Health Organisation, 2008, INT HLTH SERV WHAT W; Zidarov D, 2013, DISABIL REHABIL, V35, P1571, DOI 10.3109/09638288.2012.748841	60	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2022	17	9							e0273030	10.1371/journal.pone.0273030	http://dx.doi.org/10.1371/journal.pone.0273030			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R1RR	36107861	gold, Green Submitted, Green Published			2023-01-03	WOS:000892087100014
J	Kuehn, BM				Kuehn, Bridget M.			Most Insured People With Hepatitis C Don't Get Timely Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	2022	328	10					919	919		10.1001/jama.2022.14706	http://dx.doi.org/10.1001/jama.2022.14706			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4P2JT	36098717				2023-01-03	WOS:000855222400010
J	Chen, HS; Cui, Y; Li, XQ; Wang, XH; Ma, YT; Zhao, Y; Han, J; Deng, CQ; Hong, M; Bao, Y; Zhao, LH; Yan, TG; Zou, RL; Wang, H; Li, Z; Wan, LS; Zhang, L; Wang, LQ; Guo, LY; Li, MN; Wang, DQ; Zhang, Q; Chang, DW; Zhang, HL; Sun, J; Meng, C; Zhang, ZH; Shen, LY; Ma, L; Wang, GC; Li, RH; Zhang, L; Bi, C; Wang, LY; Wang, DL				Chen, Hui-Sheng; Cui, Yu; Li, Xiao-Qiu; Wang, Xin-Hong; Ma, Yu-Tong; Zhao, Yong; Han, Jing; Deng, Chang-Qing; Hong, Mei; Bao, Ying; Zhao, Li-Hong; Yan, Ting-Guang; Zou, Ren-Lin; Wang, Hui; Li, Zhuo; Wan, Li-Shu; Zhang, Li; Wang, Lian-Qiang; Guo, Li-Yan; Li, Ming-Nan; Wang, Dong-Qing; Zhang, Qiang; Chang, Da-Wei; Zhang, Hong-Li; Sun, Jing; Meng, Chong; Zhang, Zai-Hui; Shen, Li-Ying; Ma, Li; Wang, Gui-Chun; Li, Run-Hui; Zhang, Ling; Bi, Cheng; Wang, Li-Yun; Wang, Duo-Lao		RICAMIS Investigators	Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke The RICAMIS Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THROMBOLYSIS; STENOSIS; EFFICACY; SAFETY	IMPORTANCE Preclinical and clinical studies have suggested a neuroprotective effect of remote ischemic conditioning (RIC), which involves repeated occlusion/release cycles on bilateral upper limb arteries; however, robust evidence in patients with ischemic stroke is lacking. OBJECTIVE To assess the efficacy of RIC for acute moderate ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS This multicenter, open-label, blinded-end point, randomized clinical trial including 1893 patients with acute moderate ischemic stroke was conducted at 55 hospitals in China from December 26, 2018, through January 19, 2021, and the date of final follow-up was April 19. 2021. INTERVENTIONS Eligible patients were randomly assigned within 48 hours after symptom onset to receive treatment with RIC (using a pneumatic electronic device and consisting of 5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mm Hg) for 10 to 14 days as an adjunct to guideline-based treatment (n = 922) or guideline-based treatment alone (n = 971). MAIN OUTCOMES AND MEASURES The primary end point was excellent functional outcome at 90 days, defined as a modified Rankin Scale score of 0 to 1. All end points had blinded assessment and were analyzed on a full analysis set. RESULTS Among 1893 eligible patients with acute moderate ischemic stroke who were randomized (mean [SD] age, 65 [10.3] years; 606 women [34.1%]), 1776 (93.8%) completed the trial. The number with excellent functional outcome at 90 days was 582 (67.4%) in the RIC group and 566 (62.0%) in the control group (risk difference, 5.4% [95% CI, 1.0%-9.9%]; odds ratio, 1.27 [95% CI, 1.05-1.54]; P = .02). The proportion of patients with any adverse events was 6.8% (59/863) in the RIC group and 5.6% (51/913) in the control group. CONCLUSIONS AND RELEVANCE Among adults with acute moderate ischemic stroke, treatment with remote ischemic conditioning compared with usual care significantly increased the likelihood of excellent neurologic function at 90 days. However, these findings require replication in another trial before concluding efficacy for this intervention.	[Chen, Hui-Sheng; Cui, Yu; Li, Xiao-Qiu; Wang, Xin-Hong] Gen Hosp Northern Theatre Command, Dept Neurol, 83 Wenhua Rd, Shenyang 110016, Peoples R China; [Ma, Yu-Tong] Beipiao Cent Hosp, Dept Neurol, Beipiao, Peoples R China; [Zhao, Yong] Haicheng Chinese Med Hosp, Dept Neurol, Haicheng, Peoples R China; [Han, Jing; Li, Zhuo] Panjin Cent Hosp, Dept Neurol, Panjin, Peoples R China; [Deng, Chang-Qing; Bi, Cheng] Dandong Cent Hosp, Dept Neurol, Dandong, Peoples R China; [Hong, Mei] China Railway 19th Bur Grp Cent Hosp, Dept Neurol, Liaoyang, Peoples R China; [Bao, Ying] Fuxin Second Peoples Hosp, Dept Neurol, Fuxing, Peoples R China; [Zhao, Li-Hong] Dandong Peoples Hosp, Dept Neurol, Dandong, Peoples R China; [Yan, Ting-Guang] Chaoyang Cent Hosp, Dept Neurol, Chaoyang, Peoples R China; [Zou, Ren-Lin] Wafangdian Third Hosp, Dept Neurol, Dalian, Peoples R China; [Wang, Hui] Chinese Peoples Liberat Army 230 Hosp, Dept Neurol, Dandong, Peoples R China; [Wan, Li-Shu] Dandong First Hosp, Dept Neurol, Dandong, Peoples R China; [Zhang, Li] Suizhong Cty Hosp, Dept Neurol, Huludao, Peoples R China; [Wang, Lian-Qiang] Liaoyang Cty Stroke Hosp, Dept Neurol, Liaoyang, Peoples R China; [Guo, Li-Yan] Fushun Second Hosp, Dept Neurol, Fushun, Peoples R China; [Li, Ming-Nan] Huanren Manchu Autonomous Cty Peoples Hosp, Dept Neurol, Benxi, Peoples R China; [Wang, Dong-Qing] Panjin Peoples Hosp, Dept Neurol, Panjin, Peoples R China; [Zhang, Qiang] Fushun Cent Hosp, Dept Neurol, Fushun, Peoples R China; [Chang, Da-Wei] Sujiatun Stroke Hosp, Dept Neurol, Shenyang, Peoples R China; [Zhang, Hong-Li] Taian Cty Chinese Med Hosp, Dept Neurol, Anshan, Peoples R China; [Sun, Jing] China Med Univ, Anshan Hosp, Dept Neurol, Affiliated Hosp 1, Anshan, Peoples R China; [Meng, Chong] Liaoyang Cty Cent Hosp, Dept Neurol, Liaoyang, Peoples R China; [Zhang, Zai-Hui] Xiuyan Cty Cent Hosp, Dept Neurol, Anshan, Peoples R China; [Shen, Li-Ying] Tieling Cty Cent Hosp, Dept Neurol, Tieling, Peoples R China; [Ma, Li; Li, Run-Hui] Shenyang Med Coll, Dept Neurol, Affiliated Cent Hosp, Shenyang, Peoples R China; [Wang, Gui-Chun] Changtu Cty Cent Hosp, Dept Neurol, Tieling, Peoples R China; [Zhang, Ling] Dengta Cent Hosp, Dept Neurol, Dengta, Peoples R China; [Wang, Li-Yun] Liaoyang Petrochem Gen Hosp, Dept Neurol, Liaoyang, Peoples R China; [Wang, Duo-Lao] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England	Shenyang Medical College; Liverpool School of Tropical Medicine	Chen, HS (corresponding author), Gen Hosp Northern Theatre Command, Dept Neurol, 83 Wenhua Rd, Shenyang 110016, Peoples R China.	chszh@aliyun.com		Chen, Hui-Sheng/0000-0002-7486-1992	Science and Technology Project Plan of Liao Ning Province [2018225023, 2019JH2/10300027]; Science and Technology Project Plan of ShenYang [20-205-4-007]	Science and Technology Project Plan of Liao Ning Province; Science and Technology Project Plan of ShenYang	The study was funded by grants from the Science and Technology Project Plan of Liao Ning Province (2018225023, 2019JH2/10300027) and from the Science and Technology Project Plan of ShenYang (20-205-4-007).	An JQ, 2020, NEUROLOGY, V95, pE3355, DOI 10.1212/WNL.0000000000010884; Che RW, 2019, ANN CLIN TRANSL NEUR, V6, P364, DOI 10.1002/acn3.713; Doeppner TR, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00383; England TJ, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013572; England TJ, 2017, STROKE, V48, P1412, DOI 10.1161/STROKEAHA.116.016429; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; He YD, 2020, ANN CLIN TRANSL NEUR, V7, P972, DOI 10.1002/acn3.51063; Hess DC, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2015.223; Hou CB, 2016, INT J STROKE, V11, P831, DOI 10.1177/1747493016654489; Hougaard KD, 2014, STROKE, V45, P159, DOI 10.1161/STROKEAHA.113.001346; Khan MB, 2018, TRANSL STROKE RES, V9, P51, DOI 10.1007/s12975-017-0555-1; Landman TRJ, 2019, STROKE, V50, P1934, DOI 10.1161/STROKEAHA.119.025494; Li XQ, 2020, INT J STROKE, V15, P454, DOI 10.1177/1747493019879651; Li YJ, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.105217; Meng R, 2015, NEUROTHERAPEUTICS, V12, P667, DOI 10.1007/s13311-015-0358-6; Meng R, 2012, NEUROLOGY, V79, P1853, DOI 10.1212/WNL.0b013e318271f76a; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Pico F, 2020, JAMA NEUROL, V77, P725, DOI 10.1001/jamaneurol.2020.0326; Poalelungi A, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.663400; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Ren CH, 2018, BEHAV BRAIN RES, V340, P87, DOI 10.1016/j.bbr.2016.10.036; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Savitz SI, 2019, STROKE, V50, P1026, DOI 10.1161/STROKEAHA.118.023927; Wang Y, 2017, STROKE, V48, P3064, DOI 10.1161/STROKEAHA.117.017691; Weir P, 2021, J CEREBR BLOOD F MET, V41, P3, DOI 10.1177/0271678X20924077; Zerna C, 2018, LANCET, V392, P1247, DOI 10.1016/S0140-6736(18)31874-9; Zhao WB, 2019, ANN CLIN TRANSL NEUR, V6, P186, DOI 10.1002/acn3.691; Zhao WB, 2018, ANN CLIN TRANSL NEUR, V5, P850, DOI 10.1002/acn3.588; Zhao WB, 2017, CIRCULATION, V135, P1325, DOI 10.1161/CIRCULATIONAHA.116.024807	30	3	3	8	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2022	328	7					627	636		10.1001/jama.2022.13123	http://dx.doi.org/10.1001/jama.2022.13123			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D0ZW	35972485				2023-01-03	WOS:000846874500020
J	Biswas, J; Faruque, M; Banik, PC; Ahmad, N; Mashreky, SR				Biswas, Jheelam; Faruque, Mithila; Banik, Palash Chandra; Ahmad, Nezamuddin; Mashreky, Saidur Rahman			Quality of life of the cancer patients receiving home-based palliative care in Dhaka city of Bangladesh	PLOS ONE			English	Article							SERVICES; HOSPICE; PROGRAM; IMPACT	Background The concept of home-based palliative care has been recently introduced in Bangladesh, but the patients' quality of life remains unexplored. This study aimed to assess the quality of life and its determinants of the cancer patients receiving home-based palliative care in Dhaka, Bangladesh. Methods This cross-sectional study was conducted among 51 surviving cancer patients above 18 years registered under the home-based care service of the Department of Palliative Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Data was collected by face-to-face interview using a structured questionnaire based on the "Functional Assessment of Chronic Illness Therapy-Palliative (FACIT-Pal)" questionnaire from February to March 2019. Descriptive analysis was done for the socio-demographic, disease and treatment related factors. Mann-Whiteney U test, Kruskal-Wallis H test, and logistic regression were done to determine the relationships between independent variables and QoL. Result The majority of the patients (76.5%) were women. The mean age of the respondents was 56.2 +/- 4.8 years. Common primary sites of cancer were breast (39.2%), gastrointestinal (17.6%), and genitourinary system (23.5%). The median duration of getting home-based care was four months. The most prevalent problems were pain, sadness, feeling ill, and lack of satisfaction regarding sexual life. The majority (88.2%) of the patients had an average and above-average quality of life. Although, 92.1%patients had average or above-average social and emotional wellbeing, 60.8% had below-average physical wellbeing. Patients' marital status, belief about disease prognosis, and duration of getting home-based care had a positive influence, and age negatively influenced the quality of life. Conclusion The majority of the patients receiving home-based palliative care in Dhaka city had average or above-average quality of life. However, these patients had better social and emotional wellbeing, but the physical wellbeing and symptom control were below-average according to the individual domain.	[Biswas, Jheelam; Faruque, Mithila; Banik, Palash Chandra; Mashreky, Saidur Rahman] Bangladesh Univ Hlth Sci BUHS, Dept Noncommunicable Dis, Dhaka, Bangladesh; [Biswas, Jheelam; Ahmad, Nezamuddin] Bangabandhu Sheikh Mujib Med Univ BSMMU, Dept Palliat Med, Dhaka, Bangladesh	Bangladesh University of Health Sciences (BUHS); Bangabandhu Sheikh Mujib Medical University (BSMMU)	Biswas, J (corresponding author), Bangladesh Univ Hlth Sci BUHS, Dept Noncommunicable Dis, Dhaka, Bangladesh.; Biswas, J (corresponding author), Bangabandhu Sheikh Mujib Med Univ BSMMU, Dept Palliat Med, Dhaka, Bangladesh.	jheelam.biswas@gmail.com	Banik, Palash/P-7613-2016	Banik, Palash/0000-0003-2395-9049				Ahmad N, 2015, DAILY STAR; [Anonymous], 2019, CTR PALLIATIVE CARE; Austin P, 2011, PALLIAT SUPPORT CARE, V9, P393, DOI 10.1017/S1478951511000411; Cardona-Morrell M, 2016, INT J QUAL HEALTH C, V28, P456, DOI 10.1093/intqhc/mzw060; Datta D, 2017, INDIAN J PALLIAT CAR, V23, P331, DOI 10.4103/IJPC.IJPC_46_17; Dhiliwal SR, 2015, INDIAN J PALLIAT CAR, V21, P28, DOI 10.4103/0973-1075.150170; Doherty M, 2017, INDIAN J PALLIAT CAR, V23, P413, DOI 10.4103/IJPC.IJPC_85_17; Dow K H, 1999, Oncol Nurs Forum, V26, P519; Eremenco SL, 2005, EVAL HEALTH PROF, V28, P212, DOI 10.1177/0163278705275342; Gomes B, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007760.pub2, 10.1590/1516-3180.20161341T2]; Hinton John, 1994, Palliative Medicine, V8, P183, DOI 10.1177/026921639400800302; Hussain Syed Md Akram, 2013, South Asian J Cancer, V2, P279, DOI 10.4103/2278-330X.119901; JENKINS RA, 1988, SOC SCI MED, V26, P625, DOI 10.1016/0277-9536(88)90027-5; Kerr CW, 2014, J PAIN SYMPTOM MANAG, V48, P883, DOI 10.1016/j.jpainsymman.2014.02.003; Kim SH, 2009, ASIAN NURS RES, V3, P24, DOI 10.1016/S1976-1317(09)60013-X; Lee H, 2020, KOREAN J FAM MED, V41, P91, DOI 10.4082/kjfm.18.0113; Lemus-Riscanevo P, 2019, INDIAN J PALLIAT CAR, V25, P24, DOI 10.4103/IJPC.IJPC_183_18; Meghani SH, 2004, J ADV NURS, V46, P152, DOI 10.1111/j.1365-2648.2003.02975.x; Ornstein K, 2013, J PALLIAT MED, V16, P1048, DOI 10.1089/jpm.2012.0546; Peters L, 2006, J ADV NURS, V53, P524, DOI 10.1111/j.1365-2648.2006.03754.x; Philip RR, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0278-4; Rahman A., 2011, J BANGLADESH COLL PH, V29, P1; Shafaie FS, 2019, INDIAN J PALLIAT CAR, V25, P73, DOI 10.4103/IJPC.IJPC_119_18; Shepperd Sasha, 2011, Cochrane Database Syst Rev, pCD009231, DOI 10.1002/14651858.CD009231; Singh Divya Pal, 2010, Indian J Palliat Care, V16, P36, DOI 10.4103/0973-1075.63133; Sloan FA, 2007, CANC CONTROL OPPORTU; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; World Health Organization, 2018, PALLIATIVE CARE WHOI; World Health Organization, 2014, NONC DIS COUNTR PROF; Zeygami S., 2009, IRAN J OBSTET GYNE C, V12, P39; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	32	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2022	17	7							e0268578	10.1371/journal.pone.0268578	http://dx.doi.org/10.1371/journal.pone.0268578			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4Q0KX	35905040	Green Published, gold			2023-01-03	WOS:000855776900011
J	Heller, L				Heller, Leo			WASH services and health: syntheses and contexts	LANCET			English	Editorial Material							SANITATION; WATER; DIARRHEA		[Heller, Leo] Fundacao Oswaldo Cruz, Inst Rene Rachou, BR-30190009 Belo Horizonte, MG, Brazil	Fundacao Oswaldo Cruz	Heller, L (corresponding author), Fundacao Oswaldo Cruz, Inst Rene Rachou, BR-30190009 Belo Horizonte, MG, Brazil.	leo.heller@fiocruz.br						Amebelu A, 2021, LANCET, V398, P1469, DOI 10.1016/S0140-6736(21)02005-5; Bartram J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000367; Cairncross S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000365; Corburn J, 2022, ENVIRON PLAN B-URBAN, V49, P2044, DOI 10.1177/23998083221094836; Cumming O, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1410-x; ESREY SA, 1991, B WORLD HEALTH ORGAN, V69, P609; Heller L, 2015, ROUTLEDGE HDB WATER; UN, 2021, UN 2023 WAT C; Wolf J, 2022, LANCET, V400, P48, DOI 10.1016/S0140-6736(22)00937-0; Wolf J, 2018, TROP MED INT HEALTH, V23, P508, DOI 10.1111/tmi.13051; Wolf J, 2014, TROP MED INT HEALTH, V19, P928, DOI 10.1111/tmi.12331	11	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	2022	400	10345					5	7						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3D5QU	35780793				2023-01-03	WOS:000829357200020
J	Webber, C; Myran, DT; Milani, C; Turcotte, L; Imsirovic, H; Li, WS; Tanuseputro, P				Webber, Colleen; Myran, Daniel T.; Milani, Christina; Turcotte, Luke; Imsirovic, Haris; Li, Wenshan; Tanuseputro, Peter			Cognitive Decline in Long-term Care Residents Before and During the COVID-19 Pandemic in Ontario, Canada	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Webber, Colleen; Myran, Daniel T.] Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Milani, Christina] Bruyere Res Inst, Ottawa, ON, Canada; [Turcotte, Luke] Univ Waterloo, Waterloo, ON, Canada; [Imsirovic, Haris] ICES, Ottawa, ON, Canada; [Li, Wenshan] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada; [Tanuseputro, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Waterloo; University of Ottawa; University of Ottawa	Webber, C (corresponding author), 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	cowebber@ohri.ca		Turcotte, Luke/0000-0001-5678-7234	ICES - Ontario Ministry of Health; Ministry of Long-Term Care; Bruyere Academic Medical Organization; Canadian Institutes of Health Research project grant [177916]; PSI Knowledge Translation Fellowship	ICES - Ontario Ministry of Health; Ministry of Long-Term Care; Bruyere Academic Medical Organization; Canadian Institutes of Health Research project grant(Canadian Institutes of Health Research (CIHR)); PSI Knowledge Translation Fellowship	This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and the Ministry of Long-Term Care. This study was also supported by grants from the Bruyere Academic Medical Organization and the Canadian Institutes of Health Research project grant (funding #177916). Dr Tanuseputro is supported by a PSI Knowledge Translation Fellowship.	Abbasi J, 2020, JAMA-J AM MED ASSOC, V324, P619, DOI 10.1001/jama.2020.13484; [Anonymous], RIS COVID 19 CRIS PO; [Anonymous], 2021, CHANGES HLTH END STA; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174	6	1	1	3	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	2022	328	14					1456	1458		10.1001/jama.2022.17214	http://dx.doi.org/10.1001/jama.2022.17214		SEP 2022	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5L0OS	36094572	Bronze			2023-01-03	WOS:000854267400002
J	[Anonymous]				[Anonymous]			Lipid nanoparticle drug delivery	NATURE BIOTECHNOLOGY			English	Editorial Material								Recent patents relating to making and using lipid coatings for the delivery of therapeutic agents.											0	0	0	16	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2022	40	9					1326	1326		10.1038/s41587-022-01462-4	http://dx.doi.org/10.1038/s41587-022-01462-4			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	4L8RE	36085501				2023-01-03	WOS:000852896400013
J	Arbel, R; Sagy, YW; Hoshen, M; Battat, E; Lavie, G; Sergienko, R; Friger, M; Waxman, JG; Dagan, N; Balicer, R; Ben-Shlomo, Y; Peretz, A; Yaron, S; Serby, D; Hammerman, A; Netzer, D				Arbel, Ronen; Sagy, Yael Wolff; Hoshen, Moshe; Battat, Erez; Lavie, Gil; Sergienko, Ruslan; Friger, Michael; Waxman, Jacob G.; Dagan, Noa; Balicer, Ran; Ben-Shlomo, Yatir; Peretz, Alon; Yaron, Shlomit; Serby, Danielle; Hammerman, Ariel; Netzer, Doron			Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-risk, unvaccinated patients infected with the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data regarding the effectiveness of nirmatrelvir in preventing severe coronavirus disease 2019 (Covid-19) outcomes from the B.1.1.529 (omicron) variant are limited. METHODS We obtained data for all members of Clalit Health Services who were 40 years of age or older at the start of the study period and were assessed as being eligible to receive nirmatrelvir therapy during the omicron surge. A Cox proportional-hazards regression model with time-dependent covariates was used to estimate the association of nirmatrelvir treatment with hospitalization and death due to Covid-19, with adjustment for sociodemographic factors, coexisting conditions, and previous SARS-CoV-2 immunity status. RESULTS A total of 109,254 patients met the eligibility criteria, of whom 3902 (4%) received nirmatrelvir during the study period. Among patients 65 years of age or older, the rate of hospitalization due to Covid-19 was 14.7 cases per 100,000 person-days among treated patients as compared with 58.9 cases per 100,000 person-days among untreated patients (adjusted hazard ratio, 0.27; 95% confidence interval [CI], 0.15 to 0.49). The adjusted hazard ratio for death due to Covid-19 was 0.21 (95% CI, 0.05 to 0.82). Among patients 40 to 64 years of age, the rate of hospitalization due to Covid-19 was 15.2 cases per 100,000 person-days among treated patients and 15.8 cases per 100,000 person-days among untreated patients (adjusted hazard ratio, 0.74; 95% CI, 0.35 to 1.58). The adjusted hazard ratio for death due to Covid-19 was 1.32 (95% CI, 0.16 to 10.75). CONCLUSIONS Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than among those who did not. No evidence of benefit was found in younger adults.	[Arbel, Ronen; Peretz, Alon; Yaron, Shlomit; Serby, Danielle; Hammerman, Ariel; Netzer, Doron] Clalit Hlth Serv, Div Community Med Serv, 101 Arlozorov St, IL-6209804 Tel Aviv, Israel; [Sagy, Yael Wolff; Hoshen, Moshe; Battat, Erez; Lavie, Gil] Clalit Hlth Serv, Branch Planning & Strat, Tel Aviv, Israel; [Waxman, Jacob G.; Dagan, Noa; Balicer, Ran; Ben-Shlomo, Yatir] Clalit Hlth Serv, Div Innovat, Clalit Res Inst, Tel Aviv, Israel; [Arbel, Ronen] Jerusalem Coll Technol, Maximizing Hlth Outcomes Res Lab, Sapir Coll, Sderot, Israel; [Hoshen, Moshe] Jerusalem Coll Technol, Dept Bioinformat, Jerusalem, Israel; [Lavie, Gil] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel; [Sergienko, Ruslan; Friger, Michael; Balicer, Ran] Ben Gurion Univ Negev, Sch Publ Hlth, Fac Hlth Sci, Beer Sheva, Israel; [Dagan, Noa] Ben Gurion Univ Negev, Software & Informat Syst Engn, Beer Sheva, Israel; [Dagan, Noa] Harvard Med Sch, Ivan & Francesca Berkowitz Family Living Lab Col, Boston, MA 02115 USA; [Dagan, Noa; Balicer, Ran] Harvard Med Sch, Clalit Res Inst, Boston, MA 02115 USA; [Dagan, Noa] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA	Clalit Health Services; Clalit Health Services; Clalit Health Services; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Ben Gurion University; Ben Gurion University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Arbel, R (corresponding author), Clalit Hlth Serv, Div Community Med Serv, 101 Arlozorov St, IL-6209804 Tel Aviv, Israel.	ronenarb@clalit.org.il		Arbel, Ronen/0000-0002-6058-8665; Dagan, Noa/0000-0001-8811-7825				Arbel R, 2022, NAT MED, V28, P1486, DOI 10.1038/s41591-022-01832-0; Arbel R, 2021, NEW ENGL J MED, V385, P2413, DOI 10.1056/NEJMoa2115624; Callaway E, 2021, NATURE, V600, P197, DOI 10.1038/d41586-021-03614-z; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dryden-Peterson S., 2022, MEDRXIV, DOI [10.1101/2022.06.14.22276393v2, DOI 10.1101/2022.06.14.22276393V2]; FDA, 2021, COR COVID 19 UPD FDA; Food and Drug Administration, 2021, FACT SHEET HEALTHC P; Hammond J, 2022, NEW ENGL J MED, V386, P1397, DOI 10.1056/NEJMoa2118542; Levesque LE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5087; Li PF, 2022, CELL RES, V32, P322, DOI 10.1038/s41422-022-00618-w; National Institutes of Health, 2022, RIT BOOST NIRM PAXL; National Institutes of Health, 2021, TREATM GUID PAN COR; Rubin EJ, 2022, NEW ENGL J MED, V386, pE27, DOI 10.1056/NEJMe2202699; Rubin EJ, 2022, NEW ENGL J MED, V386, P1463, DOI 10.1056/NEJMe2202160; Takashita E, 2022, NEW ENGL J MED, V386, P1475, DOI 10.1056/NEJMc2201933; Takashita E, 2022, NEW ENGL J MED, V386, P995, DOI 10.1056/NEJMc2119407; Vangeel L, 2022, ANTIVIR RES, V198, DOI 10.1016/j.antiviral.2022.105252	17	12	12	5	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	2022	387	9					790	798		10.1056/NEJMoa2204919	http://dx.doi.org/10.1056/NEJMoa2204919		AUG 2022	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4G3XB	36001529	Bronze, Green Published			2023-01-03	WOS:000844380000001
J	Tang, LL; Guo, R; Zhang, N; Deng, B; Chen, L; Cheng, ZB; Huang, J; Hu, WH; Huang, SH; Luo, WJ; Liang, JH; Zheng, YM; Zhang, F; Mao, YP; Li, WF; Zhou, GQ; Liu, X; Chen, YP; Xu, C; Lin, L; Liu, Q; Du, XJ; Zhang, Y; Sun, Y; Ma, J				Tang, Ling-Long; Guo, Rui; Zhang, Ning; Deng, Bin; Chen, Lei; Cheng, Zhi-Bin; Huang, Jing; Hu, Wei-Han; Huang, Shao Hui; Luo, Wei-Jun; Liang, Jin-Hui; Zheng, Yu-Ming; Zhang, Fan; Mao, Yan-Ping; Li, Wen-Fei; Zhou, Guan-Qun; Liu, Xu; Chen, Yu-Pei; Xu, Cheng; Lin, Li; Liu, Qing; Du, Xiao-Jing; Zhang, Yuan; Sun, Ying; Ma, Jun			Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-INFERIORITY; STAGING SYSTEM; NODE LEVELS; OPEN-LABEL; CHEMOTHERAPY; CANCER; CISPLATIN; METAANALYSIS; GUIDELINES; EDITION	IMPORTANCE Concurrent chemoradiotherapy has been the standard treatment for stage II nasopharyngeal carcinoma (NPC) based on data using 2-dimensional conventional radiotherapy. There is limited evidence for the role of chemotherapy with use of intensity-modulated radiation therapy (IMRT). OBJECTIVE To assess whether concurrent chemotherapy can be safely omitted for patients with low-risk stage II/T3N0 NPC treated with IMRT. DESIGN, SETTING, AND PARTICIPANTS This multicenter, open-label, randomized, phase 3, noninferiority clinical trial was conducted at 5 Chinese hospitals, including 341 adult patients with low-risk NPC, defined as stage II/T3N0M0 without adverse features (all nodes <3 cm, no level IV/Vb nodes; no extranodal extension; Epstein-Barr virus DNA <4000 copies/mL), with enrollment between November 2015 and August 2020. The final date of follow-up was March 15, 2022. INTERVENTIONS Patients were randomly assigned to receive IMRT alone (n = 172) or concurrent chemoradiotherapy (IMRT with cisplatin, 100 mg/m(2) every 3 weeks for 3 cycles [n = 169]). MAIN OUTCOMES AND MEASURES The primary end point was 3-year failure-free survival (time from randomization to any disease relapse or death), with a noninferiority margin of 10%. Secondary end points comprised overall survival, locoregional relapse-free survival, distant metastasis-free survival, adverse events, and health-related quality of life (QOL) measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30; range, 0-100 points; minimum clinically important difference >= 10 for physical function, symptom control, or health-related QOL; higher score indicates better functioning and global health status or worse symptoms). RESULTS Among 341 randomized patients (mean [SD] age, 48 [10] years; 30% women), 334 (98.0%) completed the trial. Median follow-up was 46 months (IQR, 34-58). Three-year failure-free survival was 90.5% for the IMRT-alone group vs 91.9% for the concurrent chemoradiotherapy group (difference, -1.4%; 1-sided 95% CI, -7.4% to infinity; P value for noninferiority, <.001). No significant differences were observed between groups in overall survival, locoregional relapse, or distant metastasis. The IMRT-alone group experienced a significantly lower incidence of grade 3 to 4 adverse events (17% vs 46%; difference, -29% [95% CI, -39% to -20%]), including hematologic toxicities (leukopenia, neutropenia) and nonhematologic toxicities (nausea, vomiting, anorexia, weight loss, mucositis). The IMRT-alone group had significantly better QOL scores during radiotherapy including the domains of global health status, social functioning, fatigue, nausea and vomiting, pain, insomnia, appetite loss, and constipation. CONCLUSIONS AND RELEVANCE Among patients with low-risk NPC, treatment with IMRT alone resulted in 3-year failure-free survival that was not inferior to concurrent chemoradiotherapy.	[Tang, Ling-Long; Guo, Rui; Chen, Lei; Hu, Wei-Han; Mao, Yan-Ping; Li, Wen-Fei; Zhou, Guan-Qun; Liu, Xu; Chen, Yu-Pei; Xu, Cheng; Lin, Li; Du, Xiao-Jing; Zhang, Yuan; Sun, Ying; Ma, Jun] Sun Yat Sen Univ, Dept Radiat Oncol,Canc Ctr, State Key Lab Oncol South China,Collaborat Innova, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou, Guangdong, Peoples R China; [Zhang, Ning; Luo, Wei-Jun] First Peoples Hosp Foshan, Dept Radiat Oncol, Foshan, Guangdong, Peoples R China; [Deng, Bin; Liang, Jin-Hui; Zheng, Yu-Ming] Wuzhou Red Cross Hosp, Dept Radiat Oncol, Wuzhou, Guangxi, Peoples R China; [Cheng, Zhi-Bin; Zhang, Fan] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiat Oncol, Zhuhai, Guangdong, Peoples R China; [Huang, Jing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Oncol,Canc Ctr, Wuhan, Hubei, Peoples R China; [Huang, Shao Hui] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada; [Liu, Qing] Sun Yat Sen Univ, Clin Trials Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Ma, Jun] Sun Yat Sen Univ, Ctr Precis Med, Guangzhou, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Huazhong University of Science & Technology; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Ma, J (corresponding author), Sun Yat Sen Univ, Canc Ctr, Dept Radiat Oncol, 651 Dongfeng Rd E, Guangzhou 510060, Peoples R China.	majun2@mail.sysu.edu.cn		Ma, Jun/0000-0002-1137-9349	National Natural Science Foundation of China [81930072, 82172870, 82172668]; Natural Science Foundation of Guangdong Province [2017A030312003]; Key-Area Research and Development Program of Guangdong Province [2019B020230002]; Overseas Expertise Introduction Project for Discipline Innovation (111 Project) [B14035]; Sun Yat-Sen University Clinical Research 5010 Program [2016011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Key-Area Research and Development Program of Guangdong Province; Overseas Expertise Introduction Project for Discipline Innovation (111 Project); Sun Yat-Sen University Clinical Research 5010 Program	This study was supported by grants from the National Natural Science Foundation of China (81930072, 82172870, 82172668), Natural Science Foundation of Guangdong Province (2017A030312003), Key-Area Research and Development Program of Guangdong Province (2019B020230002), Overseas Expertise Introduction Project for Discipline Innovation (111 Project, B14035) and the Sun Yat-Sen University Clinical Research 5010 Program (2016011).	Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Chan ATC, 2012, ANN ONCOL, V23, P83, DOI 10.1093/annonc/mds266; Chen QY, 2011, JNCI-J NATL CANCER I, V103, P1761, DOI 10.1093/jnci/djr432; Chin O, 2021, RADIOTHER ONCOL, V165, P94, DOI 10.1016/j.radonc.2021.10.018; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Du XJ, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0729-0; Fayers P, 2001, EORTC QLQ C30 SCORIN, V3th; Gregoire V, 2014, RADIOTHER ONCOL, V110, P172, DOI 10.1016/j.radonc.2013.10.010; Huang CL, 2020, CANCER MED-US, V9, P7100, DOI 10.1002/cam4.3392; Huang XD, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01314; Kano M, 2017, AURIS NASUS LARYNX, V44, P327, DOI 10.1016/j.anl.2016.07.015; Langendijk JA, 2004, J CLIN ONCOL, V22, P4604, DOI 10.1200/JCO.2004.10.074; Lee AWM, 2005, J CLIN ONCOL, V23, P6966, DOI 10.1200/JCO.2004.00.7542; Li WF, 2013, INT J RADIAT ONCOL, V86, P249, DOI 10.1016/j.ijrobp.2012.09.003; Licitra L, 2016, ORAL ONCOL, V52, P18, DOI 10.1016/j.oraloncology.2015.10.020; Liu F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194733; Lv X, 2021, LANCET ONCOL, V22, P716, DOI 10.1016/S1470-2045(21)00075-9; Mao YP, 2021, RADIOTHER ONCOL, V157, P114, DOI 10.1016/j.radonc.2021.01.015; Mehanna H, 2019, LANCET, V393, P51, DOI 10.1016/S0140-6736(18)32752-1; Pan JJ, 2016, CANCER-AM CANCER SOC, V122, P546, DOI 10.1002/cncr.29795; Pan JJ, 2015, AM J CLIN ONCOL-CANC, V38, P189, DOI 10.1097/COC.0b013e31828f5c96; Peng H, 2016, ONCOLOGIST, V21, P1369, DOI 10.1634/theoncologist.2016-0105; Pong S, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-044480; Le QT, 2013, CLIN CANCER RES, V19, P2208, DOI 10.1158/1078-0432.CCR-12-3702; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Shen LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068660; Su SF, 2012, INT J RADIAT ONCOL, V82, P327, DOI 10.1016/j.ijrobp.2010.09.011; Tang LQ, 2018, LANCET ONCOL, V19, P461, DOI 10.1016/S1470-2045(18)30104-9; Tang LL, 2021, CANCER COMMUN, V41, P1195, DOI 10.1002/cac2.12218; Verma N, 2020, HEAD NECK-J SCI SPEC, V42, P2364, DOI 10.1002/hed.26245; Wu SO, 2022, HEAD NECK-J SCI SPEC, V44, P851, DOI 10.1002/hed.26976; Zhang AM, 2012, RADIOTHER ONCOL, V104, P279, DOI 10.1016/j.radonc.2012.08.022; Zhang F, 2015, SCI REP-UK, V5, DOI 10.1038/srep17378	34	0	0	17	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 23	2022	328	8					728	736		10.1001/jama.2022.13997	http://dx.doi.org/10.1001/jama.2022.13997			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4P0DN	35997729				2023-01-03	WOS:000855063100020
J	Kariisa, M; Seth, P; Jones, CM				Kariisa, Mbabazi; Seth, Puja; Jones, Christopher M.			Increases in Disparities in US Drug Overdose Deaths by Race and Ethnicity Opportunities for Clinicians and Health Systems	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Kariisa, Mbabazi; Seth, Puja] Ctr Dis Control & Prevent, Div Overdose Prevent, Natl Ctr Injury Prevent Arid Control, Atlanta, GA 30341 USA; [Jones, Christopher M.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4700 Buford Hwy NE, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Kariisa, M (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4700 Buford Hwy NE, Atlanta, GA 30341 USA.	mkariisa@cdc.gov						Ahmad F.B., 2018, PROVISIONAL DRUG OVE; Chang JE, 2022, J SUBST ABUSE TREAT, V138, DOI 10.1016/j.jsat.2022.108719; Kariisa M, 2022, MMWR-MORBID MORTAL W, V71, P940, DOI 10.15585/mmwr.mm7129e2; Mattson CL, 2021, MMWR-MORBID MORTAL W, V70, P202, DOI 10.15585/mmwr.mm7006a4externalicon; Perera R, 2022, HARM REDUCT J, V19, DOI 10.1186/s12954-022-00594-9; Soto C., 2019, ADDRESSING OPIOID CR; Wakeman SE, 2021, SUBST ABUS, V42, P767, DOI 10.1080/08897077.2020.1846664	7	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2022	328	5					421	422		10.1001/jama.2022.12240	http://dx.doi.org/10.1001/jama.2022.12240		JUL 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3U1CS	35853029				2023-01-03	WOS:000828807200001
J	Perez-Larraya, JG; Garcia-Moure, M; Labiano, S; Patino-Garcia, A; Dobbs, J; Gonzalez-Huarriz, M; Zalacain, M; Marrodan, L; Martinez-Velez, N; Puigdelloses, M; Laspidea, V; Astigarraga, I; Lopez-Ibor, B; Cruz, O; Lizarbe, MO; Hervas-Stubbs, S; Alkorta-Aranburu, G; Tamayo, I; Tavira, B; Hernandez-Alcoceba, R; Jones, C; Dharmadhikari, G; Ruiz-Moreno, C; Stunnenberg, H; Hulleman, E; van der Lugt, J; Idoate, MA; Diez-Valle, R; Vazquez, IE; Villalba, M; de Andrea, C; Nunez-Cordoba, JM; Ewald, B; Robbins, J; Fueyo, J; Gomez-Manzano, C; Lang, FF; Tejada, S; Alonso, MM				Gallego Perez-Larraya, Jaime; Garcia-Moure, Marc; Labiano, Sara; Patino-Garcia, Ana; Dobbs, Jessica; Gonzalez-Huarriz, Marisol; Zalacain, Marta; Marrodan, Lucia; Martinez-Velez, Naiara; Puigdelloses, Montserrat; Laspidea, Virginia; Astigarraga, Itziar; Lopez-Ibor, Blanca; Cruz, Ofelia; Oscoz Lizarbe, Miren; Hervas-Stubbs, Sandra; Alkorta-Aranburu, Gorka; Tamayo, Ibon; Tavira, Beatriz; Hernandez-Alcoceba, Ruben; Jones, Chris; Dharmadhikari, Gitanjali; Ruiz-Moreno, Cristian; Stunnenberg, Henk; Hulleman, Esther; van der Lugt, Jasper; Idoate, Miguel A.; Diez-Valle, Ricardo; Esparragosa Vazquez, Ines; Villalba, Maria; de Andrea, Carlos; Nunez-Cordoba, Jorge M.; Ewald, Brett; Robbins, Joan; Fueyo, Juan; Gomez-Manzano, Candelaria; Lang, Frederick F.; Tejada, Sonia; Alonso, Marta M.			Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REIRRADIATION	BACKGROUND Pediatric patients with diffuse intrinsic pontine glioma (DIPG) have a poor prognosis, with a median survival of less than 1 year. Oncolytic viral therapy has been evaluated in patients with pediatric gliomas elsewhere in the brain, but data regarding oncolytic viral therapy in patients with DIPG are lacking. METHODS We conducted a single-center, dose-escalation study of DNX-2401, an oncolytic adenovirus that selectively replicates in tumor cells, in patients with newly diagnosed DIPG. The patients received a single virus infusion through a catheter placed in the cerebellar peduncle, followed by radiotherapy. The primary objective was to assess the safety and adverse-event profile of DNX-2401. The secondary objectives were to evaluate the effect of DNX-2401 on overall survival and quality of life, to determine the percentage of patients who have an objective response, and to collect tumor-biopsy and peripheral-blood samples for correlative studies of the molecular features of DIPG and antitumor immune responses. RESULTS A total of 12 patients, 3 to 18 years of age, with newly diagnosed DIPG received 1x10(10) (the first 4 patients) or 5x10(10) (the subsequent 8 patients) viral particles of DNX-2401, and 11 received subsequent radiotherapy. Adverse events among the patients included headache, nausea, vomiting, and fatigue. Hemiparesis and tetraparesis developed in 1 patient each. Over a median follow-up of 17.8 months (range, 5.9 to 33.5), a reduction in tumor size, as assessed on magnetic resonance imaging, was reported in 9 patients, a partial response in 3 patients, and stable disease in 8 patients. The median survival was 17.8 months. Two patients were alive at the time of preparation of the current report, 1 of whom was free of tumor progression at 38 months. Examination of a tumor sample obtained during autopsy from 1 patient and peripheral-blood studies revealed alteration of the tumor microenvironment and T-cell repertoire. CONCLUSIONS Intratumoral infusion of oncolytic virus DNX-2401 followed by radiotherapy in pediatric patients with DIPG resulted in changes in T-cell activity and a reduction in or stabilization of tumor size in some patients but was associated with adverse events.	[Gallego Perez-Larraya, Jaime; Garcia-Moure, Marc; Labiano, Sara; Patino-Garcia, Ana; Gonzalez-Huarriz, Marisol; Zalacain, Marta; Marrodan, Lucia; Martinez-Velez, Naiara; Puigdelloses, Montserrat; Laspidea, Virginia; Hervas-Stubbs, Sandra; Tamayo, Ibon; Tavira, Beatriz; Hernandez-Alcoceba, Ruben; Villalba, Maria; de Andrea, Carlos; Tejada, Sonia; Alonso, Marta M.] Clin Univ Navarra, Hlth Res Inst Navarra, Pamplona, Spain; [Gallego Perez-Larraya, Jaime; Garcia-Moure, Marc; Labiano, Sara; Patino-Garcia, Ana; Gonzalez-Huarriz, Marisol; Zalacain, Marta; Marrodan, Lucia; Martinez-Velez, Naiara; Puigdelloses, Montserrat; Laspidea, Virginia; Tavira, Beatriz; Tejada, Sonia; Alonso, Marta M.] Clin Univ Navarra, Program Solid Tumors, Pamplona, Spain; [Hervas-Stubbs, Sandra] Clin Univ Navarra, Program Immunol, Pamplona, Spain; [Hernandez-Alcoceba, Ruben] Clin Univ Navarra, Program Gene Therapy & Regulat Gene Express, Fdn Appl Med Res, Pamplona, Spain; [Gallego Perez-Larraya, Jaime; Esparragosa Vazquez, Ines] Clin Univ Navarra, Dept Neurol, Pamplona, Spain; [Garcia-Moure, Marc; Labiano, Sara; Patino-Garcia, Ana; Gonzalez-Huarriz, Marisol; Zalacain, Marta; Marrodan, Lucia; Martinez-Velez, Naiara; Puigdelloses, Montserrat; Laspidea, Virginia; Alonso, Marta M.] Clin Univ Navarra, Dept Pediat, Pamplona, Spain; [Villalba, Maria; de Andrea, Carlos] Clin Univ Navarra, Dept Pathol, Pamplona, Spain; [Tejada, Sonia] Clin Univ Navarra, Dept Neurosurg, Pamplona, Spain; [Nunez-Cordoba, Jorge M.] Clin Univ Navarra, Div Biostat, Res Support Serv, Cent Clin Trials Unit, Pamplona, Spain; [Oscoz Lizarbe, Miren] Univ Navarra, Serv Pediat Hematooncol, Hosp Univ Navarra, Ctr Appl Med Res CIMA Lab Diagnost, Pamplona, Spain; [Alkorta-Aranburu, Gorka] Healthcare Res Inst Navarra, Pamplona, Spain; [Tamayo, Ibon] Univ Navarra, CIMA, Bioinformat Platform, Pamplona, Spain; [Astigarraga, Itziar] Biocruces Bizkaia Hlth Res Inst, Dept Pediat Oncol, Baracaldo, Spain; [Astigarraga, Itziar] Univ Basque Country, Fac Med & Nursing, Pediat Dept, Leioa, Spain; [Lopez-Ibor, Blanca] Monteprincipe Hosp, Dept Pediat Oncol, Madrid, Spain; [Diez-Valle, Ricardo; Tejada, Sonia] Quiron Hosp, Dept Neurosurg, Madrid, Spain; [Villalba, Maria] Ctr Invest Biomed Red Canc, Madrid, Spain; [Cruz, Ofelia] Hosp St Joan de Deu, Neurooncol Unit, Dept Pediat Oncol, Barcelona, Spain; [Idoate, Miguel A.] Univ Seville, Univ Hosp Virgen Macarena, Dept Pathol, Seville, Spain; [Idoate, Miguel A.] Univ Seville, Sch Med, Seville, Spain; [Dharmadhikari, Gitanjali; Ewald, Brett; Robbins, Joan] DNAtrix, Carlsbad, CA USA; [Jones, Chris] Inst Canc Res, Div Mol Pathol, London, England; [Dobbs, Jessica; Ruiz-Moreno, Cristian; Stunnenberg, Henk; Hulleman, Esther; van der Lugt, Jasper] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Fueyo, Juan; Gomez-Manzano, Candelaria] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Lang, Frederick F.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra; Servicio Navarro de Salud - Osasunbidea; University of Navarra; University of Navarra; University of Basque Country; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Barcelona; Hospital Universitario Virgen Macarena; University of Sevilla; University of Sevilla; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Alonso, MM (corresponding author), CIMA Bldg,Lab 2-03,Pio XII 55, Pamplona 31008, Spain.	mmalonso@unav.es	; Ruiz-Moreno, Cristian/P-7315-2018; Tamayo Uria, Ibon/H-5283-2019; Astigarraga, Itziar/I-1215-2014	Garcia-Moure, Marc/0000-0002-4365-7753; Ruiz-Moreno, Cristian/0000-0001-9689-7964; Tamayo Uria, Ibon/0000-0002-8183-7106; Astigarraga, Itziar/0000-0002-5012-0137; Labiano, Sara/0000-0002-2173-9416; Villalba Esparza, Maria/0000-0002-9183-0610	European Research Council under the European Union [817884]; Fundacion ACS; Fundacion Adey; Departamento de Salud del Gobierno de Navarra [54/2018]; ChadTough Defeat DIPG Foundation; Gobierno de Navarra; Instituto de Salud Carlos III y Fondos Feder [PI19/01896, PI18/00164]; Amigos de la Universidad de Navarra; Fundacion la Caixa; Fundacion Caja Navarra; Fundacion El Sueno de Vicky; Asociacion Pablo UgarteFuerza Julen; Department of Defense Team Science Award [CA 160525]; Abbie's Army	European Research Council under the European Union(European Research Council (ERC)); Fundacion ACS; Fundacion Adey; Departamento de Salud del Gobierno de Navarra; ChadTough Defeat DIPG Foundation; Gobierno de Navarra; Instituto de Salud Carlos III y Fondos Feder; Amigos de la Universidad de Navarra; Fundacion la Caixa(La Caixa Foundation); Fundacion Caja Navarra; Fundacion El Sueno de Vicky; Asociacion Pablo UgarteFuerza Julen; Department of Defense Team Science Award; Abbie's Army	Supported by the European Research Council under the European Union's Horizon 2020 Research and Innovation Program (817884 ViroPedTher, to Dr. Alonso) and grants from the Fundacion ACS and the Fundacion Adey (to Drs. Patino-Garcia and Alonso). The authors' work is supported by a grant from the Departamento de Salud del Gobierno de Navarra (54/2018, to Dr. Patino-Garcia), a postdoctoral fellowship from the ChadTough Defeat DIPG Foundation (to Dr. Garcia-Moure), a predoctoral fellowship from Gobierno de Navarra (to Ms. Laspidea), grants from the Instituto de Salud Carlos III y Fondos Feder (PI19/01896, to Dr. Alonso, and PI18/00164, to Dr. PatinoGarcia), a grant from Amigos de la Universidad de Navarra (to Dr. Puigdelloses), grants from the Fundacion la Caixa and the Fundacion Caja Navarra (to Drs. Patino-Garcia and Alonso), a grant from the Fundacion El Sueno de Vicky (to Drs. PatinoGarcia and Alonso), a grant from the Asociacion Pablo UgarteFuerza Julen (to Drs. Patino-Garcia and Alonso), the Department of Defense Team Science Award under grant CA 160525 (to Drs. Alonso, Gomez-Manzano, and Fueyo), and a grant from Abbie's Army (to Dr. Jones).	Chang EK, 2021, BRAIN PATHOL, V31, DOI 10.1111/bpa.12959; Cooney T, 2017, NEURO-ONCOLOGY, V19, P1279, DOI 10.1093/neuonc/nox107; Cooney TM, 2020, LANCET ONCOL, V21, pE330, DOI 10.1016/S1470-2045(20)30166-2; Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435; Friedman GK, 2021, NEW ENGL J MED, V384, P1613, DOI 10.1056/NEJMoa2024947; Hoffman LM, 2018, J CLIN ONCOL, V36, P1963, DOI 10.1200/JCO.2017.75.9308; Janssens GO, 2017, EUR J CANCER, V73, P38, DOI 10.1016/j.ejca.2016.12.007; Javadi Seyed Amirhossein, 2018, Asian J Neurosurg, V13, P414, DOI 10.4103/1793-5482.228540; Lang FF, 2018, J CLIN ONCOL, V36, P1419, DOI 10.1200/JCO.2017.75.8219; Mackay A, 2017, CANCER CELL, V32, P520, DOI 10.1016/j.ccell.2017.08.017; Martinez-Velez N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10043-0; Martinez-Velez N, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0714-6; Massimino M, 2014, J NEURO-ONCOL, V118, P305, DOI 10.1007/s11060-014-1428-z; Okada Hideho, 2015, Lancet Oncol, V16, pe534, DOI 10.1016/S1470-2045(15)00088-1; Ostrom QT, 2015, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou327; Tejada S, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00061; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Ye VC, 2021, J NEUROSURG CASE LES, V1, P2078	18	10	10	11	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2022	386	26					2471	2481		10.1056/NEJMoa2202028	http://dx.doi.org/10.1056/NEJMoa2202028			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D8GD	35767439				2023-01-03	WOS:000847376200008
J	Kuehn, BM				Kuehn, Bridget M.			Children With Sickle Cell Anemia Not Receiving Recommended Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	2022	328	16					1583	1584		10.1001/jama.2022.15489	http://dx.doi.org/10.1001/jama.2022.15489			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6C3UZ	36282250				2023-01-03	WOS:000881945000010
J	Lee, S; Calcaterra, HA; Lee, S; Hadibrata, W; Lee, B; Oh, E; Aydin, K; Glotzer, SC; Mirkin, CA				Lee, Seungkyu; Calcaterra, Heather A.; Lee, Sangmin; Hadibrata, Wisnu; Lee, Byeongdu; Oh, EunBi; Aydin, Koray; Glotzer, Sharon C.; Mirkin, Chad A.			Shape memory in self-adapting colloidal crystals	NATURE			English	Article								Reconfigurable, mechanically responsive crystalline materials are central components in many sensing, soft robotic, and energy conversion and storage devices(1-4). Crystalline materials can readily deform under various stimuli and the extent of recoverable deformation is highly dependent upon bond type(1,2,5-10). Indeed, for structures held together via simple electrostatic interactions, minimal deformations are tolerated. By contrast, structures held together by molecular bonds can, in principle, sustain much larger deformations and more easily recover their original configurations. Here we study the deformation properties of well-faceted colloidal crystals engineered with DNA. These crystals are large in size (greater than 100 mu m) and have a body-centred cubic (bcc) structure with a high viscoelastic volume fraction (of more than 97%). Therefore, they can be compressed into irregular shapes with wrinkles and creases, and, notably, these deformed crystals, upon rehydration, assume their initial well-formed crystalline morphology and internal nanoscale order within seconds. For most crystals, such compression and deformation would lead to permanent, irreversible damage. The substantial structural changes to the colloidal crystals are accompanied by notable and reversible optical property changes. For example, whereas the original and structurally recovered crystals exhibit near-perfect (over 98%) broadband absorption in the ultraviolet-visible region, the deformed crystals exhibit significantly increased reflection (up to 50% of incident light at certain wavelengths), mainly because of increases in their refractive index and inhomogeneity.	[Lee, Seungkyu; Oh, EunBi; Mirkin, Chad A.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; [Lee, Seungkyu; Calcaterra, Heather A.; Oh, EunBi; Mirkin, Chad A.] Northwestern Univ, Int Inst Nanotechnot Northwestern, Evanston, IL 60208 USA; [Calcaterra, Heather A.; Mirkin, Chad A.] Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA; [Lee, Sangmin; Glotzer, Sharon C.] Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; [Lee, Sangmin; Glotzer, Sharon C.] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA; [Hadibrata, Wisnu; Aydin, Koray] Northwestern Univ, Dept Elect & Comp Engn, Evanston, IL USA; [Lee, Byeongdu] Argonne Natl Lab, Xray Sci Div, Lemont, IL USA	Northwestern University; Northwestern University; Northwestern University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Northwestern University; United States Department of Energy (DOE); Argonne National Laboratory	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, Evanston, IL 60208 USA.; Mirkin, CA (corresponding author), Northwestern Univ, Int Inst Nanotechnot Northwestern, Evanston, IL 60208 USA.; Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA.	chadnano@northwestern.edu		Lee, Sangmin/0000-0002-1145-4708; Oh, EunBi/0000-0002-9467-9135; Lee, Byeongdu/0000-0003-2514-8805; Calcaterra, Heather/0000-0002-1042-1621	Air Force Office of Scientific Research [FA9550-17-1-0348, FA9550-16-1-0150, FA9550-18-1-0493]; US Department of Energy, Office of Science, Basic Energy Sciences [DE-SC0000989]; SHyNE Resource (NSF) [ECCS-2025633]; International Institute for Nanotechnology (IIN); Northwestern's MRSEC program (NSF) [DMR-1720139]; Keck Foundation; State of Illinois, through the IIN; US Department of Energy Office of Science by Argonne National Laboratory [DE-AC02-06CH11357]; National Science Foundation Graduate Research Fellowship Program grant [DGE-1842165]; Office of Naval Research Young Investigator Program (ONR-YIP) Award [N00014-17-1-2425]; CBES [DE-SC0000989]; IIN; National Science Foundation [ACI-1548562]; XSEDE [DMR 140129]	Air Force Office of Scientific Research(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); US Department of Energy, Office of Science, Basic Energy Sciences(United States Department of Energy (DOE)); SHyNE Resource (NSF)(National Science Foundation (NSF)); International Institute for Nanotechnology (IIN); Northwestern's MRSEC program (NSF); Keck Foundation(W.M. Keck Foundation); State of Illinois, through the IIN; US Department of Energy Office of Science by Argonne National Laboratory(United States Department of Energy (DOE)); National Science Foundation Graduate Research Fellowship Program grant; Office of Naval Research Young Investigator Program (ONR-YIP) Award(Office of Naval Research); CBES; IIN; National Science Foundation(National Science Foundation (NSF)); XSEDE	This material is based upon work supported by Air Force Office of Scientific Research FA9550-17-1-0348, FA9550-16-1-0150 and FA9550-18-1-0493. It was also supported as part of the Center for Bio-Inspired Energy Science, an Energy Frontier Research Center (CBES) funded by the US Department of Energy, Office of Science, Basic Energy Sciences award DE-SC0000989. This work made use of the EPIC facility of Northwestern University's NUANCE Center, which has received support from the SHyNE Resource (NSF grant no. ECCS-2025633), the International Institute for Nanotechnology (IIN) and Northwestern's MRSEC program (NSF grant no. DMR-1720139); the IIN; the Keck Foundation; and the State of Illinois, through the IIN. This research used resources of the Advanced Photon Source, a US Department of Energy Office of Science User Facility operated for the US Department of Energy Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357. X-ray diffraction experiments were carried out at the Dupont-Northwestern-Dow Collaborative Access Team beamline at Sector 5, 12-ID-B, and sector 21 at the Advanced Photon Source at Argonne National Laboratory. H.A.C. acknowledges support by the National Science Foundation Graduate Research Fellowship Program grant (DGE-1842165). K.A. acknowledges partial support from the Office of Naval Research Young Investigator Program (ONR-YIP) Award (no. N00014-17-1-2425). S.L. (UM) and S.C.G. acknowledge support from CBES (grant no. DE-SC0000989). MD simulations were supported in part through computational resources and services supported by Advanced Research Computing at the University of Michigan, Ann Arbor and also used the Extreme Science and Engineering Discovery Environment (XSEDE), which is supported by National Science Foundation grant no. ACI-1548562 and XSEDE award no. DMR 140129.	Ahmed E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11612-z; Anderson JA, 2020, COMP MATER SCI, V173, DOI 10.1016/j.commatsci.2019.109363; CHANDLER D, 1983, SCIENCE, V220, P787, DOI 10.1126/science.220.4599.787; CHU X, 1987, MATER LETT, V5, P153, DOI 10.1016/0167-577X(87)90025-5; CHYLEK P, 1976, SCIENCE, V193, P480, DOI 10.1126/science.193.4252.480; De Fazio AF, 2019, ACS NANO, V13, P5771, DOI 10.1021/acsnano.9b01294; Desiraju G.R., 2001, WEAK HYDROGEN BOND S, Vvol. 9; Diercks CS, 2017, SCIENCE, V355, DOI 10.1126/science.aal1585; Egan P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8418; Field JE, 1996, DIAM RELAT MATER, V5, P625, DOI 10.1016/0925-9635(95)00362-2; He MX, 2020, NATURE, V585, P524, DOI 10.1038/s41586-020-2718-6; Hoffmann, 1989, SOLIDS SURFACES CHEM; Jones MR, 2015, SCIENCE, V347, DOI 10.1126/science.1260901; Kobatake S, 2007, NATURE, V446, P778, DOI 10.1038/nature05669; Koshima H, 2020, MECHANICALLY RESPONSIVE MATERIALS FOR SOFT ROBOTICS, P1; LANG AR, 1968, NATURE, V220, P652, DOI 10.1038/220652a0; Laramy CR, 2019, NAT REV MATER, V4, P201, DOI 10.1038/s41578-019-0087-2; Lee S, 2019, J AM CHEM SOC, V141, P11827, DOI 10.1021/jacs.9b06106; Lequieu J, 2016, ACS CENTRAL SCI, V2, P614, DOI 10.1021/acscentsci.6b00170; Leunissen ME, 2005, NATURE, V437, P235, DOI 10.1038/nature03946; Lewis DJ, 2020, J AM CHEM SOC, V142, P19181, DOI 10.1021/jacs.0c08790; Lin HX, 2017, SCIENCE, V355, P931, DOI 10.1126/science.aal3919; Liu E. J., 2015, GeoResJ, V8, P14, DOI 10.1016/j.grj.2015.09.001; Maldovan M, 2015, NAT MATER, V14, P667, DOI [10.1038/NMAT4308, 10.1038/nmat4308]; Mason JA, 2015, NATURE, V527, P357, DOI 10.1038/nature15732; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Naumov P, 2015, CHEM REV, V115, P12440, DOI 10.1021/acs.chemrev.5b00398; Naumov P, 2013, ANGEW CHEM INT EDIT, V52, P9990, DOI 10.1002/anie.201303757; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Nykypanchuk D, 2008, NATURE, V451, P549, DOI 10.1038/nature06560; Park JY, 2010, BIOCHIP J, V4, P230, DOI 10.1007/s13206-010-4311-9; Park SY, 2008, NATURE, V451, P553, DOI 10.1038/nature06508; Pauling L., 1960, NATURE CHEM BOND STR; Rai R, 2018, P NATL ACAD SCI USA, V115, P2896, DOI 10.1073/pnas.1718965115; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Skoko Z, 2010, J AM CHEM SOC, V132, P14191, DOI 10.1021/ja105508b; Smith DR, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.036617; Sunyer R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046107; Taniguchi T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02549-2; Towns J, 2014, COMPUT SCI ENG, V16, P62, DOI 10.1109/MCSE.2014.80; Wang SZ, 2019, J AM CHEM SOC, V141, P20443, DOI 10.1021/jacs.9b11109; Zhang L, 2018, NATURE, V557, P86, DOI 10.1038/s41586-018-0057-7	42	0	0	39	39	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 27	2022	610	7933					674	+		10.1038/s41586-022-05232-9	http://dx.doi.org/10.1038/s41586-022-05232-9		OCT 2022	17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	5Q8QG	36253468				2023-01-03	WOS:000869346500002
J	[Anonymous]				[Anonymous]			Summary for Patients: Effectiveness of an Online Yoga Program on Pain and Function in Participants With Knee Osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	2	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT	2022	175	10					I32	I32		10.7326/P22-0017	http://dx.doi.org/10.7326/P22-0017		SEP 2022	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5M3CC	36122379				2023-01-03	WOS:000860851400003
J	Erchafo, B; Abute, L; Tedesse, T; Sedoro, T; Mecha, A				Erchafo, Belay; Abute, Lonsako; Tedesse, Tegegn; Sedoro, Tagesse; Mecha, Aregash			Knowledge, attitude and practice towards complementary and alternative medicine and associated factors among health care professionals in public health facilities of Hadiya Zone, South Ethiopia	PLOS ONE			English	Article							TRADITIONAL MEDICINE; ISSUES; CAM	Background Even if modern medicine is becoming more widely available, a considerable portion of the world's population continues to rely on complementary and alternative medicine. Complementary and alternative medicine is used by 80% of the population in developing countries for their health care. The study was conducted to assess Knowledge, Attitude and practice towards complementary and alternative medicine and associated factors among health care professionals in public health facilities of Hadiya Zone, South Ethiopia. Methods The study was conducted in Hadiya Zone from October 10 to October 30, 2019. A facility-based cross-sectional study design was employed using simple random sampling methods. Three hundred sixty six health care professionals were selected using a simple random sample method. The data were collected using a standardized self-administered and pretested questionnaire that was adapted from different literatures. We used descriptive statistics, as well as bivariate and multivariate logistic regression analysis. An association was determined using P-values less than 0.05 and 95 percent confidence intervals. The results of the study were presented using texts and tables. Results Three hundred and fifty-five respondents were interviewed, with a 97 percent respondent rate. Two hundred thirty-two (65.4%) of the study participants have good knowledge towards complementary and alternative medicine, 216 (60.8%) have a favorable attitude toward complementary and alternative medicine, and 182 (51.3%) have utilized it in the previous two years. Some of the factors associated with knowledge, attitude, and practice towards complementary and alternative medicine were health care professionals who have contact with patients who seek complementary and alternative medicine [AOR = 1.89(95% CI; 1.18, 3.03), female health care professionals [AOR = 2.43(95% CI; 2.68, 9.74), and more than six years work experience [AOR = 1.68(95% CI; 1.04, 2.71). Conclusion The knowledge, attitude, and practice of complementary and alternative medicine among health care professionals were low. Creating communication lines with patients and facilitating the integration of complementary and alternative medicine with modern medicine.	[Erchafo, Belay; Abute, Lonsako; Tedesse, Tegegn; Sedoro, Tagesse; Mecha, Aregash] Wachemo Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Hosaena, Ethiopia		Erchafo, B (corresponding author), Wachemo Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Hosaena, Ethiopia.	erchafobelay@gmail.com			Wachemo University [RCSD/09/2013]	Wachemo University	This study was funded by Wachemo University through a staff research grant with grant reference number RCSD/09/2013. The funders had no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.	Al Shaar I. A. M. S., 2010, Eastern Mediterranean Health Journal, V16, P522; Arcury TA, 2013, J APPL GERONTOL, V32, P627, DOI 10.1177/0733464812443084; Bahall M, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1654-y; Belachew N, 2017, J EVID-BASED INTEGR, V22, P929, DOI 10.1177/2515690X17746547; Bodeker G, 2002, AM J PUBLIC HEALTH, V92, P1582, DOI 10.2105/AJPH.92.10.1582; d'Avigdor E, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-38; Elolemy Ahmed Tawfik, 2012, Oman Med J, V27, P20, DOI 10.5001/omj.2012.04; Gari A, 2015, J PHARM BIOALLIED SC, V7, P136, DOI 10.4103/0975-7406.148782; Jacobson GM, 2009, J ONCOL PRACT, V5, P124, DOI 10.1200/JOP.0938501; Kebede Deribe Kassaye, 2006, Ethiopian Journal of Health Development, V20, P127; Kloos H, 2013, ETHIOP J HEALTH DEV, V27, P141; Ock SM, 2009, J KOREAN MED SCI, V24, P1, DOI 10.3346/jkms.2009.24.1.1; Organization WH, 2000, GEN GUID METH RES EV; Organization WH, 2001, LEG STAT TRAD MED CO; Sadik EA., 2011, ASPECTS COMMON TRADI; Sarman A, 2022, EUR J INTEGR MED, V49, DOI 10.1016/j.eujim.2021.102096; Smith K, 2016, BIOETHICS, V30, P60, DOI 10.1111/bioe.12243; Soos SA, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1426-0; Stub T, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1326-3; Suleman S, 2016, ETHIOP J HEALTH SCI, V26, P259, DOI 10.4314/ejhs.v26i3.9; Tachjian A, 2010, J AM COLL CARDIOL, V55, P515, DOI 10.1016/j.jacc.2009.07.074; Ventola C Lee, 2010, P T, V35, P461; Zerabruk S, 2012, S AFR J BOT, V78, P165, DOI 10.1016/j.sajb.2011.06.006	23	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2022	17	9							e0274333	10.1371/journal.pone.0274333	http://dx.doi.org/10.1371/journal.pone.0274333			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R1EM	36083992	gold, Green Published			2023-01-03	WOS:000892051000136
J	Munot, S; Bray, J; Bauman, A; Rugel, EJ; Giordan, LB; Marschner, S; Chow, CK; Redfern, J				Munot, Sonali J.; Bray, Janet; Bauman, Adrian; Rugel, Emily K.; Giordan, Leticia Bezerra; Marschner, Simone; Chow, Clara; Redfern, Julie			Development of an intervention to facilitate dissemination of community-based training to respond to out-of-hospital cardiac arrest: FirstCPR	PLOS ONE			English	Article							AMERICAN-HEART-ASSOCIATION; ONLY CARDIOPULMONARY-RESUSCITATION; INTERNATIONAL LIAISON COMMITTEE; IMPLEMENTATION; CPR; SCIENCE; CARE; COMPRESSION; PERFORMANCE	Background and aimOut-of-hospital cardiac arrest (OHCA) is a significant public health issue with low survival rates. Prompt bystander action can more than double survival odds. OHCA response training is primarily pursued due to work-related mandates, with few programs targeting communities with lower training levels. The aim of this research was to describe the development process of a targeted multicomponent intervention package designed to enhance confidence and training among laypeople in responding to an OHCA. MethodsAn iterative, three-phase program development process was employed using a mixed methods approach. The initial phase involved establishment of a multidisciplinary panel that informed decisions on key messages, program content, format, and delivery modes. These decisions were based on scientific evidence and guided by behavioural theories. The second phase comprised the development of the intervention package, identifying existing information and developing new material to fill identified gaps. The third phase involved refining and finalising the material via feedback from panel members, stakeholders, and community members. ResultsThrough this approach, we collaboratively developed a comprehensive evidence-based education and training package consisting of a digital intervention supplemented with free access to in-person education and training. The package was designed to teach community members the specific steps in recognising and responding to a cardiac arrest, while addressing commonly known barriers and fears related to bystander response. The tailored program and delivery format addressed the needs of individuals of diverse ages, cultural backgrounds, and varied training needs and preferences. ConclusionThe study highlights the importance of community engagement in intervention development and demonstrates the need of evidence-based and collaborative approaches in creating a comprehensive, localised, relatively low-cost intervention package to improve bystander response to OHCA.	[Munot, Sonali J.; Rugel, Emily K.; Giordan, Leticia Bezerra; Marschner, Simone; Chow, Clara] Univ Sydney, Fac Med & Hlth, Westmead Appl Res Ctr, Sydney, NSW, Australia; [Bray, Janet] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Bauman, Adrian] Univ Sydney, Fac Med & Hlth, Sch Publ Hlth, Sydney, NSW, Australia; [Chow, Clara; Redfern, Julie] Univ New South Wales, George Inst Global Hlth, Newtown, NSW, Australia; [Redfern, Julie] Univ Sydney, Fac Med & Hlth, Sch Hlth Sci, Sydney, NSW, Australia	University of Sydney; Monash University; University of Sydney; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University of Sydney	Munot, S (corresponding author), Univ Sydney, Fac Med & Hlth, Westmead Appl Res Ctr, Sydney, NSW, Australia.	sonali.munot@sydney.edu.au		Munot, Sonali/0000-0001-5439-2802	National Health and Medical Research Council (NHMRC), Australia [GNT2007946]; New South Wales Health; NHMRC Investigator Grant; Heart Foundation Fellowship; Westmead Applied Research Centre; University of Sydney Deputy Vice-Chancellor (Research) [104751];  [APP1168950];  [G201443]	National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); New South Wales Health; NHMRC Investigator Grant(National Health and Medical Research Council (NHMRC) of Australia); Heart Foundation Fellowship; Westmead Applied Research Centre; University of Sydney Deputy Vice-Chancellor (Research); ; 	Funding was obtained from the National Health and Medical Research Council (NHMRC), Australia [partnership project grant, number APP1168950]. In addition, monetary support was received from New South Wales Health and The University of Sydney Deputy Vice-Chancellor (Research) [COVID-19 Support Scheme Grant record ID: G201443]. All partner organisations provided in-kind support towards the project [see organisation list in Supplementary section S1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. JR is supported by a NHMRC Investigator Grant [GNT2007946], CC is supported by a NHMRC Investigator Grant [APP1195326], JB is supported by a Heart Foundation Fellowship [#104751] and SMunot is supported by a PhD scholarship from the Westmead Applied Research Centre.	[Anonymous], 2015, HEART SAF COMM CARD; [Anonymous], 2018, CPR TRAIN SCH NOW RE; [Anonymous], 2020, HANDS ONL CPR ED VID; [Anonymous], NATL IND 1 AID TRAIN; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Beskind DL, 2017, RESUSCITATION, V118, P96, DOI 10.1016/j.resuscitation.2017.07.011; Bobrow BJ, 2011, CIRC-CARDIOVASC QUAL, V4, P220, DOI 10.1161/CIRCOUTCOMES.110.959353; Bodison SC, 2015, CTS-CLIN TRANSL SCI, V8, P814, DOI 10.1111/cts.12342; Boland LL, 2017, RESUSCITATION, V119, P33, DOI 10.1016/j.resuscitation.2017.07.031; Bray J, 2022, RESUSCITATION, V172, P74, DOI 10.1016/j.resuscitation.2022.01.011; Bray JE, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005972; Brownson RC, 2013, AM J PUBLIC HEALTH, V103, P1693, DOI 10.2105/AJPH.2012.301165; Cartledge S, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-033722; Dobbie F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193391; Dwyer T, 2008, PREHOSP EMERG CARE, V12, P157, DOI 10.1080/10903120801907216; EISENBERG M, 1995, ANN EMERG MED, V25, P198, DOI 10.1016/S0196-0644(95)70324-1; Fratta KA, 2020, AM J EMERG MED, V38, P603, DOI 10.1016/j.ajem.2019.10.019; Giles EL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090347; Glanz K, 2010, ANNU REV PUBL HEALTH, V31, P399, DOI 10.1146/annurev.publhealth.012809.103604; Hansen CM, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004128; Introduction to program evaluation for public health programs: A self-study guide, 2011, OFFICE DIRECTOR OFFI; Kiguchi T, 2020, RESUSCITATION, V152, P39, DOI 10.1016/j.resuscitation.2020.02.044; Kirk J, 2021, J HEALTH ORGAN MANAG, V35, P140, DOI 10.1108/JHOM-02-2020-0049; Laird Y, 2020, HEALTH RES POLICY SY, V18, DOI 10.1186/s12961-020-00599-5; Lau Y, 2018, RESUSCITATION, V131, P14, DOI 10.1016/j.resuscitation.2018.07.033; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Munot S, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2021-057175; Munoz RF, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1463; Nishiyama C, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.009436; Nutbeam D., 2010, THEORY NUTSHELL; Perkins GD, 2015, RESUSCITATION, V95, pE43, DOI 10.1016/j.resuscitation.2015.07.041; Perkins GD, 2015, CIRCULATION, V132, P1286, DOI 10.1161/CIR.0000000000000144; Redfern J, 2014, EUR J PREV CARDIOL, V21, P492, DOI 10.1177/2047487312449416; Sasson C, 2013, CIRC-CARDIOVASC QUAL, V6, P550, DOI 10.1161/CIRCOUTCOMES.111.000097; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Sayre MR, 2008, CIRCULATION, V117, P2162, DOI 10.1161/CIRCULATIONAHA.107.189380; Swor R, 2006, ACAD EMERG MED, V13, P596, DOI 10.1197/j.aem.2005.12.021; Tanigawa K, 2011, RESUSCITATION, V82, P523, DOI 10.1016/j.resuscitation.2011.01.027; Yu Y, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.9256	40	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2022	17	8							e0273028	10.1371/journal.pone.0273028	http://dx.doi.org/10.1371/journal.pone.0273028			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4X7AR	36001615	gold, Green Published			2023-01-03	WOS:000860991100002
J	Slomski, A				Slomski, Anita			Virtual Reality Lessens Postoperative Pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 16	2022	328	7					610	610		10.1001/jama.2022.13772	http://dx.doi.org/10.1001/jama.2022.13772			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4D0ZW	35972497				2023-01-03	WOS:000846874500004
J	Smith, R				Smith, Richard			A dream about value, the NHS, and end of life care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																		Sallnow L, 2022, LANCET, V399, P837, DOI 10.1016/S0140-6736(21)02314-X	1	0	0	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 11	2022	378								o2004	10.1136/bmj.o2004	http://dx.doi.org/10.1136/bmj.o2004			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5A7DP	35953091	Bronze			2023-01-03	WOS:000863044400006
J	Tanne, JH				Tanne, Janice Hopkins			Drug company asks FDA to approve over-the-counter contraceptive pill	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		American College of Obstetricians and Gynecologists, 2014, ACOG STAT OTC ACC CO; American Medical Association, 2022, AMA URG FDA MAK OR C; Medicines and Healthcare Products Regulatory Agency, 2021, 1 PROG ONL CONTR PIL; Perrigo, 2022, PERR HRA PHARM SUBM; Pressley Pressley A., 2022, LEE DEGETTE CHU COLL; Tanne JH, 2022, BMJ-BRIT MED J, V378, DOI 10.1136/bmj.o1643	6	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 12	2022	378								o1727	10.1136/bmj.o1727	http://dx.doi.org/10.1136/bmj.o1727			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3S1XF	35820679				2023-01-03	WOS:000839395300014
J	Haroz, EE; Ingalls, A; Decker Sorby, K; Dozier, M; Kaye, MP; Sarche, M; Supplee, LH; Whitaker, DJ; Grubin, F; Daro, D				Haroz, Emily E.; Ingalls, Allison; Decker Sorby, Karla; Dozier, Mary; Kaye, Miranda P.; Sarche, Michelle; Supplee, Lauren H.; Whitaker, Daniel J.; Grubin, Fiona; Daro, Deborah			Expert-generated standard practice elements for evidence-based home visiting programs using a Delphi process	PLOS ONE			English	Article							INTERVENTION; FAMILIES; CHILDREN; HEALTH; TRIAL; RISK	Background States, territories, non-profits, and tribes are eligible to obtain federal funding to implement federally endorsed evidence-based home visiting programs. This represents a massive success in translational science, with $400 million a year allocated to these implementation efforts. This legislation also requires that 3% of this annual funding be allocated to tribal entities implementing home visiting in their communities. However, implementing stakeholders face challenges with selecting which program is best for their desired outcomes and context. Moreover, recent reviews have indicated that when implemented in practice and delivered at scale, many evidence-based home visiting programs fail to replicate the retention rates and effects achieved during clinical trials. To inform program implementers and better identify the active ingredients in home visiting programs that drive significant impacts, we aimed to develop an expert derived consensus taxonomy on the elements used in home visiting practice that are essential to priority outcome domains. Methods We convened a panel of 16 experts representing researchers, model representatives, and program implementers using a Delphi approach. We first elicited standard practice elements (SPEs) using open-ended inquiry, then compared these elements to behavior change techniques (BCTs) given their general importance in the field of home visiting; and finally rated their importance to 10 outcome domains. Results Our process identified 48 SPEs derived from the panel, with 83 additional BCTs added based on the literature. Six SPEs, mostly related to home visitor characteristics and skills, were rated essential across all outcome domains. Fifty-three of the 83 BCTs were rated unnecessary across all outcome domains. Conclusions This work represents the first step in a consensus-grounded taxonomy of techniques and strategies necessary for home visiting programs and provides a framework for future hypothesis testing and replication studies.	[Haroz, Emily E.; Ingalls, Allison; Grubin, Fiona] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Amer Indian Hlth, Baltimore, MD USA; [Decker Sorby, Karla] Minnesota Dept Hlth, Family Home Visiting, Bemidji, MN USA; [Dozier, Mary] Univ Delaware, Dept Psychol, Newark, DE USA; [Kaye, Miranda P.] Penn State Univ, State Coll, PA USA; [Sarche, Michelle] Colorado Sch Publ Hlth, Centers Amer Indian Alaska Native Hlth, Aurora, CO USA; [Supplee, Lauren H.] William T Grant Fdn, New York, NY USA; [Whitaker, Daniel J.] Georgia State Univ, Sch Publ Hlth, Atlanta, GA USA; [Daro, Deborah] Univ Chicago, Chapin Hall, Chicago, IL USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Minnesota Department of Health (MHD); University of Delaware; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Colorado School of Public Health; University System of Georgia; Georgia State University; University of Chicago	Haroz, EE (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Amer Indian Hlth, Baltimore, MD USA.	eharoz1@jhu.edu		Ingalls, Allison/0000-0002-3255-7351	Annie E. Casey Foundation, Inc. [GA-2020B4038]; National Institute of Mental Health [K01MH116335]	Annie E. Casey Foundation, Inc.; National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	E.E.H. received funding from the Annie E. Casey Foundation, Inc. for this research and we thank them for their support Grant #GA-2020B4038): www.aecf.org; however, the findings and conclusions presented in this report are those of the author(s) alone, and do not necessarily reflect the opinions of the Foundation. Author E.E.H. was also supported by the National Institute of Mental Health (nimh.nih.gov) grant number K01MH116335. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ammerman RT, 2013, BEHAV THER, V44, P359, DOI 10.1016/j.beth.2013.01.002; [Anonymous], OUTCOMES; [Anonymous], DEFINITION HUMAN SUB; [Anonymous], HOME VISITING EVIDEN; [Anonymous], TRIBAL MATERNAL INFA; Boustani MM, 2015, ADM POLICY MENT HLTH, V42, P209, DOI 10.1007/s10488-014-0541-9; Casillas KL, 2016, CHILD ABUSE NEGLECT, V53, P64, DOI 10.1016/j.chiabu.2015.10.009; Chorpita Bruce F, 2005, Ment Health Serv Res, V7, P5, DOI 10.1007/s11020-005-1962-6; Chorpita BF, 2009, J CONSULT CLIN PSYCH, V77, P566, DOI 10.1037/a0014565; DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458; Daro D., PEW HOME VISITING DA; Dozier M, 2014, CHILD MALTREAT CONT, V3, P43, DOI 10.1007/978-94-007-7404-9_4; Duffee JH, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-2150; Duggan A, 2018, 201876A OPRE; Duggan AK., 2021, RES SQUARE, DOI DOI 10.21203/RS.3.RS-154026/V1; Duggan AK, 2022, BMC PUBLIC HEALTH, V22, DOI 10.1186/s12889-022-13010-5; Enright G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17114099; Gershater-Molko RM, 2003, J FAM VIOLENCE, V18, P377, DOI 10.1023/A:1026219920902; Haire-Joshu D, 2018, AM J PREV MED, V54, P341, DOI 10.1016/j.amepre.2017.12.012; Hasson F, 2011, TECHNOL FORECAST SOC, V78, P1695, DOI 10.1016/j.techfore.2011.04.005; Lombard A., 1981, SUCCESS BEGINS HOME; Manson SM, 2020, PREV SCI, V21, pS93, DOI 10.1007/s11121-019-01065-7; McLeod BD, 2017, PREV SCI, V18, P204, DOI 10.1007/s11121-016-0703-y; Michalopoulos C., SUMMARY RESULTS MIHO; Michalopoulos C., 2019, IMPACTS FAMILY OUTCO; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Morshed AB, 2019, J NUTR EDUC BEHAV, V51, P237, DOI 10.1016/j.jneb.2018.09.001; Niederberger M, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00457; Norcross JC, 2018, PSYCHOTHERAPY, V55, P303, DOI 10.1037/pst0000193; O'Brien RA, 2012, PREV SCI, V13, P219, DOI 10.1007/s11121-012-0287-0; Office of Child Care (OCC), TRIB HOM VIS; Okoli C, 2004, INFORM MANAGE-AMSTER, V42, P15, DOI 10.1016/j.im.2003.11.002; Palinkas LA, 2015, ADM POLICY MENT HLTH, V42, P533, DOI 10.1007/s10488-013-0528-y; Paulsell D., 2011, MATH POLICY RES; Qualtrics, 2020, QUALTRICS SURVEY SOF; Sama-Miller E., MATH POLICY RES; Shelton RC, 2018, ANNU REV PUBL HEALTH, V39, P55, DOI 10.1146/annurev-publhealth-040617-014731; Supplee LH, 2019, CHILD DEV PERSPECT, V13, P173, DOI 10.1111/cdep.12334; Sweet MA, 2004, CHILD DEV, V75, P1435, DOI 10.1111/j.1467-8624.2004.00750.x; Walters KL, 2020, PREV SCI, V21, pS54, DOI 10.1007/s11121-018-0952-z; Zoom Video Communications Inc, 2016, SEC GUID	41	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2022	17	10							e0275981	10.1371/journal.pone.0275981	http://dx.doi.org/10.1371/journal.pone.0275981			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6T4DR	36251646	Green Published, Green Submitted, gold			2023-01-03	WOS:000893628400029
J	Heidari, SN				Heidari, Shireen N.			Finding a New Mantra	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Heidari, Shireen N.] Stanford Univ, Sch Med, Dept Med, Sect Palliat Care,Div Primary Care & Populat Hlth, Palo Alto, CA 94304 USA	Stanford University	Heidari, SN (corresponding author), Stanford Univ, Sch Med, Dept Med, Sect Palliat Care,Div Primary Care & Populat Hlth, Palo Alto, CA 94304 USA.			Heidari, Shireen/0000-0002-0127-3719					0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 15	2022	387	11					964	965		10.1056/NEJMp2206851	http://dx.doi.org/10.1056/NEJMp2206851		SEP 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5E1UZ	36094841	Bronze			2023-01-03	WOS:000859601300001
J	Bizzozero-Peroni, B; Brazo-Sayavera, J; Martinez-Vizcaino, V; de Arenas-Arroyo, SN; Luceron-Lucas-Torres, M; Diaz-Goni, V; Martinez-Ortega, IA; Mesas, AE				Bizzozero-Peroni, Bruno; Brazo-Sayavera, Javier; Martinez-Vizcaino, Vicente; de Arenas-Arroyo, Sergio Nunez; Luceron-Lucas-Torres, Maribel; Diaz-Goni, Valentina; Martinez-Ortega, Isabel Antonia; Mesas, Arthur Eumann			The associations between adherence to the Mediterranean diet and physical fitness in young, middle-aged, and older adults: A protocol for a systematic review and meta-analysis	PLOS ONE			English	Review							ALL-CAUSE MORTALITY; CARDIORESPIRATORY FITNESS; HEALTHY-MEN; PATTERN; CHILDREN	Introduction A healthy diet and high health-related physical fitness levels may be part of an overall healthy lifestyle. The relationship between adherence to the Mediterranean diet and physical fitness levels has been analyzed in several studies. However, no studies have synthesized evidence on this relationship throughout adulthood. Moreover, in addition to the overall Mediterranean dietary pattern, the associations of individual components of the Mediterranean diet with physical fitness indicators are also unclear. Methods This protocol for a systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis for Protocols statement and the Cochrane Collaboration Handbook. Systematic literature searches will be performed in the MEDLINE (PubMed), Scopus, Web of Science, SPORTDiscus and Cochrane CENTRAL databases to identify studies published up to 31 January 2022. The inclusion criteria will comprise observational studies and randomized controlled trials reporting the associations between adherence to the Mediterranean diet and physical fitness levels on general healthy or unhealthy adults (>= 18 years). When at least five studies addressing the same outcome are available, meta-analysis will be carried out to estimate the standardized mean difference of physical fitness according to the adherence to Mediterranean diet. Subgroup analyses will be performed according to the characteristics of the population, the individual dietary components of the Mediterranean diet and physical fitness parameters as long as there are sufficient studies. Ethics and dissemination This systematic review and meta-analysis protocol is designed for updating evidence on the associations between adherence to overall Mediterranean diet (and specific Mediterranean foods) and physical fitness levels in young, middle-aged, and older adults. Findings from this review may have implications for public health. The results will be disseminated through peer-reviewed publication, conference presentation, and infographics. No ethical approval will be required since only published data will be used.	[Bizzozero-Peroni, Bruno; Martinez-Vizcaino, Vicente; de Arenas-Arroyo, Sergio Nunez; Luceron-Lucas-Torres, Maribel; Martinez-Ortega, Isabel Antonia; Mesas, Arthur Eumann] Univ Castilla La Mancha, Hlth & Social Res Ctr, Cuenca, Spain; [Bizzozero-Peroni, Bruno] Univ Republ, Inst Super Educ Fis, Rivera, Uruguay; [Bizzozero-Peroni, Bruno; Brazo-Sayavera, Javier; Diaz-Goni, Valentina] Univ Republ, Grp Invest Anal Rendimiento Humano, Rivera, Uruguay; [Brazo-Sayavera, Javier] Univ Pablo de Olavide, Dept Sports & Comp Sci, Seville, Spain; [Martinez-Vizcaino, Vicente] Univ Autonoma Chile, Fac Ciencias Salud, Talca, Chile; [Diaz-Goni, Valentina] Univ Republ, Inst Super Educ Fis, Maldonado, Uruguay; [Mesas, Arthur Eumann] Univ Estadual Londrina, Postgrad Program Publ Hlth, Londrina, Parana, Brazil	Universidad de Castilla-La Mancha; Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Universidad Pablo de Olavide; Universidad Autonoma de Chile; Universidad de la Republica, Uruguay; Universidade Estadual de Londrina	Bizzozero-Peroni, B (corresponding author), Univ Castilla La Mancha, Hlth & Social Res Ctr, Cuenca, Spain.; Bizzozero-Peroni, B (corresponding author), Univ Republ, Inst Super Educ Fis, Rivera, Uruguay.; Bizzozero-Peroni, B (corresponding author), Univ Republ, Grp Invest Anal Rendimiento Humano, Rivera, Uruguay.	Bruno.Bizzozero@uclm.es	Bizzozero-Peroni, Bruno/AAL-1110-2020; Brazo-Sayavera, Javier/G-5601-2011; MARTINEZ VIZCAINO, VICENTE/R-4336-2017	Bizzozero-Peroni, Bruno/0000-0003-0614-5561; Martinez Ortega, Isabel Antonia/0000-0002-2410-1338; Diaz Goni, Valentina/0000-0002-1724-1893; Brazo-Sayavera, Javier/0000-0001-6249-5131; MARTINEZ VIZCAINO, VICENTE/0000-0001-6121-7893	Universidad de Castilla-La Mancha - European Social Fund [2020-PREDUCLM16746]; Universidad de Castilla-La Mancha [2022-PROD-20657, 2020-PREDUCLM-16704]; Spanish Ministry of Education, Culture and Sport [BEAGAL18/00093]; Agencia Nacional de Investigacion e Innovacion [POS_EXT_2020_1_165371]	Universidad de Castilla-La Mancha - European Social Fund; Universidad de Castilla-La Mancha; Spanish Ministry of Education, Culture and Sport(Spanish Government); Agencia Nacional de Investigacion e Innovacion	B.B.-P. was supported by a grant from the Universidad de Castilla-La Mancha co-financed by the European Social Fund (2020-PREDUCLM16746). M.I.L.-L.-T (2022-PROD-20657) and S.N. d.A.-A. (2020-PREDUCLM-16704) are supported by a grant from the Universidad de Castilla-La Mancha. A.E.M. was supported by a `Beatriz Galindo' contract (BEAGAL18/00093) by the Spanish Ministry of Education, Culture and Sport. This study was also supported by the Agencia Nacional de Investigacion e Innovacion (POS_EXT_2020_1_165371). The funders provided support in the form of salaries for authors [B.B.-P., S.N.d.A.-A., M.I.L.-L.-T., and A.E.M.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section. Funder websites: https://www.educacionyfp.gob.es/https://www.uclm.es/https://www.anii.org.uy/.	Afshin A., 2019, LANCET, V393, P1958; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bloom I, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030308; Castro-Pinero J, 2021, J CLIN MED, V10, DOI 10.3390/jcm10163743; Chan R, 2019, J AM MED DIR ASSOC, V20, P558, DOI 10.1016/j.jamda.2018.12.009; Craig JV, 2017, NUTR REV, V75, P830, DOI 10.1093/nutrit/nux042; Cuenca-Garcia M, 2014, ANN EPIDEMIOL, V24, P297, DOI 10.1016/j.annepidem.2014.01.007; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; Dinu M, 2018, EUR J CLIN NUTR, V72, P30, DOI 10.1038/ejcn.2017.58; Eslami O, 2020, NUTR METAB CARDIOVAS, V30, P1442, DOI 10.1016/j.numecd.2020.04.017; Ferrari R, 2011, LANCET, V377, P1730, DOI 10.1016/S0140-6736(11)60316-4; Floegel A, 2014, INT J OBESITY, V38, P1388, DOI 10.1038/ijo.2014.39; Garcia-Hermoso A, 2022, BRIT J NUTR, V128, P1433, DOI 10.1017/S0007114520004894; Goldet Gabrielle, 2013, J Evid Based Med, V6, P50, DOI 10.1111/jebm.12018; Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026; Hemmingsson E, 2022, EUR J PREV CARDIOL, V29, P959, DOI 10.1093/eurjpc/zwab169; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hutchins-Wiese HL, 2022, BRIT J NUTR, V128, P1371, DOI 10.1017/S0007114521002476; Colho HJ, 2021, AGEING RES REV, V70, DOI 10.1016/j.arr.2021.101395; Santi-Cano MJ, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030776; Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681; Lee DC, 2011, CIRCULATION, V124, P2483, DOI 10.1161/CIRCULATIONAHA.111.038422; Leon-Munoz LM, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0255-6; Leon-Munoz LM, 2012, J NUTR, V142, P1843, DOI 10.3945/jn.112.164616; Martinez-Gonzalez MA, 2019, CIRC RES, V124, P779, DOI 10.1161/CIRCRESAHA.118.313348; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; National Heart Lung and Blood Institute., QUALITY ASSESSMENT T; Oikonomou E, 2018, ANGIOLOGY, V69, P339, DOI 10.1177/0003319717721603; Ortega FB, 2015, SPORTS MED, V45, P533, DOI 10.1007/s40279-014-0281-8; Ruiz JR, 2009, BRIT J SPORT MED, V43, P909, DOI 10.1136/bjsm.2008.056499; Ruiz JR, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a439; Serra-Majem L, 2019, MOL ASPECTS MED, V67, P1, DOI 10.1016/j.mam.2019.06.001; Shaw CA, 2015, THESIS NEWCASTLE U; Silva R, 2018, J NUTR HEALTH AGING, V22, P655, DOI 10.1007/s12603-017-0993-1; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Trichopoulou A, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-112; WASSERTHEIL S, 1970, BIOMETRICS, V26, P588, DOI 10.2307/2529115; Zaragoza-Marti A, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019033; Zbeida M, 2014, J NUTR HEALTH AGING, V18, P411, DOI 10.1007/s12603-014-0003-9	42	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2022	17	7							e0271254	10.1371/journal.pone.0271254	http://dx.doi.org/10.1371/journal.pone.0271254			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3Z6OJ	35802597	gold, Green Published			2023-01-03	WOS:000844536800145
J	Raschke, R; Rangan, P; Agarwal, SC; Uppalapu, S; Sher, N; Curry, S; Heise, CW				Raschke, Robert; Rangan, Pooja; Agarwal, Sumit C.; Uppalapu, Suresh; Sher, Nehan; Curry, Steven; Heise, C. William			COVID-19 Time of Intubation Mortality Evaluation (C-TIME): A system for predicting mortality of patients with COVID-19 pneumonia at the time they require mechanical ventilation	PLOS ONE			English	Article							HOSPITAL MORTALITY; ACUTE PHYSIOLOGY; SOFA SCORE; APACHE IV	Background An accurate system to predict mortality in patients requiring intubation for COVID-19 could help to inform consent, frame family expectations and assist end-of-life decisions. Research objective To develop and validate a mortality prediction system called C-TIME (COVID-19 Time of Intubation Mortality Evaluation) using variables available before intubation, determine its discriminant accuracy, and compare it to acute physiology and chronic health evaluation (APACHE IVa) and sequential organ failure assessment (SOFA). Methods A retrospective cohort was set in 18 medical-surgical ICUs, enrolling consecutive adults, positive by SARS-CoV 2 RNA by reverse transcriptase polymerase chain reaction or positive rapid antigen test, and undergoing endotracheal intubation. All were followed until hospital discharge or death. The combined outcome was hospital mortality or terminal extubation with hospice discharge. Twenty-five clinical and laboratory variables available 48 hours prior to intubation were entered into multiple logistic regression (MLR) and the resulting model was used to predict mortality of validation cohort patients. Area under the receiver operating curve (AUROC) was calculated for C-TIME, APACHE IVa and SOFA. Results The median age of the 2,440 study patients was 66 years; 61.6 percent were men, and 50.5 percent were Hispanic, Native American or African American. Age, gender, COPD, minimum mean arterial pressure, Glasgow Coma scale score, and PaO2/FiO(2) ratio, maximum creatinine and bilirubin, receiving factor Xa inhibitors, days receiving non-invasive respiratory support and days receiving corticosteroids prior to intubation were significantly associated with the outcome variable. The validation cohort comprised 1,179 patients. C-TIME had the highest AUROC of 0.75 (95%CI 0.72-0.79), vs 0.67 (0.64-0.71) and 0.59 (0.55-0.62) for APACHE and SOFA, respectively (Chi(2) P < 0.0001). Conclusions C-TIME is the only mortality prediction score specifically developed and validated for COVID-19 patients who require mechanical ventilation. It has acceptable discriminant accuracy and goodness-of-fit to assist decision-making just prior to intubation. The C-TIME mortality prediction calculator can be freely accessed on-line at .	[Raschke, Robert; Curry, Steven; Heise, C. William] Univ Arizona, Div Clin Data Analyt & Decis Support, Coll Med Phoenix, Phoenix, AZ 85004 USA; [Raschke, Robert; Rangan, Pooja; Agarwal, Sumit C.; Uppalapu, Suresh; Sher, Nehan] Univ Arizona, Coll Med Phoenix, Phoenix, AZ 85004 USA; [Rangan, Pooja; Agarwal, Sumit C.; Uppalapu, Suresh] Banner Univ, Dept Internal Med, Med Ctr Phoenix, Phoenix, AZ USA; [Curry, Steven; Heise, C. William] Banner Univ, Dept Med Toxicol, Med Ctr Phoenix, Phoenix, AZ USA	University of Arizona; University of Arizona	Raschke, R (corresponding author), Univ Arizona, Div Clin Data Analyt & Decis Support, Coll Med Phoenix, Phoenix, AZ 85004 USA.; Raschke, R (corresponding author), Univ Arizona, Coll Med Phoenix, Phoenix, AZ 85004 USA.	Raschkebob@gmail.com		Raschke, Robert/0000-0003-3495-7065; Heise, Craig/0000-0002-4795-1060	Flinn Foundation [2196]	Flinn Foundation	Guarantor statement: Dr Raschke had full access to all of the data in the study and takes personal responsibility for the integrity of the data and the accuracy of the data analysis.	A.Montgomery, 2020, medRxiv, DOI 10.1101/2020.06.22.20137273; Abdulaal A, 2020, J MED INTERNET RES, V22, DOI 10.2196/20259; Altschul DJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73962-9; Antommaria AHM, 2020, ANN INTERN MED, V173, P188, DOI 10.7326/M20-1738; Arizona Department of Health Services, COVID 19 DAT DASHB; Berenguer J, 2021, THORAX, V76, P920, DOI 10.1136/thoraxjnl-2020-216001; Berry DA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255228; Chen B, 2021, COMPUT STRUCT BIOTEC, V19, P1694, DOI 10.1016/j.csbj.2021.03.012; Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010; Chowdhury MEH, 2021, COGN COMPUT, DOI 10.1007/s12559-020-09812-7; El-Solh AA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244629; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Ghidini M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030508; Halasz G, 2021, J MED INTERNET RES, V23, DOI 10.2196/29058; Kadri SS, 2021, ANN INTERN MED, V174, P1240, DOI 10.7326/M21-1213; Keegan MT, 2012, CHEST, V142, P851, DOI 10.1378/chest.11-2164; Knight SR, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3339; Lim ZJ, 2021, AM J RESP CRIT CARE, V203, P54, DOI 10.1164/rccm.202006-2405OC; Liu SJ, 2020, AM J EMERG MED, V38, P2074, DOI 10.1016/j.ajem.2020.07.019; Manocha KK, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.018477; Moreno-Perez O, 2021, JAMA INTERN MED, V181, P1000, DOI 10.1001/jamainternmed.2021.0491; Nattino G, 2017, STATA J, V17, P1003, DOI 10.1177/1536867X1701700414; P. D. Sottile, 2021, medRxiv, DOI 10.1101/2021.01.14.21249793; Papoutsi E, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03540-6; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Raschke RA, 2021, JAMA-J AM MED ASSOC, V325, P1469, DOI 10.1001/jama.2021.1545; Ronda VE, 2021, MED CLIN-BARCELONA, V157, P99, DOI [10.1016/j.medcli.2021.01.002, 10.1016/j.medcle.2021.01.011]; Shang YF, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100426; Shi YY, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13926; Torres-Macho J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103066; Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689; Usher-Smith JA, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3139; Vandenbrande J, 2021, CRIT CARE RES PRACT, V2021, DOI 10.1155/2021/5443083; Vasilevskis EE, 2009, CHEST, V136, P89, DOI 10.1378/chest.08-2591; Vincent JL, 2010, CRIT CARE, V14, DOI 10.1186/cc8204; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wang K, 2020, CLIN INFECT DIS, V71, P2079, DOI 10.1093/cid/ciaa538; Weng ZH, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02505-7; Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328; Yan L, 2020, NAT MACH INTELL, V2, P283, DOI 10.1038/s42256-020-0180-7; Yang Z, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026900; Yu CZ, 2020, AM J PREV MED, V59, P168, DOI 10.1016/j.amepre.2020.05.002; Yuan Y, 2022, ENGINEERING-PRC, V8, P116, DOI [10.1016/j.eng.2020.10.013, 10.1016/j.eng.2020.10.0132095-8099]; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	45	1	1	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	7								10.1371/journal.pone.0270193	http://dx.doi.org/10.1371/journal.pone.0270193			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3M3CI	35793312	Green Submitted, Green Published, gold			2023-01-03	WOS:000835338100033
J	Odagiri, K; Yamauchi, K; Toda, M; Uchida, A; Tsubota, H; Zenba, K; Okawai, H; Eda, H; Mizuno, S; Yokota, H				Odagiri, Keiichi; Yamauchi, Katsuya; Toda, Masahiro; Uchida, Ayako; Tsubota, Hiromi; Zenba, Kazuyoshi; Okawai, Hiroaki; Eda, Hideo; Mizuno, Seiichiro; Yokota, Hiroaki			Feasibility study of a LED light irradiation device for the treatment of chronic neck with shoulder muscle pain/stiffness	PLOS ONE			English	Article							LEVEL LASER THERAPY; GENERAL-POPULATION; PAIN; MANAGEMENT; EXERCISE	Neck with shoulder muscle stiffness/pain is a common disorder. Commonly used physical therapy, pharmacotherapy, acupuncture, and moxibustion only temporarily alleviate the disorder in most cases, thus the disorder often recurs. Low power laser therapy is often used for neck and shoulder stiffness/pain and has been effective in clinical trials. In this study, we evaluated the safety and effectiveness of a newly developed self-care device for disorders including neck with shoulder muscle stiffness/pain. The device incorporates light-emitting diodes (LEDs), which are safer than lasers, as its light source. Ten adults with neck with shoulder muscle stiffness/pain were subject to LED irradiation (wavelength 780 nm +/- 15 nm, output 750 mW, power density 3.8 W/cm(2), energy density 5.7x10(2) J/cm(2)) for 3 minutes on the affected shoulder at a standard acupuncture point (GB21, Jianjing). Immediately after irradiation, the subjective symptoms of the neck with shoulder muscle stiffness and pain evaluated by a visual analog scale were improved from 58.3 mm +/- 18.7 mm to 45.5 mm +/- 21.5 mm and from 45.8 mm +/- 23.3 mm to 39.4 mm +/- 21.8 mm, respectively. The symptoms further improved after 15 minutes of irradiation. The skin temperature at the irradiated point increased from 34.3 degrees C +/- 1.1 degrees C to 41.0 degrees C +/- 0.7 degrees C. The increase in skin temperature was observed within approximately 5 cm of the irradiated area. There was no effect on the heart rate variability, a measure of the autonomic nervous system; however, the baroreflex sensitivity was slightly increased. No irradiation-related adverse skin events were observed. Our LED irradiation device was found to be safe, and it improved the subjective symptoms of muscle stiff neck with shoulders.	[Odagiri, Keiichi; Uchida, Ayako; Tsubota, Hiromi] Hamamatsu Univ Hosp, Clin Res Ctr, Hamamatsu, Japan; [Yamauchi, Katsuya; Toda, Masahiro] Hamamatsu Univ Sch Med, Dept Rehabil Med, Hamamatsu, Japan; [Zenba, Kazuyoshi] Isehara Clin Trial Ctr, Zenba Acupuncture & Moxibust Clin, Isehara, Japan; [Tsubota, Hiromi] Kenkou Data House Inc, Sendai, Japan; [Eda, Hideo; Mizuno, Seiichiro; Yokota, Hiroaki] Grad Sch Creat New Photon Ind, Hamamatsu, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Odagiri, K; Yokota, H (corresponding author), Hamamatsu Univ Hosp, Clin Res Ctr, Hamamatsu, Japan.; Yokota, H (corresponding author), Grad Sch Creat New Photon Ind, Hamamatsu, Japan.	kodagiri@hama-med.ac.jp; yokota@gpi.ac.jp	Yokota, Hiroaki/H-4990-2014	Yokota, Hiroaki/0000-0002-3435-9121	Access Center for Innovation Solutions, Actions and Professionals (A-SAP) from the Photon Valley Center, the Hamamatsu Agency for Innovation [2020-023]	Access Center for Innovation Solutions, Actions and Professionals (A-SAP) from the Photon Valley Center, the Hamamatsu Agency for Innovation	This work was financially supported by the Access Center for Innovation Solutions, Actions and Professionals (A-SAP) from the Photon Valley Center, the Hamamatsu Agency for Innovation (recipient Hiroaki Yokota, Award number 2020-023). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bjordal JM, 2006, BRIT J SPORT MED, V40, P76, DOI 10.1136/bjsm.2005.020842; Borenstein David G, 2007, Curr Pain Headache Rep, V11, P436, DOI 10.1007/s11916-007-0230-4; Brosseau L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002049.pub2; Bruflat AK, 2012, PHYS THER, V92, P1348, DOI 10.2522/ptj.20110489; Chow RT, 2009, LANCET, V374, P1897, DOI 10.1016/S0140-6736(09)61522-1; Chow RT, 2005, LASER SURG MED, V37, P46, DOI 10.1002/lsm.20193; Cote P, 2004, PAIN, V112, P267, DOI 10.1016/j.pain.2004.09.004; Dundar U, 2007, CLIN RHEUMATOL, V26, P930, DOI 10.1007/s10067-006-0438-4; Enwemeka CS, 2004, PHOTOMED LASER SURG, V22, P323, DOI 10.1089/1549541041797841; Freiwald J, 2021, LIFE-BASEL, V11, DOI 10.3390/life11080780; Hogg-Johnson S, 2008, EUR SPINE J, V17, pS39, DOI 10.1007/s00586-008-624-y; Huang ZY, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0882-0; KANUI TI, 1987, BRAIN RES, V402, P160, DOI 10.1016/0006-8993(87)91060-2; Kobayashi H, 2012, J PHYSIOL ANTHROPOL, V31, DOI 10.1186/1880-6805-31-9; Luo XM, 2004, VALUE HEALTH, V7, P61, DOI 10.1111/j.1524-4733.2004.71264.x; Maiers M, 2014, SPINE J, V14, P1879, DOI 10.1016/j.spinee.2013.10.035; Ministry of Health LaW, 2019, SUMM REP COMPR SURV; Nicolau RA, 2004, LASER SURG MED, V35, P236, DOI 10.1002/lsm.20087; OLAVI A, 1989, ACUPUNCTURE ELECTRO, V14, P9, DOI 10.3727/036012989816358560; Panah HM, 2021, J BODYW MOV THER, V27, P705, DOI 10.1016/j.jbmt.2021.05.015; Leal ECP, 2009, LASER MED SCI, V24, P425, DOI 10.1007/s10103-008-0592-9; Rankin IA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012765; Siedentopf CM, 2002, NEUROSCI LETT, V327, P53, DOI 10.1016/S0304-3940(02)00383-X; SL, 1965, THERAPEUTIC HEAT COL, V2nd ed, P126; TSUCHIYA K, 1993, NEUROSCI LETT, V161, P65, DOI 10.1016/0304-3940(93)90141-7; TSUCHIYA K, 1994, BRAIN RES BULL, V34, P369, DOI 10.1016/0361-9230(94)90031-0; Verhagen AP, 2010, LANCET, V375, P721, DOI 10.1016/S0140-6736(10)60296-6; Webb R, 2003, SPINE, V28, P1195, DOI 10.1097/00007632-200306010-00021; Yamato TP, 2015, BRIT J SPORT MED, V49, P1350, DOI 10.1136/bjsports-2014-093874; Ypusefi-Nooraie R, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005107.pub4	30	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2022	17	10							e0276320	10.1371/journal.pone.0276320	http://dx.doi.org/10.1371/journal.pone.0276320			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6T4DR	36251669	Green Published, gold			2023-01-03	WOS:000893628400052
J	Cram, P; Wachter, RM; Landon, BE				Cram, Peter; Wachter, Robert M.; Landon, Bruce E.			Readmission Reduction as a Hospital Quality Measure Time to Move on to More Pressing Concerns?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTERVENTIONS		[Cram, Peter] Univ Texas Med Branch, Dept Med, Galveston, TX 77555 USA; [Cram, Peter] Univ Toronto, Fac Med, Toronto, ON, Canada; [Wachter, Robert M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Landon, Bruce E.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA; [Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Div Gen Med, Boston, MA 02215 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Toronto; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Cram, P (corresponding author), Univ Texas Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.	pecram@utmb.edu			US National Institute on Aging [R01AG058878]	US National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by a grant from the US National Institute on Aging (R01AG058878 to Drs Landon and Cram).	Conroy T, 2020, INT J QUAL HEALTH C, V32, P414, DOI 10.1093/intqhc/mzaa064; Cram P, 2022, BMJ-BRIT MED J, V377, DOI 10.1136/bmj-2021-069164; Graham KL, 2018, ANN INTERN MED, V168, P766, DOI 10.7326/M17-1724; Gupta A., 2017, IMPACTS PERFORMANCE; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; McWilliams JM, 2019, HEALTH AFFAIR, V38, P1840, DOI 10.1377/hlthaff.2019.00411; Nuckols TK, 2017, JAMA INTERN MED, V177, P975, DOI 10.1001/jamainternmed.2017.1136; Samsky MD, 2019, JAMA CARDIOL, V4, P444, DOI 10.1001/jamacardio.2019.0766; Wadhera RK, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4563; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	10	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 25	2022	328	16					1589	1590		10.1001/jama.2022.18305	http://dx.doi.org/10.1001/jama.2022.18305		OCT 2022	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6C3UZ	36201190				2023-01-03	WOS:000864837800002
J	Nichol, AD; O'Kane, C; McAuley, DF				Nichol, Alistair D.; O'Kane, Cecilia; McAuley, Daniel F.			Respiratory Support in the Time of COVID-19	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Nichol, Alistair D.] Univ Coll Dublin, Clin Res Ctr, Dublin, Ireland; [Nichol, Alistair D.] St Vincents Hosp, Dublin, Ireland; [Nichol, Alistair D.] Alfred Hlth, Dept Intens Care, Melbourne, Vic, Australia; [Nichol, Alistair D.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [O'Kane, Cecilia; McAuley, Daniel F.] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland	University College Dublin; University College Dublin; Monash University; Queens University Belfast	Nichol, AD (corresponding author), Univ Coll Dublin, St Vincents Univ Hosp, Clin Res Ctr, Elm Pk, Dublin 4, Ireland.	alistair.nichol@monash.edu		Nichol, Alistair/0000-0002-4689-1238				Bouadma L, 2022, JAMA INTERN MED, V182, P906, DOI 10.1001/jamainternmed.2022.2168; Crimi C, 2022, THORAX, DOI 10.1136/thoraxjnl-2022-218806; Deans KJ, 2010, ANESTH ANALG, V111, P444, DOI 10.1213/ane.0b013e3181aa8903; Reyes LF, 2022, ERJ OPEN RES, V8, DOI 10.1183/23120541.00552-2021; Ferreyro BL, 2020, JAMA-J AM MED ASSOC, V324, P57, DOI 10.1001/jama.2020.9524; Frat JP, 2022, JAMA-J AM MED ASSOC, V328, P1212, DOI 10.1001/jama.2022.15613; Gorman E, 2021, LANCET RESP MED, V9, P553, DOI 10.1016/S2213-2600(21)00168-5; Grieco DL, 2021, JAMA-J AM MED ASSOC, V325, P1731, DOI 10.1001/jama.2021.4682; Kousathanas A, 2022, NATURE, V607, P97, DOI 10.1038/s41586-022-04576-6; Nair PR, 2021, RESP CARE, V66, P1824, DOI 10.4187/respcare.09130; Ospina-Tascon GA, 2021, JAMA-J AM MED ASSOC, V326, P2161, DOI 10.1001/jama.2021.20714; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y; Perkins GD, 2022, JAMA-J AM MED ASSOC, V327, P546, DOI 10.1001/jama.2022.0028; Sinha P, 2020, LANCET RESP MED, V8, P1209, DOI 10.1016/S2213-2600(20)30366-0; Winslow RL, 2022, THORAX, V77, P259, DOI 10.1136/thoraxjnl-2021-218035	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	2022	328	12					1203	1205		10.1001/jama.2022.15229	http://dx.doi.org/10.1001/jama.2022.15229			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	5E8TQ	36166049	Bronze			2023-01-03	WOS:000865895100028
J	Gross, ND; Miller, DM; Khushalani, NI; Divi, V; Ruiz, ES; Lipson, EJ; Meier, F; Su, YB; Swiecicki, PL; Atlas, J; Geiger, JL; Hauschild, A; Choe, JH; Hughes, BGM; Schadendorf, D; Patel, VA; Homsi, J; Taube, JM; Lim, AM; Ferrarotto, R; Kaufman, HL; Seebach, F; Lowy, I; Yoo, SY; Mathias, M; Fenech, K; Han, H; Fury, MG; Rischin, D				Gross, N. D.; Miller, D. M.; Khushalani, N., I; Divi, V; Ruiz, E. S.; Lipson, E. J.; Meier, F.; Su, Y. B.; Swiecicki, P. L.; Atlas, J.; Geiger, J. L.; Hauschild, A.; Choe, J. H.; Hughes, B. G. M.; Schadendorf, D.; Patel, V. A.; Homsi, J.; Taube, J. M.; Lim, A. M.; Ferrarotto, R.; Kaufman, H. L.; Seebach, F.; Lowy, I; Yoo, S-Y; Mathias, M.; Fenech, K.; Han, H.; Fury, M. G.; Rischin, D.			Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Early Access							IMMUNOTHERAPY; HEAD	BACKGROUND In a pilot study involving patients with cutaneous squamous-cell carcinoma, a high percentage of patients had a pathological complete response with the use of two doses of neoadjuvant cemiplimab before surgery. Data from a phase 2 study are needed to confirm these findings. METHODS We conducted a phase 2, confirmatory, multicenter, nonrandomized study to evaluate cemiplimab as neoadjuvant therapy in patients with resectable stage II, III, or IV (M0) cutaneous squamous-cell carcinoma. Patients received cemiplimab, administered at a dose of 350 mg every 3 weeks for up to four doses, before undergoing surgery with curative intent. The primary end point was a pathological complete response (the absence of viable tumor cells in the surgical specimen) on independent review at a central laboratory, with a null hypothesis that a pathological complete response would be observed in 25% of patients. Key secondary end points included a pathological major response (the presence of viable tumor cells that constitute <= 10% of the surgical specimen) on independent review, a pathological complete response and a pathological major response on investigator assessment at a local laboratory, an objective response on imaging, and adverse events. RESULTS A total of 79 patients were enrolled and received neoadjuvant cemiplimab. On independent review, a pathological complete response was observed in 40 patients (51%; 95% confidence interval [CI], 39 to 62) and a pathological major response in 10 patients (13%; 95% CI, 6 to 22). These results were consistent with the pathological responses determined on investigator assessment. An objective response on imaging was observed in 54 patients (68%; 95% CI, 57 to 78). Adverse events of any grade that occurred during the study period, regardless of whether they were attributed to the study treatment, were observed in 69 patients (87%). Grade 3 or higher adverse events that occurred during the study period were observed in 14 patients (18%). CONCLUSIONS Neoadjuvant therapy with cemiplimab was associated with a pathological complete response in a high percentage of patients with resectable cutaneous squamous-cell carcinoma. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov number, .)	[Gross, N. D.] MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Ferrarotto, R.] MD Anderson Canc Ctr, Dept Thorac & Head & Neck Med Oncol, Houston, TX 77030 USA; [Homsi, J.] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Canc Ctr, Dallas, TX USA; [Miller, D. M.] Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA USA; [Miller, D. M.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA; [Kaufman, H. L.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Ruiz, E. S.] Harvard Med Sch, Boston, MA 02115 USA; [Ruiz, E. S.] Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA; [Khushalani, N., I] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL USA; [Divi, V] Stanford Univ, Dept Otolaryngol Head & Neck Surg, Stanford Canc Inst, Inst Stem Cell Biol & Regenerat Med,Sch Med, Stanford, CA USA; [Lipson, E. J.; Taube, J. M.] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA; [Lipson, E. J.; Taube, J. M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Taube, J. M.] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; [Meier, F.] Univ Canc Ctr, Skin Canc Ctr, Dresden, Germany; [Meier, F.] Univ Hosp Carl Gustav Carus, Natl Ctr Tumor Dis Dresden, Dept Dermatol, Dresden, Germany; [Meier, F.] Tech Univ Dresden, Dresden, Germany; [Hauschild, A.] Schleswig Holstein Univ Hosp, Dept Dermatol, Kiel, Germany; [Schadendorf, D.] Univ Hosp Essen, Dept Dermatol, Essen, Germany; [Schadendorf, D.] German Canc Consortium, Partner Site Essen, Essen, Germany; [Su, Y. B.] Nebraska Canc Specialists, Head & Neck Med Oncol, Omaha, NE USA; [Swiecicki, P. L.] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA; [Atlas, J.] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA; [Choe, J. H.] Duke Canc Inst, Durham, NC USA; [Geiger, J. L.] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA; [Hughes, B. G. M.] Royal Brisbane & Womens Hosp, Dept Canc Care Serv, Brisbane, Qld, Australia; [Hughes, B. G. M.] Univ Queensland, Brisbane, Qld, Australia; [Lim, A. M.; Rischin, D.] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia; [Lim, A. M.; Rischin, D.] Univ Melbourne, Melbourne, Vic, Australia; [Patel, V. A.] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC USA; [Patel, V. A.] George Washington Univ, Sch Med & Hlth Sci, Dept Med, Washington, DC USA; [Patel, V. A.] George Washington Univ, Sch Med & Hlth Sci, Dept Oncol, Washington, DC USA; [Seebach, F.; Lowy, I; Yoo, S-Y; Mathias, M.; Fenech, K.; Han, H.; Fury, M. G.] Regeneron Pharmaceut, Tarrytown, NY USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; H Lee Moffitt Cancer Center & Research Institute; Stanford Cancer Institute; Stanford University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; University of Kiel; Schleswig Holstein University Hospital; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Michigan System; University of Michigan; Duke University; Cleveland Clinic Foundation; Royal Brisbane & Women's Hospital; University of Queensland; Peter Maccallum Cancer Center; University of Melbourne; George Washington University; George Washington University; George Washington University; Regeneron	Gross, ND (corresponding author), MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ngross@mdanderson.org		Hughes, Brett/0000-0002-1811-0537; Miller, David/0000-0001-9736-9119; Gross, Neil/0000-0002-9427-0743	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals(Regeneron)	We thank the patients, their families, and all staff members at the study sites who were involved in this study; and Atif Riaz, Ph.D., of Prime (Knutsford, United Kingdom) for medical-writing support, funded by Regeneron Pharmaceuticals.	Amin MB, 2017, CANC STAGING MANUAL, V8th; Chabrillac E, 2022, EUR ARCH OTO-RHINO-L, V279, P2069, DOI 10.1007/s00405-021-06972-6; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Cottrell TR, 2018, ANN ONCOL, V29, P1853, DOI 10.1093/annonc/mdy218; D'heygere V, 2021, J PLAST RECONSTR AES, V74, P625, DOI 10.1016/j.bjps.2020.10.013; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ferrarotto R, 2021, CLIN CANCER RES, V27, P4557, DOI 10.1158/1078-0432.CCR-21-0585; Forde PM, 2022, NEW ENGL J MED, V386, P1973, DOI 10.1056/NEJMoa2202170; Gerring RC, 2017, EYE, V31, P379, DOI 10.1038/eye.2016.218; Grob JJ, 2020, J CLIN ONCOL, V38, P2916, DOI 10.1200/JCO.19.03054; Gross ND, 2022, J CLIN ONCOL, V40; Institute for Health Metrics and Evaluation, GLOBAL BURDEN DIS 20; Jubran J, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2019-229940; Menzies AM, 2021, NAT MED, V27, P301, DOI 10.1038/s41591-020-01188-3; Migden MR, 2018, NEW ENGL J MED, V379, P341, DOI 10.1056/NEJMoa1805131; Migden MR, 2020, LANCET ONCOL, V21, P294, DOI 10.1016/S1470-2045(19)30728-4; Mukoyama N, 2020, J NEUROL SURG PART B, V81, P585, DOI 10.1055/s-0039-1694010; Nehal KS, 2018, NEW ENGL J MED, V379, P363, DOI 10.1056/NEJMra1708701; O'Sullivan BBJ, 2015, UICC MANUAL CLIN ONC, DOI [10.1002/9781119013143, DOI 10.1002/9781119013143]; Que SKT, 2018, J AM ACAD DERMATOL, V78, P249, DOI 10.1016/j.jaad.2017.08.058; Rischin D, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002757; Shalhout SZ, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912-021-01120-z; Sweeny L, 2014, OTOLARYNG HEAD NECK, V150, P610, DOI 10.1177/0194599814520686; Uprety D, 2020, J THORAC ONCOL, V15, P1281, DOI 10.1016/j.jtho.2020.05.020; Xu V, 2022, ENT-EAR NOSE THROAT, V101, P663, DOI 10.1177/0145561320980179	25	1	1	2	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.												10.1056/NEJMoa2209813	http://dx.doi.org/10.1056/NEJMoa2209813		SEP 2022	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4M3SZ	36094839				2023-01-03	WOS:000853246600001
J	Larkin, HD				Larkin, Howard D.			FDA Warns Against Certain UV Disinfection Wands	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 6	2022	328	9					819	820						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4P1QZ	36066534				2023-01-03	WOS:000855171700011
J	Liu, YK; Tu, WJ; Chen, YJ				Liu, Yakun; Tu, Wenjun; Chen, Yajun			Point-of-Care Cardiopulmonary Resuscitation Training and Survival With Favorable Neurologic Outcome in Cardiac Arrest in Pediatric ICUs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Liu, Yakun; Chen, Yajun] Beijing Childrens Hosp, Dept Gen Surg, Beijing, Peoples R China; [Tu, Wenjun] Chinese Acad Med Sci, Inst Radiat Med, Tianjin, Peoples R China	Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Radiation Medicine - CAMS	Chen, YJ (corresponding author), Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Dept Gen Surg, 56 Nanlishi St, Beijing 100045, Peoples R China.	bch_chenyajun@163.com						Berg RA, 2018, CIRCULATION, V137, P1784, DOI 10.1161/CIRCULATIONAHA.117.032270; Sutton RM, 2022, JAMA-J AM MED ASSOC, V327, P934, DOI 10.1001/jama.2022.1738; Topjian AA, 2018, JAMA PEDIATR, V172, P143, DOI 10.1001/jamapediatrics.2017.4043; Wolfe H, 2014, CRIT CARE MED, V42, P1688, DOI 10.1097/CCM.0000000000000327	5	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	2022	328	5					479	480						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3U1CS	35916852				2023-01-03	WOS:000840708300018
J	Schniedermann, I; Dehn, LB; Micheel, S; Beblo, T; Driessen, M				Schniedermann, Ina; Dehn, Lorenz B.; Micheel, Sabrina; Beblo, Thomas; Driessen, Martin		StAB Project Grp	Evaluation of a supported education and employment program for adolescents and young adults with mental health problems: A study protocol of the StAB project	PLOS ONE			English	Article							INDIVIDUAL PLACEMENT; PSYCHOMETRIC PROPERTIES; VALIDATION; SCALE; ACHIEVEMENT; POPULATION; TRANSITION; LITERACY; DISORDER; BARRIERS	The majority of mental illnesses begins in childhood, adolescence and young adulthood before the age of 25. The transition from adolescence to adulthood is a particularly vulnerable time for adolescents with mental illness, affecting psychosocial functioning and participation in work life. Therefore, they need-in contrast to classic standard vocational interventions-a long-term, holistic and individually oriented vocational rehabilitation program. With the innovative model project "Start in education and employment (StAB)", adolescents and young adults with mental illnesses are to be supported with regard to their vocational perspectives and participation by a new type of individualized, holistic, long-term job coaching. It follows the Individual Placement and Support (IPS) concept, as a manualized form of the Supported Employment Approach and is based on the "first place-then train" principle. In order to evaluate the effectiveness and feasibility of the StAB program, a double-centre prospective single arm evaluation study in a mixed-methods design will be conducted. The focus is on quantitative research analysing pre-post-effects of the StAB intervention in a two-year observational study. Young people between 15 and 25 years with a psychiatric diagnosis who are currently in receipt of means-tested benefits or are entitled to them will be recruited. The study will take place in two major cities in the north-western part of Germany, Bielefeld and Dortmund. We expect to contribute to gain more empirical data about the implementation of Supported Employment and Education to severely mentally ill adolescents and young adults in German settings. Moreover, these results may also provide the scientific foundation for future measures focusing the improvement of vocational rehabilitation for young people with mental illness.	[Schniedermann, Ina; Dehn, Lorenz B.; Micheel, Sabrina; Beblo, Thomas; Driessen, Martin] Bielefeld Univ, Dept Psychiat & Psychotherapy, Univ Hosp OWL, Bielefeld, Germany; [Dehn, Lorenz B.; Beblo, Thomas] Bielefeld Univ, Dept Psychol, Bielefeld, Germany	University of Bielefeld; University of Bielefeld	Dehn, LB (corresponding author), Bielefeld Univ, Dept Psychiat & Psychotherapy, Univ Hosp OWL, Bielefeld, Germany.; Dehn, LB (corresponding author), Bielefeld Univ, Dept Psychol, Bielefeld, Germany.	Lorenz.Dehn@evkb.de	; Driessen, Martin/ABB-8229-2020	Dehn, Lorenz B/0000-0001-9588-7983; Driessen, Martin/0000-0003-3496-816X	Federal Ministry of Labour and Social Affairs (German: Bundesministerium fur Arbeit und Soziales, Berlin, Germany) [2Z-016/662Z0161X1]	Federal Ministry of Labour and Social Affairs (German: Bundesministerium fur Arbeit und Soziales, Berlin, Germany)	The study is funded by the Federal Ministry of Labour and Social Affairs (German: Bundesministerium fur Arbeit und Soziales, D10117 Berlin, Germany) as part of the federal program,rehapro"(2Z-016/662Z0161X1). This funding was granted through a peer review process. The funding body was not involved in writing the manuscript and the decision to submit this paper for publication, nor in the study design.	Beard C, 2016, J AFFECT DISORDERS, V193, P267, DOI 10.1016/j.jad.2015.12.075; Beierlein C., 2015, ZUSAMMENSTELLUNG SOZ, DOI [DOI 10.6102/ZIS229, 10.6102/zis229]; Bond GR, 2020, WORLD PSYCHIATRY, V19, P390, DOI 10.1002/wps.20784; Bond GR, 2016, EARLY INTERV PSYCHIA, V10, P300, DOI 10.1111/eip.12175; Bond GR, 2012, WORLD PSYCHIATRY, V11, P32, DOI 10.1016/j.wpsyc.2012.01.005; Bond R., 2001, J MENT HEALTH, V10, P383, DOI DOI 10.1080/09638230124258; Bowman S, 2017, EARLY INTERV PSYCHIA, V11, P277, DOI 10.1111/eip.12357; Brailovskaia J, 2020, CURR PSYCHOL, V39, P2192, DOI 10.1007/s12144-018-9911-x; Brennecke DJ, 2017, BOTTROP, P15; Burger W, 2009, REHABILITATION, V48, P211, DOI 10.1055/s-0029-1231062; Buhrlen B, 2005, Rehabilitation (Stuttg), V44, P63; Chmitorz A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192761; Choi J, 2014, SCHIZOPHR RES, V153, P209, DOI 10.1016/j.schres.2014.01.027; Cohen DA, 2020, COMMUNITY MENT HLT J, V56, P513, DOI 10.1007/s10597-019-00508-3; Davis M, 2003, ADM POLICY MENT HLTH, V30, P495, DOI 10.1023/A:1025027117827; Decieux JP, 2020, SWISS J PSYCHOL, V79, P15, DOI 10.1024/1421-0185/a000233; Deck R, 2015, REHABILITATION, V54, P402, DOI 10.1055/s-0035-1559670; Deck R., 2011, IMET INDEX MESSUNG E, DOI [10.23668/psycharchives.381, DOI 10.23668/PSYCHARCHIVES.381]; Dehn LB, 2021, PSYCHIAT PRAX, P1623; Deutsche Forschungsgemeinschaft, 2019, HRK GERIT GERM RES I, DOI DOI 10.5281/ZENODO.3923601; Diener E, 2013, SOC INDIC RES, V112, P497, DOI 10.1007/s11205-012-0076-y; Doll ES, 2021, ZIS COLLECT ITEMS SC; Drake RE, 1998, PSYCHIATR REHABIL J, V22, P3, DOI 10.1037/h0095273; Drake RE, 2012, INDIVIDUAL PLACEMENT, DOI DOI 10.1093/ACPROF:OSO/9780199734016.001.0001; Drake RE, 2019, PSYCHIAT CLIN NEUROS, V73, P47, DOI 10.1111/pcn.12792; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fervaha G, 2018, EARLY INTERV PSYCHIA, V12, P1038, DOI 10.1111/eip.12405; Frederick DE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212208; Gibb SJ, 2010, BRIT J PSYCHIAT, V197, P122, DOI 10.1192/bjp.bp.109.076570; Gmitroski T, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-024487; Gulliver A, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-113; Gustafsdottir SS, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8162-6; Hussenoeder FS, 2021, BMC PSYCHIATRY, V21, DOI 10.1186/s12888-021-03416-7; Jensen JH, 2015, J AFFECT DISORDERS, V187, P10, DOI 10.1016/j.jad.2015.07.039; Jones P B, 2013, Br J Psychiatry Suppl, V54, ps5, DOI 10.1192/bjp.bp.112.119164; Jordan S, 2015, BUNDESGESUNDHEITSBLA, V58, P942, DOI 10.1007/s00103-015-2200-z; Jovanovic V, 2020, APPL RES QUAL LIFE, V15, P675, DOI 10.1007/s11482-018-9680-6; Kidd SA, 2014, CAN J PSYCHIAT, V59, P243, DOI 10.1177/070674371405900503; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kunzler AM, 2018, EUR J HEALTH PSYCHOL, V25, P107, DOI 10.1027/2512-8442/a000016; Lang JWB, 2006, EUR J PSYCHOL ASSESS, V22, P216, DOI 10.1027/1015-5759.22.3.216; Liljeholm U, 2020, NURS OPEN, V7, P1755, DOI 10.1002/nop2.560; Lloyd C, 2010, VOCATIONAL REHABILIT, P115, DOI [10.1002/9781444319736.ch8, DOI 10.1002/9781444319736.CH8]; Loffler S, 2008, IDENTIFIKATION BERUF, P11; Lorini C, 2019, ANN I SUPER SANITA, V55, P10, DOI 10.4415/ANN_19_01_04; Maetzel J, 2021, DRITTER TEILHABEBERI, P827; Maraj A, 2019, PSYCHIAT SERV, V70, P302, DOI 10.1176/appi.ps.201800319; Millner UC, 2022, J CAREER DEV, V49, P393, DOI 10.1177/0894845320941256; Modini M, 2016, BRIT J PSYCHIAT, V209, P14, DOI 10.1192/bjp.bp.115.165092; Niessen D, 2020, ZISCOLLECT ITEMS SCA; Nischk D, 2018, FEASIBILITY EFFECTIV; Noel VA, 2017, ADM POLICY MENT HLTH, V44, P354, DOI 10.1007/s10488-016-0773-y; O'Brien D, 2016, BRIT J GEN PRACT, V66, pE693, DOI 10.3399/bjgp16X687061; Olesen SC, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-144; Olney MF, 1992, J APPL REHABIL COUNS, V23, P41; Pino O, 2008, SCHIZOPHR RES, V99, P139, DOI 10.1016/j.schres.2007.09.012; Pinquart M, 2014, J PEDIATR PSYCHOL, V39, P577, DOI 10.1093/jpepsy/jsu017; Prinz U, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-104; Purdon SE, 2005, SCREEN COGNITIVE IMP, P27; Ravens-Sieberer U, 2022, EUR CHILD ADOLES PSY, V31, P879, DOI 10.1007/s00787-021-01726-5; Ringeisen H, 2017, PSYCHIATR REHABIL J, V40, P197, DOI 10.1037/prj0000233; Robins RW, 2001, PERS SOC PSYCHOL B, V27, P151, DOI 10.1177/0146167201272002; Rossler W, 2017, EPIDEMIOL PSYCH SCI, V26, P216, DOI 10.1017/S2045796016000858; Sabatella F, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01391; Sabella K, 2021, PSYCHIATR REHABIL J, V44, P373, DOI 10.1037/prj0000470; Sachs G, 2021, SCHIZOPHR RES-COGN, V25, DOI 10.1016/j.scog.2021.100197; Saltychev M, 2021, DISABIL REHABIL, V43, P789, DOI 10.1080/09638288.2019.1643416; Schneider M, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.723900; Scott J, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5270; Singh JA, 2020, B WORLD HEALTH ORGAN, V98, P625, DOI 10.2471/BLT.20.257485; Singh S, 2020, PSYCHIAT RES, V293, DOI 10.1016/j.psychres.2020.113429; Sorensen K, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-948; Stengler K, 2021, NERVENARZT, V92, P955, DOI 10.1007/s00115-020-01038-0; Stone RAT, 2018, PSYCHIATR REHABIL J, V41, P290, DOI 10.1037/prj0000195; Tourjman SV, 2016, OPEN J PSYCHIAT, V06, P107, DOI [DOI 10.4236/OJPSYCH.2016.61013, 10.4236/ojpsych.2016.61013]; Ustun TB, 2010, B WORLD HEALTH ORGAN, V88, P815, DOI 10.2471/BLT.09.067231; Veldman K, 2015, J EPIDEMIOL COMMUN H, V69, P588, DOI 10.1136/jech-2014-204421; Viner RM, 2012, LANCET, V379, P1641, DOI 10.1016/S0140-6736(12)60149-4; World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Zachrisson HD, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-34	80	0	0	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2022	17	7							e0271803	10.1371/journal.pone.0271803	http://dx.doi.org/10.1371/journal.pone.0271803			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	4Q0KX	35905081	Green Published, gold			2023-01-03	WOS:000855776900049
J	Haakenstad, A; Angelino, O; Irvine, CMS; Bhutta, ZA; Bienhoff, K; Bintz, C; Causey, K; Dirac, MA; Fullman, N; Gakidou, E; Glucksman, T; Hay, SI; Henry, NJ; Martopullo, I; Mokdad, AH; Mumford, JE; Lim, SS; Murray, CJL; Lozano, R				Haakenstad, Annie; Angelino, Olivia; Irvine, Caleb M. S.; Bhutta, Zulfiqar A.; Bienhoff, Kelly; Bintz, Corinne; Causey, Kate; Dirac, M. Ashworth; Fullman, Nancy; Gakidou, Emmanuela; Glucksman, Thomas; Hay, Simon, I; Henry, Nathaniel J.; Martopullo, Ira; Mokdad, Ali H.; Mumford, John Everett; Lim, Stephen S.; Murray, Christopher J. L.; Lozano, Rafael			Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970-2019: a systematic analysis for the Global Burden of Disease Study 2019	LANCET			English	Article							UNMET NEED; REPRODUCTIVE HEALTH; WOMEN; FERTILITY; TRENDS; COVID-19; IMPACT; UNION; POWER; PILL	Background Meeting the contraceptive needs of women of reproductive age is beneficial for the health of women and children, and the economic and social empowerment of women. Higher rates of contraceptive coverage have been linked to the availability of a more diverse range of contraceptive methods. We present estimates of the contraceptive prevalence rate (CPR), modern contraceptive prevalence rate (mCPR), demand satisfied, and the method of contraception used for both partnered and unpartnered women for 5-year age groups in 204 countries and territories between 1970 and 2019. Methods We used 1162 population-based surveys capturing contraceptive use among women between 1970 and 2019, in which women of reproductive age (15-49 years) self-reported their, or their partner's, current use of contraception for family planning purposes. Spatiotemporal Gaussian process regression was used to generate estimates of the CPR, mCPR, demand satisfied, and method mix by age and marital status. We assessed how age-specific mCPR and demand satisfied changed with the Socio-demographic Index (SDI), a measure of social and economic development, using the meta-regression Bayesian, regularised, trimmed method from the Global Burden of Diseases, Injuries, and Risk Factors Study. Findings In 2019, 162middot9 million (95% uncertainty interval [UI] 155middot6-170middot2) women had unmet need for contraception, of whom 29middot3% (27middot9-30middot6) resided in sub-Saharan Africa and 27middot2% (24middot4-30middot3) resided in south Asia. Women aged 15-19 years (64middot8% [62middot9-66middot7]) and 20-24 years (71middot9% [68middot9-74middot2]) had the lowest rates of demand satisfied, with 43middot2 million (95% UI 39middot3-48middot0) women aged 15-24 years with unmet need in 2019. The mCPR and demand satisfied among women aged 15-19 years were substantially lower than among women aged 20-49 years at SDI values below 60 (on a 0-100 scale), but began to equalise as SDI increased above 60.Between 1970 and 2019, the global mCPR increased by 20middot1 percentage points (95% UI 18middot7-21middot6). During this time, traditional methods declined as a proportion of all contraceptive methods, whereas the use of implants, injections, female sterilisation, and condoms increased. Method mix differs substantially depending on age and geography, with the share of female sterilisation increasing with age and comprising more than 50% of methods in use in south Asia. In 28 countries, one method was used by more than 50% of users in 2019 Interpretation The dominance of one contraceptive method in some locations raises the question of whether family planning policies should aim to expand method mix or invest in making existing methods more accessible. Lower rates of demand satisfied among women aged 15-24 years are also concerning because unintended pregnancies before age 25 years can forestall or eliminate education and employment opportunities that lead to social and economic empowerment. Policy makers should strive to tailor family planning programmes to the preferences of the groups with the most need, while maintaining the programmes used by existing users. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd.	[Haakenstad, Annie; Angelino, Olivia; Irvine, Caleb M. S.; Bienhoff, Kelly; Bintz, Corinne; Causey, Kate; Dirac, M. Ashworth; Fullman, Nancy; Gakidou, Emmanuela; Glucksman, Thomas; Hay, Simon, I; Henry, Nathaniel J.; Martopullo, Ira; Mokdad, Ali H.; Mumford, John Everett; Lim, Stephen S.; Murray, Christopher J. L.; Lozano, Rafael] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA USA; [Haakenstad, Annie; Dirac, M. Ashworth; Gakidou, Emmanuela; Hay, Simon, I; Mokdad, Ali H.; Lim, Stephen S.; Murray, Christopher J. L.; Lozano, Rafael] Univ Washington, Dept Hlth Metr Sci, Seattle, WA USA; [Bhutta, Zulfiqar A.] Univ Toronto, Ctr Global Child Hlth, Toronto, ON, Canada; [Bhutta, Zulfiqar A.] Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, Pakistan; [Dirac, M. Ashworth] Swedish Family Med, First Hill, Seattle, WA USA; [Lozano, Rafael] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Toronto; Aga Khan University; Swedish Medical Center; Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle	Lozano, R (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.	rlozano@uw.edu	Hay, Simon Iain/F-8967-2015; Lozano, Rafael/T-5352-2018	Hay, Simon Iain/0000-0002-0611-7272; Lozano, Rafael/0000-0002-7356-8823	Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	Bill & Melinda Gates Foundation.	Ahmed S, 2019, LANCET GLOB HEALTH, V7, pE904, DOI 10.1016/S2214-109X(19)30200-1; Alkema L, 2013, LANCET, V381, P1642, DOI 10.1016/S0140-6736(12)62204-1; Bailey MJ, 2013, BROOKINGS PAP ECO AC, P341; Bailey MJ, 2006, Q J ECON, V121, P289; Baird S, WHAT HAPPENS ONCE IN; Balbo N, 2013, EUR J POPUL, V29, P1, DOI 10.1007/s10680-012-9277-y; Bertrand JT, 2020, GLOB HEALTH-SCI PRAC, V8, P666, DOI 10.9745/GHSP-D-20-00229; Bongaarts J, 2013, POPUL DEV REV, V38, P153, DOI 10.1111/j.1728-4457.2013.00557.x; Bradley SEK, REVISING UNMET NEED; Brown W, 2014, STUD FAMILY PLANN, V45, P73, DOI 10.1111/j.1728-4465.2014.00377.x; Cahill N, 2018, LANCET, V391, P870, DOI 10.1016/S0140-6736(17)33104-5; Campbell OMR, 2015, TROP MED INT HEALTH, V20, P1639, DOI 10.1111/tmi.12597; Canning D, 2012, LANCET, V380, P165, DOI 10.1016/S0140-6736(12)60827-7; Collaborators GS., 2017, LANCET, V390, P1423, DOI [10.1016/S0140-6736(17)32336-X, DOI 10.1016/S0140-6736(17)32336-X]; Conde-Agudelo A, 2012, STUD FAMILY PLANN, V43, P93, DOI 10.1111/j.1728-4465.2012.00308.x; Dasgupta Aisha, 2020, Gates Open Res, V4, P102, DOI 10.12688/gatesopenres.13148.1; Demographic and Health Surveys, 2018, DEM HLTH SURV MOD WO; Duvall S, 2014, GLOB HEALTH-SCI PRAC, V2, P72, DOI 10.9745/GHSP-D-13-00116; Field E, 2021, AM ECON REV, V111, P2342, DOI 10.1257/aer.20200705; Finlay JE, 2021, WORLD DEV, V139, DOI 10.1016/j.worlddev.2020.105313; Flor LS, 2022, LANCET, V399, P2381, DOI 10.1016/S0140-6736(22)00008-3; FP2020, 2019, FP2020 WOM CTR 2018; Francavilla F, 2011, J ASIAN ECON, V22, P412, DOI 10.1016/j.asieco.2011.06.001; Friedman J, 2020, NATURE, V580, P636, DOI 10.1038/s41586-020-2198-8; GBD 2019 Risk Factors Collaborators, 2020, LANC; Goldin C, 2002, J POLIT ECON, V110, P730, DOI 10.1086/340778; Goldin C., 1995, U SHAPED FEMALE LABO, P61; Government of India, 2005, MAN FAM PLANN INS SC; Government of India, 2011, MAN FAM PLANN INS SC; Institute for Health Metrics and Evaluation, 2021, PREM WOM HLTH COVID; Institute for Health Metrics and Evaluation, 2020, PREM WOM HLTH COVID; Jain Anrudh K, 2013, Int Perspect Sex Reprod Health, V39, P133, DOI 10.1363/3913313; Joshi S, FAMILY PLANNING INVE; Kantorova V, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247479; Kantorova V, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003026; Karp C, 2021, BMJ SEX REPROD HEAL, V47, P252, DOI 10.1136/bmjsrh-2020-200944; Oum S, 2021, FUNDING KEY HIV COMM; de Leon RGP, 2019, LANCET GLOB HEALTH, V7, pE227, DOI 10.1016/S2214-109X(18)30481-9; Reproductive Health Supplies Coalition, COMM GAP AN; Riley T, 2020, INT PERSPECT SEX R H, V46, P73, DOI 10.1363/46e9020; Rominski SD, 2019, STUD FAMILY PLANN, V50, P195, DOI 10.1111/sifp.12084; Ross J, 1997, INT FAM PLAN PERSPEC, V23, P148, DOI 10.2307/2950838; Ross JA, 2002, INT FAM PLAN PERSPEC, V28, P138, DOI 10.2307/3088256; Ross J, 2015, GLOB HEALTH-SCI PRAC, V3, P34, DOI 10.9745/GHSP-D-14-00199; Ross J, 2013, GLOB HEALTH-SCI PRAC, V1, P203, DOI 10.9745/GHSP-D-13-00010; Rothschild CW, 2021, STUD FAMILY PLANN, V52, P95, DOI 10.1111/sifp.12146; Silverman R, 2021, EVALUATING CONTRACEP; Singh A, 2012, INT PERSPECT SEX R H, V38, P187, DOI 10.1363/3818712; Slaymaker E, 2020, LANCET GLOB HEALTH, V8, pE567, DOI 10.1016/S2214-109X(20)30060-7; Sobotka T, 2011, POPUL DEV REV, V37, P267, DOI 10.1111/j.1728-4457.2011.00411.x; Sorensen R, CROSSWALK002 ADJUSTI; Stark L, 2018, MARRIAGE FAM REV, V54, P565, DOI 10.1080/01494929.2017.1403998; Stevens GA, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002056, 10.1371/journal.pmed.1002116]; Sullivan TM, 2006, J BIOSOC SCI, V38, P501, DOI 10.1017/S0021932005026647; Track20, FAM PLANN EXP LOW MI; Ugaz Jorge I, 2015, Int J Gynaecol Obstet, V130 Suppl 3, pE3, DOI 10.1016/j.ijgo.2015.03.021; UN, 2019, CONTR US METH 2019, DOI [10.18356/1bd58a10-en, DOI 10.18356/1BD58A10-EN]; UN Department of Economic and Social Affairs, 2020, WORLD FAM PLANN 2020; UN Department of Economic and Social Affairs Population Division, 2017, WORLD FAM PLANN 2017; UN Foundation, 2021, COR IND EST FP2020 2; UN Population Division, SDG IND 3 7 1 CONTR; UN Population Fund, 2021, IMP COVID 19 FAM PLA; UN Statistics Division UN Department of Economic and Social Affairs, 2008, MILLENNIUM DEV GOALS; UNICEF, 2021, TRACK SIT CHILDR COV; United Nations Department of Economic and Social Affairs Population Division, 2017, WORLD CONTR US 2017; United Nations Department of Social and Economic Affairs Population Division, 2020, EST PROJ FAM PLANN I; United Nations [UN], 2019, FAM PLANN 2030 AG SU; United States Agency for International Development, 2008, DEL PROJ GLOB FUND F; Vos T, 2020, LANCET, V396, P1562; Wang HD, 2020, LANCET, V396, P1160, DOI 10.1016/S0140-6736(20)30977-6; Wheldon M, 2018, METHODS ESTIMATING P; Wood SN, 2021, LANCET GLOB HEALTH, V9, pE793, DOI 10.1016/S2214-109X(21)00105-4; World Health Organization, 2020, 3 ROUND GLOB PULS SU; Zheng P, 2021, J COMPUT GRAPH STAT, V30, P544, DOI 10.1080/10618600.2020.1868303	74	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 23	2022	400	10348					295	327						33	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6D8YO	35871816	Green Published, hybrid			2023-01-03	WOS:000882970900014
J	Winter, JO				Winter, Jessica O.			One step closer to cancer nanomedicine	SCIENCE			English	Editorial Material							SIZE; CELL		[Winter, Jessica O.] Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, Columbus, OH 43210 USA; [Winter, Jessica O.] Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Winter, JO (corresponding author), Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, Columbus, OH 43210 USA.; Winter, JO (corresponding author), Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA.	winter.63@osu.edu						Albanese A, 2014, ACS NANO, V8, P5515, DOI 10.1021/nn4061012; Barua S, 2014, NANO TODAY, V9, P223, DOI 10.1016/j.nantod.2014.04.008; Boehnke N., 2022, SCIENCE, V377; Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o; Eugene M, 2004, CELL MOL BIOL, V50, P209; Hamblett KJ, 2015, CANCER RES, V75, P5329, DOI 10.1158/0008-5472.CAN-15-1610; Kim JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20461-0; Petersen GH, 2016, J CONTROL RELEASE, V232, P255, DOI 10.1016/j.jconrel.2016.04.028; Soares S, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00360; Sun XK, 2005, BIOMACROMOLECULES, V6, P2541, DOI 10.1021/bm050260e; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14; Yu CN, 2016, NAT BIOTECHNOL, V34, P419, DOI 10.1038/nbt.3460	13	1	1	23	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 22	2022	377	6604					371	372		10.1126/science.add3666	http://dx.doi.org/10.1126/science.add3666			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3F7HB	35862545				2023-01-03	WOS:000830834600022
J	Saul, H; Gursul, D; Cassidy, S; Smith, C				Saul, Helen; Gursul, Deniz; Cassidy, Samantha; Smith, Chris			More people survived a cardiac arrest when first aiders received an app alert	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Saul, Helen; Gursul, Deniz; Cassidy, Samantha] NIHR Ctr Engagement & Disseminat, Twickenham, England; [Smith, Chris] Univ Warwick, Coventry, England	University of Warwick	Saul, H (corresponding author), NIHR Ctr Engagement & Disseminat, Twickenham, England.	NIHRAlerts@nihr.ac.uk						Brown TP, 2022, RESUSCITATION, V170, P28, DOI 10.1016/j.resuscitation.2021.10.037; GoodSAM Medical, US; Resuscitation Council UK, PUBL RES CPR INF; Resuscitation Council UK, LIF; Smith CM, 2017, RESUSCITATION, V121, P123, DOI 10.1016/j.resuscitation.2017.10.020	5	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	2022	379								o2578	10.1136/bmj.o2578	http://dx.doi.org/10.1136/bmj.o2578			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6N1SV	36368720				2023-01-03	WOS:000889341400008
J	Brusselle, GG; Humbert, M				Brusselle, Guy G.; Humbert, Marc			Classification of COPD: fostering prevention and precision medicine in the Lancet Commission on COPD	LANCET			English	Editorial Material									[Brusselle, Guy G.] Ghent Univ Hosp, Dept Resp Med, B-9000 Ghent, Belgium; [Brusselle, Guy G.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Brusselle, Guy G.] Erasmus MC, Dept Resp Med, Rotterdam, Netherlands; [Humbert, Marc] Univ Paris Saclay, Serv Pneumol & Soins Intensifs Resp, INSERM UMR S 999, Hop Bicetre,Assistance Publ Hop Paris, Le Kremlin Bicetre, France	Ghent University; Ghent University Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Saclay	Brusselle, GG (corresponding author), Ghent Univ Hosp, Dept Resp Med, B-9000 Ghent, Belgium.; Brusselle, GG (corresponding author), Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.; Brusselle, GG (corresponding author), Erasmus MC, Dept Resp Med, Rotterdam, Netherlands.	guy.brusselle@ugent.be						Agusti A, 2019, NEW ENGL J MED, V381, P1248, DOI 10.1056/NEJMra1900475; Brusselle GG, 2022, NEW ENGL J MED, V386, P157, DOI 10.1056/NEJMra2032506; Brusselle GG, 2011, LANCET, V378, P1015, DOI 10.1016/S0140-6736(11)60988-4; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Global Strategy for the Diagnosis Management and Prevention of COPD Global Initiative for Chronic Obstructive Lung Disease, 2022, PNEUMOLOGIE; Hoffmann B, 2021, INT J PUBLIC HEALTH, V66, DOI 10.3389/ijph.2021.1604465; Humbert Marc, 2022, Eur Respir J, DOI 10.1183/13993003.00879-2022; Lange P, 2015, NEW ENGL J MED, V373, P111, DOI 10.1056/NEJMoa1411532; Martinez FJ, 2022, AM J RESP CRIT CARE, V205, P275, DOI 10.1164/rccm.202107-1663SO; Safiri Saeid, 2022, BMJ, V378, pe069679, DOI 10.1136/bmj-2021-069679; Stolz D, 2022, LANCET, V400, P921, DOI 10.1016/S0140-6736(22)01273-9	11	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 17	2022	400	10356					869	871		10.1016/S0140-6736(22)01660-9	http://dx.doi.org/10.1016/S0140-6736(22)01660-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	6O3YZ	36075257				2023-01-03	WOS:000890180700005
J	Conley, C; Brook, K; Louca, J; Haber, A; Nozari, A; Ortega, R				Conley, Christopher; Brook, Karolina; Louca, Joseph; Haber, Amy; Nozari, Ala; Ortega, Rafael			Inhalational Induction	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Conley, Christopher; Brook, Karolina; Louca, Joseph; Haber, Amy; Nozari, Ala; Ortega, Rafael] Boston Med Ctr, Dept Anesthesiol, 750 Albany St, Boston, MA 02118 USA	Boston Medical Center	Ortega, R (corresponding author), Boston Med Ctr, Dept Anesthesiol, 750 Albany St, Boston, MA 02118 USA.	rafael.ortega@bmc.org		Conley, Christopher/0000-0002-6446-2832				Hartigan PM, 2022, ANESTHESIOLOGY, V136, P104, DOI 10.1097/ALN.0000000000004011; Jo JY, 2019, JAMA OTOLARYNGOL, V145, P117, DOI 10.1001/jamaoto.2018.3097; Manso MA, 2019, PEDIATR ANESTH, V29, P1094, DOI 10.1111/pan.13747; Ortega RA, 2006, ANESTHESIOLOGY, V105, P838, DOI 10.1097/00000542-200610000-00030; Ramgolam A, 2018, ANESTHESIOLOGY, V128, P1065, DOI 10.1097/ALN.0000000000002152	5	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 8	2022	387	10							e19	10.1056/NEJMvcm2202144	http://dx.doi.org/10.1056/NEJMvcm2202144			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	4Y6KL	36069873				2023-01-03	WOS:000861634500001
J	Linkewich, E; Rios, J; Allen, KA; Avery, L; Dawson, DR; Donald, M; Egan, M; Hunt, A; Jutzi, K; McEwen, S				Linkewich, Elizabeth; Rios, Jorge; Allen, Kay-Ann; Avery, Lisa; Dawson, Deirdre R.; Donald, Michelle; Egan, Mary; Hunt, Anne; Jutzi, Katelyn; McEwen, Sara			The impact of an integrated, interprofessional knowledge translation intervention on access to inpatient rehabilitation for persons with cognitive impairment	PLOS ONE			English	Article							STROKE; STRATEGY	Introduction Stroke rehabilitation teams' skills and knowledge in treating persons with cognitive impairment (CI) contribute to their reduced access to inpatient rehabilitation. This study examined stroke inpatient rehabilitation referral acceptance rates for persons with CI before and after the implementation of a multi-faceted integrated knowledge translation (KT) intervention aimed at improving clinicians' skills in a cognitive-strategy based approach, Cognitive Orientation to daily Occupational Performance (CO-OP), CO-OP KT. Methods CO-OP KT was implemented at five inpatient rehabilitation centres, using an interrupted time series design and data from an electronic referral and database system called E-Stroke. CO-OP KT included a 2-day workshop, 4 months of implementation support, health system support, and a sustainability plan. A mixed effects model was used to model monthly acceptance rates for 12 months prior to the intervention and 6 months post. Results The dataset was comprised of 2604 pre-intervention referrals and 1354 post. In the mixed effects model, those with CI had a lower pre-intervention acceptance rate than those without. Post-intervention the model showed the acceptance rate for those with CI increased by 8.6% (p = 0.02), whereas those with no CI showed a non-significant increase of less than 1%. Conclusions Proportionally more persons with CI gained access to inpatient stroke rehabilitation following an integrated KT intervention.	[Linkewich, Elizabeth] Sunnybrook Hlth Sci Ctr, North & East GTA Stroke Network, Toronto, ON, Canada; [Linkewich, Elizabeth] Sunnybrook Res Inst, Practice Based Res, Toronto, ON, Canada; [Linkewich, Elizabeth; Dawson, Deirdre R.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Rios, Jorge; Allen, Kay-Ann; Jutzi, Katelyn; McEwen, Sara] Sunnybrook Res Inst, St Johns Rehab Res Program, Toronto, ON, Canada; [Avery, Lisa] Avery Informat Serv Ltd, Orillia, ON, Canada; [Dawson, Deirdre R.; McEwen, Sara] Univ Toronto, Rehabil Sci, Toronto, ON, Canada; [Dawson, Deirdre R.] Baycrest, Rotman Res Inst, Toronto, ON, Canada; [Donald, Michelle] Cent Local Hlth Integrat Network, Markham, ON, Canada; [Egan, Mary] Univ Ottawa, Sch Rehabil Sci, Ottawa, ON, Canada; [Hunt, Anne] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [McEwen, Sara] Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; Baycrest; University of Ottawa; University of Toronto; University Toronto Affiliates; Holland Bloorview Kids Rehabilitation Hospital; University of Toronto	Linkewich, E (corresponding author), Sunnybrook Hlth Sci Ctr, North & East GTA Stroke Network, Toronto, ON, Canada.; Linkewich, E (corresponding author), Sunnybrook Res Inst, Practice Based Res, Toronto, ON, Canada.; Linkewich, E (corresponding author), Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada.	beth.linkewich@sunnybrook.ca		Linkewich, Elizabeth/0000-0002-6327-3693	 [PHE-141799]		SM and EL were recipients of a Canadian Institutes of Health Research https://cihr-irsc.gc.ca), Partnerships for Health System Improvement (PHE-141799) grant as co-principal investigators.	Ahn SN, 2017, NEUROREHABILITATION, V40, P285, DOI 10.3233/NRE-161416; Ankolekar S, 2014, J STROKE CEREBROVASC, V23, P1821, DOI 10.1016/j.jstrokecerebrovasdis.2014.04.022; [Anonymous], 2007, R PACKAGE VERSION; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Geraghty JR, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.105027; Jutzi KSR, 2020, CAN J OCCUP THER, V87, P42, DOI 10.1177/0008417419848291; Lanctot KL, 2020, INT J STROKE, V15, P668, DOI 10.1177/1747493019847334; Linkewich E, 2014, ARCH PHYS MED REHAB, V95, P95, DOI DOI 10.1016/J.APMR.2014.07.021; Linkewich E, 2020, ARCH PHYS MED REHAB, V101, P587, DOI 10.1016/j.apmr.2019.10.185; Linkewich E, 2015, STROKE, V46; Longley V, 2019, CLIN REHABIL, V33, P1492, DOI 10.1177/0269215519843984; Lynch EA, 2017, TOP STROKE REHABIL, V24, P619, DOI 10.1080/10749357.2017.1366010; McEwen S, 2015, NEUROREHAB NEURAL RE, V29, P526, DOI 10.1177/1545968314558602; McEwen SE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212988; McEwen SE, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0346-6; McEwen SE, 2017, COGNITIVE ORIENTATIO, V1st, P93; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Ottenbacher KJ, 2007, ARCH PHYS MED REHAB, V88, P1513, DOI 10.1016/j.apmr.2007.06.761; Penfold RB, 2013, ACAD PEDIATR, V13, pS38, DOI 10.1016/j.acap.2013.08.002; Polatajko H. J., 2004, ENABLING OCCUPATION; R Core Team, 2021, R LANG ENV STAT COMP; Rabadi MH, 2008, ARCH PHYS MED REHAB, V89, P441, DOI 10.1016/j.apmr.2007.11.014; Skidmore ER, 2015, NEUROREHAB NEURAL RE, V29, P668, DOI 10.1177/1545968314562113; Teasell R, 2018, EVIDENCE BASED REV S, P27; Teasell R, 2020, INT J STROKE, V15, P763, DOI 10.1177/1747493019897843; Vassallo M, 2016, CLIN REHABIL, V30, P901, DOI 10.1177/0269215515611466; Wolf TJ, 2016, AM J OCCUP THER, V70, DOI 10.5014/ajot.2016.017293	27	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2022	17	9							e0266651	10.1371/journal.pone.0266651	http://dx.doi.org/10.1371/journal.pone.0266651			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R4GI	36048763	Green Published, gold			2023-01-03	WOS:000892263300005
J	Sehgal, A; Barnabe, C; Crowshoe, L				Sehgal, Anika; Barnabe, Cheryl; Crowshoe, Lynden			Patient complexity assessment tools containing inquiry domains important for Indigenous patient care: A scoping review	PLOS ONE			English	Article							HEALTH DISPARITIES; INTEGRATED CARE; SOCIAL-JUSTICE; HIGH-RISK; EMERGENCY; PEOPLE; PERSPECTIVE; EXPERIENCES; BARRIERS; ACCESS	Patient complexity assessment tools (PCATs) are utilized to collect vital information to effectively deliver care to patients with complexity. Indigenous patients are viewed in the clinical setting as having complex health needs, but there is no existing PCAT developed for use with Indigenous patients, although general population PCATs may contain relevant content. Our objective was to identify PCATs that include the inquiry of domains relevant in the care of Indigenous patients with complexity. A scoping review was performed on articles published between 2016 and 2021 to extend a previous scoping review of PCATs. Data extraction from existing frameworks focused on domains of social realities relevant to the care of Indigenous patients. The search resulted in 1078 articles, 82 underwent full-text review, and 9 new tools were identified. Combined with previously known and identified PCATs, only 6 items from 5 tools tangentially addressed the domains of social realities relevant to Indigenous patients. This scoping review identifies a major gap in the utility and capacity of PCATs to address the realities of Indigenous patients. Future research should focus on developing tools to address the needs of Indigenous patients and improve health outcomes.	[Sehgal, Anika] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada; [Barnabe, Cheryl] Univ Calgary, Cumming Sch Med, Dept Med, Calgary, AB, Canada; [Crowshoe, Lynden] Univ Calgary, Cumming Sch Med, Dept Family Med, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary	Sehgal, A (corresponding author), Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada.	anika.sehgal@ucalgary.ca			Canadian Institutes of Health Research [FDN 143284]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This research was funded by the Canadian Institutes of Health Research (https://cihr-irsc.gc.ca/e/193.html) grant number: FDN 143284 awarded to CB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelson N, 2005, CAN J PUBLIC HEALTH, V96, pS45, DOI 10.1007/BF03403702; Allan B., 2015, 1 PEOPLES 2 CLASS TR; Anderson I., 1997, RACE MATTERS, P191; Anderson JM, 2009, ADV NURS SCI, V32, P282, DOI 10.1097/ANS.0b013e3181bd6955; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Barnabe C, 2021, BMC MED EDUC, V21, DOI 10.1186/s12909-021-02551-9; Baskin C., 2015, ENCY SOCIAL WORK; Berry-Millett Rachel, 2009, Synth Proj Res Synth Rep, DOI 52372; Boult C, 1998, AM J MANAG CARE, V4, P1137; Boult Chad, 2004, Dis Manag, V7, P124, DOI 10.1089/1093507041253271; Boyer Y, 2017, CAN MED ASSOC J, V189, pE1408, DOI 10.1503/cmaj.171234; Browne AJ, 2011, QUAL HEALTH RES, V21, P333, DOI 10.1177/1049732310385824; Bryant J, 2021, SOCIOL HEALTH ILL, V43, P1405, DOI 10.1111/1467-9566.13311; Burnette CE, 2014, ETHICS SOC WELF, V8, P364, DOI 10.1080/17496535.2014.885987; Cameron BL., 2014, ADV NURS SCI, V37, P1; Chandler M. J., 1998, TRANSCULT PSYCHIATRY, V35, P191, DOI DOI 10.1177/136346159803500202; Cidro J, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00138; Crowshoe L, 2018, CAN J DIABETES, V42, pS296, DOI 10.1016/j.jcjd.2017.10.022; Crowshoe L, 2019, CAN FAM PHYSICIAN, V65, P25; Curtis E, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-1082-3; Czyzewski K, 2011, INT INDIG POLICY J, V2, DOI 10.18584/iipj.2011.2.1.5; Danso R, 2018, J SOC WORK, V18, P410, DOI 10.1177/1468017316654341; Durey A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-151; First Nations Health Authority, 2021, CREATING CLIMATE CHA; Gone JP, 2019, AM PSYCHOL, V74, P20, DOI 10.1037/amp0000338; Grant RW, 2011, ANN INTERN MED, V155, P797, DOI 10.7326/0003-4819-155-12-201112200-00001; Griffiths K, 2016, J POPUL RES, V33, P9, DOI 10.1007/s12546-016-9164-1; Hajizadeh M, 2018, HEALTH POLICY, V122, P854, DOI 10.1016/j.healthpol.2018.06.011; Harfield SG, 2018, GLOBALIZATION HEALTH, V14, DOI 10.1186/s12992-018-0332-2; Harkey J, 2017, PROF CASE MANAG, V22, P174, DOI 10.1097/NCM.0000000000000225; Harlow AF, 2014, CRISIS, V35, P310, DOI 10.1027/0227-5910/a000265; Hawker K, 2021, HEALTH EXPECT, V24, P556, DOI 10.1111/hex.13200; Hollinsworth D, 2013, DISABIL SOC, V28, P601, DOI 10.1080/09687599.2012.717879; Horrill T, 2018, NURS INQ, V25, DOI 10.1111/nin.12237; Hudon C, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-021-06154-4; Huyse FJ, 2000, J PSYCHOSOM RES, V48, P303; Jacklin KM, 2017, CAN MED ASSOC J, V189, pE106, DOI 10.1503/cmaj.161098; Jones R, 2019, ACAD MED, V94, P512, DOI 10.1097/ACM.0000000000002476; Kennedy A, 2022, HEALTH EDUC J, V81, P423, DOI 10.1177/00178969221088921; Khalil H, 2016, WORLDV EVID-BASED NU, V13, P118, DOI 10.1111/wvn.12144; King M, 2009, LANCET, V374, P76, DOI 10.1016/S0140-6736(09)60827-8; Kirkham SR, 2002, ADV NURS SCI, V25, P1; Kirmayer LJ, 2014, TRANSCULT PSYCHIATRY, V51, P299, DOI 10.1177/1363461514536358; Lafontaine A, 2018, CAN J SURG, V61, P300, DOI 10.1503/cjs.011718; Lambert M, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0614-1; Latour CHM, 2007, NURS HEALTH SCI, V9, P150, DOI 10.1111/j.1442-2018.2007.00292.x; Lavoie JG, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1665-2; Lavoie JG, 2013, INT J CIRCUMPOL HEAL, V72, DOI 10.3402/ijch.v72i0.22690; Lin I, 2020, PAIN REP, V5, DOI 10.1097/PR9.0000000000000838; MacDonald C., 2015, INT J REGIONAL LOCAL, V10, P32, DOI 10.1179/2051453015Z.00000000023; Marcoux V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188663; Maxwell M., 2011, NHS HLTH SCOTLAND; Miles M.B., 1994, QUALITATIVE DATA ANA, V2nd; Miller AM, 2019, PUBLIC HEALTH NURS, V36, P451, DOI 10.1111/phn.12606; Mion LC, 2001, J AM GERIATR SOC, V49, P1379, DOI 10.1046/j.1532-5415.2001.49270.x; Moore G, 2012, AUSTRALAS EMERG NURS, V15, P2, DOI 10.1016/j.aenj.2011.12.004; Nasir BF, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020196; Nelson SE, 2018, SOC SCI MED, V218, P21, DOI 10.1016/j.socscimed.2018.09.017; PACALA JT, 1995, J AM GERIATR SOC, V43, P374, DOI 10.1111/j.1532-5415.1995.tb05810.x; Peek CJ, 2009, FAM SYST HEALTH, V27, P287, DOI 10.1037/a0018048; Pratt Rebekah, 2015, J Comorb, V5, P110, DOI 10.15256/joc.2015.5.35; Quilty S, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16224306; Randall DA, 2018, MED J AUSTRALIA, V209, P19, DOI 10.5694/mja17.00878; Reading CL., 2009, HLTH INEQUALITIES SO, P1; Reuben DB, 2002, MED CARE, V40, P782, DOI 10.1097/00005650-200209000-00008; Richmond CAM, 2016, PUBLIC HEALTH REV, V37, DOI 10.1186/s40985-016-0016-5; Sackett K, 2001, Case Manager, V12, P52, DOI 10.1067/mcm.2001.114434; Safford MM, 2007, J GEN INTERN MED, V22, P382, DOI 10.1007/s11606-007-0307-0; Schaink Alexis K, 2012, J Comorb, V2, P1; Scutella R., 2020, HOUSING SOC, V48, P261; Shelton P, 2000, AM J MANAG CARE, V6, P925; Stiefel FC, 2006, MED CLIN N AM, V90, P713, DOI 10.1016/j.mcna.2006.05.006; Stout Madeleine Dion, 2006, Contemp Nurse, V22, P327; Tonelli M, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.4852; Tremblay Marie-Claude, 2020, Res Involv Engagem, V6, P44, DOI 10.1186/s40900-020-00216-3; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Tricco AC, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0116-4; Troigros O, 2014, CLIN REHABIL, V28, P499, DOI 10.1177/0269215513505300; Truth and Reconciliation Commission of Canada, 2015, TRUTH RECONCILIATION; Truth and Reconciliation Commission of Canada, 2015, HONOURING TRUTH RECO; United Nations Department of Economic and Social Affairs, 2021, INDIGENOUS PEOPLES M; Vass A, 2011, HEALTH PROMOT J AUST, V22, P33, DOI 10.1071/HE11033; Webster F, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-1010-6	83	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2022	17	8							e0273841	10.1371/journal.pone.0273841	http://dx.doi.org/10.1371/journal.pone.0273841			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6R5UO	36044532	gold, Green Published			2023-01-03	WOS:000892368200074
J	Mahase, E				Mahase, Elisabeth			Covid-19: Results from India's 12 molnupiravir clinical trials remain unpublished	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Extance A, 2022, BMJ-BRIT MED J, V377, DOI 10.1136/bmj.o926; icmr, CLIN GUIDANCE MANAGE; Mahase E, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2697; researchsquare, EVALUATION PUBLICATI	4	0	0	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2022	378								o2063	10.1136/bmj.o2063	http://dx.doi.org/10.1136/bmj.o2063			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3Y7DM	35985657	Bronze			2023-01-03	WOS:000843882000003
J	Hagey, RJ; Elazar, M; Pham, EA; Tian, SQ; Ben-Avi, L; Bernardin-Souibgui, C; Yee, MF; Moreira, FR; Rabinovitch, MV; Meganck, RM; Fram, B; Beck, A; Gibson, SA; Lam, G; Devera, J; Kladwang, W; Nguyen, K; Xiong, AM; Schaffert, S; Avisar, T; Liu, P; Rustagi, A; Fichtenbaum, CJ; Pang, PS; Khatri, P; Tseng, CT; Taubenberger, JK; Blish, CA; Hurst, BL; Sheahan, TP; Das, R; Glenn, JS				Hagey, Rachel J.; Elazar, Menashe; Pham, Edward A.; Tian, Siqi; Ben-Avi, Lily; Bernardin-Souibgui, Claire; Yee, Matthew F.; Moreira, Fernando R.; Rabinovitch, Meirav Vilan; Meganck, Rita M.; Fram, Benjamin; Beck, Aimee; Gibson, Scott A.; Lam, Grace; Devera, Josephine; Kladwang, Wipapat; Nguyen, Khanh; Xiong, Anming; Schaffert, Steven; Avisar, Talia; Liu, Ping; Rustagi, Arjun; Fichtenbaum, Carl J.; Pang, Phillip S.; Khatri, Purvesh; Tseng, Chien-Te; Taubenberger, Jeffery K.; Blish, Catherine A.; Hurst, Brett L.; Sheahan, Timothy P.; Das, Rhiju; Glenn, Jeffrey S.			Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2	NATURE MEDICINE			English	Article							LOCKED NUCLEIC-ACID; INFERRING BASE-PAIRS; ROBUST ANALYSIS; MAP STRATEGY; SHAPE; SEGMENTS; OLIGONUCLEOTIDES; OSELTAMIVIR; RIBONUCLEOPROTEIN; RESISTANT	Influenza A virus's (IAV's) frequent genetic changes challenge vaccine strategies and engender resistance to current drugs. We sought to identify conserved and essential RNA secondary structures within IAV's genome that are predicted to have greater constraints on mutation in response to therapeutic targeting. We identified and genetically validated an RNA structure (packaging stem-loop 2 (PSL2)) that mediates in vitro packaging and in vivo disease and is conserved across all known IAV isolates. A PSL2-targeting locked nucleic acid (LNA), administered 3 d after, or 14 d before, a lethal IAV inoculum provided 100% survival in mice, led to the development of strong immunity to rechallenge with a tenfold lethal inoculum, evaded attempts to select for resistance and retained full potency against neuraminidase inhibitor-resistant virus. Use of an analogous approach to target SARS-CoV-2, prophylactic administration of LNAs specific for highly conserved RNA structures in the viral genome, protected hamsters from efficient transmission of the SARS-CoV-2 USA_WA1/2020 variant. These findings highlight the potential applicability of this approach to any virus of interest via a process we term 'programmable antivirals', with implications for antiviral prophylaxis and post-exposure therapy. Targeting conserved secondary structure of RNA viruses offers the potential for a customizable therapeutic approach to viral variants.	[Hagey, Rachel J.; Elazar, Menashe; Pham, Edward A.; Glenn, Jeffrey S.] Stanford Med, ViRx Stanford, Stanford, CA 94305 USA; [Hagey, Rachel J.; Glenn, Jeffrey S.] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA; [Hagey, Rachel J.; Elazar, Menashe; Pham, Edward A.; Ben-Avi, Lily; Bernardin-Souibgui, Claire; Yee, Matthew F.; Rabinovitch, Meirav Vilan; Fram, Benjamin; Lam, Grace; Devera, Josephine; Nguyen, Khanh; Xiong, Anming; Avisar, Talia; Liu, Ping; Pang, Phillip S.; Glenn, Jeffrey S.] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, Stanford, CA 94305 USA; [Tian, Siqi; Kladwang, Wipapat; Das, Rhiju] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; [Moreira, Fernando R.; Meganck, Rita M.; Sheahan, Timothy P.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA; [Beck, Aimee; Rustagi, Arjun; Blish, Catherine A.] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; [Gibson, Scott A.; Hurst, Brett L.] Utah State Univ, Dept Anim Dairy & Vet Sci, Inst Antiviral Res, Logan, UT 84322 USA; [Schaffert, Steven; Khatri, Purvesh] Stanford Univ, Dept Med, Biomed Informat Res, Sch Med, Stanford, CA 94305 USA; [Fichtenbaum, Carl J.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Infect Dis, Cincinnati, OH USA; [Tseng, Chien-Te] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; [Tseng, Chien-Te] Univ Texas Med Branch, Ctr Biodef & Emerging Dis, Galveston Natl Lab, Galveston, TX 77555 USA; [Taubenberger, Jeffery K.] NIAID, Viral Pathogenesis & Evolut Sect, Lab Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Blish, Catherine A.] Chan Zuckerberg Biohub, San Francisco, CA USA; [Das, Rhiju] Stanford Univ, Dept Phys, Stanford, CA 94305 USA; [Glenn, Jeffrey S.] Vet Adm Med Ctr, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University; University of North Carolina; University of North Carolina Chapel Hill; Stanford University; Utah System of Higher Education; Utah State University; Stanford University; University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Glenn, JS (corresponding author), Stanford Med, ViRx Stanford, Stanford, CA 94305 USA.; Glenn, JS (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA.; Glenn, JS (corresponding author), Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, Stanford, CA 94305 USA.; Glenn, JS (corresponding author), Vet Adm Med Ctr, Palo Alto, CA 94304 USA.	jeffrey.glenn@stanford.edu		Das, Rhiju/0000-0001-7497-0972; Meganck, Rita/0000-0003-2799-3754; Schaffert, Steven/0000-0001-8842-0218; Blish, Catherine/0000-0001-6946-7627; Khatri, Purvesh/0000-0002-4143-4708; Ben-Avi, Lily/0000-0003-0154-3341; Yee, Matthew/0000-0001-5354-9820; Rustagi, Arjun/0000-0002-6921-1012	Mona M. Burgess Stanford BIO-X Interdisciplinary Graduate Fellowship; National Institutes of Health (NIH) Graduate Training Grant [5T32AI007328-24]; NIH Training Grant [5T32DK007056]; NIH [R56A1111460, U19A1109662, RO1AI132191, U19AI171421]; US Army Medical Research Acquisition Activity, Department of Defense [W81XWH1810647]; Open Philanthropy and Good Ventures Fund; COVID-19 Harrington Scholar Innovator Grant; Fastgrants; Dr. Tri Cao Nguyen Fund for Pandemic Preparedness; Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH	Mona M. Burgess Stanford BIO-X Interdisciplinary Graduate Fellowship; National Institutes of Health (NIH) Graduate Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Army Medical Research Acquisition Activity, Department of Defense(United States Department of Defense); Open Philanthropy and Good Ventures Fund; COVID-19 Harrington Scholar Innovator Grant; Fastgrants; Dr. Tri Cao Nguyen Fund for Pandemic Preparedness; Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank H. Jin and her team at MedImmune for the kind donation of chicken eggs and technical guidance at the start of the project. We thank the Stanford in vitro BSL-3 Service Center and its director J. Garhyan for assistance with the SARS-CoV-2 research. We thank additional members of R.D.'s lab, I. N. Zheludev, R. Rangan and H. Wayment-Steele, for meaningful discussions of the SARS-CoV-2 structures and design of original SARS-CoV-2 RNA constructs for SHAPE experiments. The work was supported in part by a Mona M. Burgess Stanford BIO-X Interdisciplinary Graduate Fellowship (to R.J.H.), the National Institutes of Health (NIH) Graduate Training Grant (no. 5T32AI007328-24 to R.J.H.), NIH Training Grant (no. 5T32DK007056 to E.A.P.) and the following grants to J.S.G.: NIH research grants (nos. R56A1111460, U19A1109662, RO1AI132191 and U19AI171421), an influenza Harrington Scholar Innovator grant and grant no. W81XWH1810647 from the US Army Medical Research Acquisition Activity, Department of Defense, Open Philanthropy and Good Ventures Fund, Fastgrants, a COVID-19 Harrington Scholar Innovator Grant and the Dr. Tri Cao Nguyen Fund for Pandemic Preparedness. The work was also supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. The data presented in this manuscript are tabulated in the main paper and the supplementary materials. Chemical-mapping datasets for M2 and M2R experiments have been deposited at the RMDB (http://rmdb.stanford.edu).	Akbari A, 2008, ELECTROPHORESIS, V29, P1273, DOI 10.1002/elps.200700523; [Anonymous], 2019, INFL TREATM; [Anonymous], 2022, SARS COV 2 VAR CLASS; Bloom JD, 2010, SCIENCE, V328, P1272, DOI 10.1126/science.1187816; COMPANS RW, 1972, J VIROL, V10, P795, DOI 10.1128/JVI.10.4.795-800.1972; Cordero P, 2014, METHODS MOL BIOL, V1086, P53, DOI 10.1007/978-1-62703-667-2_4; Cordero P, 2012, BIOINFORMATICS, V28, P3006, DOI 10.1093/bioinformatics/bts554; Darty K, 2009, BIOINFORMATICS, V25, P1974, DOI 10.1093/bioinformatics/btp250; De Rijk P, 2003, BIOINFORMATICS, V19, P299, DOI 10.1093/bioinformatics/19.2.299; Deigan KE, 2009, P NATL ACAD SCI USA, V106, P97, DOI 10.1073/pnas.0806929106; Dinnon KH, 2021, NATURE, DOI 10.1038/s41586-020-03107-5; Fournier E, 2012, NUCLEIC ACIDS RES, V40, P2197, DOI 10.1093/nar/gkr985; Gao QS, 2012, J VIROL, V86, P7043, DOI 10.1128/JVI.00662-12; Gavazzi C, 2013, NUCLEIC ACIDS RES, V41, P1241, DOI 10.1093/nar/gks1181; Giannecchini S, 2009, ARCH VIROL, V154, P821, DOI 10.1007/s00705-009-0380-2; Gog JR, 2007, NUCLEIC ACIDS RES, V35, P1897, DOI 10.1093/nar/gkm087; Hai R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3854; Hayden FG, 2011, J INFECT DIS, V203, P6, DOI 10.1093/infdis/jiq012; Hillebrand F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051088; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Hurt AC, 2012, J INFECT DIS, V206, P148, DOI 10.1093/infdis/jis337; Hutchinson EC, 2010, J GEN VIROL, V91, P313, DOI 10.1099/vir.0.017608-0; Javanbakht H, 2018, MOL THER-NUCL ACIDS, V11, P441, DOI 10.1016/j.omtn.2018.02.005; Kawakami E, 2011, J VIROL METHODS, V173, P1, DOI 10.1016/j.jviromet.2010.12.014; Kim H, 2013, NUCLEIC ACIDS RES, V41, pW492, DOI 10.1093/nar/gkt501; Kim J, 2009, BIOINFORMATICS, V25, P1137, DOI 10.1093/bioinformatics/btp110; Kladwang W, 2014, BIOCHEMISTRY-US, V53, P3063, DOI 10.1021/bi5003426; Kladwang W, 2011, NAT CHEM, V3, P954, DOI [10.1038/NCHEM.1176, 10.1038/nchem.1176]; Kladwang W, 2011, RNA, V17, P522, DOI 10.1261/rna.2516311; Kladwang W, 2010, BIOCHEMISTRY-US, V49, P7414, DOI 10.1021/bi101123g; Kurreck J, 2002, NUCLEIC ACIDS RES, V30, P1911, DOI 10.1093/nar/30.9.1911; Liang YH, 2008, J VIROL, V82, P229, DOI 10.1128/JVI.01541-07; Marsh GA, 2008, J VIROL, V82, P2295, DOI 10.1128/JVI.02267-07; Marsh GA, 2007, J VIROL, V81, P9727, DOI 10.1128/JVI.01144-07; Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101; Memoli MJ, 2010, CLIN INFECT DIS, V50, P1252, DOI 10.1086/651605; Mortimer SA, 2007, J AM CHEM SOC, V129, P4144, DOI 10.1021/ja0704028; Mortimer SA, 2009, NAT PROTOC, V4, P1413, DOI 10.1038/nprot.2009.126; Moss WN, 2011, RNA, V17, P991, DOI 10.1261/rna.2619511; Muramoto Y, 2006, J VIROL, V80, P2318, DOI 10.1128/JVI.80.5.2318-2325.2006; Noda T, 2010, REV MED VIROL, V20, P380, DOI 10.1002/rmv.666; Palese P., 2007, FIELDS VIROLOGY, P1647; Pang PS, 2012, J VIROL, V86, P1250, DOI 10.1128/JVI.06367-11; Pang PS, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr773; Priore SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035989; Rangan R, 2020, RNA, V26, P937, DOI 10.1261/rna.076141.120; Romero-Lopez C, 2013, REV MED VIROL, V23, P340, DOI 10.1002/rmv.1756; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Staedel C, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.18; Straarup EM, 2010, NUCLEIC ACIDS RES, V38, P7100, DOI 10.1093/nar/gkq457; Balish Amanda L, 2013, Curr Protoc Microbiol, VChapter 15, DOI [10.1002/0471729256.mc15g01s3, 10.1002/9780471729259.mc15g01s29]; Takashita E, 2019, EUROSURVEILLANCE, V24, P18, DOI 10.2807/1560-7917.ES.2019.24.3.1800698; Tian SQ, 2014, RNA, V20, P1815, DOI 10.1261/rna.044321.114; Vester B, 2004, BIOCHEMISTRY-US, V43, P13233, DOI 10.1021/bi0485732; Wang R, 2021, CELL, V184, P106, DOI 10.1016/j.cell.2020.12.004; Wilkinson KA, 2006, NAT PROTOC, V1, P1610, DOI 10.1038/nprot.2006.249; Yoon S, 2011, BIOINFORMATICS, V27, P1798, DOI 10.1093/bioinformatics/btr277	58	4	4	8	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1944	+		10.1038/s41591-022-01908-x	http://dx.doi.org/10.1038/s41591-022-01908-x		AUG 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35982307	Bronze			2023-01-03	WOS:000842362900001
J	Mylonakis, E				Mylonakis, Eleftherios			Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 A Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article; Early Access								Background: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection. Objective: To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared with standard care alone. Design: Double-blind, randomized, placebo-controlled, clinical trial. (ClinicalTrials.gov: NCT04501978) Setting: Multinational, multicenter trial. Participants: Adults hospitalized with COVID-19. Intervention: Intravenous ensovibep, 600 mg, or placebo. Measurements: Ensovibep was assessed for early futility on the basis of pulmonary ordinal scores at day 5. The primary outcome was time to sustained recovery through day 90, defined as 14 consecutive days at home or place of usual residence after hospital discharge. A composite safety outcome that included death, serious adverse events, end-organ disease, and serious infections was assessed through day 90. Results: An independent data and safety monitoring board recommended that enrollment be halted for early futility after 485 patients were randomly assigned and received an infusion of ensovibep (n =247) or placebo (n =238). The odds ratio (OR) for a more favorable pulmonary outcome in the ensovibep (vs. placebo) group at day 5 was 0.93 (95% CI, 0.67 to 1.30; P= 0.68; OR> 1 would favor ensovibep). The 90-day cumulative incidence of sustained recovery was 82% for ensovibep and 80% for placebo (subhazard ratio [sHR], 1.06 [CI, 0.88 to 1.28]; sHR> 1 would favor ensovibep). The primary composite safety outcome at day 90 occurred in 78 ensovibep participants (32%) and 70 placebo participants (29%) (HR, 1.07 [CI, 0.77 to 1.47]; HR< 1 would favor ensovibep). Limitation: The trial was prematurely stopped because of futility, limiting power for the primary outcome. Conclusion: Compared with placebo, ensovibep did not improve clinical outcomes for hospitalized participants with COVID-19 receiving standard care, including remdesivir; no safety concerns were identified.	[Mylonakis, Eleftherios] Rhode Isl Hosp, 593 Eddy St, Providence, RI 02903 USA	Lifespan Health Rhode Island; Rhode Island Hospital	Mylonakis, E (corresponding author), Rhode Isl Hosp, 593 Eddy St, Providence, RI 02903 USA.	Eleftherios_Mylonakis@Brown.edu	Chia, Po Ying/AAN-9657-2020; Jensen, Tomas/AFN-5759-2022; gunthard, huldrych f/F-1724-2011; Harboe, Zitta Barrella/AAZ-2569-2020; Chia, Po Ying/GSD-9737-2022; Brown, Samuel/E-6846-2015	Chia, Po Ying/0000-0002-8797-9527; Jensen, Tomas/0000-0003-0398-4431; gunthard, huldrych f/0000-0002-1142-6723; Harboe, Zitta Barrella/0000-0001-5552-0095; Chia, Po Ying/0000-0002-8797-9527; Staerke, Nina Breinholt/0000-0002-5834-2033; Paredes, Roger/0000-0002-6553-691X; Holodniy, Mark/0000-0002-6655-7982; Chen, Peter/0000-0002-5330-1718; ERIOBU, NNAKELU/0000-0003-2528-8082; Ashktorab, Kimia/0000-0001-6262-7560; Moschopoulos, Charalampos/0000-0001-9954-7409; Ong, Sean/0000-0002-8570-436X; Agrawal, Anika/0000-0001-7465-2771; Lindegaard, Birgitte/0000-0002-5236-8427; Brown, Samuel/0000-0003-1206-6261; Salvador, Fernando/0000-0002-0546-1354; Gibbs, Kevin/0000-0002-5272-2289; Bhagani, Sanjay/0000-0003-2557-4337	U.S. Operation Warp Speed program; National Institute of Allergy and Infectious Diseases; Leidos Biomedical Research for the INSIGHT Network; National Heart, Lung, and Blood Institute; Research Triangle Institute for the Prevention and Early Treatment of Acute Lung Injury Network; Cardiothoracic Surgical Trials Network; U.S. Department of Veterans Affairs; government of Denmark from the National Research Foundation [126]; government of Australia (from the National Health and Medical Research Council); government of United Kingdom from the Medical Research Council [MRC_UU_12023/23]; government of Singapore from the National Medical Research Council [COVID19RF-005]; National Institutes of Health [1OT2HL156812-01]; National Cancer Institute [75N91019D00024, 75N91020F00039]	U.S. Operation Warp Speed program; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Leidos Biomedical Research for the INSIGHT Network; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Research Triangle Institute for the Prevention and Early Treatment of Acute Lung Injury Network; Cardiothoracic Surgical Trials Network; U.S. Department of Veterans Affairs(US Department of Veterans Affairs); government of Denmark from the National Research Foundation; government of Australia (from the National Health and Medical Research Council); government of United Kingdom from the Medical Research Council; government of Singapore from the National Medical Research Council; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Financial Support: By the U.S. Operation Warp Speed program; the National Institute of Allergy and Infectious Diseases and Leidos Biomedical Research for the INSIGHT Network; the National Heart, Lung, and Blood Institute and the Research Triangle Institute for the Prevention and Early Treatment of Acute Lung Injury Network and the Cardiothoracic Surgical Trials Network; the U.S. Department of Veterans Affairs; and grants from the governments of Denmark (no. 126 from the National Research Foundation) , Australia (from the National Health and Medical Research Council) , the United Kingdom (MRC_UU_12023/23 from the Medical Research Council) , and Singapore (COVID19RF-005 from the National Medical Research Council) . The research was funded in part by National Institutes of Health agreement 1OT2HL156812-01 and National Cancer Institute contract 75N91019D00024, task order 75N91020F00039. Trial medica-tions were donated by Molecular Partners (ensovibep) and Gilead Sciences (remdesivir) .	ACTIV-3 TICO LY-CoV555 Study Grp, 2021, NEW ENGL J MED, V384, P905, DOI 10.1056/NEJMoa2033130; ACTIV-3-Therapeutics for Inpatients with COVID-19 (TICO) Study Group, 2022, Lancet Respir Med, V10, P972, DOI 10.1016/S2213-2600(22)00215-6; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Cohen MS, 2021, JAMA-J AM MED ASSOC, V326, P46, DOI [10.1001/jama.2021.88282021., 10.1001/jama.2021.8828]; Davey RT, 2019, LANCET RESP MED, V7, P951, DOI 10.1016/S2213-2600(19)30253-X; Dougan M, 2021, NEW ENGL J MED, V385, P1382, DOI 10.1056/NEJMoa2102685; Gupta A, 2021, NEW ENGL J MED, V385, P1941, DOI 10.1056/NEJMoa2107934; Horby PW, 2022, LANCET, V399, P665, DOI 10.1016/S0140-6736(22)00163-5; Kumarasamy N, 2022, 32 EUROPEAN C CLIN M; Lundgren JD, 2022, ANN INTERN MED, V175, P234, DOI 10.7326/M21-3507; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Montgomery Hugh, 2022, Lancet Respir Med, V10, P985, DOI 10.1016/S2213-2600(22)00180-1; Murray DD, 2022, CLIN TRIALS, V19, P52, DOI [10.1177/17407745211049829, 10.1101/2020.11.08.20227876]; O'Brien MP, 2022, JAMA-J AM MED ASSOC, V327, P432, DOI 10.1001/jama.2021.24939; Rothenberger S, BIORXIV, DOI [10.1101/2021.02.03.429164, DOI 10.1101/2021.02.03.429164]; Self WH, 2022, LANCET INFECT DIS, V22, P622, DOI 10.1016/S1473-3099(21)00751-9; Stumpp MT, 2020, BIODRUGS, V34, P423, DOI 10.1007/s40259-020-00429-8; Takashita E, 2022, NEW ENGL J MED, V386, P995, DOI 10.1056/NEJMc2119407; Walser M, 2020, BIORXIV, DOI [10.1101/2020.08.25. 256339, DOI 10.1101/2020.08.25.256339]; Weinreich DM, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2108163	22	1	1	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.												10.7326/M22-1503	http://dx.doi.org/10.7326/M22-1503		AUG 2022	10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	3U2YR	35939810	Green Published			2023-01-03	WOS:000840840500001
J	Staud, R; Carpenter, R; Godfrey, M; Robinson, ME				Staud, Roland; Carpenter, Rachel; Godfrey, Melyssa; Robinson, Michael E.			Hand size estimates of fibromyalgia patients are associated with clinical and experimental pain	PLOS ONE			English	Article							BODY PERCEPTION DISTURBANCE; REGIONAL PAIN; SOMATOSENSORY CORTEX; BRAIN PLASTICITY; IMAGE; REORGANIZATION; REPRESENTATION; PREVALENCE; IMMEDIATE; CRITERIA	Introduction Simply inspecting one's own body can reduce clinical pain and magnification of body parts can increase analgesia. Thus, body perceptions seem to play an important role for analgesia. Conversely, pain may also affect bodily perceptions. Therefore, we evaluated the effects of clinical and/or experimental pain on perceived hand size in fibromyalgia patients (FM) and healthy controls (HC). Methods To investigate the effects of chronic and/or acute pain on size perception we compared hand size estimates of 35 HC and 32 FM patients at baseline and during tonic mechanical pain stimuli applied to one ear lobe. Mechanical stimuli were adjusted for each individual pain sensitivity to achieve a rating of 4 +/- 1 VAS (0-10) units. Photographs of each subject's hands were digitally manipulated to produce a monotonic series of 5 images larger and 6 smaller than actual size which were then presented to the participants in ascending and descending order (total number of images: 12). Results FM and HC participants' clinical pain ratings at baseline were 3.3 (3.1) and .3 (.8) VAS units, respectively. At baseline, FM participants selected significantly smaller hand images than HC as representative of their actual size (p < .02). During application of tonic experimental pain, the image size chosen to represent their actual hand size decreased significantly in FM participants and HC (p < .001) but this decrease was not different between groups (p > .05). Hand size estimates of FM participants correlated negatively with their clinical pain ratings (p < .04). Conclusion The decreased hand size perception of FM patients and HC was associated with their clinical and/or experimental pain, supporting the hypothesis that pain can result in visual body distortions.	[Staud, Roland; Carpenter, Rachel; Godfrey, Melyssa] Univ Florida, Dept Med, Gainesville, FL 32611 USA; [Robinson, Michael E.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Staud, R (corresponding author), Univ Florida, Dept Med, Gainesville, FL 32611 USA.	staudr@ufl.edu		Godfrey, Melyssa/0000-0001-9545-5312; Carpenter, Rachel/0000-0003-3596-9797; Staud, Roland/0000-0002-1317-2368				Akkaya N, 2012, CLIN RHEUMATOL, V31, P983, DOI 10.1007/s10067-012-1965-9; BELL C, 1986, J CLIN PSYCHOL, V42, P431, DOI 10.1002/1097-4679(198605)42:3<431::AID-JCLP2270420305>3.0.CO;2-I; Bennett RM, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-27; CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; Cardini F, 2011, CEREB CORTEX, V21, P2014, DOI 10.1093/cercor/bhq267; Ehde DM, 2000, ARCH PHYS MED REHAB, V81, P1039, DOI 10.1053/apmr.2000.7583; Fallon N, 2013, NEUROIMAGE-CLIN, V3, P163, DOI 10.1016/j.nicl.2013.07.011; Flor H, 2006, NERVENHEILKUNDE, V25, P445; Flor H, 1997, PAIN, V73, P413, DOI 10.1016/S0304-3959(97)00137-1; Flor H, 1997, NEUROSCI LETT, V224, P5, DOI 10.1016/S0304-3940(97)13441-3; Gandevia SC, 1999, J PHYSIOL-LONDON, V514, P609, DOI 10.1111/j.1469-7793.1999.609ae.x; Gilpin HR, 2015, RHEUMATOLOGY, V54, P678, DOI 10.1093/rheumatology/keu367; Giummarra MJ, 2015, CONSCIOUS COGN, V36, P314, DOI 10.1016/j.concog.2015.07.010; Haggard P, 2013, CURR BIOL, V23, pR164, DOI 10.1016/j.cub.2013.01.047; HANDWERKER HO, 1993, PHYSIOL REV, V73, P639, DOI 10.1152/physrev.1993.73.3.639; Jones KD, 2009, JCR-J CLIN RHEUMATOL, V15, P16, DOI 10.1097/RHU.0b013e318190f991; JOURARD S M, 1955, J Abnorm Psychol, V50, P243; Kaas JH, 1997, ADV NEUROL, V73, P147; LEDINGHAM J, 1993, BRIT J RHEUMATOL, V32, P139; Lewis JS, 2012, EUR J PAIN, V16, P1320, DOI 10.1002/j.1532-2149.2012.00120.x; Lewis JS, 2007, PAIN, V133, P111, DOI 10.1016/j.pain.2007.03.013; Lewis JS, 2021, EUR J PAIN, V25, P1551, DOI 10.1002/ejp.1766; LI CX, 1994, CAN J NEUROL SCI, V21, P233, DOI 10.1017/S0317167100041214; Longo MR, 2012, J NEUROSCI, V32, P2601, DOI 10.1523/JNEUROSCI.4031-11.2012; Lotze Martin, 2007, Curr Rheumatol Rep, V9, P488; Maihofner C, 2003, NEUROLOGY, V61, P1707, DOI 10.1212/01.WNL.0000098939.02752.8E; Mancini F, 2011, PSYCHOL SCI, V22, P325, DOI 10.1177/0956797611398496; Meireles SA, 2014, ACTA ORTOP BRAS, V22, P163, DOI 10.1590/1413-78522014220300386; MELZACK R, 1973, EXP NEUROL, V39, P261, DOI 10.1016/0014-4886(73)90228-8; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; Moseley GL, 2008, PAIN, V140, P239, DOI 10.1016/j.pain.2008.08.001; Moseley GL, 2008, PAIN, V138, P7, DOI 10.1016/j.pain.2008.06.026; Moseley GL, 2012, NEUROSCI BIOBEHAV R, V36, P34, DOI 10.1016/j.neubiorev.2011.03.013; Moseley GL, 2005, NEUROLOGY, V65, P773, DOI 10.1212/01.wnl.0000174515.07205.11; O'Brien AT, 2018, J PAIN, V19, P819, DOI 10.1016/j.jpain.2018.01.010; Osumi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107376; Osumi Michihiro, 2014, Front Hum Neurosci, V8, P137, DOI 10.3389/fnhum.2014.00137; Paqueron X, 2004, ANESTHESIOLOGY, V100, P979, DOI 10.1097/00000542-200404000-00032; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Penfield W., 1950, CEREBRAL CORTEX MAN; Penn-Barwell JG, 2011, INJURY, V42, P1474, DOI 10.1016/j.injury.2011.07.005; Pleger B, 2005, ANN NEUROL, V57, P425, DOI 10.1002/ana.20394; PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3; RASMUSSON DD, 1992, SOMATOSENS MOT RES, V9, P279, DOI 10.3109/08990229209144777; Robinson ME, 2011, J PAIN, V12, P436, DOI 10.1016/j.jpain.2010.10.003; ROSSINI PM, 1994, BRAIN RES, V642, P169, DOI 10.1016/0006-8993(94)90919-9; SPITZER M, 1995, BIOL CYBERN, V72, P197, DOI 10.1007/BF00201484; Staud R, 2004, J PAIN, V5, P338, DOI 10.1016/j.jpain.2004.05.007; Staud R, 2001, PAIN, V91, P165, DOI 10.1016/S0304-3959(00)00432-2; Staud R, 2008, J MUSCULOSKELET PAIN, V16, P67, DOI 10.1080/10582450801960339; Sumitani M, 2010, EUR J PAIN, V14, P261, DOI 10.1016/j.ejpain.2009.05.003; Valenzuela-Moguillansky C, 2013, CONSTR FOUND, V8, P339; WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140	57	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2022	17	7							e0270701	10.1371/journal.pone.0270701	http://dx.doi.org/10.1371/journal.pone.0270701			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	6S4AQ	35877689	Green Published, gold			2023-01-03	WOS:000892932200019
J	Jiang, S; Hong, GS				Jiang, Shan; Hong, Guosong			HEALTH TECHNOLOGY Cooling the pain	SCIENCE			English	Editorial Material									[Jiang, Shan; Hong, Guosong] Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA; [Jiang, Shan; Hong, Guosong] Stanford Univ, Wu Tsai Neurosci Inst, Stanford, CA 94305 USA	Stanford University; Stanford University	Hong, GS (corresponding author), Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA.; Hong, GS (corresponding author), Stanford Univ, Wu Tsai Neurosci Inst, Stanford, CA 94305 USA.	guosongh@stanford.edu		Jiang, Shan/0000-0002-1567-2745				Bar-Cohen A., 1997, MICROELECTRON RELIAB, V37, P502; Berman BM, 2010, NEW ENGL J MED, V363, P454, DOI 10.1056/NEJMct0806114; Chickos JS, 2003, J PHYS CHEM REF DATA, V32, P519, DOI 10.1063/1.1529214; ERNST E, 1994, J PAIN SYMPTOM MANAG, V9, P56, DOI 10.1016/0885-3924(94)90150-3; Finnerup NB, 2019, NEW ENGL J MED, V380, P2440, DOI 10.1056/NEJMra1807061; Goldberg DS, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-770; Janssen R., 1992, NEUROSCI BIOBEHAV R, DOI DOI 10.1016/S0149-7634(05)80209-X; Johnson Mark, 2007, Rev Pain, V1, P7, DOI 10.1177/204946370700100103; Lomber SG, 1999, J NEUROSCI METH, V86, P179, DOI 10.1016/S0165-0270(98)00165-4; Morgan T, 2020, J NEUROPHYSIOL, V123, P2173, DOI 10.1152/jn.00133.2020; Nahar MM, 2021, APPL THERM ENG, V194, DOI 10.1016/j.applthermaleng.2021.117109; Ponce CR, 2008, NAT NEUROSCI, V11, P216, DOI 10.1038/nn2039; Reeder JT, 2022, SCIENCE, V377, P109, DOI 10.1126/science.abl8532; Song EM, 2020, NAT MATER, V19, P590, DOI 10.1038/s41563-020-0679-7	14	0	0	5	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	2022	377	6601					28	29		10.1126/science.abm8159	http://dx.doi.org/10.1126/science.abm8159			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	2S8AF	35771916				2023-01-03	WOS:000822009800032
J	Turner, L; Ball, J; Culliford, D; Kitson-Reynolds, E; Griffiths, P				Turner, Lesley; Ball, Jane; Culliford, David; Kitson-Reynolds, Ellen; Griffiths, Peter			Exploring the relationship between women's experience of postnatal care and reported staffing measures: An observational study	PLOS ONE			English	Article							CONSEQUENCES; SUPPORT	BackgroundWomen have reported dissatisfaction with care received on postnatal wards and this area has been highlighted for improvement. Studies have shown an association between midwifery staffing levels and postnatal care experiences, but so far, the influence of registered and support staff deployed in postnatal wards has not been studied. This work is timely as the number of support workers has increased in the workforce and there has been little research on skill mix to date. MethodsCross sectional secondary analysis including 13,264 women from 123 postnatal wards within 93 hospital Trusts. Staffing was measured in each organisation as Full Time Equivalent staff employed per 100 births, and on postnatal wards, using Hours Per Patient Day. Women's experiences were assessed using four items from the 2019 national maternity survey. Multilevel logistic regression models were used to examine relationships and adjust for maternal age, parity, ethnicity, type of birth, and medical staff. ResultsTrusts with higher levels of midwifery staffing had higher rates of women reporting positive experiences of postnatal care. However, looking at staffing on postnatal wards, there was no evidence of an association between registered nurses and midwives hours per patient day and patient experience. Wards with higher levels of support worker staffing were associated with higher rates of women reporting they had help when they needed it and were treated with kindness and understanding. ConclusionThe relationship between reported registered staffing levels on postnatal wards and women's experience is uncertain. Further work should be carried out to examine why relationships observed using whole Trust staffing were not replicated closer to the patient, with reported postnatal ward staffing. It is possible that recorded staffing levels on postnatal wards do not actually reflect staff deployment if midwives are floated to cover delivery units. This study highlights the potential contribution of support workers in providing quality care on postnatal wards.	[Turner, Lesley; Ball, Jane; Kitson-Reynolds, Ellen] Univ Southampton, Sch Hlth Sci, Southampton, England; [Culliford, David] Univ Southampton, Sch Hlth Sci, NIHR Appl Res Collaborat Wessex, Southampton, England; [Griffiths, Peter] Univ Southampton, Natl Inst Hlth Res Appl Res Ctr Wessex, Sch Hlth Sci, Southampton, England	University of Southampton; University of Southampton; University of Southampton	Turner, L (corresponding author), Univ Southampton, Sch Hlth Sci, Southampton, England.	lyt1g19@soton.ac.uk	; Griffiths, Peter/D-4016-2009	Turner, Lesley/0000-0003-1489-3471; Griffiths, Peter/0000-0003-2439-2857	National Institute for Health Research; National Institute for Health Research Applied Research Centre (Wessex); National Institute for Health Research's Health Services & Delivery Research programme [NIHR128056]; National Institute for Health Research Applied Research Collaboration (Wessex)	National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research Applied Research Centre (Wessex); National Institute for Health Research's Health Services & Delivery Research programme; National Institute for Health Research Applied Research Collaboration (Wessex)	Peter Griffiths receives support from a Senior Investigator award made by the National Institute for Health Research and the National Institute for Health Research Applied Research Centre (Wessex). This research was part funded by the National Institute for Health Research's Health Services & Delivery Research programme (Award ID: NIHR128056) and the National Institute for Health Research Applied Research Collaboration (Wessex).	Alderdice F., 2016, BIRTH NI SURVEY WOME; [Anonymous], 2011, JOGNN-J OBST GYN NEO, V40, P131, DOI 10.1111/j.1552-6909.2010.01214.x; [Anonymous], 2019, HOSP EP STAT HES; Baxter J., 2005, BRIT J MIDWIFERY, V13, P378; Beake S, 2005, EVID BASED MIDWIFERY, V3, P80; Bhavnani V, 2010, FUNDAMENTALS MIDWIFE; Bick D, 2020, MIDWIFERY, V80, DOI 10.1016/j.midw.2019.102574; Birthrights, 2022, SYST RAC NOT BROK BO; Bowers J, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-015-1214-4; Care Quality Commission, 2020, MAN WOM HAV POS EXP; Care Quality Commission Picker Institute Europe, 2021, MAT SURV 2019 DAT CO, P8790; Clark RRS, 2022, JOGNN-J OBST GYN NEO, V51, P290, DOI 10.1016/j.jogn.2022.02.001; CQC, 2019, MID S ESS NHS FDN TR; Driscoll A, 2018, EUR J CARDIOVASC NUR, V17, P6, DOI 10.1177/1474515117721561; Dykes F, 2005, MIDWIFERY, V21, P241, DOI 10.1016/j.midw.2004.12.006; Gelman A, 2009, AM STAT, V63, P1, DOI 10.1198/tast.2009.0001; Grassley JS, 2015, JOGNN-J OBST GYN NEO, V44, P567, DOI 10.1111/1552-6909.12728; Griffin R., 2012, BRIT J MIDWIFERY, V20, P884; Harrison S., 2018, NATL SURVEY HLTH CAR; Health Education England, 2019, MAT WORKF STRAT TRAN; Henderson J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-196; Independent, NURS DRAFT SHOR UP U; Indigenous Allied Health Australia, 2015, CULT RESP ACT IAHA F; Kalisch BJ, 2011, MED CARE, V49, P775, DOI 10.1097/MLR.0b013e318222a6df; Kokab F, 2022, MIDWIFERY, V104, DOI 10.1016/j.midw.2021.103183; MBRRACE-UK, 2021, SAVING LIVES IMPROVI; McLachlan HL, 2008, MIDWIFERY, V24, P358, DOI 10.1016/j.midw.2006.10.006; McLeish J, 2021, WOMEN BIRTH, V34, pE451, DOI 10.1016/j.wombi.2020.10.012; McLeish J, 2020, QUAL HEALTH RES, V30, P1876, DOI 10.1177/1049732320944141; Merkow RP, 2022, J NURS CARE QUAL, V37, P195, DOI 10.1097/NCQ.0000000000000619; Min A, 2016, J NURS MANAGE, V24, P439, DOI 10.1111/jonm.12347; Morrow J, 2013, MIDWIFERY, V29, P159, DOI 10.1016/j.midw.2011.11.006; National Federation of Women's Institutes National Childbirth Trust, 2017, SUPP OV WOM EXP MAT; National Institute for Health Research, 2019, MAKING DECISIONS HEA; National Quality Board, 2016, SUPP NHS PROV DEL RI; NHS Digital, 2019, NHS MAT STAT ENGL 20; NHS Digital, 2019, NHS WORKF STAT; NHS Improvement, 2021, CAR HOURS PAT DAY CH; NHS Improvement, 2018, CAR HOURS PAT DAY CH; NHS Improvement, 2019, CAR HOURS PAT DAY CH; Nilsen Morch M., 2019, NORWEGIAN J CLIN NUR, DOI [10.4220/Sykepleienf.2019.76793, DOI 10.4220/SYKEPLEIENF.2019.76793]; NMPA Project Team, 2021, ETHN SOC EC IN NHS M; Ockenden D, 2022, FINAL REPORT OCKENDE; Royal College of Nursing, 2019, NURS MAT CAR; Russell Samantha, 2021, Nurs Womens Health, V25, P167, DOI 10.1016/j.nwh.2021.03.005; Sandall J, 2014, EFFICIENT USE MATERN; Scottish Government, 2019, MAT CAR SURV 2018 NA; Sheen JJ, 2018, AM J OBSTET GYNECOL, V219, DOI 10.1016/j.ajog.2018.08.034; Simpson KR, 2017, J PERINAT NEONAT NUR, V31, P32, DOI 10.1097/JPN.0000000000000203; Simpson KR, 2016, JOGNN-J OBST GYN NEO, V45, P481, DOI 10.1016/j.jogn.2016.02.011; Turner L, 2022, Women Birth, V35, pe583, DOI 10.1016/j.wombi.2022.02.005; Turner L, 2021, MIDWIFERY, V103, DOI 10.1016/j.midw.2021.103118; Twigg D, 2009, INT J NURS STUD, V46, P132, DOI 10.1016/j.ijnurstu.2008.08.005; United Nations Population Fund, 2021, STATE WORLDS MIDWIFE; Vitner D, 2019, J MATERN-FETAL NEO M, V32, P2580, DOI [10.1080/14767058.2018.1440546, 10.1080/14767058.2018.1531121]; Who, 2016, WHO REC ANT CAR POS; Winter V, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-051133; Wray J., 2006, BRIT J MIDWIFERY, V14, P520	58	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One		2022	17	8								10.1371/journal.pone.0266638	http://dx.doi.org/10.1371/journal.pone.0266638			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	3P9FR	35917338	Green Published, gold			2023-01-03	WOS:000837840000046
